{"chunk_id": "cf59a7dc-84ec-4ddb-83a3-84a7547f67e0", "source_document_filename": "CPG Prevention and Treatment of Venous Thrombosis_cleaned_ultra_minimal.txt", "source_document_title": "CPG Prevention and Treatment of Venous Thrombosis cleaned ultra minimal", "text": "VTE\nCLINICAL\u00a0PRACTICE\u00a0GUIDELINES\nPrevention\u00a0and\u00a0Treatment\u00a0of\nVenous\u00a0Thromboembolism\nMalaysian\u00a0Society\u00a0of\nHaematology\nNational\u00a0Heart\u00a0Association\nof\u00a0Malaysia\nMinistry\u00a0of\u00a0Health\nMalaysia\nAcademy\u00a0of\u00a0Medicine\nMalaysia\nMOH/P/PAK/264.13(GU)\nSTATEMENT\u00a0OF\u00a0INTENT\nThese\u00a0guidelines\u00a0are\u00a0meant\u00a0to\u00a0be\u00a0a\u00a0guide\u00a0for\u00a0clinical\u00a0practice,\u00a0based\u00a0on\u00a0the\u00a0best\navailable\u00a0 evidence\u00a0 at\u00a0 the\u00a0 time\u00a0 of\u00a0 development. Adherence\u00a0to\u00a0these\u00a0guidelines\nmay\u00a0not\u00a0necessarily\u00a0ensure\u00a0the\u00a0best\u00a0outcome\u00a0in\u00a0every\u00a0case. Every\u00a0health\u00a0care\nprovider\u00a0is\u00a0responsible\u00a0for\u00a0the\u00a0management\u00a0options\u00a0available\u00a0locally. REVIEW\u00a0OF\u00a0THE\u00a0GUIDELINES\nThese\u00a0guidelines\u00a0were\u00a0issued\u00a0in\u00a02013\u00a0and\u00a0will\u00a0be\u00a0reviewed\u00a0in\u00a02017\u00a0or\u00a0sooner\u00a0if\nnew\u00a0evidence\u00a0becomes\u00a0available. Electronic\u00a0version\u00a0available\u00a0on\u00a0the\u00a0following\u00a0website:\nhttp://www.haematology.org.my\nDISCLOSURE\u00a0STATEMENT\nThe\u00a0 panel\u00a0 members\u00a0 had\u00a0 completed\u00a0 disclosure\u00a0 forms. None\u00a0 held\u00a0 shares\u00a0 in\npharmaceutical\u00a0firms\u00a0or\u00a0acted\u00a0as\u00a0consultants\u00a0to\u00a0such\u00a0firms\u00a0(details\u00a0are\u00a0available\nupon\u00a0request\u00a0from\u00a0the\u00a0CPG\u00a0Secretariat). SOURCES\u00a0OF\u00a0FUNDING\nThe\u00a0 development\u00a0 of\u00a0 the\u00a0 CPG\u00a0 on\u00a0 Prevention\u00a0 and\u00a0 Treatment\u00a0 of\u00a0 Venous\nThromboembolism\u00a0was\u00a0supported\u00a0via\u00a0unrestricted\u00a0educational\u00a0grant\u00a0from\u00a0Bayer\nHealthcare\u00a0 Pharmaceuticals. The\u00a0 funding\u00a0 body\u00a0 has\u00a0 not\u00a0 influenced\u00a0 the\ndevelopment\u00a0of\u00a0the\u00a0guidelines. August\u00a02013\n\u00a9\u00a0Ministry\u00a0of\u00a0Health\u00a0Malaysia\n01\n9\n7 8 9 6 7 1 2 1 0 0 0 0\nISBN 978-967-12100-0-0\nGUIDELINES\u00a0DEVELOPMENT\nThe\u00a0 development\u00a0 group\u00a0 for\u00a0 these\u00a0 guidelines\u00a0 consists\u00a0 of\u00a0 Haematologist,\nCardiologist,\u00a0 Neurologist,\u00a0 Obstetrician\u00a0 &\u00a0 Gynaecologist,\u00a0 Vascular\u00a0 Surgeon,\nOrthopaedic\u00a0Surgeon,\u00a0Anaesthesiologist,\u00a0Pharmacologist\u00a0and\u00a0Pharmacist\u00a0from\nthe\u00a0Ministry\u00a0of\u00a0Health\u00a0Malaysia,\u00a0Ministry\u00a0of\u00a0Higher\u00a0Education\u00a0Malaysia\u00a0and\u00a0the\nPrivate\u00a0sector. Literature\u00a0 search\u00a0 was\u00a0 carried\u00a0 out\u00a0 at\u00a0 the\u00a0 following\u00a0 electronic\u00a0 databases:\nInternational\u00a0 Health\u00a0 Technology\u00a0 Assessment\u00a0 website,\u00a0 PUBMED,\u00a0 MEDLINE,\nCochrane\u00a0Database\u00a0of\u00a0Systemic\u00a0Reviews\u00a0(CDSR),\u00a0Journal\u00a0full\u00a0text\u00a0via\u00a0OVID\nsearch\u00a0 engine\u00a0 and\u00a0 Science\u00a0 Direct. In\u00a0 addition,\u00a0 the\u00a0 reference\u00a0 lists\u00a0 of\u00a0 studies\nselected\u00a0for\u00a0inclusion\u00a0were\u00a0scanned\u00a0for\u00a0relevant\u00a0studies. The\u00a0 clinical\u00a0 questions\u00a0 were\u00a0 divided\u00a0 into\u00a0 18\u00a0 subgroups\u00a0 and\u00a0 members\u00a0 of\u00a0 the\ndevelopment\u00a0 workgroup\u00a0 were\u00a0 assigned\u00a0 individual\u00a0 topics. Literature\u00a0 searched\nwere\u00a0 appraised\u00a0 by\u00a0 workgroup\u00a0 members\u00a0 using\u00a0 Critical\u00a0 Appraisal\u00a0 Skills\nProgramme\u00a0 (CASP)\u00a0 checklist,\u00a0 presented\u00a0 in\u00a0 the\u00a0 form\u00a0 of\u00a0 evidence\u00a0 table\u00a0 and\ndiscussed\u00a0 during\u00a0 group\u00a0 meetings. All\u00a0 statements\u00a0 and\u00a0 recommendations\nformulated\u00a0were\u00a0agreed\u00a0by\u00a0both\u00a0the\u00a0development\u00a0group\u00a0and\u00a0review\u00a0committee. Where\u00a0 the\u00a0 evidence\u00a0 was\u00a0 insufficient,\u00a0 the\u00a0 recommendations\u00a0 were\u00a0 derived\u00a0 by\nconsensus\u00a0of\u00a0the\u00a0development\u00a0group\u00a0and\u00a0review\u00a0committee. The\u00a0 articles\u00a0 were\u00a0 graded\u00a0 by\u00a0 using\u00a0 the\u00a0 National\u00a0 Guidelines\u00a0 Clearinghouse\n(www.guidelines.gov),\u00a0 Agency\u00a0 for\u00a0 Healthcare\u00a0 Research\u00a0 and\u00a0 Quality,\u00a0 U.S. Department\u00a0 of\u00a0 Health\u00a0 &\u00a0 Human\u00a0 Services,\u00a0 USA,\u00a0 level\u00a0 of\u00a0 evidence\u00a0 while\u00a0 the\ngrading\u00a0of\u00a0recommendations\u00a0in\u00a0these\u00a0guidelines\u00a0was\u00a0modified\u00a0from\u00a0the\u00a0Scottish\nIntercollegiate\u00a0 Guidelines\u00a0 Network\u00a0 (SIGN). Refer\u00a0 to\u00a0Appendix\u00a0 12\u00a0 for\u00a0 further\ndetails. These\u00a0guidelines\u00a0have\u00a0been\u00a0presented\u00a0to\u00a0the\u00a0Technical\u00a0Advisory\u00a0Committee\u00a0for\nClinical\u00a0Practice\u00a0Guidelines\u00a0and\u00a0the\u00a0Health\u00a0Technology\u00a0Assessment\u00a0and\u00a0Clinical\nPractice\u00a0Guidelines\u00a0Council,\u00a0Ministry\u00a0of\u00a0Health\u00a0Malaysia\u00a0for\u00a0review\u00a0and\u00a0approval. OBJECTIVES\nGENERAL\u00a0OBJECTIVES\nTo\u00a0provide\u00a0evidence\u00adbased\u00a0guidance\u00a0in\u00a0the\u00a0management\u00a0of\u00a0venous\nthromboembolism. SPECIFIC\u00a0OBJECTIVES\n! To\u00a0provide\u00a0guidance\u00a0in\u00a0preventing\u00a0venous\u00a0thromboembolism\n! To\u00a0provide\u00a0guidance\u00a0in\u00a0diagnosing\u00a0venous\u00a0thromboembolism\n! To\u00a0provide\u00a0guidance\u00a0in\u00a0treating\u00a0venous\u00a0thromboembolism\n! To\u00a0provide\u00a0guidance\u00a0in\u00a0anticoagulation\u00a0and\u00a0monitoring\n!", "chunk_order": 0}
{"chunk_id": "81b1fd84-f3f0-4f35-b52f-b07ac8953a5a", "source_document_filename": "CPG Prevention and Treatment of Venous Thrombosis_cleaned_ultra_minimal.txt", "source_document_title": "CPG Prevention and Treatment of Venous Thrombosis cleaned ultra minimal", "text": "Refer\u00a0 to\u00a0Appendix\u00a0 12\u00a0 for\u00a0 further\ndetails. These\u00a0guidelines\u00a0have\u00a0been\u00a0presented\u00a0to\u00a0the\u00a0Technical\u00a0Advisory\u00a0Committee\u00a0for\nClinical\u00a0Practice\u00a0Guidelines\u00a0and\u00a0the\u00a0Health\u00a0Technology\u00a0Assessment\u00a0and\u00a0Clinical\nPractice\u00a0Guidelines\u00a0Council,\u00a0Ministry\u00a0of\u00a0Health\u00a0Malaysia\u00a0for\u00a0review\u00a0and\u00a0approval. OBJECTIVES\nGENERAL\u00a0OBJECTIVES\nTo\u00a0provide\u00a0evidence\u00adbased\u00a0guidance\u00a0in\u00a0the\u00a0management\u00a0of\u00a0venous\nthromboembolism. SPECIFIC\u00a0OBJECTIVES\n! To\u00a0provide\u00a0guidance\u00a0in\u00a0preventing\u00a0venous\u00a0thromboembolism\n! To\u00a0provide\u00a0guidance\u00a0in\u00a0diagnosing\u00a0venous\u00a0thromboembolism\n! To\u00a0provide\u00a0guidance\u00a0in\u00a0treating\u00a0venous\u00a0thromboembolism\n! To\u00a0provide\u00a0guidance\u00a0in\u00a0anticoagulation\u00a0and\u00a0monitoring\n! To\u00a0provide\u00a0guidance\u00a0in\u00a0managing\u00a0bleeding\u00a0complications\u00a0of\u00a0anticoagulants\n! To\u00a0provide\u00a0guidance\u00a0in\u00a0managing\u00a0VTE\u00a0in\u00a0special\u00a0populations\n! To\u00a0provide\u00a0guidance\u00a0in\u00a0managing\u00a0thrombosis\u00a0in\u00a0unusual\u00a0sites\n! To\u00a0provide\u00a0guidance\u00a0in\u00a0perioperative\u00a0management\u00a0of\u00a0anticoagulation\n! To\u00a0provide\u00a0guidance\u00a0in\u00a0establishing\u00a0a\u00a0Medication\u00a0Therapy\u00a0Adherence\u00a0Clinic\u00a0\u00ad\nWarfarin(MTAC\u00adW)\nIt\u00a0is\u00a0not\u00a0the\u00a0objective\u00a0of\u00a0these\u00a0guidelines\u00a0to\u00a0cover:\n! Management\u00a0of\u00a0arterial\u00a0thrombosis\nTARGET\u00a0POPULATION\nAll\u00a0patients\u00a0with\u00a0VTE\u00a0or\u00a0at\u00a0risk\u00a0for\u00a0VTE\nCLINICAL\u00a0QUESTIONS\nRefer\u00a0to\u00a0appendix\u00a013\nTARGET\u00a0GROUP/USER\nAll\u00a0health\u00a0care\u00a0professionals\nGUIDELINES\u00a0DEVELOPMENT\u00a0GROUP\nChairperson\nProfessor\u00a0Dr\u00a0Abdul\u00a0Rashid\u00a0Abdul\u00a0Rahman\nConsultant\u00a0Physician\u00a0and\u00a0Clinical\u00a0Pharmacologist\nCyberjaya\u00a0Unviversity\u00a0College\u00a0of\u00a0Medical\u00a0Sciences\u00a0and\u00a0Hospital\u00a0Pakar\u00a0An\u00a0Nur\nCo\u00adChairperson\nDr\u00a0Jameela\u00a0Sathar\nConsultant\u00a0Haematologist\nAmpang\u00a0Hospital\nMembers\u00a0(alphabetical\u00a0order)\nChong\u00a0Chia\u00a0Chee\nPharmacist\nAmpang\u00a0Hospital\nDr\u00a0Eeson\u00a0Sinthamoney\nConsultant\u00a0Obstetrician\u00a0&\u00a0Gynaecologist\nPantai\u00a0Hospital\u00a0Kuala\u00a0Lumpur\nDr\u00a0Hamat\u00a0Hamdi\u00a0Che\u00a0Hassan\nConsultant\u00a0Cardiologist\nHospital\u00a0Universiti\u00a0Kebangsaan\u00a0Malaysia\nAssoc\u00a0Professor\u00a0Dr\u00a0Hanafiah\u00a0Harunarashid\nConsultant\u00a0Vascular\u00a0Surgeon\nHospital\u00a0Universiti\u00a0Kebangsaan\u00a0Malaysia\nDr\u00a0Kiren\u00a0Sidhu\nConsultant\u00a0Obstetrician\u00a0&\u00a0Gynaecologist\nPantai\u00a0Hospital\u00a0Kuala\u00a0Lumpur\nAssoc\u00a0Professor\u00a0Dr\u00a0Mohammad\u00a0Hassan\u00a0Shukur\nConsultant\u00a0Orthopaedic\u00a0and\u00a0Trauma\u00a0Surgeon\nHospital\u00a0Universiti\u00a0Kebangsaan\u00a0Malaysia\nDr\u00a0Santhi\u00a0Datuk\u00a0Puvanarajah\nConsultant\u00a0Neurologist\nHospital\u00a0Kuala\u00a0Lumpur\nDr\u00a0Shanti\u00a0Rudra\u00a0Deva\nConsultant\u00a0Intensivist\nHospital\u00a0Kuala\u00a0Lumpur\nProfessor\u00a0Dr\u00a0Woo\u00a0Yin\u00a0Ling\nConsultant\u00a0Obstetrician\u00a0&\u00a0Gynaecologist\nUniversity\u00a0Malaya\u00a0Medical\u00a0Center\nREVIEW\u00a0COMMITTEE\nThe\u00a0draft\u00a0of\u00a0these\u00a0guidelines\u00a0are\u00a0reviewed\u00a0by\u00a0a\u00a0panel\u00a0of\u00a0independent\u00a0expert\nreferees\u00a0 from\u00a0 both\u00a0 public\u00a0 and\u00a0 private\u00a0 sectors,\u00a0 who\u00a0 were\u00a0 asked\u00a0 to\u00a0 comment\nprimarily\u00a0 on\u00a0 the\u00a0 comprehensiveness\u00a0 and\u00a0 accuracy\u00a0 of\u00a0 interpretation\u00a0 of\u00a0 the\nevidence\u00a0supporting\u00a0the\u00a0recommendations\u00a0in\u00a0the\u00a0guidelines.", "chunk_order": 1}
{"chunk_id": "2a823c14-6eb1-4b84-845c-e85aa8dc36cf", "source_document_filename": "CPG Prevention and Treatment of Venous Thrombosis_cleaned_ultra_minimal.txt", "source_document_title": "CPG Prevention and Treatment of Venous Thrombosis cleaned ultra minimal", "text": "Chairman\nDr\u00a0Chang\u00a0Kian\u00a0Meng\nHead\u00a0of\u00a0Haematology\u00a0&\u00a0Consultant\u00a0Haematologist\nDepartment\u00a0of\u00a0Haematology\nAmpang\u00a0Hospital\nMembers\u00a0(in\u00a0alphabetical\u00a0order)\nDr\u00a0Fitzgerald\u00a0Henry\nHead\u00a0of\u00a0Surgery\u00a0&\u00a0Consultant\u00a0Surgeon\nDepartment\u00a0of\u00a0Surgery\nSelayang\u00a0Hospital\nDr\u00a0Jay\u00a0Suriar\nConsultant\u00a0haematologist\nDepartment\u00a0of\u00a0Haematology\nAmpang\u00a0Hospital\nDr\u00a0Kauthaman\u00a0a/l\u00a0Mahendran\nHead\u00a0of\u00a0Medicine\nConsultant\u00a0Physician\nDepartment\u00a0of\u00a0Medicine\nMalacca\u00a0Hospital\nDr\u00a0Liew\u00a0Nyan\u00a0Chin\nMedical\u00a0Officer\nDepartment\u00a0of\u00a0Obstetrics\u00a0&\u00a0Gynaecology\nAmpang\u00a0Hospital\nDr\u00a0Muralitharan\u00a0Ganesalingam\nConsultant\u00a0Obstetrics\u00a0&\u00a0Gynaecology\nHead\u00a0of\u00a0Department\nDepartment\u00a0of\u00a0Obstetrics\u00a0&\u00a0Gynaecology\nAmpang\u00a0Hospital\nDr\u00a0Salmiah\u00a0Md\u00a0Shariff\nFamily\u00a0Medicine\u00a0Specialist\nBatu\u00a09,\u00a0Cheras\u00a0Health\u00a0Clinic\nDr\u00a0Shekhar\u00a0Krishnan\nConsultant\u00a0Paediatric\u00a0Haematologist\nDepartment\u00a0of\u00a0Paediatrics\nUniversity\u00a0Malaya\u00a0Medical\u00a0Center\nDr\u00a0Wan\u00a0Hamilton\u00a0bt\u00a0Wan\u00a0Hassan\nHead\u00a0and\u00a0Consultant\u00a0Obstetrician\u00a0&\u00a0Gynaecologist\nDepartment\u00a0of\u00a0Obstetrics\u00a0&\u00a0Gynaecology\nSerdang\u00a0Hospital\nDr\u00a0Wong\u00a0Jun\u00a0Ching\nMedical\u00a0Officer\nDepartment\u00a0of\u00a0Obstetrics\u00a0&\u00a0Gynaecology\nAmpang\u00a0Hospital\nDr\u00a0Zaharah\u00a0Musa\nHead\u00a0of\u00a0Radiology\u00a0&\u00a0Consultant\u00a0Radiologist\nDepartment\u00a0of\u00a0Diagnostic\u00a0Imaging\nHospital\u00a0Selayang\nDr\u00a0Zainal\u00a0Ariffin\u00a0Azizi\nHead\u00a0of\u00a0Surgery\u00a0&\u00a0Consultant\u00a0Vascular\u00a0Surgeon\nDepartment\u00a0of\u00a0Surgery\nHospital\u00a0Kuala\u00a0Lumpur\nEXTERNAL\u00a0REVIEWERS\nThe\u00a0following\u00a0external\u00a0reviewers\u00a0provided\u00a0feedback\u00a0on\u00a0the\u00a0draft. Professor\u00a0Mike\u00a0A\u00a0Laffan\nProfessor\u00a0of\u00a0Haemostasis\u00a0&\u00a0Thrombosis\nDepartment\u00a0of\u00a0Medicine\nImperial\u00a0College,\u00a0United\u00a0Kingdom\nProfessor\u00a0John\u00a0Andrew\u00a0Murie\nSenior\u00a0Consultant\u00a0Vascular\u00a0Surgeon,\u00a0Royal\u00a0Infirmary\u00a0of\u00a0Edinburgh\nHonorary\u00a0Senior\u00a0Lecturer\u00a0University\u00a0of\u00a0Edinburgh\u00a0Medical\u00a0School\nAdjunct\u00a0Professor,\u00a0Universiti\u00a0Kebangsaan\u00a0Malaysia\nProfessor\u00a0Paul\u00a0Monagle\nHead\u00a0and\u00a0Consultant\u00a0Paediatric\u00a0Haematologist\nDepartment\u00a0of\u00a0Paediatrics\nThe\u00a0University\u00a0of\u00a0Melbourne\nRoyal\u00a0Children\u2019s\u00a0Hospital\nVictoria,\u00a0Australia\nCLINICAL\u00a0PATHWAYS\nPATHWAY\u00a01:\u00a0THROMBOPROPHYLAXIS1\nName\u00a0of\u00a0Assessor:\nDate:\nThromboprophylaxis\u00a0in\u00a0Hospitalised\nPatients\nMinistry\u00a0of\u00a0Health\nMalaysia\nNAME:\nDOB:\nSEX:\nHOSPITAL\u00a0NO. IC\u00a0NO. 1. Patient\u00a0information\n2. Assess\u00a0the\u00a0risk\u00a0for\u00a0VTE\u00a0and\u00a0the\u00a0risk\u00a0for\u00a0bleeding\n3. Risk\u00a0factors\u00a0for\u00a0VTE\nv\u00a0 Assess\u00a0all\u00a0patients\u00a0on\u00a0admission\u00a0to\u00a0identify:\n\u0001\nt\u00a0those\u00a0who\u00a0are\u00a0at\u00a0increased\u00a0risk\u00a0of\u00a0VTE\n\u0001\nt\u00a0those\u00a0who\u00a0are\u00a0at\u00a0increased\u00a0risk\u00a0of\u00a0bleeding\nv\u00a0 Reassess\u00a0patients\u2019\u00a0risks\u00a0of\u00a0VTE\u00a0and\u00a0bleeding\u00a0within\u00a024\u00a0hours\u00a0of\nadmission\u00a0and\u00a0whenever\u00a0the\u00a0clinical\u00a0situation\u00a0changes\nv\u00a0 Weigh\u00a0the\u00a0risk\u00a0of\u00a0VTE\u00a0against\u00a0the\u00a0risk\u00a0of\u00a0bleeding\nv\u00a0 Active\u00a0cancer\u00a0! v\u00a0 Age\u00a0>60\u00a0years\u00a0! v\u00a0 Dehydration\u00a0! v\u00a0 Critical\u00a0care\u00a0admission\u00a0! v\u00a0 Obesity\u00a0(BMI\u00a0>30\u00a0kg/m2)\u00a0! v\u00a0 Use\u00a0of\u00a0oestrogen\u00adcontaining\u00a0oral\u00a0contraceptive\u00a0pill\u00a0! v\u00a0 Use\u00a0of\u00a0Hormone\u00a0Replacement\u00a0Therapy\u00a0! v\u00a0 Post\u00adpartum\u00a0(within\u00a06\u00a0weeks)\u00a0! v\u00a0 Previous\u00a0VTE\u00a0! v\u00a0 Family\u00a0h/o\u00a0VTE\u00a0! v\u00a0 One\u00a0or\u00a0more\u00a0significant\u00a0medical\u00a0comorbidities:\n\"\u00a0 Heart\u00a0disease\u00a0! \"\u00a0 Metabolic,\u00a0endocrine\u00a0or\u00a0respiratory\u00a0pathologies\u00a0! # \"\u00a0 Acute\u00a0infectious\u00a0disease\u00a0! # \"\u00a0 Inflammatory\u00a0conditions\u00a0! # \"\u00a0 Sickle\u00a0cell\u00a0disease\u00a0! # \"\u00a0 Thalassaemia\u00a0! v\u00a0 Varicose\u00a0veins\u00a0with\u00a0phlebitis\u00a0! v\u00a0 Active\u00a0bleeding\u00a0! v\u00a0 Acquired\u00a0bleeding\u00a0disorders\u00a0(such\u00a0as\u00a0acute\u00a0liver\u00a0failure)\u00a0! v\u00a0 Concurrent\u00a0use\u00a0of\u00a0anticoagulants\u00a0(e.g. warfarin\u00a0with\u00a0INR\u00a0>2.0)\u00a0! v\u00a0 Lumbar\u00a0puncture/epidural/spinal\u00a0anaesthesia\u00a0expected\u00a0within\u00a0the\u00a0next\n12\u00a0hours\u00a0! v\u00a0 Lumbar\u00a0puncture/epidural/spinal\u00a0anaesthesia\u00a0within\u00a0the\u00a0previous\n4\u00a0hours\u00a0! v\u00a0 Acute\u00a0stroke\u00a0!", "chunk_order": 2}
{"chunk_id": "ba1cb796-e747-4b0f-b6ce-91df45aa5c42", "source_document_filename": "CPG Prevention and Treatment of Venous Thrombosis_cleaned_ultra_minimal.txt", "source_document_title": "CPG Prevention and Treatment of Venous Thrombosis cleaned ultra minimal", "text": "v\u00a0 Family\u00a0h/o\u00a0VTE\u00a0! v\u00a0 One\u00a0or\u00a0more\u00a0significant\u00a0medical\u00a0comorbidities:\n\"\u00a0 Heart\u00a0disease\u00a0! \"\u00a0 Metabolic,\u00a0endocrine\u00a0or\u00a0respiratory\u00a0pathologies\u00a0! # \"\u00a0 Acute\u00a0infectious\u00a0disease\u00a0! # \"\u00a0 Inflammatory\u00a0conditions\u00a0! # \"\u00a0 Sickle\u00a0cell\u00a0disease\u00a0! # \"\u00a0 Thalassaemia\u00a0! v\u00a0 Varicose\u00a0veins\u00a0with\u00a0phlebitis\u00a0! v\u00a0 Active\u00a0bleeding\u00a0! v\u00a0 Acquired\u00a0bleeding\u00a0disorders\u00a0(such\u00a0as\u00a0acute\u00a0liver\u00a0failure)\u00a0! v\u00a0 Concurrent\u00a0use\u00a0of\u00a0anticoagulants\u00a0(e.g. warfarin\u00a0with\u00a0INR\u00a0>2.0)\u00a0! v\u00a0 Lumbar\u00a0puncture/epidural/spinal\u00a0anaesthesia\u00a0expected\u00a0within\u00a0the\u00a0next\n12\u00a0hours\u00a0! v\u00a0 Lumbar\u00a0puncture/epidural/spinal\u00a0anaesthesia\u00a0within\u00a0the\u00a0previous\n4\u00a0hours\u00a0! v\u00a0 Acute\u00a0stroke\u00a0! v\u00a0 Uncontrolled\u00a0systolic\u00a0hypertension\u00a0(230/120\u00a0mmHg\u00a0or\u00a0higher)\u00a0! v\u00a0 Untreated\u00a0inherited\u00a0bleeding\u00a0disorder\u00a0! (e.g. haemophilia\u00a0or\u00a0von\u00a0Willebrand\u00a0disease)\nv\u00a0 Regard\u00a0medical\u00a0patients\u00a0as\u00a0being\u00a0at\u00a0increased\u00a0risk\u00a0of\u00a0VTE\u00a0if\u00a0they:\nt\u00a0have\u00a0had\u00a0or\u00a0are\u00a0expected\u00a0to\u00a0have\u00a0significantly\u00a0reduced\u00a0mobility\n\"\n\" #$%\"&'\"()*+\",-\nt\u00a0are\u00a0expected\u00a0to\u00a0have\u00a0ongoing\u00a0reduced\u00a0mobility\u00a0relative\u00a0to\u00a0their\u00a0normal\nstate\u00a0AND\n\u0001\nt\u00a0have\u00a0one\u00a0or\u00a0more\u00a0of\u00a0the\u00a0risk\u00a0factors\u00a0for\u00a0VTE\nv\u00a0 Regard\u00a0surgical\u00a0patients\u00a0and\u00a0patients\u00a0with\u00a0trauma\u00a0as\u00a0being\u00a0at\u00a0increased\nrisk\u00a0of\u00a0VTE\u00a0if\u00a0they\u00a0meet\u00a0one\u00a0of\u00a0the\u00a0following\u00a0criteria:\nt\u00a0Surgical\u00a0procedure\u00a0with\u00a0a\u00a0total\u00a0anaesthetic\u00a0and\u00a0surgical\u00a0time\u00a0of\n>90\u00a0minutes,\u00a0or\u00a060\u00a0minutes\u00a0if\u00a0the\u00a0surgery\u00a0involves\u00a0the\u00a0pelvis\u00a0or\nlower\u00a0limb\nt\u00a0Acute\u00a0surgical\u00a0admission\u00a0with\u00a0inflammatory\u00a0or\u00a0intra\u00adabdominal\ncondition\n\u0001\nt\u00a0Expected\u00a0significant\u00a0reduction\u00a0in\u00a0mobility\n\u0001\nt\u00a0One\u00a0or\u00a0more\u00a0of\u00a0the\u00a0risk\u00a0factors\u00a0for\u00a0VTE\n4. Risk\u00a0factors\u00a0for\u00a0bleeding\n5. Hospitalised\u00a0Patients\u00a0at\u00a0increased\u00a0Risk\u00a0for\u00a0VTE\nMedical\u00a0patients\nSurgical\u00a0&\u00a0trauma\u00a0patients\n6. Methods\u00a0for\u00a0VTE\u00a0prophylaxis\nA. Mechanical\nAnti\u00adembolism\u00a0stockings\u00a0(thigh\u00a0or\u00a0knee\u00a0length)\nv\u00a0 Base\u00a0the\u00a0choice\u00a0of\u00a0mechanical\u00a0VTE\u00a0prophylaxis\u00a0on\u00a0individual\u00a0patient\nfactors\u00a0including\u00a0clinical\u00a0condition,\u00a0surgical\u00a0procedure,\u00a0patient\u00a0preference\nand\u00a0if\u00a0bleeding\u00a0risk\u00a0outweighs\u00a0the\u00a0risk\u00a0of\u00a0VTE\nv\u00a0 Choose\u00a0any\u00a0one\u00a0of:\n# \"\u00a0 Anti\u00adembolism\u00a0stockings\u00a0! # \"\u00a0 Foot\u00a0impulse\u00a0devices\u00a0! # \"\u00a0 Intermittent\u00a0pneumatic\u00a0compression\u00a0devices\u00a0! v\u00a0 Do\u00a0not\u00a0offer\u00a0anti\u00adembolism\u00a0stockings\u00a0to\u00a0patients\u00a0who\u00a0have:\n# \"\u00a0 Suspected\u00a0or\u00a0proven\u00a0peripheral\u00a0artery\u00a0disease\n# \"\u00a0 Peripheral\u00a0arterial\u00a0bypass\u00a0grafting\n# \"\u00a0 Peripheral\u00a0neuropathy\n# \"\u00a0 Any\u00a0local\u00a0conditions\u00a0in\u00a0which\u00a0stockings\u00a0may\u00a0cause\u00a0damage\u00a0e.g.", "chunk_order": 3}
{"chunk_id": "ff0a4c7d-8d5d-4790-b082-258a1d99102e", "source_document_filename": "CPG Prevention and Treatment of Venous Thrombosis_cleaned_ultra_minimal.txt", "source_document_title": "CPG Prevention and Treatment of Venous Thrombosis cleaned ultra minimal", "text": "Mechanical\nAnti\u00adembolism\u00a0stockings\u00a0(thigh\u00a0or\u00a0knee\u00a0length)\nv\u00a0 Base\u00a0the\u00a0choice\u00a0of\u00a0mechanical\u00a0VTE\u00a0prophylaxis\u00a0on\u00a0individual\u00a0patient\nfactors\u00a0including\u00a0clinical\u00a0condition,\u00a0surgical\u00a0procedure,\u00a0patient\u00a0preference\nand\u00a0if\u00a0bleeding\u00a0risk\u00a0outweighs\u00a0the\u00a0risk\u00a0of\u00a0VTE\nv\u00a0 Choose\u00a0any\u00a0one\u00a0of:\n# \"\u00a0 Anti\u00adembolism\u00a0stockings\u00a0! # \"\u00a0 Foot\u00a0impulse\u00a0devices\u00a0! # \"\u00a0 Intermittent\u00a0pneumatic\u00a0compression\u00a0devices\u00a0! v\u00a0 Do\u00a0not\u00a0offer\u00a0anti\u00adembolism\u00a0stockings\u00a0to\u00a0patients\u00a0who\u00a0have:\n# \"\u00a0 Suspected\u00a0or\u00a0proven\u00a0peripheral\u00a0artery\u00a0disease\n# \"\u00a0 Peripheral\u00a0arterial\u00a0bypass\u00a0grafting\n# \"\u00a0 Peripheral\u00a0neuropathy\n# \"\u00a0 Any\u00a0local\u00a0conditions\u00a0in\u00a0which\u00a0stockings\u00a0may\u00a0cause\u00a0damage\u00a0e.g. dermatitis,\u00a0gangrene,\u00a0recent\u00a0skin\u00a0graft\n\"\u00a0 Known\u00a0allergy\u00a0to\u00a0material\n# \"\u00a0 Cardiac\u00a0failure\n# \"\u00a0 Severe\u00a0leg\u00a0oedema\n# \"\u00a0 Unusual\u00a0leg\u00a0size\n# \"\u00a0 Major\u00a0limb\u00a0deformity\nv\u00a0 Use\u00a0stockings\u00a0that\u00a0provide\u00a0graduated\u00a0compression\u00a0and\u00a0produce\u00a0a\u00a0calf\npressure\u00a0of\u00a014\u00a0\u00ad\u00a015\u00a0mmHg\nv\u00a0 Encourage\u00a0patients\u00a0to\u00a0wear\u00a0their\u00a0stockings\u00a0day\u00a0and\u00a0night\u00a0until\u00a0they\u00a0no\nlonger\u00a0have\u00a0significantly\u00a0reduced\u00a0mobility\nv\u00a0 Remove\u00a0stockings\u00a0daily\u00a0for\u00a0hygiene\u00a0purposes\u00a0and\u00a0to\u00a0inspect\u00a0skin\nv\u00a0 Encourage\u00a0patient\u00a0to\u00a0use\u00a0foot\u00a0devices\u00a0both\u00a0in\u00a0bed\u00a0and\u00a0when\u00a0sitting\u00a0in\na\u00a0chair\nFoot\u00a0impulse\u00a0devices\nv\u00a0 Encourage\u00a0patient\u00a0to\u00a0use\u00a0IPC\u00a0devices\u00a0for\u00a0as\u00a0much\u00a0time\u00a0as\u00a0possible\u00a0both\nin\u00a0bed\u00a0and\u00a0when\u00a0sitting\u00a0in\u00a0a\u00a0chair\nIntermittent\u00a0pneumatic\u00a0compression\u00a0devices\u00a0(thigh\u00a0or\u00a0knee\u00a0length)\nv\u00a0 Base\u00a0the\u00a0choice\u00a0of\u00a0pharmacological\u00a0VTE\u00a0agents\u00a0on\u00a0individual\u00a0patient\nfactors,\u00a0including\u00a0clinical\u00a0condition\u00a0and\u00a0patient\u00a0preferences\nB. Pharmacological\nv\u00a0 Choose\u00a0any\u00a0one\u00a0of:\n# \"\u00a0 Low\u00a0molecular\u00a0weight\u00a0heparin\u00a0SC\u00a0! # \"\u00a0 Fondaparinux\u00a0sodium\u00a0SC\u00a0! # \"\u00a0 Rivaroxaban\u00a0PO\u00a0(at\u00a0present,\u00a0licensed\u00a0for\u00a0THR\u00a0and\u00a0TKR)\u00a0! # \"\u00a0 Dabigatran\u00a0etexilate\u00a0PO\u00a0(at\u00a0present,\u00a0licensed\u00a0for\u00a0THR\u00a0and\u00a0TKR)\u00a0! # \"\u00a0 Unfractionated\u00a0heparin\u00a0SC\u00a0! v\u00a0 Choose\u00a0either:\n# \"\u00a0 Enoxaparin\u00a0! \uf020\uf020t\u0001Enoxaparin\u00a040\u00a0mg\u00a0daily\u00a0or\n\u0001\n\u0001\nt\u00a0Enoxaparin\u00a020\u00a0mg\u00a0daily\u00a0(for\u00a0moderate\u00a0renal\u00a0impairment\u00a0with\u00a0eGFR\n15\u00a0\u00ad\u00a030\u00a0mL/min/1.73/m2)\n# \"\u00a0 Tinzaparin\u00a0! \uf020\uf020t\u0001Tinzaparin\u00a03500\u00a0units\u00a0daily\u00a0(lower\u00a0VTE\u00a0risk\u00a0or\u00a0moderate\nrenal\u00a0impairment)\u00a0or\n\u0001\n\u0001\nt\u00a0Tinzaparin\u00a04500\u00a0units\u00a0daily\u00a0(higher\u00a0VTE\u00a0risk\u00a0e.g. hip\u00a0or\u00a0knee\nsurgery\u00a0or\u00a0during\u00a0pregnancy)\nLow\u00a0molecular\u00a0weight\u00a0heparin\n\"\u00a0 Fondaparinux\u00a0! \uf020\uf020t\u0001Starting\u00a0dose\u00a0at\u00a02.5\u00a0mg\u00a0(6\u00a0hours\u00a0after\u00a0surgery)\u00a0followed\u00a0by\n2.5\u00a0mg\u00a0daily\n\uf020\uf020t\u0001Contraindicated\u00a0in\u00a0severe\u00a0renal\u00a0impairment\n(eGFR\u00a0<30\u00a0mL/min/1.73/m2)\nFondaparinux\u00a0sodium\n\"\u00a0 Rivaroxaban\u00a0! \uf020\uf020t\u00a0Starting\u00a0dose\u00a0at\u00a010\u00a0mg\u00a0(6\u00a0\u00ad\u00a010\u00a0hours\u00a0after\u00a0surgery)\u00a0followed\u00a0by\n10\u00a0mg\u00a0daily\n\uf020\uf020t\u0001No\u00a0dose\u00a0adjustment\u00a0in\u00a0renal\u00a0impairment\u00a0with\u00a0prophylactic\u00a0dose\nRivaroxaban\n\"\u00a0 Dabigatran\u00a0! \uf020\uf020t\u00a0Starting\u00a0dose\u00a0at\u00a0110\u00a0mg\u00a0(1\u00a0\u00ad\u00a04\u00a0hours\u00a0after\u00a0surgery)\u00a0followed\u00a0by\n220\u00a0mg\u00a0daily\n\uf020\uf020t\u0001For\u00a0elderly\u00a0>75\u00a0years,\u00a0moderate\u00a0renal\u00a0impairment:\u00a075\u00a0mg\u00a0starting\ndose,\u00a0followed\u00a0by\u00a0150\u00a0mg\u00a0daily\nDabigatran\u00a0etexilate\nv\u00a0 Choose\u00a0UFH\u00a0for\u00a0patients\u00a0with\u00a0severe\u00a0renal\u00a0impairment\n(eGFR\u00a0<15\u00a0mL/min/1.73/m2)\n# \"\u00a0 UFH\u00a0dose\u00a0is\u00a05000\u00a0units\u00a0bd\u00a0!", "chunk_order": 4}
{"chunk_id": "95fc5a1e-03b7-4905-820d-1692aab8002f", "source_document_filename": "CPG Prevention and Treatment of Venous Thrombosis_cleaned_ultra_minimal.txt", "source_document_title": "CPG Prevention and Treatment of Venous Thrombosis cleaned ultra minimal", "text": "\uf020\uf020t\u00a0Starting\u00a0dose\u00a0at\u00a010\u00a0mg\u00a0(6\u00a0\u00ad\u00a010\u00a0hours\u00a0after\u00a0surgery)\u00a0followed\u00a0by\n10\u00a0mg\u00a0daily\n\uf020\uf020t\u0001No\u00a0dose\u00a0adjustment\u00a0in\u00a0renal\u00a0impairment\u00a0with\u00a0prophylactic\u00a0dose\nRivaroxaban\n\"\u00a0 Dabigatran\u00a0! \uf020\uf020t\u00a0Starting\u00a0dose\u00a0at\u00a0110\u00a0mg\u00a0(1\u00a0\u00ad\u00a04\u00a0hours\u00a0after\u00a0surgery)\u00a0followed\u00a0by\n220\u00a0mg\u00a0daily\n\uf020\uf020t\u0001For\u00a0elderly\u00a0>75\u00a0years,\u00a0moderate\u00a0renal\u00a0impairment:\u00a075\u00a0mg\u00a0starting\ndose,\u00a0followed\u00a0by\u00a0150\u00a0mg\u00a0daily\nDabigatran\u00a0etexilate\nv\u00a0 Choose\u00a0UFH\u00a0for\u00a0patients\u00a0with\u00a0severe\u00a0renal\u00a0impairment\n(eGFR\u00a0<15\u00a0mL/min/1.73/m2)\n# \"\u00a0 UFH\u00a0dose\u00a0is\u00a05000\u00a0units\u00a0bd\u00a0! v\u00a0 Patients\u00a0who\u00a0are\u00a0to\u00a0receive\u00a0any\u00a0heparin\u00a0should\u00a0have\u00a0a\u00a0baseline\nplatelet\u00a0count\nv\u00a0 Post\u00adoperative\u00a0patients,\u00a0including\u00a0obstetric\u00a0cases,\u00a0receiving\u00a0UFH\u00a0should\nhave\u00a0platelet\u00a0count\u00a0monitoring\u00a0performed\u00a0every\u00a02\u00a0\u00ad\u00a03\u00a0days\u00a0from\u00a0days\n4\u00a0to\u00a014\u00a0until\u00a0heparin\u00a0is\u00a0stopped\nv\u00a0 Post\u00adcardiopulmonary\u00a0bypass\u00a0patients\u00a0receiving\u00a0LMWH\u00a0should\u00a0have\nplatelet\u00a0count\u00a0monitoring\u00a0performed\u00a0every\u00a02\u00a0\u00ad\u00a03\u00a0days\u00a0from\u00a0days\u00a04\u00a0to\u00a014\nuntil\u00a0heparin\u00a0is\u00a0stopped\nv\u00a0 Post\u00adoperative\u00a0patients\u00a0(other\u00a0than\u00a0cardiopulmonary\u00a0bypass\u00a0patients)\nreceiving\u00a0LMWH\u00a0do\u00a0not\u00a0need\u00a0routine\u00a0platelet\u00a0monitoring\nv\u00a0 Post\u00adoperative\u00a0patients\u00a0and\u00a0cardiopulmonary\u00a0bypass\u00a0patients\u00a0who\u00a0have\nbeen\u00a0exposed\u00a0to\u00a0heparin\u00a0in\u00a0the\u00a0previous\u00a0100\u00a0days\u00a0and\u00a0are\u00a0receiving\u00a0any\ntype\u00a0of\u00a0heparin\u00a0should\u00a0have\u00a0a\u00a0platelet\u00a0count\u00a0determined\u00a024\u00a0hours\u00a0after\nstarting\u00a0heparin\nv\u00a0 Medical\u00a0patients\u00a0and\u00a0obstetric\u00a0patients\u00a0receiving\u00a0heparin\u00a0do\u00a0not\u00a0need\nroutine\u00a0platelet\u00a0monitoring\nGeneral\u00a0medical\u00a0patients\nv\u00a0 Offer\u00a0pharmacological\u00a0VTE\u00a0prophylaxis\nv\u00a0 Start\u00a0pharmacological\u00a0VTE\u00a0prophylaxis\u00a0as\u00a0soon\u00a0as\u00a0possible\u00a0after\u00a0risk\nassessment\nv\u00a0 Continue\u00a0until\u00a0patient\u00a0is\u00a0no\u00a0longer\u00a0at\u00a0risk\u00a0of\u00a0VTE\nPatients\u00a0with\u00a0stroke\nv\u00a0 Do\u00a0not\u00a0offer\u00a0anti\u00adembolism\u00a0stockings\u00a0for\u00a0VTE\u00a0prophylaxis\u00a0to\u00a0patients\nwho\u00a0are\u00a0admitted\u00a0for\u00a0stroke\nv\u00a0 Consider\u00a0prophylactic\u00addose\u00a0LMWH\u00a0if\u00a0a\u00a0haemorrhagic\u00a0stroke\u00a0has\u00a0been\nexcluded\u00a0and\u00a0the\u00a0risk\u00a0of\u00a0bleeding\u00a0is\u00a0low\nv\u00a0 Until\u00a0the\u00a0patient\u00a0can\u00a0have\u00a0pharmacological\u00a0VTE\u00a0prophylaxis\u00a0consider\na\u00a0foot\u00a0impulse\u00a0or\u00a0IPC\u00a0device\nUnfractionated\u00a0heparin\n7. Monitoring\u00a0platelet\u00a0counts\n8.", "chunk_order": 5}
{"chunk_id": "67d73eb3-3beb-494f-bf46-e89749f33045", "source_document_filename": "CPG Prevention and Treatment of Venous Thrombosis_cleaned_ultra_minimal.txt", "source_document_title": "CPG Prevention and Treatment of Venous Thrombosis cleaned ultra minimal", "text": "Monitoring\u00a0platelet\u00a0counts\n8. Using\u00a0VTE\u00a0prophylaxis\u00a0in\u00a0hospitalised\u00a0patients\nPatients\u00a0with\u00a0cancer\nv\u00a0 Offer\u00a0pharmacological\u00a0VTE\u00a0prophylaxis\u00a0and\u00a0continue\u00a0until\u00a0the\u00a0patient\nis\u00a0no\u00a0longer\u00a0at\u00a0increased\u00a0risk\u00a0of\u00a0VTE\nPatients\u00a0in\u00a0palliative\u00a0care\nv\u00a0 Consider\u00a0pharmacological\u00a0VTE\u00a0prophylaxis\u00a0in\u00a0patients\u00a0who\u00a0have\npotentially\u00a0reversible\u00a0acute\u00a0pathology\nv\u00a0 Do\u00a0not\u00a0routinely\u00a0offer\u00a0pharmacological\u00a0or\u00a0mechanical\u00a0VTE\u00a0prophylaxis\nto\u00a0patients\u00a0admitted\u00a0for\u00a0terminal\u00a0care\nAll\u00a0surgical\u00a0patients\nv\u00a0 Assess\u00a0the\u00a0risks\u00a0and\u00a0benefits\u00a0of\u00a0stopping\u00a0pre\u00adexisting\u00a0established\nantiplatelet\u00a0therapy\u00a01\u00a0week\u00a0before\u00a0surgery\nv\u00a0 Consider\u00a0regional\u00a0anaesthesia\u00a0for\u00a0individual\u00a0patients\u00a0as\u00a0it\u00a0carries\u00a0a\nlower\u00a0risk\u00a0of\u00a0VTE\u00a0than\u00a0general\u00a0anaesthesia\nv\u00a0 If\u00a0regional\u00a0anaesthesia\u00a0is\u00a0used,\u00a0plan\u00a0the\u00a0timing\u00a0of\u00a0pharmacological\nVTE\u00a0prophylaxis\u00a0to\u00a011\u00a0inimize\u00a0the\u00a0risk\u00a0of\u00a0epidural\u00a0haematoma\nv\u00a0 Continue\u00a0pharmacological\u00a0VTE\u00a0prophylaxis\u00a0until\u00a0the\u00a0patient\u00a0no\u00a0longer\nhas\u00a0significantly\u00a0reduced\u00a0mobility\u00a0(generally\u00a05\u00a0\u00ad\u00a07\u00a0days)\nCardiac\u00a0surgery\nv\u00a0 Start\u00a0mechanical\u00a0VTE\u00a0prophylaxis\nv\u00a0 Add\u00a0pharmacological\u00a0VTE\u00a0prophylaxis\u00a0for\u00a0patients\u00a0who\u00a0have\u00a0a\nlow\u00a0risk\u00a0of\u00a0bleeding\nGastrointestinal,\u00a0gynaecological,\u00a0thoracic\u00a0and\u00a0urological\u00a0surgery\nv\u00a0 Start\u00a0mechanical\u00a0VTE\u00a0prophylaxis\nv\u00a0 Add\u00a0pharmacological\u00a0VTE\u00a0prophylaxis\u00a0for\u00a0patients\u00a0who\u00a0have\u00a0a\nlow\u00a0risk\u00a0of\u00a0bleeding\nv\u00a0 Extend\u00a0pharmacological\u00a0VTE\u00a0prophylaxis\u00a0to\u00a028\u00a0days\u00a0post\u00adoperatively\nfor\u00a0patients\u00a0who\u00a0have\u00a0had\u00a0major\u00a0cancer\u00a0surgery\u00a0in\u00a0the\u00a0abdomen\nor\u00a0pelvis\nNeurological\u00a0(cranial\u00a0or\u00a0spinal)\u00a0surgery\nv\u00a0 Start\u00a0mechanical\u00a0VTE\u00a0prophylaxis\nv\u00a0 Add\u00a0pharmacological\u00a0VTE\u00a0prophylaxis\u00a0for\u00a0patients\u00a0who\u00a0have\u00a0a\nlow\u00a0risk\u00a0of\u00a0bleeding\nv\u00a0 Do\u00a0not\u00a0offer\u00a0pharmacological\u00a0VTE\u00a0prophylaxis\u00a0to\u00a0patients\u00a0with\nt\u00a0ruptured\u00a0cranial\u00a0or\u00a0spinal\u00a0vascular\u00a0malformations\u00a0or\nt\u00a0acute\u00a0traumatic\u00a0or\u00a0non\u00adtraumatic\u00a0haemorrhage\u00a0until\u00a0the\u00a0lesion\u00a0has\nbeen\u00a0secured\u00a0or\u00a0the\u00a0condition\u00a0is\u00a0stable\nOrthopaedic\u00a0surgery\nv\u00a0 Offer\u00a0combined\u00a0VTE\u00a0prophylaxis\u00a0with\u00a0mechanical\u00a0and\npharmacological\u00a0methods\u00a0for\u00a0lower\u00a0limb\u00a0surgery\nv\u00a0 Do\u00a0not\u00a0routinely\u00a0offer\u00a0VTE\u00a0prophylaxis\u00a0to\u00a0patients\u00a0undergoing\u00a0upper\nlimb\u00a0surgery\n\"\u00a0 Start\u00a0mechanical\u00a0VTE\u00a0prophylaxis\u00a0at\u00a0admission\u00a0and\u00a0continue\u00a0until\u00a0the\npatient\u00a0no\u00a0longer\u00a0has\u00a0significantly\u00a0reduced\u00a0mobility\n# \"\u00a0 Start\u00a0pharmacological\u00a0VTE\u00a0prophylaxis\u00a0after\u00a0surgery. Choose\u00a0any\u00a0one\u00a0of:\nt\u00a0LMWH:\u00a0starting\u00a06\u00a0\u00ad\u00a012\u00a0hours\u00a0after\u00a0surgery\u00a0! t\u00a0Fondaparinux:\u00a0starting\u00a06\u00a0hours\u00a0after\u00a0surgical\u00a0closure,\u00a0provided\nhaemostasis\u00a0has\u00a0been\u00a0established\u00a0! \u0001\n\u0001\nt\u0001Rivaroxaban:\u00a0starting\u00a06\u00a0\u00ad\u00a010\u00a0hours\u00a0after\u00a0surgery\u00a0! t\u00a0Dabigatran\u00a0etexilate:\u00a0starting\u00a01\u00a0\u00ad\u00a04\u00a0hours\u00a0after\u00a0surgery\u00a0! \"\u00a0 Continue\u00a0pharmacological\u00a0VTE\u00a0prophylaxis\u00a0for\u00a035\u00a0days\nElective\u00a0hip\u00a0replacement\n\"\u00a0 Start\u00a0mechanical\u00a0VTE\u00a0prophylaxis\u00a0at\u00a0admission\u00a0and\u00a0continue\u00a0until\u00a0the\npatient\u00a0no\u00a0longer\u00a0has\u00a0significantly\u00a0reduced\u00a0mobility\n# \"\u00a0 Start\u00a0pharmacological\u00a0VTE\u00a0prophylaxis\u00a0after\u00a0surgery. Choose\u00a0any\u00a0one\u00a0of:\nt\u00a0LMWH:\u00a0starting\u00a06\u00a0\u00ad\u00a012\u00a0hours\u00a0after\u00a0surgery\u00a0! t\u00a0Fondaparinux:\u00a0starting\u00a06\u00a0hours\u00a0after\u00a0surgical\u00a0closure,\u00a0provided\nhaemostasis\u00a0has\u00a0been\u00a0established\u00a0! t\u00a0Rivaroxaban:\u00a0starting\u00a06\u00a0\u00ad\u00a010\u00a0hours\u00a0after\u00a0surgery\u00a0! t\u00a0Dabigatran\u00a0etexilate:\u00a0starting\u00a01\u00a0\u00ad\u00a04\u00a0hours\u00a0after\u00a0surgery\u00a0! # \"\u00a0 Continue\u00a0pharmacological\u00a0VTE\u00a0prophylaxis\u00a0for\u00a035\u00a0days\nElective\u00a0knee\u00a0replacement\n\"\u00a0 Start\u00a0mechanical\u00a0VTE\u00a0prophylaxis\u00a0at\u00a0admission\n# \"\u00a0 Add\u00a0pharmacological\u00a0VTE\u00a0prophylaxis.", "chunk_order": 6}
{"chunk_id": "625f2105-d05e-4a39-aa56-ac8382c7d320", "source_document_filename": "CPG Prevention and Treatment of Venous Thrombosis_cleaned_ultra_minimal.txt", "source_document_title": "CPG Prevention and Treatment of Venous Thrombosis cleaned ultra minimal", "text": "Choose\u00a0any\u00a0one\u00a0of:\nt\u00a0LMWH:\u00a0starting\u00a06\u00a0\u00ad\u00a012\u00a0hours\u00a0after\u00a0surgery\u00a0! t\u00a0Fondaparinux:\u00a0starting\u00a06\u00a0hours\u00a0after\u00a0surgical\u00a0closure,\u00a0provided\nhaemostasis\u00a0has\u00a0been\u00a0established\u00a0! t\u00a0Rivaroxaban:\u00a0starting\u00a06\u00a0\u00ad\u00a010\u00a0hours\u00a0after\u00a0surgery\u00a0! t\u00a0Dabigatran\u00a0etexilate:\u00a0starting\u00a01\u00a0\u00ad\u00a04\u00a0hours\u00a0after\u00a0surgery\u00a0! # \"\u00a0 Continue\u00a0pharmacological\u00a0VTE\u00a0prophylaxis\u00a0for\u00a035\u00a0days\nElective\u00a0knee\u00a0replacement\n\"\u00a0 Start\u00a0mechanical\u00a0VTE\u00a0prophylaxis\u00a0at\u00a0admission\n# \"\u00a0 Add\u00a0pharmacological\u00a0VTE\u00a0prophylaxis. Choose\u00a0any\u00a0one\u00a0of:\nt\u00a0LMWH:\u00a0starting\u00a0at\u00a0admission,\u00a0stopping\u00a012\u00a0hours\u00a0before\u00a0surgery\u00a0and\nrestarting\u00a06\u00a0\u00ad\u00a012\u00a0hours\u00a0after\u00a0surgery\u00a0! t\u00a0Fondaparinux:\u00a0starting\u00a06\u00a0hours\u00a0after\u00a0surgical\u00a0closure. It\u00a0is\u00a0not\nrecommended\u00a0for\u00a0use\u00a0pre\u00adoperatively\u00a0for\u00a0patients\u00a0undergoing\u00a0hip\nfracture\u00a0surgery\u00a0!", "chunk_order": 7}
{"chunk_id": "b6d92b46-2d8a-4982-b1f8-6d4965c2528a", "source_document_filename": "CPG Prevention and Treatment of Venous Thrombosis_cleaned_ultra_minimal.txt", "source_document_title": "CPG Prevention and Treatment of Venous Thrombosis cleaned ultra minimal", "text": "Choose\u00a0any\u00a0one\u00a0of:\nt\u00a0LMWH:\u00a0starting\u00a0at\u00a0admission,\u00a0stopping\u00a012\u00a0hours\u00a0before\u00a0surgery\u00a0and\nrestarting\u00a06\u00a0\u00ad\u00a012\u00a0hours\u00a0after\u00a0surgery\u00a0! t\u00a0Fondaparinux:\u00a0starting\u00a06\u00a0hours\u00a0after\u00a0surgical\u00a0closure. It\u00a0is\u00a0not\nrecommended\u00a0for\u00a0use\u00a0pre\u00adoperatively\u00a0for\u00a0patients\u00a0undergoing\u00a0hip\nfracture\u00a0surgery\u00a0! # \"\u00a0 Continue\u00a0pharmacological\u00a0VTE\u00a0prophylaxis\u00a0for\u00a035\u00a0days\nHip\u00a0fracture\nVascular\u00a0surgery\nv\u00a0 Offer\u00a0VTE\u00a0prophylaxis\u00a0to\u00a0patients\u00a0undergoing\u00a0vascular\u00a0surgery\u00a0who\nare\u00a0not\u00a0having\u00a0other\u00a0anticoagulant\u00a0therapy\u00a0and\u00a0are\u00a0assessed\u00a0to\u00a0be\u00a0at\nincreased\u00a0risk\u00a0of\u00a0VTE\nv\u00a0 Start\u00a0mechanical\u00a0VTE\u00a0prophylaxis\nv\u00a0 Add\u00a0pharmacological\u00a0VTE\u00a0prophylaxis\u00a0for\u00a0patients\u00a0who\u00a0have\u00a0a\nlow\u00a0risk\u00a0of\u00a0bleeding\nv\u00a0 Continue\u00a0pharmacological\u00a0VTE\u00a0prophylaxis\u00a0until\u00a0the\u00a0patient\u00a0no\u00a0longer\nhas\u00a0significantly\u00a0reduced\u00a0mobility\nMajor\u00a0trauma\nv\u00a0 Offer\u00a0combined\u00a0VTE\u00a0prophylaxis\u00a0with\u00a0mechanical\u00a0and\npharmacological\u00a0methods\u00a0to\u00a0patients\u00a0with\u00a0major\u00a0trauma\nv\u00a0 Regularly\u00a0reassess\u00a0the\u00a0patient\u2019s\u00a0risks\u00a0of\u00a0VTE\u00a0and\u00a0bleeding\nv\u00a0 Start\u00a0mechanical\u00a0VTE\u00a0prophylaxis\u00a0at\u00a0admission\u00a0or\u00a0as\u00a0early\u00a0as\nclinically\u00a0possible\nv\u00a0 Continue\u00a0mechanical\u00a0VTE\u00a0prophylaxis\u00a0until\u00a0the\u00a0patient\u00a0no\u00a0longer\u00a0has\nsignificantly\u00a0reduced\u00a0mobility\nv\u00a0 Add\u00a0pharmacological\u00a0VTE\u00a0prophylaxis\u00a0if\u00a0the\u00a0benefits\u00a0of\u00a0reducing\u00a0the\nrisk\u00a0of\u00a0VTE\u00a0outweighs\u00a0the\u00a0risk\u00a0of\u00a0bleeding\u00a0and\u00a0the\u00a0bleeding\u00a0risk\u00a0has\nbeen\u00a0established\u00a0as\u00a0low\nv\u00a0 Continue\u00a0pharmacological\u00a0VTE\u00a0prophylaxis\u00a0until\u00a0the\u00a0patient\u00a0no\u00a0longer\nhas\u00a0significantly\u00a0reduced\u00a0mobility\nSpinal\u00a0injury\nv\u00a0 Offer\u00a0combined\u00a0VTE\u00a0prophylaxis\u00a0with\u00a0mechanical\u00a0and\npharmacological\u00a0methods\u00a0to\u00a0patients\u00a0with\u00a0spinal\u00a0injury\nv\u00a0 Regularly\u00a0reassess\u00a0the\u00a0patient\u2019s\u00a0risks\u00a0of\u00a0VTE\u00a0and\u00a0bleeding\nv\u00a0 Start\u00a0mechanical\u00a0VTE\u00a0prophylaxis\u00a0at\u00a0admission\u00a0or\u00a0as\u00a0early\u00a0as\nclinically\u00a0possible\nv\u00a0 Continue\u00a0mechanical\u00a0VTE\u00a0prophylaxis\u00a0until\u00a0the\u00a0patient\u00a0no\u00a0longer\u00a0has\nsignificantly\u00a0reduced\u00a0mobility\nv\u00a0 Add\u00a0pharmacological\u00a0VTE\u00a0prophylaxis\u00a0if\u00a0the\u00a0benefits\u00a0of\u00a0reducing\u00a0the\nrisk\u00a0of\u00a0VTE\u00a0outweighs\u00a0the\u00a0risk\u00a0of\u00a0bleeding\u00a0and\u00a0the\u00a0bleeding\u00a0risk\u00a0has\nbeen\u00a0established\u00a0as\u00a0low\nv\u00a0 Continue\u00a0pharmacological\u00a0VTE\u00a0prophylaxis\u00a0until\u00a0the\u00a0patient\u00a0no\u00a0longer\nhas\u00a0significantly\u00a0reduced\u00a0mobility\nLower\u00a0limb\u00a0plaster\u00a0casts\nv\u00a0 Consider\u00a0pharmacological\u00a0VTE\u00a0prophylaxis\u00a0to\u00a0patients\u00a0with\u00a0lower\u00a0limb\nplaster\u00a0casts\u00a0after\u00a0evaluating\u00a0the\u00a0risks\u00a0and\u00a0benefits\u00a0based\u00a0on\u00a0clinical\ndiscussion\u00a0with\u00a0the\u00a0patient\nv\u00a0 Offer\u00a0pharmacological\u00a0VTE\u00a0prophylaxis\u00a0until\u00a0lower\u00a0limb\u00a0plaster\u00a0cast\u00a0removal\nPregnancy\u00a0and\u00a0up\u00a0to\u00a06\u00a0weeks\u00a0post\u00adpartum\nv\u00a0 All\u00a0women\u00a0should\u00a0be\u00a0assessed\u00a0at\u00a0booking\u00a0and\u00a0after\u00a0delivery\u00a0and\nstratified\u00a0into\u00a0risk\u00a0groups\u00a0according\u00a0to\u00a0risk\u00a0factors\u00a0and\u00a0offered\nthromboprophylaxis\u00a0with\u00a0LMWH\u00a0where\u00a0appropriate\nv\u00a0 This\u00a0assessment\u00a0should\u00a0be\u00a0repeated\u00a0if\u00a0the\u00a0woman\u00a0is\u00a0admitted\u00a0to\u00a0the\nhospital\u00a0for\u00a0any\u00a0reason\u00a0or\u00a0develops\u00a0other\u00a0intercurrent\u00a0problems\u00a0during\nthe\u00a0antenatal\u00a0and\u00a0postpartum\u00a0period\nCritical\u00a0care\nv\u00a0 Assess\u00a0all\u00a0patients\u00a0on\u00a0admission\u00a0to\u00a0the\u00a0critical\u00a0care\u00a0unit\u00a0for\u00a0their\u00a0risks\nof\u00a0VTE\u00a0and\u00a0bleeding\nv\u00a0 Reassess\u00a0patients\u2019\u00a0risks\u00a0of\u00a0VTE\u00a0and\u00a0bleeding\u00a0daily\u00a0and\u00a0more\nfrequently\u00a0if\u00a0their\u00a0clinical\u00a0condition\u00a0is\u00a0changing\u00a0rapidly\nv\u00a0 Offer\u00a0VTE\u00a0prophylaxis\u00a0to\u00a0patients\u00a0admitted\u00a0to\u00a0the\u00a0critical\u00a0care\u00a0unit\naccording\u00a0to\u00a0the\u00a0reason\u00a0for\u00a0admission,\u00a0taking\u00a0into\u00a0account:\nt\u00a0Any\u00a0planned\u00a0interventions\nt\u00a0The\u00a0use\u00a0of\u00a0other\u00a0therapies\u00a0that\u00a0may\u00a0increase\u00a0the\u00a0risk\u00a0of\ncomplications\nUnfractionated\u00a0heparin\u00a0(subcutaneous)\nv\u00a0 Wait\u00a0at\u00a0least\u00a04\u00a0hours\u00a0after\u00a0a\u00a0dose\u00a0before\u00a0block\u00a0or\u00a0catheter\u00a0removal\nv\u00a0 Wait\u00a0at\u00a0least\u00a01\u00a0hour\u00a0before\u00a0dosing\u00a0after\u00a0procedure\u00a0(catheter\u00a0insertion\nor\u00a0withdrawal)\nUnfractionated\u00a0heparin\u00a0(intraveneous)\nv\u00a0 Stop\u00a0infusion\u00a02\u00a0\u00ad\u00a04\u00a0hours\u00a0before\u00a0block\nPatients\u00a0taking\u00a0anti\u00adplatelet\u00a0agents\u00a0or\u00a0anticoagulants\u00a0on\u00a0admission\u00a0or\nneeding\u00a0them\u00a0for\u00a0treatment\nv\u00a0 Consider\u00a0additional\u00a0pharmacological\u00a0VTE\u00a0prophylaxis\u00a0to\u00a0patients\nwho\u00a0are\u00a0taking\u00a0one\u00a0but\u00a0not\u00a0two\u00a0anti\u00adplatelet\u00a0agents\u00a0to\u00a0treat\u00a0other\nconditions\u00a0and\u00a0who\u00a0are\u00a0assessed\u00a0to\u00a0be\u00a0at\u00a0increased\u00a0risk\u00a0of\u00a0VTE\nv\u00a0 Consider\u00a0additional\u00a0mechanical\u00a0prophylaxis\u00a0to\u00a0patients\u00a0who\u00a0are\u00a0taking\ntwo\u00a0anti\u00adplatelet\u00a0agents\u00a0to\u00a0treat\u00a0other\u00a0conditions\u00a0and\u00a0who\u00a0are\nassessed\u00a0to\u00a0be\u00a0at\u00a0increased\u00a0risk\u00a0of\u00a0VTE\nv\u00a0 Do\u00a0not\u00a0offer\u00a0additional\u00a0pharmacological\u00a0or\u00a0mechanical\u00a0VTE\nprophylaxis\u00a0to\u00a0patients\u00a0who\u00a0are\u00a0taking\u00a0vitamin\u00a0K\u00a0antagonists\u00a0and\nwho\u00a0are\u00a0within\u00a0their\u00a0therapeutic\u00a0range,\u00a0provided\u00a0anticoagulant\u00a0therapy\nis\u00a0continued\nv\u00a0 Do\u00a0not\u00a0offer\u00a0additional\u00a0pharmacological\u00a0or\u00a0mechanical\u00a0VTE\nprophylaxis\u00a0to\u00a0patients\u00a0who\u00a0are\u00a0having\u00a0full\u00a0anticoagulant\u00a0therapy\n9.", "chunk_order": 8}
{"chunk_id": "1baa2219-bd6e-4f97-be1b-c6dfab15d054", "source_document_filename": "CPG Prevention and Treatment of Venous Thrombosis_cleaned_ultra_minimal.txt", "source_document_title": "CPG Prevention and Treatment of Venous Thrombosis cleaned ultra minimal", "text": "Timing\u00a0of\u00a0regional\u00a0anaesthesia/\u00a0analgesia\nv\u00a0 Start\u00a0infusion\u00a0>1\u00a0hour\u00a0after\u00a0block\nv\u00a0 Remove\u00a0epidural\u00a0catheter\u00a0no\u00a0sooner\u00a0than\u00a02\u00a0\u00ad\u00a04\u00a0hours\u00a0after\ndiscontinuation\u00a0of\u00a0infusion\nLow\u00a0Molecular\u00a0Weight\u00a0Heparin\nv\u00a0 Wait\u00a0at\u00a0least\u00a012\u00a0hours\u00a0after\u00a0a\u00a0prophylactic\u00a0dose\u00a0before\u00a0block\nv\u00a0 Wait\u00a0at\u00a0least\u00a024\u00a0hours\u00a0after\u00a0a\u00a0therapeutic\u00a0dose\u00a0before\u00a0block\nv\u00a0 Wait\u00a0at\u00a0least\u00a010\u00a0hours\u00a0after\u00a0dose\u00a0before\u00a0removing\u00a0catheter\nv\u00a0 After\u00a0catheter\u00a0removal\u00a0wait\u00a02\u00a0\u00ad\u00a04\u00a0hours\u00a0before\u00a0next\u00a0dose\nWarfarin\nv\" .%$/00(\"1#\"23-\"4567\nAspirin\u00a0and\u00a0NSAIDs\nv\u00a0 No\u00a0issue\nClopidogrel\nv\u00a0 Stop\u00a07\u00a0days\u00a0pre\u00adop\u00a0if\u00a0possible\nv\u00a0 If\u00a0not,\u00a0proceed\u00a0with\u00a0caution\nv\u00a0 Be\u00a0aware\u00a0that\u00a0heparins\u00a0are\u00a0of\u00a0animal\u00a0origin\u00a0and\u00a0this\u00a0may\u00a0be\u00a0of\nconcern\u00a0to\u00a0some\u00a0patients\nv\u00a0 For\u00a0patients\u00a0who\u00a0have\u00a0concerns\u00a0about\u00a0using\u00a0animal\u00a0products,\nconsider\u00a0offering\u00a0synthetic\u00a0alternatives\u00a0based\u00a0on\u00a0clinical\u00a0judgement\nand\u00a0after\u00a0discussing\u00a0their\u00a0suitability,\u00a0advantages\u00a0and\u00a0disadvantages\nwith\u00a0the\u00a0patient\nv\u00a0 In\u00a0specific\u00a0conditions\u00a0such\u00a0as\u00a0pregnancy,\u00a0LMWH\u00a0is\u00a0the\u00a0anticoagulant\nof\u00a0choice\u00a0and\u00a0is\u00a0superior\u00a0to\u00a0UFH\u00a0in\u00a0its\u00a0efficacy\u00a0with\u00a0less\u00a0bleeding\ncomplications\nRivaroxaban\nRivaroxaban\u00a0is\u00a0started\u00a0post\u00adoperatively\nv\u00a0 Wait\u00a012\u00a0\u00ad\u00a018\u00a0hours\u00a0after\u00a0dose\u00a0for\u00a0epidural\u00a0catheter\u00a0removal\nv\u00a0 Wait\u00a06\u00a0hours\u00a0before\u00a0next\u00a0dose\nDabigatran\nDabigatran\u00a0is\u00a0started\u00a0post\u00adoperatively\nv\u00a0 Wait\u00a012\u00a0\u00ad\u00a018\u00a0hours\u00a0after\u00a0dose\u00a0for\u00a0epidural\u00a0catheter\u00a0removal\nv\u00a0 Wait\u00a06\u00a0hours\u00a0before\u00a0next\u00a0dose\n10. Patient\u00a0information\nv\u00a0 Before\u00a0starting\u00a0VTE\u00a0prophylaxis,\u00a0offer\u00a0patients\u00a0and\u00a0their\u00a0families\nverbal\u00a0and\u00a0written\u00a0information\u00a0on:\nt\u00a0The\u00a0risks\u00a0and\u00a0possible\u00a0consequences\u00a0of\u00a0VTE\nt\u00a0The\u00a0importance\u00a0of\u00a0VTE\u00a0prophylaxis\u00a0and\u00a0its\u00a0possible\u00a0side\u00adeffects\nt\u00a0The\u00a0correct\u00a0use\u00a0of\u00a0VTE\u00a0prophylaxis\nt\u00a0How\u00a0patients\u00a0can\u00a0reduce\u00a0the\u00a0risk\u00a0of\u00a0VTE\u00a0(keeping\u00a0well\u00a0hydrated\nand\u00a0mobilizing\u00a0early)\nv\u00a0 As\u00a0part\u00a0of\u00a0the\u00a0discharge\u00a0plan,\u00a0offer\u00a0patients\u00a0and\u00a0their\u00a0families\u00a0or\ncarers\u00a0verbal\u00a0and\u00a0written\u00a0information\u00a0on:\n# # \"#The\u00a0signs\u00a0and\u00a0symptoms\u00a0of\u00a0DVT\u00a0and\u00a0PE\n# # \"\u00a0The\u00a0recommended\u00a0duration\u00a0of\u00a0use\u00a0of\u00a0VTE\u00a0prophylaxis\u00a0at\u00a0home\u00a0(if\ndischarged\u00a0with\u00a0prophylaxis)\n# # \"\u00a0Ensure\u00a0that\u00a0patients\u00a0who\u00a0are\u00a0discharged\u00a0with\u00a0pharmacological\u00a0or\nmechanical\u00a0VTE\u00a0prophylaxis\u00a0are\u00a0able\u00a0to\u00a0use\u00a0it\u00a0correctly\n# # \"\u00a0Know\u00a0who\u00a0to\u00a0contact\u00a0if\u00a0DVT,\u00a0PE\u00a0or\u00a0adverse\u00a0events\u00a0are\u00a0suspected\n11. Discharge\u00a0plan\nPATHWAY\u00a02:\u00a0MANAGEMENT\u00a0OF\u00a0VTE2\nName\u00a0of\u00a0Assessor:\nDate:\nDiagnosis\u00a0and\u00a0Treatment\u00a0of\u00a0Venous\nThromboembolism\nMinistry\u00a0of\u00a0Health\nMalaysia\nO2\u00a0sat\nPedal\nL\nSkin:\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Warm\u00a0/\nCold\nWt\u00a0(kg)\nHt\u00a0(cm)\nBMI\nTemp\nCalf\ncircumference\n(cm)\nPeripheral\u00a0pulses\nPulse\nRR\nR\nPopliteal\nBP\nR\n\"\u00a0Suspected\u00a0PE\n! \"\u00a0Suspected\u00a0DVT\n! \"\u00a0Suspected\u00a0PE\u00a0+\u00a0DVT\u00a0 ! Site:\n\uf020\" Leg\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0R ! L\u00a0 ! \uf020\" Chest\u00a0\u00a0\u00a0\u00a0\u00a0R ! L\u00a0 ! Duration\u00a0of\u00a0Symptom(s):\nNAME:\nDOB:\nSEX:\nHOSPITAL\u00a0NO. IC\u00a0NO. 1. Patient\u00a0information\n2. Triaging\n3.", "chunk_order": 9}
{"chunk_id": "aac9461e-f76c-4613-8c6c-a8fb20844699", "source_document_filename": "CPG Prevention and Treatment of Venous Thrombosis_cleaned_ultra_minimal.txt", "source_document_title": "CPG Prevention and Treatment of Venous Thrombosis cleaned ultra minimal", "text": "Discharge\u00a0plan\nPATHWAY\u00a02:\u00a0MANAGEMENT\u00a0OF\u00a0VTE2\nName\u00a0of\u00a0Assessor:\nDate:\nDiagnosis\u00a0and\u00a0Treatment\u00a0of\u00a0Venous\nThromboembolism\nMinistry\u00a0of\u00a0Health\nMalaysia\nO2\u00a0sat\nPedal\nL\nSkin:\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Warm\u00a0/\nCold\nWt\u00a0(kg)\nHt\u00a0(cm)\nBMI\nTemp\nCalf\ncircumference\n(cm)\nPeripheral\u00a0pulses\nPulse\nRR\nR\nPopliteal\nBP\nR\n\"\u00a0Suspected\u00a0PE\n! \"\u00a0Suspected\u00a0DVT\n! \"\u00a0Suspected\u00a0PE\u00a0+\u00a0DVT\u00a0 ! Site:\n\uf020\" Leg\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0R ! L\u00a0 ! \uf020\" Chest\u00a0\u00a0\u00a0\u00a0\u00a0R ! L\u00a0 ! Duration\u00a0of\u00a0Symptom(s):\nNAME:\nDOB:\nSEX:\nHOSPITAL\u00a0NO. IC\u00a0NO. 1. Patient\u00a0information\n2. Triaging\n3. Vital\u00a0Signs\nDVT\nYes\u00a0 No\nPE\nYes\u00a0 No\nActive\u00a0cancer\u00a0or\u00a0cancer\nwithin\u00a06\u00a0months\n1\n0\nClinical\u00a0signs\u00a0&\u00a0symptoms\nof\u00a0DVT\u00a0(minimum\u00a0of\u00a0leg\nswelling\u00a0and\u00a0pain\u00a0with\npalpation\u00a0of\u00a0the\u00a0deep\u00a0veins\n3\n0\nParalysis\u00a0or\u00a0recent\u00a0leg\nplaster\n1\n0\nAn\u00a0alternative\u00a0diagnosis\u00a0is\nless\u00a0likely\u00a0than\u00a0PE\n3\n0\nBedridden\u00a0>3\u00a0days\nor\u00a0major\u00a0surgery\u00a0<12\nweeks\n1\n0\nHeart\u00a0rate\u00a0>100\u00a0beats/min\n1.5\n0\nTenderness\u00a0along\u00a0deep\nvenous\u00a0system\n1\n0\nImmobilization\u00a0>3\u00a0days\u00a0or\nsurgery\u00a0in\u00a0the\u00a0previous\u00a04\nweeks\n1.5\n0\nPitting\u00a0edema\n(symptomatic\u00a0leg)\n1\n0\nMalignancy\u00a0(on\u00a0treatment\u037e\ntreated\u00a0in\u00a0the\u00a0last\u00a06\nmonths\u037e\u00a0or\u00a0palliative\n1\n0\nCalf\u00a0swelling\u00a0>3\u00a0cm\u00a0than\nasymptomatic\u00a0leg\n1\n0\nHaemoptysis\n1\n0\nCollateral\u00a0superficial\nveins\n1\n0\nPreviously\u00a0documented\nDVT\n1\n0\nAlternative\u00a0diagnosis\nmore\u00a0likely\n\u00ad2\n0\nEntire\u00a0leg\u00a0swollen\n1\n0\nPrevious\u00a0DVT/PE\n1.5\n0\nDVT\u00a0likely\n!2\nPE\u00a0likely\n>4\nDVT\u00a0unlikely\n<1\nPE\u00a0unlikely\n\"#\n4. Clinical\u00a0Probability\n5. History\n7. Blood\u00a0tests\nHistory\u00a0of\u00a0present\u00a0illness\nPast\u00a0medical\u00a0history\nAllergies\nDrug\u00a0history\n6. Risk\u00a0Factors\nv\u00a0 Obesity\u00a0! v\u00a0 Smoking\u00a0! v\u00a0 Malignancy\u00a0! v\u00a0 Anti\u00adphospholipid\u00a0syndrome\u00a0! v\u00a0 OCP\u00a0! v\u00a0 HRT\u00a0! v\u00a0 Pregnancy\u00a0! v\u00a0 Post\u00adpartum\u00a0(within\u00a012\u00a0weeks)\u00a0! v\u00a0 Previous\u00a0VTE\u00a0! v\u00a0 Family\u00a0h/o\u00a0VTE\u00a0! v\u00a0 Recent\u00a0leg\u00a0trauma\u00a0or\u00a0plaster\u00a0! v\u00a0 Recent\u00a0abdominal\u00a0or\u00a0pelvic\u00a0surgery\u00a0! v\u00a0 Bedridden\u00a0>3\u00a0days\u00a0! v\u00a0 Nephrotic\u00a0syndrome\u00a0! v\u00a0 Sickle\u00a0cell\u00a0disease\u00a0! v\u00a0 Thalassaemia\u00a0! v\u00a0 Inflammatory\u00a0bowel\u00a0disease\u00a0! FBC\nCoagulation\u00a0profile\nRenal\u00a0profile\nLiver\u00a0function\nUrinalysis\nSuggest\u00a0repeat\u00a0scan\u00a0in\u00a07\u00a0days\nDate:\nBelow\u00a0knee\nAbove\u00a0knee\nProceed\u00a0to\u00a0treatment\nRepeat\u00a0scan\u00a0negative\nDischarge\u00a0patient\u00a0to\u00a0Health\u00a0Clinic\n8. DVT\u00a0likely\nRequest\u00a0for\u00a0Doppler\u00a0Ultrasound\nDate\u00a0of\u00a0US:\nDVT\u00a0confirmed\nDVT\u00a0not\u00a0confirmed\n9. Other\u00a0investigations\n10.", "chunk_order": 10}
{"chunk_id": "9bbf8dd7-ddee-4f4c-b07f-58b5c775ed98", "source_document_filename": "CPG Prevention and Treatment of Venous Thrombosis_cleaned_ultra_minimal.txt", "source_document_title": "CPG Prevention and Treatment of Venous Thrombosis cleaned ultra minimal", "text": "v\u00a0 Post\u00adpartum\u00a0(within\u00a012\u00a0weeks)\u00a0! v\u00a0 Previous\u00a0VTE\u00a0! v\u00a0 Family\u00a0h/o\u00a0VTE\u00a0! v\u00a0 Recent\u00a0leg\u00a0trauma\u00a0or\u00a0plaster\u00a0! v\u00a0 Recent\u00a0abdominal\u00a0or\u00a0pelvic\u00a0surgery\u00a0! v\u00a0 Bedridden\u00a0>3\u00a0days\u00a0! v\u00a0 Nephrotic\u00a0syndrome\u00a0! v\u00a0 Sickle\u00a0cell\u00a0disease\u00a0! v\u00a0 Thalassaemia\u00a0! v\u00a0 Inflammatory\u00a0bowel\u00a0disease\u00a0! FBC\nCoagulation\u00a0profile\nRenal\u00a0profile\nLiver\u00a0function\nUrinalysis\nSuggest\u00a0repeat\u00a0scan\u00a0in\u00a07\u00a0days\nDate:\nBelow\u00a0knee\nAbove\u00a0knee\nProceed\u00a0to\u00a0treatment\nRepeat\u00a0scan\u00a0negative\nDischarge\u00a0patient\u00a0to\u00a0Health\u00a0Clinic\n8. DVT\u00a0likely\nRequest\u00a0for\u00a0Doppler\u00a0Ultrasound\nDate\u00a0of\u00a0US:\nDVT\u00a0confirmed\nDVT\u00a0not\u00a0confirmed\n9. Other\u00a0investigations\n10. PE\u00a0likely\nCXR\nECG\nProceed\u00a0to\u00a0treatment\nDoppler\u00a0US\u00a0both\u00a0legs\nPerform\u00a0immediate\u00a0computed\ntomography\u00a0pulmonary\u00a0angiogram\n(CTPA)\nConsider\u00a0systemic\u00a0thrombolytic\ntherapy\u00a0for\u00a0patients\u00a0with\u00a0PE\u00a0and\nhaemodynamic\u00a0instability\nFull\u00a0report\nDate\u00a0of\u00a0CTPA:\nDVT\u00a0confirmed\nNo\u00a0DVT\nProceed\u00a0to\ntreatment\nNo\u00a0further\naction\nPE\u00a0confirmed\nPE\u00a0not\u00a0confirmed\nv\u00a0 Offer\u00a0a\u00a0choice\u00a0of\u00a0low\u00a0molecular\u00a0weight\u00a0heparin\u00a0(LMWH)\u00a0or\nfondaparinux\u00a0to\u00a0patients\u00a0with\u00a0confirmed\u00a0proximal\u00a0DVT\u00a0or\u00a0PE\u00a0taking\ninto\u00a0account\u00a0comorbidities,\u00a0contraindications\u00a0and\u00a0drug\u00a0costs\nv\u00a0 Start\u00a0LMWH\u00a0(enoxaparin\u00a0or\u00a0tinzaparin)\u00a0or\u00a0fondaparinux\u00a0as\u00a0soon\u00a0as\npossible\u00a0and\u00a0continue\u00a0for\u00a0at\u00a0least\u00a05\u00a0days\u00a0or\u00a0until\u00a0the\u00a0INR\u00a0is\u00a02\u00a0or\nabove\u00a0for\u00a02\u00a0consecutive\u00a0days,\u00a0whichever\u00a0is\u00a0longer\n# # \"\u00a0Tinzaparin\u00a0dose\u00a0is\u00a0175\u00a0IU/kg\u00a0once\u00a0daily\u00a0! # # \"\u00a0Enoxaparin\u00a0dose\u00a0is\u00a01\u00a0mg/kg\u00a0twice\u00a0daily\u00a0! # # \"\u00a0Fondaparinux\u00a0dose\u00a0is\u00a07.5\u00a0mg\u00a0daily\n(5\u00a0mg\u00a0if\u00a0<50\u00a0kg\u037e\u00a010\u00a0mg\u00a0if\u00a0>100\u00a0kg)\u00a0! v\u00a0 Start\u00a0VKA\u00a0i.e. warfarin\u00a0at\u00a05\u00a0mg\u00a0daily\u00a0within\u00a024\u00a0hours\u00a0of\u00a0diagnosis\u00a0and\ncontinue\u00a0for\u00a03\u00a0months\u00a0for\u00a0provoked\u00a0VTE\u00a0or\u00a0consider\u00a0long\u00a0term\u00a0for\nunprovoked\u00a0VTE\nv\u00a0 For\u00a0pregnancy,\u00a0LMWH\u00a0is\u00a0the\u00a0treatment\u00a0of\u00a0choice\nv\u00a0 Fondaparinux\u00a0is\u00a0not\u00a0recommended\u00a0in\u00a0pregnancy\u00a0as\u00a0it\u00a0may\u00a0cross\u00a0the\nplacenta\nv\u00a0 For\u00a0severe\u00a0renal\u00a0impairment\u00a0or\u00a0established\u00a0renal\u00a0failure\n(eGFR\u00a0<30\u00a0mL/min/1.73\u00a0m2)\nt\u00a0offer\u00a0intravenous\u00a0unfractionated\u00a0heparin\u00a0with\u00a0dose\u00a0adjustment\nbased\u00a0on\u00a0APTT\u00a0or\nt\u00a0LMWH\u00a0daily\u00a0with\u00a0dose\u00a0adjustments\u00a0based\u00a0on\u00a0anti\u00adXa\u00a0assay\n(Fondaparinux\u00a0is\u00a0contraindicated\u00a0in\u00a0patients\u00a0with\u00a0renal\u00a0impairment)\nv\u00a0 For\u00a0patients\u00a0with\u00a0PE\u00a0and\u00a0haemodynamic\u00a0instability\nt\u00a0offer\u00a0IV\u00a0UFH\u00a0and\u00a0consider\u00a0thrombolytic\u00a0therapy\nt\u00a0once\u00a0patient\u00a0is\u00a0haemodynamically\u00a0stable,\u00a0switch\u00a0to\u00a0LMWH\u00a0and\nstart\u00a0warfarin\nv\u00a0 For\u00a0patients\u00a0with\u00a0active\u00a0cancer\u00a0and\u00a0confirmed\u00a0proximal\u00a0DVT\u00a0or\u00a0PE,\ncontinue\u00a0LMWH\u00a0for\u00a06\u00a0months. At\u00a06\u00a0months,\u00a0assess\u00a0the\u00a0risks\u00a0and\nbenefits\u00a0of\u00a0continuing\u00a0anticoagulation\n11. Initial\u00a0treatment\u00a0for\u00a0confirmed\u00a0VTE\na. Heparin\u00a0or\u00a0Fondaparinux\u00a0and\u00a0vitamin\u00a0K\u00a0antagonists\u00a0(VKA)\nRivaroxaban\u00a0is\u00a0indicated\u00a0for\u00a0the\u00a0treatment\u00a0of\u00a0acute\u00a0deep\u00a0vein\u00a0thrombosis\nand\u00a0pulmonary\u00a0embolism\u00a0and\u00a0the\u00a0prevention\u00a0of\u00a0recurrence\nb. Rivaroxaban\nv\u00a0 For\u00a0the\u00a0initial\u00a0treatment\u00a0of\u00a0acute\u00a0DVT\u00a0or\u00a0PE\nt\u00a0the\u00a0recommended\u00a0dose\u00a0of\u00a0rivaroxaban\u00a0is\u00a015\u00a0mg\u00a0twice\u00a0daily\u00a0for\u00a0the\nfirst\u00a021\u00a0days\u00a0followed\u00a0by\u00a020\u00a0mg\u00a0once\u00a0daily\u00a0for\u00a0continued\u00a0treatment\nand\u00a0prevention\u00a0of\u00a0recurrence\u00a0!", "chunk_order": 11}
{"chunk_id": "6742aece-989b-477b-ab59-92fa941dfe48", "source_document_filename": "CPG Prevention and Treatment of Venous Thrombosis_cleaned_ultra_minimal.txt", "source_document_title": "CPG Prevention and Treatment of Venous Thrombosis cleaned ultra minimal", "text": "At\u00a06\u00a0months,\u00a0assess\u00a0the\u00a0risks\u00a0and\nbenefits\u00a0of\u00a0continuing\u00a0anticoagulation\n11. Initial\u00a0treatment\u00a0for\u00a0confirmed\u00a0VTE\na. Heparin\u00a0or\u00a0Fondaparinux\u00a0and\u00a0vitamin\u00a0K\u00a0antagonists\u00a0(VKA)\nRivaroxaban\u00a0is\u00a0indicated\u00a0for\u00a0the\u00a0treatment\u00a0of\u00a0acute\u00a0deep\u00a0vein\u00a0thrombosis\nand\u00a0pulmonary\u00a0embolism\u00a0and\u00a0the\u00a0prevention\u00a0of\u00a0recurrence\nb. Rivaroxaban\nv\u00a0 For\u00a0the\u00a0initial\u00a0treatment\u00a0of\u00a0acute\u00a0DVT\u00a0or\u00a0PE\nt\u00a0the\u00a0recommended\u00a0dose\u00a0of\u00a0rivaroxaban\u00a0is\u00a015\u00a0mg\u00a0twice\u00a0daily\u00a0for\u00a0the\nfirst\u00a021\u00a0days\u00a0followed\u00a0by\u00a020\u00a0mg\u00a0once\u00a0daily\u00a0for\u00a0continued\u00a0treatment\nand\u00a0prevention\u00a0of\u00a0recurrence\u00a0! v\u00a0 Consider\u00a0catheter\u00addirected\u00a0thrombolytic\u00a0therapy\u00a0for\u00a0patients\u00a0with\nsymptomatic\u00a0ilio\u00adfemoral\u00a0DVT\u00a0who\u00a0have:\nt\u00a0Symptoms\u00a0of\u00a0less\u00a0than\u00a014\u00a0days\u00a0duration\u00a0AND\nt\u00a0Good\u00a0functional\u00a0status\u00a0AND\nt\u00a0A\u00a0life\u00a0expectancy\u00a0of\u00a01\u00a0year\u00a0or\u00a0more\u00a0AND\nt\u00a0A\u00a0low\u00a0risk\u00a0of\u00a0bleeding\nv\u00a0 Consider\u00a0systemic\u00a0thrombolytic\u00a0therapy\u00a0for\u00a0patients\u00a0with\u00a0PE\u00a0and\nhaemodynamic\u00a0instability\u00a0(e.g. systolic\u00a0BP\u00a0<90\u00a0mmHg)\nv\u00a0 Do\u00a0not\u00a0offer\u00a0systemic\u00a0thrombolytic\u00a0therapy\u00a0to\u00a0patients\u00a0with\u00a0PE\u00a0and\nhaemodynamic\u00a0stability\nv\u00a0 The\u00a0most\u00a0commonly\u00a0used\u00a0agent\u00a0is\u00a0t\u00adPA\u00a0infused\u00a0at\u00a0100\u00a0mg\u00a0over\u00a02\nhours\u00a0followed\u00a0by\u00a0continuation\u00a0of\u00a0therapeutic\u00a0heparin\u00a0infusion\nv\u00a0 Consider\u00a0thoracotomy\u00a0in\u00a0critically\u00a0ill\u00a0/\u00a0not\u00a0suitable\u00a0for\u00a0thrombolysis\nv\u00a0 Prescribe\u00a0below\u00adknee\u00a0graduated\u00a0compression\u00a0stockings\u00a0with\u00a0an\u00a0ankle\npressure\u00a0greater\u00a0than\u00a023\u00a0mmHg\u00a0to\u00a0patients\u00a0with\u00a0proximal\u00a0DVT\u00a0a\u00a0week\nafter\u00a0diagnosis\u00a0or\u00a0when\u00a0swelling\u00a0is\u00a0reduced\u00a0sufficiently\u00a0and\u00a0if\u00a0there\nare\u00a0no\u00a0contraindications\nv\u00a0 advice\u00a0patients\u00a0to\u00a0continue\u00a0wearing\u00a0the\u00a0stockings\u00a0for\u00a0at\u00a0least\u00a02\u00a0years\nv\u00a0 ensure\u00a0that\u00a0the\u00a0stockings\u00a0are\u00a0replaced\u00a0two\u00a0or\u00a0three\u00a0times\u00a0per\u00a0year\nor\u00a0according\u00a0to\u00a0the\u00a0manufacturer's\u00a0instructions\nv\u00a0 advice\u00a0patients\u00a0that\u00a0the\u00a0stockings\u00a0need\u00a0to\u00a0be\u00a0worn\u00a0only\u00a0on\u00a0the\naffected\u00a0leg\u00a0or\u00a0legs\nv\u00a0 Offer\u00a0temporary\u00a0inferior\u00a0vena\u00a0cava\u00a0filters\u00a0ONLY\u00a0to\u00a0patients\u00a0with\nproximal\u00a0DVT\u00a0or\u00a0PE\u00a0who\u00a0cannot\u00a0have\u00a0anticoagulation\u00a0treatment\n12. Thrombolytic\u00a0Therapy\nDeep\u00a0vein\u00a0thrombosis\n13. Mechanical\u00a0Intervention\nCompression\u00a0stockings\nInferior\u00a0vena\u00a0cava\u00a0filters\nPulmonary\u00a0embolism\nv\u00a0 Remove\u00a0the\u00a0inferior\u00a0vena\u00a0cava\u00a0filter\u00a0when\u00a0the\u00a0patient\u00a0becomes\neligible\u00a0for\u00a0anticoagulation\u00a0treatment,\u00a0at\u00a0the\u00a0earliest\u00a0possible\nopportunity\n14. Investigations\u00a0for\u00a0Cancer\n15.", "chunk_order": 12}
{"chunk_id": "0bfc4ac9-7763-4063-bc85-0647b6a99e40", "source_document_filename": "CPG Prevention and Treatment of Venous Thrombosis_cleaned_ultra_minimal.txt", "source_document_title": "CPG Prevention and Treatment of Venous Thrombosis cleaned ultra minimal", "text": "Thrombolytic\u00a0Therapy\nDeep\u00a0vein\u00a0thrombosis\n13. Mechanical\u00a0Intervention\nCompression\u00a0stockings\nInferior\u00a0vena\u00a0cava\u00a0filters\nPulmonary\u00a0embolism\nv\u00a0 Remove\u00a0the\u00a0inferior\u00a0vena\u00a0cava\u00a0filter\u00a0when\u00a0the\u00a0patient\u00a0becomes\neligible\u00a0for\u00a0anticoagulation\u00a0treatment,\u00a0at\u00a0the\u00a0earliest\u00a0possible\nopportunity\n14. Investigations\u00a0for\u00a0Cancer\n15. Thrombophilia\u00a0testing\nv\u00a0 All\u00a0patients\u00a0diagnosed\u00a0with\u00a0unprovoked\u00a0DVT\u00a0or\u00a0PE\u00a0who\u00a0are\u00a0not\nknown\u00a0to\u00a0have\u00a0cancer\u00a0should\u00a0be\u00a0offered:\n# # \"\u00a0A\u00a0physical\u00a0examination\u00a0(further\u00a0specific\u00a0tests\u00a0are\u00a0guided\u00a0by\u00a0the\npatient\u2019s\u00a0history)\n# # \"\u00a0Chest\u00a0X\u00adray\n# # \"\u00a0Blood\u00a0tests\u00a0(FBC,\u00a0LFT,\u00a0RP,\u00a0urinalysis)\nv\u00a0 Consider\u00a0further\u00a0investigations\u00a0for\u00a0cancer\u00a0with\u00a0an\u00a0abdomino\u00adpelvic\u00a0CT\nscan\u00a0(and\u00a0a\u00a0mammogram\u00a0for\u00a0women)\u00a0in\u00a0all\u00a0patients\u00a0aged\u00a0over\u00a040\nyears\u00a0with\u00a0a\u00a0first\u00a0unprovoked\u00a0VTE\u00a0who\u00a0do\u00a0not\u00a0have\u00a0signs\u00a0and\nsymptoms\u00a0of\u00a0cancer\u00a0based\u00a0on\u00a0initial\u00a0investigation\nv\u00a0 Tumour\u00a0markers\u00a0are\u00a0not\u00a0recommended\u00a0for\u00a0cancer\u00a0screening\nv\u00a0 DO\u00a0NOT\u00a0offer\u00a0thrombophilia\u00a0testing\u00a0to\u00a0patients\u00a0who\u00a0are\u00a0continuing\nanticoagulant\u00a0treatment\nv\u00a0 Consider\u00a0testing\u00a0for\u00a0lupus\u00a0anticoagulant\u00a0and\u00a0anti\u00adphospholipid\nantibodies\u00a0in\u00a0patients\u00a0who\u00a0have\u00a0had\u00a0an\u00a0unprovoked\u00a0DVT\u00a0or\u00a0PE\u00a0if\u00a0it\u00a0is\nplanned\u00a0to\u00a0stop\u00a0anticoagulant\u00a0treatment\nv\u00a0 Consider\u00a0testing\u00a0for\u00a0hereditary\u00a0thrombophilia\u00a0in\u00a0patients\u00a0who\u00a0have\nhad\u00a0an\u00a0unprovoked\u00a0DVT\u00a0or\u00a0PE\u00a0and\u00a0who\u00a0have\u00a0a\u00a0first\u00addegree\u00a0relative\nwho\u00a0has\u00a0had\u00a0a\u00a0DVT\u00a0or\u00a0PE\u00a0if\u00a0it\u00a0is\u00a0planned\u00a0to\u00a0stop\u00a0anticoagulant\ntreatment\nv\u00a0 DO\u00a0NOT\u00a0offer\u00a0thrombophilia\u00a0testing\u00a0to\u00a0patients\u00a0who\u00a0have\u00a0had\u00a0a\nprovoked\u00a0DVT\u00a0or\u00a0PE\nv\u00a0 DO\u00a0NOT\u00a0offer\u00a0thrombophilia\u00a0testing\u00a0to\u00a0first\u00addegree\u00a0relatives\u00a0of\u00a0people\nwith\u00a0a\u00a0history\u00a0of\u00a0DVT\u00a0or\u00a0PE\u00a0and\u00a0thrombophilia\nv\u00a0 DO\u00a0NOT\u00a0offer\u00a0heritable\u00a0thrombophilia\u00a0testing\u00a0to\u00a0patients\u00a0who\u00a0have\nhad\u00a0an\u00a0arterial\u00a0thrombosis\u00a0(young\u00a0stroke\u00a0or\u00a0myocardial\u00a0infarction)\nv\u00a0 Consider\u00a0testing\u00a0for\u00a0lupus\u00a0anticoagulant\u00a0and\u00a0anti\u00adphospholipid\nantibodies\u00a0in\u00a0the\u00a0following:\n# # \"#in\u00a0the\u00a0presence\u00a0of\u00a0both\u00a0arterial\u00a0and\u00a0venous\u00a0thrombosis\n# # \"\u00a0unexplained\u00a0arterial\u00a0thrombosis\u00a0(young\u00a0stroke\u00a0or\u00a0myocardial\ninfarction\u00a0with\u00a0no\u00a0risk\u00a0factors)\n# # \"\"&'\"890:;<)190(\"=1+/)%%1)>0+\"?5@\"A00B+\">0+C)C1$9\n# # \"\u00a0a\u00a0fetal\u00a0death\u00a0>10\u00a0weeks\u00a0gestation\n# # \"\u00a0premature\u00a0birth\u00a0<35\u00a0weeks\u00a0gestation\u00a0due\u00a0to\u00a0severe\u00a0pre\u00adeclampsia\nor\u00a0IUGR\n16. Duration\u00a0of\u00a0anticoagulation\u00a0therapy\n17. Follow\u00a0up\n18. Patient\u00a0information\nv\u00a0 Consider\u00a0extending\u00a0anticoagulation\u00a0beyond\u00a03\u00a0months\u00a0for\u00a0patients\nwith\u00a0unprovoked\u00a0proximal\u00a0DVT\u00a0if\u00a0their\u00a0risk\u00a0of\u00a0VTE\u00a0recurrence\u00a0is\u00a0high\n(e.g. male,\u00a0family\u00a0history)\u00a0and\u00a0there\u00a0is\u00a0no\u00a0additional\u00a0risk\u00a0of\u00a0major\nbleeding. Discuss\u00a0with\u00a0the\u00a0patient\u00a0the\u00a0benefits\u00a0and\u00a0risks\u00a0of\u00a0extending\ntheir\u00a0treatment\nv\u00a0 Offer\u00a0anticoagulation\u00a0beyond\u00a03\u00a0months\u00a0to\u00a0patients\u00a0with\u00a0an\nunprovoked\u00a0PE,\u00a0taking\u00a0into\u00a0account\u00a0the\u00a0patient's\u00a0risk\u00a0of\u00a0VTE\nrecurrence\u00a0and\u00a0whether\u00a0they\u00a0are\u00a0at\u00a0increased\u00a0risk\u00a0of\u00a0bleeding. Discuss\u00a0with\u00a0the\u00a0patient\u00a0the\u00a0benefits\u00a0and\u00a0risks\u00a0of\u00a0extending\u00a0their\ntreatment\nv\u00a0 Offer\u00a0LMWH\u00a0to\u00a0patients\u00a0with\u00a0active\u00a0cancer\u00a0and\u00a0confirmed\u00a0proximal\nDVT\u00a0or\u00a0PE,\u00a0and\u00a0continue\u00a0the\u00a0LMWH\u00a0for\u00a06\u00a0months.", "chunk_order": 13}
{"chunk_id": "f9fc68be-2971-4955-b8db-ebed03e3b9cc", "source_document_filename": "CPG Prevention and Treatment of Venous Thrombosis_cleaned_ultra_minimal.txt", "source_document_title": "CPG Prevention and Treatment of Venous Thrombosis cleaned ultra minimal", "text": "male,\u00a0family\u00a0history)\u00a0and\u00a0there\u00a0is\u00a0no\u00a0additional\u00a0risk\u00a0of\u00a0major\nbleeding. Discuss\u00a0with\u00a0the\u00a0patient\u00a0the\u00a0benefits\u00a0and\u00a0risks\u00a0of\u00a0extending\ntheir\u00a0treatment\nv\u00a0 Offer\u00a0anticoagulation\u00a0beyond\u00a03\u00a0months\u00a0to\u00a0patients\u00a0with\u00a0an\nunprovoked\u00a0PE,\u00a0taking\u00a0into\u00a0account\u00a0the\u00a0patient's\u00a0risk\u00a0of\u00a0VTE\nrecurrence\u00a0and\u00a0whether\u00a0they\u00a0are\u00a0at\u00a0increased\u00a0risk\u00a0of\u00a0bleeding. Discuss\u00a0with\u00a0the\u00a0patient\u00a0the\u00a0benefits\u00a0and\u00a0risks\u00a0of\u00a0extending\u00a0their\ntreatment\nv\u00a0 Offer\u00a0LMWH\u00a0to\u00a0patients\u00a0with\u00a0active\u00a0cancer\u00a0and\u00a0confirmed\u00a0proximal\nDVT\u00a0or\u00a0PE,\u00a0and\u00a0continue\u00a0the\u00a0LMWH\u00a0for\u00a06\u00a0months. At\u00a06\u00a0months,\nassess\u00a0the\u00a0risks\u00a0and\u00a0benefits\u00a0of\u00a0continuing\u00a0anticoagulation\nv\u00a0 Experience\u00a0with\u00a0rivaroxaban\u00a0in\u00a0extending\u00a0anticoagulation\u00a0beyond\u00a012\nmonths\u00a0is\u00a0limited\nv\u00a0 DO\u00a0NOT\u00a0routinely\u00a0do\u00a0D\u00addimer\u00a0test\u00a0and\u00a0Doppler\u00a0US\u00a0on\u00a0completion\u00a0of\nanticoagulation\u00a0except\u00a0guided\u00a0by\u00a0clinical\u00a0symptoms\u00a0and\u00a0signs\nv\u00a0 Verbal\u00a0and\u00a0written\u00a0information\u00a0are\u00a0given\u00a0to\u00a0patients\u00a0having\nanticoagulant\u00a0treatment\u00a0about:\nt\u00a0 Duration\u00a0of\u00a0anticoagulation\u00a0treatment\nt\u00a0 Anticoagulation\u00a0booklet\nt\u00a0 Possible\u00a0side\u00a0effects\u00a0and\u00a0what\u00a0to\u00a0do\u00a0if\u00a0these\u00a0occur\nt\u00a0 The\u00a0effects\u00a0of\u00a0other\u00a0medication,\u00a0food\u00a0and\u00a0alcohol\u00a0on\u00a0oral\nanticoagulant\nt\u00a0 Monitoring\u00a0their\u00a0anticoagulant\u00a0treatment\nt\u00a0 Pregnancy\u00a0and\u00a0contraception\nt\u00a0 Surgery\u00a0and\u00a0dental\u00a0treatment\nt\u00a0 Future\u00a0risk\u00a0reduction\u00a0measures\u00a0including\u00a0travel\nt\u00a0 Clear\u00a0advice\u00a0on\u00a0long\u00a0term\u00a0use\u00a0of\u00a0stockings\nv\u00a0 Arrange\u00a0for\u00a0follow\u00adup\u00a0at\u00a0medical\u00a0or\u00a0haematology\u00a0clinic\nv\u00a0 Arrange\u00a0for\u00a0INR\u00a0monitoring\u00a0at\u00a0the\u00a0anticoagulation\u00a0clinic\n(MTAC\u00adWarfarin)\nTABLE\u00a0OF\u00a0CONTENTS\nCHAPTER\u00a0 TITLE\nPAGE\n1.0\nEPIDEMIOLOGY\u00a0AND\u00a0PATHOGENESIS\n28\u00ad30\n1.1\nEpidemiology\u00a0of\u00a0Venous\u00a0Thromboembolism\u00a0(VTE)\n28\n1.2\nPathogenesis\u00a0and\u00a0natural\u00a0history\u00a0of\u00a0VTE\n29\u00ad30\n2.0\nVTE\u00a0PROPHYLAXIS\n31\u00ad43\n2.1\nIntroduction\n31\n2.2\nMethods\u00a0of\u00a0prophylaxis\n31\u00ad33\n2.3\nRisk\u00a0assessment\u00a0for\u00a0VTE\n33\u00ad37\n2.4\nRisk\u00a0assessment\u00a0for\u00a0bleeding\n38\n2.5\nTiming\u00a0and\u00a0initiation\u00a0of\u00a0prophylaxis\n39\n2.6\nAntithrombotic\u00a0therapy\u00a0and\u00a0regional\u00a0anaesthesia\n40\u00ad41\n2.7\nDuration\u00a0of\u00a0prophylaxis\n42\n2.8\nSpecial\u00a0considerations:\u00a0stroke\n42\u00ad43\n3.0\nCLINICAL\u00a0DIAGNOSIS\n44\u00ad49\n3.1\nClinical\u00a0prediction\u00a0model\n44\u00ad45\n3.2\nAlgorithm\u00a0for\u00a0diagnosis\u00a0of\u00a0VTE\n45\u00ad47\n3.3\nInvestigations\u00a0for\u00a0cancer\n48\n3.4\nThrombophilia\u00a0testing\n48\u00ad49\n4.0\nTREATMENT\u00a0OF\u00a0VTE\n50\u00ad57\n4.1\nIntroduction\n50\n4.2\nInitial\u00a0treatment\u00a0of\u00a0VTE\n50\u00ad52\n4.3\nMaintenance\u00a0treatment\u00a0of\u00a0VTE\n52\u00ad54\n4.4\nThrombolytic\u00a0therapy\n55\n4.5\nVena\u00a0caval\u00a0filters\n56\u00ad57\n4.6\nPrevention\u00a0of\u00a0post\u00adthrombotic\u00a0syndrome\n57\n5.0\nMONITORING\u00a0ANTICOAGULATION\n58\u00ad62\n5.1\nIntroduction\n58\n5.2\nWarfarin\n58\n5.3\nUnfractionated\u00a0heparin\u00a0(UFH)\n58\n5.4\nLow\u00a0molecular\u00a0weight\u00a0heparin\u00a0(LMWH)\n59\n5.5\nFondaparinux\n59\n5.6\nRivaroxaban\n59\u00ad60\n5.7\nHeparin\u00adinduced\u00a0thrombocytopenia\u00a0and\u00a0monitoring\u00a0platelet\u00a0counts\n61\u00ad62\n6.0\nPERIOPERATIVE\u00a0MANAGEMENT\u00a0OF\u00a0ANTICOAGULATION\n63\u00ad68\n6.1\nIntroduction\n63\n6.2\nThromboembolic\u00a0risk\n63\u00ad64\n6.3\nBleeding\u00a0risk\u00a0in\u00a0surgery\n64\u00ad65\n6.4\nManaging\u00a0anticoagulation\u00a0in\u00a0surgery\n65\u00ad68\n7.0\nMANAGEMENT\u00a0OF\u00a0OVER\u00adANTICOAGULATION\n69\u00ad75\n7.1\nWarfarin\u00a0and\u00a0bleeding\n69\n7.2\nWarfarin\u00a0reversal\n69\u00ad70\n7.3\nManagement\u00a0of\u00a0over\u00adwarfarinisation\n70\u00ad71\n7.4\nSpecific\u00a0clinical\u00a0scenarios\n72\u00ad73\n7.5\nHeparin\u00a0and\u00a0bleeding\n73\u00ad74\n7.6\nFondaparinux\u00a0and\u00a0bleeding\n74\n7.7\nThe\u00a0novel\u00a0oral\u00a0anticoagulants\u00a0and\u00a0bleeding\n74\u00ad75\nTABLE\u00a0OF\u00a0CONTENTS\nCHAPTER\u00a0TITLE\nPAGE\n8.0\nVTE\u00a0IN\u00a0OBSTETRICS\n76\u00ad86\n8.1\nIntroduction\n76\n8.2\nPathogenesis\u00a0and\u00a0risk\u00a0factors\n76\n8.3\nDiagnosis\n76\u00ad78\n8.4\nAlgorithm\u00a0for\u00a0diagnosis\u00a0of\u00a0VTE\u00a0in\u00a0pregnancy\n78\u00ad79\n8.5\nTreatment\u00a0of\u00a0VTE\u00a0in\u00a0pregnancy\n80\u00ad81\n8.6\nPrevention\u00a0of\u00a0VTE\u00a0in\u00a0pregnancy\n81\u00ad85\n8.7\nManagement\u00a0of\u00a0pregnant\u00a0women\u00a0with\u00a0the\u00a0antiphospholipid\u00a0antibody\u00a0syndrome\n85\u00ad86\n9.0\nTHE\u00a0TREATMENT\u00a0OF\u00a0VTE\u00a0IN\u00a0SPECIAL\u00a0POPULATIONS\u00a0AND\u00a0UNUSUAL\u00a0SITES 87\u00ad105\n9.1\nThe\u00a0elderly,\u00a0renal\u00a0impairment\u00a0and\u00a0obesity\n87\u00ad88\n9.2\nAnticoagulation\u00a0for\u00a0established\u00a0VTE\u00a0in\u00a0stroke\u00a0patients\n88\n9.3\nAntithrombotic\u00a0therapy\u00a0in\u00a0children\n88\u00ad96\n9.4\nFertility\u00a0treatment\u00a0and\u00a0VTE\n96\u00ad98\n9.5\nHormonal\u00a0contraception\u00a0and\u00a0VTE\n99\u00ad101\n9.6\nVTE\u00a0and\u00a0cancer\n102\u00ad103\n9.7\nThrombosis\u00a0in\u00a0unusual\u00a0sites\n104\u00ad105\n10.0\nMEDICATION\u00a0THERAPY\u00a0ADHERENCE\u00a0CLINIC\u00adWARFARIN\u00a0(MTAC\u00adW)\n106\u00ad112\n10.1\nIntroduction\n106\n10.2\nNational\u00a0guidance\u00a0and\u00a0additional\u00a0resources\n106\n10.3\nObjectives\n107\n10.4\nResponsibilities\u00a0of\u00a0the\u00a0clinical\u00a0pharmacist\u00a0in\u00adcharge\n107\u00a0\u00ad108\n10.5\nManpower\u00a0requirement\n108\n10.6\nAppointment\n108\n10.7\nWork\u00a0procedures\n108\n10.8\nPatient\u00a0selection\n108\u00a0\u00ad109\n10.9\nINR\u00a0testing\n109\n10.10\u00a0 Patient\u00a0counseling\n109\u00a0\u00ad110\n10.11\u00a0 Monitoring\u00a0and\u00a0evaluation\n110\n10.12\u00a0 Dosage\u00a0adjustment\n111\n10.13\u00a0\u00a0 Dispensing\n111\n10.14\u00a0\u00a0 Missed\u00a0appointments\n112\n10.15\u00a0\u00a0 Documentation\n112\n10.16\u00a0 Quality\u00a0assurance\n112\nAPPENDICES\n113\u00ad147\nAppendix\u00a01\u00a0\u00a0\u00a0Warfarin\u00a0Dosage\u00a0Adjustment\n113\u00ad117\nAppendix\u00a02\u00a0\u00a0\u00a0MTAC\u00a0Warfarin\u00a0Clinic\u00a0Workflow\n118\nAppendix\u00a03\u00a0\u00a0\u00a0MTAC\u00a0\u00ad\u00a0Warfarin:\u00a0Referral\u00a0Form\u00a0(MTAC\u00adW\u00a0F/1)\n119\u00ad120\nAppendix\u00a04\u00a0\u00a0\u00a0Checklist\u00a0for\u00a0warfarin\u00a0counseling\n121\u00ad124\nAppendix\u00a05\u00a0\u00a0\u00a0MTAC\u00a0\u00ad\u00a0Warfarin:\u00a0First\u00a0Visit\u00a0Form\u00a0(MTAC\u00adW\u00a0F/2)\n125\u00ad126\nAppendix\u00a06\u00a0\u00a0\u00a0MTAC\u00a0\u00ad\u00a0Warfarin:\u00a0Follow\u00adup\u00a0Form\u00a0(MTAC\u00adW\u00a0F/3)\n127\u00ad128\nAppendix\u00a07\u00a0\u00a0\u00a0Drug\u00a0Check\u00a0List\n129\u00ad133\nAppendix\u00a08\u00a0\u00a0\u00a0Warfarin\u00a0Label\n134\nAppendix\u00a09\u00a0\u00a0\u00a0Warfarin\u00a0Dosing\u00a0Note\n135\nAppendix\u00a010\u00a0Missed\u00a0Appointment\u00a0Record\n136\nAppendix\u00a011\u00a0Management\u00a0Of\u00a0Warfarin\u00a0Anticoagulation\u00a0In\u00a0Children\u00a0(UMMC\u00a0Guidelines\u00a02013)\n137\u00ad144\nAppendix\u00a012\u00a0Level\u00a0Of\u00a0Evidence\n145\nAppendix\u00a013\u00a0Clinical\u00a0Questions\n146\u00ad147\nREFERENCES\n148\u00ad168\n1.", "chunk_order": 14}
{"chunk_id": "24ba77b6-aa85-4d6d-b925-f324bdfa2925", "source_document_filename": "CPG Prevention and Treatment of Venous Thrombosis_cleaned_ultra_minimal.txt", "source_document_title": "CPG Prevention and Treatment of Venous Thrombosis cleaned ultra minimal", "text": "EPIDEMIOLOGY\u00a0AND\u00a0PATHOGENESIS\n1.1\u00a0EPIDEMIOLOGY\u00a0OF\u00a0VENOUS\u00a0THROMBOEMBOLISM\nVenous\u00a0thromboembolism\u00a0(VTE)\u00a0is\u00a0a\u00a0major\u00a0health\u00a0problem. It\u00a0is\u00a0the\u00a0third\u00a0most\ncommon\u00a0 cardiovascular\u00a0 disease\u00a0 after\u00a0 myocardial\u00a0 infarction\u00a0 and\u00a0 stroke.3\u00a0The\noverall\u00a0VTE\u00a0rates\u00a0are\u00a0100\u00a0per\u00a0100,000\u00a0population\u00a0per\u00a0year,\u00a0of\u00a0which\u00a070%\u00a0are\nhospital\u00adacquired.4\nIt\u00a0is\u00a0estimated\u00a0that\u00a025,000\u00a0people\u00a0in\u00a0the\u00a0UK\u00a0die\u00a0from\u00a0preventable\u00a0hospital\u00adacquired\nVTE\u00a0every\u00a0year. In\u00a0Europe,\u00a0the\u00a0annual\u00a0mortality\u00a0from\u00a0VTE\u00a0surpasses\u00a0the\u00a0sum\u00a0of\u00a0the\nmortalities\u00a0from\u00a0breast\u00a0cancer,\u00a0prostate\u00a0cancer,\u00a0AIDS\u00a0and\u00a0traffic\u00a0accidents.5\nIt\u00a0 has\u00a0 long\u00a0 been\u00a0 perceived\u00a0 that\u00a0 VTE\u00a0 is\u00a0 rare\u00a0 in\u00a0Asia. However,\u00a0 several\u00a0 recent\nepidemiological\u00a0studies\u00a0seem\u00a0to\u00a0refute\u00a0this. The\u00a0incidences\u00a0of\u00a0VTE\u00a0after\u00a0major\northopedic\u00a0surgery,\u00a0stroke,\u00a0medically\u00a0ill\u00a0and\u00a0critical\u00a0care\u00a0patients\u00a0approach\u00a0that\u00a0of\nWestern\u00a0countries.5\u00ad18\nHospital\u00adacquired\u00a0VTE\u00a0in\u00a0Asia\u00a0is\u00a0increasing.14\u00ad16\u00a0Pulmonary\u00a0embolism\u00a0accounts\u00a0for\nup\u00a0 to\u00a0 6%\u00a0 of\u00a0 hospital\u00a0 deaths.5\u00a0Acquired\u00a0 factors\u00a0 such\u00a0 as\u00a0 immobilisation,\u00a0 active\ncancer,\u00a0 infections,\u00a0 advancing\u00a0 age,\u00a0 heart\u00a0 diseases\u00a0 and\u00a0 major\u00a0 surgeries\u00a0 are\nassociated\u00a0with\u00a0an\u00a0increase\u00a0risk\u00a0of\u00a0VTE.12\u00ad17\nVenous\u00a0thromboembolism\u00a0in\u00a0obstetrics\u00a0is\u00a0also\u00a0on\u00a0the\u00a0rise\u00a0in\u00a0the\u00a0East\u00a0due\u00a0to\u00a0several\nfactors\u00a0 such\u00a0 as\u00a0 increasing\u00a0 maternal\u00a0 age,\u00a0 obesity,\u00a0 rising\u00a0 trend\u00a0 for\u00a0 caesarean\ndeliveries,\u00a0multiple\u00a0pregnancies\u00a0and\u00a0low\u00a0rate\u00a0for\u00a0thromboprophylaxis.21\u00a0Obstetric\nVTE\u00a0is\u00a0now\u00a0the\u00a0leading\u00a0cause\u00a0of\u00a0maternal\u00a0death\u00a0in\u00a0Malaysia.22\nHence,\u00a0VTE\u00a0should\u00a0no\u00a0longer\u00a0be\u00a0considered\u00a0a\u00a0Western\u00a0disease\u00a0but\u00a0a\u00a0worldwide\nhealth\u00a0crisis. Appropriate\u00a0measures\u00a0must\u00a0be\u00a0taken\u00a0to\u00a0prevent\u00a0it\u00a0in\u00a0the\u00a0correct\u00a0setting. EPIDEMIOLOGY\u00a0OF\u00a0VTE\nv\u00a0 Venous\u00a0thromboembolism\u00a0is\u00a0a\u00a0major\u00a0health\u00a0problem\u00a0worldwide\nv\u00a0 The\u00a0overall\u00a0rate\u00a0of\u00a0VTE\u00a0is\u00a0100\u00a0per\u00a0100,000\u00a0population\u00a0per\u00a0year\nv\" D$%0\"CE)9\"F\"$#\"GHI+\")%0\"E$+;1C)<J)/K81%0(\nv\u00a0 About\u00a010%\u00a0die\u00a0within\u00a0the\u00a0first\u00a0month\u00a0of\u00a0VTE\u00a0diagnosis\nv\u00a0 In\u00a0Asia,\u00a0VTE\u00a0is\u00a0increasing\u00a0due\u00a0to\u00a0several\u00a0factors:\n\"\u00a0 Aging\u00a0population\n\"\u00a0 Higher\u00a0rates\u00a0of\u00a0major\u00a0complex\u00a0surgeries\n\"\u00a0 Higher\u00a0rates\u00a0of\u00a0caesarean\u00a0deliveries\n\"\u00a0 Rise\u00a0in\u00a0Obesity\n\"\u00a0 Rise\u00a0in\u00a0Cancer\n\"\u00a0 Low\u00a0rates\u00a0for\u00a0thromboprophylaxis\n1.2\u00a0PATHOGENESIS\u00a0AND\u00a0THE\u00a0NATURAL\u00a0HISTORY\u00a0OF\u00a0VTE\nVenous\u00a0 thromboembolism\u00a0 comprises\u00a0 both\u00a0 deep\u00a0 vein\u00a0 thrombosis\u00a0 (DVT)\u00a0 and\npulmonary\u00a0embolism\u00a0(PE). Three\u00a0major\u00a0pathophysiologic\u00a0determinants\u00a0of\u00a0VTE\u00a0were\nproposed\u00a0by\u00a0Virchow:\u00a0venous\u00a0stasis,\u00a0endothelial\u00a0injury\u00a0and\u00a0hypercoagulability. All\u00a0risk\nfactors\u00a0for\u00a0VTE\u00a0influence\u00a0at\u00a0least\u00a0one\u00a0of\u00a0these\u00a03\u00a0mechanisms.", "chunk_order": 15}
{"chunk_id": "d0d188fa-41a5-4a6a-96b7-ffb700578248", "source_document_filename": "CPG Prevention and Treatment of Venous Thrombosis_cleaned_ultra_minimal.txt", "source_document_title": "CPG Prevention and Treatment of Venous Thrombosis cleaned ultra minimal", "text": "Three\u00a0major\u00a0pathophysiologic\u00a0determinants\u00a0of\u00a0VTE\u00a0were\nproposed\u00a0by\u00a0Virchow:\u00a0venous\u00a0stasis,\u00a0endothelial\u00a0injury\u00a0and\u00a0hypercoagulability. All\u00a0risk\nfactors\u00a0for\u00a0VTE\u00a0influence\u00a0at\u00a0least\u00a0one\u00a0of\u00a0these\u00a03\u00a0mechanisms. Venous\u00a0 thrombi\u00a0 originate\u00a0 in\u00a0 venous\u00a0 valve\u00a0 pockets\u00a0 at\u00a0 sites\u00a0 of\u00a0 venous\u00a0 stasis\u00a0 or\nfollowing\u00a0vessel\u00a0wall\u00a0injury.23,24\u00a0The\u00a0symptoms\u00a0of\u00a0VTE\u00a0are\u00a0caused\u00a0by\u00a0obstruction\u00a0of\nvenous\u00a0outflow\u00a0by\u00a0thrombi,\u00a0causing\u00a0inflammation\u00a0of\u00a0the\u00a0vein\u00a0wall,\u00a0inflammation\u00a0of\u00a0the\ntissues\u00a0surrounding\u00a0it\u00a0or\u00a0embolisation\u00a0into\u00a0the\u00a0pulmonary\u00a0circulation.24\nAbout\u00a0half\u00a0of\u00a0DVT\u00a0associated\u00a0with\u00a0surgery\u00a0start\u00a0intra\u00adoperatively\u00a0and\u00a0many\u00a0resolve\nspontaneously.24,26,27\u00a0The\u00a0risk\u00a0of\u00a0progression\u00a0of\u00a0post\u00adoperative\u00a0VTE\u00a0is\u00a0greater\u00a0when\nthere\u00a0are\u00a0continuing\u00a0risk\u00a0factors\u00a0for\u00a0thrombosis.24,27,48\nThe\u00a0 risk\u00a0 of\u00a0 VTE\u00a0 differs\u00a0 with\u00a0 the\u00a0 type\u00a0 of\u00a0 surgery:\u00a0 major\u00a0 orthopedic\u00a0 surgery\u00a0 is\nassociated\u00a0with\u00a0twice\u00a0the\u00a0risk\u00a0of\u00a0VTE\u00a0associated\u00a0with\u00a0major\u00a0general\u00a0surgery.32\u00a0The\nrisk\u00a0of\u00a0symptomatic\u00a0VTE\u00a0is\u00a0highest\u00a0within\u00a02\u00a0weeks\u00a0of\u00a0surgery\u00a0and\u00a0remains\u00a0elevated\nfor\u00a0a\u00a0further\u00a02\u00a0to\u00a03\u00a0months.28,49\u00a0The\u00a0risk\u00a0of\u00a0fatal\u00a0PE\u00a0is\u00a0highest\u00a03\u00a0to\u00a07\u00a0days\u00a0following\nsurgery.27,32,33,35\nMost\u00a0DVT\u00a0begin\u00a0in\u00a0the\u00a0calf.23\u00ad25\u00a0Eighty\u00a0percent\u00a0of\u00a0symptomatic\u00a0DVT\u00a0involve\u00a0the\u00a0proximal\nveins.24\u00a0Isolated\u00a0calf\u00a0DVT\u00a0rarely\u00a0cause\u00a0leg\u00a0symptoms\u00a0or\u00a0clinically\u00a0significant\u00a0PE.24,25\nAbout\u00a025%\u00a0of\u00a0untreated\u00a0symptomatic\u00a0calf\u00a0DVT\u00a0extend\u00a0to\u00a0the\u00a0proximal\u00a0veins,\u00a0mostly\nwithin\u00a01\u00a0week\u00a0of\u00a0presentation.31,32\u00a0Without\u00a0treatment,\u00a050%\u00a0of\u00a0patients\u00a0with\u00a0symptomatic\nproximal\u00a0DVT\u00a0or\u00a0PE\u00a0have\u00a0recurrent\u00a0thrombosis\u00a0within\u00a03\u00a0months.40,41\u00a0Ten\u00a0percent\u00a0of\nsymptomatic\u00a0PE\u00a0are\u00a0fatal\u00a0within\u00a0one\u00a0hour\u00a0of\u00a0onset\u00a0of\u00a0symptoms.42\nIsolated\u00a0proximal\u00a0DVT\u00a0(without\u00a0involvement\u00a0in\u00a0the\u00a0calf\u00a0veins)\u00a0is\u00a0more\u00a0common\u00a0during\npregnancy. Two\u00adthirds\u00a0of\u00a0VTE\u00a0in\u00a0pregnancy\u00a0occur\u00a0during\u00a0the\u00a0antepartum\u00a0period\u00a0while\nthe\u00a0occurrence\u00a0of\u00a0PE\u00a0is\u00a0more\u00a0common\u00a0during\u00a0the\u00a0post\u00adpartum\u00a0period.31\u00a0The\u00a0natural\ncourse\u00a0of\u00a0DVT\u00a0in\u00a0pregnancy\u00a0is\u00a0less\u00a0well\u00a0known.50\u00ad52\nResolution\u00a0of\u00a0proximal\u00a0DVT\u00a0is\u00a0slow\u00a0and\u00a0less\u00a0than\u00a0half\u00a0have\u00a0complete\u00a0lysis\u00a0after\u00a06\nmonths\u00a0 of\u00a0 anticoagulation.37\u00a0 However,\u00a0 more\u00a0 than\u00a0 90%\u00a0 will\u00a0 have\u00a0 complete\nrecanalisation\u00a0with\u00a0development\u00a0of\u00a0collaterals.37\u00a0As\u00a0for\u00a0PE,\u00a050%\u00a0resolution\u00a0occurs\u00a0after\n2\u00a0to\u00a04\u00a0weeks\u00a0of\u00a0treatment.40\u00a0Eventually,\u00a0complete\u00a0resolution\u00a0of\u00a0PE\u00a0occurs\u00a0in\u00a0about\ntwo\u00adthirds\u00a0of\u00a0patients.42\u00ad44\nThe\u00a0risk\u00a0of\u00a0recurrence\u00a0after\u00a0stopping\u00a0anticoagulation\u00a0is\u00a0similar\u00a0following\u00a0proximal\nDVT\u00a0and\u00a0PE.36,45\u00a0However\u00a0the\u00a0risk\u00a0of\u00a0mortality\u00a0is\u00a02\u00a0to\u00a03\u00adfold\u00a0higher\u00a0with\u00a0recurrent\u00a0PE. The\u00a0 risk\u00a0 of\u00a0 recurrent\u00a0 VTE\u00a0 is\u00a0 higher\u00a0 in\u00a0 patients\u00a0 with\u00a0 unprovoked\u00a0 VTE\u00a0 or\u00a0 with\npersisting\u00a0risk\u00a0factors\u00a0for\u00a0thrombosis\u00a0(e.g. cancer\u00a0and\u00a0anti\u00adphospholipid\u00a0syndrome)\ncompared\u00a0to\u00a0patients\u00a0with\u00a0transient\u00a0risk\u00a0factors\u00a0(e.g. recent\u00a0surgery).29,30,46,47\nComplications\u00a0of\u00a0VTE\u00a0include\u00a0post\u00adthrombotic\u00a0syndrome\u00a0and\u00a0chronic\u00a0thromboembolic\npulmonary\u00a0 hypertension. Following\u00a0 symptomatic\u00a0 DVT,\u00a0 the\u00a0 incidence\u00a0 of\u00a0 severe\npost\u00adthrombotic\u00a0 syndrome\u00a0 is\u00a0 10%\u00a0 after\u00a0 5\u00a0 years\u00a0 but\u00a0 is\u00a0 as\u00a0 high\u00a0 as\u00a0 80%\u00a0 following\npregnancy\u00adassociated\u00a0VTE\u037e\u00a0mostly\u00a0occurring\u00a0within\u00a0the\u00a0first\u00a02\u00a0years.29,38,39\u00a0Chronic\nthromboembolic\u00a0pulmonary\u00a0hypertension\u00a0occurs\u00a0in\u00a05%\u00a0of\u00a0patients\u00a0with\u00a0treated\u00a0PE.41\nNATURAL\u00a0HISTORY\u00a0OF\u00a0VTE\nv\u00a0 Most\u00a0DVT\u00a0begin\u00a0in\u00a0the\u00a0calf.", "chunk_order": 16}
{"chunk_id": "647cb38b-6eaf-4266-8534-096c44b80882", "source_document_filename": "CPG Prevention and Treatment of Venous Thrombosis_cleaned_ultra_minimal.txt", "source_document_title": "CPG Prevention and Treatment of Venous Thrombosis cleaned ultra minimal", "text": "The\u00a0 risk\u00a0 of\u00a0 recurrent\u00a0 VTE\u00a0 is\u00a0 higher\u00a0 in\u00a0 patients\u00a0 with\u00a0 unprovoked\u00a0 VTE\u00a0 or\u00a0 with\npersisting\u00a0risk\u00a0factors\u00a0for\u00a0thrombosis\u00a0(e.g. cancer\u00a0and\u00a0anti\u00adphospholipid\u00a0syndrome)\ncompared\u00a0to\u00a0patients\u00a0with\u00a0transient\u00a0risk\u00a0factors\u00a0(e.g. recent\u00a0surgery).29,30,46,47\nComplications\u00a0of\u00a0VTE\u00a0include\u00a0post\u00adthrombotic\u00a0syndrome\u00a0and\u00a0chronic\u00a0thromboembolic\npulmonary\u00a0 hypertension. Following\u00a0 symptomatic\u00a0 DVT,\u00a0 the\u00a0 incidence\u00a0 of\u00a0 severe\npost\u00adthrombotic\u00a0 syndrome\u00a0 is\u00a0 10%\u00a0 after\u00a0 5\u00a0 years\u00a0 but\u00a0 is\u00a0 as\u00a0 high\u00a0 as\u00a0 80%\u00a0 following\npregnancy\u00adassociated\u00a0VTE\u037e\u00a0mostly\u00a0occurring\u00a0within\u00a0the\u00a0first\u00a02\u00a0years.29,38,39\u00a0Chronic\nthromboembolic\u00a0pulmonary\u00a0hypertension\u00a0occurs\u00a0in\u00a05%\u00a0of\u00a0patients\u00a0with\u00a0treated\u00a0PE.41\nNATURAL\u00a0HISTORY\u00a0OF\u00a0VTE\nv\u00a0 Most\u00a0DVT\u00a0begin\u00a0in\u00a0the\u00a0calf. In\u00a0pregnancy\u00a0it\u00a0begins\u00a0in\u00a0the\u00a0proximal\u00a0and\npelvic\u00a0veins\nv\u00a0 The\u00a0risk\u00a0factors\u00a0for\u00a0VTE\u00a0influence\u00a0at\u00a0least\u00a0one\u00a0of\u00a0Virchow\u2019s\u00a0triad:\u00a0blood\ncoagulability,\u00a0vessel\u00a0integrity\u00a0and\u00a0blood\u00a0flow\nv\u00a0 The\u00a0risk\u00a0of\u00a0VTE\u00a0is\u00a0highest\u00a0following\u00a0major\u00a0orthopedic\u00a0surgery\u00a0where\nvessel\u00a0damage\u00a0and\u00a0immobility\u00a0play\u00a0a\u00a0major\u00a0role\nv\u00a0 The\u00a0risk\u00a0of\u00a0symptomatic\u00a0VTE\u00a0is\u00a0highest\u00a0within\u00a02\u00a0weeks\u00a0of\u00a0surgery\u00a0and\nremains\u00a0elevated\u00a0for\u00a0a\u00a0further\u00a02\u00a0to\u00a03\u00a0months\nv\u00a0 The\u00a0risk\u00a0of\u00a0fatal\u00a0PE\u00a0is\u00a0highest\u00a0within\u00a01\u00a0week\u00a0of\u00a0surgery\nv\u00a0 Following\u00a0treatment,\u00a0the\u00a0resolution\u00a0of\u00a0DVT\u00a0is\u00a0slower\u00a0than\u00a0for\u00a0PE\u00a0with\ncomplete\u00a0resolution\u00a0being\u00a0more\u00a0common\u00a0with\u00a0PE\u00a0than\u00a0in\u00a0DVT,\u00a0where\nrecanalisation\u00a0is\u00a0commoner\nv\u00a0 The\u00a0risk\u00a0of\u00a0VTE\u00a0recurrence\u00a0is\u00a0higher\u00a0in\u00a0unprovoked\u00a0than\u00a0in\u00a0provoked\n(recent\u00a0surgery)\u00a0VTE\nv\u00a0 The\u00a0risk\u00a0of\u00a0recurrence\u00a0remains\u00a0elevated\u00a0after\u00a0a\u00a0first\u00a0episode\u00a0of\u00a0VTE\nv\u00a0 Active\u00a0cancer\u00a0and\u00a0the\u00a0anti\u00adphospholipid\u00a0syndrome\u00a0are\u00a0risk\u00a0factors\u00a0for\nVTE\u00a0recurrence\nv\u00a0 The\u00a0risk\u00a0of\u00a0mortality\u00a0is\u00a0higher\u00a0with\u00a0recurrent\u00a0PE\u00a0than\u00a0recurrent\u00a0DVT\nv\u00a0 Post\u00adthrombotic\u00a0syndrome\u00a0and\u00a0chronic\u00a0thromboembolic\u00a0pulmonary\nhypertension\u00a0are\u00a0complications\u00a0of\u00a0VTE\nv\u00a0 Post\u00adthrombotic\u00a0syndrome\u00a0occurs\u00a0more\u00a0frequently\u00a0following\npregnancy\u00adassociated\u00a0VTE\u00a0because\u00a0the\u00a0proximal\u00a0ilio\u00adfemoral\u00a0veins\u00a0are\nusually\u00a0involved\n2.0\u00a0VTE\u00a0PROPHYLAXIS\n2.1\u00a0INTRODUCTION\nVTE\u00a0is\u00a0an\u00a0important\u00a0cause\u00a0of\u00a0death\u00a0in\u00a0hospital\u00a0patients\u00a0and\u00a0treatment\u00a0of\u00a0VTE\u00a0and\nits\u00a0related\u00a0long\u00adterm\u00a0morbidities\u00a0are\u00a0associated\u00a0with\u00a0considerable\u00a0cost\u00a0to\u00a0the\u00a0health\nservice. Efforts\u00a0should\u00a0be\u00a0made\u00a0to\u00a0prevent\u00a0the\u00a0occurrence\u00a0of\u00a0VTE\u00a0by\u00a0stratifying\nhospitalised\u00a0patients\u00a0according\u00a0to\u00a0risk\u00a0categories\u00a0and\u00a0offering\u00a0thromboprophylaxis\nwhen\u00a0appropriate. 2.2\u00a0METHODS\u00a0OF\u00a0PROPHYLAXIS\n2.2.1\u00a0Mechanical\u00a0Prophylaxis\nApplication\u00a0 of\u00a0 Graded\u00a0 Elastic\u00a0 Compression\u00a0 Stockings\u00a0 (GECS),\u00a0 Intermittent\nPneumatic\u00a0Compression\u00a0(IPC)\u00a0of\u00a0the\u00a0calf\u00a0or\u00a0calf\u00a0and\u00a0thigh\u00a0or\u00a0Venous\u00a0Foot\u00a0Pump\n(VFP)\u00a0provide\u00a0a\u00a0valuable\u00a0adjunct\u00a0to\u00a0pharmacologic\u00a0methods\u00a0in\u00a0patients\u00a0at\u00a0high\u00adrisk\nfor\u00a0 VTE\u00a0 and\u00a0 serve\u00a0 as\u00a0 the\u00a0 preferred\u00a0 alternative\u00a0 in\u00a0 patients\u00a0 who\u00a0 are\u00a0 ineligible\u00a0 for\npharmacologic\u00a0 therapy. Mechanical\u00a0 prophylaxis\u00a0 is\u00a0 also\u00a0 effective\u00a0 when\u00a0 used\u00a0 in\ncombination\u00a0with\u00a0early\u00a0ambulation\u00a0but\u00a0less\u00a0efficacious\u00a0than\u00a0pharmacologic\u00a0methods\nwhen\u00a0used\u00a0as\u00a0a\u00a0stand\u00adalone\u00a0modality.55,56,68\nMechanical\u00a0prophylaxis\u00a0are\u00a0applicable\u00a0pre\u00ad\u00a0and\u00a0intra\u00adoperatively,\u00a0and\u00a0should\u00a0be\ncontinued\u00a0post\u00adoperatively\u00a0until\u00a0the\u00a0patient\u00a0is\u00a0fully\u00a0ambulating. They\u00a0have\u00a0no\u00a0major\nclinically\u00a0 significant\u00a0 adverse\u00a0 effects,\u00a0 particularly\u00a0 bleeding.", "chunk_order": 17}
{"chunk_id": "4b8f2b87-705f-4a59-bda5-c041d6421f9d", "source_document_filename": "CPG Prevention and Treatment of Venous Thrombosis_cleaned_ultra_minimal.txt", "source_document_title": "CPG Prevention and Treatment of Venous Thrombosis cleaned ultra minimal", "text": "Mechanical\u00a0 prophylaxis\u00a0 is\u00a0 also\u00a0 effective\u00a0 when\u00a0 used\u00a0 in\ncombination\u00a0with\u00a0early\u00a0ambulation\u00a0but\u00a0less\u00a0efficacious\u00a0than\u00a0pharmacologic\u00a0methods\nwhen\u00a0used\u00a0as\u00a0a\u00a0stand\u00adalone\u00a0modality.55,56,68\nMechanical\u00a0prophylaxis\u00a0are\u00a0applicable\u00a0pre\u00ad\u00a0and\u00a0intra\u00adoperatively,\u00a0and\u00a0should\u00a0be\ncontinued\u00a0post\u00adoperatively\u00a0until\u00a0the\u00a0patient\u00a0is\u00a0fully\u00a0ambulating. They\u00a0have\u00a0no\u00a0major\nclinically\u00a0 significant\u00a0 adverse\u00a0 effects,\u00a0 particularly\u00a0 bleeding. The\u00a0 IPC\u00a0 has\u00a0 relative\ncontraindications\u00a0in\u00a0patients\u00a0with\u00a0severe\u00a0leg\u00a0ischemia/\u00a0peripheral\u00a0artery\u00a0disease,\nacute\u00a0superficial\u00a0and\u00a0deep\u00a0vein\u00a0thrombosis,\u00a0and\u00a0congestive\u00a0heart\u00a0failure.55,56,72\nHome\u00a0 use\u00a0 of\u00a0 mechanical\u00a0 prophylaxis\u00a0 is\u00a0 important\u00a0 because\u00a0 VTE\u00a0 is\u00a0 reported\u00a0 to\ndevelop\u00a0between\u00a08\u00a0and\u00a021\u00a0days\u00a0after\u00a0TKA\u00a0and\u00a0THA\u00a0respectively. Portable\u00a0motorized\nmechanical\u00a0compression\u00a0devices\u00a0are\u00a0available\u00a0and\u00a0are\u00a0superior\u00a0to\u00a0compression\nstockings\u00a0but\u00a0are\u00a0expensive.60,62\n2.2.2\u00a0Pharmacological\u00a0Prophylaxis\nProphylactic\u00a0drugs\u00a0include\u00a0low\u00a0molecular\u00a0weight\u00a0heparin\u00a0(LMWH),\u00a0pentasaccharide\nsodium\u00a0(fondaparinux),\u00a0unfractionated\u00a0heparin\u00a0(UFH)\u00a0and\u00a0the\u00a0newer\u00a0oral\u00a0anticoagulants\n(dabigatran,\u00a0rivaroxaban,\u00a0apixaban).62,65\n2.2.2.1\u00a0Low\u00a0Molecular\u00a0Weight\u00a0Heparins\nLow\nmolecular\nweight\nheparins\nhave\nbecome\nthe\nstandard\nfirst\nline\nthromboprophylactic\u00a0 agents. Although\u00a0 relatively\u00a0 costly,\u00a0 LMWHs\u00a0 have\u00a0 been\u00a0 widely\nused\u00a0 for\u00a0 prophylaxis\u00a0 owing\u00a0 to\u00a0 their\u00a0 cost\u00adeffectiveness. Studies\u00a0 comparing\u00a0 LMWH\n(once\u00a0or\u00a0twice\u00a0daily)\u00a0with\u00a0UFH\u00a0have\u00a0shown\u00a0that\u00a0LMWH\u00a0is\u00a0more\u00a0effective\u00a0than\u00a0UFH\u00a0in\npreventing\u00a0 thrombosis\u00a0 without\u00a0 increasing\u00a0 the\u00a0 risk\u00a0 of\u00a0 bleeding.60\u00ad64\u00a0 Low\u00a0 molecular\nweight\u00a0heparin\u00a0is\u00a0less\u00a0likely\u00a0to\u00a0produce\u00a0haematomas\u00a0at\u00a0injection\u00a0site,\u00a0heparin\u00adinduced\nthrombocytopenia/\u00a0thrombosis\u00a0(HITT)\u00a0and\u00a0osteoporosis\u00a0than\u00a0UFH.67,70\n2.2.2.2\u00a0Fondaparinux\nFondaparinux\u00a0 is\u00a0 a\u00a0 synthetic\u00a0 pentasaccharide\u00a0 sodium\u00a0 that\u00a0 selectively\u00a0 binds\u00a0 to\nantithrombin,\u00a0 inducing\u00a0 a\u00a0 conformational\u00a0 change\u00a0 that\u00a0 increases\u00a0 anti\u00adfactor\u00a0 Xa\nwithout\u00a0inhibiting\u00a0thrombin. It\u2019s\u00a0predictable\u00a0pharmacokinetic\u00a0and\u00a0a\u00a0long\u00a0elimination\nhalf\u00adlife\u00a0of\u00a017\u00a0to\u00a021\u00a0hours\u00a0allows\u00a0once\u00addaily\u00a0dosing. It\u00a0is\u00a0eliminated\u00a0unchanged\u00a0in\nurine\u037e\u00a0but\u00a0its\u00a0elimination\u00a0is\u00a0prolonged\u00a0in\u00a0patients\u00a0aged\u00a0>75\u00a0years\u00a0and\u00a0in\u00a0those\nweighing\u00a0<50kg.57\nFondaparinux\u00a0has\u00a0been\u00a0shown\u00a0to\u00a0be\u00a0effective\u00a0in\u00a0preventing\u00a0VTE\u00a0in\u00a0knee\u00a0and\u00a0hip\nreplacement\u00a0surgeries,\u00a0hip\u00a0fracture\u00a0surgeries,\u00a0abdominal\u00a0surgeries\u00a0and\u00a0acute\nmedically\u00a0ill\u00a0patients. It\u00a0can\u00a0be\u00a0used\u00a0as\u00a0an\u00a0alternative\u00a0to\u00a0LMWH. It\u00a0is\u00a0licensed\u00a0for\nuse\u00a0outside\u00a0pregnancy. The\u00a0prophylactic\u00a0dose\u00a0is\u00a02.5\u00a0mg\u00a0given\u00a0no\u00a0earlier\u00a0than\u00a06\nto\u00a08\u00a0hours\u00a0after\u00a0surgery.57,61\n2.2.2.3\u00a0Unfractionated\u00a0Heparin\nUnfractionated\u00a0heparin\u00a0is\u00a0no\u00a0longer\u00a0the\u00a0preferred\u00a0first\u00a0line\u00a0agent\u00a0as\u00a0it\u00a0requires\ncomplex\u00a0labor\u00adintensive\u00a0administration,\u00a0monitoring\u00a0and\u00a0dose\u00a0adjustment. Major\nbleeding\u00a0events,\u00a0risk\u00a0of\u00a0HITT\u00a0and\u00a0associated\u00a0costs\u00a0favour\u00a0other\u00a0newly\u00a0available\nagents.61\nSubcutaneous\u00a0low\u00addose\u00a0UFH\u00a0administered\u00a0in\u00a0a\u00a0dose\u00a0of\u00a05000\u00a0IU\u00a0every\u00a012\u00a0hours\nafter\u00a0the\u00a0surgery\u00a0reduces\u00a0the\u00a0rate\u00a0of\u00a0VTE\u00a0in\u00a0patients\u00a0undergoing\u00a0a\u00a0moderate\u00a0risk\nsurgery.55,56\u00a0 However,\u00a0 it\u00a0 is\u00a0 less\u00a0 effective\u00a0 than\u00a0 warfarin,\u00a0 adjusted\u00addose\u00a0 UFH\u00a0 and\nLMWH\u00a0when\u00a0used\u00a0as\u00a0prophylaxis\u00a0in\u00a0elective\u00a0hip\u00a0surgery. In\u00a0elective\u00a0hip\u00a0surgery,\u00a0the\nefficacy\u00a0of\u00a0UFH\u00a0is\u00a0enhanced\u00a0by\u00a0adjusting\u00a0the\u00a0dose,\u00a0e.g.", "chunk_order": 18}
{"chunk_id": "43fbd631-fc37-41a5-a8d9-34b907376d3c", "source_document_filename": "CPG Prevention and Treatment of Venous Thrombosis_cleaned_ultra_minimal.txt", "source_document_title": "CPG Prevention and Treatment of Venous Thrombosis cleaned ultra minimal", "text": "Major\nbleeding\u00a0events,\u00a0risk\u00a0of\u00a0HITT\u00a0and\u00a0associated\u00a0costs\u00a0favour\u00a0other\u00a0newly\u00a0available\nagents.61\nSubcutaneous\u00a0low\u00addose\u00a0UFH\u00a0administered\u00a0in\u00a0a\u00a0dose\u00a0of\u00a05000\u00a0IU\u00a0every\u00a012\u00a0hours\nafter\u00a0the\u00a0surgery\u00a0reduces\u00a0the\u00a0rate\u00a0of\u00a0VTE\u00a0in\u00a0patients\u00a0undergoing\u00a0a\u00a0moderate\u00a0risk\nsurgery.55,56\u00a0 However,\u00a0 it\u00a0 is\u00a0 less\u00a0 effective\u00a0 than\u00a0 warfarin,\u00a0 adjusted\u00addose\u00a0 UFH\u00a0 and\nLMWH\u00a0when\u00a0used\u00a0as\u00a0prophylaxis\u00a0in\u00a0elective\u00a0hip\u00a0surgery. In\u00a0elective\u00a0hip\u00a0surgery,\u00a0the\nefficacy\u00a0of\u00a0UFH\u00a0is\u00a0enhanced\u00a0by\u00a0adjusting\u00a0the\u00a0dose,\u00a0e.g. 3500\u00a0IU\u00a08\u00adhourly,\u00a0starting\ntwo\u00a0days\u00a0before\u00a0surgery\u00a0and\u00a0adjusting\u00a0the\u00a0dose\u00a0to\u00a0maintain\u00a0the\u00a0activated\u00a0partial\nthromboplastin\u00a0time\u00a0(APTT)\u00a0ratio\u00a0in\u00a0the\u00a0upper\u00a0normal\u00a0range.58,60,61\n2.2.2.4\u00a0Vitamin\u00a0K\u00a0Antagonist\nAdjusted\u00addose\u00a0warfarin,\u00a0historically\u00a0the\u00a0primary\u00a0agent\u00a0used\u00a0peri\u00adoperatively\u00a0and\ncompared\u00a0 with\u00a0 mechanical\u00a0 thromboprophylaxis\u00a0 or\u00a0 placebo,\u00a0 was\u00a0 effective\u00a0 in\nreducing\u00a0VTE\u00a0and\u00a0its\u00a0consequences.62,71\nVTE\u00a0prophylaxis\u00a0with\u00a0warfarin\u00a0can\u00a0be\u00a0commenced\u00a0pre\u00adoperatively\u00a0(risk\u00a0of\u00a0major\nbleeding\u00a0event),\u00a0at\u00a0the\u00a0time\u00a0of\u00a0surgery\u00a0or\u00a0at\u00a0the\u00a0early\u00a0post\u00adoperative\u00a0period\u00a0(may\u00a0not\nprevent\u00a0 small\u00a0 venous\u00a0 thrombi\u00a0 formation\u00a0 during\u00a0 or\u00a0 soon\u00a0 after\u00a0 surgery\u00a0 because\nanticoagulation\u00a0effect\u00a0is\u00a0not\u00a0achieved\u00a0until\u00a0the\u00a0third\u00a0or\u00a0fourth\u00a0post\u00adoperative\u00a0day). If\nstarted\u00a0at\u00a0a\u00a0low\u00a0dose\u00a0before\u00a0surgery,\u00a0it\u00a0may\u00a0reduce\u00a0the\u00a0risk\u00a0of\u00a0bleeding\u00a0compared\u00a0to\nfull\u00a0anticoagulation\u00a0at\u00a0the\u00a0time\u00a0of\u00a0surgery.69\nThe\u00a0advantages\u00a0are\u00a0its\u00a0ease\u00a0of\u00a0oral\u00a0administration\u00a0and\u00a0low\u00a0cost. The\u00a0disadvantages\ninclude\u00a0delayed\u00a0onset\u00a0on\u00a0action,\u00a0narrow\u00a0therapeutic\u00a0range,\u00a0drug\u00addrug\u00a0interaction\u00a0and\nrequirement\u00a0for\u00a0daily\u00a0monitoring\u00a0of\u00a0the\u00a0INR\u00a0(the\u00a0recommended\u00a0therapeutic\u00a0range\u00a0is\n2.0\u00a0to\u00a02.5\u00a0in\u00a0orthopaedic\u00a0surgery). These\u00a0shortcomings\u00a0along\u00a0with\u00a0wide\u00a0availability\u00a0of\nother\u00a0 effective\u00a0 options\u00a0 narrow\u00a0 the\u00a0 rationale\u00a0 for\u00a0 warfarin\u00a0 to\u00a0 be\u00a0 used\u00a0 routinely\u00a0 as\nprophylaxis. It\u00a0should\u00a0be\u00a0reserved\u00a0for\u00a0patients\u00a0who\u00a0have\u00a0contraindications\u00a0to\u00a0the\nalternative\u00a0agents.62,71\n2.2.2.5\u00a0Oral\u00a0Direct\u00a0Thrombin\u00a0Inhibitors\nDabigatran\u00a0etexilate\u00a0has\u00a0been\u00a0evaluated\u00a0for\u00a0VTE\u00a0prophylaxis\u00a0in\u00a0patients\u00a0undergoing\nTHR\u00a0and\u00a0TKR\u00a0and\u00a0the\u00a0results\u00a0show\u00a0that\u00a0it\u00a0is\u00a0non\u00adinferior\u00a0to\u00a0LMWH\u00a0with\u00a0similar\nbleeding\u00a0 rates. Dabigatran\u00a0 can\u00a0 be\u00a0 considered\u00a0 an\u00a0 alternative\u00a0 to\u00a0 LMWH\u00a0 and\nfondaprinux\u00a0for\u00a0the\u00a0prevention\u00a0of\u00a0VTE\u00a0following\u00a0THR\u00a0and\u00a0TKR\u00a0surgeries.60\nThe\u00a0dose\u00a0is\u00a0110\u00a0mg\u00a0given\u00a01\u00a0to\u00a04\u00a0hours\u00a0post\u00adoperatively\u00a0and\u00a0continued\u00a0with\u00a0a\u00a0dose\u00a0of\n220\u00a0mg\u00a0daily\u00a0for\u00a010\u00a0days\u00a0after\u00a0knee\u00a0replacement\u00a0and\u00a0for\u00a035\u00a0days\u00a0after\u00a0hip\u00a0replacement. For\u00a0patients\u00a0with\u00a0moderate\u00a0renal\u00a0impairment\u00a0and\u00a0age\u00a0>75\u00a0years,\u00a0a\u00a0reduced\u00a0dose\u00a0of\u00a075\nmg\u00a0starting\u00a0dose\u00a0and\u00a0150\u00a0mg\u00a0continuing\u00a0dose\u00a0once\u00a0daily\u00a0is\u00a0recommended.71,73\n2.2.2.6\u00a0Oral\u00a0Direct\u00a0Factor\u00a0Xa\u00a0Antagonists/Inhibitors\n2.2.2.6.1\u00a0Rivaroxaban\nRivaroxaban\u00a0 has\u00a0 a\u00a0 rapid\u00a0 onset\u00a0 of\u00a0 action\u00a0 by\u00a0 reaching\u00a0 peak\u00a0 concentration\u00a0 at\u00a0 3\nhours. Bioavailability\u00a0ranges\u00a0between\u00a060\u00a0to\u00a080%\u00a0after\u00a0oral\u00a0administration. It\u00a0is\nmainly\u00a0metabolized\u00a0via\u00a0CYP3A4\u00a0and\u00a0eliminated\u00a0by\u00a0both\u00a0the\u00a0renal\u00a0and\u00a0fecal/\u00a0biliary\nroutes. It\u00a0has\u00a0an\u00a0elimination\u00a0half\u00adlife\u00a0between\u00a05\u00a0to\u00a09\u00a0hours.59\nA\u00a0single\u00a0dose\u00a0of\u00a0rivaroxaban\u00a0produces\u00a0pharmacologic\u00a0effects\u00a0that\u00a0persist\u00a0for\u00a024\nhours,\u00a0 making\u00a0 it\u00a0 suitable\u00a0 for\u00a0 once\u00a0 daily\u00a0 administration. It\u00a0 has\u00a0 predictable\npharmacokinetics\u00a0and\u00a0does\u00a0not\u00a0require\u00a0monitoring.59,70\nRivaroxaban\u00a0has\u00a0been\u00a0shown\u00a0to\u00a0be\u00a0superior\u00a0to\u00a0enoxaparin\u00a0in\u00a0VTE\u00a0prevention\nstudies\u00a0during\u00a0hip\u00a0and\u00a0knee\u00a0replacement\u00a0surgeries\u00a0with\u00a0similar\u00a0bleeding\u00a0rates.", "chunk_order": 19}
{"chunk_id": "67d1f813-33ec-44e7-a879-80585fb62383", "source_document_filename": "CPG Prevention and Treatment of Venous Thrombosis_cleaned_ultra_minimal.txt", "source_document_title": "CPG Prevention and Treatment of Venous Thrombosis cleaned ultra minimal", "text": "Bioavailability\u00a0ranges\u00a0between\u00a060\u00a0to\u00a080%\u00a0after\u00a0oral\u00a0administration. It\u00a0is\nmainly\u00a0metabolized\u00a0via\u00a0CYP3A4\u00a0and\u00a0eliminated\u00a0by\u00a0both\u00a0the\u00a0renal\u00a0and\u00a0fecal/\u00a0biliary\nroutes. It\u00a0has\u00a0an\u00a0elimination\u00a0half\u00adlife\u00a0between\u00a05\u00a0to\u00a09\u00a0hours.59\nA\u00a0single\u00a0dose\u00a0of\u00a0rivaroxaban\u00a0produces\u00a0pharmacologic\u00a0effects\u00a0that\u00a0persist\u00a0for\u00a024\nhours,\u00a0 making\u00a0 it\u00a0 suitable\u00a0 for\u00a0 once\u00a0 daily\u00a0 administration. It\u00a0 has\u00a0 predictable\npharmacokinetics\u00a0and\u00a0does\u00a0not\u00a0require\u00a0monitoring.59,70\nRivaroxaban\u00a0has\u00a0been\u00a0shown\u00a0to\u00a0be\u00a0superior\u00a0to\u00a0enoxaparin\u00a0in\u00a0VTE\u00a0prevention\nstudies\u00a0during\u00a0hip\u00a0and\u00a0knee\u00a0replacement\u00a0surgeries\u00a0with\u00a0similar\u00a0bleeding\u00a0rates. The\u00a0dose\u00a0is\u00a010\u00a0mg\u00a0orally\u00a0once\u00a0daily\u00a0with\u00a0or\u00a0without\u00a0food\u00a0and\u00a0the\u00a0initial\u00a0dose\u00a0should\nbe\u00a0 taken\u00a0 at\u00a0 least\u00a0 6\u00a0 to\u00a0 10\u00a0 hours\u00a0 after\u00a0 surgery\u00a0 once\u00a0 haemostasis\u00a0 has\u00a0 been\nestablished.59,60\n2.2.2.6.2\u00a0Apixaban\nA\u00a0small\u00a0molecular\u00a0weight\u00a0agent\u00a0with\u00a0bioavailability\u00a0of\u00a050\u00a0to\u00a085%\u00a0after\u00a0oral\u00a0intake\nreaches\u00a0 peak\u00a0 concentration\u00a0 at\u00a0 3\u00a0 hours,\u00a0 and\u00a0 excretes\u00a0 predominantly\u00a0 via\u00a0 the\nbiliary\u00a0tract. Apixaban\u00a0has\u00a0been\u00a0found\u00a0to\u00a0be\u00a0superior\u00a0to\u00a0enoxaparin\u00a0in\u00a0reducing\u00a0VTE\u00a0following\nhip\u00a0and\u00a0knee\u00a0replacement\u00a0surgeries\u00a0with\u00a0no\u00a0difference\u00a0in\u00a0the\u00a0bleeding\u00a0rates. The\nrecommended\u00a0dose\u00a0is\u00a02.5\u00a0mg\u00a0orally\u00a0twice\u00a0daily. The\u00a0initial\u00a0dose\u00a0should\u00a0be\u00a0taken\u00a012\nto\u00a024\u00a0hours\u00a0after\u00a0surgery. It\u00a0is\u00a0safe\u00a0to\u00a0be\u00a0used\u00a0in\u00a0patients\u00a0with\u00a0renal\u00a0impairment.71\n2.3\u00a0RISK\u00a0ASSESSMENT\u00a0FOR\u00a0VTE\n2.3.1\u00a0Non\u00adsurgical/\u00a0medical\u00a0patients\nPatients\u00a0 seen\u00a0 in\u00a0 medical\u00a0 wards\u00a0 differ\u00a0 from\u00a0 surgical\u00a0 patients\u00a0 with\u00a0 many\u00a0 having\nco\u00admorbidities\u00a0 including\u00a0 renal\u00a0 or\u00a0 hepatic\u00a0 impairment,\u00a0 and\u00a0 increased\u00a0 risk\u00a0 of\nbleeding. The\u00a0 Padua\u00a0 Prediction\u00a0 Score\u00a0 (PPS)\u00a0 is\u00a0 the\u00a0 best\u00a0 available\u00a0 validated\nprediction\u00a0for\u00a0VTE\u00a0risk\u00a0in\u00a0medical\u00a0patients\u00a0(table\u00a02.3.1.1)\u00a0with\u00a0low\u00adrisk\u00a0patients\nhaving\u00a0 a\u00a0 0.3%\u00a0 rate\u00a0 of\u00a0 developing\u00a0 symptomatic\u00a0 VTE\u00a0 in\u00a0 90\u00a0 days\u00a0 and\u00a0 high\u00a0 risk\npatients\u00a0having\u00a0an\u00a011%\u00a0rate\u00a0of\u00a0developing\u00a0VTE\u00a0within\u00a090\u00a0days.1\u00a0The\u00a0PPS\u00a0should\nnot\u00a0be\u00a0applied\u00a0to\u00a0critically\u00a0ill\u00a0patients. Table\u00a02.3.1.1:\u00a0Padua\u00a0Risk\u00a0Assessment\u00a0Model\u00a0for\u00a0Medical\u00a0Patients 74\n(RAM\u00a0Score\u00a0of\u00a04\u00a0and\u00a0above\u00a0=\u00a0high\u00a0risk\u00a0of\u00a0VTE)\nBaseline\u00a0Features\nScore\nAn\u00a0active\u00a0cancer\n3\nPrevious\u00a0VTE\n3\nReduced\u00a0mobility\n3\nAlready\u00a0known\u00a0thrombophilic\u00a0condition\n3\nRecent\u00a0(<1\u00a0month)\u00a0trauma\u00a0and/or\u00a0surgery\n2\nAge\u00a070\u00a0years\u00a0and\u00a0above\n1\nHeart\u00a0and/or\u00a0respiratory\u00a0failure\n1\nAMI\u00a0or\u00a0ischemic\u00a0stroke\n1\nAcute\u00a0infection\u00a0and/or\u00a0rheumatologic\u00a0disorder\n1\nObesity\u00a0BMI\u00a0>30kg/m2\n1\nOngoing\u00a0hormonal\u00a0therapy\nPrior\u00a0VTE\nImmobilization\nAngiogenesis\ninhibitors\u00adlenalidomide,\nthalidomide\nHormonal\u00a0therapy\nLMWH\u00a0daily\nB\n1. Leg\u00a0Compression\u00a0Device\n(IPC\u00a0or\u00a0GECS)\u00a0only\n2. Switch\u00a0to\u00a0anticoagulant\u00a0prophylaxis\u00a0as\nsoon\u00a0as\u00a0bleeding\u00a0risk\u00a0is\u00a0considered\u00a0to\nbe\u00a0low\n3. Early\u00a0ambulation\nCancer\nCancer\nPrevious\u00a0VTE\nSevere\u00a0obesity\nPregnancy\n1. Encouraged\u00a0to\u00a0get\u00a0up\u00a0and\u00a0walk\u00a0around\nperiodically,\u00a0flex\u00a0calf\u00a0muscles\u00a0and\u00a0sit\u00a0in\nan\u00a0aisle\u00a0seat\u00a0when\u00a0possible\n2. Consider\u00a0using\u00a0below\u00adthe\u00adknee\ncompression\u00a0stockings\u00a0at\u00a015\u00ad30\u00a0mmHg\n3.", "chunk_order": 20}
{"chunk_id": "77a648ae-cc9d-4b56-8d4c-872478b08931", "source_document_filename": "CPG Prevention and Treatment of Venous Thrombosis_cleaned_ultra_minimal.txt", "source_document_title": "CPG Prevention and Treatment of Venous Thrombosis cleaned ultra minimal", "text": "Leg\u00a0Compression\u00a0Device\n(IPC\u00a0or\u00a0GECS)\u00a0only\n2. Switch\u00a0to\u00a0anticoagulant\u00a0prophylaxis\u00a0as\nsoon\u00a0as\u00a0bleeding\u00a0risk\u00a0is\u00a0considered\u00a0to\nbe\u00a0low\n3. Early\u00a0ambulation\nCancer\nCancer\nPrevious\u00a0VTE\nSevere\u00a0obesity\nPregnancy\n1. Encouraged\u00a0to\u00a0get\u00a0up\u00a0and\u00a0walk\u00a0around\nperiodically,\u00a0flex\u00a0calf\u00a0muscles\u00a0and\u00a0sit\u00a0in\nan\u00a0aisle\u00a0seat\u00a0when\u00a0possible\n2. Consider\u00a0using\u00a0below\u00adthe\u00adknee\ncompression\u00a0stockings\u00a0at\u00a015\u00ad30\u00a0mmHg\n3. Aspirin\u00a0or\u00a0anticoagulant\u00a0is\u00a0not\nrecommended\u00a0for\u00a0the\u00a0purpose\u00a0of\nprophylaxis\u00a0against\u00a0VTE\u00a0on\u00a0a\nlong\u00addistance\u00a0flight\nB\nC\nB\nHigh\u00a0risk\u00a0on\nlong\u00addistance\u00a0flights\nTable\u00a02.3.1.2:\u00a0\u00a0Risk\u00a0Stratification\u00a0of\u00a0Medical\u00a0Patients\u00a0and\nProphylactic\u00a0Recommendation\nCategory\nRecommendations\nGrade\nPPS\u00a0<4\nNo\u00a0prophylaxis\nB\n\" ..L\"&M\nLMWH\nFondaparinux\nA\nB\n2D.-,GI\"+/$%0\"&N\n(see\u00a0Table\u00a02.4)\nC\nB\nB\nLow\u00a0Risk\nHigh\u00a0Risk\nHigh\u00a0Risk\u00a0for\u00a0bleeding\n2.3.1.2\u00a0Prophylactic\u00a0Recommendation\u00a0For\u00a0Medical\u00a0Patients\nBased\u00a0on\u00a0the\u00a0risk\u00a0assessment\u00a0score,\u00a0recommendations\u00a0for\u00a0VTE\u00a0prophylaxis\u00a0can\nbe\u00a0made\u00a0for\u00a0medical\u00a0patients\u00a0(Table\u00a02.3.1.2)74\n2.3.2\u00a0Surgical\u00a0patients\nFor\u00a0surgical\u00a0patients,\u00a0the\u00a0primary\u00a0prophylactic\u00a0measures\u00a0depend\u00a0on\u00a0the\u00a0risk\nstratification\u00a0of\u00a0the\u00a0individual\u00a0patient\u00a0and\u00a0the\u00a0clinical\u00a0situation\u00a0(Table\u00a02.3.2).75,76\nTable\u00a02.3.2:\u00a0Risk\u00a0Stratification\u00a0of\u00a0Surgical\u00a0Patients\u00a0and\nProphylactic\u00a0Recommendation\nLow\u00a0Risk\n\u0001 t\u00a0Ambulatory\u00a0patient\u00a0<40\nyears\u00a0without\u00a0risk\u00a0factor*\n\u0001 t\u00a0Minor\u00a0surgery\u00a0(<30\u00a0min)\n\u0001 t\u00a0Knee\u00a0arthroscopy\u00a0with\nno\u00a0additional\u00a0risk*\nEarly\u00a0aggressive\u00a0ambulation\nA\nModerate\u00a0Risk\n\u0001 t\u00a0Patient\u00a0with\u00a0an\u00a0extra\u00a0risk*\n\u0001 t\u00a0Patient\u00a040\u00ad60\u00a0years\nwithout\u00a0risk*\n\u0001 t\u00a0Major\u00a0surgery\u00a0(>30\u00a0min)\nfor\u00a0benign\u00a0disease\nLMWH\nFondaparinux\nLD\u00adUFH,\u00a012\u00a0hrly\nGESC,\u00a0IPC,\u00a0VFP\nA\nA\nB\nC\nHigh\u00a0Risk\nSurgery\u00a0in\u00a0patient\n\u0001 t\u00a0>60\u00a0years\n\u0001 t\u00a040\u00ad60\u00a0years\u00a0with\u00a0an\nextra\u00a0risk*\n\u0001 t\u00a0with\u00a0multiple\u00a0risk\u00a0factors*\nMajor\u00a0surgery\u00a0for\u00a0cancer\nMajor\u00a0trauma,\u00a0Spinal\u00a0Cord\nInjury\nLMWH\nFondaparinux\nLD\u00adUFH,\u00a08\u00a0hrly\nWarfarin\u00a0INR\u00a02\u00ad3\nplus\u00a0IPC\u00a0or\u00a0GESC\nA\nA\nB\nB\nA\nHighest\u00a0Risk\nHip\u00a0arthroplasty\nKnee\u00a0arthroplasty**\nHip\u00a0fracture\u00a0surgery\nLMWH\u00a0>\u00a0fondaparinux\u00a0>\nwarfarin,\u00a0and\u00a0IPC**\nRivaroxaban\nA\nA\nRisk\u00a0category\nRecommended\u00a0prophylaxis\nGrade\n*\u00a0Risk\u00a0factors:\nv\u00a0 Active\u00a0cancer\nv\u00a0 Obesity\u00a0(BMI\u00a0>30\u00a0kg/m2)\nv\u00a0 Use\u00a0of\u00a0oestrogen\u00adcontaining\u00a0oral\u00a0contraceptive\u00a0pill\nv\u00a0 Use\u00a0of\u00a0Hormone\u00a0Replacement\u00a0Therapy\nv\u00a0 Previous\u00a0VTE\nv\u00a0 Family\u00a0h/o\u00a0VTE\nv\u00a0 One\u00a0or\u00a0more\u00a0significant\u00a0medical\u00a0comorbidities:\n\"\u00a0Heart\u00a0disease\n# # \"\u00a0Metabolic,\u00a0endocrine\u00a0or\u00a0respiratory\u00a0pathologies\n# # \"\u00a0Acute\u00a0infectious\u00a0disease\n# # \"\u00a0Inflammatory\u00a0conditions\n# # \"\u00a0Sickle\u00a0cell\u00a0disease\n# # \"\u00a0Thalassaemia\n# # \"\u00a0Varicose\u00a0veins\u00a0with\u00a0phlebitis\n2.4\u00a0RISK\u00a0ASSESSMENT\u00a0FOR\u00a0BLEEDING\nBoth\u00a0the\u00a0PPS\u00a0and\u00a0Wells\u2019\u00a0Score\u00a0do\u00a0not\u00a0address\u00a0the\u00a0risk\u00a0of\u00a0bleeding\u00a0events. To\naddress\u00a0this\u00a0issue,\u00a0some\u00a0forms\u00a0of\u00a0clinical\u00a0judgments\u00a0are\u00a0required\u00a0when\u00a0weighing\nup\u00a0the\u00a0risk\u00a0of\u00a0thrombosis\u00a0versus\u00a0bleeding\u00a0events\u00a0with\u00a0thromboprophylaxis.", "chunk_order": 21}
{"chunk_id": "713d2976-4401-487d-8b2f-4b720aa360ee", "source_document_filename": "CPG Prevention and Treatment of Venous Thrombosis_cleaned_ultra_minimal.txt", "source_document_title": "CPG Prevention and Treatment of Venous Thrombosis cleaned ultra minimal", "text": "To\naddress\u00a0this\u00a0issue,\u00a0some\u00a0forms\u00a0of\u00a0clinical\u00a0judgments\u00a0are\u00a0required\u00a0when\u00a0weighing\nup\u00a0the\u00a0risk\u00a0of\u00a0thrombosis\u00a0versus\u00a0bleeding\u00a0events\u00a0with\u00a0thromboprophylaxis. For\nthis\u00a0purpose,\u00a0the\u00a0IMPROVE\u00a0Bleeding\u00a0Risk\u00a0Score\u00a0is\u00a0used\u00a0(Table\u00a02.4).77\nBleeding\u00a0Risk\u00a0Factors\nScore\nActive\u00a0gastro\u00adduodenal\u00a0ulcer\n4.5\nBleeding\u00a0<3\u00a0months\u00a0prior\u00a0to\u00a0admission*\n4\nPlatelet\u00a0count\u00a0<50x109/L**\n4\nAge\u00a0>85\u00a0years\n3.5\nLiver\u00a0failure\u00a0with\u00a0PT>1.5x\u00a0Normal\n2.5\nSevere\u00a0renal\u00a0failure\u00a0GFR\u00a0<30\u00a0mL/min/1.73m2\n2.5\nICU/CCU\u00a0admission\n2.5\nCentral\u00a0line\u00a0catheter\u00a0in\u00a0place\n2\nRheumatic/autoimmune\u00a0disease\n2\nCurrent\u00a0cancer\n2\nAge\u00a040\u00ad84\u00a0years\n1\nMale\n1\nGFR\u00a030\u00ad59\u00a0mL/min/1.73m2\n1\nHigh\u00a0risk\nRisk\u00a0score:\u00a0!7\nLow\u00a0risk\nRisk\u00a0score:\u00a0<7\n*\u00a0 include\u00a0previous\u00a0GI\u00a0bleeding\u00a0of\u00a0irreversible\u00a0cause,\u00a0non\u00adcardiac\u00a0embolic\nstroke\u00a0and\u00a0concomitant\u00a0use\u00a0of\u00a0oral\u00a0anticoagulant\n**\u00a0include\u00a0previous\u00a0history\u00a0of\u00a0HITT\u00a0and\u00a0concomitant\u00a0antiplatelet\u00a0therapy\nwith\u00a0aspirin\u00a0or\u00a0clopidogrel\nTable\u00a02.4:\u00a0The\u00a0IMPROVE\u00a0Bleeding\u00a0Risk\u00a0Score\n2.5\u00a0TIMING\u00a0AND\u00a0INITIATION\u00a0OF\u00a0PROPHYLAXIS\nIssues\u00a0 related\u00a0 to\u00a0 the\u00a0 optimal\u00a0 timing\u00a0 of\u00a0 initiation\u00a0 and\u00a0 duration\u00a0 of\u00a0 peri\u00adoperative\nthromboprophylaxis\u00a0in\u00a0the\u00a0peri\u00adoperative\u00a0setting\u00a0and\u00a0in\u00a0medical\u00a0patients\u00a0remain\nunsettled. The\u00a0 timing\u00a0 of\u00a0 initiation\u00a0 depends\u00a0 on\u00a0 the\u00a0 clinical\u00a0 situation,\u00a0 specific\nprophylactic\u00a0agent\u00a0of\u00a0choice\u00a0and\u00a0type\u00a0of\u00a0anaesthesia\u00a0used.78,79,80\nTable\u00a02.5:\u00a0Timing\u00a0of\u00a0Thromboprophylaxis\u00a0Initiation\n(Grade\u00a0B\u00a0Recommendation)\nClinical\u00a0Situation\nGeneral\u00a0Surgery\nOrthopaedics\nProphylactic\u00a0Agent\nTiming\u00a0of\u00a0Initiation\nLow\u00a0Dose\u00a0UFH\n2\u00a0hr\u00a0prior\u00a0to\u00a0surgery\nFondaparinux\u00a02.5mg\n6\u00a0hr\u00a0post\u00adop\nFondaparinux\u00a02.5\u00a0mg\u00a0OD\n6\u00ad24\u00a0hr\u00a0post\u00adop\nRivaroxaban\u00a010\u00a0mg\u00a0OD\n6\u00ad10\u00a0hr\u00a0post\u00adop\nFondaparinux\u00a02.5\u00a0mg\u00a0OD\n6\u00ad24\u00a0hr\u00a0post\u00adop\nRivaroxaban\u00a010\u00a0mg\u00a0OD\n6\u00ad10\u00a0hr\u00a0post\u00adop\nWarfarin\u00a02\u00ad10\u00a0mg\u00a0OD\n(INR\u00a02\u00ad2.5)\n1\u00ad12\u00a0hr\u00a0pre\u00adop\u00a0or\u00a0early\npost\u00adop\nWarfarin\u00a0(INR\u00a02\u00ad3)\n1\u00ad12\u00a0hr\u00a0pre\u00ad\u00a0or\u00a0early\npost\u00adop\nLMWH:\nEnoxaparin\u00a040\u00a0mg\u00a0OD\nTinzaparin\u00a03500\u00a0IU\n12\u00ad24\u00a0hr\u00a0post\u00adop\nTKR/\u00a0THR\nLMWH:\nEnoxaparin\u00a030mg\u00a0BD\u00a0or\n40\u00a0mg\u00a0OD\nTinzaparin\u00a04500\u00a0IU\u00a0OD\n12\u00ad24\u00a0hr\u00a0post\u00adop\nHip\u00a0Fractures\nLMWH:\nEnoxaparin\u00a040\u00a0mg\u00a0OD\nTinzaparin\u00a04500\u00a0IU\u00a0OD\n12\u00ad24\u00a0hr\u00a0post\u00adop\n2.6\u00a0\u00a0ANTI\u00adTHROMBOTIC\u00a0THERAPY\u00a0AND\u00a0REGIONAL\u00a0ANAESTHESIA\nThe\u00a0decision\u00a0to\u00a0perform\u00a0spinal\u00a0or\u00a0epidural\u00a0anesthesia/analgesia\u00a0and\u00a0the\u00a0timing\u00a0of\ncatheter\u00a0 removal\u00a0 in\u00a0 a\u00a0 patient\u00a0 receiving\u00a0 antithrombotic\u00a0 therapy\u00a0 is\u00a0 made\u00a0 on\u00a0 an\nindividual\u00a0basis,\u00a0weighing\u00a0the\u00a0small,\u00a0although\u00a0definite\u00a0risk\u00a0of\u00a0spinal\u00a0hematoma\u00a0with\nthe\u00a0benefits\u00a0of\u00a0regional\u00a0anaesthesia\u00a0for\u00a0a\u00a0specific\u00a0patient. Overall,\u00a0the\u00a0risk\u00a0of\u00a0clinically\u00a0significant\u00a0bleeding\u00a0increases\u00a0with\u00a0age,\u00a0associated\nabnormalities\u00a0of\u00a0the\u00a0spinal\u00a0cord\u00a0or\u00a0vertebral\u00a0column,\u00a0the\u00a0presence\u00a0of\u00a0an\u00a0underlying\ncoagulopathy,\u00a0 difficulty\u00a0 during\u00a0 needle\u00a0 placement,\u00a0 and\u00a0 an\u00a0 indwelling\u00a0 neuraxial\ncatheter\u00a0during\u00a0sustained\u00a0anticoagulation,\u00a0perhaps\u00a0in\u00a0a\u00a0multifactorial\u00a0manner.81\u00a0Its\nbeen\u00a0consistently\u00a0reported\u00a0that\u00a0prompt\u00a0diagnosis\u00a0and\u00a0intervention\u00a0is\u00a0necessary\u00a0to\noptimize\u00a0neurologic\u00a0outcome. 2.6.1\u00a0Patients\u00a0receiving\u00a0unfractionated\u00a0heparin\nThe\u00a0safety\u00a0of\u00a0neuraxial\u00a0blockade\u00a0in\u00a0patients\u00a0receiving\u00a0daily\u00a0or\u00a0more\u00a0than\u00a0twice\u00addaily\ndosing\u00a0of\u00a0UFH\u00a0is\u00a0not\u00a0established.82,83\u00a0The\u00a0risk/benefits\u00a0of\u00a0neuroaxial\u00a0blockade\u00a0needs\nto\u00a0be\u00a0assessed\u00a0on\u00a0an\u00a0individual\u00a0basis\u00a0and\u00a0implement\u00a0more\u00a0frequent\u00a0neurological\nmonitoring.", "chunk_order": 22}
{"chunk_id": "e8af2dbd-eb25-4944-baa5-7aa5d3bdccd2", "source_document_filename": "CPG Prevention and Treatment of Venous Thrombosis_cleaned_ultra_minimal.txt", "source_document_title": "CPG Prevention and Treatment of Venous Thrombosis cleaned ultra minimal", "text": "Overall,\u00a0the\u00a0risk\u00a0of\u00a0clinically\u00a0significant\u00a0bleeding\u00a0increases\u00a0with\u00a0age,\u00a0associated\nabnormalities\u00a0of\u00a0the\u00a0spinal\u00a0cord\u00a0or\u00a0vertebral\u00a0column,\u00a0the\u00a0presence\u00a0of\u00a0an\u00a0underlying\ncoagulopathy,\u00a0 difficulty\u00a0 during\u00a0 needle\u00a0 placement,\u00a0 and\u00a0 an\u00a0 indwelling\u00a0 neuraxial\ncatheter\u00a0during\u00a0sustained\u00a0anticoagulation,\u00a0perhaps\u00a0in\u00a0a\u00a0multifactorial\u00a0manner.81\u00a0Its\nbeen\u00a0consistently\u00a0reported\u00a0that\u00a0prompt\u00a0diagnosis\u00a0and\u00a0intervention\u00a0is\u00a0necessary\u00a0to\noptimize\u00a0neurologic\u00a0outcome. 2.6.1\u00a0Patients\u00a0receiving\u00a0unfractionated\u00a0heparin\nThe\u00a0safety\u00a0of\u00a0neuraxial\u00a0blockade\u00a0in\u00a0patients\u00a0receiving\u00a0daily\u00a0or\u00a0more\u00a0than\u00a0twice\u00addaily\ndosing\u00a0of\u00a0UFH\u00a0is\u00a0not\u00a0established.82,83\u00a0The\u00a0risk/benefits\u00a0of\u00a0neuroaxial\u00a0blockade\u00a0needs\nto\u00a0be\u00a0assessed\u00a0on\u00a0an\u00a0individual\u00a0basis\u00a0and\u00a0implement\u00a0more\u00a0frequent\u00a0neurological\nmonitoring. Heparin\u00adinduced\u00a0 thrombocytopenia\u00a0 may\u00a0 occur\u00a0 during\u00a0 heparin\u00a0 administration,\ntherefore\u00a0patients\u00a0receiving\u00a0heparin\u00a0for\u00a0more\u00a0than\u00a04\u00a0days\u00a0should\u00a0have\u00a0a\u00a0platelet\ncount\u00a0assessed\u00a0before\u00a0neuraxial\u00a0blockade\u00a0and\u00a0catheter\u00a0removal.84\n2.6.2\u00a0Patients\u00a0receiving\u00a0LMWH\nPerform\u00a0neuroaxial\u00a0techniques\u00a0at\u00a0least\u00a010\u00a0to\u00a012\u00a0hours\u00a0after\u00a0a\u00a0thromboprophylaxis\ndose\u00a0and\u00a024\u00a0hours\u00a0after\u00a0a\u00a0high\u00a0or\u00a0therapeutic\u00a0dose\u00a0of\u00a0LMWH. In\u00a0patients\u00a0administered\na\u00a0dose\u00a0of\u00a0LMWH\u00a02\u00a0hours\u00a0preoperatively,\u00a0neuroaxial\u00a0technique\u00a0is\u00a0not\u00a0recommended\nbecause\u00a0needle\u00a0placement\u00a0would\u00a0occur\u00a0during\u00a0peak\u00a0anticoagulant\u00a0activity. Post\u00adoperative\u00a0 LMWH\u00a0 twice\u00a0 daily\u00a0 dosing\u00a0 is\u00a0 associated\u00a0 with\u00a0 increased\u00a0 risk\u00a0 of\nspinal\u00a0haematoma. The\u00a0first\u00a0dose\u00a0of\u00a0LMWH\u00a0is\u00a0administered\u00a0no\u00a0earlier\u00a0than\u00a024\nhours\u00a0 postoperative\u00a0 regardless\u00a0 of\u00a0 the\u00a0 anaesthetic\u00a0 technique\u00a0 and\u00a0 only\u00a0 in\u00a0 the\npresence\u00a0 of\u00a0 adequate\u00a0 surgical\u00a0 hemostasis. Indwelling\u00a0 catheters\u00a0 should\u00a0 be\nremoved\u00a0 before\u00a0 initiation\u00a0 of\u00a0 twice\u00a0 daily\u00a0 LMWH. The\u00a0 first\u00a0 dose\u00a0 of\u00a0 LMWH\u00a0 is\nadministered\u00a02\u00a0hours\u00a0after\u00a0catheter\u00a0removal\u00a0and\u00a024\u00a0hours\u00a0after\u00a0needle/catheter\nplacement,\u00a0whichever\u00a0is\u00a0later.85,86\nWith\u00a0 daily\u00a0 dosing,\u00a0 the\u00a0 first\u00a0 dose\u00a0 of\u00a0 LMWH\u00a0 is\u00a0 administered\u00a0 6\u00a0 to\u00a0 8\u00a0 hrs\u00a0 after\nneedle/catheter\u00a0placement. Subsequent\u00a0dosing\u00a0should\u00a0occur\u00a0no\u00a0sooner\u00a0than\u00a024\nhours\u00a0later. 2.6.3\u00a0Patients\u00a0receiving\u00a0Fondaparinux\nThe\u00a0actual\u00a0risk\u00a0of\u00a0spinal\u00a0hematoma\u00a0with\u00a0fondaparinux\u00a0is\u00a0unknown. Until\u00a0further\nclinical\u00a0experience\u00a0is\u00a0available,\u00a0performance\u00a0of\u00a0neuraxial\u00a0techniques\u00a0should\u00a0occur\nunder\u00a0 conditions\u00a0 used\u00a0 in\u00a0 clinical\u00a0 trials\u00a0 (single\u00adneedle\u00a0 pass,\u00a0 atraumatic\u00a0 needle\nplacement,\u00a0avoidance\u00a0of\u00a0indwelling\u00a0neuraxial\u00a0catheters).", "chunk_order": 23}
{"chunk_id": "94452b54-a74b-4895-bca3-2806ba651cd1", "source_document_filename": "CPG Prevention and Treatment of Venous Thrombosis_cleaned_ultra_minimal.txt", "source_document_title": "CPG Prevention and Treatment of Venous Thrombosis cleaned ultra minimal", "text": "The\u00a0 first\u00a0 dose\u00a0 of\u00a0 LMWH\u00a0 is\nadministered\u00a02\u00a0hours\u00a0after\u00a0catheter\u00a0removal\u00a0and\u00a024\u00a0hours\u00a0after\u00a0needle/catheter\nplacement,\u00a0whichever\u00a0is\u00a0later.85,86\nWith\u00a0 daily\u00a0 dosing,\u00a0 the\u00a0 first\u00a0 dose\u00a0 of\u00a0 LMWH\u00a0 is\u00a0 administered\u00a0 6\u00a0 to\u00a0 8\u00a0 hrs\u00a0 after\nneedle/catheter\u00a0placement. Subsequent\u00a0dosing\u00a0should\u00a0occur\u00a0no\u00a0sooner\u00a0than\u00a024\nhours\u00a0later. 2.6.3\u00a0Patients\u00a0receiving\u00a0Fondaparinux\nThe\u00a0actual\u00a0risk\u00a0of\u00a0spinal\u00a0hematoma\u00a0with\u00a0fondaparinux\u00a0is\u00a0unknown. Until\u00a0further\nclinical\u00a0experience\u00a0is\u00a0available,\u00a0performance\u00a0of\u00a0neuraxial\u00a0techniques\u00a0should\u00a0occur\nunder\u00a0 conditions\u00a0 used\u00a0 in\u00a0 clinical\u00a0 trials\u00a0 (single\u00adneedle\u00a0 pass,\u00a0 atraumatic\u00a0 needle\nplacement,\u00a0avoidance\u00a0of\u00a0indwelling\u00a0neuraxial\u00a0catheters). If\u00a0this\u00a0is\u00a0not\u00a0feasible,\u00a0an\nalternate\u00a0method\u00a0of\u00a0prophylaxis\u00a0should\u00a0be\u00a0considered.87,88\nTable\u00a02.6:\u00a0Guidelines\u00a0for\u00a0Epidural\u00a0Use\u00a0With\u00a0Anticoagulant\u00a0Therapy\nProphylactic\u00a0Agent\nTiming\u00a0for\u00a0Catheter\u00a0Placement\u00a0and\u00a0Removal\nGrade\nUFH\nC\nA\nA\nLMWH\nPlacement\u00a0of\u00a0catheter\u00a0at\u00a0least\u00a012\u00a0hours\u00a0after\nprophylactic\u00a0LMWH\u00a0dose\u00a0or\u00a024\u00a0hours\u00a0after\ntherapeutic\u00a0LMWH\u00a0dose\nIn\u00a0patients\u00a0who\u00a0received\u00a0LMWH\u00a02\u00a0hours\u00a0before\nsurgery,\u00a0neuroaxial\u00a0blockade\u00a0is\u00a0not\nrecommended\nIn\u00a0single\u00a0daily\u00a0dosing:\nAdminister\u00a0the\u00a0first\u00a0dose\u00a06\u00a0\u00ad\u00a08\u00a0hours\u00a0after\nneedle/catheter\u00a0placement\nRemove\u00a0catheter\u00a0when\u00a0LMWH\u00a0effect\u00a0is\nminimum\u00a0(2\u00a0hours\u00a0before\u00a0next\u00a0injection)\nDelay\u00a0LMWH\u00a0at\u00a0least\u00a02\u00a0hours\u00a0after\u00a0spinal\u00a0needle\nor\u00a0epidural\u00a0catheter\u00a0removal\nIn\u00a0twice\u00a0daily\u00a0dosing:\nAdminister\u00a0the\u00a0first\u00a0dose\u00a0of\u00a0LMWH\u00a0no\u00a0earlier\nthan\u00a024\u00a0hours\u00a0after\u00a0operation,\u00a0regardless\u00a0of\nanesthetic\u00a0technique,\u00a0and\u00a0only\u00a0in\u00a0the\u00a0presence\nof\u00a0adequate\u00a0haemostasis\nIndwelling\u00a0catheters\u00a0should\u00a0be\u00a0removed\u00a0before\ninitiation\u00a0of\u00a0LMWH\nThe\u00a0first\u00a0dose\u00a0of\u00a0LMWH\u00a0is\u00a0administered\u00a02\u00a0hours\nafter\u00a0catheter\u00a0removal\u00a0and\u00a024\u00a0h\u00a0after\nneedle/catheter\u00a0placement\nC\nA\nC\nC\nC\nC\nWarfarin\nContinuous\u00a0epidural\u00a0should\u00a0not\u00a0be\u00a0used\u00a0more\nthan\u00a01\u00ad2\u00a0days\u00a0because\u00a0of\u00a0unprotected\nanticoagulation\u00a0effect\u00a0Target\u00a0INR\u00a0of\u00a0<1.5\u00a0at\u00a0time\nof\u00a0catheter\u00a0removal\nA\nFondaparinux\nDo\u00a0not\u00a0use\u00a0pre\u00adoperatively\u00a0with\u00a0neuroaxial\u00a0block\u00a0or\nwith\u00a0continuous\u00a0epidural\u00a0block\u00a0(lack\u00a0of\u00a0safety\u00a0data)\nC\nRivaroxaban\nDo\u00a0not\u00a0use\u00a0pre\u00adoperatively\u00a0with\u00a0neuroaxial\u00a0block\u00a0or\nwith\u00a0continuous\u00a0epidural\u00a0block\u00a0(lack\u00a0of\u00a0safety\u00a0data)\nC\nThe\u00a0safety\u00a0of\u00a0neuroaxial\u00a0blockade\u00a0in\u00a0patients\nreceiving\u00a0daily\u00a0or\u00a0more\u00a0than\u00a0twice\u00a0daily\u00a0dosing\u00a0of\nUFH\u00a0is\u00a0not\u00a0well\u00a0established. The\u00a0risk\u00a0and\nbenefits\u00a0need\u00a0to\u00a0be\u00a0assessed\u00a0on\u00a0an\u00a0individual\nbasis\u00a0and\u00a0techniques\u00a0to\u00a0facilitate\u00a0detection\u00a0of\nneurological\u00a0deficit\u00a0be\u00a0applied\nHeparin\u00a0administration\u00a0delayed\u00a0for\u00a01\u00a0hour\u00a0after\nneedle\u00a0placement\u00a0(this\u00a0is\u00a0in\u00a0neuroaxial\u00a0blocks\nwith\u00a0intraoperative\u00a0anticoagulation)\nCatheter\u00a0removal\u00a02\u00a0\u00ad\u00a04\u00a0hours\u00a0after\u00a0last\u00a0heparin\ndose\n2.8\u00a0SPECIAL\u00a0CONSIDERATIONS:\u00a0STROKE\nThe\u00a0 immobility\u00a0 that\u00a0 is\u00a0 often\u00a0 associated\u00a0 with\u00a0 stroke\u00a0 (either\u00a0 ischaemic\u00a0 or\nhaemorrhagic)\u00a0 remains\u00a0 an\u00a0 important\u00a0 risk\u00a0 factor\u00a0 for\u00a0 the\u00a0 development\u00a0 of\u00a0 VTE. Advanced\u00a0age,\u00a0dehydration\u00a0and\u00a0the\u00a0severity\u00a0of\u00a0paralysis\u00a0are\u00a0important\u00a0risk\u00a0factors. Patients\u00a0with\u00a0hemiplegia\u00a0may\u00a0develop\u00a0DVT\u00a0in\u00a0up\u00a0to\u00a060\u00a0to\u00a070%\u00a0of\u00a0cases,\u00a0if\u00a0DVT\nprophylaxis\u00a0is\u00a0not\u00a0prescribed\u00a0within\u00a07\u00a0to\u00a010\u00a0days. In\u00a0a\u00a0retrospective\u00a0cohort\u00a0study,\nDVT\u00a0prophylaxis\u00a0was\u00a0identified\u00a0as\u00a0one\u00a0of\u00a0the\u00a0three\u00a0processes\u00a0of\u00a0care\u00a0that\u00a0was\nindependently\u00a0associated\u00a0with\u00a0an\u00a0improvement\u00a0in\u00a0acute\u00a0stroke\u00a0outcomes. Deep\u00a0vein\u00a0thrombosis\u00a0was\u00a0initially\u00a0thought\u00a0to\u00a0be\u00a0uncommon\u00a0in\u00a0the\u00a0Asian\u00a0stroke\npopulation.", "chunk_order": 24}
{"chunk_id": "a57ad35b-2680-4fc9-9a16-e3c639eff5e0", "source_document_filename": "CPG Prevention and Treatment of Venous Thrombosis_cleaned_ultra_minimal.txt", "source_document_title": "CPG Prevention and Treatment of Venous Thrombosis cleaned ultra minimal", "text": "Advanced\u00a0age,\u00a0dehydration\u00a0and\u00a0the\u00a0severity\u00a0of\u00a0paralysis\u00a0are\u00a0important\u00a0risk\u00a0factors. Patients\u00a0with\u00a0hemiplegia\u00a0may\u00a0develop\u00a0DVT\u00a0in\u00a0up\u00a0to\u00a060\u00a0to\u00a070%\u00a0of\u00a0cases,\u00a0if\u00a0DVT\nprophylaxis\u00a0is\u00a0not\u00a0prescribed\u00a0within\u00a07\u00a0to\u00a010\u00a0days. In\u00a0a\u00a0retrospective\u00a0cohort\u00a0study,\nDVT\u00a0prophylaxis\u00a0was\u00a0identified\u00a0as\u00a0one\u00a0of\u00a0the\u00a0three\u00a0processes\u00a0of\u00a0care\u00a0that\u00a0was\nindependently\u00a0associated\u00a0with\u00a0an\u00a0improvement\u00a0in\u00a0acute\u00a0stroke\u00a0outcomes. Deep\u00a0vein\u00a0thrombosis\u00a0was\u00a0initially\u00a0thought\u00a0to\u00a0be\u00a0uncommon\u00a0in\u00a0the\u00a0Asian\u00a0stroke\npopulation. However\u00a0more\u00a0recent\u00a0data\u00a0has\u00a0shown\u00a0otherwise.92\u00a0In\u00a0Malaysia,\u00a0DVT\nprophylaxis\u00a0is\u00a0recommended\u00a0as\u00a0one\u00a0of\u00a0the\u00a0nine\u00a0key\u00a0performance\u00a0indicators\u00a0(KPI)\nin\u00a0stroke\u00a0management.93\n2.8.1\u00a0Non\u00adpharmacological\nNon\u00adpharmacological\u00a0 measures\u00a0 commonly\u00a0 utilised\u00a0 in\u00a0 preventing\u00a0 DVT\u00a0 are\u00a0 the\nuse\u00a0of\u00a0graduated\u00a0elastic\u00a0compression\u00a0stockings\u00a0(GECS),\u00a0either\u00a0at\u00a0below\u00adknee\u00a0or\nthigh\u00adlevel,\u00a0as\u00a0well\u00a0as\u00a0intermittent\u00a0pneumatic\u00a0compression\u00a0(IPC)\u00a0devices. In\u00a0 two\u00a0 recent\u00a0 studies,\u00a0 the\u00a0 routine\u00a0 use\u00a0 of\u00a0 GECS\u00a0 after\u00a0 an\u00a0 acute\u00a0 stroke\u00a0 is\u00a0 not\nsupported. Smaller\u00a0 RCTs\u00a0 showed\u00a0 that\u00a0 IPC\u00a0 is\u00a0 associated\u00a0 with\u00a0 a\u00a0 non\u00adsignificant\ntrend\u00a0 towards\u00a0 lower\u00a0 risk\u00a0 of\u00a0 DVTs\u00a0 and\u00a0 this\u00a0 is\u00a0 currently\u00a0 being\u00a0 evaluated\u00a0 in\u00a0 an\non\u00adgoing\u00a0RCT.94\nIndication\nDuration\nGrade\nMajor\u00a0general\u00a0surgery\nUntil\u00a0hospital\u00a0discharge\u00a0(7\u00ad10\u00a0days)\nA\nHip\u00a0fracture\u00a0repair\n35\u00a0days\u00a0with\u00a0LMWH\u00a0or\u00a0fondaparinux\u00a0or\nA,\u00a0C,\nwarfarin\nC\nHip\u00a0arthroplasty\n35\u00a0days\u00a0with\u00a0LMWH\u00a0or\u00a0fondaparinux\u00a0or\nA,\u00a0C,\nwarfarin\nB\nIPC\nB\nKnee\u00a0arthroplasty\n35\u00a0days\u00a0with\u00a0LMWH\u00a0or\u00a0fondaparinux\u00a0or\nC,\u00a0A,\nwarfarin\nC\nBariatric\u00a0surgery\n21\u00a0days\nB\nMedical\u00a0prophylaxis\n10\u00ad14\u00a0days\nB\n2.7\u00a0DURATION\u00a0OF\u00a0PROPHYLAXIS\nDepending\u00a0on\u00a0the\u00a0clinical\u00a0situations,\u00a0standard\u00a0thromboprophylaxis\u00a0of\u00a07\u00a0to\u00a014\u00a0days\u00a0is\nusually\u00a0 commenced\u00a0 until\u00a0 the\u00a0 patient\u00a0 is\u00a0 ambulating. It\u00a0 has\u00a0 been\u00a0 shown\u00a0 that\u00a0 the\nactivation\u00a0of\u00a0coagulation\u00a0persists\u00a0for\u00a0at\u00a0least\u00a030\u00a0days\u00a0after\u00a0THR. For\u00a0certain\u00a0high\u00adrisk\nsituations\u00a0especially\u00a0after\u00a0major\u00a0orthopaedic\u00a0procedures\u00a0(THR\u00a0more\u00a0than\u00a0TKR\u00a0and\u00a0hip\nfracture\u00a0 repair),\u00a0 extended\u00a0 thromboprophylaxis\u00a0 for\u00a0 up\u00a0 to\u00a0 35\u00a0 days\u00a0 is\u00a0 recommended\n(Table\u00a02.7).89\u00ad91\nTable\u00a02.7:\u00a0Recommended\u00a0Duration\u00a0of\u00a0VTE\u00a0Prophylaxis\u00a0for\nVarious\u00a0Indications\nA\u00a0 retrospective\u00a0 observational\u00a0 study\u00a0 showed\u00a0 that\u00a0 IVC\u00a0 filter\u00a0 used\u00a0 in\u00a0 post\u00a0 stroke\npatients\u00a0did\u00a0not\u00a0offer\u00a0significant\u00a0protection.95\n2.8.2\u00a0Pharmacological\nEvidence\u00a0 strongly\u00a0 supports\u00a0 the\u00a0 effectiveness\u00a0 of\u00a0 prophylactic\u00a0 dose\u00a0 LMWH\u00a0 or\nsubcutaneous\u00a0UFH\u00a05000\u00a0IU\u00a0BD\u00a0in\u00a0reducing\u00a0the\u00a0incidence\u00a0of\u00a0DVT. Despite\u00a0the\nfact\u00a0that\u00a0over\u00a0the\u00a0years,\u00a0rigorous\u00a0clinical\u00a0trials\u00a0have\u00a0been\u00a0published\u00a0reporting\u00a0the\neffectiveness\u00a0and\u00a0safety\u00a0of\u00a0pharmacological\u00a0prevention\u00a0with\u00a0low,\u00a0fixed\u00a0doses\u00a0of\nanticoagulant\u00a0medications,\u00a0prophylaxis\u00a0remains\u00a0underused\u00a0among\u00a0in\u00adpatients\u00a0at\nrisk\u00a0for\u00a0VTE.96\nIn\u00a0patients\u00a0with\u00a0intracerebral\u00a0haemorrhage,\u00a0prophylactic\u00a0LMWH\u00a0therapy\u00a0when\ngiven\u00a0 after\u00a0 48\u00a0 hours\u00a0 of\u00a0 stroke\u00a0 were\u00a0 not\u00a0 observed\u00a0 to\u00a0 be\u00a0 associated\u00a0 with\u00a0 an\nincreased\u00a0haematoma\u00a0growth.97\u00a0A\u00a0meta\u00adanalysis\u00a0on\u00a0the\u00a0efficacy\u00a0and\u00a0safety\u00a0of\u00a0all\nanticoagulants\u00a0in\u00a0VTE\u00a0reported\u00a0early\u00a0anticoagulation\u00a0as\u00a0being\u00a0associated\u00a0with\u00a0a\nsignificant\u00a0reduction\u00a0in\u00a0pulmonary\u00a0embolism\u00a0and\u00a0a\u00a0non\u00adsignificant\u00a0reduction\u00a0in\nmortality. A\u00a0 non\u00adsignificant\u00a0 increase\u00a0 in\u00a0 haematoma\u00a0 enlargement\u00a0 was\u00a0 also\nobserved.98\n2.8.3\u00a0Combination\u00a0Treatment\nEleven\u00a0studies\u00a0(including\u00a0six\u00a0randomized\u00a0controlled\u00a0trials)\u00a0evaluated\u00a0the\u00a0efficacy\u00a0of\ncombined\u00a0methods\u00a0of\u00a0treatment\u00a0(IPC\u00a0+\u00a0pharmacological\u00a0prophylaxis)\u00a0versus\u00a0single\nmodalities\u00a0 (IPC\u00a0 or\u00a0 pharmacological\u00a0 prophylaxis)\u00a0 in\u00a0 VTE\u00a0 prevention\u00a0 among\nhigh\u00adrisk\u00a0patients.", "chunk_order": 25}
{"chunk_id": "2b422c48-8ad3-4bec-988b-77d1693a226a", "source_document_filename": "CPG Prevention and Treatment of Venous Thrombosis_cleaned_ultra_minimal.txt", "source_document_title": "CPG Prevention and Treatment of Venous Thrombosis cleaned ultra minimal", "text": "A\u00a0 non\u00adsignificant\u00a0 increase\u00a0 in\u00a0 haematoma\u00a0 enlargement\u00a0 was\u00a0 also\nobserved.98\n2.8.3\u00a0Combination\u00a0Treatment\nEleven\u00a0studies\u00a0(including\u00a0six\u00a0randomized\u00a0controlled\u00a0trials)\u00a0evaluated\u00a0the\u00a0efficacy\u00a0of\ncombined\u00a0methods\u00a0of\u00a0treatment\u00a0(IPC\u00a0+\u00a0pharmacological\u00a0prophylaxis)\u00a0versus\u00a0single\nmodalities\u00a0 (IPC\u00a0 or\u00a0 pharmacological\u00a0 prophylaxis)\u00a0 in\u00a0 VTE\u00a0 prevention\u00a0 among\nhigh\u00adrisk\u00a0patients. The\u00a0combined\u00a0modalities\u00a0when\u00a0compared\u00a0with\u00a0IPC,\u00a0significantly\ndecreased\u00a0the\u00a0incidence\u00a0of\u00a0VTE.99\nRecommendations\nGrade\nTable\u00a02.8:\u00a0VTE\u00a0Prophylaxis\u00a0In\u00a0Patients\u00a0With\u00a0Stroke\nProphylaxis\u00a0for\u00a0VTE\u00a0should\u00a0be\u00a0tailored\u00a0to\u00a0the\u00a0individual\u00a0patient\u00a0after\ncautious\u00a0 assessment\u00a0 of\u00a0 benefits\u00a0 versus\u00a0 risks. Any\u00a0 prophylaxis\nshould\u00a0be\u00a0started\u00a0early\u00a0and\u00a0ideally\u00a0continued\u00a0for\u00a0at\u00a0least\u00a0a\u00a0period\u00a0of\n4\u00a0weeks\nCurrent\u00a0 guidelines\u00a0 recommend\u00a0 that\u00a0 patients\u00a0 with\u00a0 acute\u00a0 stroke,\nrestricted\u00a0mobility\u00a0and\u00a0no\u00a0contraindications\u00a0to\u00a0anticoagulant\u00a0should\nbe\u00a0 prescribed\u00a0 thromboprophylaxis\u00a0 \u00ad\u00a0 prophylactic\u00a0 dose\u00a0 preferably\nLMWH\u00a0over\u00a0low\u00a0dose\u00a0UFH\nIn\u00a0high\u00adrisk\u00a0patients,\u00a0combined\u00a0modalities\u00a0of\u00a0IPC\u00a0+\u00a0pharmacological\nprophylaxis\u00a0appear\u00a0more\u00a0effective\u00a0in\u00a0preventing\u00a0VTE\nEvidence\u00a0 from\u00a0 randomized\u00a0 trials\u00a0 is\u00a0 no\u00a0 longer\u00a0 supportive\u00a0 of\u00a0 the\nroutine\u00a0use\u00a0of\u00a0GECS\u00a0after\u00a0acute\u00a0stroke\nThe\u00a0timing\u00a0of\u00a0pharmacological\u00a0thromboprophylaxis\u00a0in\u00a0haemorrhagic\nstroke\u00a0is\u00a0yet\u00a0to\u00a0be\u00a0defined\u00a0but\u00a0may\u00a0be\u00a0used\u00a072\u00a0\u00ad\u00a096\u00a0hours\u00a0after\u00a0onset,\nif\u00a0 no\u00a0 further\u00a0 volume\u00a0 expansion\u00a0 of\u00a0 the\u00a0 intracranial\u00a0 haematoma\u00a0 is\nobserved\nA\nA\nA\nA\n3.0\u00a0CLINICAL\u00a0DIAGNOSIS\n3.1\u00a0CLINICAL\u00a0PREDICTION\u00a0MODEL\nThere\u00a0are\u00a0clinical\u00a0prediction\u00a0models\u00a0to\u00a0help\u00a0with\u00a0the\u00a0diagnosis\u00a0of\u00a0VTE. The\nmost\u00a0widely\u00a0used\u00a0is\u00a0the\u00a0Wells\u2019\u00a0score\u00a0that\u00a0has\u00a0been\u00a0validated\u00a0for\u00a0non\u00adpregnant\npatients.103\u00ad108\n3.1.1\u00a0 Deep\u00a0vein\u00a0thrombosis\n*\u00a0 In\u00a0patients\u00a0with\u00a0symptoms\u00a0in\u00a0both\u00a0legs,\u00a0use\u00a0the\u00a0more\u00a0symptomatic\u00a0leg\n**\u00a0An\u00a0alternative\u00a0diagnosis\u00a0may\u00a0include:\u00a0superficial\u00a0phlebitis,\u00a0post\u00adthrombotic\nsyndrome,\u00a0cellulitis,\u00a0muscle\u00a0strain\u00a0or\u00a0tear,\u00a0leg\u00a0swelling\u00a0in\u00a0paralysed\u00a0limb,\nvenous\u00a0insufficiency,\u00a0oedema\u00a0due\u00a0to\u00a0CCF\u00a0or\u00a0cirrhosis,\u00a0external\u00a0venous\nobstruction\u00a0(eg. due\u00a0to\u00a0tumour),\u00a0lymphangitis\u00a0or\u00a0lymphoedema,\u00a0popliteal\n(Baker\u2019s)\u00a0cyst,\u00a0haematoma,\u00a0pseudoaneurysm\u00a0or\u00a0knee\u00a0abnormality\nClinical\u00a0probability\u00a0score\nDVT\u00a0likely\n! 2\u00a0points\nDVT\u00a0unlikely\n\"1\u00a0point\nClinical\u00a0feature\nPoints\n1\n1\n1\n1\n1\n1\n1\n1\n1\nActive\u00a0 cancer\u00a0 (treatment\u00a0 ongoing\u00a0 or\u00a0 within\u00a0 previous\u00a0 6\u00a0 months\u00a0 or\npalliative)\nParalysis,\u00a0paresis\u00a0or\u00a0recent\u00a0immobilization\u00a0of\u00a0lower\u00a0extremities\nRecently\u00a0 bedridden\u00a0 more\u00a0 than\u00a0 3\u00a0 days\u00a0 or\u00a0 major\u00a0 surgery\u00a0 within\u00a0 4\nweeks\nLocalized\u00a0 tenderness\u00a0 along\u00a0 the\u00a0 distribution\u00a0 of\u00a0 the\u00a0 deep\u00a0 venous\nsystem\nEntire\u00a0leg\u00a0swollen\nCalf\u00a0 swelling\u00a0 3\u00a0 cm\u00a0 >asymptomatic\u00a0 side\u00a0 (measured\u00a0 10\u00a0 cm\u00a0 below\ntibial\u00a0tuberosity)\nPitting\u00a0odema,\u00a0greater\u00a0in\u00a0the\u00a0symptomatic\u00a0leg*\nCollateral\u00a0superficial\u00a0veins\u00a0(non\u00advaricose)\nPreviously\u00a0documented\u00a0DVT\nAlternative\u00a0diagnosis**\u00a0to\u00a0DVT\u00a0as\u00a0likely\u00a0or\u00a0more\u00a0likely\n\u00ad2\nTable\u00a03.1.1:\u00a0DVT\u00a0Wells\u2019\u00a0Score\nPatients\u00a0with\u00a0PE\u00a0may\u00a0also\u00a0have\u00a0symptoms\u00a0of\u00a0shortness\u00a0of\u00a0breath,\u00a0pleuritic\u00a0chest\npain\u00a0and\u00a0cough. Other\u00a0clinical\u00a0signs\u00a0such\u00a0as\u00a0hypotension\u00a0and\u00a0elevated\u00a0JVP\u00a0may\u00a0be\npresent. The\u00a0ABG\u00a0may\u00a0reveal\u00a0low\u00a0PaO2\u00a0and\u00a0low\u00a0O2\u00a0saturation.", "chunk_order": 26}
{"chunk_id": "fdf8195a-c286-4f39-add2-9f7228ce3203", "source_document_filename": "CPG Prevention and Treatment of Venous Thrombosis_cleaned_ultra_minimal.txt", "source_document_title": "CPG Prevention and Treatment of Venous Thrombosis cleaned ultra minimal", "text": "Other\u00a0clinical\u00a0signs\u00a0such\u00a0as\u00a0hypotension\u00a0and\u00a0elevated\u00a0JVP\u00a0may\u00a0be\npresent. The\u00a0ABG\u00a0may\u00a0reveal\u00a0low\u00a0PaO2\u00a0and\u00a0low\u00a0O2\u00a0saturation. Chest\u00a0X\u00adray\u00a0would\nbe\u00a0 normal\u00a0 most\u00a0 of\u00a0 the\u00a0 time\u00a0 but\u00a0 sometimes\u00a0 may\u00a0 show\u00a0 the\u00a0 classical\u00a0 findings\u00a0 of\natelectasis,\u00a0wedge\u00a0shape\u00a0lesion\u00a0and\u00a0pruning\u00a0of\u00a0pulmonary\u00a0vessels.102,238\nThe\u00a0 ECG\u00a0 findings\u00a0 in\u00a0 PE\u00a0 can\u00a0 also\u00a0 be\u00a0 non\u00adspecific\u00a0 such\u00a0 as\u00a0 tachycardia\u00a0 but\nsometimes\u00a0 can\u00a0 have\u00a0 a\u00a0 classical\u00a0 finding\u00a0 of\u00a0 S1,\u00a0 Q3,\u00a0 T3\u00a0 and\u00a0 right\u00a0 strain\u00a0 pattern\nincluding\u00a0RBBB\u00a0and\u00a0RV\u00a0hypertrophy. Echocardiogram\u00a0can\u00a0also\u00a0be\u00a0very\u00a0useful\u00a0to\ndiagnose\u00a0PE,\u00a0which\u00a0shows\u00a0right\u00a0side\u00a0strain\u00a0and\u00a0in\u00a0severe\u00a0cases,\u00a0a\u00a0blood\u00a0clot\u00a0can\u00a0be\nseen\u00a0inside\u00a0the\u00a0RA,\u00a0RV,\u00a0RVOT\u00a0and\u00a0also\u00a0in\u00a0pulmonary\u00a0artery.96\n3.2\u00a0ALGORITHM\u00a0FOR\u00a0DIAGNOSIS\u00a0OF\u00a0VTE\n3.2.1\u00a0Deep\u00a0Vein\u00a0Thrombosis\nIf\u00a0scoring\u00a0suggests\u00a0likely\u00a0DVT,\u00a0offer\u00a0Compression\u00a0US\u00a0scan\u00a0(CUS)\u00a0on\u00a0the\u00a0same\nday. If\u00a0the\u00a0CUS\u00a0cannot\u00a0be\u00a0performed\u00a0within\u00a0the\u00a0same\u00a0day,\u00a0commence\u00a0LMWH\u00a0and\nperform\u00a0CUS\u00a0in\u00a0the\u00a0next\u00a024\u00a0hours. If\u00a0the\u00a0CUS\u00a0is\u00a0normal,\u00a0repeat\u00a0within\u00a01\u00a0week. If\nthis\u00a0is\u00a0normal,\u00a0patient\u00a0can\u00a0be\u00a0discharged\u00a0to\u00a0the\u00a0health\u00a0clinic.100\n3.1.2\u00a0Pulmonary\u00a0embolism\nClinical\u00a0feature\nPoints\n3\nClinical\u00a0signs\u00a0&\u00a0symptoms\u00a0of\u00a0DVT\u00a0(minimum\u00a0of\u00a0leg\u00a0swelling\u00a0&\u00a0pain\nwith\u00a0palpation\u00a0of\u00a0deep\u00a0vein)\nAn\u00a0alternative\u00a0diagnosis\u00a0is\u00a0less\u00a0likely\u00a0than\u00a0PE\nHeart\u00a0rate\u00a0greater\u00a0than\u00a0100\u00a0beats/min\nImmobilization\u00a0or\u00a0surgery\u00a0in\u00a0previous\u00a04\u00a0weeks\nPrevious\u00a0DVT/PE\nHaemoptysis\nMalignancy\u00a0(on\u00a0treatment,\u00a0treated\u00a0in\u00a0the\u00a0last\u00a06\u00a0months\u00a0or\u00a0palliative)\n3\n1.5\n1.5\n1.5\n1\n1\nTable\u00a03.1.2:\u00a0PE\u00a0Wells\u2019\u00a0Score\nClinical\u00a0Probability\u00a0Score\nPE\u00a0likely\n>\u00a04\u00a0points\nPE\u00a0unlikely\n\"\u00a0\u00a04\u00a0points\nIf\u00a0the\u00a0score\u00a0suggests\u00a0that\u00a0DVT\u00a0is\u00a0unlikely,\u00a0no\u00a0further\u00a0investigation\u00a0is\u00a0required. The\nutility\u00a0of\u00a0D\u00addimer\u00a0in\u00a0clinical\u00a0practice\u00a0has\u00a0its\u00a0limitations. There\u00a0are\u00a0many\u00a0commercial\nD\u00addimer\u00a0 assays\u00a0 but\u00a0 they\u00a0 lack\u00a0 standardisation\u00a0 and\u00a0 the\u00a0 appropriate\u00a0 cut\u00adoff\nvalues.333\u00a0\u00a0The\u00a0whole\u00a0blood\u00a0agglutination\u00a0method\u00a0for\u00a0D\u00addimer\u00a0testing\u00a0that\u00a0is\u00a0used\nin\u00a0most\u00a0laboratories\u00a0in\u00a0Malaysia\u00a0is\u00a0not\u00a0sensitive\u00a0in\u00a0ruling\u00a0out\u00a0VTE.106,108,333\u00a0\u00a0On\u00a0the\nother\u00a0 hand,\u00a0 there\u00a0 are\u00a0 many\u00a0 causes\u00a0 for\u00a0 a\u00a0 raised\u00a0 D\u00addimer\u00a0 (e.g. inflammation,\ninfection,\u00a0 normal\u00a0 pregnancy,\u00a0 cancer,\u00a0 haematoma,\u00a0 disseminated\u00a0 intravascular\ncoagulation,\u00a0 surgery/\u00a0 trauma,\u00a0 stroke,\u00a0 myocardial\u00a0 infarction,\u00a0 liver\u00a0 failure,\u00a0 renal\nfailure,\u00a0pre\u00adeclampsia\u00a0and\u00a0eclampsia,\u00a0etc.)\u00a0which\u00a0limits\u00a0its\u00a0value\u00a0in\u00a0the\u00a0exclusion\nof\u00a0VTE\u00a0in\u00a0the\u00a0hospitalised\u00a0patients.333\nALGORITHM\u00a0FOR\u00a0DVT\u00a0DIAGNOSIS\nCould\u00a0it\u00a0be\u00a0DVT? Apply\u00a0DVT\u00a0Wells\u2019\u00a0score\nDVT\u00a0likely\nDVT\u00a0unlikely\nCUS\nPositive\nNegative\nPositive\nNegative\nExclude\u00a0DVT\nRepeat\u00a0CUS\nin\u00a01\u00a0week\nDiagnose\u00a0DVT\nand\u00a0Treat\n3.2.2\u00a0Pulmonary\u00a0Embolism\nWells\u2019\u00a0Criteria\u00a0as\u00a0described\u00a0in\u00a0Table\u00a03.1.2\u00a0was\u00a0well\u00a0tested\u00a0in\u00a0the\u00a0clinical\u00a0testing\u00a0to\nmanage\u00a0non\u00adpregnant\u00a0patients\u00a0with\u00a0suspected\u00a0PE. If\u00a0 the\u00a0 score\u00a0 suggests\u00a0 likely\u00a0 PE,\u00a0 cover\u00a0 patient\u00a0 with\u00a0 LMWH\u00a0 and\u00a0 perform\ncomputerized\u00a0tomography\u00a0pulmonary\u00a0angiogram\u00a0(CTPA)\u00a0on\u00a0the\u00a0same\u00a0day\u00a0or\nwithin\u00a0next\u00a024\u00a0hours. If\u00a0CTPA\u00a0is\u00a0normal,\u00a0proceed\u00a0with\u00a0bilateral\u00a0compression\nUS\u00a0scan\u00a0(CUS). If\u00a0these\u00a0are\u00a0negative,\u00a0patient\u00a0can\u00a0be\u00a0discharged\u00a0to\u00a0the\u00a0health\nclinic.100,107\nComputerized\u00a0 tomography\u00a0 pulmonary\u00a0 angiogram\u00a0 is\u00a0 now\u00a0 the\u00a0 radiological\ninvestigation\u00a0of\u00a0choice\u00a0for\u00a0PE\u00a0and\u00a0has\u00a0superseded\u00a0the\u00a0ventilation\u00adperfusion\nscan.", "chunk_order": 27}
{"chunk_id": "34708c69-2a1b-4572-8baf-1ddc26e9cae8", "source_document_filename": "CPG Prevention and Treatment of Venous Thrombosis_cleaned_ultra_minimal.txt", "source_document_title": "CPG Prevention and Treatment of Venous Thrombosis cleaned ultra minimal", "text": "If\u00a0 the\u00a0 score\u00a0 suggests\u00a0 likely\u00a0 PE,\u00a0 cover\u00a0 patient\u00a0 with\u00a0 LMWH\u00a0 and\u00a0 perform\ncomputerized\u00a0tomography\u00a0pulmonary\u00a0angiogram\u00a0(CTPA)\u00a0on\u00a0the\u00a0same\u00a0day\u00a0or\nwithin\u00a0next\u00a024\u00a0hours. If\u00a0CTPA\u00a0is\u00a0normal,\u00a0proceed\u00a0with\u00a0bilateral\u00a0compression\nUS\u00a0scan\u00a0(CUS). If\u00a0these\u00a0are\u00a0negative,\u00a0patient\u00a0can\u00a0be\u00a0discharged\u00a0to\u00a0the\u00a0health\nclinic.100,107\nComputerized\u00a0 tomography\u00a0 pulmonary\u00a0 angiogram\u00a0 is\u00a0 now\u00a0 the\u00a0 radiological\ninvestigation\u00a0of\u00a0choice\u00a0for\u00a0PE\u00a0and\u00a0has\u00a0superseded\u00a0the\u00a0ventilation\u00adperfusion\nscan. Ventilation\u00adperfusion\u00a0scan\u00a0is\u00a0limited\u00a0to\u00a0very\u00a0few\u00a0centres\u00a0in\u00a0Malaysia\u00a0and\nis\u00a0not\u00a0readily\u00a0available. However\u00a0V/Q\u00a0scan\u00a0still\u00a0has\u00a0a\u00a0role\u00a0in\u00a0certain\u00a0situations\nsuch\u00a0as\u00a0allergy\u00a0to\u00a0ionized\u00a0contrast\u00a0and\u00a0if\u00a0peripheral\u00a0PE\u00a0is\u00a0suspected.100,107\nALGORITHM\u00a0FOR\u00a0PE\u00a0DIAGNOSIS\nCould\u00a0it\u00a0be\u00a0PE? Apply\u00a0PE\u00a0Wells\u2019\u00a0score\nPE\u00a0likely\nPE\u00a0unlikely\nCTPA\nPositive\nNegative\nPositive\nNegative\nExclude\u00a0PE\nCUS\nDiagnose\u00a0PE\nand\u00a0Treat\n3.3 INVESTIGATIONS FOR CANCER\nAll\u00a0patients\u00a0diagnosed\u00a0with\u00a0unprovoked\u00a0VTE\u00a0who\u00a0are\u00a0not\u00a0known\u00a0to\u00a0have\u00a0cancer\nshould\u00a0 be\u00a0 offered\u00a0 a\u00a0 physical\u00a0 examination\u00a0 (further\u00a0 specific\u00a0 tests\u00a0 guided\u00a0 by\u00a0 the\npatient\u2019s\u00a0history\u00a0and\u00a0examination),\u00a0a\u00a0chest\u00a0X\u00adray\u00a0and\u00a0blood\u00a0tests\u00a0(FBC,\u00a0RP,\u00a0LFT,\nurinalysis).110\nConsider\u00a0further\u00a0investigations\u00a0for\u00a0cancer\u00a0with\u00a0an\u00a0abdomino\u00adpelvic\u00a0CT\u00a0scan\u00a0(and\u00a0a\nmammogram\u00a0for\u00a0women)\u00a0in\u00a0all\u00a0patients\u00a0aged\u00a0over\u00a040\u00a0years\u00a0with\u00a0a\u00a0first\u00a0unprovoked\nVTE. Tumour\u00a0markers\u00a0are\u00a0not\u00a0recommended\u00a0for\u00a0cancer\u00a0screening.110\n3.4 THROMBOPHILIA TESTING\nThrombophilia\u00a0means\u00a0a\u00a0predisposition\u00a0to\u00a0clot\u00a0formation. It\u00a0can\u00a0either\u00a0be\u00a0inherited\nor\u00a0acquired. The\u00a0known\u00a0heritable\u00a0thrombophilias\u00a0are\u00a0factor\u00a0V\u00a0Leiden,\u00a0prothrombin\ngene\u00a0mutation\u00a0and\u00a0deficiencies\u00a0of\u00a0the\u00a0natural\u00a0anticoagulants\u00a0(protein\u00a0C,\u00a0protein\u00a0S\nand\u00a0 antithrombin).111,112\u00a0There\u00a0 may\u00a0 be\u00a0 other\u00a0 genetic\u00a0 defects\u00a0 that\u00a0 remain\u00a0 to\u00a0 be\nidentified. Factor\u00a0V\u00a0Leiden\u00a0and\u00a0prothrombin\u00a0gene\u00a0mutation\u00a0are\u00a0disorders\u00a0of\u00a0Caucasians\u00a0and\nrecent\u00a0studies\u00a0have\u00a0shown\u00a0that\u00a0they\u00a0are\u00a0rare\u00a0in\u00a0East\u00a0Asia.113,114\u00a0Deficiencies\u00a0of\nprotein\u00a0C,\u00a0protein\u00a0S\u00a0and\u00a0antithrombin\u00a0are\u00a0very\u00a0uncommon\u00a0but\u00a0seem\u00a0to\u00a0be\u00a0higher\nin\u00a0East\u00a0Asia\u00a0when\u00a0compared\u00a0to\u00a0Europe.113,114\nThe\u00a0most\u00a0common\u00a0thrombophilia\u00a0is\u00a0the\u00a0acquired\u00a0antiphospholipid\u00a0syndrome. It\u00a0is\nassociated\u00a0 with\u00a0 both\u00a0 arterial\u00a0 and\u00a0 venous\u00a0 thrombosis\u00a0 as\u00a0 well\u00a0 as\u00a0 recurrent\npregnancy\u00a0 losses.115,116\u00a0Other\u00a0 rare\u00a0 acquired\u00a0 causes\u00a0 are\u00a0 the\u00a0 myeloproliferative\nneoplasia\u00a0and\u00a0paroxysmal\u00a0nocturnal\u00a0haemoglobinuria. Thrombophilia\u00a0testing\u00a0does\u00a0not\u00a0influence\u00a0the\u00a0initial\u00a0management\u00a0of\u00a0a\u00a0VTE\u00a0nor\u00a0the\nintensity\u00a0 of\u00a0 anticoagulant\u00a0 therapy.111,112,117\u00ad119\u00a0 Recurrence\u00a0 of\u00a0 VTE\u00a0 after\u00a0 stopping\nanticoagulant\u00a0treatment\u00a0has\u00a0not\u00a0been\u00a0shown\u00a0to\u00a0be\u00a0predictable\u00a0by\u00a0thrombophilia\ntesting\u00a0except\u00a0in\u00a0the\u00a0presence\u00a0of\u00a0the\u00a0lupus\u00a0anticoagulant\u00a0(LA)/\u00a0antiphospholipid\nantibodies\u00a0(APA).111\u00ad113,115,119\u00ad122\nThrombophilia\u00a0 testing\u00a0 is\u00a0 affected\u00a0 by\u00a0 pre\u00adanalytical\u00a0 variables\u00a0 and\u00a0 errors\u00a0 in\ninterpretation\u00a0are\u00a0frequent,\u00a0which\u00a0results\u00a0in\u00a0both\u00a0reduced\u00a0sensitivity\u00a0and\u00a0specificity\nfor\u00a0accurate\u00a0diagnosis. Thus\u00a0genuine\u00a0deficiencies\u00a0and\u00a0abnormalities\u00a0may\u00a0not\u00a0be\ndetected\u00a0and\u00a0false\u00a0positive\u00a0diagnoses\u00a0are\u00a0common.111,112\nThe\u00a0other\u00a0drawbacks\u00a0of\u00a0thrombophilia\u00a0testing\u00a0are\u00a0the\u00a0high\u00a0costs\u00a0of\u00a0testing\u00a0and\u00a0its\npsychosocial\u00a0impact.", "chunk_order": 28}
{"chunk_id": "715adad5-9172-497d-91ee-7741182be547", "source_document_filename": "CPG Prevention and Treatment of Venous Thrombosis_cleaned_ultra_minimal.txt", "source_document_title": "CPG Prevention and Treatment of Venous Thrombosis cleaned ultra minimal", "text": "Thus\u00a0genuine\u00a0deficiencies\u00a0and\u00a0abnormalities\u00a0may\u00a0not\u00a0be\ndetected\u00a0and\u00a0false\u00a0positive\u00a0diagnoses\u00a0are\u00a0common.111,112\nThe\u00a0other\u00a0drawbacks\u00a0of\u00a0thrombophilia\u00a0testing\u00a0are\u00a0the\u00a0high\u00a0costs\u00a0of\u00a0testing\u00a0and\u00a0its\npsychosocial\u00a0impact. Positive\u00a0tests\u00a0may\u00a0cause\u00a0unnecessary\u00a0anxiety\u00a0and\u00a0carriers\nof\u00a0thrombophilia\u00a0may\u00a0find\u00a0it\u00a0difficult\u00a0to\u00a0obtain\u00a0life\u00a0or\u00a0disability\u00a0insurance,\u00a0whether\nsymptomatic\u00a0or\u00a0not.123\nThere\u00a0 is\u00a0 also\u00a0 no\u00a0 strong\u00a0 evidence\u00a0 linking\u00a0 the\u00a0 heritable\u00a0 thrombophilias\u00a0 to\u00a0 the\ndevelopment\u00a0 of\u00a0 arterial\u00a0 thrombosis\u00a0 and\u00a0 recurrent\u00a0 miscarriages\u00a0 except\u00a0 for\u00a0 the\nacquired\u00a0antiphospholipid\u00a0syndrome.115,116,122\nHence,\u00a0 thrombophilia\u00a0 testing\u00a0 has\u00a0 very\u00a0 little\u00a0 clinical\u00a0 utility\u00a0 and\u00a0 should\u00a0 not\u00a0 be\nperformed\u00a0 on\u00a0 a\u00a0 routine\u00a0 basis. Environmental\u00a0 and\u00a0 acquired\u00a0 risk\u00a0 factors\u00a0 play\u00a0 a\nbigger\u00a0role\u00a0in\u00a0the\u00a0development\u00a0of\u00a0VTE.111,112\nRecommendations\nGrade\nDo\u00a0 not\u00a0 offer\u00a0 thrombophilia\u00a0 testing\u00a0 during\u00a0 the\u00a0 acute\u00a0 thrombotic\nevent\u00a0or\u00a0prior\u00a0to\u00a0initiation\u00a0of\u00a0anticoagulant\u00a0therapy\nDo\u00a0not\u00a0offer\u00a0thrombophilia\u00a0testing\u00a0to\u00a0patients\u00a0who\u00a0are\u00a0continuing\nanticoagulant\u00a0treatment\nConsider\u00a0 testing\u00a0 for\u00a0 APA\u00a0 and\u00a0 LA\u00a0 in\u00a0 patients\u00a0 who\u00a0 have\u00a0 had\nunprovoked\u00a0 DVT\u00a0 or\u00a0 PE\u00a0 if\u00a0 it\u00a0 is\u00a0 planned\u00a0 to\u00a0 stop\u00a0 anticoagulant\ntreatment\nConsider\u00a0 testing\u00a0 for\u00a0 hereditary\u00a0 thrombophilia\u00a0 in\u00a0 patients\u00a0 who\nhave\u00a0unprovoked\u00a0DVT\u00a0or\u00a0PE\u00a0and\u00a0who\u00a0have\u00a0a\u00a0first\u00addegree\u00a0relative\nwho\u00a0has\u00a0had\u00a0a\u00a0DVT\u00a0or\u00a0PE\u00a0if\u00a0it\u00a0is\u00a0planned\u00a0to\u00a0stop\u00a0anticoagulant\ntreatment\nDo\u00a0 not\u00a0 offer\u00a0 thrombophilia\u00a0 testing\u00a0 to\u00a0 patients\u00a0 who\u00a0 have\u00a0 had\u00a0 a\nprovoked\u00a0DVT\u00a0or\u00a0PE\nDo\u00a0not\u00a0offer\u00a0thrombophilia\u00a0testing\u00a0in\u00a0women\u00a0with\u00a0a\u00a0previous\u00a0VTE\nassociated\u00a0with\u00a0pregnancy\u00a0or\u00a0the\u00a0oral\u00a0contraceptive\u00a0pill\nDo\u00a0 not\u00a0 offer\u00a0 thrombophilia\u00a0 testing\u00a0 to\u00a0 first\u00addegree\u00a0 relatives\u00a0 of\npatients\u00a0with\u00a0thrombophilia\u00a0who\u00a0have\u00a0had\u00a0a\u00a0DVT\u00a0or\u00a0PE\nDo\u00a0 not\u00a0 offer\u00a0 thrombophilia\u00a0 testing\u00a0 to\u00a0 patients\u00a0 who\u00a0 have\u00a0 had\u00a0 an\narterial\u00a0thrombosis\u00a0but\u00a0consider\u00a0APA\u00a0and\u00a0LA\u00a0if\u00a0there\u00a0are\u00a0no\u00a0other\nrisk\u00a0factors\nDo\u00a0 not\u00a0 offer\u00a0 thrombophilia\u00a0 testing\u00a0 in\u00a0 recurrent\u00a0 miscarriages\u00a0 or\npregnancy\u00a0losses\u00a0except\u00a0for\u00a0APA\u00a0and\u00a0LA\nNeonates\u00a0and\u00a0children\u00a0with\u00a0purpura\u00a0fulminans\u00a0should\u00a0be\u00a0tested\nurgently\u00a0for\u00a0protein\u00a0C\u00a0or\u00a0protein\u00a0S\u00a0deficiency\nB\nB\nB\nC\nA\nC\nB\nB\nB\nA\nTable\u00a03.4:\u00a0Thrombophilia\u00a0Testing124,125\nLow\u00a0molecular\u00a0weight\u00a0heparin\u00a0is\u00a0continued\u00a0for\u00a0at\u00a0least\u00a05\u00a0days\u00a0or\u00a0until\u00a0the\u00a0INR\u00a0is\nabove\u00a02\u00a0for\u00a0at\u00a0least\u00a024\u00a0hours,\u00a0whichever\u00a0is\u00a0longer.134,136\nTable\u00a04.2.1:\u00a0LMWHs\u00a0and\u00a0the\u00a0recommended\u00a0doses\u00a0for\u00a0the\u00a0treatment\nof\u00a0acute\u00a0VTE\n4.0\u00a0TREATMENT\u00a0OF\u00a0VTE\n4.1\u00a0INTRODUCTION\nThe\u00a0aim\u00a0of\u00a0treatment\u00a0of\u00a0VTE\u00a0is\u00a0to\u00a0reduce\u00a0morbidity\u00a0and\u00a0mortality. This\u00a0is\u00a0achieved\nby\u00a0 optimal\u00a0 therapy\u00a0 with\u00a0 anticoagulants\u00a0 to\u00a0 prevent\u00a0 thrombus\u00a0 extension\u00a0 and\nembolisation. Graduated\u00a0elastic\u00a0compression\u00a0stockings\u00a0are\u00a0important\u00a0to\u00a0prevent\npost\u00adthrombotic\u00a0complications\u00a0following\u00a0a\u00a0proximal\u00a0DVT.126,127\n4.2\u00a0INITIAL\u00a0TREATMENT\u00a0OF\u00a0VTE\nIn\u00a0clinically\u00a0suspected\u00a0cases\u00a0with\u00a0high\u00a0probability\u00a0VTE,\u00a0treatment\u00a0with\u00a0LMWH\u00a0or\nfondaparinux\u00a0should\u00a0be\u00a0given\u00a0until\u00a0the\u00a0diagnosis\u00a0is\u00a0excluded\u00a0by\u00a0objective\u00a0testing. In\u00a0patients\u00a0with\u00a0confirmed\u00a0DVT\u00a0or\u00a0PE,\u00a0offer\u00a0a\u00a0choice\u00a0of\u00a0LMWH,\u00a0fondaparinux\u00a0or\nrivaroxaban,\u00a0taking\u00a0into\u00a0account\u00a0comorbidities,\u00a0contraindications\u00a0and\u00a0drug\u00a0costs. Start\u00a0 treatment\u00a0 as\u00a0 soon\u00a0 as\u00a0 possible.129,130,137\u00a0 \u00a0Adequate\u00a0 analegesia\u00a0 should\u00a0 be\ngiven\u00a0and\u00a0the\u00a0leg\u00a0elevated.136,137\nOffer\u00a0 warfarin\u00a0 within\u00a0 24\u00a0 hours\u00a0 of\u00a0 diagnosis\u00a0 in\u00a0 combination\u00a0 with\u00a0 LMWH\u00a0 or\nfondaparinux.", "chunk_order": 29}
{"chunk_id": "909960bf-2268-4fad-8430-b564209b6b15", "source_document_filename": "CPG Prevention and Treatment of Venous Thrombosis_cleaned_ultra_minimal.txt", "source_document_title": "CPG Prevention and Treatment of Venous Thrombosis cleaned ultra minimal", "text": "Graduated\u00a0elastic\u00a0compression\u00a0stockings\u00a0are\u00a0important\u00a0to\u00a0prevent\npost\u00adthrombotic\u00a0complications\u00a0following\u00a0a\u00a0proximal\u00a0DVT.126,127\n4.2\u00a0INITIAL\u00a0TREATMENT\u00a0OF\u00a0VTE\nIn\u00a0clinically\u00a0suspected\u00a0cases\u00a0with\u00a0high\u00a0probability\u00a0VTE,\u00a0treatment\u00a0with\u00a0LMWH\u00a0or\nfondaparinux\u00a0should\u00a0be\u00a0given\u00a0until\u00a0the\u00a0diagnosis\u00a0is\u00a0excluded\u00a0by\u00a0objective\u00a0testing. In\u00a0patients\u00a0with\u00a0confirmed\u00a0DVT\u00a0or\u00a0PE,\u00a0offer\u00a0a\u00a0choice\u00a0of\u00a0LMWH,\u00a0fondaparinux\u00a0or\nrivaroxaban,\u00a0taking\u00a0into\u00a0account\u00a0comorbidities,\u00a0contraindications\u00a0and\u00a0drug\u00a0costs. Start\u00a0 treatment\u00a0 as\u00a0 soon\u00a0 as\u00a0 possible.129,130,137\u00a0 \u00a0Adequate\u00a0 analegesia\u00a0 should\u00a0 be\ngiven\u00a0and\u00a0the\u00a0leg\u00a0elevated.136,137\nOffer\u00a0 warfarin\u00a0 within\u00a0 24\u00a0 hours\u00a0 of\u00a0 diagnosis\u00a0 in\u00a0 combination\u00a0 with\u00a0 LMWH\u00a0 or\nfondaparinux. For\u00a0rivaroxaban,\u00a0no\u00a0overlap\u00a0with\u00a0LMWH\u00a0or\u00a0fondaparinux\u00a0is\u00a0needed\nas\u00a0 rivaroxaban\u00a0 has\u00a0 a\u00a0 rapid\u00a0 onset\u00a0 of\u00a0 action\u00a0 and\u00a0 predictable\u00a0 bioavailability. In\npatients\u00a0 with\u00a0 severe\u00a0 renal\u00a0 impairment\u00a0 or\u00a0 established\u00a0 renal\u00a0 failure\u00a0 (eGFR\u00a0 <30\nmL/min)\u00a0offer\u00a0UFH\u00a0with\u00a0dose\u00a0adjustments\u00a0based\u00a0on\u00a0APTT\u00a0or\u00a0LMWH\u00a0with\u00a0dose\nadjustments\u00a0 based\u00a0 on\u00a0 anti\u00adXa\u00a0 assay.130,134,136\u00a0 For\u00a0 patients\u00a0 with\u00a0 PE\u00a0 and\nhemodynamic\u00a0 instability,\u00a0 offer\u00a0 IV\u00a0 UFH\u00a0 and\u00a0 consider\u00a0 systemic\u00a0 thrombolytic\ntherapy.128,131,132\n4.2.1\u00a0Low\u00a0molecular\u00a0weight\u00a0heparin\nLow\u00a0 molecular\u00a0 weight\u00a0 heparin\u00a0 is\u00a0 associated\u00a0 with\u00a0 decreased\u00a0 mortality,\u00a0 lower\nrecurrence\u00a0of\u00a0VTE\u00a0and\u00a0decreased\u00a0incidence\u00a0of\u00a0major\u00a0bleeding\u00a0when\u00a0compared\nwith\u00a0unfractionated\u00a0heparin.133\u00ad135,138\u00a0\u00a0It\u00a0does\u00a0not\u00a0require\u00a0monitoring\u00a0and\u00a0it\u2019s\u00a0ease\u00a0of\nuse\u00a0makes\u00a0outpatient\u00a0treatment\u00a0feasible. Currently\u00a0 available\u00a0 LMWHs\u00a0 in\u00a0 Malaysia\u00a0 and\u00a0 recommended\u00a0 doses\u00a0 for\u00a0 the\ntreatment\u00a0of\u00a0acute\u00a0VTE\u00a0are\u00a0as\u00a0shown\u00a0in\u00a0Table\u00a04.2.1.134,139\n1\u00a0mg/kg\u00a0twice\u00a0daily\nTinzaparin\n(0.5\u00a0and\u00a00.7\u00a0mL\u00a0of\u00a020,000\nanti\u00adXa\u00a0IU/mL\u00a0prefilled\u00a0syringes)\nLMWH\nTreatment\u00a0dose\nEnoxaparin\n(20,\u00a040,\u00a0and\u00a060\u00a0mg\u00a0prefilled\u00a0syringes)\n175\u00a0units/kg\u00a0once\u00a0daily\nA\u00a0simple\u00a0way\u00a0to\u00a0calculate\u00a0tinzaparin\ndose:\u00a0Volume\u00a0of\u00a0tinzaparin\u00a0in\u00a0mL\nrequired\u00a0=\u00a0(weight\u00a0in\u00a0Kg\u00a0\u00ad\u00a010)\u00a0\u00f7\u00a0100\ne.g. 60\u00a0kg\u00a0patient\u00a0=\u00a00.5\u00a0mL\u037e\u00a070\u00a0kg\n=\u00a00.6\u00a0mL\u037e\u00a045\u00a0kg\u00a0=\u00a00.35\u00a0mL\u00a0tinzaparin)\n4.2.2\u00a0Fondaparinux\nFondaparinux\u00a0 is\u00a0 an\u00a0 indirect\u00a0 inhibitor\u00a0 of\u00a0 activated\u00a0 factor\u00a0 X. It\u00a0 does\u00a0 not\u00a0 inhibit\nthrombin\u00a0and\u00a0has\u00a0no\u00a0effect\u00a0on\u00a0platelets. It\u00a0is\u00a0given\u00a0subcutaneously\u00a0and\u00a0the\u00a0dosing\nfor\u00a0the\u00a0treatment\u00a0of\u00a0VTE\u00a0is\u00a0based\u00a0on\u00a0the\u00a0body\u00a0weight\u00a0(Table\u00a04.2.2). Fondaparinux\nmust\u00a0be\u00a0used\u00a0with\u00a0caution\u00a0in\u00a0patients\u00a0with\u00a0renal\u00a0impairment\u00a0as\u00a0it\u00a0is\u00a0eliminated\nunchanged\u00a0in\u00a0the\u00a0kidneys.129,131\u00a0Fondaparinux,\u00a0like\u00a0LMWH\u00a0is\u00a0continued\u00a0for\u00a0at\u00a0least\n5\u00a0days\u00a0or\u00a0until\u00a0the\u00a0INR\u00a0is\u00a0above\u00a02\u00a0for\u00a0at\u00a0least\u00a024\u00a0hours,\u00a0whichever\u00a0is\u00a0longer. 4.2.3\u00a0Rivaroxaban\nRivaroxaban\u00a0is\u00a0a\u00a0highly\u00a0selective,\u00a0direct\u00a0factor\u00a0Xa\u00a0inhibitor\u00a0that\u00a0is\u00a0orally\u00a0active\u00a0with\na\u00a0rapid\u00a0onset\u00a0of\u00a0action. The\u00a0dose\u00a0used\u00a0in\u00a0the\u00a0treatment\u00a0of\u00a0VTE\u00a0is\u00a015\u00a0mg\u00a0twice\u00a0a\nday\u00a0as\u00a0the\u00a0loading\u00a0dose\u00a0for\u00a03\u00a0weeks\u00a0followed\u00a0by\u00a020\u00a0mg\u00a0daily. At\u00a0these\u00a0doses,\u00a0it\u00a0has\nbeen\u00a0shown\u00a0to\u00a0be\u00a0non\u00adinferior\u00a0to\u00a0enoxaparin\u00a0followed\u00a0by\u00a0warfarin\u00a0with\u00a0significantly\nless\u00a0major\u00a0bleeding\u00a0complications.130,136\n4.2.3.1\u00a0Switching\u00a0heparin\u00a0to\u00a0rivaroxaban\nFor\u00a0patients\u00a0currently\u00a0receiving\u00a0a\u00a0parenteral\u00a0anticoagulant,\u00a0rivaroxaban\u00a0should\u00a0be\nstarted\u00a00\u00a0to\u00a02\u00a0hours\u00a0before\u00a0the\u00a0time\u00a0of\u00a0the\u00a0next\u00a0scheduled\u00a0administration\u00a0of\u00a0LMWH\u00a0or\nat\u00a0the\u00a0time\u00a0of\u00a0discontinuation\u00a0of\u00a0continuous\u00a0intravenous\u00a0unfractionated\u00a0heparin.", "chunk_order": 30}
{"chunk_id": "b99d87a1-f4f0-4d9f-b7c7-faedf7297a2a", "source_document_filename": "CPG Prevention and Treatment of Venous Thrombosis_cleaned_ultra_minimal.txt", "source_document_title": "CPG Prevention and Treatment of Venous Thrombosis cleaned ultra minimal", "text": "The\u00a0dose\u00a0used\u00a0in\u00a0the\u00a0treatment\u00a0of\u00a0VTE\u00a0is\u00a015\u00a0mg\u00a0twice\u00a0a\nday\u00a0as\u00a0the\u00a0loading\u00a0dose\u00a0for\u00a03\u00a0weeks\u00a0followed\u00a0by\u00a020\u00a0mg\u00a0daily. At\u00a0these\u00a0doses,\u00a0it\u00a0has\nbeen\u00a0shown\u00a0to\u00a0be\u00a0non\u00adinferior\u00a0to\u00a0enoxaparin\u00a0followed\u00a0by\u00a0warfarin\u00a0with\u00a0significantly\nless\u00a0major\u00a0bleeding\u00a0complications.130,136\n4.2.3.1\u00a0Switching\u00a0heparin\u00a0to\u00a0rivaroxaban\nFor\u00a0patients\u00a0currently\u00a0receiving\u00a0a\u00a0parenteral\u00a0anticoagulant,\u00a0rivaroxaban\u00a0should\u00a0be\nstarted\u00a00\u00a0to\u00a02\u00a0hours\u00a0before\u00a0the\u00a0time\u00a0of\u00a0the\u00a0next\u00a0scheduled\u00a0administration\u00a0of\u00a0LMWH\u00a0or\nat\u00a0the\u00a0time\u00a0of\u00a0discontinuation\u00a0of\u00a0continuous\u00a0intravenous\u00a0unfractionated\u00a0heparin. 309,310\n4.2.3.2\u00a0Switching\u00a0rivaroxaban\u00a0to\u00a0heparin\nTo\u00a0convert\u00a0rivaroxaban\u00a0to\u00a0LMWH,\u00a0give\u00a0the\u00a0first\u00a0dose\u00a0of\u00a0LMWH\u00a0at\u00a0the\u00a0time\u00a0the\nnext\u00a0 rivaroxaban\u00a0 dose\u00a0 would\u00a0 be\u00a0 taken\u00a0 or\u00a0 12\u00a0 hours\u00a0 after\u00a0 the\u00a0 last\u00a0 dose\u00a0 of\nrivaroxaban.309,310\n4.2.3.3\u00a0Switching\u00a0VKAs\u00a0to\u00a0rivaroxaban\nStop\u00a0VKA\u00a0and\u00a0allow\u00a0INR\u00a0to\u00a0fall. Rivaroxaban\u00a0can\u00a0be\u00a0given\u00a0as\u00a0soon\u00a0as\u00a0INR\n4O676309,310\n4.2.3.4\u00a0Switching\u00a0rivaroxaban\u00a0to\u00a0VKA\nThere\u00a0 is\u00a0 a\u00a0 potential\u00a0 for\u00a0 inadequate\u00a0 anticoagulation\u00a0 during\u00a0 the\u00a0 transition\u00a0 from\nrivaroxaban\u00a0 to\u00a0 VKA. Continuous\u00a0 adequate\u00a0 anticoagulation\u00a0 should\u00a0 be\u00a0 ensured\nduring\u00a0 any\u00a0 transition\u00a0 to\u00a0 an\u00a0 alternate\u00a0 anticoagulant. It\u00a0 should\u00a0 be\u00a0 noted\u00a0 that\nrivaroxaban\u00a0can\u00a0contribute\u00a0to\u00a0an\u00a0elevated\u00a0INR.309,310\nIn\u00a0patients\u00a0converting\u00a0from\u00a0rivaroxaban\u00a0to\u00a0VKA,\u00a0VKA\u00a0should\u00a0be\u00a0given\u00a0concurrently\n89C1<\"CE0\"23-\"1+\"&O6@6\"P$%\"CE0\"#1%+C\"O\"()*+\"$#\"CE0\"/$9Q0%+1$9\";0%1$(R\"+C)9()%(\"191C1)<\"\ndosing\u00a0of\u00a0VKA\u00a0should\u00a0be\u00a0used\u00a0followed\u00a0by\u00a0VKA\u00a0dosing\u00a0guided\u00a0by\u00a0INR\u00a0testing. While\u00a0patients\u00a0are\u00a0on\u00a0both\u00a0rivaroxaban\u00a0and\u00a0VKA,\u00a0the\u00a0INR\u00a0should\u00a0not\u00a0be\u00a0tested\nearlier\u00a0 than\u00a0 24\u00a0 hours\u00a0 after\u00a0 the\u00a0 previous\u00a0 dose\u00a0 but\u00a0 prior\u00a0 to\u00a0 the\u00a0 next\u00a0 dose\u00a0 of\nrivaroxaban. Once\u00a0rivaroxaban\u00a0is\u00a0discontinued,\u00a0INR\u00a0testing\u00a0may\u00a0be\u00a0done\u00a0reliably\nat\u00a0least\u00a024\u00a0hours\u00a0after\u00a0the\u00a0last\u00a0dose.309,310\n<50\n5\n50\u00a0\u00ad\u00a0100\n7.5\n>100\n10\nBody\u00a0weight,\u00a0kg\nDosing,\u00a0mg\nTable\u00a04.2.2:\u00a0The\u00a0recommended\u00a0doses\u00a0for\u00a0fondaparinux\u00a0in\u00a0the\ntreatment\u00a0of\u00a0acute\u00a0VTE\n4.2.4\u00a0Dabigatran\nAt\u00a0the\u00a0time\u00a0of\u00a0writing\u00a0this\u00a0cpg,\u00a0dabigatran\u00a0is\u00a0not\u00a0licensed\u00a0for\u00a0use\u00a0in\u00a0the\u00a0treatment\u00a0of\nVTE. 4.2.5\u00a0Intravenous\u00a0unfractionated\u00a0heparin\nIntravenous\u00a0UFH\u00a0is\u00a0no\u00a0longer\u00a0the\u00a0standard\u00a0treatment\u00a0in\u00a0DVT\u00a0and\u00a0PE\u00a0because\u00a0it\nhas\u00a0to\u00a0be\u00a0given\u00a0as\u00a0an\u00a0infusion\u00a0with\u00a0frequent\u00a0APTT\u00a0monitoring\u00a0and\u00a0may\u00a0take\u00a0more\nthan\u00a0 12\u00a0 hours\u00a0 to\u00a0 achieve\u00a0 therapeutic\u00a0 level. All\u00a0 patients\u00a0 receiving\u00a0 UFH\u00a0 should\nhave\u00a0a\u00a0platelet\u00a0count\u00a0performed\u00a0at\u00a0baseline\u00a0but\u00a0do\u00a0not\u00a0necessitate\u00a0platelet\u00a0count\nmonitoring\u00a0unless\u00a0post\u00adoperative.128,131,133,134\nThe\u00a0duration\u00a0of\u00a0initial\u00a0IV\u00a0UFH\u00a0therapy\u00a0in\u00a0patients\u00a0with\u00a0VTE\u00a0is\u00a0between\u00a05\u00a0to\u00a07\ndays. To\u00a0standardize\u00a0the\u00a0management\u00a0of\u00a0IV\u00a0UFH,\u00a0a\u00a0weight\u00adbased\u00a0normogram\u00a0is\nused\u00a0(Table\u00a04.2.5).134,136,138\n4.3\u00a0\u00a0MAINTENANCE\u00a0TREATMENT\u00a0OF\u00a0VTE\nFollowing\u00a0initial\u00a0heparinisation\u00a0or\u00a0fondaparinux\u00a0in\u00a0patients\u00a0with\u00a0VTE,\u00a0maintenance\nof\u00a0anticoagulation\u00a0with\u00a0oral\u00a0anticoagulants\u00a0is\u00a0recommended. Following\u00a0discharge,\nthose\u00a0on\u00a0warfarin\u00a0should\u00a0be\u00a0followed\u00a0up\u00a0within\u00a0a\u00a0week\u00a0with\u00a0a\u00a0repeat\u00a0INR. If\u00a0the\u00a0INR\u00a0remains\u00a0within\u00a0therapeutic\u00a0range,\u00a0the\u00a0same\u00a0dose\u00a0is\u00a0maintained\u00a0and\u00a0the\nnext\u00a0 follow\u00adup\u00a0 will\u00a0 be\u00a0 2\u00a0 weeks\u00a0 later. If\u00a0 the\u00a0 INR\u00a0 still\u00a0 remains\u00a0 within\u00a0 therapeutic\nrange,\u00a0 then\u00a0 monthly\u00a0 follow\u00adup\u00a0 with\u00a0 INR\u00a0 is\u00a0 advised. More\u00a0 frequent\u00a0 visits\u00a0 are\nrequired\u00a0if\u00a0therapeutic\u00a0INR\u00a0is\u00a0not\u00a0achieved\u00a0(see\u00a0chapter\u00a010.0:\u00a0MTAC\u00adW).", "chunk_order": 31}
{"chunk_id": "4bd9617a-7a01-41f8-bcf4-4bccdcba86ce", "source_document_filename": "CPG Prevention and Treatment of Venous Thrombosis_cleaned_ultra_minimal.txt", "source_document_title": "CPG Prevention and Treatment of Venous Thrombosis cleaned ultra minimal", "text": "Following\u00a0discharge,\nthose\u00a0on\u00a0warfarin\u00a0should\u00a0be\u00a0followed\u00a0up\u00a0within\u00a0a\u00a0week\u00a0with\u00a0a\u00a0repeat\u00a0INR. If\u00a0the\u00a0INR\u00a0remains\u00a0within\u00a0therapeutic\u00a0range,\u00a0the\u00a0same\u00a0dose\u00a0is\u00a0maintained\u00a0and\u00a0the\nnext\u00a0 follow\u00adup\u00a0 will\u00a0 be\u00a0 2\u00a0 weeks\u00a0 later. If\u00a0 the\u00a0 INR\u00a0 still\u00a0 remains\u00a0 within\u00a0 therapeutic\nrange,\u00a0 then\u00a0 monthly\u00a0 follow\u00adup\u00a0 with\u00a0 INR\u00a0 is\u00a0 advised. More\u00a0 frequent\u00a0 visits\u00a0 are\nrequired\u00a0if\u00a0therapeutic\u00a0INR\u00a0is\u00a0not\u00a0achieved\u00a0(see\u00a0chapter\u00a010.0:\u00a0MTAC\u00adW). Table 4.2.5: Management with IV UFH\n<1.2\n(APTT\u00a0<35s)\n6\u00a0h\n80\u00a0IU/kg\u00a0bolus,\u00a0then\u00a0increase\u00a0rate\u00a0by\n4\u00a0IU/kg/h\n1.2\u00a0\u00ad\u00a01.5\n(APTT\u00a035\u00a0to\u00a045s)\n6\u00a0h\n40\u00a0IU/kg\u00a0bolus,\u00a0then\u00a0increase\u00a0infusion\nrate\u00a0by\u00a02\u00a0IU/kg/h\n1.5\u00a0\u00ad\u00a02.5\n(APTT\u00a046\u00a0to\u00a070s)\n24\u00a0h\nNo\u00a0change\n2.5\u00a0\u00ad\u00a03.0\n(APTT\u00a071\u00a0to\u00a090s)\n6\u00a0h\nDecrease\u00a0infusion\u00a0rate\u00a0by\u00a02\u00a0IU/kg/h\n>3.0\n(APTT\u00a0>90s)\n6\u00a0h\nWithold\u00a0infusion\u00a0for\u00a01\u00a0hour,\u00a0then\ndecrease\u00a0infusion\u00a0rate\u00a0by\u00a03\u00a0IU/kg/h\nInitial\u00a0dose\n80\u00a0IU/kg\u00a0bolus,\u00a0then\u00a018\u00a0IU/kg/h\nAPTT\u00a0ratio\nNext\u00a0APTT\nAction\u00a0and\u00a0Dose\u00a0change\nPatients\u00a0on\u00a0rivaroxaban\u00a0do\u00a0not\u00a0need\u00a0initial\u00a0heparinisation\u00a0or\u00a0laboratory\u00a0monitoring. Patients\u00a0are\u00a0seen\u00a0within\u00a01\u00a0to\u00a02\u00a0weeks\u00a0of\u00a0treatment\u00a0to\u00a0monitor\u00a0response\u00a0and\u00a0to\nassess\u00a0drug\u00a0tolerability. Thereafter\u00a0monthly\u00a0follow\u00adup\u00a0is\u00a0advised. 4.3.1\u00a0Duration\u00a0of\u00a0anticoagulation\nThe\u00a0aim\u00a0of\u00a0anticoagulant\u00a0therapy\u00a0is\u00a0to\u00a0prevent\u00a0extension\u00a0of\u00a0the\u00a0thrombus\u00a0and\nrecurrence\u00a0 of\u00a0 the\u00a0 disease\u037e\u00a0 however,\u00a0 the\u00a0 optimal\u00a0 duration\u00a0 is\u00a0 still\u00a0 not\u00a0 known. Anticoagulant\u00a0therapy\u00a0should\u00a0be\u00a0continued\u00a0until\u00a0the\u00a0reduction\u00a0of\u00a0recurrent\u00a0VTE\u00a0no\nlonger\u00a0outweighs\u00a0the\u00a0increase\u00a0risk\u00a0of\u00a0bleeding.140\u00ad143,146\n4.3.1.1\u00a0Risk\u00a0factors\u00a0for\u00a0VTE\u00a0recurrence\nThe\u00a0 risk\u00a0 of\u00a0 recurrence\u00a0 after\u00a0 stopping\u00a0 therapy\u00a0 is\u00a0 primarily\u00a0 determined\u00a0 by\u00a0 two\nfactors:\n(1)\u00a0whether\u00a0the\u00a0acute\u00a0episode\u00a0of\u00a0VTE\u00a0has\u00a0been\u00a0effectively\u00a0treated\u00a0and\n(2)\u00a0the\u00a0patient\u2019s\u00a0intrinsic\u00a0risk\u00a0of\u00a0having\u00a0a\u00a0new\u00a0episode\u00a0of\u00a0VTE\u00a0(Table\u00a04.3.1.1).140\u00ad143,146\nThe\u00a0 most\u00a0 important\u00a0 factors\u00a0 that\u00a0 influence\u00a0 the\u00a0 risk\u00a0 of\u00a0 recurrence\u00a0 after\u00a0 stopping\nanticoagulant\u00a0 therapy\u00a0 are\u00a0 the\u00a0 presence\u00a0 of\u00a0 a\u00a0 reversible\u00a0 provoking\u00a0 risk\u00a0 factor,\nunprovoked\u00a0(idiopathic)\u00a0VTE\u00a0and\u00a0the\u00a0presence\u00a0of\u00a0active\u00a0cancer.140,142,143,147\nAmong\u00a0patients\u00a0with\u00a0VTE\u00a0provoked\u00a0by\u00a0a\u00a0reversible\u00a0risk\u00a0factor,\u00a0the\u00a0risk\u00a0of\u00a0recurrence\nis\u00a0 much\u00a0 lower\u00a0 if\u00a0 the\u00a0 provoking\u00a0 factor\u00a0 was\u00a0 recent\u00a0 surgery\u00a0 compared\u00a0 with\u00a0 a\nnonsurgical\u00a0trigger\u00a0(e.g.", "chunk_order": 32}
{"chunk_id": "33e130e2-699a-4620-b921-36f9027e0dd4", "source_document_filename": "CPG Prevention and Treatment of Venous Thrombosis_cleaned_ultra_minimal.txt", "source_document_title": "CPG Prevention and Treatment of Venous Thrombosis cleaned ultra minimal", "text": "estrogen\u00a0therapy,\u00a0pregnancy,\u00a0long\u00adhaul\u00a0flight).140,141,143\n4.3.1.2\u00a0Risk\u00a0factors\u00a0for\u00a0increased\u00a0bleeding\nThe\u00a0risk\u00a0factors\u00a0for\u00a0increased\u00a0bleeding\u00a0in\u00a0patients\u00a0on\u00a0anticoagulation\u00a0are\u00a0listed\nbelow\u00a0(Table\u00a04.3.1.2):143,147\nv\u00a0Unprovoked\u00a0(idiopathic)\u00a0VTE\nv\u00a0Previous\u00a0VTE\nv\u00a0Male\u00a0gender\nv\u00a0Active\u00a0cancer\nv\u00a0Antiphospholipid\u00a0syndrome\nv\u00a0Proximal\u00a0versus\u00a0distal\u00a0DVT\nv\u00a0Post\u00adthrombotic\u00a0syndrome\nTable\u00a04.3.1.1:\u00a0Risk\u00a0factors\u00a0for\u00a0recurrence\n4.3.1.3\u00a0Completion\u00a0of\u00a0anticoagulation\nThere\u00a0 is\u00a0 no\u00a0 strong\u00a0 evidence\u00a0 to\u00a0 recommend\u00a0 routine\u00a0 D\u00addimer\u00a0 testing\u00a0 or\u00a0 US\nexamination\u00a0 upon\u00a0 completion\u00a0 of\u00a0 anticoagulation\u00a0 in\u00a0 order\u00a0 to\u00a0 determine\u00a0 VTE\nrecurrence\u00a0 and\u00a0 the\u00a0 decision\u00a0 to\u00a0 prolong\u00a0 therapy,\u00a0 unless\u00a0 guided\u00a0 by\u00a0 clinical\nsymptoms.311,312\u00a0A\u00a0 high\u00a0 D\u00addimer\u00a0 does\u00a0 not\u00a0 typically\u00a0 predict\u00a0 recurrence\u00a0 while\u00a0 a\nnormal\u00a0 D\u00addimer\u00a0 does\u00a0 not\u00a0 exclude\u00a0 recurrence.141\u00a0 Ultrasound\u00a0 examination\u00a0 is\noperator\u00addependent\u00a0and\u00a0an\u00a0old\u00a0thrombus\u00a0with\u00a0partial\u00a0recanalization\u00a0may\u00a0falsely\nsuggest\u00a0a\u00a0recurrrence.141\n54\nThe\u00a0 recommended\u00a0 duration\u00a0 of\u00a0 anticoagulation\u00a0 hence\u00a0 depends\u00a0 on\u00a0 the\u00a0 risk\u00a0 of\nrecurrence\u00a0and\u00a0the\u00a0risk\u00a0of\u00a0bleeding\u00a0(Table\u00a04.3.1).142,143,145\nProvoked\u00a0by\u00a0a\u00a0transient\u00a0surgical\n3\u00a0months\nrisk\u00a0factor\nProvoked\u00a0by\u00a0a\u00a0transient\u00a0nonsurgical\n3\u00a0months\nrisk\u00a0factor\nUnprovoked\u00a0VTE\u00a0and\u00a0one\u00a0or\u00a0more\n3\u00a0months\nbleeding\u00a0risk\nUnprovoked\u00a0VTE\u00a0in\u00a0association\nwith\u00a0 active\u00a0 cancer\u00a0 and\u00a0 the\nanti\u00adphospholipid\u00a0syndrome\nAnticoagulation\u00a0 is\u00a0 continued\u00a0 as\nlong\u00a0as\u00a0the\u00a0risk\u00a0factor\u00a0remains\nUnprovoked\u00a0VTE\nOffer\u00a0indefinite\u00a0anticoagulation\u00a0after\ntaking\u00a0into\u00a0account:\nt Patient\u2019s\u00a0preference\nt Low\u00a0bleeding\u00a0risk\nt Good\u00a0anticoagulant\u00a0monitoring\nis\u00a0achievable\nFirst\u00a0VTE\nRecommended\u00a0Duration\u00a0of\u00a0AC\nv\u00a0Uncontrolled\u00a0hypertension\nv\u00a0Age\u00a0>75\u00a0years\nv\u00a0Renal\u00a0impairment\nv\u00a0Anaemia\nv\u00a0Recent\u00a0major\u00a0bleeding\nTable\u00a04.3.1.2:\u00a0Risk\u00a0factors\u00a0for\u00a0increased\u00a0bleeding\nTable\u00a04.3.1:\u00a0Duration\u00a0of\u00a0anticoagulation\u00a0(Grade\u00a0B\u00a0Recommendation)\n4.4\u00a0THROMBOLYTIC\u00a0THERAPY\n4.4.1\u00a0Pulmonary\u00a0embolism\nWhere\u00a0life\u00adthreatening\u00a0massive\u00a0PE\u00a0occurs,\u00a0cardiorespiratory\u00a0resuscitation\u00a0is\nusually\u00a0 required\u00a0 and\u00a0 intravenous\u00a0 heparin\u00a0 given. Thrombolytic\u00a0 therapy,\npercutaneous\u00a0catheter\u00a0thrombus\u00a0fragmentation\u00a0or\u00a0surgical\u00a0embolectomy\u00a0will\nbe\u00a0required. This\u00a0will\u00a0vary\u00a0with\u00a0local\u00a0expertise.153\n4.4.1.1\u00a0Pulmonary\u00a0embolectomy\nThis\u00a0procedure\u00a0is\u00a0very\u00a0rarely\u00a0done\u00a0and\u00a0has\u00a0a\u00a0high\u00a0peri\u00adoperative\u00a0morbidity\u00a0and\nmortality\u00a0rates\u00a0(30\u00ad50%).157\u00a0However,\u00a0the\u00a0long\u00adterm\u00a0outcome\u00a0for\u00a0survivors\u00a0is\ngood. It\u00a0 is\u00a0 indicated\u00a0 in\u00a0 massive\u00a0 PE\u00a0 (proven\u00a0 by\u00a0 imaging\u00a0 modalities)\u00a0 with\nhaemodynamic\u00a0compromise. It\u00a0is\u00a0done\u00a0as\u00a0an\u00a0emergency\u00a0procedure\u00a0following\nfailed\u00a0conservative\u00a0measures\u00a0including\u00a0thrombolysis.156\nRecently,\u00a0 percutaneous\u00a0 cathether\u00addirected\u00a0 embolectomy\u00a0 devices\u00a0 had\u00a0 been\ndeveloped. These\u00a0are\u00a0quicker\u00a0and\u00a0easier\u00a0to\u00a0perform. This\u00a0can\u00a0be\u00a0augmented\nby\u00a0 the\u00a0 administration\u00a0 of\u00a0 thrombolytic\u00a0 drugs,\u00a0 which\u00a0 speeds\u00a0 up\u00a0 clot\nfragmentation.148,150,151\n4.4.2\u00a0Deep\u00a0Vein\u00a0Thrombosis\nWhere\u00a0DVT\u00a0threatens\u00a0leg\u00a0viability\u00a0through\u00a0venous\u00a0gangrene,\u00a0the\u00a0leg\u00a0should\u00a0be\nelevated,\u00a0 anticoagulation\u00a0 commenced\u00a0 and\u00a0 consideration\u00a0 given\u00a0 to\u00a0 venous\nthrombectomy\u00a0 or\u00a0 thrombolytic\u00a0 therapy. Catheter\u00addirected\u00a0 thrombolysis\u00a0 is\npreferred\u00a0to\u00a0systemic\u00a0thrombolysis.152\n4.4.2.1\u00a0Venous\u00a0thrombectomy\nThis\u00a0 procedure\u00a0 is\u00a0 done\u00a0 to\u00a0 prevent\u00a0 severe\u00a0 complications\u00a0 of\u00a0 post\u00adthrombotic\nsyndrome. Venous\u00a0thrombectomy\u00a0is\u00a0indicated\u00a0in\u00a0impending\u00a0venous\u00a0gangrene\nof\u00a0the\u00a0lower\u00a0limbs\u00a0due\u00a0to\u00a0phlegmasia\u00a0caerulea\u00a0dolens. Phlegmasia\u00a0caerulea\ndolens\u00a0is\u00a0associated\u00a0with\u00a0considerable\u00a0morbidity\u00a0(50%\u00a0amputation\u00a0rate\u00a0and\u00a012\nto\u00a014%\u00a0PE)\u00a0and\u00a0a\u00a020%\u00a0mortality\u00a0rate.148\nA\u00a0 multicentre\u00a0 randomized\u00a0 trial\u00a0 shows\u00a0 significant\u00a0 benefit\u00a0 of\u00a0 surgical\u00a0 venous\nthrombectomy\u00a0plus\u00a0anticoagulation\u00a0versus\u00a0anticoagulation\u00a0alone\u00a0in\u00a0iliofemoral\nDVT.155\n4.4.3\u00a0Thrombolytic\u00a0agents\nThrombolytic\u00a0 agents\u00a0 used\u00a0 are\u00a0 tissue\u00a0 plasminogen\u00a0 activator\u00a0 (tPA)\u00a0 and\nstreptokinase. They\u00a0 are\u00a0 indicated\u00a0 in\u00a0 massive\u00a0 PE.", "chunk_order": 33}
{"chunk_id": "8afa6230-d990-4d9a-b528-4614daa99e28", "source_document_filename": "CPG Prevention and Treatment of Venous Thrombosis_cleaned_ultra_minimal.txt", "source_document_title": "CPG Prevention and Treatment of Venous Thrombosis cleaned ultra minimal", "text": "Catheter\u00addirected\u00a0 thrombolysis\u00a0 is\npreferred\u00a0to\u00a0systemic\u00a0thrombolysis.152\n4.4.2.1\u00a0Venous\u00a0thrombectomy\nThis\u00a0 procedure\u00a0 is\u00a0 done\u00a0 to\u00a0 prevent\u00a0 severe\u00a0 complications\u00a0 of\u00a0 post\u00adthrombotic\nsyndrome. Venous\u00a0thrombectomy\u00a0is\u00a0indicated\u00a0in\u00a0impending\u00a0venous\u00a0gangrene\nof\u00a0the\u00a0lower\u00a0limbs\u00a0due\u00a0to\u00a0phlegmasia\u00a0caerulea\u00a0dolens. Phlegmasia\u00a0caerulea\ndolens\u00a0is\u00a0associated\u00a0with\u00a0considerable\u00a0morbidity\u00a0(50%\u00a0amputation\u00a0rate\u00a0and\u00a012\nto\u00a014%\u00a0PE)\u00a0and\u00a0a\u00a020%\u00a0mortality\u00a0rate.148\nA\u00a0 multicentre\u00a0 randomized\u00a0 trial\u00a0 shows\u00a0 significant\u00a0 benefit\u00a0 of\u00a0 surgical\u00a0 venous\nthrombectomy\u00a0plus\u00a0anticoagulation\u00a0versus\u00a0anticoagulation\u00a0alone\u00a0in\u00a0iliofemoral\nDVT.155\n4.4.3\u00a0Thrombolytic\u00a0agents\nThrombolytic\u00a0 agents\u00a0 used\u00a0 are\u00a0 tissue\u00a0 plasminogen\u00a0 activator\u00a0 (tPA)\u00a0 and\nstreptokinase. They\u00a0 are\u00a0 indicated\u00a0 in\u00a0 massive\u00a0 PE. Tissue\u00a0 plasminogen\nactivator\u00a0is\u00a0the\u00a0agent\u00a0of\u00a0choice\u00a0as\u00a0it\u00a0is\u00a0clot\u00adspecific. The\u00a0dose\u00a0for\u00a0streptokinase\nis\u00a0250,000IU\u00a0IV\u00a0bolus\u00a0followed\u00a0by\u00a0100,000\u00a0IU/hr\u00a0for\u00a024\u00a0hours. The\u00a0dose\u00a0for\u00a0tPA\nis\u00a0100mg\u00a0IV\u00a0over\u00a02\u00a0hours\u00a0followed\u00a0by\u00a0therapeutic\u00a0heparin\u00a0infusion.149\n4.5\u00a0VENA\u00a0CAVAL\u00a0FILTERS\nA\u00a0 temporary\u00a0 caval\u00a0 filter\u00a0 may\u00a0 be\u00a0 required\u00a0 in\u00a0 situations\u00a0 where\u00a0 anticoagulation\u00a0 is\ncontraindicated. There\u00a0is\u00a0no\u00a0evidence\u00a0for\u00a0the\u00a0role\u00a0of\u00a0prophylactic\u00a0IVC\u00a0filters\u00a0in\u00a0high\nrisk\u00a0patients.158\n4.5.1\u00a0Vena\u00a0Caval\u00a0Filters\nVena\u00a0 caval\u00a0 filters\u00a0 are\u00a0 recognized\u00a0 treatment\u00a0 modalities\u00a0 to\u00a0 prevent\u00a0 pulmonary\nembolism\u00a0secondary\u00a0to\u00a0DVT.158\u00a0They\u00a0can\u00a0be\u00a0inserted\u00a0through\u00a0the\u00a0internal\u00a0jugular\u00a0or\nfemoral\u00a0vein,\u00a0and\u00a0placed\u00a0in\u00a0the\u00a0IVC\u00a0under\u00a0fluoroscopic\u00a0or\u00a0ultrasound\u00a0guidance. There\u00a0are\u00a0two\u00a0types\u00a0of\u00a0filters\u037e\u00a0temporary\u00a0and\u00a0permanent. The\u00a0current\u00a0practice\u00a0is\u00a0to\ninsert\u00a0temporary\u00a0rather\u00a0than\u00a0permanent\u00a0filters\u00a0because\u00a0the\u00a0long\u00adterm\u00a0effect\u00a0of\u00a0IVC\nfilters\u00a0 is\u00a0 unproven. Due\u00a0 to\u00a0 lack\u00a0 of\u00a0 long\u00adterm\u00a0 data,\u00a0 IVC\u00a0 filters\u00a0 cannot\u00a0 be\nrecommended\u00a0in\u00a0young\u00a0patients. There\u00a0is\u00a0a\u00a0disturbing\u00a0trend\u00a0among\u00a0interventionists\u00a0to\u00a0insert\u00a0IVC\u00a0filters\u00a0even\u00a0when\nthere\u00a0is\u00a0no\u00a0contraindication\u00a0to\u00a0anticoagulation\u00a0and\u00a0then\u00a0forgeting\u00a0to\u00a0remove\u00a0them. This\u00a0practice\u00a0is\u00a0strongly\u00a0discouraged. Strict\u00a0criteria\u00a0should\u00a0be\u00a0applied\u00a0when\u00a0assessing\u00a0patients\u00a0for\u00a0caval\u00a0filter\u00a0insertion,\u00a0as\nthere\u00a0are\u00a0significant\u00a0associated\u00a0risks. The\u00a0indications\u00a0for\u00a0placement\u00a0of\u00a0IVC\u00a0filter\u00a0and\nits\u00a0complications\u00a0are\u00a0listed\u00a0below\u00a0(Table\u00a04.5).160\u00a0The\u00a0absolute\u00a0contraindications\u00a0to\nIVC\u00a0filter\u00a0insertion\u00a0are\u00a0complete\u00a0IVC\u00a0thrombosis\u00a0and\u00a0lack\u00a0of\u00a0vascular\u00a0access.158\nAnticoagulation\u00a0 should\u00a0 be\u00a0 resumed\u00a0 after\u00a0 insertion\u00a0 of\u00a0 caval\u00a0 filters\u00a0 unless\u00a0 it\u00a0 is\ncontraindicated.159\u00a0The\u00a0long\u00adterm\u00a0effects\u00a0of\u00a0IVC\u00a0filters\u00a0are\u00a0untested,\u00a0therefore\nfilters\u00a0should\u00a0be\u00a0safely\u00a0removed\u00a0once\u00a0there\u00a0is\u00a0no\u00a0risk\u00a0of\u00a0emboli. Most\u00a0filters\u00a0can\nbe\u00a0removed\u00a0between\u00a014\u00a0to\u00a025\u00a0days\u00a0of\u00a0insertion,\u00a0however\u00a0the\u00a0newer\u00a0filters\u00a0can\nbe\u00a0left\u00a0in\u00adsitu\u00a0for\u00a0up\u00a0to\u00a090\u00a0days. Indications\u00a0for\u00a0IVC\u00a0filter\n1. Contraindication\u00a0to\u00a0anticoagulation\n2. Large\u00a0free\u00a0floating\u00a0iliocaval\u00a0thrombus\nComplications\u00a0reported\u00a0with\u00a0IVC\u00a0filters\nt Procedural\u00a0complications\u00a0are\u00a0reported\u00a0at\u00a04\u00a0to\u00a011%\nt Known\u00a0complications\u00a0include\u00a0filter\u00a0migration,\u00a0venous\u00a0insufficiency,\u00a0IVC\nobstruction,\u00a0venous\u00a0access\u00a0site\u00a0thrombosis,\u00a0penetration\u00a0of\u00a0IVC,\u00a0filter\nfracture\u00a0and\u00a0death\nt Pulmonary\u00a0embolism\u00a0due\u00a0to\u00a0device\u00a0failure\u00a0occurs\u00a0in\u00a02\u00a0to\u00a05%\u00a0of\u00a0cases\nTable\u00a04.5:\u00a0IVC\u00a0filter\u00a0insertion\nPatients\u00a0who\u00a0had\u00a0IVC\u00a0filter\u00a0insertion\u00a0MUST\u00a0be\u00a0given\u00a0a\u00a0date\u00a0for\u00a0removal\u00a0of\u00a0the\nfilter\u00a0with\u00a0the\u00a0stipulated\u00a0time\u00a0according\u00a0to\u00a0the\u00a0manufacturer\u2019s\u00a0recommendation.", "chunk_order": 34}
{"chunk_id": "5854f8ce-50a4-4e8b-9d58-0de9270dab01", "source_document_filename": "CPG Prevention and Treatment of Venous Thrombosis_cleaned_ultra_minimal.txt", "source_document_title": "CPG Prevention and Treatment of Venous Thrombosis cleaned ultra minimal", "text": "Indications\u00a0for\u00a0IVC\u00a0filter\n1. Contraindication\u00a0to\u00a0anticoagulation\n2. Large\u00a0free\u00a0floating\u00a0iliocaval\u00a0thrombus\nComplications\u00a0reported\u00a0with\u00a0IVC\u00a0filters\nt Procedural\u00a0complications\u00a0are\u00a0reported\u00a0at\u00a04\u00a0to\u00a011%\nt Known\u00a0complications\u00a0include\u00a0filter\u00a0migration,\u00a0venous\u00a0insufficiency,\u00a0IVC\nobstruction,\u00a0venous\u00a0access\u00a0site\u00a0thrombosis,\u00a0penetration\u00a0of\u00a0IVC,\u00a0filter\nfracture\u00a0and\u00a0death\nt Pulmonary\u00a0embolism\u00a0due\u00a0to\u00a0device\u00a0failure\u00a0occurs\u00a0in\u00a02\u00a0to\u00a05%\u00a0of\u00a0cases\nTable\u00a04.5:\u00a0IVC\u00a0filter\u00a0insertion\nPatients\u00a0who\u00a0had\u00a0IVC\u00a0filter\u00a0insertion\u00a0MUST\u00a0be\u00a0given\u00a0a\u00a0date\u00a0for\u00a0removal\u00a0of\u00a0the\nfilter\u00a0with\u00a0the\u00a0stipulated\u00a0time\u00a0according\u00a0to\u00a0the\u00a0manufacturer\u2019s\u00a0recommendation. Hence\u00a0it\u00a0is\u00a0the\u00a0duty\u00a0of\u00a0the\u00a0practitioner\u00a0to\u00a0establish\u00a0a\u00a0recall\u00a0system\u00a0to\u00a0ensure\npatient\u00a0is\u00a0not\u00a0lost\u00a0to\u00a0follow\u00adup.158\n4.6\u00a0PREVENTION\u00a0OF\u00a0POST\u00adTHROMBOTIC\u00a0SYNDROME\nThe\u00a0most\u00a0common\u00a0complication\u00a0of\u00a0VTE\u00a0is\u00a0chronic\u00a0venous\u00a0insufficiency\u00a0(CVI)\nleading\u00a0to\u00a0post\u00adthrombotic\u00a0syndrome\u00a0(PTS). Post\u00adthrombotic\u00a0syndrome\u00a0results\nin\u00a0debilitating\u00a0pain,\u00a0swelling,\u00a0and\u00a0ulceration\u00a0and\u00a0is\u00a0a\u00a0significant\u00a0cause\u00a0of\u00a0loss\u00a0of\nworking\u00a0 days. It\u00a0 can\u00a0 contribute\u00a0 to\u00a0 an\u00a0 increase\u00a0 in\u00a0 recurrent\u00a0 DVT\u00a0 and\u00a0 PE.161\nPrevention\u00a0of\u00a0PTS\u00a0will\u00a0significantly\u00a0reduce\u00a0the\u00a0morbidity\u00a0and\u00a0late\u00a0mortality\u00a0of\nDVT.162\n4.6.1\u00a0Thrombo\u00adEmbolic\u00a0Deterent\u00a0Stockings\nWearing\u00a0 graduated\u00a0 elastic\u00a0 compression\u00a0 stockings\u00a0 with\u00a0 an\u00a0 ankle\u00a0 pressure\ngreater\u00a0than\u00a023\u00a0mmHg\u00a0following\u00a0a\u00a0proximal\u00a0DVT\u00a0have\u00a0been\u00a0shown\u00a0to\u00a0reduce\npost\u00adthrombotic\u00a0complications. It\u00a0should\u00a0be\u00a0applied\u00a0as\u00a0soon\u00a0as\u00a0the\u00a0patient\u00a0can\ntolerate\u00a0it\u00a0and\u00a0mobilisation\u00a0encouraged.163,164\nPatients\u00a0are\u00a0advised\u00a0to\u00a0continue\u00a0wearing\u00a0the\u00a0stockings\u00a0on\u00a0the\u00a0affected\u00a0leg\u00a0for\u00a0at\nleast\u00a02\u00a0years\u00a0and\u00a0also\u00a0to\u00a0ensure\u00a0that\u00a0they\u00a0are\u00a0replaced\u00a02\u00a0to\u00a03\u00a0times\u00a0per\u00a0year\u00a0or\naccording\u00a0to\u00a0the\u00a0manufacturer\u2019s\u00a0instructions.163,164\n5.0\u00a0\u00a0MONITORING\u00a0ANTICOAGULATION\n5.1\u00a0INTRODUCTION\nMonitoring\u00a0the\u00a0intensity\u00a0of\u00a0anticoagulants\u00a0especially\u00a0in\u00a0the\u00a0treatment\u00a0of\u00a0acute\u00a0VTE\nis\u00a0considered\u00a0desirable\u00a0in\u00a0an\u00a0attempt\u00a0to\u00a0secure\u00a0maximal\u00a0anti\u00adthrombotic\u00a0effect\nwithout\u00a0excessive\u00a0risk\u00a0of\u00a0bleeding\u00a0through\u00a0over\u00adanticoagulation. Accurate\u00a0 laboratory\u00a0 monitoring\u00a0 has\u00a0 been\u00a0 achieved\u00a0 for\u00a0 warfarin\u00a0 with\u00a0 the\nstandardization\u00a0of\u00a0the\u00a0INR\u00a0however,\u00a0it\u00a0has\u00a0proven\u00a0to\u00a0be\u00a0difficult\u00a0to\u00a0achieve\u00a0for\u00a0both\nunfractionated\u00a0 heparin\u00a0 and\u00a0 low\u00a0 molecular\u00a0 weight\u00a0 heparins.165,171\u00a0 Laboratories\nshould\u00a0determine\u00a0the\u00a0APTT\u00a0range\u00a0that\u00a0corresponds\u00a0to\u00a0the\u00a0measured\u00a0levels\u00a0of\nheparin\u00a0activity\u00a0given. 5.2\u00a0WARFARIN\nPrior\u00a0to\u00a0initiation\u00a0of\u00a0warfarin\u00a0therapy,\u00a0samples\u00a0should\u00a0be\u00a0drawn\u00a0for\u00a0PT\u00a0and\u00a0APTT\nto\u00a0establish\u00a0a\u00a0baseline. A\u00a0first\u00a0sample\u00a0for\u00a0INR\u00a0is\u00a0taken\u00a02\u00a0to\u00a03\u00a0days\u00a0after\u00a0the\u00a0initiation\nof\u00a0warfarin\u00a0and\u00a0monitored\u00a0every\u00a02\u00a0to\u00a04\u00a0days\u00a0until\u00a0the\u00a0INR\u00a0is\u00a0in\u00a0the\u00a0patient\u2019s\u00a0target\nrange,\u00a0after\u00a0which\u00a0it\u00a0can\u00a0be\u00a0monitored\u00a0weekly.170,171\nOnce\u00a0therapeutic\u00a0level\u00a0is\u00a0achieved\u00a0and\u00a0is\u00a0consistent\u00a0for\u00a02\u00a0consecutive\u00a0readings,\nINR\u00a0testing\u00a0is\u00a0then\u00a0carried\u00a0out\u00a0every\u00a02\u00a0weeks,\u00a0then\u00a04\u00a0weekly\u00a0if\u00a0the\u00a0INR\u00a0remains\nstable. For\u00a0patients\u00a0on\u00a0long\u00adterm\u00a0anticoagulation\u00a0with\u00a0consistently\u00a0stable\u00a0INRs,\ntesting\u00a0can\u00a0be\u00a0done\u00a0every\u00a012\u00a0weeks.170,175\nFor\u00a0 most\u00a0 indications,\u00a0 a\u00a0 therapeutic\u00a0 range\u00a0 of\u00a0 2.0\u00a0 to\u00a0 3.0\u00a0 (target\u00a0 INR\u00a0 2.5)\u00a0 is\nrecommended\u00a0 except\u00a0 for\u00a0 metallic\u00a0 heart\u00a0 valves\u00a0 and\u00a0 recurrent\u00a0 VTE\u00a0 while\u00a0 on\nadequate\u00a0anticoagulation\u00a0where\u00a0a\u00a0higher\u00a0intensity\u00a0INR\u00a0between\u00a02.5\u00a0to\u00a03.5\u00a0(target\nINR\u00a03.0)\u00a0is\u00a0recommended.169,170,171\nThere\u00a0is\u00a0no\u00a0maximum\u00a0warfarin\u00a0dose\u00a0to\u00a0maintain\u00a0a\u00a0therapeutic\u00a0range.", "chunk_order": 35}
{"chunk_id": "63e35ceb-e01a-4e7d-8569-cde475825ed4", "source_document_filename": "CPG Prevention and Treatment of Venous Thrombosis_cleaned_ultra_minimal.txt", "source_document_title": "CPG Prevention and Treatment of Venous Thrombosis cleaned ultra minimal", "text": "For\u00a0patients\u00a0on\u00a0long\u00adterm\u00a0anticoagulation\u00a0with\u00a0consistently\u00a0stable\u00a0INRs,\ntesting\u00a0can\u00a0be\u00a0done\u00a0every\u00a012\u00a0weeks.170,175\nFor\u00a0 most\u00a0 indications,\u00a0 a\u00a0 therapeutic\u00a0 range\u00a0 of\u00a0 2.0\u00a0 to\u00a0 3.0\u00a0 (target\u00a0 INR\u00a0 2.5)\u00a0 is\nrecommended\u00a0 except\u00a0 for\u00a0 metallic\u00a0 heart\u00a0 valves\u00a0 and\u00a0 recurrent\u00a0 VTE\u00a0 while\u00a0 on\nadequate\u00a0anticoagulation\u00a0where\u00a0a\u00a0higher\u00a0intensity\u00a0INR\u00a0between\u00a02.5\u00a0to\u00a03.5\u00a0(target\nINR\u00a03.0)\u00a0is\u00a0recommended.169,170,171\nThere\u00a0is\u00a0no\u00a0maximum\u00a0warfarin\u00a0dose\u00a0to\u00a0maintain\u00a0a\u00a0therapeutic\u00a0range. Dose\u00a0can\u00a0be\nincreased\u00a0as\u00a0long\u00a0as\u00a0the\u00a0target\u00a0INR\u00a0is\u00a0not\u00a0achieved.170,171\n5.3\u00a0UNFRACTIONATED\u00a0HEPARIN\nThe\u00a0APTT\u00a0 has\u00a0 been\u00a0 widely\u00a0 used\u00a0 for\u00a0 monitoring\u00a0 therapeutic\u00a0 doses\u00a0 of\u00a0 UFH. A\ntarget\u00a0ratio\u00a0of\u00a01.5\u00a0to\u00a02.5\u00a0is\u00a0based\u00a0on\u00a0the\u00a0apparent\u00a0efficacy\u00a0and\u00a0safety\u00a0of\u00a0a\u00a0plasma\nheparin\u00a0concentration\u00a0by\u00a0protamine\u00a0titration\u00a0of\u00a00.2\u00a0to\u00a00.4\u00a0IU/mL\u00a0or\u00a0by\u00a0anti\u00adXa\u00a0of\u00a00.3\nto\u00a00.7\u00a0IU/mL.165,166,169\nStandardization\u00a0between\u00a0laboratories\u00a0in\u00a0the\u00a0control\u00a0of\u00a0heparin\u00a0therapy\u00a0using\u00a0the\nAPTT\u00a0has\u00a0not\u00a0been\u00a0achieved\u00a0because\u00a0of\u00a0the\u00a0considerable\u00a0reagent\u00a0and\u00a0instrument\nvariability\u00a0employed\u00a0in\u00a0the\u00a0APTT,\u00a0which\u00a0results\u00a0in\u00a0inconsistency\u00a0in\u00a0sensitivity\u00a0to\nheparin.167,168,172\u00a0 Laboratories\u00a0 are\u00a0 now\u00a0 moving\u00a0 towards\u00a0 anti\u00adXa\u00a0 for\u00a0 monitoring\ntreatment\u00a0with\u00a0UFH.166,168,172,174,177\nHeparin\u00a0resistance\u00a0is\u00a0common\u00a0in\u00a0pregnancy\u00a0making\u00a0APTT\u00a0monitoring\u00a0unreliable\nwith\u00a0the\u00a0danger\u00a0of\u00a0over\u00adheparinisation\u00a0with\u00a0unfractionated\u00a0heparin. Furthermore\nthe\u00a0APTT\u00a0ratio\u00a0uses\u00a0control\u00a0plasma\u00a0from\u00a0normal\u00a0individuals\u00a0and\u00a0not\u00a0from\u00a0plasma\nof\u00a0pregnant\u00a0women.166,167\n5.4\u00a0LOW\u00a0MOLECULAR\u00a0WEIGHT\u00a0HEPARIN\nLow\u00a0molecular\u00a0weight\u00a0heparin\u00a0(LMWH)\u00a0has\u00a0a\u00a0highly\u00a0predictable\u00a0anticoagulant\nresponse\u00a0 because\u00a0 of\u00a0 its\u00a0 excellent\u00a0 bioavailability\u00a0 and\u00a0 hence\u00a0 does\u00a0 not\u00a0 require\nmonitoring. However\u00a0in\u00a0some\u00a0clinical\u00a0settings\u00a0such\u00a0as\u00a0renal\u00a0impairment\u00a0(delayed\nclearance\u00a0of\u00a0LMWH),\u00a0pregnancy\u00a0with\u00a0mechanical\u00a0heart\u00a0valves\u00a0and\u00a0neonates,\nmonitoring\u00a0heparin\u00a0with\u00a0anti\u00adXa\u00a0activity\u00a0assay\u00a0by\u00a0the\u00a0chromogenic\u00a0method\u00a0may\nbe\u00a0useful\u00a0if\u00a0there\u00a0is\u00a0a\u00a0concern\u00a0of\u00a0over\u00ad\u00a0or\u00a0under\u00adcoagulation.165,169,170\nHowever,\u00a0 the\u00a0 anti\u00adXa\u00a0 assay\u00a0 has\u00a0 significant\u00a0 limitations. Different\u00a0 LMWH\npreparations\u00a0have\u00a0different\u00a0anti\u00adIIa\u00a0activity\u00a0in\u00a0relation\u00a0to\u00a0anti\u00adXa\u00a0activity. The\ndegree\u00a0of\u00a0anticoagulation\u00a0of\u00a0different\u00a0LMWHs\u00a0may\u00a0not\u00a0be\u00a0comparable\u00a0at\u00a0the\nsame\u00a0plasma\u00a0anti\u00adXa\u00a0concentration.173,176\nMonitoring\u00a0of\u00a0LMWH\u00a0using\u00a0anti\u00adXa\u00a0assay\u00a0requires\u00a0careful\u00a0assay\u00a0validation,\nprovides\u00a0 an\u00a0 incomplete\u00a0 picture\u00a0 of\u00a0 the\u00a0 anticoagulant\u00a0 effect\u00a0 and\u00a0 is\u00a0 poorly\npredictive\u00a0of\u00a0antithrombotic\u00a0efficacy\u00a0and\u00a0risk\u00a0of\u00a0haemorrhage.173,176\nIf\u00a0LMWH\u00a0is\u00a0monitored,\u00a0the\u00a0blood\u00a0sample\u00a0should\u00a0be\u00a0drawn\u00a0approximately\u00a04\nhours\u00a0after\u00a0subcutaneous\u00a0injection. If\u00a0accumulation\u00a0of\u00a0LMWH\u00a0is\u00a0suspected,\nfor\u00a0example\u00a0in\u00a0renal\u00a0failure,\u00a0a\u00a0trough\u00a0level\u00a0on\u00a0a\u00a0sample\u00a0taken\u00a024\u00a0hours\u00a0after\nthe\u00a0last\u00a0dose\u00a0may\u00a0be\u00a0informative. The\u00a0standard\u00a0should\u00a0be\u00a0a\u00a0sample\u00a0of\u00a0the\nadministered\u00a0 LMWH. Alternatively\u00a0 the\u00a0 WHO\u00a0 standard\u00a0 for\u00a0 LMWH\u00a0 may\u00a0 be\nused.165,169,170\n5.5\u00a0FONDAPARINUX\nFondaparinux\u00a0produces\u00a0a\u00a0predictable\u00a0anticoagulant\u00a0response\u00a0and\u00a0does\u00a0not\u00a0require\nmonitoring.", "chunk_order": 36}
{"chunk_id": "78940497-12da-4d9f-84e9-1be881f682b9", "source_document_filename": "CPG Prevention and Treatment of Venous Thrombosis_cleaned_ultra_minimal.txt", "source_document_title": "CPG Prevention and Treatment of Venous Thrombosis cleaned ultra minimal", "text": "If\u00a0accumulation\u00a0of\u00a0LMWH\u00a0is\u00a0suspected,\nfor\u00a0example\u00a0in\u00a0renal\u00a0failure,\u00a0a\u00a0trough\u00a0level\u00a0on\u00a0a\u00a0sample\u00a0taken\u00a024\u00a0hours\u00a0after\nthe\u00a0last\u00a0dose\u00a0may\u00a0be\u00a0informative. The\u00a0standard\u00a0should\u00a0be\u00a0a\u00a0sample\u00a0of\u00a0the\nadministered\u00a0 LMWH. Alternatively\u00a0 the\u00a0 WHO\u00a0 standard\u00a0 for\u00a0 LMWH\u00a0 may\u00a0 be\nused.165,169,170\n5.5\u00a0FONDAPARINUX\nFondaparinux\u00a0produces\u00a0a\u00a0predictable\u00a0anticoagulant\u00a0response\u00a0and\u00a0does\u00a0not\u00a0require\nmonitoring. If\u00a0required,\u00a0fondaparinux\u00a0can\u00a0be\u00a0measured\u00a0using\u00a0fondaparinux\u00adspecific\nanti\u00adXa\u00a0activity.313\n5.6\u00a0RIVAROXABAN\nRivaroxaban\u00a0has\u00a0predictable\u00a0pharmacokinetics\u00a0and\u00a0does\u00a0not\u00a0require\u00a0monitoring.314\nIf\u00a0 required,\u00a0 rivaroxaban\u00a0 can\u00a0 be\u00a0 measured\u00a0 using\u00a0 rivaroxaban\u00adspecific\u00a0 anti\u00adXa\nactivity.314\nRecommendations\nGrade\nThe\u00a0 International\u00a0 Normalised\u00a0 Ratio\u00a0 (INR)\u00a0 is\u00a0 used\u00a0 to\u00a0 monitor\nwarfarin\nA\nFor\u00a0most\u00a0indications,\u00a0the\u00a0target\u00a0INR\u00a0is\u00a02.5\u00a0(therapeutic\u00a0range\nbetween\u00a02.0\u00ad3.0)\nB\nOnce\u00a0 therapeutic\u00a0 level\u00a0 is\u00a0 achieved\u00a0 and\u00a0 is\u00a0 consistent\u00a0 for\u00a0 2\nconsecutive\u00a0readings,\u00a0INR\u00a0testing\u00a0is\u00a0then\u00a0carried\u00a0out\u00a0every\u00a02\nweeks,\u00a0then\u00a04\u00a0weekly\u00a0if\u00a0INR\u00a0is\u00a0stable\nB\nTable 5.0: Monitoring anticoagulants\nWarfarin\nB\nA\nA\nA\nA\nA\nA\nA\nB\nB\nA\nA\nA\nFor\u00a0 patients\u00a0 on\u00a0 long\u00adterm\u00a0 anticoagulation\u00a0 with\u00a0 consistently\nstable\u00a0INRs,\u00a0INR\u00a0testing\u00a0can\u00a0be\u00a0done\u00a0every\u00a012\u00a0weeks\nThere\u00a0is\u00a0no\u00a0maximum\u00a0warfarin\u00a0dose\u00a0to\u00a0maintain\u00a0a\u00a0therapeutic\nrange\nUnfractionated\u00a0heparin\nMonitoring\u00a0prophylactic\u00a0doses\u00a0of\u00a0UFH\u00a0is\u00a0not\u00a0required\nMonitoring\u00a0 therapeutic\u00a0 doses\u00a0 of\u00a0 UFH\u00a0 can\u00a0 be\u00a0 achieved\u00a0 using\nthe\u00a0APTT. However\u00a0local\u00a0calibration\u00a0of\u00a0the\u00a0test\u00a0using\u00a0anti\u00adXa\u00a0or\nprotamine\u00a0 titration\u00a0 must\u00a0 be\u00a0 carried\u00a0 out\u00a0 to\u00a0 determine\u00a0 the\nrecommended\u00a0target\u00a0APTT\u00a0ratio\u00a0of\u00a01.5\u00ad2.5\nAPTT\u00a0monitoring\u00a0for\u00a0UFH\u00a0is\u00a0not\u00a0standardised\u00a0producing\u00a0unreliable\nresults\u00a0with\u00a0the\u00a0hazards\u00a0of\u00a0over\u00ad\u00a0or\u00a0under\u00adcoagulation\nHeparin\u00a0resistance\u00a0is\u00a0common\u00a0in\u00a0pregnancy\u00a0with\u00a0the\u00a0danger\u00a0of\nover\u00adheparinisation\u00a0when\u00a0APTT\u00a0is\u00a0used\u00a0for\u00a0monitoring\nIn\u00a0 the\u00a0 absence\u00a0 of\u00a0 proper\u00a0 calibration\u00a0 with\u00a0 factor\u00a0 Xa\u00a0 for\u00a0APTT\ntest,\u00a0LMWH\u00a0is\u00a0preferred\nLMWH\nMonitoring\u00a0of\u00a0prophylactic\u00a0&\u00a0therapeutic\u00a0doses\u00a0of\u00a0LMWH\u00a0is\u00a0not\nrequired\nMonitoring\u00a0with\u00a0anti\u00adXa\u00a0assay\u00a0may\u00a0be\u00a0of\u00a0value\u00a0in\u00a0certain\u00a0clinical\nsettings\u00a0where\u00a0there\u00a0is\u00a0a\u00a0concern\u00a0of\u00a0over\u00ad\u00a0or\u00a0under\u00adcoagulation\n(e.g. renal\u00a0 impairment,\u00a0 neonates,\u00a0 mechanical\u00a0 heart\u00a0 valves\u00a0 in\npregnancy)\nWhen\u00a0 LMWH\u00a0 is\u00a0 monitored,\u00a0 the\u00a0 blood\u00a0 sample\u00a0 should\u00a0 be\nobtained\u00a04\u00a0hours\u00a0after\u00a0subcutaneous\u00a0injection\u00a0or\u00a024\u00a0hours\u00a0after\nthe\u00a0last\u00a0dose\u00a0if\u00a0accumulation\u00a0in\u00a0renal\u00a0failure\u00a0is\u00a0suspected\nA\u00a0calibrated\u00a0LMWH\u00a0should\u00a0be\u00a0used\u00a0to\u00a0establish\u00a0the\u00a0standard\ncurve\u00a0for\u00a0the\u00a0anti\u00adXa\u00a0assay\nFondaparinux\nFondaparinux\u00a0produces\u00a0a\u00a0predictable\u00a0anticoagulant\u00a0response\nand\u00a0does\u00a0not\u00a0require\u00a0monitoring\nRivaroxaban\nRivaroxaban\u00a0 has\u00a0 predictable\u00a0 pharmacokinetics\u00a0 and\u00a0 does\u00a0 not\nrequire\u00a0monitoring\n5.7\u00a0HEPARIN\u00adINDUCED\u00a0THROMBOCYTOPENIA\u00a0AND\u00a0MONITORING\nPLATELET\u00a0COUNTS\n5.7.1\u00a0Introduction\nAll\u00a0 patients\u00a0 receiving\u00a0 any\u00a0 heparin\u00a0 should\u00a0 have\u00a0 a\u00a0 baseline\u00a0 platelet\u00a0 count\u00a0 as\nheparin\u00adinduced\u00a0thrombocytopenia\u00a0and\u00a0thrombosis\u00a0(HITT)\u00a0is\u00a0a\u00a0known\u00a0complication\nof\u00a0heparins. HITT\u00a0is\u00a0caused\u00a0by\u00a0the\u00a0development\u00a0of\u00a0IgG\u00a0antibodies\u00a0directed\u00a0against\na\u00a0complex\u00a0of\u00a0platelet\u00a0factor\u00a04\u00a0(PF4)\u00a0and\u00a0heparin. The\u00a0IgG/\u00a0PF4/\u00a0heparin\u00a0complexes\nbind\u00a0to\u00a0and\u00a0activate\u00a0platelets\u00a0through\u00a0their\u00a0Fc\u00a0receptors\u00a0resulting\u00a0in\u00a0a\u00a0prothrombotic\ncondition\u00a0that\u00a0is\u00a0associated\u00a0with\u00a0venous\u00a0and\u00a0arterial\u00a0thrombosis.315,316\nThe\u00a0incidence\u00a0of\u00a0HITT\u00a0is\u00a0greater\u00a0with\u00a0bovine\u00a0than\u00a0with\u00a0procine\u00a0heparin\u00a0and\u00a0greater\nwith\u00a0unfractionated\u00a0heparin\u00a0than\u00a0with\u00a0LMWH\u00a0(5%\u00a0vs. 0.5%).", "chunk_order": 37}
{"chunk_id": "77412bb8-cd8e-49b2-9209-bf440ab36c1e", "source_document_filename": "CPG Prevention and Treatment of Venous Thrombosis_cleaned_ultra_minimal.txt", "source_document_title": "CPG Prevention and Treatment of Venous Thrombosis cleaned ultra minimal", "text": "HITT\u00a0is\u00a0caused\u00a0by\u00a0the\u00a0development\u00a0of\u00a0IgG\u00a0antibodies\u00a0directed\u00a0against\na\u00a0complex\u00a0of\u00a0platelet\u00a0factor\u00a04\u00a0(PF4)\u00a0and\u00a0heparin. The\u00a0IgG/\u00a0PF4/\u00a0heparin\u00a0complexes\nbind\u00a0to\u00a0and\u00a0activate\u00a0platelets\u00a0through\u00a0their\u00a0Fc\u00a0receptors\u00a0resulting\u00a0in\u00a0a\u00a0prothrombotic\ncondition\u00a0that\u00a0is\u00a0associated\u00a0with\u00a0venous\u00a0and\u00a0arterial\u00a0thrombosis.315,316\nThe\u00a0incidence\u00a0of\u00a0HITT\u00a0is\u00a0greater\u00a0with\u00a0bovine\u00a0than\u00a0with\u00a0procine\u00a0heparin\u00a0and\u00a0greater\nwith\u00a0unfractionated\u00a0heparin\u00a0than\u00a0with\u00a0LMWH\u00a0(5%\u00a0vs. 0.5%). The\u00a0frequency\u00a0of\u00a0HITT\nis\u00a0greater\u00a0in\u00a0surgical\u00a0than\u00a0medical\u00a0patients.315,316\n5.7.2\u00a0Platelet\u00a0monitoring\nAll\u00a0 post\u00adoperative\u00a0 patients\u00a0 on\u00a0 unfractionated\u00a0 heparin\u00a0 should\u00a0 have\u00a0 their\u00a0 platelet\ncounts\u00a0 monitored,\u00a0 while\u00a0 those\u00a0 on\u00a0 LMWH\u00a0 should\u00a0 have\u00a0 their\u00a0 platelet\u00a0 counts\nmonitored\u00a0only\u00a0after\u00a0cardiopulmonary\u00a0bypass\u00a0(Table\u00a05.7.2).315,316\nRcommendations\nGrade\nPatients\u00a0who\u00a0are\u00a0to\u00a0receive\u00a0any\u00a0heparin\u00a0should\u00a0have\u00a0a\u00a0baseline\nplatelet\u00a0count\nC\nPost\u00adoperative\u00a0patients,\u00a0including\u00a0obstetric\u00a0cases,\u00a0receiving\u00a0UFH\nshould\u00a0have\u00a0platelet\u00a0count\u00a0monitoring\u00a0performed\u00a0every\u00a02\u00ad3\u00a0days\nfrom\u00a0days\u00a04\u00a0to\u00a014\u00a0until\u00a0heparin\u00a0is\u00a0stopped\nC\nPost\u00adcardiopulmonary\u00a0bypass\u00a0patients\u00a0receiving\u00a0LMWH\u00a0should\nhave\u00a0 platelet\u00a0 count\u00a0 monitoring\u00a0 performed\u00a0 every\u00a0 2\u00ad3\u00a0 days\u00a0 from\ndays\u00a04\u00a0to\u00a014\u00a0until\u00a0heparin\u00a0is\u00a0stopped\nC\nPost\u00adoperative\u00a0 patients\u00a0 (other\u00a0 than\u00a0 cardiopulmonary\u00a0 bypass\npatients)\u00a0receiving\u00a0LMWH\u00a0do\u00a0not\u00a0need\u00a0routine\u00a0platelet\u00a0monitoring\nC\nPost\u00adoperative\u00a0 patients\u00a0 and\u00a0 cardiopulmonary\u00a0 bypass\u00a0 patients\nwho\u00a0have\u00a0been\u00a0exposed\u00a0to\u00a0heparin\u00a0in\u00a0the\u00a0previous\u00a0100\u00a0days\u00a0and\nare\u00a0receiving\u00a0any\u00a0type\u00a0of\u00a0heparin\u00a0should\u00a0have\u00a0a\u00a0platelet\u00a0count\ndetermined\u00a024\u00a0hours\u00a0after\u00a0starting\u00a0heparin\nC\nMedical\u00a0patients\u00a0and\u00a0obstetric\u00a0patients\u00a0receiving\u00a0heparin\u00a0do\u00a0not\nneed\u00a0routine\u00a0platelet\u00a0monitoring\nC\nTable\u00a05.7.2:\u00a0Monitoring\u00a0platelet\u00a0counts\u00a0during\u00a0heparin\u00a0therapy\nHeparin\u00adinduced\u00a0thrombocytopenia\u00a0and\u00a0thrombosis\u00a0is\u00a0a\u00a0clinical\u00a0diagnosis. Tests\nfor\u00a0HIT\u00a0antibodies\u00a0e.g. platelet\u00a0activation\u00a0assays\u00a0and\u00a0antigen\u00a0assays\u00a0are\u00a0time\nconsuming\u00a0and\u00a0have\u00a0limited\u00a0sensitivity\u00a0and\u00a0specificity.315,316\nPatients\u00a0should\u00a0be\u00a0therapeutically\u00a0anticoagulated\u00a0for\u00a03\u00a0months\u00a0after\u00a0HIT\u00a0with\u00a0a\nthrombotic\u00a0 complication\u00a0 and\u00a0 for\u00a0 4\u00a0 weeks\u00a0 following\u00a0 HIT\u00a0 without\u00a0 a\u00a0 thrombotic\ncomplication.315,316\nv\u00a0Deep\u00a0vein\u00a0thrombosis*\nv\u00a0Pulmonary\u00a0embolism*\nv\u00a0Arterial\u00a0thrombosis:\u00a0stroke,\u00a0coronary\u00a0artery\u00a0syndrome,\u00a0peripheral\u00a0arterial\ndisease\nv\u00a0Skin\u00a0lesions\nv\u00a0Adrenal\u00a0haemorrhage\nv\u00a0Venous\u00a0limb\u00a0gangrene\nv\u00a0Total\u00a0global\u00a0amnesia\nv\u00a0Acute\u00a0systemic\u00a0reactions\u00a0\u00ad\u00a0chills,\u00a0rigors\nv\u00a0Acute\u00a0onset\u00a0with\u00a0collapse\u00a0and\u00a0death\nv\u00a0Warfarin\u00adinduced\u00a0skin\u00a0necrosis\n* more\u00a0common\u00a0manifestations\nTable\u00a05.7.3:\u00a0Manifestations\u00a0of\u00a0HITT1\n5.7.3\u00a0Diagnosis\u00a0and\u00a0management\u00a0of\u00a0HIT/T\nIf\u00a0 heparin\u00adinduced\u00a0 thrombocytopenia\u00a0 (HIT)\u00a0 develops,\u00a0 the\u00a0 platelet\u00a0 count\ntypically\u00a0begins\u00a0to\u00a0fall\u00a05\u00a0to\u00a010\u00a0days\u00a0after\u00a0starting\u00a0heparin,\u00a0although\u00a0in\u00a0patients\nwho\u00a0have\u00a0received\u00a0heparin\u00a0in\u00a0the\u00a0previous\u00a03\u00a0months\u00a0it\u00a0can\u00a0have\u00a0a\u00a0rapid\u00a0onset\ndue\u00a0to\u00a0pre\u00adexisting\u00a0antibodies.315,316\nIf\u00a0the\u00a0platelet\u00a0count\u00a0falls\u00a0by\u00a030%\u00a0or\u00a0more\u00a0and/or\u00a0the\u00a0patient\u00a0develops\u00a0new\nthrombosis\u00a0or\u00a0skin\u00a0allergy\u00a0or\u00a0any\u00a0of\u00a0the\u00a0other\u00a0rarer\u00a0manifestations\u00a0of\u00a0HITT\n(Table\u00a05.7.3)\u00a0between\u00a0days\u00a04\u00a0to\u00a014\u00a0of\u00a0heparin\u00a0administration,\u00a0HITT\u00a0should\u00a0be\nconsidered\u00a0and\u00a0heparin\u00a0should\u00a0be\u00a0stopped\u00a0and\u00a0an\u00a0alternative\u00a0anticoagulant\nstarted\u00a0 in\u00a0 full\u00a0 dosage\u00a0 e.g. danaparoid,\u00a0 argatroban\u00a0 or\u00a0 fondaparinux\u00a0 (not\nlicensed\u00a0for\u00a0use\u00a0at\u00a0present).315,316\n6.0\u00a0PERIOPERATIVE\u00a0MANAGEMENT\u00a0OF\u00a0ANTICOAGULATION\n6.1\u00a0INTRODUCTION\nThe\u00a0most\u00a0common\u00a0indications\u00a0for\u00a0warfarin\u00a0anticoagulation\u00a0are\u00a0atrial\u00a0fibrillation\n(AF),\u00a0 mechanical\u00a0 heart\u00a0 valve\u00a0 (MHV)\u00a0 and\u00a0 venous\u00a0 thromboembolism\u00a0 (VTE).", "chunk_order": 38}
{"chunk_id": "b65e90f1-1cc3-4c9f-adf2-387a1b704c0f", "source_document_filename": "CPG Prevention and Treatment of Venous Thrombosis_cleaned_ultra_minimal.txt", "source_document_title": "CPG Prevention and Treatment of Venous Thrombosis cleaned ultra minimal", "text": "danaparoid,\u00a0 argatroban\u00a0 or\u00a0 fondaparinux\u00a0 (not\nlicensed\u00a0for\u00a0use\u00a0at\u00a0present).315,316\n6.0\u00a0PERIOPERATIVE\u00a0MANAGEMENT\u00a0OF\u00a0ANTICOAGULATION\n6.1\u00a0INTRODUCTION\nThe\u00a0most\u00a0common\u00a0indications\u00a0for\u00a0warfarin\u00a0anticoagulation\u00a0are\u00a0atrial\u00a0fibrillation\n(AF),\u00a0 mechanical\u00a0 heart\u00a0 valve\u00a0 (MHV)\u00a0 and\u00a0 venous\u00a0 thromboembolism\u00a0 (VTE). Treatment\u00a0 with\u00a0 warfarin\u00a0 presents\u00a0 a\u00a0 problem\u00a0 if\u00a0 these\u00a0 patients\u00a0 need\u00a0 surgery\nbecause\u00a0 the\u00a0 interruption\u00a0 of\u00a0 anticoagulant\u00a0 therapy\u00a0 may\u00a0 increase\u00a0 the\u00a0 risk\u00a0 of\nthromboembolism.178,179,180\nAfter\u00a0warfarin\u00a0therapy\u00a0is\u00a0discontinued,\u00a0it\u00a0takes\u00a0several\u00a0days\u00a0for\u00a0its\u00a0antithrombotic\neffect\u00a0 to\u00a0 recede,\u00a0 and\u00a0 when\u00a0 it\u00a0 is\u00a0 resumed,\u00a0 several\u00a0 days\u00a0 are\u00a0 needed\u00a0 to\nre\u00adestablish\u00a0therapeutic\u00a0anticoagulation.181,182,183,195\u00a0With\u00a0the\u00a0introduction\u00a0of\u00a0novel\noral\u00a0 anticoagulants\u00a0 (NOACs)\u00a0 such\u00a0 as\u00a0 dabigatran,\u00a0 rivaroxaban\u00a0 and\u00a0 apixaban,\nthis\u00a0will\u00a0no\u00a0longer\u00a0pose\u00a0a\u00a0problem\u00a0as\u00a0these\u00a0agents\u00a0have\u00a0a\u00a0quick\u00a0onset\u00a0of\u00a0action\nand\u00a0a\u00a0short\u00a0half\u00adlife.184\nFor\u00a0emergency\u00a0surgery,\u00a0IV\u00a0vitamin\u00a0K\u00a02\u00a0to\u00a04\u00a0mg\u00a0is\u00a0given\u00a0to\u00a0correct\u00a0the\u00a0INR\u00a0with\ninfusion\u00a0of\u00a015\u00a0to\u00a030\u00a0IU/kg\u00a0of\u00a0prothrombin\u00a0complex\u00a0concentrate\u00a0or\u00a015\u00a0to\u00a020\u00a0mL/kg\nfresh\u00a0frozen\u00a0plasma\u00a0if\u00a0needed.185\u00ad188\nThe\u00a0risk\u00a0of\u00a0recurrence\u00a0following\u00a0an\u00a0episode\u00a0of\u00a0VTE\u00a0is\u00a0highest\u00a0during\u00a0the\u00a0first\u00a03\nmonths\u00a0and\u00a0declines\u00a0rapidly\u00a0to\u00a0about\u00a05%\u00a0per\u00a0year. Patients\u00a0with\u00a0non\u00advalvular\u00a0AF\nwho\u00a0 do\u00a0 not\u00a0 receive\u00a0 antithrombotic\u00a0 therapy\u00a0 have\u00a0 an\u00a0 average\u00a0 risk\u00a0 of\u00a0 systemic\nembolism\u00a0of\u00a04.5%\u00a0per\u00a0year\u037e\u00a0in\u00a0patients\u00a0with\u00a0previous\u00a0cerebral\u00a0embolism\u00a0it\u00a0is\napproximately\u00a012%\u00a0per\u00a0year.179,180,182\u00a0\u00a0In\u00a0patients\u00a0with\u00a0prosthetic\u00a0valve\u00a0who\u00a0are\nnot\u00a0on\u00a0anticoagulant\u00a0therapy,\u00a0the\u00a0estimated\u00a0risk\u00a0of\u00a0major\u00a0thromboembolism\u00a0is\n8%\u00a0per\u00a0year.179,180,182,197\nThe\u00a0risk\u00a0of\u00a0bleeding\u00a0depends\u00a0on\u00a0the\u00a0type\u00a0of\u00a0surgery,\u00a0patient\u2019s\u00a0age,\u00a0presence\u00a0of\nother\u00a0 medical\u00a0 illnesses\u00a0 and\u00a0 bridging\u00a0 therapy\u00a0 with\u00a0 intravenous\u00a0 unfractionated\nheparin\u00a0(IV\u00a0UFH).178,180,182,188\u00a0It\u00a0is\u00a0estimated\u00a0that\u00a0two\u00a0days\u00a0of\u00a0IV\u00a0UFH\u00a0will\u00a0increase\nthe\u00a0absolute\u00a0rate\u00a0of\u00a0major\u00a0postoperative\u00a0bleeding\u00a0by\u00a0about\u00a03%.179,180,182\nThe\u00a0 absolute\u00a0 risk\u00a0 of\u00a0 thromboembolism\u00a0 associated\u00a0 with\u00a0 a\u00a0 few\u00a0 days\u00a0 of\nperioperative\u00a0sub\u00adtherapeutic\u00a0anticoagulation\u00a0is\u00a0generally\u00a0very\u00a0low,\u00a0and\u00a0the\u00a0risk\nof\u00a0 bleeding\u00a0 associated\u00a0 with\u00a0 postoperative\u00a0 IV\u00a0 UFH\u00a0 therapy\u00a0 is\u00a0 often\u00a0 relatively\nhigh.179,180,182\u00a0\u00a0Low\u00a0molecular\u00a0weight\u00a0heparin\u00a0may\u00a0cause\u00a0less\u00a0bleeding\u00a0than\u00a0IV\u00a0UH\nbecause\u00a0it\u00a0does\u00a0not\u00a0interfere\u00a0with\u00a0platelet\u00a0aggregation.183,190,194,196,197\n6.2\u00a0 THROMBOEMBOLIC\u00a0RISK\nPatients\u00a0can\u00a0be\u00a0stratified\u00a0into\u00a0risk\u00a0groups\u00a0according\u00a0to\u00a0their\u00a0risks\u00a0for\u00a0thromboembolism\n(Table\u00a06.2).180\u00ad183\nClinical\u00a0indication\u00a0for\u00a0warfarin\u00a0therapy\nHigh\nModerate\nLow\nAtrial\u00a0fibrillation\nProsthetic\u00a0valves\nVenous\nthromboembolism\nRecent\u00a0VTE\n(<3\u00a0months)\nCHADS2\nscore\u00a03\u00a0or\u00a04\nBi\u00adleaflet\u00a0aortic\nvalve\u00a0with\u00a0at\u00a0least\none\u00a0risk\u00a0factor\nCHADS2\u00a0score\n0\u00a0to\u00a02\u00a0(without\nprevious\u00a0stroke\u00a0or\nTIA)\nBi\u00adleaflet\u00a0aortic\nvalve\u00a0without\u00a0any\nrisk\u00a0factors\nVTE\u00a0>12\nmonths\u00a0ago\n1. CHADS2\nscore\u00a05\u00a0or\u00a06\n2. Recent\nstroke/TIA\n(<3\u00a0months)\n3. Rheumatic\nvalvular\nheart\u00a0disease\nHigh\u00a0bleeding\u00a0risk\u00a0surgeries\nLow\u00a0bleeding\u00a0risk\nsurgeries\nMajor\u00a0surgeries\nMinor\u00a0surgeries\nMinor\u00a0surgeries\nHeart\u00a0surgery:\nCoronary\u00a0artery\nbypass,\u00a0heart\u00a0valve\nreplacement\nBiopsy\u00a0of\u00a0prostate\u00a0or\nkidney\u00a0(endogenous\nurokinase\u00a0may\u00a0promote\nbleeding)\nSkin:\nSmall\u00a0skin\u00a0excisions\n6.3\u00a0BLEEDING\u00a0RISK\u00a0IN\u00a0SURGERY\nSurgeries\u00a0can\u00a0be\u00a0associated\u00a0with\u00a0a\u00a0high\u00a0or\u00a0low\u00a0risk\u00a0of\u00a0bleeding\u00a0(Table\u00a06.3).180\u00ad183,193\n1. Any\u00a0mechanical\nmitral\u00a0valve\n2. Older\u00a0aortic\nmechanical\u00a0valve\n(caged\u00adball,\ntilting\u00a0disk)\n3. Recent\nstroke\u00a0or\u00a0TIA\n(<3\u00a0months)\n1.", "chunk_order": 39}
{"chunk_id": "15bf0b9e-7b50-4f18-a68f-7e48deea768d", "source_document_filename": "CPG Prevention and Treatment of Venous Thrombosis_cleaned_ultra_minimal.txt", "source_document_title": "CPG Prevention and Treatment of Venous Thrombosis cleaned ultra minimal", "text": "CHADS2\nscore\u00a05\u00a0or\u00a06\n2. Recent\nstroke/TIA\n(<3\u00a0months)\n3. Rheumatic\nvalvular\nheart\u00a0disease\nHigh\u00a0bleeding\u00a0risk\u00a0surgeries\nLow\u00a0bleeding\u00a0risk\nsurgeries\nMajor\u00a0surgeries\nMinor\u00a0surgeries\nMinor\u00a0surgeries\nHeart\u00a0surgery:\nCoronary\u00a0artery\nbypass,\u00a0heart\u00a0valve\nreplacement\nBiopsy\u00a0of\u00a0prostate\u00a0or\nkidney\u00a0(endogenous\nurokinase\u00a0may\u00a0promote\nbleeding)\nSkin:\nSmall\u00a0skin\u00a0excisions\n6.3\u00a0BLEEDING\u00a0RISK\u00a0IN\u00a0SURGERY\nSurgeries\u00a0can\u00a0be\u00a0associated\u00a0with\u00a0a\u00a0high\u00a0or\u00a0low\u00a0risk\u00a0of\u00a0bleeding\u00a0(Table\u00a06.3).180\u00ad183,193\n1. Any\u00a0mechanical\nmitral\u00a0valve\n2. Older\u00a0aortic\nmechanical\u00a0valve\n(caged\u00adball,\ntilting\u00a0disk)\n3. Recent\nstroke\u00a0or\u00a0TIA\n(<3\u00a0months)\n1. VTE\u00a0within\npast\u00a03\u00a0\u00ad12\nmonths\n2. Recurrent\nVTE\n3. Active\u00a0cancer\nCHADS2\u00a0indicates\u00a0cardiac\u00a0failure,\u00a0hypertension,\u00a0age,\u00a0diabetes,\u00a0stroke\nRisk\u00a0factors:\u00a0AF,\u00a0cardiac\u00a0failure,\u00a0hypertension,\u00a0age>75\u00a0years,\u00a0diabetes,\u00a0stroke\nor\u00a0TIA\u00a0(Use\u00a0CHA2DS2\u00a0Vasc:\u00a0predicts\u00a0better\u00a0than\u00a0CHADS2\u00a0score)\nThromboembolic\nrisk\nTable\u00a06.3:\u00a0Surgical\u00a0bleeding\u00a0risk\nTable\u00a06.2:\u00a0Risk\u00a0stratification\u00a0for\u00a0perioperative\u00a0thromboembolism\nSpinal\u00a0surgery:\nIntracranial\u00a0surgery,\nintra\u00adspinal\u00a0surgery\nColon\u00a0polypectomy\n(ongoing\u00a0bleeding\u00a0from\npolyp\u00a0stalk\u00a0resection\nsite)\nEye:\nCataract\u00a0removal\nMajor\u00a0orthopaedic\nsurgery,\u00a0\u00a0reconstructive\nplastic\u00a0surgery\nUrogenital\u00a0surgery:\nProstate\u00a0and\u00a0bladder\nresection\nMajor\u00a0cancer\u00a0surgery\nCardiac\u00a0pacemaker\nimplantation\n(unopposed\u00a0tissue\nlayers\u00a0of\u00a0the\u00a0pacemaker\npocket\u00a0heal\u00a0by\nsecondary\u00a0intent)\n6.4\u00a0MANAGING\u00a0ANTICOAGULATION\u00a0IN\u00a0SURGERY\n6.4.1\u00a0Warfarin\u00a0interruption\nWarfarin\u00a0interruption\u00a0is\u00a0not\u00a0required\u00a0for\u00a0minor\u00a0surgical\u00a0procedures\u00a0with\u00a0low\u00a0risk\u00a0of\nbleeding. Warfarin\u00a0interruption\u00a0is\u00a0required\u00a0for\u00a0high\u00a0bleeding\u00a0risk\u00a0surgeries. When\nwarfarin\u00a0 is\u00a0 stopped,\u00a0 bridging\u00a0 therapy\u00a0 with\u00a0 LMWH,\u00a0 fondaparinux\u00a0 or\u00a0 IV\u00a0 UFH\u00a0 is\nindicated\u00a0 for\u00a0 high\u00a0 risk\u00a0 group\u00a0 and\u00a0 case\u00adby\u00adcase\u00a0 for\u00a0 moderate\u00a0 risk\u00a0 group\u00a0 for\nthromboembolism.181\u00ad183\nIt\u00a0takes\u00a0approximately\u00a05\u00a0days\u00a0after\u00a0stopping\u00a0warfarin\u00a0for\u00a0the\u00a0INR\u00a0to\u00a0normalize.192,195\nA\u00a0safe\u00a0INR\u00a0for\u00a0major\u00a0surgeries\u00a0is\u00a0<1.5\u00a0and\u00a0<1.2\u00a0for\u00a0neurosurgeries. Warfarin\u00a0can\nbe\u00a0resumed\u00a012\u00a0to\u00a024\u00a0hours\u00a0(evening\u00a0or\u00a0next\u00a0morning)\u00a0after\u00a0surgery\u00a0and\u00a0when\nadequate\u00a0haemostasis\u00a0is\u00a0achieved.189\u00ad192\n6.4.2\u00a0Bridging\u00a0therapy\nBridging\u00a0therapy\u00a0is\u00a0started\u00a0on\u00a0the\u00a0third\u00a0day\u00a0before\u00a0surgery. On\u00a0the\u00a0day\u00a0before\nsurgery\u00a0 patients\u00a0 should\u00a0 receive\u00a0 only\u00a0 the\u00a0 morning\u00a0 dose\u00a0 if\u00a0 a\u00a0 twice\u00addaily\u00a0 LMWH\nregimen\u00a0 is\u00a0 used\u00a0 or\u00a0 50%\u00a0 of\u00a0 the\u00a0 total\u00a0 dose\u00a0 if\u00a0 a\u00a0 once\u00addaily\u00a0 LMWH\u00a0 regimen\u00a0 or\nfondaparinux\u00a0is\u00a0used. If\u00a0IV\u00a0UFH\u00a0is\u00a0used,\u00a0this\u00a0should\u00a0be\u00a0stopped\u00a04\u00a0to\u00a06\u00a0hours\u00a0before\nsurgery.178\u00ad183\nResuming\u00a0 therapeutic\u00a0 LMWH\u00a0 or\u00a0 fondaparinux\u00a0 after\u00a0 surgery\u00a0 will\u00a0 depend\u00a0 on\nwhether\u00a0haemostasis\u00a0is\u00a0secured\u037e\u00a0in\u00a0general\u00a0for\u00a0surgeries\u00a0with\u00a0high\u00a0bleeding\u00a0risk,\nLMWH\u00a0or\u00a0fondaparinux\u00a0is\u00a0resumed\u00a0after\u00a048\u00a0to\u00a072\u00a0hours\u037e\u00a0for\u00a0surgeries\u00a0with\u00a0low\nbleeding\u00a0risk,\u00a0LMWH\u00a0or\u00a0fondaparinux\u00a0is\u00a0resumed\u00a0after\u00a024\u00a0hours.178\u00ad183,194\nVascular\u00a0surgery:\nAortic\u00a0aneurysm\u00a0repair,\nperipheral\u00a0artery\nbypass\nDental:\nTooth\u00a0extraction,\nendodontic\u00a0(root\u00a0canal)\nprocedures\nOther\u00a0procedures:\nBone\u00a0marrow\u00a0aspiration\nand\u00a0trephine\u00a0biopsy\nDiagnostic\u00a0ERCP\nwithout\u00a0sphincterotomy\nDiagnostic\u00a0endoscopy\n6.4.3 The novel oral anticoagulants\nTwo\u00a0 novel\u00a0 oral\u00a0 anticoagulants\u00a0 (NOACs),\u00a0 dabigatran\u00a0 and\u00a0 rivaroxaban\u00a0 have\nrecently\u00a0been\u00a0approved. Dabigatran\u00a0is\u00a0licensed\u00a0for\u00a0use\u00a0in\u00a0stroke\u00a0prevention\u00a0in\nnon\u00advalvular\u00a0 atrial\u00a0 fibrillation\u00a0 and\u00a0 in\u00a0 VTE\u00a0 prevention\u00a0 in\u00a0 hip\u00a0 and\u00a0 knee\u00a0 surgery. Besides\u00a0stroke\u00a0and\u00a0VTE\u00a0prevention\u00a0as\u00a0for\u00a0dabigatran,\u00a0rivaroxaban\u00a0is\u00a0also\u00a0licensed\nfor\u00a0use\u00a0as\u00a0an\u00a0option\u00a0for\u00a0the\u00a0treatment\u00a0of\u00a0DVT\u00a0and\u00a0PE.", "chunk_order": 40}
{"chunk_id": "3b579f27-18c2-4dc2-aaec-a92a94a6c3e1", "source_document_filename": "CPG Prevention and Treatment of Venous Thrombosis_cleaned_ultra_minimal.txt", "source_document_title": "CPG Prevention and Treatment of Venous Thrombosis cleaned ultra minimal", "text": "Dabigatran\u00a0is\u00a0licensed\u00a0for\u00a0use\u00a0in\u00a0stroke\u00a0prevention\u00a0in\nnon\u00advalvular\u00a0 atrial\u00a0 fibrillation\u00a0 and\u00a0 in\u00a0 VTE\u00a0 prevention\u00a0 in\u00a0 hip\u00a0 and\u00a0 knee\u00a0 surgery. Besides\u00a0stroke\u00a0and\u00a0VTE\u00a0prevention\u00a0as\u00a0for\u00a0dabigatran,\u00a0rivaroxaban\u00a0is\u00a0also\u00a0licensed\nfor\u00a0use\u00a0as\u00a0an\u00a0option\u00a0for\u00a0the\u00a0treatment\u00a0of\u00a0DVT\u00a0and\u00a0PE. Continue\nwarfarin\nWarfarin\ninterruption\nBridging\nNo\u00a0bridging\nLow\u00a0bleeding\nrisk\u00a0surgeries\nHigh\u00a0bleeding\nrisk\u00a0surgeries\nHigh/moderate\nthrombo\u00adembolic\nrisk\nLow\nthrombo\u00adembolic\nrisk\nTable\u00a06.4:\u00a0Managing\u00a0warfarin\u00a0anticoagulation\u00a0in\u00a0surgery\nRecommendations\nGrade\nElective\u00a0surgery\u00a0should\u00a0be\u00a0avoided\u00a0in\u00a0the\u00a0first\u00a0month\u00a0after\u00a0an\u00a0acute\nepisode\u00a0of\u00a0VTE\nWarfarin\u00a0should\u00a0be\u00a0stopped\u00a0at\u00a0least\u00a05\u00a0days\u00a0before\u00a0surgery\nWarfarin\u00a0should\u00a0be\u00a0restarted\u00a012\u00a0to\u00a024\u00a0hours\u00a0after\u00a0surgery\u00a0once\nhaemostasis\u00a0is\u00a0achieved\u00a0and\u00a0there\u00a0is\u00a0no\u00a0ongoing\u00a0bleeding\nNo\u00a0 bridging\u00a0 therapy\u00a0 is\u00a0 required\u00a0 for\u00a0 patients\u00a0 with\u00a0AF,\u00a0 prosthetic\nvalve\u00a0or\u00a0VTE\u00a0with\u00a0low\u00a0risk\u00a0for\u00a0thromboembolism\nPatients\u00a0at\u00a0high\u00a0risk\u00a0of\u00a0thromboembolism\u00a0should\u00a0receive\u00a0bridging\ntherapy\nPatients\u00a0at\u00a0moderate\u00a0risk\u00a0should\u00a0be\u00a0considered\u00a0on\u00a0case\u00adby\u00adcase\nbasis\u00a0 for\u00a0 bridging\u00a0 therapy\u00a0 according\u00a0 to\u00a0 the\u00a0 risks\u00a0 of\u00a0 surgical\nbleeding\u00a0and\u00a0of\u00a0thromboembolism\nBridging\u00a0therapy\u00a0is\u00a0started\u00a0on\u00a0the\u00a0third\u00a0day\u00a0before\u00a0surgery\nThe\u00a0last\u00a0dose\u00a0of\u00a0LMWH\u00a0or\u00a0fondaparinux\u00a0is\u00a0given\u00a024\u00a0hours\u00a0before\nsurgery\nIf\u00a0IV\u00a0UFH\u00a0is\u00a0used,\u00a0it\u00a0should\u00a0be\u00a0stopped\u00a04\u00a0to\u00a06\u00a0hours\u00a0prior\u00a0to\u00a0surgery\nLMWH\u00a0or\u00a0fondaparinux\u00a0is\u00a0resumed\u00a0after\u00a024\u00a0hours\u00a0for\u00a0surgeries\nwith\u00a0low\u00a0bleeding\u00a0risk\u00a0and\u00a048\u00a0to\u00a072\u00a0hours\u00a0for\u00a0surgeries\u00a0with\u00a0high\nbleeding\u00a0risk\nFor\u00a0emergency\u00a0surgery,\u00a0warfarin\u00a0is\u00a0stopped\u00a0and\u00a0iv\u00a0vitamin\u00a0K\u00a02\u00a0to\u00a04\nmg\u00a0is\u00a0given\u00a0with\u00a0infusion\u00a0of\u00a0prothrombin\u00a0complex\u00a0concentrate\u00a0or\nfresh\u00a0frozen\u00a0plasma\u00a0if\u00a0needed\nA\u00a0safe\u00a0INR\u00a0for\u00a0major\u00a0surgeries\u00a0is\u00a0<1.5\u00a0and\u00a0<1.2\u00a0for\u00a0neurosurgeries\nMinor\u00a0surgeries\u00a0such\u00a0as\u00a0dental\u00a0extractions,\u00a0cataract\u00a0surgeries\u00a0and\nsmall\u00a0skin\u00a0excisions\u00a0do\u00a0not\u00a0require\u00a0interruption\u00a0of\u00a0anticoagulation\nC\nB\nC\nB\nB\nC\nC\nC\nC\nC\nB\nC\nB\nA\u00a0 normal\u00a0 thrombin\u00a0 time\u00a0 rules\u00a0 out\u00a0 the\u00a0 presence\u00a0 of\u00a0 important\u00a0 levels\u00a0 of\ndabigatran\u037e\u00a0this\u00a0test\u00a0could\u00a0be\u00a0used\u00a0pre\u00adoperatively\u00a0in\u00a0patients\u00a0in\u00a0whom\u00a0there\nis\u00a0 a\u00a0 potential\u00a0 for\u00a0 persistent\u00a0 anticoagulant\u00a0 effect,\u00a0 or\u00a0 for\u00a0 those\u00a0 undergoing\nsurgery\u00a0 with\u00a0 a\u00a0 high\u00a0 risk\u00a0 of\u00a0 complications\u00a0 from\u00a0 bleeding,\u00a0 such\u00a0 as\u00a0 spinal\u00a0 or\nneurosurgery.317,318\u00a0 Prothrombin\u00a0 time\u00a0 may\u00a0 be\u00a0 prolonged\u00a0 in\u00a0 rivaroxaban\u00a0 but\nthis\u00a0does\u00a0not\u00a0reliably\u00a0predict\u00a0rivaroxaban\u00a0levels.317\nHalf\u00adlife,\u00a0hours\nCalculated\ncreatinine\nclearance,\u00a0mL/min\nTiming\u00a0of\u00a0last\u00a0dose\u00a0before\u00a0surgery\nLow\u00a0bleeding\u00a0risk\nHigh\u00a0bleeding\u00a0risk\n13\u00a0(11\u00a0\u00ad\u00a022)\n>80\n24\u00a0hours\n2\u00a0days\n15\u00a0(12\u00a0\u00ad\u00a034)\n>50\u00a0\u00ad\u00a080\n24\u00a0hours\n2\u00a0days\n18\u00a0(13\u00a0\u00ad\u00a023)\n>30\u00a0\u00ad\u00a050\n2\u00a0days\n4\u00a0days\n27\u00a0(22\u00a0\u00ad\u00a035)\n430\n4\u00a0days\n6\u00a0days\n12\u00a0(11\u00a0\u00ad\u00a013)\n>30\n24\u00a0hours\n2\u00a0days\nunknown\n<30\n2\u00a0days\n4\u00a0days\nThe\u00a0 management\u00a0 of\u00a0 these\u00a0 anticoagulants\u00a0 when\u00a0 transitioning\u00a0 from\u00a0 or\u00a0 back\u00a0 to\nwarfarin,\u00a0around\u00a0surgery\u00a0or\u00a0in\u00a0case\u00a0of\u00a0major\u00a0haemorrhage\u00a0requires\u00a0knowledge\u00a0of\ntheir\u00a0pharmacokinetics\u00a0and\u00a0mechanism\u00a0of\u00a0action. 6.4.3.1\u00a0Peri\u00adoperative\u00a0management\u00a0of\u00a0dabigatran\u00a0or\u00a0rivaroxaban\nThe\u00a0principles\u00a0that\u00a0are\u00a0important\u00a0for\u00a0the\u00a0peri\u00adoperative\u00a0management\u00a0with\u00a0the\u00a0new\nanticoagulants\u00a0are:\n1.", "chunk_order": 41}
{"chunk_id": "1229eab3-7db4-46e4-98d3-7f418c2e2870", "source_document_filename": "CPG Prevention and Treatment of Venous Thrombosis_cleaned_ultra_minimal.txt", "source_document_title": "CPG Prevention and Treatment of Venous Thrombosis cleaned ultra minimal", "text": "6.4.3.1\u00a0Peri\u00adoperative\u00a0management\u00a0of\u00a0dabigatran\u00a0or\u00a0rivaroxaban\nThe\u00a0principles\u00a0that\u00a0are\u00a0important\u00a0for\u00a0the\u00a0peri\u00adoperative\u00a0management\u00a0with\u00a0the\u00a0new\nanticoagulants\u00a0are:\n1. The\u00a0half\u00adlife\u00a0is\u00a0shorter\u00a0than\u00a0with\u00a0warfarin\n2. The\u00a0onset\u00a0of\u00a0effect\u00a0is\u00a0within\u00a02\u00a0hours,\u00a0provided\u00a0that\u00a0intestinal\u00a0absorption\u00a0is\nnormal. 6.4.3.1.1\u00a0Pre\u00adoperative\u00a0management\nFor\u00a0elective\u00a0surgery\u00a0in\u00a0patients\u00a0with\u00a0normal\u00a0renal\u00a0function,\u00a0it\u00a0is\u00a0safe\u00a0to\u00a0recommend\nthe\u00a0patient\u00a0to\u00a0simply\u00a0interrupt\u00a0therapy\u00a0for\u00a01\u00a0to\u00a02\u00a0days\u00a0(depending\u00a0on\u00a0the\u00a0type\u00a0of\nprocedure)\u00a0prior\u00a0to\u00a0their\u00a0planned\u00a0procedure\u00a0(Table\u00a06.4.3.1.1).317\u00a0With\u00a0decreasing\nrenal\u00a0 function\u00a0 the\u00a0 period\u00a0 of\u00a0 interruption\u00a0 should\u00a0 be\u00a0 longer. This\u00a0 short\u00a0 period\u00a0 of\ninterruption\u00a0does\u00a0not\u00a0require\u00a0bridging\u00a0therapy.317\nTable\u00a06.4.3.1.1:\u00a0\u00a0Timing\u00a0of\u00a0interruption\u00a0of\u00a0dabigatran\u00a0or\u00a0rivaroxaban\nbefore\u00a0surgery\u00a0or\u00a0invasive\u00a0procedures\nDabigatran\nRivaroxaban\n6.4.3.2. Post-operative management\nThe\u00a0time\u00a0point\u00a0for\u00a0the\u00a0resumption\u00a0of\u00a0dabigatran\u00a0or\u00a0rivaroxaban\u00a0depends\u00a0almost\nexcusively\u00a0 on\u00a0 the\u00a0 post\u00adoperative\u00a0 risk\u00a0 of\u00a0 bleeding. For\u00a0 procedures\u00a0 with\u00a0 good\nhaemostasis\u00a0 shortly\u00a0 after\u00a0 the\u00a0 end\u00a0 of\u00a0 the\u00a0 procedure,\u00a0 resumption\u00a0 of\u00a0 drug\u00a0 is\nrecommended\u00a0after\u00a0a\u00a0minimum\u00a0of\u00a04\u00a0to\u00a06\u00a0hours\u00a0following\u00a0surgery.317\nFor\u00a0 dabigatran,\u00a0 a\u00a0 half\u00addose\u00a0 (75\u00a0 mg)\u00a0 is\u00a0 recommended\u00a0 for\u00a0 the\u00a0 first\u00a0 dose,\u00a0 and\nthereafter\u00a0 the\u00a0 usual\u00a0 maintenance\u00a0 dose. For\u00a0 rivaroxaban,\u00a0 a\u00a0 10\u00a0 mg\u00a0 dose\u00a0 is\nrecommended\u00a0 for\u00a0 the\u00a0 first\u00a0 dose. Patients\u00a0 with\u00a0 bowel\u00a0 paralysis\u00a0 may\u00a0 require\nbridging\u00a0with\u00a0parenteral\u00a0anticoagulants\u00a0until\u00a0they\u00a0are\u00a0able\u00a0to\u00a0tolerate\u00a0orally.317\n7.0\u00a0MANAGEMENT\u00a0OF\u00a0OVER\u00adANTICOAGULATION\n7.1\u00a0WARFARIN\u00a0AND\u00a0BLEEDING\nAnticoagulation\u00a0with\u00a0warfarin\u00a0is\u00a0very\u00a0effective\u00a0in\u00a0the\u00a0prevention\u00a0and\u00a0treatment\u00a0of\nthromboembolic\u00a0 events. However,\u00a0 major\u00a0 bleeding\u00a0 complications\u00a0 leading\u00a0 to\nhospitalisation\u00a0and\u00a0death\u00a0has\u00a0been\u00a0reported\u00a0in\u00a01\u00a0to\u00a08%\u00a0of\u00a0patients\u00a0during\u00a0each\u00a0year\nof\u00a0long\u00adterm\u00a0warfarin\u00a0therapy.198,203\nThe\u00a0risk\u00a0for\u00a0bleeding\u00a0increases\u00a0with\u00a0age,\u00a0history\u00a0of\u00a0past\u00a0bleeding,\u00a0specific\u00a0co\u00admorbid\nconditions\u00a0and\u00a0the\u00a0level\u00a0of\u00a0the\u00a0INR. Although\u00a0the\u00a0bleeding\u00a0risk\u00a0increases\u00a0as\u00a0the\u00a0INR\nincreases,\u00a050%\u00a0of\u00a0bleeding\u00a0episodes\u00a0occur\u00a0when\u00a0the\u00a0INR\u00a0is\u00a0less\u00a0than\u00a04.0.198,203,204,206\n7.2\u00a0WARFARIN\u00a0REVERSAL\nThe\u00a0management\u00a0for\u00a0warfarin\u00a0reversal\u00a0will\u00a0depend\u00a0on\u00a0the\u00a0INR\u00a0and\u00a0whether\u00a0or\u00a0not\nbleeding\u00a0is\u00a0present. There\u00a0are\u00a0several\u00a0options\u00a0for\u00a0warfarin\u00a0reversal:\u00a0stopping\u00a0the\nwarfarin,\u00a0giving\u00a0vitamin\u00a0K\u00a0and\u00a0replacing\u00a0the\u00a0coagulation\u00a0factors\u00a0with\u00a0prothrombin\ncomplex\u00a0concentrate\u00a0(PCC)\u00a0or\u00a0fresh\u00a0frozen\u00a0plasma\u00a0(FFP). 7.2.1\u00a0Vitamin\u00a0K\nVitamin\u00a0K\u00a0is\u00a0available\u00a0as\u00a0ampoules\u00a0for\u00a0intravenous\u00a0administration\u00a0but\u00a0can\u00a0also\u00a0be\ngiven\u00a0 orally\u00a0 mixed\u00a0 with\u00a0 a\u00a0 glass\u00a0 of\u00a0 juice\u00a0 or\u00a0 water. The\u00a0 ampoules\u00a0 are\u00a0 not\nrecommended\u00a0 for\u00a0 subcutaneous\u00a0 or\u00a0 intramuscular\u00a0 use\u00a0 as\u00a0 the\u00a0 response\u00a0 is\nunpredictable\u00a0with\u00a0a\u00a0risk\u00a0of\u00a0haematoma\u00a0formation\u00a0in\u00a0the\u00a0latter.198\u00ad200,209\nOral\u00a0 vitamin\u00a0 K\u00a0 is\u00a0 the\u00a0 treatment\u00a0 of\u00a0 choice\u00a0 unless\u00a0 very\u00a0 rapid\u00a0 reversal\u00a0 of\nanticoagulation\u00a0is\u00a0required. For\u00a0most\u00a0patients\u00a01.0\u00a0to\u00a02.0\u00a0mg\u00a0of\u00a0oral\u00a0vitamin\u00a0K\u00a0is\nsufficient. If\u00a0the\u00a0INR\u00a0is\u00a0particularly\u00a0high,\u00a05\u00a0mg\u00a0may\u00a0be\u00a0required.199\u00ad201\nThe\u00a0optimal\u00a0intravenous\u00a0dose\u00a0of\u00a0vitamin\u00a0K\u00a0for\u00a0partial\u00a0reversal\u00a0of\u00a0over\u00adwarfarinisation\nis\u00a00.5\u00a0to\u00a01.0\u00a0mg. If\u00a0full\u00a0correction\u00a0of\u00a0the\u00a0INR\u00a0is\u00a0desired,\u00a0larger\u00a0doses\u00a0are\u00a0needed.", "chunk_order": 42}
{"chunk_id": "739fc01d-fd47-4263-a725-95134408d108", "source_document_filename": "CPG Prevention and Treatment of Venous Thrombosis_cleaned_ultra_minimal.txt", "source_document_title": "CPG Prevention and Treatment of Venous Thrombosis cleaned ultra minimal", "text": "The\u00a0 ampoules\u00a0 are\u00a0 not\nrecommended\u00a0 for\u00a0 subcutaneous\u00a0 or\u00a0 intramuscular\u00a0 use\u00a0 as\u00a0 the\u00a0 response\u00a0 is\nunpredictable\u00a0with\u00a0a\u00a0risk\u00a0of\u00a0haematoma\u00a0formation\u00a0in\u00a0the\u00a0latter.198\u00ad200,209\nOral\u00a0 vitamin\u00a0 K\u00a0 is\u00a0 the\u00a0 treatment\u00a0 of\u00a0 choice\u00a0 unless\u00a0 very\u00a0 rapid\u00a0 reversal\u00a0 of\nanticoagulation\u00a0is\u00a0required. For\u00a0most\u00a0patients\u00a01.0\u00a0to\u00a02.0\u00a0mg\u00a0of\u00a0oral\u00a0vitamin\u00a0K\u00a0is\nsufficient. If\u00a0the\u00a0INR\u00a0is\u00a0particularly\u00a0high,\u00a05\u00a0mg\u00a0may\u00a0be\u00a0required.199\u00ad201\nThe\u00a0optimal\u00a0intravenous\u00a0dose\u00a0of\u00a0vitamin\u00a0K\u00a0for\u00a0partial\u00a0reversal\u00a0of\u00a0over\u00adwarfarinisation\nis\u00a00.5\u00a0to\u00a01.0\u00a0mg. If\u00a0full\u00a0correction\u00a0of\u00a0the\u00a0INR\u00a0is\u00a0desired,\u00a0larger\u00a0doses\u00a0are\u00a0needed. The\nINR\u00a0 can\u00a0 usually\u00a0 be\u00a0 normalized\u00a0 within\u00a0 24\u00a0 hours\u00a0 with\u00a0 an\u00a0 intravenous\u00a0 dose\u00a0 of\u00a0 5\nmg.198,203,206\n7.2.2\u00a0Prothrombin\u00a0Complex\u00a0Concentrate\nProthrombin\u00a0complex\u00a0concentrate\u00a0is\u00a0made\u00a0from\u00a0pooled\u00a0donor\u00a0plasma\u00a0and\u00a0has\nundergone\u00a0viral\u00a0inactivation. It\u00a0contains\u00a0clotting\u00a0factors\u00a0II,\u00a0IX\u00a0and\u00a0X\u00a0with\u00a0variability\nin\u00a0their\u00a0factor\u00a0VII\u00a0content. Concentrates\u00a0with\u00a0little\u00a0factor\u00a0VII\u00a0(3\u00adfactor\u00a0PCC)\u00a0produce\npoor\u00a0correction\u00a0of\u00a0the\u00a0INR\u00a0and\u00a0are\u00a0not\u00a0recommended.202,203\nPatients\u00a0on\u00a0warfarin\u00a0have\u00a0reduced\u00a0levels\u00a0of\u00a0factors\u00a0II,\u00a0VII,\u00a0IX\u00a0and\u00a0X\u00a0and\u00a0rapid\ncorrection\u00a0 involves\u00a0 replacement\u00a0 of\u00a0 these\u00a0 4\u00a0 factors. This\u00a0 is\u00a0 achieved\u00a0 with\u00a0 the\n4\u00adfactor\u00a0 PCC. The\u00a0 4\u00adfactor\u00a0 PCCs\u00a0 that\u00a0 are\u00a0 currently\u00a0 available\u00a0 in\u00a0 Malaysia\u00a0 are\noctaplex\u00a0and\u00a0beriplex.203,205,206\nFour\u00adfactor\u00a0PCCs\u00a0are\u00a0able\u00a0to\u00a0completely\u00a0reverse\u00a0warfarin\u00adinduced\u00a0anticoagulation\nwithin\u00a010\u00a0minutes\u00a0but\u00a0the\u00a0infused\u00a0clotting\u00a0factors\u00a0have\u00a0a\u00a0finite\u00a0half\u00adlife,\u00a0the\u00a0shortest\nof\u00a0which\u00a0is\u00a0factor\u00a0VII\u00a0at\u00a06\u00a0hours. For\u00a0this\u00a0reason,\u00a05\u00a0mg\u00a0of\u00a0intravenous\u00a0vitamin\u00a0K\nshould\u00a0be\u00a0given\u00a0with\u00a0the\u00a0PCC.205,206\nRecombinant\u00a0activated\u00a0factor\u00a0VII\u00a0(rFVIIa)\u00a0has\u00a0been\u00a0used\u00a0in\u00a0warfarin\u00a0reversal\u00a0but\u00a0all\nreports\u00a0 have\u00a0 been\u00a0 retrospective,\u00a0 small\u00a0 series\u00a0 or\u00a0 without\u00a0 adequate\u00a0 controls. Although\u00a0rFVIIa\u00a0rapidly\u00a0corrects\u00a0the\u00a0INR,\u00a0its\u00a0impact\u00a0on\u00a0stopping\u00a0bleeding\u00a0is\u00a0unclear\nand\u00a0its\u00a0use\u00a0cannot\u00a0be\u00a0recommended\u00a0for\u00a0warfarin\u00a0reversal.203,210\n7.2.3\u00a0Fresh\u00a0frozen\u00a0plasma\nFresh\u00a0 frozen\u00a0 plasma\u00a0 cannot\u00a0 provide\u00a0 a\u00a0 rapid\u00a0 and\u00a0 complete\u00a0 correction\u00a0 of\nwarfarin\u00adinduced\u00a0coagulopathy. At\u00a0doses\u00a0of\u00a015\u00a0to\u00a020\u00a0mL/kg,\u00a0factor\u00a0levels\u00a0rise\u00a0no\nmore\u00a0 than\u00a0 30%,\u00a0 hence\u00a0 FFP\u00a0 cannot\u00a0 be\u00a0 recommended\u00a0 for\u00a0 life\u00adthreatening\nbleeding.205,206\nAll\u00a0hospitals\u00a0and\u00a0units\u00a0responsible\u00a0for\u00a0the\u00a0care\u00a0of\u00a0patients\u00a0on\u00a0anticoagulant\u00a0must\nstock\u00a0a\u00a04\u00adfactor\u00a0PCC\u00a0as\u00a0this\u00a0will\u00a0achieve\u00a0factor\u00a0levels\u00a0between\u00a080\u00a0to\u00a0100%\u00a0within\u00a010\nminutes\u00a0in\u00a0life\u00adthreatening\u00a0bleeding.205,206\n7.3\u00a0MANAGEMENT\u00a0OF\u00a0OVER\u00adWARFARINISATION\nThe\u00a0management\u00a0of\u00a0over\u00adwarfarinisation\u00a0and\u00a0warfarin\u00a0reversal\u00a0are\u00a0summarized\u00a0in\nTables\u00a07.3\u00a0and\u00a07.4. 7.3.1\u00a0Major\u00a0bleeding\nMajor\u00a0bleeding\u00a0can\u00a0be\u00a0defined\u00a0as\u00a0limb\u00a0or\u00a0life\u00adthreatening\u00a0bleeding\u00a0that\u00a0requires\ncomplete\u00a0reversal\u00a0of\u00a0warfarinisation\u00a0within\u00a06\u00a0to\u00a08\u00a0hours. Rapid\u00a0correction\u00a0is\u00a0most\neffectively\u00a0achieved\u00a0by\u00a0the\u00a0administration\u00a0of\u00a04\u00adfactor\u00a0PCC\u00a0and\u00a0must\u00a0be\u00a0combined\nwith\u00a0intravenous\u00a0vitamin\u00a0K\u00a05\u00a0mg.198,203,206\n7.3.2\u00a0Non\u00admajor\u00a0bleeding\nPatients\u00a0with\u00a0non\u00admajor\u00a0bleeding\u00a0can\u00a0be\u00a0managed\u00a0with\u00a0vitamin\u00a0K\u00a0combined\u00a0with\ntemporary\u00a0discontinuation\u00a0of\u00a0warfarin. Intravenous\u00a0vitamin\u00a0K\u00a0produces\u00a0a\u00a0more\u00a0rapid\ncorrection\u00a0of\u00a0the\u00a0INR\u00a0than\u00a0oral\u00a0vitamin\u00a0K\u00a0and\u00a0should\u00a0be\u00a0used\u00a0in\u00a0preference\u00a0in\u00a0the\nbleeding\u00a0patient.211,212\n7.3.3\u00a0INR\u00a0>8\u00a0in\u00a0non\u00adbleeding\u00a0patients\nThe\u00a0risk\u00a0of\u00a0bleeding\u00a0increases\u00a0exponentially\u00a0with\u00a0increasing\u00a0INR.", "chunk_order": 43}
{"chunk_id": "3b47b75e-1a94-40a1-999f-11d2120c4216", "source_document_filename": "CPG Prevention and Treatment of Venous Thrombosis_cleaned_ultra_minimal.txt", "source_document_title": "CPG Prevention and Treatment of Venous Thrombosis cleaned ultra minimal", "text": "Rapid\u00a0correction\u00a0is\u00a0most\neffectively\u00a0achieved\u00a0by\u00a0the\u00a0administration\u00a0of\u00a04\u00adfactor\u00a0PCC\u00a0and\u00a0must\u00a0be\u00a0combined\nwith\u00a0intravenous\u00a0vitamin\u00a0K\u00a05\u00a0mg.198,203,206\n7.3.2\u00a0Non\u00admajor\u00a0bleeding\nPatients\u00a0with\u00a0non\u00admajor\u00a0bleeding\u00a0can\u00a0be\u00a0managed\u00a0with\u00a0vitamin\u00a0K\u00a0combined\u00a0with\ntemporary\u00a0discontinuation\u00a0of\u00a0warfarin. Intravenous\u00a0vitamin\u00a0K\u00a0produces\u00a0a\u00a0more\u00a0rapid\ncorrection\u00a0of\u00a0the\u00a0INR\u00a0than\u00a0oral\u00a0vitamin\u00a0K\u00a0and\u00a0should\u00a0be\u00a0used\u00a0in\u00a0preference\u00a0in\u00a0the\nbleeding\u00a0patient.211,212\n7.3.3\u00a0INR\u00a0>8\u00a0in\u00a0non\u00adbleeding\u00a0patients\nThe\u00a0risk\u00a0of\u00a0bleeding\u00a0increases\u00a0exponentially\u00a0with\u00a0increasing\u00a0INR. Patients\u00a0with\u00a0INR\nmore\u00a0than\u00a08\u00a0are\u00a0at\u00a0a\u00a0significantly\u00a0high\u00a0risk\u00a0of\u00a0bleeding.203,204\nIn\u00a0the\u00a0non\u00adbleeding\u00a0patient,\u00a0the\u00a0use\u00a0of\u00a0vitamin\u00a0K\u00a0results\u00a0in\u00a0more\u00a0rapid\u00a0reduction\u00a0in\nINR\u00a0than\u00a0discontinuation\u00a0of\u00a0warfarin\u00a0alone. Oral\u00a0vitamin\u00a0K\u00a0is\u00a0preferred\u00a0over\u00a0the\nintravenous\u00a0 route\u00a0 as\u00a0 equal\u00a0 correction\u00a0 is\u00a0 achieved\u00a0 at\u00a0 24\u00a0 hours.199,201,203\u00a0 The\nrecommended\u00a0 dose\u00a0 is\u00a0 between\u00a0 1\u00a0 to\u00a0 5\u00a0 mg\u00a0 oral\u00a0 vitamin\u00a0 K. At\u00a0 these\u00a0 doses\nover\u00adcorrection\u00a0 is\u00a0 infrequent\u00a0 and\u00a0 resistance\u00a0 to\u00a0 re\u00adanticoagulation\u00a0 does\u00a0 not\noccur.199,201,211,212\nClinical\u00a0Scenarios\nRecommendations\nGrade\nMajor\u00a0Bleeding\n(Life\u00a0/\u00a0Limb\nThreatening)\nB\nB\nB\nC\nNon\u00adMajor\nBleeding\nFor\u00a0all\u00a0consider:\nTemporary\u00a0discontinuation\u00a0or\u00a0dose\u00a0reduction\nof\u00a0warfarin\u00a0(depending\u00a0on\u00a0clinical\u00a0scenario)\nIV\u00a0vitamin\u00a0K:\u00a01\u00a0to\u00a03\u00a0mg\nB\nB\nElevated\u00a0INR\n(No\u00a0bleeding)\n1.INR\u00a0>5.0\n<8.0\n2.INR\u00a0>8.0\nFor\u00a0all,\u00a0the\u00a0cause\u00a0for\u00a0the\u00a0elevated\u00a0INR\nshould\u00a0be\u00a0investigated\nWithhold\u00a01\u00a0to\u00a02\u00a0doses\u00a0of\u00a0warfarin\u00a0and\u00a0reduce\nmaintenance\u00a0dose\nGive\u00a0oral\u00a0vitamin\u00a0K\u00a01\u00a0to\u00a05\u00a0mg\u00a0and\u00a0withold\nwarfarin\u00a0(as\u00a0above)\nB\nC\nC\n7.3.4\u00a0INR\u00a0>5\u00a0but\u00a0<8\u00a0in\u00a0non\u00adbleeding\u00a0patients\nThe\u00a0 decision\u00a0 to\u00a0 give\u00a0 vitamin\u00a0 K\u00a0 to\u00a0 a\u00a0 non\u00adbleeding\u00a0 patient\u00a0 with\u00a0 INR\u00a0 <8\u00a0 is\u00a0 more\ncontroversial. It\u00a0is\u00a0reasonable\u00a0to\u00a0consider\u00a0giving\u00a0oral\u00a0vitamin\u00a0K\u00a0to\u00a0patients\u00a0with\u00a0an\u00a0INR\nbetween\u00a0 5.0\u00a0 to\u00a0 8.0\u00a0 if\u00a0 they\u00a0 are\u00a0 judged\u00a0 to\u00a0 be\u00a0 at\u00a0 high\u00a0 risk\u00a0 of\u00a0 bleeding,\u00a0 but\u00a0 it\u00a0 is\u00a0 not\nnecessary\u00a0to\u00a0offer\u00a0this\u00a0routinely\u00a0to\u00a0all\u00a0patients. Witholding\u00a01\u00a0to\u00a02\u00a0doses\u00a0of\u00a0warfarin\u00a0and\nreducing\u00a0maintenance\u00a0dose\u00a0may\u00a0be\u00a0all\u00a0that\u00a0is\u00a0required.198,203,206\nTable\u00a07.3:\u00a0Management\u00a0of\u00a0over\u00adwarfarinisation\nFor\u00a0all\u00a0give:\n1. IV\u00a0vitamin\u00a0K\u00a05\u00a0mg\n2. PCC\u00a0as\u00a0follows:\n#\"#INR\u00a0<5.0\u00a0give\u00a015\u00a0IU/kg\n#\"#INR\u00a0>5.0\u00a0give\u00a030\u00a0IU/kg\nFor\u00a0intracranial\u00a0haemorrhage,\u00a0doses\u00a0of\u00a0up\u00a0to\n50\u00a0IU/kg\u00a0can\u00a0be\u00a0given\nIf\u00a0PCC\u00a0not\u00a0available,\u00a0give\u00a0FFP\u00a015\u00a0to\u00a020\u00a0mL/kg\n7.4\u00a0SPECIFIC\u00a0CLINICAL\u00a0SCENARIOS\n7.4.1\u00a0Emergency\u00a0surgery\u00a0for\u00a0patients\u00a0on\u00a0warfarin\nFor\u00a0surgery\u00a0that\u00a0requires\u00a0reversal\u00a0of\u00a0warfarin\u00a0and\u00a0that\u00a0can\u00a0be\u00a0delayed\u00a0for\u00a06\u00a0to\u00a012\u00a0hours,\nthe\u00a0INR\u00a0can\u00a0be\u00a0corrected\u00a0by\u00a0giving\u00a0intravenous\u00a0vitamin\u00a0K.", "chunk_order": 44}
{"chunk_id": "1047b715-935b-4c50-8fc3-4e7f9773ce0d", "source_document_filename": "CPG Prevention and Treatment of Venous Thrombosis_cleaned_ultra_minimal.txt", "source_document_title": "CPG Prevention and Treatment of Venous Thrombosis cleaned ultra minimal", "text": "IV\u00a0vitamin\u00a0K\u00a05\u00a0mg\n2. PCC\u00a0as\u00a0follows:\n#\"#INR\u00a0<5.0\u00a0give\u00a015\u00a0IU/kg\n#\"#INR\u00a0>5.0\u00a0give\u00a030\u00a0IU/kg\nFor\u00a0intracranial\u00a0haemorrhage,\u00a0doses\u00a0of\u00a0up\u00a0to\n50\u00a0IU/kg\u00a0can\u00a0be\u00a0given\nIf\u00a0PCC\u00a0not\u00a0available,\u00a0give\u00a0FFP\u00a015\u00a0to\u00a020\u00a0mL/kg\n7.4\u00a0SPECIFIC\u00a0CLINICAL\u00a0SCENARIOS\n7.4.1\u00a0Emergency\u00a0surgery\u00a0for\u00a0patients\u00a0on\u00a0warfarin\nFor\u00a0surgery\u00a0that\u00a0requires\u00a0reversal\u00a0of\u00a0warfarin\u00a0and\u00a0that\u00a0can\u00a0be\u00a0delayed\u00a0for\u00a06\u00a0to\u00a012\u00a0hours,\nthe\u00a0INR\u00a0can\u00a0be\u00a0corrected\u00a0by\u00a0giving\u00a0intravenous\u00a0vitamin\u00a0K. For\u00a0surgery\u00a0that\u00a0requires\nreversal\u00a0of\u00a0warfarin\u00a0that\u00a0cannot\u00a0be\u00a0delayed,\u00a0the\u00a0INR\u00a0can\u00a0be\u00a0corrected\u00a0with\u00a0PCC\u00a0and\nintravenous\u00a0vitamin\u00a0K.198,203,206\n7.4.2\u00a0Head\u00a0injury\u00a0in\u00a0patients\u00a0on\u00a0warfarin\nPatients\u00a0on\u00a0warfarin\u00a0are\u00a0more\u00a0likely\u00a0to\u00a0have\u00a0a\u00a0cerebral\u00a0bleed\u00a0with\u00a0more\u00a0minor\u00a0injury\u00a0and\nthere\u00a0should\u00a0be\u00a0a\u00a0lower\u00a0threshold\u00a0for\u00a0CT\u00a0scanning.203\nPatients\u00a0with\u00a0a\u00a0strong\u00a0suspicion\u00a0of\u00a0intracerebral\u00a0haematoma\u00a0after\u00a0a\u00a0head\u00a0injury\u00a0should\nhave\u00a0their\u00a0INR\u00a0reversed\u00a0with\u00a0PCC\u00a0immediately\u00a0before\u00a0the\u00a0CT\u00a0scan\u00a0and\u00a0INR\u00a0results\u00a0are\navailable.203,208\n7.4.3\u00a0Dengue\u00a0infection\u00a0in\u00a0patients\u00a0on\u00a0warfarin\nAs\u00a0it\u00a0is\u00a0difficult\u00a0to\u00a0predict\u00a0which\u00a0patient\u00a0will\u00a0progress\u00a0to\u00a0severe\u00a0dengue,\u00a0all\u00a0patients\nshould\u00a0discontinue\u00a0warfarin\u00a0when\u00a0platelets\u00a0fall\u00a0below\u00a050\u00a0x\u00a0109/L. Bridging\u00a0with\u00a0LMWH\nis\u00a0carried\u00a0out\u00a0only\u00a0in\u00a0patients\u00a0with\u00a0a\u00a0high\u00a0risk\u00a0for\u00a0thrombosis\u00a0e.g. prosthetic\u00a0heart\u00a0valve\nwith\u00a0atrial\u00a0fibrillation\u00a0or\u00a0a\u00a0history\u00a0of\u00a0thromboembolic\u00a0stroke\u00a0when\u00a0the\u00a0INR\u00a0falls\u00a0below\ntherapeutic\u00a0levels.207\nWarfarin\u00a0can\u00a0be\u00a0resumed\u00a0once\u00a0patient\u00a0is\u00a0out\u00a0of\u00a0the\u00a0defervescence\u00a0phase\u00a0and\u00a0is\u00a0in\u00a0the\nrecovery\u00a0phase\u00a0with\u00a0a\u00a0rising\u00a0platelet\u00a0count.207\nClinical\u00a0Scenarios\nRecommendations\nGrade\nEmergency\u00a0surgery:\nCan\u00a0be\u00a0delayed\u00a0for\n6\u00a0to\u00a012\u00a0hours\nImmediate\nIV\u00a0vitamin\u00a0K,\u00a02\u00a0mg\u00a0to\u00a05\u00a0mg\nIV\u00a0vitamin\u00a0K,\u00a02\u00a0mg\u00a0to\u00a05\u00a0mg\u00a0AND\u00a0PCC\u00a030\u00a0IU/kg\nC\nC\nTable\u00a07.4:\u00a0Warfarin\u00a0reversal\u00a0in\u00a0specific\u00a0clinical\u00a0scenarios\nTrauma/Head\nInjury:\nStrong\u00a0suspicion\u00a0of\nintracranial\u00a0bleed\nIntracranial\u00a0bleed\nconfirmed\nCheck\u00a0INR\nReverse\u00a0anticoagulation\u00a0with\u00a0PCC\u00a0before\u00a0the\nresults\u00a0of\u00a0any\u00a0investigations\nAdd\u00a0IV\u00a0vitamin\u00a0K\u00a05\u00a0mg\nC\nC\nC\nDengue\nWithhold\u00a0warfarin\u00a0if:\nt platelet\u00a0count\u00a0is\u00a0<50x109/L\nt bleeding\nt shock\nC\n7.5\u00a0HEPARIN\u00a0AND\u00a0BLEEDING\nOver\u00adheparinisation\u00a0 may\u00a0 occur\u00a0 in\u00a0 conditions\u00a0 such\u00a0 as\u00a0 \u2018heparin\u00a0 resistance\u2019\u00a0 in\npregnancy\u00a0or\u00a0accidental\u00a0heparin\u00a0overdose\u00a0as\u00a0a\u00a0result\u00a0of\u00a0drug\u00a0error,\u00a0with\u00a05000\nunits/mL\u00a0vials\u00a0being\u00a0mistaken\u00a0for\u00a050\u00a0units/mL\u00a0vials. 7.5.1\u00a0Heparin\u00a0reversal\nFor\u00a0 immediate\u00a0 reversal,\u00a0 protamine\u00a0 sulfate\u00a0 rapidly\u00a0 neutralises\u00a0 UFH\u00a0 activity. In\nanimal\u00a0models,\u00a0LMWH\u00adassociated\u00a0bleeding\u00a0is\u00a0completely\u00a0reversed\u00a0by\u00a0protamine\nsulfate\u00a0although\u00a0it\u00a0results\u00a0in\u00a0partial\u00a0neutralisation\u00a0of\u00a0anti\u00adXa\u00a0activity. The\u00a0protamine\ndosage\u00a0to\u00a0neutralise\u00a0heparin\u00a0is\u00a0listed\u00a0in\u00a0Table\u00a07.5.1. Protamine\u00a0is\u00a0made\u00a0from\u00a0the\nsperm\u00a0of\u00a0salmon.", "chunk_order": 45}
{"chunk_id": "58a282d1-8d0e-449b-9dd1-360f44c50e20", "source_document_filename": "CPG Prevention and Treatment of Venous Thrombosis_cleaned_ultra_minimal.txt", "source_document_title": "CPG Prevention and Treatment of Venous Thrombosis cleaned ultra minimal", "text": "7.5.1\u00a0Heparin\u00a0reversal\nFor\u00a0 immediate\u00a0 reversal,\u00a0 protamine\u00a0 sulfate\u00a0 rapidly\u00a0 neutralises\u00a0 UFH\u00a0 activity. In\nanimal\u00a0models,\u00a0LMWH\u00adassociated\u00a0bleeding\u00a0is\u00a0completely\u00a0reversed\u00a0by\u00a0protamine\nsulfate\u00a0although\u00a0it\u00a0results\u00a0in\u00a0partial\u00a0neutralisation\u00a0of\u00a0anti\u00adXa\u00a0activity. The\u00a0protamine\ndosage\u00a0to\u00a0neutralise\u00a0heparin\u00a0is\u00a0listed\u00a0in\u00a0Table\u00a07.5.1. Protamine\u00a0is\u00a0made\u00a0from\u00a0the\nsperm\u00a0of\u00a0salmon. Reversal\u00a0of\u00a0unfractionated\u00a0heparin\nTime\u00a0since\u00a0last\u00a0UFH\u00a0dose,\u00a0min\nProtamine\u00a0dose\u00a0/\u00a0100\u00a0units\u00a0UFH\nreceived\n<30\n1.0\u00a0mg\n30\u00a0\u00ad\u00a060\n0.5\u00a0\u00ad\u00a00.75\u00a0mg\n60\u00a0\u00ad\u00a0120\n0.375\u00a0\u00ad\u00a00.5\u00a0mg\n>120\n0.25\u00a0\u00ad\u00a00.375\u00a0mg\nTable\u00a07.5.1:\u00a0Reversal\u00a0of\u00a0heparin\n7.6\u00a0FONDAPARINUX\u00a0AND\u00a0BLEEDING\nAlthough\u00a0there\u00a0is\u00a0no\u00a0antidote\u00a0for\u00a0fondaparinux,\u00a0recent\u00a0studies\u00a0suggest\u00a0that\u00a0rFVIIa\nmay\u00a0be\u00a0beneficial\u00a0in\u00a0reversing\u00a0its\u00a0anticoagulant\u00a0effects.319\n7.7\u00a0THE\u00a0NOVEL\u00a0ORAL\u00a0ANTICOAGULANTS\u00a0AND\u00a0BLEEDING\nWhen\u00a0bleeding\u00a0occurs\u00a0the\u00a0event\u00a0should\u00a0be\u00a0risk\u00adstratified:\u00a0minor\u00a0bleeding\u00a0(such\u00a0as\nepistaxis,\u00a0ecchymoses\u00a0or\u00a0menorrhagia)\u00a0can\u00a0be\u00a0managed\u00a0with\u00a0simple\u00a0withdrawal\nof\u00a0the\u00a0anticoagulant\u00a0for\u00a0one\u00a0or\u00a0two\u00a0days. The\u00a0drug\u00a0could\u00a0then\u00a0be\u00a0re\u00adstarted\u00a0at\u00a0a\nlower\u00a0 dose\u00a0 (e.g. dabigatran\u00a0 75\u00a0 mg/day\u00a0 or\u00a0 rivaroxaban\u00a0 10\u00a0 mg/day)\u00a0 for\u00a0 a\u00a0 short\nperiod\u00a0of\u00a0time.322\nModerate\u00a0 bleeding\u00a0 (e.g. upper\u00a0 or\u00a0 lower\u00a0 gastrointestinal\u00a0 bleeding)\u00a0 should\u00a0 be\nmanaged\u00a0with\u00a0withdrawal\u00a0of\u00a0anticoagulant,\u00a0close\u00a0clinical\u00a0monitoring,\u00a0interventions\nto\u00a0 identify\u00a0 and\u00a0 definitely\u00a0 treat\u00a0 the\u00a0 bleeding\u00a0 source\u00a0 and\u00a0 consideration\u00a0 for\u00a0 an\nextended\u00a0period\u00a0of\u00a0withdrawal\u00a0of\u00a0the\u00a0oral\u00a0anticoagulant\u00a0(perhaps\u00a0with\u00a0the\u00a0addition\nof\u00a0 a\u00a0 parenteral\u00a0 anticoagulant\u00a0 for\u00a0 patients\u00a0 at\u00a0 high\u00a0 risk\u00a0 of\u00a0 thrombosis)\u00a0 to\u00a0 allow\nhealing. Transfusion\u00a0therapy\u00a0with\u00a0red\u00a0cells\u00a0may\u00a0be\u00a0required\u00a0to\u00a0treat\u00a0symptomatic\nanaemia.322\nMajor\u00a0and\u00a0life\u00adthreatening\u00a0bleeding\u00a0should\u00a0be\u00a0treated\u00a0with\u00a0immediate\u00a0anticoagulant\nwithdrawal,\u00a0 aggressive\u00a0 cinical\u00a0 monitoring,\u00a0 transfusion\u00a0 of\u00a0 packed\u00a0 red\u00a0 cells\u00a0 for\nanaemia\u00a0and\u00a0aggressive\u00a0interventions\u00a0to\u00a0identify\u00a0and\u00a0treat\u00a0the\u00a0bleeding\u00a0source. Other\u00a0 blood\u00a0 products\u00a0 such\u00a0 as\u00a0 plasma\u00a0 or\u00a0 cryoprecipitate\u00a0 do\u00a0 not\u00a0 reverse\u00a0 the\nanticoagulant\u00a0 effect\u00a0 of\u00a0 NOACs. Interventional\u00a0 therapy\u00a0 may\u00a0 be\u00a0 life\u00a0 saving\u00a0 and\ncannot\u00a0wait\u00a0reversal\u00a0of\u00a0anticoagulant\u00a0effect\u037e\u00a0thus\u00a0interventionists\u00a0will\u00a0be\u00a0required\u00a0to\nprovide\u00a0therapeutic\u00a0inerventions\u00a0despite\u00a0the\u00a0associated\u00a0risk\u00a0of\u00a0bleeding.322\nReversal\u00a0of\u00a0low\u00a0molecular\u00a0weight\u00a0heparin\nMaximum\u00a0dose\u00a0of\u00a050\u00a0mg. Infusion\u00a0rate\u00a0of\u00a0a\u00a010\u00a0mg/mL\u00a0solution\u00a0should\u00a0not\nexceed\u00a05\u00a0mg/min. 1\u00a0mg\u00a0enoxaparin\u00a0equals\u00a0approximately\u00a0100\u00a0anti\u00adXa\u00a0units. Hypersensitivity\u00a0reactions\u00a0to\u00a0protamine\u00a0sulfate\u00a0may\u00a0occur\u00a0in\u00a0patients\u00a0with\nknown\u00a0 hypersensitivity\u00a0 reactions\u00a0 to\u00a0 fish\u00a0 or\u00a0 those\u00a0 previously\u00a0 exposed\u00a0 to\nprotamine. Within\u00a08\u00a0hours\n1.0\u00a0mg\nIf\u00a0bleeding\u00a0continues\n0.5\u00a0mg\n>8\u00a0hours\n0.5\u00a0mg\nTime\u00a0since\u00a0last\u00a0LMWH\u00a0dose\nProtamine\u00a0dose\u00a0/\u00a0100\u00a0anti\u00adXa\u00a0units\nLMWH\u00a0received\n7.7.1\u00a0Dabigatran\nIf\u00a0detected\u00a0soon\u00a0after\u00a0ingestion\u00a0the\u00a0absorption\u00a0of\u00a0dabigatran\u00a0may\u00a0be\u00a0reduced\u00a0by\u00a0the\nadministration\u00a0 of\u00a0 activated\u00a0 charcoal. There\u00a0 is\u00a0 currently\u00a0 no\u00a0 antidote\u00a0 for\u00a0 the\nanticoagulant\u00a0effect\u00a0of\u00a0dabigatran. Fresh\u00a0frozen\u00a0plasma,\u00a0PCC\u00a0or\u00a0rFVIIa\u00a0have\u00a0not\nbeen\u00a0demonstrated\u00a0to\u00a0reverse\u00a0bleeding\u00a0complications\u00a0due\u00a0to\u00a0dabigatran.320,321\nIn\u00a0 extreme\u00a0 cases,\u00a0 acute\u00a0 hemodialysis\u00a0 should\u00a0 be\u00a0 considered\u00a0 since\u00a0 only\u00a0 35%\u00a0 of\ndabigatran\u00a0is\u00a0bound\u00a0to\u00a0plasma\u00a0proteins. The\u00a0thrombin\u00a0time\u00a0can\u00a0be\u00a0used\u00a0as\u00a0a\u00a0guide\nto\u00a0further\u00a0dialysis.", "chunk_order": 46}
{"chunk_id": "4a77663b-b000-4f1f-88fa-19a77f7cbf20", "source_document_filename": "CPG Prevention and Treatment of Venous Thrombosis_cleaned_ultra_minimal.txt", "source_document_title": "CPG Prevention and Treatment of Venous Thrombosis cleaned ultra minimal", "text": "There\u00a0 is\u00a0 currently\u00a0 no\u00a0 antidote\u00a0 for\u00a0 the\nanticoagulant\u00a0effect\u00a0of\u00a0dabigatran. Fresh\u00a0frozen\u00a0plasma,\u00a0PCC\u00a0or\u00a0rFVIIa\u00a0have\u00a0not\nbeen\u00a0demonstrated\u00a0to\u00a0reverse\u00a0bleeding\u00a0complications\u00a0due\u00a0to\u00a0dabigatran.320,321\nIn\u00a0 extreme\u00a0 cases,\u00a0 acute\u00a0 hemodialysis\u00a0 should\u00a0 be\u00a0 considered\u00a0 since\u00a0 only\u00a0 35%\u00a0 of\ndabigatran\u00a0is\u00a0bound\u00a0to\u00a0plasma\u00a0proteins. The\u00a0thrombin\u00a0time\u00a0can\u00a0be\u00a0used\u00a0as\u00a0a\u00a0guide\nto\u00a0further\u00a0dialysis. 7.7.2\u00a0Rivaroxaban\nA\u00a0ceiling\u00a0effect\u00a0with\u00a0no\u00a0further\u00a0increase\u00a0in\u00a0average\u00a0plasma\u00a0exposure\u00a0is\u00a0expected\u00a0at\nsupra\u00adtherapeutic\u00a0doses\u00a0of\u00a050\u00a0mg\u00a0rivaroxaban\u00a0and\u00a0above. The\u00a0use\u00a0of\u00a0activated\ncharcoal\u00a0to\u00a0reduce\u00a0absorption\u00a0in\u00a0case\u00a0of\u00a0overdose\u00a0may\u00a0be\u00a0considered. Due\u00a0to\u00a0a\u00a0high\u00a0degree\u00a0of\u00a0albumin\u00a0binding\u00a0in\u00a0plasma\u00a0(92\u00a0to\u00a095%),\u00a0rivaroxaban\u00a0is\u00a0not\ndialysable. All\u00a0 its\u00a0 measurable\u00a0 anticoagulant\u00a0 effects\u00a0 are,\u00a0 however,\u00a0 reversed\u00a0 by\u00a0 a\nfour\u00adfactor\u00a0 PCC,\u00a0 as\u00a0 studied\u00a0 in\u00a0 healthy\u00a0 volunteers. Clinical\u00a0 data\u00a0 is\u00a0 lacking\u00a0 but\u00a0 it\nseems\u00a0 reasonable\u00a0 to\u00a0 give\u00a0 a\u00a0 dose\u00a0 of\u00a0 between\u00a0 30\u00a0 to\u00a0 50\u00a0 IU/kg\u00a0 in\u00a0 case\u00a0 of\u00a0 acute,\nlife\u00adthreatening\u00a0bleeding.320\n8.0\u00a0VENOUS\u00a0THROMBOEMBOLISM\u00a0IN\u00a0OBSTETRICS\n8.1\u00a0INTRODUCTION\nVenous\u00a0thromboembolism\u00a0complicates\u00a0between\u00a01\u00a0in\u00a0500\u00a0and\u00a01\u00a0in\u00a02000\u00a0pregnancies\nand\u00a0is\u00a0more\u00a0common\u00a0postpartum\u00a0than\u00a0antepartum.213,214,216,217\u00ad222\u00a0Obstetric\u00a0VTE\u00a0is\nnow\u00a0the\u00a0leading\u00a0cause\u00a0of\u00a0maternal\u00a0death\u00a0in\u00a0Malaysia.244\n8.2\u00a0\u00a0PATHOGENESIS\u00a0AND\u00a0RISK\u00a0FACTORS\nThe\u00a0increased\u00a0incidence\u00a0of\u00a0VTE\u00a0in\u00a0pregnancy\u00a0and\u00a0the\u00a0puerperium\u00a0may\u00a0be\u00a0related\nto\u00a0venous\u00a0stasis\u00a0(due\u00a0to\u00a0pregnancy\u00adassociated\u00a0changes\u00a0in\u00a0venous\u00a0capacitance\nand\u00a0compression\u00a0of\u00a0large\u00a0veins\u00a0by\u00a0the\u00a0gravid\u00a0uterus),\u00a0endothelial\u00a0injury\u00a0(due\u00a0to\nchanges\u00a0at\u00a0the\u00a0uteroplacental\u00a0surface\u00a0and\u00a0vascular\u00a0injury\u00a0during\u00a0delivery),\u00a0and\u00a0a\nhypercoagulable\u00a0 state\u00a0 (pregnancy\u00a0 is\u00a0 associated\u00a0 with\u00a0 progressive\u00a0 increases\u00a0 in\nseveral\u00a0coagulation\u00a0factors,\u00a0a\u00a0decrease\u00a0in\u00a0protein\u00a0S,\u00a0and\u00a0a\u00a0progressive\u00a0increase\nin\u00a0resistance\u00a0to\u00a0activated\u00a0protein\u00a0C).215,220,222\nThe\u00a0 risk\u00a0 of\u00a0 DVT\u00a0 is\u00a0 approximately\u00a0 twice\u00a0 as\u00a0 high\u00a0 after\u00a0 caesarean\u00a0 delivery\u00a0 than\nvaginal\u00a0birth. 221,222\u00a0In\u00a0addition,\u00a0DVT\u00a0is\u00a0far\u00a0more\u00a0common\u00a0in\u00a0the\u00a0left\u00a0than\u00a0the\u00a0right\nleg.223\u00a0This\u00a0striking\u00a0distribution\u00a0has\u00a0been\u00a0attributed\u00a0to\u00a0increased\u00a0venous\u00a0stasis\u00a0in\nthe\u00a0left\u00a0leg\u00a0related\u00a0to\u00a0compression\u00a0of\u00a0the\u00a0left\u00a0iliac\u00a0vein\u00a0by\u00a0the\u00a0right\u00a0iliac\u00a0artery,\ncoupled\u00a0 with\u00a0 compression\u00a0 of\u00a0 the\u00a0 inferior\u00a0 vena\u00a0 cava\u00a0 by\u00a0 the\u00a0 gravid\u00a0 uterus\nitself.223,225,226\n8.3\u00a0\u00a0DIAGNOSIS\nDiagnosis\u00a0of\u00a0VTE\u00a0during\u00a0pregnancy\u00a0can\u00a0be\u00a0complicated\u00a0by\u00a0physiological\u00a0changes\nassociated\u00a0 with\u00a0 pregnancy\u00a0 and\u00a0 by\u00a0 the\u00a0 reluctance\u00a0 of\u00a0 parents\u00a0 and\u00a0 clinicians\u00a0 to\nexpose\u00a0the\u00a0fetus\u00a0to\u00a0even\u00a0small\u00a0amounts\u00a0of\u00a0ionising\u00a0radiation. 8.3.1\u00a0Clinical\u00a0examination\nThe\u00a0 clinical\u00a0 diagnosis\u00a0 of\u00a0 both\u00a0 DVT\u00a0 and\u00a0 PE\u00a0 is\u00a0 notoriously\u00a0 insensitive\u00a0 and\nnonspecific.220\u00ad222\u00a0 This\u00a0 problem\u00a0 is\u00a0 heightened\u00a0 in\u00a0 pregnant\u00a0 women\u00a0 since\u00a0 lower\nextremity\u00a0 swelling\u00a0 and\u00a0 discomfort\u00a0 are\u00a0 common\u00a0 in\u00a0 advanced\u00a0 pregnancy,\u00a0 and\nwomen\u00a0 with\u00a0 DVT\u00a0 may\u00a0 present\u00a0 with\u00a0 diffuse\u00a0 pain\u00a0 in\u00a0 the\u00a0 lower\u00a0 abdomen\u00a0 or\nleg.218,220,224,225\u00a0Dyspnoea,\u00a0the\u00a0most\u00a0frequent\u00a0symptom\u00a0of\u00a0PE,\u00a0occurs\u00a0at\u00a0some\u00a0point\nin\u00a0up\u00a0to\u00a070\u00a0percent\u00a0of\u00a0normal\u00a0pregnancies,\u00a0often\u00a0stabilising\u00a0near\u00a0term.228,230\u00a0Iliac\nvein\u00a0 thrombosis\u00a0 is\u00a0 suspected\u00a0 when\u00a0 there\u00a0 is\u00a0 swelling\u00a0 of\u00a0 the\u00a0 entire\u00a0 limb\u00a0 and\nassociated\u00a0with\u00a0back\u00adpain.226\n8.3.2\u00a0Laboratory\u00a0studies\nArterial\u00a0blood\u00a0gases\u00a0are\u00a0neither\u00a0sensitive\u00a0nor\u00a0specific\u00a0for\u00a0the\u00a0diagnosis\u00a0of\u00a0PE,\u00a0and\nrespiratory\u00a0alkalosis\u00a0is\u00a0a\u00a0very\u00a0common\u00a0feature\u00a0of\u00a0both\u00a0pregnancy\u00a0and\u00a0PE.", "chunk_order": 47}
{"chunk_id": "c053a7b0-f15a-4ca5-9282-a92e5d4a858b", "source_document_filename": "CPG Prevention and Treatment of Venous Thrombosis_cleaned_ultra_minimal.txt", "source_document_title": "CPG Prevention and Treatment of Venous Thrombosis cleaned ultra minimal", "text": "As\u00a0in\nthe\u00a0non\u00adpregnant\u00a0population,\u00a0a\u00a0normal\u00a0PO2,\u00a0PCO2,\u00a0or\u00a0alveolar\u00adarterial\u00a0difference\nis\u00a0 common\u00a0 with\u00a0 PE.234\u00a0 Elevations\u00a0 in\u00a0 D\u00addimer\u00a0 are\u00a0 found\u00a0 in\u00a0 uncomplicated\npregnancy,\u00a0increasing\u00a0with\u00a0gestational\u00a0age\u00a0and\u00a0peaking\u00a0at\u00a0the\u00a0time\u00a0of\u00a0delivery\u00a0and\nin\u00a0 the\u00a0 early\u00a0 postpartum\u00a0 period\u00a0 making\u00a0 the\u00a0 utility\u00a0 of\u00a0 this\u00a0 test\u00a0 in\u00a0 pregnancy\nlimited.232,235\n8.3.3\u00a0Radiologic\u00a0evaluation\nThere\u00a0are\u00a0no\u00a0systematic\u00a0differences\u00a0in\u00a0the\u00a0diagnostic\u00a0strategies\u00a0for\u00a0deep\u00a0venous\nthrombosis\u00a0 and\u00a0 pulmonary\u00a0 embolism\u00a0 in\u00a0 the\u00a0 pregnant\u00a0 and\u00a0 the\u00a0 non\u00adpregnant\npatient.238\n8.3.3.1\u00a0Deep\u00a0vein\u00a0thrombosis\nThe\u00a0accuracy\u00a0of\u00a0non\u00adinvasive\u00a0tests\u00a0for\u00a0DVT\u00a0of\u00a0the\u00a0lower\u00a0extremities\u00a0in\u00a0the\u00a0general\npopulation\u00a0 approaches\u00a0 that\u00a0 of\u00a0 venography,\u00a0 with\u00a0 the\u00a0 caveat\u00a0 that\u00a0 they\u00a0 are\u00a0 less\nsensitive\u00a0 for\u00a0 calf\u00a0 vein\u00a0 thrombosis\u00a0 (which\u00a0 is\u00a0 less\u00a0 common\u00a0 in\u00a0 the\u00a0 pregnant\npopulation)\u00a0 and\u00a0 pelvic\u00a0 vein\u00a0 thrombosis. Large,\u00a0 direct\u00a0 prospective\u00a0 comparisons\nbetween\u00a0individual\u00a0diagnostic\u00a0modalities\u00a0have\u00a0not\u00a0been\u00a0performed\u00a0specifically\u00a0in\npregnant\u00a0patients.226,229\n8.3.3.1.1\u00a0Compression\u00a0duplex\u00a0Doppler\u00a0ultrasound\nCompression\u00a0duplex\u00a0Doppler\u00a0ultrasound\u00a0is\u00a0the\u00a0most\u00a0commonly\u00a0employed\u00a0study\u00a0in\nthis\u00a0setting\u037e\u00a0lack\u00a0of\u00a0compressibility\u00a0of\u00a0a\u00a0femoral\u00a0vein\u00a0with\u00a0the\u00a0ultrasound\u00a0probe\u00a0is\nhighly\u00a0sensitive\u00a0and\u00a0specific\u00a0for\u00a0symptomatic\u00a0proximal\u00a0vein\u00a0thrombosis.232,233,236\nThe\u00a0addition\u00a0of\u00a0Doppler\u00a0analysis\u00a0of\u00a0flow\u00a0variation\u00a0with\u00a0respiration\u00a0in\u00a0the\u00a0left\u00a0lateral\ndecubitus\u00a0position\u00a0assists\u00a0in\u00a0diagnosing\u00a0isolated\u00a0iliac\u00a0vein\u00a0thrombosis.231\n8.3.3.1.2\u00a0Magnetic\u00a0resonance\u00a0venography\nMagnetic\u00a0resonance\u00a0venographyis\u00a0a\u00a0modality\u00a0that\u00a0may\u00a0find\u00a0increasing\u00a0use\u00a0in\u00a0the\npregnant\u00a0 population. It\u00a0 can\u00a0 detect\u00a0 both\u00a0 femoral\u00a0 and\u00a0 pelvic\u00a0 vein\u00a0 DVT\u00a0 with\u00a0 a\nsensitivity\u00a0that\u00a0approaches\u00a0100\u00a0percent\u00a0in\u00a0the\u00a0non\u00adpregnant\u00a0population. Although\nno\u00a0 comparison\u00a0 studies\u00a0 have\u00a0 been\u00a0 performed\u00a0 in\u00a0 pregnancy,\u00a0 one\u00a0 case\u00a0 series\ndocumented\u00a0the\u00a0usefulness\u00a0of\u00a0MRI,\u00a0permitting\u00a0diagnosis\u00a0of\u00a0pelvic\u00a0vein\u00a0thrombosis\nor\u00a0the\u00a0presence\u00a0of\u00a0a\u00a0patent\u00a0but\u00a0extrinsically\u00a0compressed\u00a0inferior\u00a0vena\u00a0cava\u00a0in\nsituations\u00a0where\u00a0non\u00adinvasive\u00a0examinations\u00a0were\u00a0equivocal.237\n8.3.3.1.3\u00a0Ascending\u00a0contrast\u00a0venography\nAscending\u00a0 contrast\u00a0 venography\u00a0 is\u00a0 rarely\u00a0 performed\u00a0 because\u00a0 the\u00a0 test\u00a0 requires\nionising\u00a0 radiation\u00a0 and\u00a0 percutaneous\u00a0 cannulation\u00a0 of\u00a0 lower\u00a0 extremity\u00a0 veins. Although\u00a0 the\u00a0 delivered\u00a0 radiation\u00a0 to\u00a0 the\u00a0 fetus\u00a0 is\u00a0 small\u00a0 (<500\u00a0 mcGy)\u00a0 when\nvenography\u00a0is\u00a0performed\u00a0with\u00a0abdominal\u00adpelvic\u00a0shielding,\u00a0shielding\u00a0renders\u00a0the\ntest\u00a0relatively\u00a0insensitive\u00a0to\u00a0isolated\u00a0ilio\u00adfemoral\u00a0thrombosis.213,226,231,245\n8.3.3.2\u00a0Pulmonary\u00a0embolism\nA\u00a0 patient\u00a0 who\u00a0 presents\u00a0 with\u00a0 respiratory\u00a0 but\u00a0 no\u00a0 lower\u00a0 extremity\u00a0 symptoms,\u00a0 first\nundergoes\u00a0a\u00a0chest\u00a0X\u00adray. If\u00a0this\u00a0is\u00a0normal,\u00a0a\u00a0bilateral\u00a0CUS\u00a0is\u00a0performed. If\u00a0both\u00a0these\ntests\u00a0are\u00a0negative\u00a0with\u00a0persistent\u00a0clinical\u00a0suspicion\u00a0of\u00a0PE,\u00a0a\u00a0ventilation\u00adperfusion\nscan\u00a0(V/Q\u00a0scan)\u00a0or\u00a0computed\u00a0tomography\u00a0pulmonary\u00a0angiogram\u00a0(CTPA)\u00a0should\u00a0be\nperformed.227,238,239\nIf\u00a0the\u00a0clinical\u00a0suspicion\u00a0of\u00a0PE\u00a0is\u00a0high\u00a0at\u00a0presentation\u00a0a\u00a0CTPA\u00a0or\u00a0V/Q\u00a0scan\u00a0should\nbe\u00a0performed\u00a0from\u00a0the\u00a0outset.249\n8.3.3.2.1\u00a0Chest\u00a0X\u00adray\nChest\u00a0 X\u00adray\u00a0 may\u00a0 identify\u00a0 other\u00a0 pulmonary\u00a0 disease\u00a0 such\u00a0 as\u00a0 pneumonia,\npneumothorax\u00a0or\u00a0lobar\u00a0collapse. Whilst\u00a0the\u00a0X\u00adray\u00a0is\u00a0normal\u00a0in\u00a050%\u00a0of\u00a0pregnant\nwomen\u00a0 with\u00a0 objectively\u00a0 proven\u00a0 PE,\u00a0 abnormal\u00a0 features\u00a0 caused\u00a0 by\u00a0 PE\u00a0 include\natelectasis,\u00a0effusion,\u00a0focal\u00a0opacities,\u00a0regional\u00a0oligaemia\u00a0or\u00a0pulmonary\u00a0oedema.243\n8.3.3.2.2\u00a0CT\u00a0pulmonary\u00a0angiography\nCT\u00a0pulmonary\u00a0angiography\u00a0is\u00a0the\u00a0study\u00a0of\u00a0choice\u00a0for\u00a0the\u00a0diagnosis\u00a0of\u00a0pulmonary\nembolism\u00a0in\u00a0the\u00a0non\u00adpregnant\u00a0population.", "chunk_order": 48}
{"chunk_id": "abb50023-2be4-448b-ac02-b4a2faf7f308", "source_document_filename": "CPG Prevention and Treatment of Venous Thrombosis_cleaned_ultra_minimal.txt", "source_document_title": "CPG Prevention and Treatment of Venous Thrombosis cleaned ultra minimal", "text": "Whilst\u00a0the\u00a0X\u00adray\u00a0is\u00a0normal\u00a0in\u00a050%\u00a0of\u00a0pregnant\nwomen\u00a0 with\u00a0 objectively\u00a0 proven\u00a0 PE,\u00a0 abnormal\u00a0 features\u00a0 caused\u00a0 by\u00a0 PE\u00a0 include\natelectasis,\u00a0effusion,\u00a0focal\u00a0opacities,\u00a0regional\u00a0oligaemia\u00a0or\u00a0pulmonary\u00a0oedema.243\n8.3.3.2.2\u00a0CT\u00a0pulmonary\u00a0angiography\nCT\u00a0pulmonary\u00a0angiography\u00a0is\u00a0the\u00a0study\u00a0of\u00a0choice\u00a0for\u00a0the\u00a0diagnosis\u00a0of\u00a0pulmonary\nembolism\u00a0in\u00a0the\u00a0non\u00adpregnant\u00a0population. This\u00a0technique\u00a0has\u00a0better\u00a0sensitivity\u00a0and\nspecificity\u00a0 with\u00a0 a\u00a0 lower\u00a0 radiation\u00a0 dose\u00a0 to\u00a0 the\u00a0 fetus\u00a0 when\u00a0 compared\u00a0 with\u00a0 a\u00a0 V/Q\nscan.240,241\u00a0The\u00a0 main\u00a0 disadvantage\u00a0 is\u00a0 the\u00a0 higher\u00a0 radiation\u00a0 dose\u00a0 to\u00a0 the\u00a0 maternal\nbreasts.242,245\n8.3.3.2.3\u00a0Ventilation/\u00a0Perfusion\u00a0(V/Q)\u00a0scan\nA\u00a0ventilation/\u00a0perfusion\u00a0scan\u00a0is\u00a0limited\u00a0to\u00a0very\u00a0few\u00a0centres\u00a0and\u00a0testing\u00a0depends\u00a0on\nthe\u00a0availability\u00a0of\u00a0isotope. It\u00a0carries\u00a0a\u00a0slightly\u00a0increased\u00a0risk\u00a0of\u00a0childhood\u00a0cancer\ncompared\u00a0with\u00a0CTPA\u00a0(1/280,000\u00a0versus\u00a0<1/1,000,000)\u00a0but\u00a0carries\u00a0a\u00a0lower\u00a0risk\u00a0of\nmaternal\u00a0breast\u00a0cancer.242,245\n8.4\u00a0ALGORITHM\u00a0FOR\u00a0DIAGNOSIS\u00a0OF\u00a0VTE\u00a0IN\u00a0PREGNANCY\n8.4.1\u00a0 Deep\u00a0vein\u00a0thrombosis\nCompression\u00a0 duplex\u00a0 ultrasound\u00a0 should\u00a0 be\u00a0 undertaken\u00a0 when\u00a0 there\u00a0 is\u00a0 a\u00a0 clinical\nsuspicion\u00a0 of\u00a0 DVT. If\u00a0 this\u00a0 is\u00a0 negative\u00a0 but\u00a0 a\u00a0 high\u00a0 level\u00a0 of\u00a0 clinical\u00a0 suspicion\u00a0 exists,\nanticoagulation\u00a0is\u00a0continued\u00a0and\u00a0CUS\u00a0is\u00a0repeated\u00a0in\u00a01\u00a0week. If\u00a0iliac\u00a0vein\u00a0thrombosis\nis\u00a0suspected\u00a0(back\u00adpain\u00a0and\u00a0swelling\u00a0entire\u00a0limb),\u00a0a\u00a0magnetic\u00a0resonance\u00a0venography\n(MRV)\u00a0or\u00a0contrast\u00a0venography\u00a0should\u00a0be\u00a0considered.245\nDIAGNOSTIC\u00a0ALGORITHM\u00a0FOR\u00a0SUSPECTED\u00a0DVT\u00a0IN\u00a0PREGNANCY\nClinical\u00a0suspicion\u00a0of\u00a0DVT\u00a0in\u00a0pregnancy\nIs\u00a0DVT\u00a0still\u00a0likely\u00a0or\u00a0iliac\u00a0vein\nthrombosis\u00a0suspected? Positive\nNegative\nCUS\nYes\nNo\nPositive\nNegative\nExclude\u00a0DVT\nRepeat\u00a0CUS\u00a0in\n1\u00a0week\u00a0or\u00a0perform\u00a0MRV\nDiagnose\u00a0DVT\nand\u00a0Treat\n8.4.2\u00a0Pulmonary\u00a0embolism\nIf\u00a0the\u00a0clinical\u00a0suspicion\u00a0of\u00a0PE\u00a0is\u00a0high,\u00a0a\u00a0V/Q\u00a0scan\u00a0or\u00a0CTPA\u00a0should\u00a0be\u00a0performed. Where\u00a0feasible,\u00a0women\u00a0should\u00a0be\u00a0involved\u00a0in\u00a0the\u00a0decision\u00a0to\u00a0undergo\u00a0CTPA\u00a0or\nV/Q\u00a0scanning. Ideally\u00a0informed\u00a0consent\u00a0should\u00a0be\u00a0obtained\u00a0before\u00a0the\u00a0tests\u00a0are\nundertaken.245\nCUS\nDIAGNOSTIC\u00a0ALGORITHM\u00a0FOR\u00a0SUSPECTED\u00a0PE\u00a0IN\u00a0PREGNANCY\nClinical\u00a0suspicion\u00a0of\nPE\u00a0in\u00a0Pregnancy\nNegative\nPositive\nNegative\nExclude\u00a0PE\nPositive\nDiagnose\u00a0PE\nand\u00a0Treat\nCTPA\u00a0or\nV/Q\u00a0scan\nMassive\u00a0life\u00adthreatening\u00a0PE\u00a0should\u00a0be\u00a0treated\u00a0with\u00a0initial\u00a0intravenous\u00a0heparin\u00a0followed\nby\u00a0immediate\u00a0thrombolysis\u00a0with\u00a0thrombolytic\u00a0therapy\u00a0or\u00a0surgical\u00a0embolectomy\u00a0(see\nsection\u00a04.4).230,246\n8.5.3\u00a0Monitoring\u00a0LMWH\nRoutine\u00a0measurement\u00a0of\u00a0peak\u00a0anti\u00adXa\u00a0is\u00a0not\u00a0recommended\u00a0for\u00a0patients\u00a0on\u00a0LMWH\nfor\u00a0the\u00a0treatment\u00a0of\u00a0VTE\u00a0in\u00a0pregnancy\u00a0except\u00a0in\u00a0women\u00a0of\u00a0extremes\u00a0body\u00a0weight\u00a0or\nwith\u00a0other\u00a0complicating\u00a0factors\u00a0(renal\u00a0impairment\u00a0or\u00a0recurrent\u00a0VTE)\u00a0putting\u00a0them\u00a0at\nhigh\u00a0risk.245\n8.5.4\u00a0Maintenance\u00a0treatment\u00a0of\u00a0VTE\nTreatment\u00a0 with\u00a0 LMWH\u00a0 should\u00a0 be\u00a0 continued\u00a0 throughout\u00a0 pregnancy. Warfarin\u00a0 is\ncontraindicated\u00a0during\u00a0pregnancy.247\n8.5.5\u00a0Anticoagulant\u00a0therapy\u00a0during\u00a0labour\u00a0and\u00a0delivery\nWomen\u00a0taking\u00a0LMWH\u00a0for\u00a0maintenance\u00a0therapy\u00a0should\u00a0be\u00a0advised\u00a0that\u00a0once\u00a0she\u00a0is\nin\u00a0 labour,\u00a0 she\u00a0 should\u00a0 not\u00a0 inject\u00a0 any\u00a0 further\u00a0 heparin. Where\u00a0 delivery\u00a0 is\u00a0 planned,\nLMWH\u00a0therapy\u00a0should\u00a0be\u00a0discontinued\u00a024\u00a0hours\u00a0before\u00a0planned\u00a0delivery.245,247\n8.5\u00a0TREATMENT\u00a0OF\u00a0VTE\u00a0IN\u00a0PREGNANCY\n8.5.1\u00a0Initial\u00a0treatment\u00a0of\u00a0VTE\nIn\u00a0clinically\u00a0suspected\u00a0DVT\u00a0or\u00a0PE,\u00a0treatment\u00a0with\u00a0LMWH\u00a0should\u00a0be\u00a0given\u00a0until\u00a0the\ndiagnosis\u00a0is\u00a0excluded\u00a0by\u00a0objective\u00a0testing,\u00a0unless\u00a0treatment\u00a0is\u00a0strongly\u00a0contraindicated.", "chunk_order": 49}
{"chunk_id": "da6a8afa-25b6-4414-9946-9bfc5c1cddab", "source_document_filename": "CPG Prevention and Treatment of Venous Thrombosis_cleaned_ultra_minimal.txt", "source_document_title": "CPG Prevention and Treatment of Venous Thrombosis cleaned ultra minimal", "text": "Warfarin\u00a0 is\ncontraindicated\u00a0during\u00a0pregnancy.247\n8.5.5\u00a0Anticoagulant\u00a0therapy\u00a0during\u00a0labour\u00a0and\u00a0delivery\nWomen\u00a0taking\u00a0LMWH\u00a0for\u00a0maintenance\u00a0therapy\u00a0should\u00a0be\u00a0advised\u00a0that\u00a0once\u00a0she\u00a0is\nin\u00a0 labour,\u00a0 she\u00a0 should\u00a0 not\u00a0 inject\u00a0 any\u00a0 further\u00a0 heparin. Where\u00a0 delivery\u00a0 is\u00a0 planned,\nLMWH\u00a0therapy\u00a0should\u00a0be\u00a0discontinued\u00a024\u00a0hours\u00a0before\u00a0planned\u00a0delivery.245,247\n8.5\u00a0TREATMENT\u00a0OF\u00a0VTE\u00a0IN\u00a0PREGNANCY\n8.5.1\u00a0Initial\u00a0treatment\u00a0of\u00a0VTE\nIn\u00a0clinically\u00a0suspected\u00a0DVT\u00a0or\u00a0PE,\u00a0treatment\u00a0with\u00a0LMWH\u00a0should\u00a0be\u00a0given\u00a0until\u00a0the\ndiagnosis\u00a0is\u00a0excluded\u00a0by\u00a0objective\u00a0testing,\u00a0unless\u00a0treatment\u00a0is\u00a0strongly\u00a0contraindicated. Randomised\u00a0control\u00a0trials\u00a0indicate\u00a0that\u00a0LMWHs\u00a0are\u00a0more\u00a0effective,\u00a0are\u00a0associated\u00a0with\na\u00a0lower\u00a0risk\u00a0of\u00a0haemorrhagic\u00a0complications\u00a0and\u00a0are\u00a0associated\u00a0with\u00a0lower\u00a0mortality\nthan\u00a0UFH\u00a0in\u00a0the\u00a0treatment\u00a0of\u00a0VTE.245\nTreatment\u00a0with\u00a0fondaparinux\u00a0is\u00a0not\u00a0recommended\u00a0in\u00a0pregnancy\u00a0as\u00a0it\u00a0can\u00a0cross\u00a0the\nplacenta. It\u00a0is\u00a0licensed\u00a0outside\u00a0pregnancy,\u00a0with\u00a0very\u00a0limited\u00a0experience\u00a0in\u00a0pregnancy. No\u00a0adverse\u00a0effects\u00a0have\u00a0been\u00a0observed\u00a0but\u00a0there\u00a0is\u00a0insufficient\u00a0evidence\u00a0to\u00a0conclude\nsafety\u00a0during\u00a0pregnancy. It\u00a0is\u00a0reserved\u00a0for\u00a0women\u00a0intolerant\u00a0to\u00a0heparin.250\n8.5.2\u00a0Dosing\u00a0of\u00a0LMWH\nLMWH\u00a0should\u00a0be\u00a0given\u00a0daily\u00a0with\u00a0dosage\u00a0titrated\u00a0against\u00a0the\u00a0woman\u2019s\u00a0booking\u00a0or\u00a0most\nrecent\u00a0weight\u00a0(Table\u00a08.5.2)\nPregnancy\u00a0weight\u00a0(kg)\nInitial\u00a0dose\n175\u00a0units/kg\u00a0once\u00a0daily\nVolume\u00a0of\u00a0tinzaparin\u00a0in\u00a0mL\u00a0required\u00a0=\u00a0(weight\u00a0in\u00a0Kg\u00a0\u00ad\u00a010)\u00a0\u00f7\u00a0100\nTinzaparin\n(20,000\u00a0IU/mL)\n<50\n50\u00a0\u00ad\u00a069\n70\u00a0\u00ad\u00a089\n>90\n40\u00a0mg\u00a0BD\nEnoxaparin\n60\u00a0mg\u00a0BD\n80\u00a0mg\u00a0BD\n100\u00a0mg\u00a0BD\nTable\u00a08.5.2:\u00a0Dosing\u00a0of\u00a0LMWH\u00a0in\u00a0pregnancy\n8.5.6\u00a0Regional\u00a0anaesthesia\u00a0during\u00a0labour\u00a0and\u00a0delivery\nRegional\u00a0anaesthesia\u00a0should\u00a0not\u00a0be\u00a0undertaken\u00a0until\u00a0at\u00a0least\u00a024\u00a0hours\u00a0after\u00a0the\nlast\u00a0dose\u00a0of\u00a0therapeutic\u00a0LMWH. A\u00a0thromboprophylactic\u00a0dose\u00a0of\u00a0LMWH\u00a0should\u00a0be\ngiven\u00a0by\u00a03\u00a0hours\u00a0after\u00a0a\u00a0caesarean\u00a0section\u00a0(more\u00a0than\u00a04\u00a0hours\u00a0after\u00a0removal\u00a0of\nthe\u00a0epidural\u00a0catheter). The\u00a0epidural\u00a0catheter\u00a0should\u00a0not\u00a0be\u00a0removed\u00a0within\u00a012\nhours\u00a0of\u00a0the\u00a0most\u00a0recent\u00a0injection.245,247\n8.5.7\u00a0Post\u00adnatal\u00a0anticoagulation\nTherapeutic\u00a0anticoagulation\u00a0therapy\u00a0should\u00a0be\u00a0continued\u00a0for\u00a0the\u00a0duration\u00a0of\u00a0the\npregnancy\u00a0and\u00a0for\u00a0at\u00a0least\u00a06\u00a0weeks\u00a0post\u00adnatally\u00a0and\u00a0until\u00a0at\u00a0least\u00a03\u00a0months\u00a0of\ntreatment\u00a0 has\u00a0 been\u00a0 given\u00a0 in\u00a0 total. Women\u00a0 should\u00a0 be\u00a0 offered\u00a0 the\u00a0 choice\u00a0 of\nLMWH\u00a0or\u00a0warfarin\u00a0post\u00adnatally\u00a0after\u00a0discussion\u00a0about\u00a0the\u00a0need\u00a0for\u00a0regular\u00a0blood\ntests\u00a0for\u00a0INR\u00a0monitoring\u00a0with\u00a0warfarin. Both\u00a0LMWH\u00a0and\u00a0warfarin\u00a0are\u00a0safe\u00a0for\nbreastfeeding.245\n8.5.8\u00a0Prevention\u00a0of\u00a0post\u00adthrombotic\u00a0syndrome\nGraduated\u00a0elastic\u00a0compression\u00a0stockings\u00a0should\u00a0be\u00a0worn\u00a0on\u00a0the\u00a0affected\u00a0leg\u00a0for\nat\u00a0least\u00a02\u00a0years\u00a0after\u00a0the\u00a0acute\u00a0event\u00a0to\u00a0reduce\u00a0the\u00a0risk\u00a0of\u00a0PTS.245,248\n8.6\u00a0PREVENTION\u00a0OF\u00a0VTE\u00a0IN\u00a0PREGNANCY\nAll\u00a0women\u00a0should\u00a0undergo\u00a0a\u00a0documented\u00a0assessment\u00a0of\u00a0risk\u00a0factors\u00a0for\u00a0VTE\u00a0in\nearly\u00a0 pregnancy\u00a0 or\u00a0 before\u00a0 pregnancy\u00a0 and\u00a0 following\u00a0 delivery. This\u00a0 assessment\nshould\u00a0be\u00a0repeated\u00a0if\u00a0the\u00a0woman\u00a0is\u00a0admitted\u00a0to\u00a0the\u00a0hospital\u00a0for\u00a0any\u00a0reason\u00a0or\ndevelops\u00a0other\u00a0intercurrent\u00a0problems\u00a0during\u00a0the\u00a0antenatal\u00a0and\u00a0postpartum\u00a0period.", "chunk_order": 50}
{"chunk_id": "41de9c54-1727-436e-be2b-1fdf20b1a378", "source_document_filename": "CPG Prevention and Treatment of Venous Thrombosis_cleaned_ultra_minimal.txt", "source_document_title": "CPG Prevention and Treatment of Venous Thrombosis cleaned ultra minimal", "text": "Both\u00a0LMWH\u00a0and\u00a0warfarin\u00a0are\u00a0safe\u00a0for\nbreastfeeding.245\n8.5.8\u00a0Prevention\u00a0of\u00a0post\u00adthrombotic\u00a0syndrome\nGraduated\u00a0elastic\u00a0compression\u00a0stockings\u00a0should\u00a0be\u00a0worn\u00a0on\u00a0the\u00a0affected\u00a0leg\u00a0for\nat\u00a0least\u00a02\u00a0years\u00a0after\u00a0the\u00a0acute\u00a0event\u00a0to\u00a0reduce\u00a0the\u00a0risk\u00a0of\u00a0PTS.245,248\n8.6\u00a0PREVENTION\u00a0OF\u00a0VTE\u00a0IN\u00a0PREGNANCY\nAll\u00a0women\u00a0should\u00a0undergo\u00a0a\u00a0documented\u00a0assessment\u00a0of\u00a0risk\u00a0factors\u00a0for\u00a0VTE\u00a0in\nearly\u00a0 pregnancy\u00a0 or\u00a0 before\u00a0 pregnancy\u00a0 and\u00a0 following\u00a0 delivery. This\u00a0 assessment\nshould\u00a0be\u00a0repeated\u00a0if\u00a0the\u00a0woman\u00a0is\u00a0admitted\u00a0to\u00a0the\u00a0hospital\u00a0for\u00a0any\u00a0reason\u00a0or\ndevelops\u00a0other\u00a0intercurrent\u00a0problems\u00a0during\u00a0the\u00a0antenatal\u00a0and\u00a0postpartum\u00a0period. 8.6.1\u00a0Antenatal\u00a0Risk\u00a0Assessment\nWomen\u00a0should\u00a0be\u00a0assessed\u00a0at\u00a0booking\u00a0and\u00a0stratified\u00a0into\u00a0risk\u00a0groups\u00a0according\u00a0to\nrisk\u00a0factors\u00a0and\u00a0offered\u00a0thromboprophylaxis\u00a0with\u00a0LMWH\u00a0where\u00a0appropriate\u00a0(Table\n8.6.1).249\nANTENATAL\u00a0RISK\u00a0ASSESSMENT\nv\u00a0 To\u00a0be\u00a0assessed\u00a0at\u00a0booking\u00a0and\u00a0with\u00a0every\u00a0admission\u00a0into\u00a0hospital\nv\u00a0 Can\u00a0be\u00a0divided\u00a0into\u00a03\u00a0risk\u00a0groups\nv\u00a0 Management\u00a0will\u00a0depend\u00a0on\u00a0the\u00a0risk\u00a0group\nThese\u00a0risk\u00a0groups\u00a0do\u00a0not\u00a0include\u00a0those\u00a0who\u00a0are\u00a0sufficiently\u00a0high\u00a0risk\u00a0(very\nhigh\u00a0risk)\u00a0to\u00a0require\u00a0anticoagulation\u00a0when\u00a0not\u00a0pregnant\u00a0(on\u00a0long\u00adterm\nwarfarin):\nt\u00a0Previous\u00a0VTE\u00a0on\u00a0warfarin\nt\u00a0APLS\u00a0with\u00a0previous\u00a0VTE\nThis\u00a0group\u00a0requires\u00a0therapeutic\u00a0dose\u00a0of\u00a0LMWH\u00a0antenatally\nTable\u00a08.6.1:\u00a0Risk\u00a0groups\u00a0and\u00a0indications\u00a0for\u00a0antenatal\nthromboprophylaxis\u00a0(Grade\u00a0C\u00a0Recommendation)\nRisk\u00a0factors\nManagement\n1. High\u00a0risk\nRecommendations\nAny\u00a0one\n#\"#Single\u00a0previous\u00a0VTE\u00a0with\u00a0! t\u00a0Family\u00a0history\u00a0or\nt Unprovoked\u00a0/\u00a0estrogen\u00adrelated\n#\"#Previous\u00a0recurrent\u00a0VTE\u00a0>1\u00a0! Requires\u00a0antenatal\u00a0prophylaxis\u00a0with\nLMWH\n#\"#Enoxaparin\u00a01\u00a0mg/kg\u00a0daily\u00a0! or\n\"#Tinzaparin\u00a04500\u00a0units\u00a0daily\u00a0! (if\u00a0BW\u00a0>90kg,\u00a0to\u00a0dose\u00a0at\n75\u00a0units/kg\u00a0daily)\nB. Patient\u00a0risk\u00a0factors\u00a0(see\u00a0below)\n#\"#S9*\"&'\u00a0! or\uf020\n#\"#&O\"T1#\")(=1CC0(\"19C$\"E$+;1C)<U\"! Any\u00a0one\u00a0(if\u00a0admitted\u00a0into\u00a0hospital):\n#\"#Single\u00a0previous\u00a0VTE\u00a0with\u00a0no\nfamily\u00a0history\u00a0! #\"#Medical\u00a0comorbidities\u00a0e.g. \u0001\n\u0001\u0001\nt\u00a0Heart/lung\u00a0diseaser\u00a0! \u0001\n\u0001\u0001\nt\u00a0SLE\u00a0! t\u00a0Cancer\u00a0! t\u00a0Inflammatory\u00a0conditions\u00a0! t\u00a0Nephrotic\u00a0syndrome\u00a0! t\u00a0Sickle\u00a0cell\u00a0disease\u00a0! t\u00a0Thalassaemia\u00a0! t\u00a0IVDU\u00a0! #\"#Surgical\u00a0procedures\u00a0e.g. \u0001\n\u0001\u0001\nt\u00a0Appendicectomy\u00a0! Consider\u00a0antenatal\u00a0prophylaxis\u00a0with\nLMWH\n#\"#Enoxaparin\u00a01\u00a0mg/kg\u00a0daily\u00a0! or\n\"#Tinzaparin\u00a04500\u00a0units\u00a0daily\u00a0! (if\u00a0BW\u00a0>90kg,\u00a0to\u00a0dose\u00a0at\n75\u00a0units/kg\u00a0daily)\nA. Risk\u00a0factors\nManagement\n2. Intermediate\u00a0risk\nRecommendations\nAny\u00a02\u00a0or\u00a0less\u00a0(not\u00a0admitted\u00a0into\nhospital):\n#\"#Age\u00a0>35\u00a0years\u00a0! #\"#Obesity\u00a0BMI\u00a0>30\u00a0! #\"\".)%1C*\"&'\"! #\"\u00a0Smoker\u00a0! #\"\u00a0Gross\u00a0varicose\u00a0veins\u00a0! #\"\u00a0Current\u00a0systemic\u00a0infection\u00a0! #\"\u00a0Immobility\u00a0e.g. paraplegia,\nlong\u00adhaul\u00a0travel\u00a0>4\u00a0hours\u00a0! #\"\u00a0Pre\u00adeclampsia\u00a0! #\"\u00a0Dehydration/\u00a0hyperemesis/\nOHSS\u00a0! #\"\u00a0Multiple\u00a0pregnancy\u00a0! #\"\u00a0Assisted\u00a0reproductive\ntreatment\u00a0! Mobilisation\nAvoid\u00a0dehydration\nPatient\u00a0risk\u00a0factors\nManagement\n3.", "chunk_order": 51}
{"chunk_id": "d8ec2e24-d9a4-496d-a1b3-fe8fc0c03871", "source_document_filename": "CPG Prevention and Treatment of Venous Thrombosis_cleaned_ultra_minimal.txt", "source_document_title": "CPG Prevention and Treatment of Venous Thrombosis cleaned ultra minimal", "text": "Consider\u00a0antenatal\u00a0prophylaxis\u00a0with\nLMWH\n#\"#Enoxaparin\u00a01\u00a0mg/kg\u00a0daily\u00a0! or\n\"#Tinzaparin\u00a04500\u00a0units\u00a0daily\u00a0! (if\u00a0BW\u00a0>90kg,\u00a0to\u00a0dose\u00a0at\n75\u00a0units/kg\u00a0daily)\nA. Risk\u00a0factors\nManagement\n2. Intermediate\u00a0risk\nRecommendations\nAny\u00a02\u00a0or\u00a0less\u00a0(not\u00a0admitted\u00a0into\nhospital):\n#\"#Age\u00a0>35\u00a0years\u00a0! #\"#Obesity\u00a0BMI\u00a0>30\u00a0! #\"\".)%1C*\"&'\"! #\"\u00a0Smoker\u00a0! #\"\u00a0Gross\u00a0varicose\u00a0veins\u00a0! #\"\u00a0Current\u00a0systemic\u00a0infection\u00a0! #\"\u00a0Immobility\u00a0e.g. paraplegia,\nlong\u00adhaul\u00a0travel\u00a0>4\u00a0hours\u00a0! #\"\u00a0Pre\u00adeclampsia\u00a0! #\"\u00a0Dehydration/\u00a0hyperemesis/\nOHSS\u00a0! #\"\u00a0Multiple\u00a0pregnancy\u00a0! #\"\u00a0Assisted\u00a0reproductive\ntreatment\u00a0! Mobilisation\nAvoid\u00a0dehydration\nPatient\u00a0risk\u00a0factors\nManagement\n3. Low\u00a0risk\nRecommendations\n8.6.2\u00a0Postnatal\u00a0risk\u00a0assessment\nAll\u00a0 women\u00a0 should\u00a0 be\u00a0 assessed\u00a0 after\u00a0 delivery\u00a0 and\u00a0 stratified\u00a0 into\u00a0 risk\u00a0 groups\naccording\u00a0 to\u00a0 risk\u00a0 factors\u00a0 and\u00a0 offered\u00a0 thromboprophylaxis\u00a0 with\u00a0 LMWH\u00a0 where\nappropriate\u00a0(Table\u00a08.6.2).249\nPOSTNATAL\u00a0RISK\u00a0ASSESSMENT\nv\u00a0 To\u00a0be\u00a0assessed\u00a0in\u00a0delivery\u00a0suite\nv\u00a0 Can\u00a0be\u00a0divided\u00a0into\u00a03\u00a0risk\u00a0groups\nThese\u00a0risk\u00a0groups\u00a0do\u00a0not\u00a0include\u00a0those\u00a0who\u00a0are\u00a0sufficiently\u00a0high\u00a0risk\u00a0(very\nhigh\u00a0risk)\u00a0to\u00a0require\u00a0anticoagulation\u00a0when\u00a0not\u00a0pregnant\u00a0(on\u00a0long\u00adterm\nwarfarin):\nt\u00a0 Previous\u00a0VTE\u00a0on\u00a0warfarin\nt\u00a0 APLS\u00a0with\u00a0previous\u00a0VTE\nSwitch\u00a0from\u00a0therapeutic\u00a0LMWH\u00a0to\u00a0long\u00adterm\u00a0warfarin\u00a0postnatally\nRisk\u00a0factors\nManagement\n\"#Any\u00a0previous\u00a0VTE\u00a0! #\"#Anyone\u00a0requiring\u00a0antenatal\nprophylactic\u00a0LMWH\u00a0! At\u00a0least\u00a06\u00a0weeks\u00a0postnatal\nprophylactic\u00a0LMWH\nB. Patient\u00a0risk\u00a0factors\u00a0(see\u00a0below)\n&2\u00a0risk\u00a0factors\u00a0! Any\u00a0one\n#\"#Caesarean\u00a0section\u00a0in\u00a0labour\u00a0! #\"#BMI\u00a0>40\u00a0! #\"#Prolonged\u00a0hospital\nadmission\u00a0! #\"#Medical\u00a0comorbidities\u00a0e.g. ! \u0001\n\u0001\u0001\nt\u00a0Heart/lung\u00a0disease\u00a0! t\u00a0SLE\u00a0! \u0001\n\u0001\u0001\nt Cancer\u00a0! \u0001\n\u0001\u0001\nt Inflammatory\u00a0conditions\u00a0! \u0001\n\u0001\u0001\nt Nephrotic\u00a0syndrome\u00a0! \u0001\n\u0001\u0001\nt\u00a0Sickle\u00a0cell\u00a0disease\u00a0\u00a0! t\u00a0Thalassaemia\u00a0! \u0001\n\u0001\u0001\nt\u00a0IVDU\u00a0! At\u00a0least\u00a07\u00a0days\u00a0postnatal\nprophylactic\u00a0LMWH\nIf\u00a0persisting\u00a0or\u00a0>3\u00a0risk\u00a0factors,\nconsider\u00a0extending\nthromboprophylaxis\u00a0with\u00a0LMWH\nA. Risk\u00a0factors\nManagement\nTable\u00a08.6.2:\u00a0Risk\u00a0groups\u00a0and\u00a0indications\u00a0for\u00a0postnatal\nthromboprophylaxis\u00a0(Grade\u00a0C\u00a0Recommendation)\n1. High\u00a0risk\nRecommendations\n2. Intermediate\u00a0risk\nRecommendations\n8.7\u00a0MANAGEMENT\u00a0OF\u00a0PREGNANT\u00a0WOMEN\u00a0WITH\u00a0THE\nANTIPHOSPHOLIPID\u00a0ANTIBODY\u00a0SYNDROME\nWomen\u00a0with\u00a0APLS\u00a0of\u00a0childbearing\u00a0age\u00a0already\u00a0on\u00a0established\u00a0anticoagulation\u00a0who\nare\u00a0contemplating\u00a0a\u00a0pregnancy\u00a0should\u00a0be\u00a0commenced\u00a0on\u00a0aspirin\u00a0and\u00a0be\u00a0switched\nfrom\u00a0warfarin\u00a0to\u00a0therapeutic\u00a0dose\u00a0LMWH\u00a0upon\u00a0confirmation\u00a0of\u00a0pregnancy,\u00a0which\nshould\u00a0 be\u00a0 continued\u00a0 until\u00a0 delivery,\u00a0 at\u00a0 which\u00a0 point\u00a0 they\u00a0 may\u00a0 recommence\nwarfarin.323,324\nThe\u00a0 management\u00a0 of\u00a0 women\u00a0 with\u00a0APLS\u00a0 with\u00a0 a\u00a0 history\u00a0 of\u00a0 pregnancy\u00a0 loss\u00a0 in\u00a0 the\nabsence\u00a0of\u00a0a\u00a0history\u00a0of\u00a0thrombosis\u00a0is\u00a0more\u00a0controversial\u00a0because\u00a0of\u00a0conflicting\u00a0data\nfrom\u00a0clinical\u00a0trials. Women\u00a0with\u00a0recurrent\u00a0early\u00a0fetal\u00a0loss\u00a0as\u00a0the\u00a0predominant\u00a0manifestation\u00a0of\u00a0APLS\nshould\u00a0be\u00a0offered\u00a0aspirin\u00a0alone\u00a0or\u00a0aspirin\u00a0plus\u00a0prophylactic\u00a0dose\u00a0UFH\u00a0or\u00a0LMWH\nfrom\u00a0 the\u00a0 time\u00a0 of\u00a0 pregnancy\u00a0 confirmation\u00a0 until\u00a0 delivery\u037e323,324\u00a0the\u00a0 latter\u00a0 option\u00a0 is\npreferred\u00a0in\u00a0women\u00a0who\u00a0have\u00a0predominantly\u00a0manifested\u00a0previous\u00a0late\u00a0pregnancy\nloss\u00a0or\u00a0placentally\u00a0mediated\u00a0pregnancy\u00a0morbidity\u00a0(pre\u00adeclampsia\u00a0or\u00a0IUGR).323,324\nAny\u00a01\u00a0risk\u00a0factor:\n#\"#Age\u00a0>35\u00a0years\u00a0! #\"#Obesity\u00a0BMI\u00a0>30\u00a0! #\"\".)%1C*\"&'\"! #\"\u00a0Smoker\u00a0! #\"\u00a0Elective\u00a0CS\u00a0! #\"\u00a0Any\u00a0surgical\u00a0procedure\u00a0in\u00a0the\npuerperium\u00a0! #\"\u00a0Gross\u00a0varicose\u00a0veins\u00a0! #\"\u00a0Current\u00a0systemic\u00a0infection\u00a0!", "chunk_order": 52}
{"chunk_id": "c4f8e786-330d-4469-835c-8c69c129534f", "source_document_filename": "CPG Prevention and Treatment of Venous Thrombosis_cleaned_ultra_minimal.txt", "source_document_title": "CPG Prevention and Treatment of Venous Thrombosis cleaned ultra minimal", "text": "Women\u00a0with\u00a0recurrent\u00a0early\u00a0fetal\u00a0loss\u00a0as\u00a0the\u00a0predominant\u00a0manifestation\u00a0of\u00a0APLS\nshould\u00a0be\u00a0offered\u00a0aspirin\u00a0alone\u00a0or\u00a0aspirin\u00a0plus\u00a0prophylactic\u00a0dose\u00a0UFH\u00a0or\u00a0LMWH\nfrom\u00a0 the\u00a0 time\u00a0 of\u00a0 pregnancy\u00a0 confirmation\u00a0 until\u00a0 delivery\u037e323,324\u00a0the\u00a0 latter\u00a0 option\u00a0 is\npreferred\u00a0in\u00a0women\u00a0who\u00a0have\u00a0predominantly\u00a0manifested\u00a0previous\u00a0late\u00a0pregnancy\nloss\u00a0or\u00a0placentally\u00a0mediated\u00a0pregnancy\u00a0morbidity\u00a0(pre\u00adeclampsia\u00a0or\u00a0IUGR).323,324\nAny\u00a01\u00a0risk\u00a0factor:\n#\"#Age\u00a0>35\u00a0years\u00a0! #\"#Obesity\u00a0BMI\u00a0>30\u00a0! #\"\".)%1C*\"&'\"! #\"\u00a0Smoker\u00a0! #\"\u00a0Elective\u00a0CS\u00a0! #\"\u00a0Any\u00a0surgical\u00a0procedure\u00a0in\u00a0the\npuerperium\u00a0! #\"\u00a0Gross\u00a0varicose\u00a0veins\u00a0! #\"\u00a0Current\u00a0systemic\u00a0infection\u00a0! #\"\u00a0Immobility\u00a0e.g. paraplegia,\nlong\u00adhaul\u00a0travel\u00a0>4\u00a0hours\u00a0! #\"\u00a0Pre\u00adeclampsia\u00a0! #\"\u00a0Mid\u00adcavity\u00a0rotational\u00a0operative\ndelivery\u00a0! #\"\u00a0Prolonged\u00a0labour\u00a0>24\u00a0hours\u00a0! #\"\u00a0Assisted\u00a0reproductive\ntreatment\u00a0! #\"\u00a0PPH\u00a0>1\u00a0litre\u00a0or\u00a0blood\ntransfusion\u00a0! Mobilisation\nAvoid\u00a0dehydration\nPatient\u00a0risk\u00a0factors\nManagement\n3. Low\u00a0risk\nRecommendations\nRecommendations\u00a0for\u00a0Management\u00a0of\u00a0Pregnant\u00a0Women\nwith\u00a0APLS\nGrade\nTable\u00a08.7:\u00a0Managing\u00a0APLS\u00a0in\u00a0pregnancy\nC\nC\nC\nC\nC\nWomen\u00a0 with\u00a0 APLS\u00a0 of\u00a0 childbearing\u00a0 age\u00a0 already\u00a0 on\u00a0 established\nanticoagulation\u00a0 who\u00a0 are\u00a0 contemplating\u00a0 a\u00a0 pregnancy\u00a0 should\u00a0 be\ncommenced\u00a0on\u00a0aspirin\nWomen\u00a0with\u00a0APLS\u00a0already\u00a0on\u00a0established\u00a0anticoagulation\u00a0should\u00a0be\nswitched\u00a0from\u00a0warfarin\u00a0to\u00a0therapeutic\u00a0dose\u00a0LMWH\u00a0upon\u00a0confirmation\nof\u00a0pregnancy\u00a0plus\u00a0aspirin\nWomen\u00a0with\u00a0APLS\u00a0on\u00a0established\u00a0anticoagulation\u00a0should\u00a0continue\ntherapeutic\u00a0 LMWH\u00a0 until\u00a0 delivery,\u00a0 at\u00a0 which\u00a0 point\u00a0 they\u00a0 may\nrecommence\u00a0warfarin\nWomen\u00a0 with\u00a0 recurrent\u00a0 early\u00a0 fetal\u00a0 loss\u00a0 as\u00a0 the\u00a0 predominant\nmanifestation\u00a0of\u00a0APLS\u00a0should\u00a0be\u00a0offered\u00a0aspirin\u00a0alone\u00a0or\u00a0aspirin\u00a0plus\nprophylactic\u00a0 dose\u00a0 UFH\u00a0 or\u00a0 LMWH\u00a0 from\u00a0 the\u00a0 time\u00a0 of\u00a0 pregnancy\nconfirmation\u00a0until\u00a0delivery\nAspirin\u00a0plus\u00a0prophylactic\u00a0dose\u00a0UFH\u00a0or\u00a0LMWHis\u00a0preferred\u00a0in\u00a0women\nwho\u00a0have\u00a0predominantly\u00a0manifested\u00a0previous\u00a0late\u00a0pregnancy\u00a0loss\u00a0or\nplacentally\u00a0mediated\u00a0pregnancy\u00a0morbidity\u00a0(pre\u00adeclampsia\u00a0or\u00a0IUGR)\nRecommendations\nGrade\nB\nThe\u00a0elimination\u00a0half\u00adlife\u00a0of\u00a0LMWH\u00a0is\u00a0increased\u00a0in\u00a0renal\u00a0insufficiency,\ntherefore\u00a0reducing\u00a0the\u00a0dose\u00a0to\u00a01\u00a0mg/kg\u00a0once\u00a0daily\u00a0enoxaparin\u00a0and\nmonitoring\u00a0the\u00a0trough\u00a0anti\u00adXa\u00a0for\u00a0toxicity\u00a0and\u00a0peak\u00a0anti\u00adXa\u00a0to\u00a0adjust\ndosage\u00a0is\u00a0necessary\nB\nTinzaparin\u00a0is\u00a0safe\u00a0to\u00a0be\u00a0used\u00a0up\u00a0to\u00a0a\u00a0Cr\u00a0Cl\u00a0of\u00a020\u00a0mL/min\u00a0with\u00a0no\u00a0dose\nadjustment\nA\nElderly\nRenal impairment\n9.0\u00a0THE\u00a0TREATMENT\u00a0OF\u00a0VTE\u00a0IN\u00a0SPECIAL\u00a0POPULATIONS\nAND\u00a0IN\u00a0UNUSUAL\u00a0SITES\n9.1\u00a0THE\u00a0ELDERLY,\u00a0RENAL\u00a0IMPAIRMENT\u00a0AND\u00a0OBESITY\nThe\u00a0 occurrence\u00a0 of\u00a0 VTE\u00a0 is\u00a0 not\u00a0 uncommon\u00a0 in\u00a0 patients\u00a0 with\u00a0 renal\u00a0 impairment,\nmorbid\u00a0obesity\u00a0and\u00a0the\u00a0elderly. However,\u00a0the\u00a0optimal\u00a0treatment\u00a0of\u00a0VTE\u00a0in\u00a0these\npatients\u00a0is\u00a0controversial\u00a0and\u00a0remains\u00a0a\u00a0challenge.251,253,255\nWarfarin\u00a0with\u00a0INR\u00a0monitoring\u00a0is\u00a0safe\u00a0for\u00a0all\u00a0patient\u00a0population\u00a0as\u00a0well\u00a0as\u00a0in\u00a0patients\nwith\u00a0renal\u00a0impairment. Low\u00a0molecular\u00a0weight\u00a0heparin\u00a0is\u00a0however\u00a0metabolized\u00a0in\nthe\u00a0kidneys\u00a0and\u00a0must\u00a0be\u00a0used\u00a0with\u00a0caution\u00a0in\u00a0these\u00a0patients.253,254,255\nReducing\u00a0 the\u00a0 dose\u00a0 of\u00a0 LMWH\u00a0 to\u00a0 once\u00a0 daily\u00a0 and\u00a0 monitoring\u00a0 with\u00a0 anti\u00adXa\u00a0 is\nnecessary. Unfractionated\u00a0heparin\u00a0is\u00a0safe\u00a0in\u00a0renal\u00a0failure\u00a0and\u00a0is\u00a0recommended\u00a0in\npatients\u00a0with\u00a0creatinine\u00a0clearance\u00a0<30\u00a0mL/min.", "chunk_order": 53}
{"chunk_id": "31c55dff-0768-48d3-b6b5-70e6906c9c03", "source_document_filename": "CPG Prevention and Treatment of Venous Thrombosis_cleaned_ultra_minimal.txt", "source_document_title": "CPG Prevention and Treatment of Venous Thrombosis cleaned ultra minimal", "text": "However,\u00a0the\u00a0optimal\u00a0treatment\u00a0of\u00a0VTE\u00a0in\u00a0these\npatients\u00a0is\u00a0controversial\u00a0and\u00a0remains\u00a0a\u00a0challenge.251,253,255\nWarfarin\u00a0with\u00a0INR\u00a0monitoring\u00a0is\u00a0safe\u00a0for\u00a0all\u00a0patient\u00a0population\u00a0as\u00a0well\u00a0as\u00a0in\u00a0patients\nwith\u00a0renal\u00a0impairment. Low\u00a0molecular\u00a0weight\u00a0heparin\u00a0is\u00a0however\u00a0metabolized\u00a0in\nthe\u00a0kidneys\u00a0and\u00a0must\u00a0be\u00a0used\u00a0with\u00a0caution\u00a0in\u00a0these\u00a0patients.253,254,255\nReducing\u00a0 the\u00a0 dose\u00a0 of\u00a0 LMWH\u00a0 to\u00a0 once\u00a0 daily\u00a0 and\u00a0 monitoring\u00a0 with\u00a0 anti\u00adXa\u00a0 is\nnecessary. Unfractionated\u00a0heparin\u00a0is\u00a0safe\u00a0in\u00a0renal\u00a0failure\u00a0and\u00a0is\u00a0recommended\u00a0in\npatients\u00a0with\u00a0creatinine\u00a0clearance\u00a0<30\u00a0mL/min. Tinzaparin\u00a0is\u00a0safe\u00a0to\u00a0be\u00a0used\u00a0up\u00a0to\na\u00a0CrCl\u00a0of\u00a0<20\u00a0mL/min.255,256,257\nManagement\u00a0of\u00a0the\u00a0elderly\u00a0patients\u00a0with\u00a0VTE\u00a0is\u00a0similar\u00a0to\u00a0the\u00a0general\u00a0population\nhowever\u00a0care\u00a0must\u00a0be\u00a0taken\u00a0as\u00a0these\u00a0patients\u00a0may\u00a0have\u00a0renal\u00a0impairment\u00a0and\u00a0are\nat\u00a0a\u00a0higher\u00a0risk\u00a0of\u00a0bleeding.255\nStudies\u00a0have\u00a0shown\u00a0that\u00a0the\u00a0pharmacokinetics\u00a0of\u00a0LMWH\u00a0is\u00a0similar\u00a0in\u00a0obese\u00a0and\nnon\u00adobese\u00a0patients\u00a0with\u00a0no\u00a0significant\u00a0difference\u00a0in\u00a0the\u00a0incidence\u00a0of\u00a0haemorrhage\u00a0or\nVTE\u00a0recurrence.252,257\nIt\u00a0is\u00a0recommended\u00a0that\u00a0in\u00a0obese\u00a0patients,\u00a0LMWH\u00a0is\u00a0dosed\u00a0by\u00a0actual\u00a0weight\u00a0and\ncapping\u00a0 the\u00a0 dose\u00a0 is\u00a0 not\u00a0 recommended\u00a0 as\u00a0 this\u00a0 could\u00a0 lead\u00a0 to\u00a0 sub\u00adtherapeutic\nanticoagulation\u00a0and\u00a0increased\u00a0risk\u00a0of\u00a0recurrent\u00a0VTE.252,255\nTable\u00a09.1:\u00a0Treatment\u00a0of\u00a0VTE\u00a0in\u00a0special\u00a0populations\nAnticoagulation\u00a0in\u00a0the\u00a0elderly\u00a0is\u00a0similar\u00a0to\u00a0the\u00a0general\u00a0population\u00a0but\u00a0it\nmust\u00a0be\u00a0noted\u00a0that\u00a0these\u00a0patients\u00a0may\u00a0have\u00a0underlying\u00a0renal\u00a0insufficiency\n9.2\u00a0\u00a0ANTICOAGULATION\u00a0FOR\u00a0ESTABLISHED\u00a0VTE\u00a0IN\u00a0STROKE\u00a0PATIENTS\nOnce\u00a0the\u00a0diagnosis\u00a0of\u00a0DVT\u00a0has\u00a0been\u00a0confirmed\u00a0with\u00a0compression\u00a0duplex\u00a0Doppler\nultrasound,\u00a0 most\u00a0 patients\u00a0 with\u00a0 venous\u00a0 thromboembolism\u00a0 will\u00a0 respond\u00a0 to\nanticoagulation.258\u00a0The\u00a0current\u00a0practice\u00a0in\u00a0ischaemic\u00a0stroke\u00a0patients\u00a0is\u00a0to\u00a0commence\nwith\u00a0subcutaneous\u00a0LMWH\u00a0which\u00a0will\u00a0continue\u00a0(usually\u00a05\u00a0to\u00a010\u00a0days)\u00a0until\u00a0warfarin,\ninitiated\u00a0concurrently,\u00a0achieves\u00a0an\u00a0INR\u00a0above\u00a02.0\u00a0for\u00a0>24\u00a0hours.259\nThe\u00a0new\u00a0oral\u00a0anticoagulant,\u00a0rivaroxaban\u00a0although\u00a0not\u00a0evaluated\u00a0in\u00a0the\u00a0treatment\u00a0of\nVTE\u00a0 in\u00a0 stroke\u00a0 patients\u00a0 seem\u00a0 to\u00a0 be\u00a0 a\u00a0 promising\u00a0 anticoagulant\u00a0 as\u00a0 it\u00a0 causes\u00a0 less\nintracranial\u00a0bleeding\u00a0complications\u00a0than\u00a0LMWH/warfarin. While\u00a0 anticoagulation\u00a0 is\u00a0 recommended\u00a0 for\u00a0 the\u00a0 duration\u00a0 of\u00a0 three\u00a0 months\u00a0 in\nnon\u00adstroke\u00a0patients,\u00a0the\u00a0ideal\u00a0duration\u00a0of\u00a0treatment\u00a0in\u00a0established\u00a0VTE\u00a0in\u00a0stroke\npatients\u00a0is\u00a0still\u00a0unresolved\u00a0and\u00a0should\u00a0be\u00a0guided\u00a0by\u00a0the\u00a0presence\u00a0of\u00a0continuing\u00a0risk\nfactors\u00a0in\u00a0the\u00a0individual\u00a0patient\u00a0or\u00a0the\u00a0recurrence\u00a0of\u00a0venous\u00a0thromboembolism. 9.3\u00a0ANTITHROMBOTIC\u00a0THERAPY\u00a0IN\u00a0CHILDREN\nVenous\u00a0thromboembolism\u00a0in\u00a0paediatrics\u00a0is\u00a0rare. The\u00a0leading\u00a0contributor\u00a0of\u00a0VTE\u00a0in\nchildhood\u00a0is\u00a0the\u00a0placement\u00a0of\u00a0central\u00a0venous\u00a0access\u00a0devices.260,262\u00a0Other\u00a0conditions\nassociated\u00a0 with\u00a0 the\u00a0 development\u00a0 of\u00a0 VTE\u00a0 in\u00a0 childhood\u00a0 are\u00a0 malignancy,\u00a0 vascular\nmalformations,\u00a0trauma\u00a0or\u00a0surgery.", "chunk_order": 54}
{"chunk_id": "1faa49d9-caef-4e06-a555-cec2de395f10", "source_document_filename": "CPG Prevention and Treatment of Venous Thrombosis_cleaned_ultra_minimal.txt", "source_document_title": "CPG Prevention and Treatment of Venous Thrombosis cleaned ultra minimal", "text": "While\u00a0 anticoagulation\u00a0 is\u00a0 recommended\u00a0 for\u00a0 the\u00a0 duration\u00a0 of\u00a0 three\u00a0 months\u00a0 in\nnon\u00adstroke\u00a0patients,\u00a0the\u00a0ideal\u00a0duration\u00a0of\u00a0treatment\u00a0in\u00a0established\u00a0VTE\u00a0in\u00a0stroke\npatients\u00a0is\u00a0still\u00a0unresolved\u00a0and\u00a0should\u00a0be\u00a0guided\u00a0by\u00a0the\u00a0presence\u00a0of\u00a0continuing\u00a0risk\nfactors\u00a0in\u00a0the\u00a0individual\u00a0patient\u00a0or\u00a0the\u00a0recurrence\u00a0of\u00a0venous\u00a0thromboembolism. 9.3\u00a0ANTITHROMBOTIC\u00a0THERAPY\u00a0IN\u00a0CHILDREN\nVenous\u00a0thromboembolism\u00a0in\u00a0paediatrics\u00a0is\u00a0rare. The\u00a0leading\u00a0contributor\u00a0of\u00a0VTE\u00a0in\nchildhood\u00a0is\u00a0the\u00a0placement\u00a0of\u00a0central\u00a0venous\u00a0access\u00a0devices.260,262\u00a0Other\u00a0conditions\nassociated\u00a0 with\u00a0 the\u00a0 development\u00a0 of\u00a0 VTE\u00a0 in\u00a0 childhood\u00a0 are\u00a0 malignancy,\u00a0 vascular\nmalformations,\u00a0trauma\u00a0or\u00a0surgery. The\u00a0 pharmacokinetics\u00a0 of\u00a0 LMWH\u00a0 in\u00a0 obese\u00a0 patients\u00a0 are\u00a0 similar\u00a0 to\nnon\u00adobese\u00a0patients\nA\nLMWH\u00a0should\u00a0be\u00a0dosed\u00a0by\u00a0actual\u00a0weight\u00a0and\u00a0capping\u00a0the\u00a0dose\u00a0is\u00a0not\nrecommended\nB\nB\nFondaparinux\u00a0should\u00a0not\u00a0be\u00a0used\u00a0in\u00a0patients\u00a0with\u00a0renal\u00a0impairment\nA\nWarfarin\u00a0with\u00a0INR\u00a0monitoring\u00a0is\u00a0safe\u00a0in\u00a0patients\u00a0with\u00a0renal\u00a0failure\nThe\u00a0dose\u00a0for\u00a0fondaparinux\u00a0is\u00a010\u00a0mg\u00a0daily\u00a0for\u00a0body\u00a0weight\u00a0>100\u00a0kg\nB\nUFH\u00a0is\u00a0recommended\u00a0in\u00a0patients\u00a0with\u00a0a\u00a0CrCl\u00a0<30\u00a0mL/min\u00a0with\u00a0dose\nadjustments\u00a0based\u00a0on\u00a0the\u00a0APTT\u00a0if\u00a0no\u00a0anti\u00adXa\u00a0testing\u00a0is\u00a0available\u00a0to\nmonitor\u00a0the\u00a0effects\u00a0of\u00a0LMWH\nB\nObesity\nRecommendation\nGrade\nThe\u00a0duration\u00a0of\u00a0anticoagulation\u00a0for\u00a0established\u00a0VTE\u00a0in\u00a0stroke\npatients\u00a0is\u00a0at\u00a0least\u00a03\u00a0months\u00a0but\u00a0may\u00a0be\u00a0extended\u00a0if\u00a0the\u00a0risk\u00a0of\nVTE\u00a0recurrence\u00a0remains\u00a0high\nC\nTable\u00a09.2:\u00a0Anticoagulation\u00a0of\u00a0established\u00a0VTE\u00a0in\u00a0stroke\u00a0patients\nAnticoagulation\u00a0 poses\u00a0 a\u00a0 significant\u00a0 challenge\u00a0 in\u00a0 the\u00a0 paediatric\u00a0 population. The\nresponse,\u00a0distribution,\u00a0binding\u00a0and\u00a0clearance\u00a0of\u00a0antithrombotics\u00a0are\u00a0age\u00addependent\nwhich\u00a0makes\u00a0dosing\u00a0and\u00a0monitoring\u00a0difficult.260,261,262\nLimited\u00a0vascular\u00a0access\u00a0reduces\u00a0the\u00a0ability\u00a0to\u00a0deliver\u00a0some\u00a0antithrombotic\u00a0therapy\u00a0and\nto\u00a0accurately\u00a0monitor\u00a0blood\u00a0anticoagulant\u00a0levels. The\u00a0need\u00a0for\u00a0general\u00a0anaesthesia\u00a0to\nperform\u00a0 diagnostic\u00a0 studies\u00a0 in\u00a0 paediatric\u00a0 patients\u00a0 has\u00a0 an\u00a0 impact\u00a0 on\u00a0 the\u00a0 ability\u00a0 to\ninvestigate\u00a0and\u00a0on\u00a0the\u00a0confidence\u00a0in\u00a0therapeutic\u00a0decisions.261,262\nThe\u00a0 choice\u00a0 of\u00a0 antithrombotic\u00a0 is\u00a0 also\u00a0 influenced\u00a0 by\u00a0 the\u00a0 unavailability\u00a0 of\u00a0 paediatric\nformulation\u00a0 as\u00a0 in\u00a0 the\u00a0 case\u00a0 of\u00a0 vitamin\u00a0 K\u00a0 antagonist\u00a0 (VKA\u037e\u00a0 no\u00a0 suspension\u00a0 or\u00a0 liquid\nformulation)\u00a0and\u00a0low\u00a0molecular\u00a0weight\u00a0heparin\u00a0(LMWH\u037e\u00a0pre\u00addosed\u00a0syringes\u00a0based\u00a0on\nadult\u00a0weights). Dietary\u00a0differences\u00a0also\u00a0make\u00a0the\u00a0use\u00a0of\u00a0VKA\u00a0difficult\u00a0(breast\u00a0milk\u00a0and\ninfant\u00a0formula\u00a0have\u00a0very\u00a0different\u00a0vitamin\u00a0K\u00a0content).161,262\nImportant\u00a0 issues\u00a0 when\u00a0 considering\u00a0 treatment\u00a0 options\u00a0 include\u00a0 the\u00a0 site,\u00a0 extent\u00a0 and\nclinical\u00a0 consequences\u00a0 of\u00a0 the\u00a0 thrombosis\u00a0 and\u00a0 the\u00a0 risks\u00a0 of\u00a0 bleeding\u00a0 complications\nassociated\u00a0with\u00a0the\u00a0use\u00a0of\u00a0anticoagulant\u00a0or\u00a0thrombolytic\u00a0therapy. The\u00a0later\u00a0will\u00a0vary\u00a0with\ngestational\u00a0 age,\u00a0 birth\u00a0 weight\u00a0 and\u00a0 comorbidities\u00a0 such\u00a0 as\u00a0 lung\u00a0 disease,\u00a0 necrotising\nenterocolitis,\u00a0sepsis\u00a0and\u00a0intraventricular\u00a0haemorrhage.260\nManagement\u00a0 should\u00a0 be\u00a0 individualised\u00a0 with\u00a0 appropriate\u00a0 consideration\u00a0 of\u00a0 the\nrisk\u00adbenefit\u00a0ratio\u00a0for\u00a0each\u00a0case. Options\u00a0for\u00a0treatment\u00a0include\u00a0supportive\u00a0care\u00a0only,\nanticoagulant\u00a0therapy,\u00a0thrombolytic\u00a0therapy\u00a0and\u00a0surgery. v\u00a0Physiologically\u00a0evolving\u00a0haemostatic\u00a0mechanism\u00a0in\u00a0children\nv\u00a0Absence\u00a0of\u00a0paediatric\u00adspecific\u00a0formulations\nv\u00a0Difficulty\u00a0of\u00a0frequent\u00a0sampling\u00a0in\u00a0young\u00a0children\u00a0(especially\u00a0the\u00a0absence\u00a0of\nestablished\u00a0capillary\u00a0PT\u00adINR\u00a0testing)\nv\u00a0Absence\u00a0of\u00a0robust\u00a0paediatric\u00adspecific\u00a0evidence\u00a0to\u00a0guide\u00a0practice\nTable\u00a09.3:\u00a0Factors\u00a0that\u00a0complicate\u00a0delivery\u00a0of\u00a0anti\u00adthrombotic\ntherapy\u00a0in\u00a0children\n9.3.1\u00a0Unfractionated\u00a0heparin\n9.3.1.1\u00a0Monitoring\u00a0UFH\nDespite\u00a0 its\u00a0 difficulties,\u00a0 UFH\u00a0 is\u00a0 commonly\u00a0 used\u00a0 in\u00a0 paediatric\u00a0 patients.", "chunk_order": 55}
{"chunk_id": "03929d29-aea5-4801-a9dc-3c805ba2c75c", "source_document_filename": "CPG Prevention and Treatment of Venous Thrombosis_cleaned_ultra_minimal.txt", "source_document_title": "CPG Prevention and Treatment of Venous Thrombosis cleaned ultra minimal", "text": "Options\u00a0for\u00a0treatment\u00a0include\u00a0supportive\u00a0care\u00a0only,\nanticoagulant\u00a0therapy,\u00a0thrombolytic\u00a0therapy\u00a0and\u00a0surgery. v\u00a0Physiologically\u00a0evolving\u00a0haemostatic\u00a0mechanism\u00a0in\u00a0children\nv\u00a0Absence\u00a0of\u00a0paediatric\u00adspecific\u00a0formulations\nv\u00a0Difficulty\u00a0of\u00a0frequent\u00a0sampling\u00a0in\u00a0young\u00a0children\u00a0(especially\u00a0the\u00a0absence\u00a0of\nestablished\u00a0capillary\u00a0PT\u00adINR\u00a0testing)\nv\u00a0Absence\u00a0of\u00a0robust\u00a0paediatric\u00adspecific\u00a0evidence\u00a0to\u00a0guide\u00a0practice\nTable\u00a09.3:\u00a0Factors\u00a0that\u00a0complicate\u00a0delivery\u00a0of\u00a0anti\u00adthrombotic\ntherapy\u00a0in\u00a0children\n9.3.1\u00a0Unfractionated\u00a0heparin\n9.3.1.1\u00a0Monitoring\u00a0UFH\nDespite\u00a0 its\u00a0 difficulties,\u00a0 UFH\u00a0 is\u00a0 commonly\u00a0 used\u00a0 in\u00a0 paediatric\u00a0 patients. The\ntherapeutic\u00a0APTT\u00a0 range\u00a0 of\u00a0 UFH\u00a0 in\u00a0 neonates\u00a0 or\u00a0 children\u00a0 is\u00a0 not\u00a0 known\u00a0 but\u00a0 is\nextrapolated\u00a0 from\u00a0 adults.261,262\u00a0 Baseline\u00a0APTT\u00a0 in\u00a0 paediatric\u00a0 patients\u00a0 especially\nneonates\u00a0are\u00a0often\u00a0increased\u00a0compared\u00a0with\u00a0adults. Therefore\u00a0the\u00a0therapeutic\nranges\u00a0 represent\u00a0 a\u00a0 reduced\u00a0 relative\u00a0 increment\u00a0 in\u00a0 APTT\u00a0 values\u00a0 and\u00a0 hence\nunderestimate\u00a0UFH\u00a0concentration. Thus\u00a0there\u00a0is\u00a0uncertainty\u00a0over\u00a0how\u00a0best\u00a0to\u00a0monitor\u00a0unfractionated\u00a0heparin\u00a0therapy\nin\u00a0children,\u00a0given\u00a0the\u00a0non\u00aduniformity\u00a0and\u00a0lack\u00a0of\u00a0calibration\u00a0of\u00a0institutional\u00a0APTT\nvalues\u00a0to\u00a0other\u00a0measures\u00a0of\u00a0heparin\u00a0activity\u00a0such\u00a0as\u00a0anti\u00adXa\u00a0activity\u00a0or\u00a0protamine\nneutralisation\u00a0and\u00a0the\u00a0lack\u00a0of\u00a0ready\u00a0availability\u00a0of\u00a0the\u00a0alternative\u00a0assays.325\n9.3.1.2\u00a0Dosing\u00a0UFH\nOne\u00a0prospective\u00a0study\u00a0used\u00a0weight\u00adbased\u00a0normogram\u00a0to\u00a0dose\u00a0UFH\u00a0in\u00a0paediatric\npopulation\u00a0(Table\u00a09.3.1). Bolus\u00a0doses\u00a0of\u00a075\u00ad100\u00a0units/kg\u00a0resulted\u00a0in\u00a0therapeutic\nAPTT\u00a0values\u00a0in\u00a090%\u00a0of\u00a0children\u00a0at\u00a04\u00a0to\u00a06\u00a0hours\u00a0post\u00addose,\u00a0however\u00a0in\u00a0recent\nstudies,\u00a0this\u00a0dosing\u00a0has\u00a0resulted\u00a0in\u00a0unrecordable\u00a0values.260,261\u00a0Thus,\u00a0there\u00a0is\u00a0also\nuncertainty\u00a0over\u00a0the\u00a0requirement\u00a0of\u00a0a\u00a0loading\u00a0dose\u00a0prior\u00a0to\u00a0commencing\u00a0heparin\ninfusion. Individual\u00a0risk\u00a0factors\u00a0for\u00a0bleeding\u00a0and\u00a0thrombosis\u00a0especially\u00a0in\u00a0premature\u00a0infants\nneed\u00a0to\u00a0be\u00a0taken\u00a0into\u00a0consideration\u00a0before\u00a0recommending\u00a0initial\u00a0bolus\u00a0strategy. Maintenance\u00a0 doses\u00a0 are\u00a0 age\u00a0 dependent,\u00a0 with\u00a0 infants\u00a0 having\u00a0 the\u00a0 highest\nrequirements\u00a0because\u00a0of\u00a0faster\u00a0clearance\u00a0due\u00a0to\u00a0a\u00a0larger\u00a0volume\u00a0of\u00a0distribution. APTT,\u00a0sec\nBolus,\nunits/\u00a0kg\nHold,\u00a0min\n%\u00a0rate\nchange\nRepeat\u00a0APTT\n<50\n50\n0\n+\u00a010\n4\u00a0h\n50\u00a0\u00ad\u00a059\n0\n0\n+\u00a010\n4\u00a0h\n60\u00a0\u00ad\u00a085\n0\n0\n0\nNext\u00a0day\n86\u00a0\u00ad\u00a095\n0\n0\n\u00ad\u00a010\n4\u00a0h\n96\u00a0\u00ad\u00a0120\n0\n30\n\u00ad\u00a010\n4\u00a0h\n>120\n0\n60\n\u00ad\u00a015\n4\u00a0h\nTable\u00a09.3.1:\u00a0Protocol\u00a0for\u00a0intravenous\u00a0unfractionated\u00a0heparin\nadministration\u00a0in\u00a0paediatric\u00a0patients260\nI. Loading\u00a0dose:\u00a0\u00a0UFH\u00a075\u00a0units/kg\u00a0over\u00a010\u00a0minutes\u00a0(requirement\u00a0is\nuncertain\u00a0and\u00a0has\u00a0to\u00a0be\u00a0individualised)\nII. Initial\u00a0maintenance\u00a0dose:\u00a028\u00a0units/\u00a0kg\u00a0per\u00a0hour\u00a0for\u00a0infants\u00a0<1\u00a0year\u037e\u00a020\nunits/kg\u00a0for\u00a0children\u00a0>1\u00a0year\nIII. Adjust\u00a0heparin\u00a0to\u00a0maintain\u00a0APTT\u00a0of\u00a060\u00ad85\u00a0sec\u00a0(correlates\u00a0to\u00a0anti\u00adXa\nlevel\u00a0of\u00a00.35\u00ad0.70)\nIV. Obtain\u00a0blood\u00a0for\u00a0APTT\u00a04\u00a0hours\u00a0after\u00a0heparin\u00a0loading\u00a0dose\u00a0and\u00a04\u00a0hours\nafter\u00a0every\u00a0change\u00a0in\u00a0the\u00a0infusion\u00a0rate\nV. When\u00a0APTT\u00a0values\u00a0are\u00a0therapeutic,\u00a0do\u00a0a\u00a0daily\u00a0FBC\u00a0and\u00a0APTT\nThere\u00a0is\u00a0no\u00a0data\u00a0to\u00a0define\u00a0optimal\u00a0prophylactic\u00a0doses\u00a0of\u00a0UFH. The\u00a0efficacy\u00a0of\u00a0using\na\u00a0dose\u00a0of\u00a010\u00a0units/kg\u00a0per\u00a0hour\u00a0as\u00a0a\u00a0continuous\u00a0infusion\u00a0has\u00a0not\u00a0been\u00a0proven.", "chunk_order": 56}
{"chunk_id": "568a9963-b2bc-471a-8a22-e1922ad2ba65", "source_document_filename": "CPG Prevention and Treatment of Venous Thrombosis_cleaned_ultra_minimal.txt", "source_document_title": "CPG Prevention and Treatment of Venous Thrombosis cleaned ultra minimal", "text": "Initial\u00a0maintenance\u00a0dose:\u00a028\u00a0units/\u00a0kg\u00a0per\u00a0hour\u00a0for\u00a0infants\u00a0<1\u00a0year\u037e\u00a020\nunits/kg\u00a0for\u00a0children\u00a0>1\u00a0year\nIII. Adjust\u00a0heparin\u00a0to\u00a0maintain\u00a0APTT\u00a0of\u00a060\u00ad85\u00a0sec\u00a0(correlates\u00a0to\u00a0anti\u00adXa\nlevel\u00a0of\u00a00.35\u00ad0.70)\nIV. Obtain\u00a0blood\u00a0for\u00a0APTT\u00a04\u00a0hours\u00a0after\u00a0heparin\u00a0loading\u00a0dose\u00a0and\u00a04\u00a0hours\nafter\u00a0every\u00a0change\u00a0in\u00a0the\u00a0infusion\u00a0rate\nV. When\u00a0APTT\u00a0values\u00a0are\u00a0therapeutic,\u00a0do\u00a0a\u00a0daily\u00a0FBC\u00a0and\u00a0APTT\nThere\u00a0is\u00a0no\u00a0data\u00a0to\u00a0define\u00a0optimal\u00a0prophylactic\u00a0doses\u00a0of\u00a0UFH. The\u00a0efficacy\u00a0of\u00a0using\na\u00a0dose\u00a0of\u00a010\u00a0units/kg\u00a0per\u00a0hour\u00a0as\u00a0a\u00a0continuous\u00a0infusion\u00a0has\u00a0not\u00a0been\u00a0proven. 9.3.1.3\u00a0Side\u00a0effects\u00a0of\u00a0UFH\nBleeding\u00a0is\u00a0a\u00a0known\u00a0side\u00a0effect\u00a0of\u00a0intravenous\u00a0UFH\u00a0with\u00a0major\u00a0bleeding\u00a0rates\u00a0as\nhigh\u00a0as\u00a024%\u00a0in\u00a0one\u00a0study\u00a0in\u00a0paediatric\u00a0ICU\u00a0patients\u00a0who\u00a0received\u00a0UFH\u00a0therapy. A\ncommon\u00a0cause\u00a0of\u00a0fatal\u00a0bleeding\u00a0is\u00a0accidental\u00a0heparin\u00a0overdose\u00a0as\u00a0a\u00a0result\u00a0of\u00a0drug\nerror,\u00a0with\u00a05000\u00a0units/mL\u00a0vials\u00a0being\u00a0mistakenly\u00a0selected\u00a0instead\u00a0of\u00a050\u00a0units/mL\nvials.260\u00ad263\nOther\u00a0 side\u00a0 effects\u00a0 that\u00a0 are\u00a0 uncommon\u00a0 are\u00a0 osteoporosis\u00a0 and\u00a0 alopecia. Heparin\u00adinduced\u00a0 thrombocytopenia\u00a0 is\u00a0 a\u00a0 distinct\u00a0 rarity\u00a0 in\u00a0 paediatric\u00a0 thrombosis\nmanagement. The\u00a0cases\u00a0of\u00a0HIT\u00a0reported\u00a0have\u00a0been\u00a0exposed\u00a0to\u00a0low\u00addose\u00a0heparin\nflushes\u00a0 used\u00a0 in\u00a0 maintaining\u00a0 patency\u00a0 of\u00a0 CVADs\u00a0 and\u00a0 during\u00a0 hemodialysis\u00a0 and\u00a0 to\nsupra\u00adtherapeutic\u00a0doses\u00a0given\u00a0during\u00a0cardiopulmonary\u00a0bypass. 9.3.2\u00a0Low\u00a0molecular\u00a0weight\u00a0heparin\nDespite\u00a0 the\u00a0 lack\u00a0 of\u00a0 studies,\u00a0 LMWH\u00a0 has\u00a0 become\u00a0 the\u00a0 anticoagulant\u00a0 of\u00a0 choice\u00a0 in\npaediatric\u00a0patients\u00a0due\u00a0to\u00a0its\u00a0better\u00a0bioavailability,\u00a0less\u00a0need\u00a0for\u00a0monitoring\u00a0and\u00a0less\nside\u00a0effects.260,262\nThere\u00a0are\u00a03\u00a0factors\u00a0that\u00a0influence\u00a0the\u00a0decision\u00a0to\u00a0use\u00a0LMWH:\n1. patient\u00a0stability\u00a0(balance\u00a0between\u00a0thrombosis\u00a0and\u00a0bleeding)\n2. renal\u00a0function\n3. need\u00a0for\u00a0invasive\u00a0intervention\u00a0and\u00a0rapid\u00a0reversibility\u00a0of\u00a0anticoagulation\nWhen\u00a0 transitioning\u00a0 from\u00a0 UFH\u00a0 to\u00a0 LMWH,\u00a0 LMWH\u00a0 is\u00a0 administered\u00a0 at\u00a0 time\u00a0 of\ndiscontinuation\u00a0of\u00a0UFH. 9.3.2.1\u00a0Monitoring\u00a0LMWH\nDue\u00a0to\u00a0its\u00a0good\u00a0bioavailability\u00a0and\u00a0predictable\u00a0response,\u00a0monitoring\u00a0is\u00a0not\u00a0required\nin\u00a0paediatric\u00a0patients\u00a0on\u00a0LMWH\u00a0therapy\u00a0for\u00a0VTE\u00a0prophylaxis\u00a0and\u00a0treatment\u00a0except\nfor\u00a0premature\u00a0infants\u00a0and\u00a0neonates\u00a0where\u00a0higher\u00a0doses\u00a0may\u00a0be\u00a0needed. The\u00a0drug\nshould\u00a0be\u00a0monitored\u00a0to\u00a0achieve\u00a0a\u00a0target\u00a0anti\u00adXa\u00a0range\u00a0of\u00a00.5\u00a0to\u00a01.0\u00a0units/mL\u00a0in\u00a0a\nsample\u00a0taken\u00a04\u00a0to\u00a06\u00a0hours\u00a0after\u00a0subcutaneous\u00a0injection.260,262\n9.3.2.2\u00a0Dosing\u00a0of\u00a0LMWH\nThe\u00a0 therapeutic\u00a0 doses\u00a0 of\u00a0 LMWH\u00a0 required\u00a0 for\u00a0 paediatric\u00a0 patients\u00a0 have\u00a0 been\nassessed\u00a0and\u00a0are\u00a0listed\u00a0in\u00a0Table\u00a09.3.2. LMWH\nAge\nInitial\u00a0treatment\ndose\nInitial\u00a0prophylactic\ndose\nEnoxaparin\n<2\u00a0months\n>2\u00a0months\nTinzaparin\n0\u00a0\u00ad\u00a02\u00a0 months\n2\u00a0\u00ad\u00a012\u00a0months\n1\u00a0\u00ad\u00a05\u00a0 years\n5\u00a0\u00ad\u00a010\u00a0years\n10\u00a0\u00ad\u00a01\u00a0 years\n275\u00a0u/kg/dose\u00a0OD\n250\u00a0u/kg/dose\u00a0OD\n240\u00a0u/kg/dose\u00a0OD\n200\u00a0u/kg/dose\u00a0OD\n175\u00a0u/kg/dose\u00a0OD\n\u00ad\n\u00ad\n\u00ad\n\u00ad\n\u00ad\n9.3.2.3\u00a0Dose\u00a0adjustment\u00a0for\u00a0invasive\u00a0procedures\nFor\u00a0lumbar\u00a0punctures\u00a0or\u00a0invasive\u00a0procedures,\u00a0omit\u00a02\u00a0doses\u00a0of\u00a0enoxaparin\u00a0(24\u00adhour\ndrug\u00a0washout)\u00a0prior\u00a0to\u00a0procedure\u00a0(e.g. scheduled\u00a0lumbar\u00a0puncture\u00a0and\u00a0intra\u00adthecal\ntherapy\u00a0on\u00a0Friday\u037e\u00a0omit\u00a0Thursday\u00a0evening\u00a0dose\u00a0and\u00a0Friday\u00a0morning\u00a0dose).", "chunk_order": 57}
{"chunk_id": "f7e57fc8-c622-4635-b60c-890d7ab0e45c", "source_document_filename": "CPG Prevention and Treatment of Venous Thrombosis_cleaned_ultra_minimal.txt", "source_document_title": "CPG Prevention and Treatment of Venous Thrombosis cleaned ultra minimal", "text": "LMWH\nAge\nInitial\u00a0treatment\ndose\nInitial\u00a0prophylactic\ndose\nEnoxaparin\n<2\u00a0months\n>2\u00a0months\nTinzaparin\n0\u00a0\u00ad\u00a02\u00a0 months\n2\u00a0\u00ad\u00a012\u00a0months\n1\u00a0\u00ad\u00a05\u00a0 years\n5\u00a0\u00ad\u00a010\u00a0years\n10\u00a0\u00ad\u00a01\u00a0 years\n275\u00a0u/kg/dose\u00a0OD\n250\u00a0u/kg/dose\u00a0OD\n240\u00a0u/kg/dose\u00a0OD\n200\u00a0u/kg/dose\u00a0OD\n175\u00a0u/kg/dose\u00a0OD\n\u00ad\n\u00ad\n\u00ad\n\u00ad\n\u00ad\n9.3.2.3\u00a0Dose\u00a0adjustment\u00a0for\u00a0invasive\u00a0procedures\nFor\u00a0lumbar\u00a0punctures\u00a0or\u00a0invasive\u00a0procedures,\u00a0omit\u00a02\u00a0doses\u00a0of\u00a0enoxaparin\u00a0(24\u00adhour\ndrug\u00a0washout)\u00a0prior\u00a0to\u00a0procedure\u00a0(e.g. scheduled\u00a0lumbar\u00a0puncture\u00a0and\u00a0intra\u00adthecal\ntherapy\u00a0on\u00a0Friday\u037e\u00a0omit\u00a0Thursday\u00a0evening\u00a0dose\u00a0and\u00a0Friday\u00a0morning\u00a0dose). 9.3.2.4\u00a0Stability\u00a0of\u00a0reconstituted\u00a0LMWH\nThe\u00a0stability\u00a0of\u00a0reconstituted\u00a0fixed\u00addose\u00a0preparations\u00a0enables\u00a0multi\u00addosing326\nfor\u00a0example,\u00a0if\u00a0an\u00a0infant\u00a0weighing\u00a06\u00a0kg\u00a0requires\u00a0enoxaparin\u00a0at\u00a06\u00a0mg\u00a012\u00a0hourly,\na\u00a020\u00a0mg/0.2\u00a0mL\u00a0pre\u00adfilled\u00a0syringe\u00a0preparation\u00a0may\u00a0be\u00a0reconstituted\u00a0with\u00a0sterile\n0.9%\u00a0 saline\u00a0 to\u00a0 create\u00a0 a\u00a0 20\u00a0 mg/mL\u00a0 solution,\u00a0 from\u00a0 which\u00a0 stock\u00a0 0.3\u00a0 mL\u00a0 may\u00a0 be\ninjected\u00a0subcutaneously\u00a0twice\u00a0daily,\u00a0enabling\u00a0optimum\u00a0use\u00a0of\u00a0the\u00a0pre\u00adfilled\u00a0syringe\n\u00addispensed\u00a0volumes. 9.3.3\u00a0Heparin\u00a0reversal\nHeparin\u00a0 can\u00a0 be\u00a0 reversed\u00a0 by\u00a0 protamine\u00a0 with\u00a0 partial\u00a0 reversibility\u00a0 for\u00a0 LMWH\u00a0 (see\nTable\u00a07.5.1). 9.3.4\u00a0Warfarin\nWarfarin\u00a0is\u00a0problematic\u00a0in\u00a0neonates\u00a0for\u00a0several\u00a0reasons. 1. Plasma\u00a0levels\u00a0of\u00a0vitamin\u00a0K\u00addependent\u00a0factors\u00a0are\u00a0physiologically\u00a0decreased\u00a0in\nnewborns\u00a0to\u00a0levels\u00a0that\u00a0are\u00a0comparable\u00a0to\u00a0adults\u00a0receiving\u00a0warfarin\u00a0with\u00a0INR\u00a0of\n2.0\u00a0to\u00a03.0\n2. Infant\u00a0formula\u00a0is\u00a0supplemented\u00a0with\u00a0vitamin\u00a0K\u00a0to\u00a0prevent\u00a0haemorrhagic\u00a0disease\nof\u00a0the\u00a0newborn\n3. Warfarin\u00a0is\u00a0only\u00a0available\u00a0in\u00a0tablet\u00a0form\n4. Warfarin\u00a0requires\u00a0frequent\u00a0monitoring\n5. Problems\u00a0with\u00a0vascular\u00a0access\nWarfarin\u00a0is\u00a0the\u00a0most\u00a0commonly\u00a0used\u00a0oral\u00a0anticoagulant. The\u00a0therapeutic\u00a0ranges\u00a0are\ndirectly\u00a0extrapolated\u00a0from\u00a0adult\u00a0patients.260,262\nFor\u00a0 the\u00a0 management\u00a0 of\u00a0 warfarin\u00a0 anticoagulation\u00a0 in\u00a0 children,\u00a0 refer\u00a0 to\u00a0 UMMC\nguidelines\u00a02013\u00a0in\u00a0appendix\u00a011. Table 9.3.2: Dosing of LMWH in children260\n1.5\u00a0mg/kg/dose\u00a0OD\n1.0\u00a0mg/kg/dose\u00a0OD\n0.75\u00a0mg/kg/dose\u00a0BD\n0.5\u00a0mg/kg/dose\u00a0BD\n9.3.5\u00a0Thrombolysis\u00a0in\u00a0neonates\u00a0and\u00a0children\nThrombolysis,\u00a0either\u00a0systemic\u00a0or\u00a0catheter\u00addirected\u00a0is\u00a0indicated\u00a0for\u00a0life\u00ad,\u00a0limb\u00ad\u00a0or\norgan\u00adthreatening\u00a0 thrombosis. Success\u00a0 rates\u00a0 for\u00a0 thrombolysis\u00a0 in\u00a0 paediatric\npatients\u00a0vary\u00a0between\u00a060\u00a0to\u00a080%. Tissue\u00a0plasminogen\u00a0activator\u00a0is\u00a0the\u00a0agent\u00a0of\nchoice\u00a0because\u00a0of\u00a0experimental\u00a0evidence\u00a0of\u00a0improved\u00a0clot\u00a0lysis,\u00a0fibrin\u00a0specificity\nand\u00a0low\u00a0immunogenicity\u00a0when\u00a0compared\u00a0with\u00a0streptokinase\u00a0or\u00a0urokinase. 9.3.5.1\u00a0Thrombolysis\u00a0and\u00a0bleeding\nMild\u00a0bleeding\u00a0(such\u00a0as\u00a0oozing\u00a0from\u00a0wound)\u00a0can\u00a0be\u00a0treated\u00a0by\u00a0local\u00a0pressure\u00a0and\nsupportive\u00a0care. Major\u00a0bleeding\u00a0may\u00a0be\u00a0treated\u00a0by\u00a0stopping\u00a0thrombolytic\u00a0therapy\nand\u00a0 administering\u00a0 cryoprecipitate\u00a0 (1\u00a0 unit/5\u00a0 kg\u00a0 or\u00a0 5\u00a0 to\u00a0 10\u00a0 mL/kg\u00a0 dose)\u00a0 and\u00a0 an\nantifibrinolytic\u00a0or\u00a0both.260\n9.3.6\u00a0Surgical\u00a0thrombectomy\nSurgical\u00a0thrombectomy\u00a0is\u00a0rarely\u00a0used\u00a0in\u00a0children\u00a0and\u00a0is\u00a0restricted\u00a0to\u00a0the\u00a0following\nsituations\u00a0(Table\u00a09.3.6):\n9.3.7\u00a0Specific\u00a0recommendations\nListed\u00a0 in\u00a0 Table\u00a0 9.3.7\u00a0 are\u00a0 the\u00a0 summarised\u00a0 recommendations\u00a0 from\u00a0 the\u00a0 9th\u00a0 ACCP\nguidelines\u00a02012\u00a0on\u00a0antithrombotic\u00a0therapy\u00a0in\u00a0neonates\u00a0and\u00a0children.260\n1. Before\u00a0thrombolysis\u00a0is\u00a0used,\u00a0concurrent\u00a0haemostatic\u00a0problems\u00a0such\u00a0as\nthrombocytopenia\u00a0and\u00a0vitamin\u00a0K\u00a0deficiency\u00a0should\u00a0be\u00a0corrected\n2. Pre\u00adtherapy\u00a0plasminogen\u00a0replenishment\u00a0through\u00a0fresh\u00a0frozen\u00a0plasma\n(10\u00ad15\u00a0mL/kg)\u00a0is\u00a0given\n3. UFH\u00a0is\u00a0reduced\u00a0to\u00a010\u00a0units/kg/hour\u00a0throughout\u00a0the\u00a0duration\u00a0of\u00a0tPA\ntherapy\u00a0and\u00a0resumed\u00a0at\u00a0previous\u00a0therapeutic\u00a0dose\u00a0subsequently\n4.", "chunk_order": 58}
{"chunk_id": "50ddac9b-b060-4bb4-8f8d-8a3255102a48", "source_document_filename": "CPG Prevention and Treatment of Venous Thrombosis_cleaned_ultra_minimal.txt", "source_document_title": "CPG Prevention and Treatment of Venous Thrombosis cleaned ultra minimal", "text": "Before\u00a0thrombolysis\u00a0is\u00a0used,\u00a0concurrent\u00a0haemostatic\u00a0problems\u00a0such\u00a0as\nthrombocytopenia\u00a0and\u00a0vitamin\u00a0K\u00a0deficiency\u00a0should\u00a0be\u00a0corrected\n2. Pre\u00adtherapy\u00a0plasminogen\u00a0replenishment\u00a0through\u00a0fresh\u00a0frozen\u00a0plasma\n(10\u00ad15\u00a0mL/kg)\u00a0is\u00a0given\n3. UFH\u00a0is\u00a0reduced\u00a0to\u00a010\u00a0units/kg/hour\u00a0throughout\u00a0the\u00a0duration\u00a0of\u00a0tPA\ntherapy\u00a0and\u00a0resumed\u00a0at\u00a0previous\u00a0therapeutic\u00a0dose\u00a0subsequently\n4. t\u00adPA\u00a0at\u00a00.5\u00a0mg/kg/hour\u00a0infused\u00a0over\u00a06\u00a0hour\nTable\u00a09.3.5:\u00a0Thrombolytic\u00a0therapy\u00a0with\u00a0tPA260\n1. IVC\u00a0thrombosis\u00a0in\u00a0association\u00a0with\u00a0intravascular\u00a0extension\u00a0of\u00a0Wilms\u2019\ntumour\n2. Acute\u00a0thrombosis\u00a0of\u00a0Blalock\u00adTaussig\u00a0shunt\n3. Life\u00adthreatening\u00a0intracardiac\u00a0thrombosis\u00a0immediately\u00a0after\u00a0complex\ncardiac\u00a0surgery\n4. Prosthetic\u00a0valve\u00a0thrombosis\n5. Septic\u00a0thrombosis\n6.", "chunk_order": 59}
{"chunk_id": "84803996-6548-4fc3-8e55-2fb3f462516c", "source_document_filename": "CPG Prevention and Treatment of Venous Thrombosis_cleaned_ultra_minimal.txt", "source_document_title": "CPG Prevention and Treatment of Venous Thrombosis cleaned ultra minimal", "text": "t\u00adPA\u00a0at\u00a00.5\u00a0mg/kg/hour\u00a0infused\u00a0over\u00a06\u00a0hour\nTable\u00a09.3.5:\u00a0Thrombolytic\u00a0therapy\u00a0with\u00a0tPA260\n1. IVC\u00a0thrombosis\u00a0in\u00a0association\u00a0with\u00a0intravascular\u00a0extension\u00a0of\u00a0Wilms\u2019\ntumour\n2. Acute\u00a0thrombosis\u00a0of\u00a0Blalock\u00adTaussig\u00a0shunt\n3. Life\u00adthreatening\u00a0intracardiac\u00a0thrombosis\u00a0immediately\u00a0after\u00a0complex\ncardiac\u00a0surgery\n4. Prosthetic\u00a0valve\u00a0thrombosis\n5. Septic\u00a0thrombosis\n6. Peripheral\u00a0artery\u00a0thrombosis\u00a0secondary\u00a0to\u00a0vascular\u00a0access\u00a0in\nneonates\nTable\u00a09.3.6:\u00a0Indications\u00a0for\u00a0surgical\u00a0thrombectomy\u00a0in\u00a0children260\nRecommendations\nGrade\nTable\u00a09.3.7:\u00a0Antithrombotic\u00a0Therapy\u00a0and\u00a0Prevention\u00a0of\u00a0Thrombosis\nin\u00a0Children\nCVADs\u00a0and\u00a0UVCs\u00a0associated\u00a0with\u00a0confirmed\u00a0thrombosis\nInitial\u00a0anticoagulation\u00a0with\u00a0LMWH\u00a0or\u00a0UFH\u00a0followed\u00a0by\u00a0LMWH\u00a0or\nsupportive\u00a0care\u00a0with\u00a0radiologic\u00a0monitoring\u00a0for\u00a0extension\nStart\u00a0anticoagulation\u00a0if\u00a0extension\u00a0occurs\nRemove\u00a0after\u00a03\u00a0to\u00a05\u00a0days\u00a0of\u00a0therapeutic\u00a0anticoagulation\u00a0rather\nthan\u00a0left\u00a0in\u00adsitu\nTotal\u00a0 duration\u00a0 of\u00a0 anticoagulation\u00a0 of\u00a0 between\u00a0 6\u00a0 weeks\u00a0 and\u00a0 3\nmonths\nIf\u00a0 either\u00a0 a\u00a0 CVAD\u00a0 or\u00a0 UVC\u00a0 is\u00a0 still\u00a0 in\u00a0 place\u00a0 on\u00a0 completion\u00a0 of\nanticoagulation,\u00a0prophylactic\u00a0dose\u00a0of\u00a0anticoagulation\u00a0should\u00a0be\ngiven\u00a0until\u00a0catheter\u00a0is\u00a0removed\nUnilateral\u00a0renal\u00a0vein\u00a0thrombosis\u00a0without\u00a0renal\u00a0impairment\u00a0or\u00a0IVC\u00a0extension\nInitial\u00a0anticoagulation\u00a0with\u00a0LMWH\u00a0or\u00a0UFH\u00a0followed\u00a0by\u00a0LMWH\u00a0or\nsupportive\u00a0care\u00a0with\u00a0radiologic\u00a0monitoring\u00a0for\u00a0extension\nStart\u00a0anticoagulation\u00a0if\u00a0extension\u00a0occurs\nTotal\u00a0 duration\u00a0 of\u00a0 anticoagulation\u00a0 of\u00a0 between\u00a0 6\u00a0 weeks\u00a0 and\u00a0 3\nmonths\nUnilateral\u00a0renal\u00a0vein\u00a0thrombosis\u00a0with\u00a0IVC\u00a0extension\nAnticoagulation\u00a0 with\u00a0 LMWH\u00a0 or\u00a0 UFH/LMWH\u00a0 for\u00a0 6\u00a0 weeks\u00a0 to\u00a0 3\nmonths\nBilateral\u00a0renal\u00a0vein\u00a0thrombosis\u00a0with\u00a0renal\u00a0impairment\nUFH/LMWH\u00a0or\u00a0initial\u00a0thrombolytic\u00a0therapy\u00a0with\u00a0t\u00adPA\u00a0followed\u00a0by\nUFH/LMWH\nNeonates\u00a0with\u00a0CVADs\nMaintain\u00a0 patency\u00a0 with\u00a0 continuous\u00a0 infusion\u00a0 of\u00a0 UFH\u00a0 at\u00a0 0.5\nunits/kg/h\u00a0or\u00a0intermittent\u00a0local\u00a0thrombolysis\nBlocked\u00a0CVADs\nLocal\u00a0thrombolysis\u00a0after\u00a0clinical\u00a0assessment\nAcute\u00a0femoral\u00a0artery\u00a0thrombosis\nIV\u00a0UFH\u00a0or\u00a0LMWH\u00a0for\u00a05\u00a0to\u00a07\u00a0days\nC\nC\nC\nC\nC\nC\nC\nC\nC\nC\nC\nC\nC\nLimb\u00adthreatening\u00a0or\u00a0organ\u00adthreatening\u00a0acute\u00a0femoral\u00a0artery\u00a0thrombosis\nwho\u00a0fail\u00a0to\u00a0respond\u00a0to\u00a0initial\u00a0IV\u00a0UFH\nThrombolytic\u00a0therapy\nSurgical\u00a0 thrombectomy\u00a0 if\u00a0 contraindication\u00a0 to\u00a0 thrombolytic\ntherapy\u00a0or\u00a0limb\u00a0death\u00a0is\u00a0imminent\nPeripheral\u00a0arterial\u00a0catheters\u00a0in\u00adsitu\nUFH\u00a0continuous\u00a0infusion\u00a0at\u00a00.5\u00a0units/mL\u00a0at\u00a01\u00a0mL/h\nPeripheral\u00a0arterial\u00a0catheter\u00adrelated\u00a0TE\nImmediate\u00a0removal\u00a0of\u00a0catheter\nUFH\u00a0 or\u00a0 LMWH\u00a0 with\u00a0 or\u00a0 without\u00a0 thrombolysis\u00a0 or\u00a0 surgical\nthrombectomy\nNeonates\u00a0with\u00a0UAC\nProphylaxis\u00a0 with\u00a0 low\u00addose\u00a0 UFH\u00a0 infusion\u00a0 via\u00a0 UAC\u00a0 (heparin\nconcentration\u00a0 0.25\u00ad1\u00a0 unit/mL,\u00a0 total\u00a0 heparin\u00a0 dose\u00a0 of\u00a0 25\u00ad200\nunits/kg/day)\u00a0to\u00a0maintain\u00a0patency\nCardiac\u00a0catheterization\u00a0via\u00a0an\u00a0artery\nIV\u00a0UFH\u00a0(100\u00a0units/kg\u00a0bolus)\u00a0as\u00a0thromboprophylaxis\u00a0or\u00a0aspirin\nCerebral\u00a0sino\u00advenous\u00a0thrombosis\u00a0without\u00a0significant\u00a0intracranial\nhaemorrhage\nUFH/LMWH\u00a0or\u00a0LMWH\u00a0for\u00a0between\u00a06\u00a0weeks\u00a0and\u00a03\u00a0months\nCerebral\u00a0sino\u00advenous\u00a0thrombosis\u00a0with\u00a0significant\u00a0intracranial\nhaemorrhage\nSupportive\u00a0care\u00a0with\u00a0radiologic\u00a0monitoring\u00a0at\u00a05\u00a0to\u00a07\u00a0days\nAnticoagulation\u00a0if\u00a0thrombus\u00a0extends\nFirst\u00a0arterial\u00a0ischaemic\u00a0stroke\u00a0(AIS)\u00a0in\u00a0the\u00a0absence\u00a0of\u00a0documented\nembolic\u00a0source\nSupportive\u00a0care\nFirst\u00a0AIS\u00a0with\u00a0a\u00a0documented\u00a0embolic\u00a0source\nAnticoagulation\u00a0with\u00a0LMWH\u00a0or\u00a0VKA\u00a0for\u00a0at\u00a0least\u00a03\u00a0months\nRecurrent\u00a0AIS\nAnticoagulant\u00a0or\u00a0aspirin\nC\nA\nB\nC\nA\nA,B\nC\nC\nC\nC\nC\nB\nC\nC\nC\nC\nC,C,B,C\nA\n9.4\u00a0FERTILITY\u00a0TREATMENT\u00a0AND\u00a0VENOUS\u00a0THROMBOEMBOLISM\n9.4.1\u00a0Introduction\nWorldwide,\u00a0 the\u00a0 use\u00a0 of\u00a0 assisted\u00a0 reproductive\u00a0 technology\u00a0 (ART)\u00a0 has\u00a0 increased\nexponentially\u00a0over\u00a0the\u00a0past\u00a0three\u00a0decades\u00a0and\u00a0Malaysia\u00a0has\u00a0seen\u00a0a\u00a0similar\u00a0trend.", "chunk_order": 60}
{"chunk_id": "aeb143b0-ccca-4175-8e81-187d41f86af6", "source_document_filename": "CPG Prevention and Treatment of Venous Thrombosis_cleaned_ultra_minimal.txt", "source_document_title": "CPG Prevention and Treatment of Venous Thrombosis cleaned ultra minimal", "text": "While\u00a0 ART\u00a0 is\u00a0 an\u00a0 umbrella\u00a0 term\u00a0 that\u00a0 refers\u00a0 to\u00a0 all\u00a0 fertility\u00a0 procedures,\u00a0 in\u00advitro\nfertilization\u00a0(IVF)\u00a0with\u00a0concurrent\u00a0ovarian\u00a0stimulation\u00a0is\u00a0the\u00a0most\u00a0common\u00a0form\u00a0of\nART\u00a0that\u00a0may\u00a0result\u00a0in\u00a0venous\u00a0thromboembolism. 9.4.2\u00a0Complication\u00a0of\u00a0ART\nA\u00a0known\u00a0but\u00a0rare\u00a0complication\u00a0of\u00a0ART\u00a0is\u00a0arterial\u00a0and\u00a0venous\u00a0thromboembolism. The\u00a0incidence\u00a0ofarterial\u00a0and\u00a0venous\u00a0thromboembolic\u00a0complications\u00a0during\u00a0IVF\u00a0is\napproximately\u00a00.1%\u00a0of\u00a0treatment\u00a0cycles\u00a0and\u00a0has\u00a0primarily\u00a0been\u00a0ascribed\u00a0to\u00a0the\npresence\u00a0of\u00a0ovarian\u00a0hyperstimulation\u00a0syndrome\u00a0(OHSS).263,327\u00a0This\u00a0risk\u00a0is\u00a0even\ngreater\u00a0should\u00a0the\u00a0IVF\u00a0cycle\u00a0be\u00a0successful. Idiopathic\u00a0first\u00a0VTE\nLMWH\u00a0or\u00a0UFH\u00a0followed\u00a0by\u00a0VKA\u00a0for\u00a06\u00a0to\u00a012\u00a0months\nProvoked\u00a0VTE\nAnticoagulant\u00a0therapy\u00a0for\u00a03\u00a0months\nLife\u00a0or\u00a0limb\u00adthreatening\u00a0thrombosis\nSystemic\u00a0thrombolysis\u00a0or\u00a0catheter\u00addirected\u00a0thrombolysis\nLife\u00adthreatening\u00a0VTE\nSurgical\u00a0thrombectomy\nLong\u00adterm\u00a0home\u00a0total\u00a0parenteral\u00a0nutrition\nThromboprophylaxis\u00a0with\u00a0VKAs\nHomozygous\u00a0Protein\u00a0C\u00a0deficiency\u00a0with\u00a0purpura\u00a0fulminans\n10\u00a0to\u00a020\u00a0mL/kg\u00a0of\u00a0FFP\u00a0every\u00a012h\u00a0or\u00a0protein\u00a0C\u00a0concentrate\u00a0at\n20\u00ad60\u00a0uints/kg\u00a0until\u00a0lesions\u00a0resolved\nLong\u00a0 term\u00a0 VKA,\u00a0 LMWH,\u00a0 protein\u00a0 C\u00a0 replacement\u00a0 or\u00a0 liver\ntransplantation\nCVAD\u00a0=\u00a0Central\u00a0Venous\u00a0Access\u00a0Devices\nUVC\u00a0=\u00a0Umbilical\u00a0Venous\u00a0Catheters\nVKA\u00a0=\u00a0Vitamin\u00a0K\u00a0antagonist\nAmong\u00a0IVF\u00a0patients\u00a0who\u00a0conceived,\u00a0women\u00a0with\u00a0a\u00a0diagnosis\u00a0of\u00a0OHSS\u00a0were\u00a0at\u00a0a\n100\u00adfold\u00a0increased\u00a0risk\u00a0of\u00a0VTE\u00a0during\u00a0the\u00a0first\u00a0trimester,\u00a0whereas\u00a0women\u00a0without\nOHSS\u00a0were\u00a0at\u00a0a\u00a0five\u00adfold\u00a0increased\u00a0risk\u00a0as\u00a0compared\u00a0to\u00a0pregnant\u00a0women\u00a0who\nconceived\u00a0spontaneously.328\u00a0Up\u00a0to\u00a031%\u00a0of\u00a0thromboembolic\u00a0events\u00a0occurred\u00a0even\nin\u00a0women\u00a0who\u00a0did\u00a0not\u00a0get\u00a0pregnant.263\n9.4.2.1\u00a0Ovarian\u00a0Hyperstimulation\u00a0Syndrome\nOvarian\u00a0hyperstimulation\u00a0syndrome\u00a0(OHSS)\u00a0is\u00a0an\u00a0iatrogenic\u00a0and\u00a0potentially\u00a0fatal\ncomplication\u00a0and\u00a0occurs\u00a0in\u00a0its\u00a0mild\u00a0form\u00a0in\u00a0up\u00a0to\u00a033%\u00a0of\u00a0all\u00a0IVF\u00a0cycles. However,\nmoderate\u00a0or\u00a0severe\u00a0OHSS\u00a0may\u00a0complicate\u00a03\u00a0to\u00a08%\u00a0of\u00a0successful\u00a0IVF\u00a0cycles\u00a0(see\nTable\u00a09.4.2.1).266,268,329\n9.4.2.1.1\u00a0Pathogenesis\u00a0of\u00a0thrombosis\u00a0in\u00a0OHSS\nThe\u00a0mechanism\u00a0by\u00a0which\u00a0OHSS\u00a0creates\u00a0a\u00a0prothrombotic\u00a0state\u00a0remains\u00a0uncertain\nbut\u00a0 may\u00a0 involve\u00a0 changes\u00a0 in\u00a0 coagulation\u00a0 factors,\u00a0 markers\u00a0 of\u00a0 fibrinolysis,\u00a0 high\nlocalised\u00a0estrogen\u00a0and\u00a0the\u00a0possible\u00a0presence\u00a0of\u00a0rudimentary\u00a0brachial\u00a0cysts. Venous\u00a0events\u00a0occur\u00a0in\u00a0approximately\u00a075%\u00a0of\u00a0cases.330\u00a0While\u00a0arterial\u00a0events\nusually\u00a0occur\u00a0concurrently\u00a0with\u00a0the\u00a0onset\u00a0of\u00a0OHSS,\u00a0at\u00a0a\u00a0mean\u00a0of\u00a010\u00a0days\u00a0after\nthe\u00a0embryo\u00a0transfer,\u00a0venous\u00a0events\u00a0occur\u00a0several\u00a0weeks\u00a0later\u00a0even\u00a0after\u00a0the\nclinical\u00a0 resolution\u00a0 of\u00a0 OHSS,\u00a0 occurring\u00a0 at\u00a0 a\u00a0 mean\u00a0 of\u00a0 40\u00a0 to\u00a0 42\u00a0 days\u00a0 after\u00a0 the\nembryo\u00a0transfer.263\nGrade\nSymptoms\nMild\u00a0OHSS\nModerate\u00a0OHSS\nSevere\u00a0OHSS\nCritical\u00a0OHSS\nTable\u00a09.4.2.1:\u00a0Classification\u00a0of\u00a0severity\u00a0of\u00a0OHSS6\nAbdominal\u00a0bloating\nMild\u00a0abdominal\u00a0pain\nOvarian\u00a0size\u00a0usually\u00a0<8\u00a0cm\nModerate\u00a0abdominal\u00a0pain\nNausea\u00a0\u00b1\u00a0vomiting\nUltrasound\u00a0evidence\u00a0of\u00a0ascites\nOvarian\u00a0size\u00a08\u00a0\u00ad\u00a012\u00a0cm\nClinical\u00a0ascites\u00a0(occasionally\nhydrothorax)\nOliguria\nHaematocrit\u00a0>45%\nHypoproteinemia\nOvarian\u00a0size\u00a0usually\u00a0>12\u00a0cm\nTense\u00a0ascites\u00a0or\u00a0large\u00a0hydrothorax\nHaematocrit\u00a0>55%\nWhite\u00a0cell\u00a0count\u00a0>25\u00a0x\u00a0109/L\nOliguria/\u00a0anuria\nThromboembolism\nAcute\u00a0respiratory\u00a0distress\u00a0syndrome\n9.4.2.1.2\u00a0Diagnosis\u00a0of\u00a0thrombosis\u00a0following\u00a0ART\nArterial\u00a0 thromboses\u00a0 are\u00a0 predominantly\u00a0 cerebrovascular\u00a0 accidents,\u00a0 whereas\nvenous\u00a0 events\u00a0 are\u00a0 mostly\u00a0 reported\u00a0 in\u00a0 unusual\u00a0 sites\u00a0 such\u00a0 as\u00a0 the\u00a0 upper\nextremities.", "chunk_order": 61}
{"chunk_id": "f469af91-57b6-4d5b-a323-4118a6c2e986", "source_document_filename": "CPG Prevention and Treatment of Venous Thrombosis_cleaned_ultra_minimal.txt", "source_document_title": "CPG Prevention and Treatment of Venous Thrombosis cleaned ultra minimal", "text": "In\u00a0 patients\u00a0 who\u00a0 develop\u00a0 unusual\u00a0 symptoms\u00a0 (neurological\u00a0 symptoms\u00a0 or\u00a0 neck\npain)\u00a0following\u00a0ART,\u00a0and\u00a0especially\u00a0in\u00a0those\u00a0who\u00a0develop\u00a0OHSS,\u00a0the\u00a0presence\nof\u00a0arterial\u00a0and\u00a0venous\u00a0thrombotic\u00a0events\u00a0should\u00a0be\u00a0considered\u00a0and\u00a0appropriate\ninvestigations\u00a0carried\u00a0out. 9.4.2.1.3\u00a0Treatment\u00a0of\u00a0thrombosis\u00a0following\u00a0ART\nPatients\u00a0 who\u00a0 develop\u00a0 venous\u00a0 thrombosis\u00a0 should\u00a0 be\u00a0 treated\u00a0 with\u00a0 therapeutic\nLMWH\u00a0throughout\u00a0pregnancy\u00a0and\u00a0for\u00a0up\u00a0to\u00a0six\u00a0weeks\u00a0postpartum. All\u00a0 patients\u00a0 who\u00a0 develop\u00a0 venous\u00a0 thrombosis\u00a0 should\u00a0 be\u00a0 monitored\u00a0 closely\u00a0 as\napproximately\u00a010%\u00a0of\u00a0these\u00a0patients\u00a0may\u00a0develop\u00a0progression\u00a0of\u00a0thrombi,\u00a0within\ndays,\u00a0even\u00a0after\u00a0they\u00a0have\u00a0been\u00a0initiated\u00a0on\u00a0therapeutic\u00a0coagulation.267\u00a0Future\nstudies\u00a0 are\u00a0 needed\u00a0 to\u00a0 determine\u00a0 the\u00a0 appropriate\u00a0 dosage\u00a0 of\u00a0 anticoagulation\nrequired. 9.4.3\u00a0Thromboprophylaxis\u00a0in\u00a0OHSS\nThere\u00a0is\u00a0no\u00a0evidence\u00a0to\u00a0recommend\u00a0routine\u00a0use\u00a0of\u00a0thromboprophylaxis\u00a0in\u00a0all\npatients\u00a0undergoing\u00a0IVF. In\u00a0patients\u00a0who\u00a0develop\u00a0moderate\u00a0to\u00a0severe\u00a0OHSS,\nthromboprophylaxis\u00a0 should\u00a0 be\u00a0 initiated. Consideration\u00a0 should\u00a0 be\u00a0 given\u00a0 to\ncontinue\u00a0thromboprophylaxis\u00a0for\u00a0a\u00a0minimum\u00a0of\u00a04\u00a0weeks\u00a0beyond\u00a0the\u00a0resolution\u00a0of\nsymptomatic\u00a0OHSS\u00a0if\u00a0the\u00a0cycle\u00a0is\u00a0unsuccessful\u00a0and\u00a0possibly\u00a0for\u00a0up\u00a0to\u00a013\u00a0weeks\nduration\u00a0if\u00a0the\u00a0patient\u00a0conceives. It\u00a0is\u00a0recommended\u00a0that\u00a0this\u00a0option\u00a0is\u00a0discussed\nwith\u00a0the\u00a0patient\u00a0taking\u00a0into\u00a0consideration\u00a0that\u00a0while\u00a0the\u00a0actual\u00a0risk\u00a0of\u00a0thrombosis\nis\u00a0small,\u00a0the\u00a0consequences\u00a0may\u00a0be\u00a0significant\u00a0and\u00a0the\u00a0use\u00a0of\u00a0thromboprohylaxis\nhas\u00a0cost\u00a0implications. Recommendations\nGrade\nC\nB\nC\nTable\u00a09.4.3:\u00a0Thromboprophylaxis\u00a0and\u00a0treatment\u00a0of\u00a0VTE\u00a0following\u00a0ART\nThromboprophylaxis\u00a0 should\u00a0 be\u00a0 initiated\u00a0 In\u00a0 patients\u00a0 who\u00a0 develop\nmoderate\u00a0to\u00a0severe\u00a0OHSS\nThromboprophylaxis\u00a0should\u00a0be\u00a0continued\u00a0for\u00a0a\u00a0minimum\u00a0of\u00a04\u00a0weeks\nbeyond\u00a0 the\u00a0 resolution\u00a0 of\u00a0 symptomatic\u00a0 OHSS\u00a0 if\u00a0 the\u00a0 cycle\u00a0 is\nunsuccessful\u00a0and\u00a0possibly\u00a0for\u00a0up\u00a0to\u00a013\u00a0weeks\u00a0duration\u00a0if\u00a0the\u00a0patient\nconceives\u00a0(option\u00a0discussed\u00a0with\u00a0patient)\nPatients\u00a0who\u00a0develop\u00a0venous\u00a0thrombosis\u00a0following\u00a0ART\u00a0should\u00a0be\ntreated\u00a0with\u00a0therapeutic\u00a0LMWH\u00a0throughout\u00a0pregnancy\u00a0and\u00a0for\u00a0up\u00a0to\nsix\u00a0weeks\u00a0postpartum\n9.5\u00a0HORMONAL\u00a0CONTRACEPTION\u00a0AND\u00a0VTE\n9.5.1\u00a0Introduction\nCombined\u00a0hormonal\u00a0contraception\u00a0includes\u00a0the\u00a0combined\u00a0oral\u00a0contraceptive\u00a0pills\n(COC),\u00a0 the\u00a0 combined\u00a0 hormonal\u00a0 patch,\u00a0 the\u00a0 combined\u00a0 hormonal\u00a0 ring\u00a0 and\u00a0 the\ncombined\u00a0injectable\u00a0variety. The\u00a0COC\u00a0is\u00a0by\u00a0far\u00a0the\u00a0most\u00a0commonly\u00a0utilised\u00a0form\u00a0of\ncombined\u00a0hormonal\u00a0contraception\u00a0and\u00a0therefore\u00a0most\u00a0data\u00a0regarding\u00a0the\u00a0use\u00a0of\ncombined\u00a0 contraceptives\u00a0 are\u00a0 extrapolated\u00a0 from\u00a0 evidence\u00a0 from\u00a0 COC\u00a0 use. In\naddition\u00a0to\u00a0combined\u00a0hormonal\u00a0contraception,\u00a0certain\u00a0options\u00a0may\u00a0contain\u00a0only\u00a0a\nprogestogen\u00a0and\u00a0is\u00a0used\u00a0either\u00a0orally,\u00a0an\u00a0injectable\u00a0or\u00a0as\u00a0an\u00a0implant.269\u00ad276\n9.5.2\u00a0Oral\u00a0contraception\u00a0and\u00a0VTE\u00a0risk\nIn\u00a0women\u00a0in\u00a0the\u00a0reproductive\u00a0age\u00a0group\u00a0who\u00a0do\u00a0not\u00a0use\u00a0oral\u00a0contraception,\u00a0the\nrisk\u00a0of\u00a0VTE\u00a0is\u00a0approximately\u00a04\u00a0to\u00a05/10,000\u00a0women\u00adyears. The\u00a0risk\u00a0of\u00a0VTE\u00a0amongst\nCOC\u00a0users\u00a0is\u00a0approximately\u00a0twice\u00a0that\u00a0of\u00a0non\u00adusers\u00a0(9\u00a0to\u00a010/10,000\u00a0woman\u00adyears\n\u2013\u00a0average\u00a0across\u00a0all\u00a0brands\u00a0studied).274\nThe\u00a0risk\u00a0of\u00a0VTE\u00a0is\u00a0greatest\u00a0in\u00a0the\u00a0first\u00a0few\u00a0months\u00a0of\u00a0starting\u00a0COC,\u00a0after\u00a0which\u00a0the\nrisk\u00a0falls\u00a0although\u00a0is\u00a0still\u00a0higher\u00a0than\u00a0among\u00a0non\u00adusers\u00a0until\u00a0COC\u00a0is\u00a0stopped.270\u00ad274\nThe\u00a0risk\u00a0returns\u00a0to\u00a0levels\u00a0that\u00a0of\u00a0non\u00adusers\u00a0within\u00a0weeks\u00a0of\u00a0discontinuation.274\nBoth\u00a0the\u00a0estrogen\u00a0and\u00a0progestogen\u00a0content\u00a0of\u00a0the\u00a0combined\u00a0oral\u00a0contraceptive\npill\u00a0 have\u00a0 been\u00a0 implicated\u00a0 in\u00a0 differences\u00a0 in\u00a0 venous\u00a0 thrombotic\u00a0 risk\u00a0 between\nproducts.", "chunk_order": 62}
{"chunk_id": "e0135db3-eed6-4b0a-a3fb-5b56214f3be6", "source_document_filename": "CPG Prevention and Treatment of Venous Thrombosis_cleaned_ultra_minimal.txt", "source_document_title": "CPG Prevention and Treatment of Venous Thrombosis cleaned ultra minimal", "text": "The\u00a0risk\u00a0of\u00a0VTE\u00a0amongst\nCOC\u00a0users\u00a0is\u00a0approximately\u00a0twice\u00a0that\u00a0of\u00a0non\u00adusers\u00a0(9\u00a0to\u00a010/10,000\u00a0woman\u00adyears\n\u2013\u00a0average\u00a0across\u00a0all\u00a0brands\u00a0studied).274\nThe\u00a0risk\u00a0of\u00a0VTE\u00a0is\u00a0greatest\u00a0in\u00a0the\u00a0first\u00a0few\u00a0months\u00a0of\u00a0starting\u00a0COC,\u00a0after\u00a0which\u00a0the\nrisk\u00a0falls\u00a0although\u00a0is\u00a0still\u00a0higher\u00a0than\u00a0among\u00a0non\u00adusers\u00a0until\u00a0COC\u00a0is\u00a0stopped.270\u00ad274\nThe\u00a0risk\u00a0returns\u00a0to\u00a0levels\u00a0that\u00a0of\u00a0non\u00adusers\u00a0within\u00a0weeks\u00a0of\u00a0discontinuation.274\nBoth\u00a0the\u00a0estrogen\u00a0and\u00a0progestogen\u00a0content\u00a0of\u00a0the\u00a0combined\u00a0oral\u00a0contraceptive\npill\u00a0 have\u00a0 been\u00a0 implicated\u00a0 in\u00a0 differences\u00a0 in\u00a0 venous\u00a0 thrombotic\u00a0 risk\u00a0 between\nproducts. However,\u00a0even\u00a0if\u00a0these\u00a0risks\u00a0are\u00a0real,\u00a0the\u00a0absolute\u00a0difference\u00a0in\u00a0risk\nbetween\u00a0 products\u00a0 is\u00a0 small,\u00a0 because\u00a0 the\u00a0 background\u00a0 incidence\u00a0 of\u00a0 venous\nthromboembolism\u00a0in\u00a0young\u00a0women\u00a0is\u00a0essentially\u00a0low.274\nCurrent\u00a0 use\u00a0 of\u00a0 drospirenone\u00a0 or\u00a0 cyproterone\u00a0 oral\u00a0 combined\u00a0 contraceptives\nincreases\u00a0the\u00a0risk\u00a0of\u00a0VTE\u00a0compared\u00a0with\u00a0second\u00a0generation\u00a0pills. In\u00a0the\u00a0context\u00a0of\ncontraceptive\u00a0use,\u00a0non\u00adoral\u00a0route\u00a0of\u00a0ethinyl\u00adestradiol\u00a0administration\u00a0seems\u00a0to\u00a0be\nmore\u00a0thrombogenic\u00a0than\u00a0oral\u00a0route.274\nVenous\u00a0 thromboembolism\u00a0 appears\u00a0 to\u00a0 be\u00a0 higher\u00a0 in\u00a0 overweight\u00a0 users\u00a0 while\u00a0 the\nassociation\u00a0 with\u00a0 smoking\u00a0 is\u00a0 still\u00a0 controversial\u00a0 (smoking\u00a0 increases\u00a0 the\u00a0 risk\u00a0 of\narterial\u00a0thrombosis\u00a0by\u00a02\u00a0to\u00a04\u00a0fold).331\u00a0It\u00a0is\u00a0recommended\u00a0that\u00a0for\u00a0women\u00a0with\u00a0a\u00a0body\nmass\u00a0index\u00a0of\u00a035\u00a0kg/m2\u00a0or\u00a0greater,\u00a0the\u00a0risks\u00a0of\u00a0CHC\u00a0may\u00a0outweigh\u00a0the\u00a0benefits. For\u00a0women\u00a0aged\u00a0over\u00a035\u00a0years\u00a0who\u00a0are\u00a0current\u00a0smokers\u00a0or\u00a0who\u00a0have\u00a0stopped\nsmoking\u00a0less\u00a0than\u00a01\u00a0year\u00a0ago,\u00a0the\u00a0use\u00a0of\u00a0CHC\u00a0is\u00a0not\u00a0recommended.332\n9.5.3\u00a0Medical\u00a0Eligibility\u00a0Criteria\u00a0for\u00a0Contraceptive\u00a0Use\nThe\u00a0\u2018Medical\u00a0eligibility\u00a0criteria\u00a0for\u00a0contraceptive\u00a0use\u2019\u00a0is\u00a0an\u00a0evidence\u00adbased\u00a0family\nplanning\u00a0 guideline\u00a0 produced\u00a0 by\u00a0 the\u00a0 World\u00a0 Health\u00a0 Organization\u00a0 that\u00a0 provides\nguidance\u00a0regarding\u00a0\u201cwho\u201d\u00a0can\u00a0use\u00a0contraceptive\u00a0methods\u00a0safely.276\nMedical\u00a0Elligibility\nCategory\n1\n2\n3\n4\nRecommendations\nGrade\nB\nB\nC\nB\nB\nTable\u00a09.5:\u00a0Combined\u00a0hormonal\u00a0contraception\nHealthcare\u00a0 professionals\u00a0 should\u00a0 be\u00a0 aware\u00a0 that\u00a0 when\ncompared\u00a0to\u00a0non\u00adusers,\u00a0the\u00a0risk\u00a0of\u00a0VTE\u00a0with\u00a0use\u00a0of\u00a0Combined\nHormonal\u00a0 Contraceptives\u00a0 (CHC)\u00a0 is\u00a0 approximately\u00a0 double.", "chunk_order": 63}
{"chunk_id": "6439dc49-59d8-4ace-a7bd-f555f7c4b92b", "source_document_filename": "CPG Prevention and Treatment of Venous Thrombosis_cleaned_ultra_minimal.txt", "source_document_title": "CPG Prevention and Treatment of Venous Thrombosis cleaned ultra minimal", "text": "However,\u00a0the\u00a0absolute\u00a0risk\u00a0is\u00a0still\u00a0very\u00a0low\nHealthcare\u00a0 professionals\u00a0 who\u00a0 prescribe\u00a0 CHCs\u00a0 should\u00a0 be\nguided\u00a0by\u00a0their\u00a0individual\u00a0preferences,\u00a0risk\u00a0of\u00a0VTE,\u00a0presence\nof\u00a0 contraindications,\u00a0 likely\u00a0 non\u00adcontraceptive\u00a0 benefits\u00a0 and\nexperience\u00a0with\u00a0other\u00a0contraceptive\u00a0formulations\nA\u00a0 history\u00a0 of\u00a0 VTE\u00a0 or\u00a0 a\u00a0 known\u00a0 thrombogenic\u00a0 mutation\u00a0 is\u00a0 a\ncontraindication\u00a0to\u00a0the\u00a0use\u00a0of\u00a0CHC\nFor\u00a0 women\u00a0 with\u00a0 a\u00a0 family\u00a0 history\u00a0 of\u00a0 VTE,\u00a0 a\u00a0 negative\nthrombophilia\u00a0 screen\u00a0 does\u00a0 not\u00a0 necessarily\u00a0 exclude\u00a0 all\nthrombogenic\u00a0mutations\nA\u00a0thrombophilia\u00a0screen\u00a0is\u00a0not\u00a0recommended\u00a0routinely\u00a0before\nprescribing\u00a0CHC\nA\u00a0condition\u00a0where\u00a0the\u00a0advantages\u00a0of\u00a0using\u00a0the\u00a0method\ngenerally\u00a0outweigh\u00a0the\u00a0theoretical\u00a0or\u00a0proven\u00a0risks\nA\u00a0condition\u00a0where\u00a0the\u00a0theoretical\u00a0or\u00a0proven\u00a0risks\u00a0usually\noutweigh\u00a0the\u00a0advantages\u00a0of\u00a0using\u00a0the\u00a0method\nA\u00a0condition\u00a0which\u00a0represents\u00a0an\u00a0unacceptable\u00a0health\u00a0risk\u00a0if\u00a0the\ncontraceptive\u00a0method\u00a0is\u00a0used\nA\u00a0condition\u00a0for\u00a0which\u00a0there\u00a0is\u00a0no\u00a0restriction\u00a0for\u00a0the\u00a0use\u00a0of\u00a0the\ncontraceptive\u00a0method\nDMPA\nNET\u00adET\nLNG/\u00a0ETG\nIMPLANTS\nLNG\nIUD\nCOC\nPOP\n4\n2\n2\n2\n2\n4\n3\n3\n3\n3\n4\n2\n2\n2\n2\n4\n2\n2\n2\n2\n2\n1\n1\n1\n1\n1\n1\n1\n1\n1\n4\n2\n2\n2\n2\n1\n1\n1\n1\n1\n2\n1\n1\n1\n1\n3\n1\n1\n1\n1\n2\n1\n1\n1\n1\nMedical\u00a0Eligibility\u00a0Criteria\u00a0for\u00a0common\u00a0hormonal\u00a0contraceptives\nGlossary\nCombined\u00a0 Hormonal\u00a0 Contraceptives\u00a0 (CHC)\u00a0 includes\u00a0 the\u00a0 combined\u00a0 oral\ncontraceptives\u00a0 (COC),\u00a0 the\u00a0 combined\u00a0 contraceptive\u00a0 patch,\u00a0 the\u00a0 combined\ncontraceptive\u00a0 vaginal\u00a0 ring\u00a0 and\u00a0 the\u00a0 combined\u00a0 injectable\u00a0 contraceptives. All\nthese\u00a0options\u00a0other\u00a0than\u00a0the\u00a0COC\u00a0are\u00a0relatively\u00a0new. Therefore\u00a0only\u00a0the\u00a0COC\u00a0is\nalluded\u00a0to. POP:\u00a0progestogen\u00adonly\u00a0pills\nDMPA\u00a0NET\u00adEN:\u00a0depot\u00a0medroxyprogesterone\u00a0or\u00a0acetate\u00a0norethisterone\u00a0enantate\nLNG/ETG:\u00a0levonorgestrel\u00a0and\u00a0etonogestrel\u00a0implants\nV3WJ2XYZ\"<0Q$9$%>0+C%0<J%0<0)+19>\"2XY\"TO@\"[>\\OM\"E$8%+U\nHistory\u00a0of\u00a0DVT/\u00a0PE\nAcute\u00a0DVT/\u00a0PE\nDVT/\u00a0PE\u00a0and\u00a0established\u00a0on\nanti\u00adcoagulant\u00a0therapy\nFamily\u00a0history\u00a0(first\u00addegree\nrelatives\u00a0<45\u00a0years)\nFamily\u00a0history\u00a0(first\u00addegree\n%0<)C1Q0+\"&M7\"*0)%+U\nMajor\u00a0surgery\u00a0with\u00a0prolonged\nimmobilization\nMajor\u00a0surgery\u00a0without\u00a0prolonged\nimmobilization\nMinor\u00a0surgery\u00a0without\nimmobilization\nKnown\u00a0thrombogenic\u00a0mutations\nVaricose\u00a0veins\nSuperficial\u00a0thrombophlebitis\n9.6\u00a0VENOUS\u00a0THROMBOEMBOLISM\u00a0AND\u00a0CANCER\n9.6.1\u00a0Introduction\nVenous\u00a0 thromboembolism\u00a0 poses\u00a0 a\u00a0 significant\u00a0 clinical\u00a0 problem\u00a0 in\u00a0 patients\u00a0 with\ncancer. Nearly\u00a0 all\u00a0 patients\u00a0 with\u00a0 active\u00a0 malignancy\u00a0 demonstrate\u00a0 some\u00a0 degree\u00a0 of\nactivation\u00a0of\u00a0coagulation\u00a0resulting\u00a0in\u00a0a\u00a0hypercoagulable\u00a0state. Underlying\u00a0malignancy\naccounts\u00a0for\u00a0one\u00a0in\u00a0four\u00a0symptomatic\u00a0VTE. More\u00a0significantly,\u00a0cancer\u00a0associated\nVTE\u00a0has\u00a0a\u00a0high\u00a028\u00adday\u00a0case\u00adfatality\u00a0rate\u00a0of\u00a025%.280\nVTE\u00a0is\u00a0an\u00a0independent\u00a0poor\u00a0prognostic\u00a0factor\u00a0for\u00a0patients\u00a0with\u00a0cancer. Patients\nwith\u00a0cancer\u00a0diagnosed\u00a0at\u00a0the\u00a0same\u00a0time\u00a0of\u00a0acute\u00a0VTE\u00a0have\u00a0a\u00a0greater\u00a0likelihood\u00a0of\ndistant\u00a0metastases\u00a0and\u00a0lower\u00a0survival\u00a0rates. The\u00a0activated\u00a0coagulation\u00a0cascade\nassociated\u00a0with\u00a0VTE\u00a0is\u00a0thought\u00a0to\u00a0promote\u00a0angiogenesis\u00a0and\u00a0metastases. There\u00a0is\nnow\u00a0evidence\u00a0to\u00a0suggest\u00a0that\u00a0LMWH\u00a0treatment\u00a0could\u00a0delay\u00a0metastases\u00a0in\u00a0different\ntumours\u00a0and\u00a0improve\u00a0survival.281,282,284\n9.6.2\u00a0Pathophysiology\u00a0of\u00a0cancer\u00adrelated\u00a0thrombosis\nThe\u00a0natural\u00a0history\u00a0of\u00a0VTE\u00a0in\u00a0cancer\u00a0patients\u00a0is\u00a0different\u00a0from\u00a0non\u00adcancer\u00a0patients. It\u00a0 usually\u00a0 presents\u00a0 with\u00a0 larger\u00a0 and\u00a0 more\u00a0 significant\u00a0 thrombus,\u00a0 greater\u00a0 clinical\ndeterioration\u00a0despite\u00a0anticoagulation\u00a0therapy\u00a0and\u00a0a\u00a0higher\u00a0recurrence\u00a0rate.", "chunk_order": 64}
{"chunk_id": "c57ed39b-c03c-4064-9ebc-478bbb62e2ba", "source_document_filename": "CPG Prevention and Treatment of Venous Thrombosis_cleaned_ultra_minimal.txt", "source_document_title": "CPG Prevention and Treatment of Venous Thrombosis cleaned ultra minimal", "text": "Patients\nwith\u00a0cancer\u00a0diagnosed\u00a0at\u00a0the\u00a0same\u00a0time\u00a0of\u00a0acute\u00a0VTE\u00a0have\u00a0a\u00a0greater\u00a0likelihood\u00a0of\ndistant\u00a0metastases\u00a0and\u00a0lower\u00a0survival\u00a0rates. The\u00a0activated\u00a0coagulation\u00a0cascade\nassociated\u00a0with\u00a0VTE\u00a0is\u00a0thought\u00a0to\u00a0promote\u00a0angiogenesis\u00a0and\u00a0metastases. There\u00a0is\nnow\u00a0evidence\u00a0to\u00a0suggest\u00a0that\u00a0LMWH\u00a0treatment\u00a0could\u00a0delay\u00a0metastases\u00a0in\u00a0different\ntumours\u00a0and\u00a0improve\u00a0survival.281,282,284\n9.6.2\u00a0Pathophysiology\u00a0of\u00a0cancer\u00adrelated\u00a0thrombosis\nThe\u00a0natural\u00a0history\u00a0of\u00a0VTE\u00a0in\u00a0cancer\u00a0patients\u00a0is\u00a0different\u00a0from\u00a0non\u00adcancer\u00a0patients. It\u00a0 usually\u00a0 presents\u00a0 with\u00a0 larger\u00a0 and\u00a0 more\u00a0 significant\u00a0 thrombus,\u00a0 greater\u00a0 clinical\ndeterioration\u00a0despite\u00a0anticoagulation\u00a0therapy\u00a0and\u00a0a\u00a0higher\u00a0recurrence\u00a0rate. VTE\u00a0in\ncancer\u00a0patients\u00a0should\u00a0also\u00a0not\u00a0be\u00a0considered\u00a0as\u00a0a\u00a0\u2018one\u00a0off\u2019\u00a0event\u00a0but\u00a0rather,\u00a0a\nrecurring\u00a0complication\u00a0with\u00a0prognostic\u00a0implications\u037e\u00a0the\u00a0factors\u00a0that\u00a0predispose\u00a0a\ncancer\u00a0patient\u00a0to\u00a0VTE\u00a0usually\u00a0persist\u00a0till\u00a0the\u00a0patient\u00a0is\u00a0in\u00a0remission.285,287\nThe\u00a0mechanisms\u00a0of\u00a0VTE\u00a0in\u00a0patients\u00a0with\u00a0cancer\u00a0are\u00a0summarized\u00a0in\u00a0Table\u00a09.6.2.278\nTumour\u00adassociated\nNon\u00adtumour\u00a0associated\nTable\u00a09.6.2:\u00a0Mechanisms\u00a0of\u00a0VTE\u00a0in\u00a0Cancer\u00a0Patients\nExtrinsic\u00a0vascular\u00a0compression\u00a0&\ninvasion\nTissue\u00a0factor\u00a0production\nCancer\u00a0pro\u00adcoagulant\u00a0production\nAccentuated\u00a0platelet\u00a0activation\nInflammation\u00admediated\u00a0increases\u00a0in\nfactor\u00a0VIII,\u00a0vWF\u00a0and\u00a0fibrinogen\nImpaired\u00a0fibrinolysis\u00a0due\u00a0to\u00a0high\u00a0PAI\u00ad1\nAcquired\u00a0deficiencies\u00a0of\u00a0natural\nanticoagulants\nCentral\u00a0venous\u00a0access\u00a0devices\nAnti\u00adneoplastic\u00a0mediated\u00a0platelet\nactivation\nAnti\u00adneoplastic\u00a0mediated\u00a0endothelial\ncell\u00a0damage\nAnti\u00adangiogenesis\u00a0therapy\nAnthracycline\u00adinduced\u00a0congestive\nheart\u00a0failure\nImmobility\n9.6.3\u00a0Management\u00a0of\u00a0VTE\u00a0in\u00a0cancers\nLow\u00a0 molecular\u00a0 weight\u00a0 heparin\u00a0 is\u00a0 the\u00a0 treatment\u00a0 of\u00a0 choice\u00a0 for\u00a0 the\u00a0 initial\u00a0 and\nlong\u00adterm\u00a0therapy\u00a0of\u00a0patients\u00a0with\u00a0cancer.288,289\u00a0Patients\u00a0with\u00a0cancer\u00a0are\u00a0not\u00a0only\nat\u00a0increased\u00a0risk\u00a0of\u00a0developing\u00a0VTE\u00a0but\u00a0also\u00a0at\u00a0significant\u00a0risk\u00a0of\u00a0recurrent\u00a0VTEs. Therefore,\u00a0 indefinite\u00a0 anticoagulation\u00a0 or\u00a0 until\u00a0 the\u00a0 cancer\u00a0 is\u00a0 resolved\u00a0 is\nrecommended.279\nMany\u00a0 studies\u00a0 have\u00a0 shown\u00a0 that\u00a0 LMWH\u00a0 has\u00a0 superior\u00a0 efficacy\u00a0 with\u00a0 lower\nrecurrence\u00a0 rate\u00a0 and\u00a0 no\u00a0 increase\u00a0 in\u00a0 bleeding\u00a0 compared\u00a0 to\u00a0 warfarin.281,282,284,291\nInterestingly,\u00a0 in\u00a0 the\u00a0 CLOT\u00a0 study,\u00a0 the\u00a0 majority\u00a0 of\u00a0 recurrent\u00a0 VTE\u00a0 occurred\u00a0 in\npatients\u00a0on\u00a0warfarin\u00a0with\u00a0INR\u00a0of\u00a0>2.284\n9.6.4\u00a0Gynaecological\u00a0cancers\n9.6.4.1\u00a0Thromboprophylaxis\nGynaecological\u00a0 cancer\u00a0 patients\u00a0 undergoing\u00a0 surgery\u00a0 are\u00a0 at\u00a0 significant\u00a0 risk\u00a0 of\ndeveloping\u00a0VTE.", "chunk_order": 65}
{"chunk_id": "fb9e8109-c93c-494b-ac6b-5a734bc8fa48", "source_document_filename": "CPG Prevention and Treatment of Venous Thrombosis_cleaned_ultra_minimal.txt", "source_document_title": "CPG Prevention and Treatment of Venous Thrombosis cleaned ultra minimal", "text": "Therefore,\u00a0 indefinite\u00a0 anticoagulation\u00a0 or\u00a0 until\u00a0 the\u00a0 cancer\u00a0 is\u00a0 resolved\u00a0 is\nrecommended.279\nMany\u00a0 studies\u00a0 have\u00a0 shown\u00a0 that\u00a0 LMWH\u00a0 has\u00a0 superior\u00a0 efficacy\u00a0 with\u00a0 lower\nrecurrence\u00a0 rate\u00a0 and\u00a0 no\u00a0 increase\u00a0 in\u00a0 bleeding\u00a0 compared\u00a0 to\u00a0 warfarin.281,282,284,291\nInterestingly,\u00a0 in\u00a0 the\u00a0 CLOT\u00a0 study,\u00a0 the\u00a0 majority\u00a0 of\u00a0 recurrent\u00a0 VTE\u00a0 occurred\u00a0 in\npatients\u00a0on\u00a0warfarin\u00a0with\u00a0INR\u00a0of\u00a0>2.284\n9.6.4\u00a0Gynaecological\u00a0cancers\n9.6.4.1\u00a0Thromboprophylaxis\nGynaecological\u00a0 cancer\u00a0 patients\u00a0 undergoing\u00a0 surgery\u00a0 are\u00a0 at\u00a0 significant\u00a0 risk\u00a0 of\ndeveloping\u00a0VTE. Post\u00adoperatively,\u00a0extended\u00a0duration\u00a0of\u00a0LMWH\u00a0(from\u00a07\u00a0to\u00a028\ndays\u00a0 after\u00a0 surgery)\u00a0 has\u00a0 been\u00a0 shown\u00a0 to\u00a0 significantly\u00a0 reduce\u00a0 the\u00a0 incidence\u00a0 of\nDVT.277\u00a0 Consequently,\u00a0 thromboprophylaxis\u00a0 with\u00a0 extended\u00a0 duration\u00a0 LMWH\nshould\u00a0 be\u00a0 considered\u00a0 in\u00a0 all\u00a0 patients\u00a0 undergoing\u00a0 surgery\u00a0 for\u00a0 gynaecological\nmalignancy.286\n9.6.4.2\u00a0Treatment\u00a0of\u00a0VTE\u00a0in\u00a0patients\u00a0with\u00a0gynaecological\u00a0cancers\nLow\u00a0molecular\u00a0weight\u00a0heparin\u00a0instead\u00a0of\u00a0UFH\u00a0should\u00a0be\u00a0used\u00a0for\u00a0the\u00a0treatment\nof\u00a0VTE\u00a0in\u00a0gynaecological\u00a0cancers.283\u00a0Tinzaparin\u00a0has\u00a0been\u00a0shown\u00a0to\u00a0be\u00a0effective\nwith\u00a0 a\u00a0 once\u00a0 daily\u00a0 dosing.290\u00a0 There\u00a0 is\u00a0 no\u00a0 direct\u00a0 evidence\u00a0 that\u00a0 rivaroxaban\u00a0 is\nsuperior\u00a0to\u00a0LMWH\u00a0in\u00a0patients\u00a0with\u00a0cancer\u00a0but\u00a0may\u00a0be\u00a0an\u00a0alternative\u00a0especially\u00a0in\npatients\u00a0who\u00a0decline\u00a0regular\u00a0injections\u00a0with\u00a0LMWH.1\nB\nRecommendations\nGrade\nA\nA\nTable\u00a09.6.4:\u00a0Prevention\u00a0and\u00a0Treatment\u00a0of\u00a0VTE\u00a0in\u00a0Cancers\nExtended\u00a0thromboprophylaxis\u00a0with\u00a0LMWH\u00a0should\u00a0be\u00a0considered\nin\u00a0all\u00a0patients\u00a0undergoing\u00a0gynaecological\u00a0oncology\u00a0surgery\nLMWH\u00a0instead\u00a0of\u00a0UFH\u00a0should\u00a0be\u00a0used\u00a0for\u00a0treatment\u00a0of\u00a0VTE\u00a0in\npatients\u00a0with\u00a0cancers\nIn\u00a0 patients\u00a0 with\u00a0 cancers\u00a0 and\u00a0 confirmed\u00a0 VTE,\u00a0 indefinite\nanticoagulation\u00a0should\u00a0be\u00a0considered\u00a0or\u00a0at\u00a0least\u00a0until\u00a0the\u00a0cancer\u00a0is\nresolved\n9.7\u00a0THROMBOSIS\u00a0IN\u00a0UNUSUAL\u00a0SITES\n9.7.1\u00a0Introduction\nThrombosis\u00a0 in\u00a0 sites\u00a0 such\u00a0 as\u00a0 the\u00a0 upper\u00a0 limb,\u00a0 cerebral\u00a0 venous\u00a0 sinuses\u00a0 or\nsplanchnic\u00a0veins\u00a0are\u00a0uncommon. Management\u00a0with\u00a0anticoagulation\u00a0is\u00a0important\nas\u00a0complications\u00a0can\u00a0be\u00a0life\u00a0or\u00a0limb\u00a0threatening. 9.7.2\u00a0Upper\u00a0Limb\u00a0DVT\nUpper\u00a0limb\u00a0DVT\u00a0is\u00a0relatively\u00a0unusual\u00a0and\u00a0most\u00a0cases\u00a0are\u00a0secondary\u00a0to\u00a0a\u00a0venous\ncatheter,\u00a0malignancy,\u00a0compression\u00a0of\u00a0the\u00a0vein\u00a0or\u00a0OHSS. There\u00a0may\u00a0also\u00a0be\u00a0a\nhistory\u00a0of\u00a0unaccustomed\u00a0upper\u00a0limb\u00a0exercise.294\nIn\u00a0 patients\u00a0 with\u00a0 upper\u00a0 limb\u00a0 DVT\u00a0 without\u00a0 underlying\u00a0 risk\u00a0 factors\u00a0 (e.g. anti\u00adphospholipid\u00a0syndrome\u00a0or\u00a0cancer),\u00a0the\u00a0risk\u00a0of\u00a0recurrence\u00a0is\u00a0significantly\u00a0less\nthan\u00a0 lower\u00a0 limb\u00a0 DVT\u00a0 (2%\u00a0 v.s. 19%\u00a0 at\u00a0 5\u00a0 years).295\u00a0 Prolonged\u00a0 anticoagulation\nbeyond\u00a03\u00a0months\u00a0is\u00a0generally\u00a0not\u00a0indicated\u00a0for\u00a0upper\u00a0limb\u00a0DVT.295\n9.7.3\u00a0Cerebral\u00a0Vein\u00a0Thrombosis\nThrombosis\u00a0of\u00a0the\u00a0cerebral\u00a0veins\u00a0and\u00a0sinuses\u00a0is\u00a0uncommon\u00a0with\u00a0an\u00a0estimated\nannual\u00a0incidence\u00a0of\u00a03\u00a0to\u00a04\u00a0per\u00a0million. The\u00a0majority\u00a0of\u00a0patients\u00a0make\u00a0full\u00a0recovery\nalthough\u00a0 there\u00a0 is\u00a0 an\u00a0 early\u00a0 in\u00adhospital\u00a0 fatality\u00a0 rate\u00a0 of\u00a0 about\u00a0 5%\u00a0 and\u00a0 an\u00a0 overall\nmortality\u00a0rate\u00a0of\u00a0approximately\u00a010%.296\nAnticoagulation\u00a0with\u00a0heparin\u00a0and\u00a0with\u00a0or\u00a0without\u00a0warfarin\u00a0results\u00a0in\u00a0lower\u00a0mortality\nand\u00a0dependency\u00a0when\u00a0compared\u00a0to\u00a0no\u00a0anticoagulation\u00a0with\u00a0an\u00a0absolute\u00a0reduction\nin\u00a0the\u00a0risk\u00a0of\u00a0death\u00a0of\u00a013%. There\u00a0was\u00a0no\u00a0new\u00a0or\u00a0enlarging\u00a0cerebral\u00a0haemorrhage\nwith\u00a0 anticoagulation.298\u00a0 Clinical\u00a0 use\u00a0 of\u00a0 thrombolytic\u00a0 therapy\u00a0 in\u00a0 cerebral\u00a0 sinus\nthrombosis\u00a0cannot\u00a0be\u00a0supported\u00a0as\u00a0there\u00a0is\u00a0insufficient\u00a0evidence.297\nLong\u00adterm\u00a0 cohort\u00a0 follow\u00adup\u00a0 studies\u00a0 indicate\u00a0 that\u00a0 recurrent\u00a0 cerebral\u00a0 vein\nthrombosis\u00a0is\u00a0uncommon\u00a0perhaps\u00a0because\u00a0many\u00a0initial\u00a0events\u00a0occur\u00a0in\u00a0young\npatients\u00a0with\u00a0temporary\u00a0precipitating\u00a0factors\u00a0(e.g.", "chunk_order": 66}
{"chunk_id": "fe8cf47e-64e8-45a9-a201-8bb1e84410ee", "source_document_filename": "CPG Prevention and Treatment of Venous Thrombosis_cleaned_ultra_minimal.txt", "source_document_title": "CPG Prevention and Treatment of Venous Thrombosis cleaned ultra minimal", "text": "There\u00a0was\u00a0no\u00a0new\u00a0or\u00a0enlarging\u00a0cerebral\u00a0haemorrhage\nwith\u00a0 anticoagulation.298\u00a0 Clinical\u00a0 use\u00a0 of\u00a0 thrombolytic\u00a0 therapy\u00a0 in\u00a0 cerebral\u00a0 sinus\nthrombosis\u00a0cannot\u00a0be\u00a0supported\u00a0as\u00a0there\u00a0is\u00a0insufficient\u00a0evidence.297\nLong\u00adterm\u00a0 cohort\u00a0 follow\u00adup\u00a0 studies\u00a0 indicate\u00a0 that\u00a0 recurrent\u00a0 cerebral\u00a0 vein\nthrombosis\u00a0is\u00a0uncommon\u00a0perhaps\u00a0because\u00a0many\u00a0initial\u00a0events\u00a0occur\u00a0in\u00a0young\npatients\u00a0with\u00a0temporary\u00a0precipitating\u00a0factors\u00a0(e.g. hyperemesis\u00a0gravidarum).292,293\nFurthermore,\u00a0 the\u00a0 presence\u00a0 of\u00a0 heritable\u00a0 thrombophilia\u00a0 does\u00a0 not\u00a0 influence\u00a0 the\nrecurrence\u00a0risk. Therefore,\u00a0long\u00adterm\u00a0anticoagulation\u00a0should\u00a0not\u00a0be\u00a0necessary\u00a0in\nmost\u00a0patients.297\n9.7.4\u00a0Splanchnic\u00a0Vein\u00a0Thrombosis\nThrombosis\u00a0 of\u00a0 hepatic,\u00a0 portal\u00a0 and\u00a0 mesenteric\u00a0 veins\u00a0 is\u00a0 rare\u00a0 and\u00a0 most\u00a0 often\nassociated\u00a0with\u00a0an\u00a0underlying\u00a0myeloproliferative\u00a0neoplasm\u00a0(especially\u00a0for\u00a0hepatic\nand\u00a0portal\u00a0vein\u00a0thrombosis)\u00a0or\u00a0local\u00a0or\u00a0systemic\u00a0inflammation.296\nCase\u00a0series\u00a0and\u00a0cohort\u00a0studies\u00a0indicate\u00a0a\u00a0mortality\u00a0rate\u00a0of\u00a0around\u00a010%\u00a0and\u00a0a\nrecurrence\u00a0 rate\u00a0 of\u00a0 18%\u00a0 at\u00a0 41\u00a0 months\u00a0 in\u00a0 non\u00adanticoagulated\u00a0 patients.296\nApproximately\u00a0 40%\u00a0 of\u00a0 patients\u00a0 with\u00a0 underlying\u00a0 myeloproliferative\u00a0 neoplasms\nsuffered\u00a0 a\u00a0 recurrent\u00a0 thrombosis. Anticoagulation\u00a0 reduces\u00a0 recurrence\u00a0 and\u00a0 was\nassociated\u00a0with\u00a0recanalisation\u00a0in\u00a045%\u00a0of\u00a0patients.297\nThe\u00a0 presence\u00a0 of\u00a0 liver\u00a0 cirrhosis\u00a0 and/or\u00a0 portal\u00a0 hypertension\u00a0 with\u00a0 oesophageal\nvarices\u00a0and\u00a0hypersplenism\u00a0with\u00a0thrombocytopenia,\u00a0the\u00a0sequelae\u00a0to\u00a0splanchnic\nvein\u00a0thrombosis\u00a0further\u00a0increase\u00a0the\u00a0risk\u00a0of\u00a0bleeding\u00a0should\u00a0anticoagulation\u00a0be\nprescribed.297\n9.7.5\u00a0Incidental\u00a0thrombosis\u00a0at\u00a0imaging\nIn\u00a0 patients\u00a0 with\u00a0 incidentally\u00a0 detected\u00a0 hepatic\u00a0 or\u00a0 portal\u00a0 vein\u00a0 thrombosis,\u00a0 no\nanticoagulation\u00a0 is\u00a0 recommended.170,297\u00a0 In\u00a0 patients\u00a0 with\u00a0 incidentally\u00a0 detected\nthrombosis\u00a0at\u00a0imaging\u00a0for\u00a0the\u00a0staging\u00a0of\u00a0a\u00a0cancer\u00a0e.g. subclavian\u00a0vein\u00a0thrombosis\nassociated\u00a0 with\u00a0 a\u00a0 mediastinal\u00a0 lymphoma,\u00a0 anticoagulation\u00a0 with\u00a0 LMWH\u00a0 is\nrecommended\u00a0as\u00a0long\u00a0as\u00a0the\u00a0cancer\u00a0is\u00a0present\u00a0and\u00a0is\u00a0causing\u00a0the\u00a0obstruction\u00a0with\na\u00a0minimum\u00a0duration\u00a0of\u00a03\u00a0months.170,295\nRecommendations\nGrade\nB\nB\nB\nB\nC\nTable\u00a09.7:\u00a0Recommendations\u00a0in\u00a0the\u00a0management\u00a0of\u00a0thrombosis\u00a0in\nunsual\u00a0sites 170,297,299\nUpper\u00a0limb\u00a0DVT\nIn\u00a0patients\u00a0who\u00a0have\u00a0upper\u00a0extremity\u00a0DVT\u00a0that\u00a0is\u00a0associated\u00a0with\u00a0a\ncentral\u00a0 venous\u00a0 catheter\u00a0 that\u00a0 is\u00a0 removed,\u00a0 anticoagulation\u00a0 for\u00a0 a\nduration\u00a0of\u00a03\u00a0months\u00a0is\u00a0recommended\nPatients\u00a0 with\u00a0 upper\u00a0 extremity\u00a0 DVT\u00a0 without\u00a0 underlying\u00a0 risk\u00a0 factors\nsuch\u00a0 as\u00a0 anti\u00adphospholipid\u00a0 syndrome\u00a0 or\u00a0 cancer\u00a0 do\u00a0 no\u00a0 require\nextended\u00a0anticoagulation\u00a0beyond\u00a03\u00a0months\nCerebral\u00a0sinus\u00a0thrombosis\nPatients\u00a0 with\u00a0 cerebal\u00a0 sinus\u00a0 thrombosis\u00a0 do\u00a0 no\u00a0 require\u00a0 extended\nanticoagulation\u00a0beyond\u00a03\u00a0months\nSplanchnic\u00a0vein\u00a0thrombosis\nPatients\u00a0 with\u00a0 acute\u00a0 splanchnic\u00a0 vein\u00a0 thrombosis\u00a0 should\u00a0 have\ntreatment\u00a0 for\u00a0 any\u00a0 underlying\u00a0 disease\u00a0 and\u00a0 be\u00a0 considered\u00a0 for\nanticoagulation\u00a0 after\u00a0 careful\u00a0 assessment\u00a0 of\u00a0 individual\u00a0 risks\u00a0 and\nbenefits\nIn\u00a0 patients\u00a0 with\u00a0 incidentally\u00a0 detected\u00a0 hepatic\u00a0 or\u00a0 portal\u00a0 vein\nthrombosis,\u00a0no\u00a0anticoagulation\u00a0is\u00a0recommended\n10.0\u00a0MEDICATION\u00a0THERAPY\u00a0ADHERENCE\nCLINIC\u00adWARFARIN\u00a0(MTAC\u00adW)\n10.1\u00a0INTRODUCTION300,301\n1. Warfarin\u00a0therapy\u00a0for\u00a0the\u00a0prevention\u00a0and\u00a0treatment\u00a0of\u00a0thromboembolic\u00a0diseases\nis\u00a0safe\u00a0and\u00a0effective\u00a0only\u00a0when\u00a0it\u00a0is\u00a0maintained\u00a0within\u00a0a\u00a0narrow\u00a0therapeutic\nwindow.300,301\n2. Existing\u00a0 evidence\u00a0 suggests\u00a0 that\u00a0 management\u00a0 of\u00a0 warfarin\u00a0 sodium\u00a0 by\npharmacist\u00admanaged\u00a0anticoagulation\u00a0clinics\u00a0is\u00a0more\u00a0likely\u00a0to\u00a0attain\u00a0the\u00a0desired\npatient\u00a0outcomes\u00a0in\u00a0term\u00a0of\u00a0percentage\u00a0of\u00a0time\u00a0in\u00a0therapeutic\u00a0and\u00a0expanded\nrange,\u00a0reduced\u00a0rates\u00a0of\u00a0thromboembolic\u00a0and\u00a0bleeding\u00a0episodes\u00a0and\u00a0reduce\ncosts\u00a0 per\u00a0 person\u00adyear\u00a0 of\u00a0 follow\u00adup\u00a0 than\u00a0 routine\u00a0 medical\u00a0 care\u00a0 by\u00a0 physicians\nalthough\u00a0both\u00a0models\u00a0of\u00a0care\u00a0provided\u00a0very\u00a0high\u00a0quality\u00a0oral\u00a0anticoagulation\nmanagement.301\n3. In\u00a0Malaysia,\u00a0pharmacist\u00admanaged\u00a0physician\u00adsupported\u00a0anticoagulation\u00a0clinic\u00a0is\ncalled\u00a0 \u00a0 Medication\u00a0 Therapy\u00a0 Adherence\u00a0 Clinic\u00adWarfarin\u00a0 (MTAC\u00adW).", "chunk_order": 67}
{"chunk_id": "c0e4c227-af66-44ec-9e37-8bda41a7f982", "source_document_filename": "CPG Prevention and Treatment of Venous Thrombosis_cleaned_ultra_minimal.txt", "source_document_title": "CPG Prevention and Treatment of Venous Thrombosis cleaned ultra minimal", "text": "Existing\u00a0 evidence\u00a0 suggests\u00a0 that\u00a0 management\u00a0 of\u00a0 warfarin\u00a0 sodium\u00a0 by\npharmacist\u00admanaged\u00a0anticoagulation\u00a0clinics\u00a0is\u00a0more\u00a0likely\u00a0to\u00a0attain\u00a0the\u00a0desired\npatient\u00a0outcomes\u00a0in\u00a0term\u00a0of\u00a0percentage\u00a0of\u00a0time\u00a0in\u00a0therapeutic\u00a0and\u00a0expanded\nrange,\u00a0reduced\u00a0rates\u00a0of\u00a0thromboembolic\u00a0and\u00a0bleeding\u00a0episodes\u00a0and\u00a0reduce\ncosts\u00a0 per\u00a0 person\u00adyear\u00a0 of\u00a0 follow\u00adup\u00a0 than\u00a0 routine\u00a0 medical\u00a0 care\u00a0 by\u00a0 physicians\nalthough\u00a0both\u00a0models\u00a0of\u00a0care\u00a0provided\u00a0very\u00a0high\u00a0quality\u00a0oral\u00a0anticoagulation\nmanagement.301\n3. In\u00a0Malaysia,\u00a0pharmacist\u00admanaged\u00a0physician\u00adsupported\u00a0anticoagulation\u00a0clinic\u00a0is\ncalled\u00a0 \u00a0 Medication\u00a0 Therapy\u00a0 Adherence\u00a0 Clinic\u00adWarfarin\u00a0 (MTAC\u00adW). It\u00a0 was\nintroduced\u00a0 in\u00a0 2004\u00a0 in\u00a0 Malaysia\u00a0 as\u00a0 part\u00a0 of\u00a0 clinical\u00a0 pharmacy\u00a0 services\u00a0 in\u00a0 the\nAmbulatory\u00a0Clinic\u00a0System. 4. MTAC\u00adW\u00a0 service\u00a0 is\u00a0 designed\u00a0 to\u00a0 coordinate\u00a0 and\u00a0 optimize\u00a0 the\u00a0 delivery\u00a0 of\nanticoagulant\u00a0 therapy\u00a0 by\u00a0 determining\u00a0 the\u00a0 appropriateness\u00a0 of\u00a0 therapy,\nmanaging\u00a0 warfarin\u00a0 sodium\u00a0 dosing,\u00a0 and\u00a0 providing\u00a0 continuous\u00a0 monitoring\u00a0 of\npatients\u2019\u00a0INR\u00a0results,\u00a0dietary\u00a0factors,\u00a0concomitant\u00a0medications\u00a0and\u00a0interfering\ndisease\u00a0states. 5. The\u00a0 patients'\u00a0 primary\u00a0 physicians\u00a0 retained\u00a0 responsibility\u00a0 for\u00a0 overall\u00a0 care\u00a0 and\nwere\u00a0consulted\u00a0by\u00a0pharmacists\u00a0regarding\u00a0complications\u00a0of\u00a0anticoagulation\u00a0and\npatient\u00a0unreliability. 6. Clinical\u00a0pharmacists\u00a0in\u00adcharged\u00a0provided\u00a0patient\u00a0education,\u00a0monitored\u00a0patients\nfor\u00a0 hemorrhagic\u00a0 and\u00a0 thromboembolic\u00a0 complications,\u00a0 and\u00a0 adjusted\u00a0 warfarin\nsodium\u00a0dosage\u00a0to\u00a0maintain\u00a0therapeutic\u00a0INR. 7. This\u00a0document\u00a0sets\u00a0out\u00a0standardised\u00a0guidelines\u00a0for\u00a0the\u00a0operation\u00a0of\u00a0MTAC\u00adW\nclinic\u00a0 incorporating\u00a0 MTAC\u00ad\u00a0 Warfarin\u00a0 Protocol\u00a0 published\u00a0 by\u00a0 Pharmaceutical\nServices\u00a0Division,\u00a0MOH\u00a0Malaysia.302\n10.2\u00a0NATIONAL\u00a0GUIDANCE\u00a0AND\u00a0ADDITIONAL\u00a0RESOURCES\n1. Protocol\u00adMedication\u00a0 Therapy\u00a0 Adherence\u00a0 Clinic:\u00a0 Warfarin. Pharmaceutical\nServices\u00a0Division,\u00a0Ministry\u00a0of\u00a0Health\u00a0Malaysia. First\u00a0Edition\u00a02010. 2. Guidelines\u00a0on\u00a0Oral\u00a0Anticoagulation:\u00a0Third\u00a0edition. British\u00a0Journal\u00a0of\u00a0\u00a0Haematology\n3rd\u00a0edition\u00a01998\u037e101,374\u00ad387\n10.3\u00a0OBJECTIVES\n1. To\u00a0provide\u00a0continuity\u00a0and\u00a0enhance\u00a0patient\u00a0care\u00a0through\u00a0education,\u00a0monitoring,\nand\u00a0close\u00a0follow\u00adup\u00a0to\u00a0patients\u00a0who\u00a0require\u00a0anticoagulation\u00a0therapy. 2. To\u00a0maximize\u00a0the\u00a0benefits\u00a0of\u00a0antithrombotic\u00a0therapy\u00a0and\u00a0minimize\u00a0the\u00a0adverse\neffect\u00a0and\u00a0complications\u00a0resulting\u00a0from\u00a0antithrombotic\u00a0therapy. 3. Assist\u00a0physicians\u00a0in\u00a0the\u00a0management\u00a0of\u00a0patient\u00a0prescribed\u00a0with\u00a0anticoagulant\ntherapy. 4. Serve\u00a0as\u00a0an\u00a0information\u00a0resource\u00a0for\u00a0patients\u00a0and\u00a0family/care\u00a0provider. 5. Provide\u00a0consultative\u00a0and\u00a0educational\u00a0services\u00a0to\u00a0physicians,\u00a0dentists,\u00a0and\u00a0other\nhealthcare\u00a0providers\u00a0on\u00a0antithrombotic\u00a0drug\u00a0management\u00a0and\u00a0related\u00a0issues. 10.4\u00a0RESPONSIBILITIES\u00a0OF\u00a0THE\u00a0CLINICAL\u00a0PHARMACIST\u00a0IN\u00adCHARGE302\n1. Ensure\u00a0\u00a0patient\u00a0\u00a0receive\u00a0\u00a0education\u00a0\u00a0regarding\u00a0\u00a0warfarin\u00a0\u00a0at\u00a0\u00a0the\u00a0\u00a0initial\u00a0\u00a0visit\u00a0and\nreinforce\u00a0this\u00a0education\u00a0at\u00a0each\u00a0visit. 2. Be\u00a0 aware\u00a0 of\u00a0 the\u00a0 potential\u00a0 effects\u00a0 of\u00a0 additional\u00a0 therapy\u00a0 (drug/herbal/\nsupplement/elective\u00a0procedure)\u00a0given\u00a0to\u00a0a\u00a0patient\u00a0on\u00a0anticoagulants,\u00a0and\narranging\u00a0earlier\u00a0INR\u00a0testing\u00a0as\u00a0required. 3. Ensure\u00a0 patient\u00a0 receive\u00a0 appropriate\u00a0 INR\u00a0 monitoring\u00a0 and\u00a0 make\u00a0 dosage\nrecommendation\u00a0guided\u00a0by\u00a0the\u00a0approved\u00a0protocol\u00a0(Appendix\u00a01)\n4. Transcribe\u00a0warfarin\u00a0prescriptions:\na. This\u00a0 activity\u00a0 should\u00a0 be\u00a0 done\u00a0 based\u00a0 on\u00a0 the\u00a0 agreement\u00a0 by\u00a0 the\u00a0 hospital\nmanagement\u00a0and\u00a0the\u00a0doctor\u00a0in\u00adcharge. The\u00a0doctor\u00a0must\u00a0be\u00a0aware\u00a0that\u00a0the\nfinal\u00a0responsibilities\u00a0for\u00a0the\u00a0prescription\u00a0should\u00a0be\u00a0liaised\u00a0with\u00a0the\u00a0doctor. Prescription\u00a0has\u00a0to\u00a0be\u00a0initiated\u00a0by\u00a0the\u00a0pharmacist\u00a0and\u00a0counter\u00adsigned\u00a0by\u00a0the\ndoctor. b. Act\u00a0promptly\u00a0to\u00a0patients\u00a0with\u00a0bleeding\u00a0problems\u00a0and/or\u00a0INR\u00a0>4\u00a0or\u00a0who\u00a0are\notherwise\u00a0considered\u00a0to\u00a0be\u00a0at\u00a0risk\u00a0of\u00a0bleeding. 5. The\u00a0patient\u00a0shall\u00a0be\u00a0referred\u00a0to\u00a0the\u00a0physician\u00a0in\u00a0the\u00a0following\u00a0situations:\na. Actual\u00a0or\u00a0suspected\u00a0signs\u00a0and\u00a0symptoms\u00a0of\u00a0severe\u00a0haemorrhage\u00a0regardless\nof\u00a0the\u00a0INR\u00a0value. b.", "chunk_order": 68}
{"chunk_id": "48c4c032-bc41-44b6-b6ae-2a1bb5ade358", "source_document_filename": "CPG Prevention and Treatment of Venous Thrombosis_cleaned_ultra_minimal.txt", "source_document_title": "CPG Prevention and Treatment of Venous Thrombosis cleaned ultra minimal", "text": "This\u00a0 activity\u00a0 should\u00a0 be\u00a0 done\u00a0 based\u00a0 on\u00a0 the\u00a0 agreement\u00a0 by\u00a0 the\u00a0 hospital\nmanagement\u00a0and\u00a0the\u00a0doctor\u00a0in\u00adcharge. The\u00a0doctor\u00a0must\u00a0be\u00a0aware\u00a0that\u00a0the\nfinal\u00a0responsibilities\u00a0for\u00a0the\u00a0prescription\u00a0should\u00a0be\u00a0liaised\u00a0with\u00a0the\u00a0doctor. Prescription\u00a0has\u00a0to\u00a0be\u00a0initiated\u00a0by\u00a0the\u00a0pharmacist\u00a0and\u00a0counter\u00adsigned\u00a0by\u00a0the\ndoctor. b. Act\u00a0promptly\u00a0to\u00a0patients\u00a0with\u00a0bleeding\u00a0problems\u00a0and/or\u00a0INR\u00a0>4\u00a0or\u00a0who\u00a0are\notherwise\u00a0considered\u00a0to\u00a0be\u00a0at\u00a0risk\u00a0of\u00a0bleeding. 5. The\u00a0patient\u00a0shall\u00a0be\u00a0referred\u00a0to\u00a0the\u00a0physician\u00a0in\u00a0the\u00a0following\u00a0situations:\na. Actual\u00a0or\u00a0suspected\u00a0signs\u00a0and\u00a0symptoms\u00a0of\u00a0severe\u00a0haemorrhage\u00a0regardless\nof\u00a0the\u00a0INR\u00a0value. b. Actual\u00a0or\u00a0suspected\u00a0signs\u00a0and\u00a0symptoms\u00a0of\u00a0thromboembolism. c. INR\u00a0values\u00a0over\u00a04.0\u00a0or\u00a0values\u00a0less\u00a0than\u00a01.0\u00a0(INR\u00a0range\u00a0at\u00a0the\u00a0discretion\u00a0of\u00a0the\nrespective\u00a0hospital)\nd. INR\u00a0<1.5\u00a0for\u00a0patients\u00a0with\u00a0prosthetic\u00a0valve\u00a0replacement. e. When\u00a0the\u00a0duration\u00a0of\u00a0therapy\u00a0has\u00a0been\u00a0completed. f. When\u00a0patients\u00a0consistently\u00a0miss\u00a0appointments\u00a0or\u00a0remain\u00a0non\u00adcompliant\u00a0to\ntherapy. 6. Ensure\u00a0correct\u00a0dispensing\u00a0of\u00a0warfarin\u00a0tablets\u00a0in\u00a0the\u00a0clinic\u00a0to\u00a0the\u00a0patients/care\ngivers. 7. Ensure\u00a0all\u00a0patients\u00a0have\u00a0been\u00a0given\u00a0warfarin\u00a0booklet. 8. Ensure\u00a0 at\u00a0 the\u00a0 end\u00a0 of\u00a0 the\u00a0 session,\u00a0 a\u00a0 summary\u00a0 of\u00a0 important\u00a0 information\u00a0 is\nprovided\u00a0to\u00a0the\u00a0patients\u00a0and\u00a0their\u00a0understanding\u00a0is\u00a0reassessed. 10.5\u00a0MANPOWER\u00a0REQUIREMENT 302\nAt\u00a0least\u00a0one\u00a0pharmacist\u00a0should\u00a0be\u00a0placed\u00a0in\u00a0the\u00a0clinic. The\u00a0pharmacist\u00a0should\nspend\u00a0 an\u00a0 average\u00a0 of\u00a0 10\u00a0 to\u00a0 15\u00a0 minutes\u00a0 per\u00a0 case\u00a0 but\u00a0 longer\u00a0 time\u00a0 (around\u00a0 30\nminutes)\u00a0will\u00a0be\u00a0needed\u00a0for\u00a0newly\u00a0referred\u00a0cases. 10.6\u00a0APPOINTMENT\nAll\u00a0appointment\u00a0will\u00a0be\u00a0scheduled\u00a0by\u00a0pharmacists\u00a0in\u00adcharge\u00a0of\u00a0the\u00a0clinic. 10.7\u00a0WORK\u00a0PROCEDURES\nThe\u00a0workflow\u00a0of\u00a0MTAC\u00a0Warfarin\u00a0is\u00a0as\u00a0shown\u00a0in\u00a0Appendix\u00a02. 10.8\u00a0PATIENT\u00a0SELECTION\n1. Adult\u00a0patients\u00a0who\u00a0are\u00a0currently\u00a0on\u00a0warfarin\u00a0therapy\u00a0as\u00a0out\u00adpatient\u00a0from\u00a0any\nrelevant\u00a0disciplines\u00a0(as\u00a0agreed\u00a0by\u00a0the\u00a0individual\u00a0institution)\n2. All\u00a0new\u00a0cases\u00a0shall\u00a0be\u00a0referred\u00a0by\u00a0physicians\u00a0using\u00a0the\u00a0standardised\u00a0referral\nform\u00a0(MTAC_Warfarin/F1:\u00a0Appendix\u00a03). For\u00a0patient\u00a0started\u00a0on\u00a0warfarin\u00a0therapy\nin\u00a0the\u00a0ward,\u00a0referrals\u00a0should\u00a0be\u00a0made\u00a0prior\u00a0to\u00a0the\u00a0discharge. 3. Patients\u00a0who\u00a0are\u00a0\u2018stable\u2019\u00a0and\u00a0considered\u00a0appropriate\u00a0for\u00a0management\u00a0at\u00a0the\nMTAC\u00adWarfarin. 4. Complex\u00a0 high\u00a0 risk\u00a0 patients\u00a0 need\u00a0 to\u00a0 be\u00a0 identified\u00a0 and\u00a0 assessed\u00a0 for\u00a0 the\nappropriateness\u00a0of\u00a0monitoring\u00a0at\u00a0the\u00a0MTAC\u00adW. Some\u00a0of\u00a0these\u00a0conditions\u00a0may\nbe\u00a0referred\u00a0back\u00a0to\u00a0the\u00a0doctor:303\na. A\u00a0known\u00a0hereditary\u00a0or\u00a0acquired\u00a0bleeding\u00a0disorder\u00a0(Discuss\u00a0with\u00a0Consultant\nHaematologist)\nb. Alcoholics\u00a0due\u00a0to\u00a0instability\u00a0in\u00a0anticoagulation\u00a0management\nc. Severe\u00a0malnourishment\u00a0due\u00a0to\u00a0absorption\u00a0difficulties\nd. Mentally\u00a0ill\u00a0with\u00a0no\u00a0carer\u00a0support\u00a0in\u00a0the\u00a0community\ne. Dementia\u00a0with\u00a0no\u00a0carer\u00a0support\u00a0in\u00a0the\u00a0community\nf. Liver\u00a0failure\ng. Severe\u00a0renal\u00a0impairment\nh. Documented\u00a0evidence\u00a0of\u00a0CNS\u00a0haemorrhage\ni. Severe\u00a0heart\u00a0failure\nj. Uncontrolled\u00a0severe\u00a0hypertension\nk. Gastric\u00adintestinal\u00a0bleeding\u00a0in\u00a0the\u00a0last\u00a06\u00a0months\nl. Pregnancy\u00a0 (Urgent\u00a0 referral\u00a0 to\u00a0 appropriate\u00a0 Haematologist/Consultant\nObstetrician)\nm.Those\u00a0on\u00a0chemotherapy\u00a0for\u00a0malignant\u00a0tumours\u00a0(consider\u00a0LMWH)\nn. Homozygous\u00a0protein\u00a0C\u00a0deficiency\u00a0(high\u00a0risk\u00a0of\u00a0skin\u00a0necrosis)\n10.9\u00a0INR\u00a0TESTING\n1. The\u00a0method\u00a0for\u00a0INR\u00a0monitoring\u00a0should\u00a0be\u00a0determined\u00a0by\u00a0individual\u00a0institution\nand\u00a0blood\u00a0sampling\u00a0for\u00a0INR\u00a0reading\u00a0should\u00a0be\u00a0performed\u00a0by\u00a0trained\u00a0healthcare\nstaff. 2.", "chunk_order": 69}
{"chunk_id": "02ad2a9c-ac18-4338-925e-c54b226ff0d4", "source_document_filename": "CPG Prevention and Treatment of Venous Thrombosis_cleaned_ultra_minimal.txt", "source_document_title": "CPG Prevention and Treatment of Venous Thrombosis cleaned ultra minimal", "text": "Dementia\u00a0with\u00a0no\u00a0carer\u00a0support\u00a0in\u00a0the\u00a0community\nf. Liver\u00a0failure\ng. Severe\u00a0renal\u00a0impairment\nh. Documented\u00a0evidence\u00a0of\u00a0CNS\u00a0haemorrhage\ni. Severe\u00a0heart\u00a0failure\nj. Uncontrolled\u00a0severe\u00a0hypertension\nk. Gastric\u00adintestinal\u00a0bleeding\u00a0in\u00a0the\u00a0last\u00a06\u00a0months\nl. Pregnancy\u00a0 (Urgent\u00a0 referral\u00a0 to\u00a0 appropriate\u00a0 Haematologist/Consultant\nObstetrician)\nm.Those\u00a0on\u00a0chemotherapy\u00a0for\u00a0malignant\u00a0tumours\u00a0(consider\u00a0LMWH)\nn. Homozygous\u00a0protein\u00a0C\u00a0deficiency\u00a0(high\u00a0risk\u00a0of\u00a0skin\u00a0necrosis)\n10.9\u00a0INR\u00a0TESTING\n1. The\u00a0method\u00a0for\u00a0INR\u00a0monitoring\u00a0should\u00a0be\u00a0determined\u00a0by\u00a0individual\u00a0institution\nand\u00a0blood\u00a0sampling\u00a0for\u00a0INR\u00a0reading\u00a0should\u00a0be\u00a0performed\u00a0by\u00a0trained\u00a0healthcare\nstaff. 2. Two\u00a0 methods\u00a0 available:\u00a0 Point\u00adOf\u00adCare\u00a0 (Fingerstick/Coagucheck\u00a0 XR)\u00a0 or\nlaboratory\u00a0testing. 3. INR\u00a0results\u00a0from\u00a02\u00a0methods\u00a0are\u00a0said\u00a0to\u00a0be\u00a0in\u00a0reasonable\u00a0agreement\u00a0if\u00a0the\u00a0two\nresults\u00a0are\u00a0within\u00a00.5\u00a0INR\u00a0units\u00a0of\u00a0each\u00a0other.304\n4. Certain\u00a0 conditions\u00a0 can\u00a0 interfere\u00a0 with\u00a0 the\u00a0 INR\u00a0 test\u00a0 e.g. anti\u00adphospholipid\nantibody\u00a0 syndrome\u00a0 which\u00a0 may\u00a0 cause\u00a0 the\u00a0 INR\u00a0 to\u00a0 be\u00a0 falsely\u00a0 high.304,305\u00a0Such\ninterference\u00a0can\u00a0wrongly\u00a0suggest\u00a0patient\u00a0being\u00a0over\u00adwarfarinised. Alternative\nlaboratory\u00a0test\u00a0called\u00a0the\u00a0chromogenic\u00a0factor\u00a0X\u00a0level,\u00a0which\u00a0is\u00a0a\u00a0measure\u00a0of\nwarfarin\u00a0effect\u00a0that\u00a0is\u00a0not\u00a0altered\u00a0by\u00a0the\u00a0anti\u00adphospholipid\u00a0antibodies\u00a0may\u00a0offer\nmore\u00a0accurate\u00a0testing. 10.10\u00a0PATIENT\u00a0COUNSELLING\n1. Patient\u00a0education\u00a0is\u00a0imperative\u00a0to\u00a0ensure\u00a0safe\u00a0and\u00a0effective\u00a0use\u00a0of\u00a0warfarin\ntherapy. All\u00a0 new\u00a0 patients\u00a0 to\u00a0 MTAC\u00adW\u00a0 should\u00a0 have\u00a0 the\u00a0 warfarin\u00a0 counseling\nchecklist\u00a0 completed\u00a0 and\u00a0 being\u00a0 given\u00a0 a\u00a0 comprehensive\u00a0 warfarin\u00a0 education\nbased\u00a0on\u00a0their\u00a0level\u00a0of\u00a0understanding. 2. Each\u00a0patient\u00a0should\u00a0be\u00a0provided\u00a0with\u00a0a\u00a0MOH\u00adapproved\u00a0warfarin\u00a0booklet\u00a0and/or\nother\u00a0compliance\u00a0aids. 3. Existing\u00a0patients\u00a0may\u00a0benefit\u00a0from\u00a0PERIODIC\u00a0educational\u00a0efforts\u00a0reinforcing\nkey\u00a0 medication\u00a0 safety\u00a0 information,\u00a0 even\u00a0 after\u00a0 initial\u00a0 education\u00a0 and\u00a0 ongoing\nmonitoring.306\n4. Incorporating\u00a0patient\u00a0anecdotes\u00a0into\u00a0physician\u00adpatient\u00a0dialogues\u00a0or\u00a0educational\nmaterials\u00a0may\u00a0increase\u00a0the\u00a0effectiveness\u00a0of\u00a0the\u00a0message.306\n5. Patient\u00a0education\u00a0should\u00a0include\u00a0the\u00a0following:\na. Drug\u00a0name,\u00a0strength\u00a0and\u00a0description\u00a0of\u00a0tablet\nb. Current\u00a0dosage\u00a0and\u00a0administration\u00a0time\nc. Reason\u00a0for\u00a0taking\u00a0warfarin\u00a0and\u00a0how\u00a0it\u00a0works\nd. Therapeutic\u00a0goals\u00a0and\u00a0the\u00a0anticipated\u00a0length\u00a0of\u00a0treatment\ne. How\u00a0to\u00a0handle\u00a0missed\u00a0doses\nf. Medications/supplements\u00a0and\u00a0dietary\u00a0interactions\ng. Recognition\u00a0of\u00a0symptoms\u00a0of\u00a0bleeding/thrombosis,\u00a0adverse\u00a0reactions\u00a0and\u00a0the\nappropriate\u00a0procedures\u00a0to\u00a0follow\nh. Importance\u00a0of\u00a0adherence\u00a0to\u00a0drug\u00a0regimen\u00a0and\u00a0clinic\u00a0appointments\ni. Emphasis\u00a0on\u00a0the\u00a0importance\u00a0of\u00a0follow\u00a0up\u00a0and\u00a0documentation\nj. What\u00a0to\u00a0do\u00a0if\u00a0dental\u00a0treatment/surgery\u00a0is\u00a0required\nk. What\u00a0to\u00a0do\u00a0if\u00a0surgery\u00a0is\u00a0indicated/required\nl. Patient\u00a0 education\u00a0 on\u00a0 the\u00a0 use\u00a0 of\u00a0 warfarin\u00a0 in\u00a0 pregnancy\u00a0 and\u00a0 lactation\u00a0 (if\nrelated)\nm. Who\u00a0to\u00a0contact\u00a0regarding\u00a0any\u00a0worries\u00a0or\u00a0concerns\u00a0relating\u00a0to\u00a0their\u00a0warfarin\ntherapy. 6. Patient\u00a0education\u00a0checklist\u00a0is\u00a0provided\u00a0in\u00a0Appendix\u00a04. 10.11\u00a0MONITORING\u00a0AND\u00a0EVALUATION\n1. Patient\u2019s\u00a0response\u00a0to\u00a0warfarin\u00a0therapy\u00a0should\u00a0be\u00a0evaluated\u00a0based\u00a0on\u00a0INR\nresults\u00a0and\u00a0information\u00a0gathered\u00a0from\u00a0patient\u2019s\u00a0interview. 2. Two\u00a0documents\u00a0are\u00a0used:\u00a0First\u00a0Visit\u00a0Form\u00a0(MTAC_Warfarin/F2:\u00a0Appendix\u00a05)\u00a0or\nFollow\u00adUp\u00a0Visit\u00a0Form\u00a0(MTAC_Warfarin/F3:\u00a0Appendix\u00a06). 3. The\u00a0following\u00a0criteria\u00a0should\u00a0be\u00a0assessed\u00a0to\u00a0check/evaluate\u00a0patient\u2019s\u00a0response\nto\u00a0 warfarin\u00a0 therapy\u00a0 and\u00a0 detect\u00a0 any\u00a0 potential\u00a0 problems\u00a0 prior\u00a0 to\u00a0 dosage\nadjustments:\na. Signs\u00a0and\u00a0symptoms\u00a0of\u00a0haemorrhage\u00a0and\u00a0thromboembolism\nb. Change\u00a0in\u00a0condition(s)\u00a0requiring\u00a0warfarin\u00a0therapy\nc.", "chunk_order": 70}
{"chunk_id": "56669881-cb8b-4dbb-bbb9-98dafbfb291f", "source_document_filename": "CPG Prevention and Treatment of Venous Thrombosis_cleaned_ultra_minimal.txt", "source_document_title": "CPG Prevention and Treatment of Venous Thrombosis cleaned ultra minimal", "text": "6. Patient\u00a0education\u00a0checklist\u00a0is\u00a0provided\u00a0in\u00a0Appendix\u00a04. 10.11\u00a0MONITORING\u00a0AND\u00a0EVALUATION\n1. Patient\u2019s\u00a0response\u00a0to\u00a0warfarin\u00a0therapy\u00a0should\u00a0be\u00a0evaluated\u00a0based\u00a0on\u00a0INR\nresults\u00a0and\u00a0information\u00a0gathered\u00a0from\u00a0patient\u2019s\u00a0interview. 2. Two\u00a0documents\u00a0are\u00a0used:\u00a0First\u00a0Visit\u00a0Form\u00a0(MTAC_Warfarin/F2:\u00a0Appendix\u00a05)\u00a0or\nFollow\u00adUp\u00a0Visit\u00a0Form\u00a0(MTAC_Warfarin/F3:\u00a0Appendix\u00a06). 3. The\u00a0following\u00a0criteria\u00a0should\u00a0be\u00a0assessed\u00a0to\u00a0check/evaluate\u00a0patient\u2019s\u00a0response\nto\u00a0 warfarin\u00a0 therapy\u00a0 and\u00a0 detect\u00a0 any\u00a0 potential\u00a0 problems\u00a0 prior\u00a0 to\u00a0 dosage\nadjustments:\na. Signs\u00a0and\u00a0symptoms\u00a0of\u00a0haemorrhage\u00a0and\u00a0thromboembolism\nb. Change\u00a0in\u00a0condition(s)\u00a0requiring\u00a0warfarin\u00a0therapy\nc. Recent\u00a0alterations\u00a0in\u00a0diet,medications,\u00a0tobacco\u00a0or\u00a0alcohol\u00a0intake\nd. Alterations\u00a0in\u00a0other\u00a0medical\u00a0problems\u00a0or\u00a0recent\u00a0illnesses\ne. Adherence\u00a0to\u00a0warfarin\u00a0therapy\nf. Patient\u00a0undergoing\u00a0surgical\u00a0or\u00a0dental\u00a0procedures\n10.12\u00a0DOSAGE\u00a0ADJUSTMENT\n1. Marked\u00a0individual\u00a0inter\u00advariability\u00a0exists\u00a0for\u00a0the\u00a0metabolism\u00a0of\u00a0warfarin. Patient\u2019s\ngenetic\u00a0make\u00a0up,\u00a0disease\u00a0states\u00a0and\u00a0other\u00a0concurrent\u00a0medications\u00a0also\u00a0affect\nthe\u00a0 response\u00a0 of\u00a0 warfarin\u00a0 in\u00a0 different\u00a0 patient. Therefore,\u00a0 the\u00a0 response\u00a0 in\nindividual\u00a0cannot\u00a0be\u00a0reliably\u00a0predicted. 2. The\u00a0 warfarin\u00a0 dose\u00a0 should\u00a0 be\u00a0 selected\u00a0 to\u00a0 maintain\u00a0 INR\u00a0 within\u00a0 the\u00a0 range\naccording\u00a0to\u00a0current\u00a0guidelines\u00a0established\u00a0by\u00a0the\u00a0American\u00a0College\u00a0of\u00a0Chest\nDoctors\u00a0Consensus\u00a0Conference\u00a0on\u00a0Antithrombotic\u00a0Therapy\u00a0(ACCP\u00a02012). 3. Dosage\u00a0 adjustments\u00a0 should\u00a0 be\u00a0 guided\u00a0 by\u00a0 clinically\u00a0 approved\u00a0 protocol\u00a0 and\nindividualized\u00a0according\u00a0to\u00a0clinical\u00a0judgement. 4. Dose\u00a0adjustments\u00a0should\u00a0be\u00a0considered\u00a0in\u00a0the\u00a0following\u00a0instances:\na. When\u00a0two\u00a0consecutive\u00a0INR\u00a0values\u00a0are\u00a0sub\u00adtherapeutic\u00a0or\nb. Supra\u00adtherapeutic\u00a0when\u00a0prior\u00a0control\u00a0has\u00a0been\u00a0good(+/\u00ad\u00a00.2\u00a0of\u00a0target\u00a0INR\nrange)\nc. When\u00a0 patients\u00a0 has\u00a0 just\u00a0 been\u00a0 referred\u00a0 for\u00a0 follow\u00a0 up\u00a0 after\u00a0 the\u00a0 initiation\u00a0 of\nanticoagulation\nd. When\u00a0there\u00a0is\u00a0indication\u00a0to\u00a0adjust\u00a0the\u00a0dose\u00a0due\u00a0to\u00a0warfarin\u00addrug/supplement/\nherbal/diet/disease\u00adstate\u00a0 interactions. (List\u00a0 of\u00a0 warfarin\u00addrug\u00a0 interactions\u00a0 in\nAppendix\u00a07)\n5. Compliance\u00a0 and\u00a0 patient\u00a0 satisfaction\u00a0 is\u00a0 highest\u00a0 with\u00a0 whole\u00a0 tablet\u00a0 warfarin\nregimen.307,308{e.g. 5\u00a0mg\u00a0once\u00a0daily}\n6. Higher\u00a0patient\u00a0satisfaction\u00a0is\u00a0associated\u00a0with\u00a0split\u00a0tablet\u00a0regimen\u00a0indicating\u00a0that\nalternating\u00a0dose\u00a0regimen\u00a0makes\u00a0taking\u00a0their\u00a0medications\u00a0more\u00a0difficult.307,308\n10.13\u00a0DISPENSING\n1. Warfarin\u00a0will\u00a0be\u00a0dispensed\u00a0in\u00a0the\u00a0MTAC\u00adW\u00a0clinic\u00a0to\u00a0the\u00a0patients/care\u00a0givers. 2. Patients\u00a0should\u00a0be\u00a0dispensed\u00a0with\u00a0the\u00a0correct\u00a0dose\u00a0and\u00a0quantity\u00a0of\u00a0warfarin\ntablets\u00a0 and\u00a0 re\u00ademphasised\u00a0 on\u00a0 the\u00a0 correct\u00a0 dose,\u00a0 route\u00a0 and\u00a0 time\u00a0 of\nadministration. 3. The\u00a0pharmacist\u00a0will\u00a0need\u00a0to\u00a0update\u00a0the\u00a0MOH\u00a0warfarin\u00a0booklet\u00a0giving\u00a0dosage\ninstructions\u00a0to\u00a0include\u00a0details\u00a0of\u00a0dose,\u00a0frequency,\u00a0colour\u00a0and\u00a0number\u00a0of\u00a0tablets\ne.g. 7\u00a0mg\u00a0once\u00a0a\u00a0day\u00a0(2\u00a0x\u00a03\u00a0mg\u00a0\u2013\u00a0blue\u00a0tabletsand\u00a01\u00a0x\u00a01\u00a0mg\u00a0\u00ad\u00a0brown\u00a0tablets). 4. Standardised\u00a0label\u00a0as\u00a0in\u00a0Appendix\u00a08\u00a0isused\u00a0upon\u00a0dispensing. 5. Warfarin\u00a0Dosing\u00a0Note\u00a0(Appendix\u00a09)\u00a0is\u00a0attached\u00a0to\u00a0the\u00a0patient\u2019s\u00a0Warfarin\u00a0Booklet\nto\u00a0facilitate\u00a0warfarin\u00a0administration. 6. At\u00a0the\u00a0end\u00a0of\u00a0the\u00a0session,\u00a0a\u00a0summary\u00a0of\u00a0important\u00a0information\u00a0is\u00a0provided\u00a0to\u00a0the\npatients\u00a0and\u00a0their\u00a0understanding\u00a0is\u00a0assessed. 10.14\u00a0MISSED\u00a0APPOINTMENTS\n1. Patients\u00a0who\u00a0missed\u00a0the\u00a0scheduled\u00a0appointment\u00a0should\u00a0be\u00a0contacted\u00a0at\u00a0the\nend\u00a0of\u00a0clinic\u00a0day\u00a0or\u00a0the\u00a0next\u00a0working\u00a0day\u00a0to\u00a0reschedule\u00a0a\u00a0new\u00a0appointment. A\n\u2018Missed\u00a0Appointment\u2019\u00a0sheet\u00a0(Appendix\u00a010)\u00a0should\u00a0be\u00a0filled\u00a0and\u00a0filed\u00a0in\u00a0the\npatient\u2019s\u00a0medical\u00a0record. 2.", "chunk_order": 71}
{"chunk_id": "3aee4a13-6d2c-48e5-bde9-04ebf7d4b684", "source_document_filename": "CPG Prevention and Treatment of Venous Thrombosis_cleaned_ultra_minimal.txt", "source_document_title": "CPG Prevention and Treatment of Venous Thrombosis cleaned ultra minimal", "text": "4. Standardised\u00a0label\u00a0as\u00a0in\u00a0Appendix\u00a08\u00a0isused\u00a0upon\u00a0dispensing. 5. Warfarin\u00a0Dosing\u00a0Note\u00a0(Appendix\u00a09)\u00a0is\u00a0attached\u00a0to\u00a0the\u00a0patient\u2019s\u00a0Warfarin\u00a0Booklet\nto\u00a0facilitate\u00a0warfarin\u00a0administration. 6. At\u00a0the\u00a0end\u00a0of\u00a0the\u00a0session,\u00a0a\u00a0summary\u00a0of\u00a0important\u00a0information\u00a0is\u00a0provided\u00a0to\u00a0the\npatients\u00a0and\u00a0their\u00a0understanding\u00a0is\u00a0assessed. 10.14\u00a0MISSED\u00a0APPOINTMENTS\n1. Patients\u00a0who\u00a0missed\u00a0the\u00a0scheduled\u00a0appointment\u00a0should\u00a0be\u00a0contacted\u00a0at\u00a0the\nend\u00a0of\u00a0clinic\u00a0day\u00a0or\u00a0the\u00a0next\u00a0working\u00a0day\u00a0to\u00a0reschedule\u00a0a\u00a0new\u00a0appointment. A\n\u2018Missed\u00a0Appointment\u2019\u00a0sheet\u00a0(Appendix\u00a010)\u00a0should\u00a0be\u00a0filled\u00a0and\u00a0filed\u00a0in\u00a0the\npatient\u2019s\u00a0medical\u00a0record. 2. Patients\u00a0who\u00a0have\u00a0missed\u00a0appointment\u00a0for\u00a0more\u00a0than\u00a03\u00a0consecutive\u00a0times\u00a0or\nmore\u00a0than\u00a01\u00a0month\u00a0from\u00a0the\u00a0scheduled\u00a0appointment\u00a0shall\u00a0be\u00a0referred\u00a0back\u00a0to\nthe\u00a0respective\u00a0clinicians. 10.15\u00a0DOCUMENTATION\n1. MTAC\u00a0Warfarin\u00a0Referral\u00a0Form\u00a0(\u00a0MTAC_Warfarin/F1)\n2. MTAC\u00a0Warfarin\u00a0First\u00a0Visit\u00a0Form(MTAC_Warfarin/F2)\n3. MTAC\u00a0Warfarin\u00a0Follow\u00adup\u00a0Visit\u00a0Form(MTAC_Warfarin/F3)\n4. Missed\u00a0Appointment\u00a0Sheet(MTAC_Warfarin/F4)\n10.16\u00a0QUALITY\u00a0ASSURANCE\n1. This\u00a0 service\u00a0 should\u00a0 be\u00a0 continuously\u00a0 assessed\u00a0 to\u00a0 ensure\u00a0 patients\u00a0 receive\noptimal\u00a0care. 2. Outcome\u00a0measurement\u00a0from\u00a0anticoagulation\u00a0therapy\u00a0will\u00a0include\u00a0percentage\nof\u00a0 patients\u00a0 achieving\u00a0 INR\u00a0 goal,\u00a0 response\u00a0 to\u00a0 therapy,\u00a0 adverse\u00a0 events\u00a0 and\ngeneral\u00a0evaluation\u00a0on\u00a0patients\u00a0understanding\u00a0towards\u00a0therapy. APPENDICES\nAppendix\u00a01\nWARFARIN\u00a0DOSAGE\u00a0ADJUSTMENT\nWARFARIN\u00a0THERAPY\u00a0INITIATION\u00a0GUIDELINES\n1.0\u00a0Dosing\u00a0Initiation\n1. In\u00a0patients\u00a0beginning\u00a0warfarin\u00a0therapy,\u00a0the\u00a0initiation\u00a0dose\u00a0may\u00a0start\u00a0with\u00a0doses\nbetween\u00a0 5\u00a0 and\u00a0 10\u00a0 mg\u00a0 for\u00a0 the\u00a0 first\u00a0 1\u00a0 or\u00a0 2\u00a0 days\u00a0 for\u00a0 most\u00a0 individuals\u00a0 and\nsubsequent\u00a0dosing\u00a0based\u00a0on\u00a0the\u00a0INR\u00a0response. 2. In\u00a0elderly\u00a0patients\u00a0or\u00a0in\u00a0patients\u00a0who\u00a0are\u00a0debilitated,\u00a0malnourished,\u00a0have\u00a0CHF,\nhave\u00a0liver\u00a0disease,\u00a0have\u00a0had\u00a0recent\u00a0major\u00a0surgery,\u00a0or\u00a0are\u00a0taking\u00a0medications\nknown\u00a0 to\u00a0 increase\u00a0 the\u00a0 sensitivity\u00a0 to\u00a0 warfarin\u00a0 (e.g. amiodarone),\u00a0 the\u00a0 starting\ndose\u00a0should\u00a0be\u00a0of\u00a0<5\u00a0mg\u00a0with\u00a0subsequent\u00a0dosing\u00a0based\u00a0on\u00a0the\u00a0INR\u00a0response. 2.0\u00a0Monitoring\n1. Baseline\u00a0PT/INR/PTT,\u00a0full\u00a0blood\u00a0count\u00a0(FBC)\u00a0with\u00a0platelets\u00a0and\u00a0liver\u00a0function\ntest\u00a0 (LFT)\u00a0 shall\u00a0 be\u00a0 obtained\u00a0 prior\u00a0 to\u00a0 warfarin\u00a0 initiation. If\u00a0 baseline\u00a0 level\u00a0 not\navailable,\u00a0it\u00a0should\u00a0be\u00a0obtained\u00a0within\u00a024\u00a0hours. 2. In\u00a0hospitalised\u00a0patients,\u00a0INR\u00a0monitoring\u00a0is\u00a0usually\u00a0performed\u00a0daily,\u00a0starting\u00a0after\nthe\u00a0second\u00a0or\u00a0third\u00a0dose\u00a0until\u00a0the\u00a0target\u00a0therapeutic\u00a0range\u00a0has\u00a0been\u00a0achieved\nand\u00a0maintained\u00a0for\u00a0at\u00a0least\u00a02\u00a0consecutive\u00a0days\u037e\u00a0then\u00a0two\u00a0or\u00a0three\u00a0times\u00a0weekly\nfor\u00a01\u00a0to\u00a02\u00a0weeks\u037e\u00a0then\u00a0less\u00a0often,\u00a0depending\u00a0on\u00a0the\u00a0stability\u00a0of\u00a0INR\u00a0results. 3. In\u00a0outpatients\u00a0starting\u00a0warfarin\u00a0therapy,\u00a0initial\u00a0monitoring\u00a0may\u00a0be\u00a0reduced\u00a0to\nevery\u00a0few\u00a0days\u00a0until\u00a0a\u00a0stable\u00a0dose\u00a0response\u00a0has\u00a0been\u00a0achieved. When\u00a0the\u00a0INR\nresponse\u00a0is\u00a0stable,\u00a0the\u00a0frequency\u00a0of\u00a0testing\u00a0can\u00a0be\u00a0reduced\u00a0to\u00a0intervals\u00a0as\u00a0long\nas\u00a0every\u00a04\u00a0to\u00a08\u00a0weeks.", "chunk_order": 72}
{"chunk_id": "a7a4940f-4197-4da4-b7a6-50c38c652982", "source_document_filename": "CPG Prevention and Treatment of Venous Thrombosis_cleaned_ultra_minimal.txt", "source_document_title": "CPG Prevention and Treatment of Venous Thrombosis cleaned ultra minimal", "text": "2. In\u00a0hospitalised\u00a0patients,\u00a0INR\u00a0monitoring\u00a0is\u00a0usually\u00a0performed\u00a0daily,\u00a0starting\u00a0after\nthe\u00a0second\u00a0or\u00a0third\u00a0dose\u00a0until\u00a0the\u00a0target\u00a0therapeutic\u00a0range\u00a0has\u00a0been\u00a0achieved\nand\u00a0maintained\u00a0for\u00a0at\u00a0least\u00a02\u00a0consecutive\u00a0days\u037e\u00a0then\u00a0two\u00a0or\u00a0three\u00a0times\u00a0weekly\nfor\u00a01\u00a0to\u00a02\u00a0weeks\u037e\u00a0then\u00a0less\u00a0often,\u00a0depending\u00a0on\u00a0the\u00a0stability\u00a0of\u00a0INR\u00a0results. 3. In\u00a0outpatients\u00a0starting\u00a0warfarin\u00a0therapy,\u00a0initial\u00a0monitoring\u00a0may\u00a0be\u00a0reduced\u00a0to\nevery\u00a0few\u00a0days\u00a0until\u00a0a\u00a0stable\u00a0dose\u00a0response\u00a0has\u00a0been\u00a0achieved. When\u00a0the\u00a0INR\nresponse\u00a0is\u00a0stable,\u00a0the\u00a0frequency\u00a0of\u00a0testing\u00a0can\u00a0be\u00a0reduced\u00a0to\u00a0intervals\u00a0as\u00a0long\nas\u00a0every\u00a04\u00a0to\u00a08\u00a0weeks. 1\n5\n3\n<1.2\n6\u00ad8\n4\n1.2\u00a0\u00ad\u00a01.5\n5\n3\n1.5\u00a0\u00ad\u00a02\n3\n2\n2\u00a0\u00ad\u00a03\n2\n1\n>3\nNil\nNil\n2\n5\n3\n<1.3\n6\n5\n1.3\u00a0\u00ad\u00a01.5\n5\n4\n1.5\u00a0\u00ad\u00a01.7\n4\n3\n1.7\u00a0\u00ad\u00a02\n3\n2\n2\u00a0\u00ad\u00a02.5\n2.5\n1.5\n2.5\u00a0\u00ad\u00a03\n2\n1\n3\u00a0\u00ad\u00a03.5\n1.5\nOmit\u00a01\u00a0day,\u00a0then\u00a01\u00a0mg\n3.5\u00a0\u00ad\u00a04\nOmit\u00a01\u00a0day,\u00a0then\u00a01\u00a0mg\nOmit\u00a01\u00a0day,\u00a0then\u00a01\u00a0mg\n>4\nOmit\u00a02\u00a0days,\u00a0then\u00a00.5\u00a0mg Omit\u00a02\u00a0days,\u00a0then\u00a00.5\u00a0mg\nINR\nDay\nDose\u00a0(mg)\nAge\u00a0<70\u00a0years\nAge\u00a0>70\u00a0years\n3.0\u00a0Suggested\u00a0algorithm\u00a0for\u00a0initiating\u00a0warfarin\u00a0(Goal\u00a0INR\u00a02\u00ad3)*\nAdapted\u00a0from:\n1. The\u00a0 University\u00a0 of\u00a0 Michigan\u00a0 Cardiovascular\u00a0 Center,\u00a0 Anticoagulation\nMnagement\u00a0Service\u00a0for\u00a0Health\u00a0Professionals\u00a0Guideline,\u00a0Revised\u00a010/08/08\n2. Singapore\u00a0 General\u00a0 Hospital,\u00a0 Warfarin\u00a0 Treatment\u00a0 Guidelines\u00a0 and\nPrescription\u00a0Chart. Revised\u00a0January\u00a02009\n*\u00a0Deviation\u00a0from\u00a0this\u00a0algorithm\u00a0may\u00a0be\u00a0necessary\u00a0for\u00a0goal\u00a0INR\u00a02.5\u00a0\u00ad\u00a03.5\n3\nWARFARIN\u00a0DOSE\u00a0ADJUSTMENT\u00a0GUIDELINES\n*\u00a0 If\u00a0INR\u00a01.8\u00a0\u00ad\u00a01.9,\u00a0consider\u00a0no\u00a0change\u00a0with\u00a0repeat\u00a0INR\u00a0in\u00a07\u00a0\u00ad\u00a014\u00a0days\n**\u00a0If\u00a0INR\u00a03.1\u00a0\u00ad\u00a03.2,\u00a0consider\u00a0no\u00a0change\u00a0with\u00a0repeat\u00a0INR\u00a0in\u00a07\u00a0\u00ad\u00a014\u00a0days\nFollow\u00adup\u00a0Algorithm\nPatient\u2019s\nINR\n<1.5\n1.5\u00a0\u00ad\u00a01.9\n2.0\u00a0\u00ad\u00a03.0\n3.1\u00a0\u00ad\u00a03.9\n4.0\u00a0\u00ad\u00a04.9\n>5.0\nDose\nchange\nIncrease\n10\u00a0\u00ad\u00a020%\nIncrease\n5\u00a0\u00ad\u00a010%\nNo\nchange\nDecrease\n5\u00a0\u00ad\u00a010%\nHold\u00a00\u00a0\u00ad\u00a02\ndays\u00a0and\ndecrease\n10%\nRefer\u00a0to\nappropriate\nalgorithm\nNext\u00a0INR\n3\u00a0\u00ad\u00a08\ndays\n7\u00a0\u00ad\u00a014\ndays\nSee\nfollow\u00adup\nalgorithm\n7\u00a0\u00ad\u00a014\ndays\n3\u00a0\u00ad\u00a08\ndays\nNo.", "chunk_order": 73}
{"chunk_id": "daa8dd35-f2b2-4269-87e0-ed147585f111", "source_document_filename": "CPG Prevention and Treatment of Venous Thrombosis_cleaned_ultra_minimal.txt", "source_document_title": "CPG Prevention and Treatment of Venous Thrombosis cleaned ultra minimal", "text": "of\u00a0consecutive\u00a0in\u00adrange\u00a0INRs\nRepeat\u00a0INR\u00a0in\n1\n5\u00a0\u00ad\u00a014\u00a0days\n2\n2\u00a0\u00ad\u00a03\u00a0weeks\n3\n4\u00a0\u00ad\u00a08\u00a0weeks\nTarget\u00a0INR\u00a02.5\u00a0(Range\u00a02.0\u00a0\u00ad\u00a03.0)\n*\u00a0 If\u00a0INR\u00a02.2\u00a0\u00ad\u00a02.4,\u00a0consider\u00a0no\u00a0change\u00a0with\u00a0repeat\u00a0INR\u00a0in\u00a07\u00a0\u00ad\u00a014\u00a0days\n**\u00a0If\u00a0INR\u00a03.6\u00a0\u00ad\u00a03.8,\u00a0consider\u00a0no\u00a0change\u00a0with\u00a0repeat\u00a0INR\u00a0in\u00a07\u00a0\u00ad\u00a014\u00a0days\nPatient\u2019s\nINR\n<1.5\n1.5\u00a0\u00ad\u00a02.4\n2.5\u00a0\u00ad\u00a03.5\n3.6\u00a0\u00ad\u00a04.4\n4.5\u00a0\u00ad\u00a04.9\n>5.0\nDose\nchange\nIncrease\n10\u00a0\u00ad\u00a020%\nConsider\nextra\u00a0dose\nIncrease\n5\u00a0\u00ad\u00a010%\nNo\nchange\nDecrease\n5\u00a0\u00ad\u00a010%\nConsider\nholding\n1\u00a0dose\nHold\u00a00\u00a0\u00ad\u00a01\ndays\u00a0and\ndecrease\n10%\nRefer\u00a0to\nappropriate\nalgorithm\nNext\u00a0INR\n4\u00a0\u00ad\u00a08\ndays\n7\u00a0\u00ad\u00a014\ndays\nSee\nfollow\u00adup\nalgorithm\n7\u00a0\u00ad\u00a014\ndays\n4\u00a0\u00ad\u00a07\ndays\nFollow\u00adup\u00a0Algorithm\nNo. of\u00a0consecutive\u00a0in\u00adrange\u00a0INRs\nRepeat\u00a0INR\u00a0in\n1\n5\u00a0\u00ad\u00a014\u00a0days\n2\n2\u00a0\u00ad\u00a03\u00a0weeks\n3\n4\u00a0\u00ad\u00a08\u00a0weeks\nTarget\u00a0INR\u00a03.0\u00a0(Range\u00a02.5\u00a0\u00ad\u00a03.5)\nNotes:\n1. Always\u00a0consider\u00a0trend\u00a0in\u00a0INRs\u00a0when\u00a0making\u00a0warfarin\u00a0management\ndecisions. Exclusion\u00a0of\u00a0factors\u00a0affecting\u00a0INR\u00a0must\u00a0be\u00a0done\u00a0prior\u00a0to\u00a0dosage\nadjustment\n2. Consider\u00a0repeating\u00a0INR\u00a0same\u00a0day\u00a0or\u00a0next\u00a0day\u00a0if\u00a0observed\u00a0value\u00a0markedly\ndifferent\u00a0than\u00a0expected\u00a0value\u00a0(Potential\u00a0for\u00a0lab\u00a0errors\u00a0exist)\n3. Dose\u00a0should\u00a0be\u00a0rounded\u00a0up\u00a0to\u00a0nearest\u00a00.5\u00a0mg\n4. Maximum\u00a0changes\u00a0of\u00a0daily\u00a0dose\u00a0is\u00a0+\u00a01.0\u00a0mg\nAdapted\u00a0from:\nThe\u00a0University\u00a0of\u00a0Michigan\u00a0Cardiovascular\u00a0Center,\u00a0Anticoagulation\nManagement\u00a0Service\u00a0For\u00a0Health\u00a0Professionals\u00a0Guideline,\u00a0Revised\u00a010/08/08\nGUIDELINE\u00a0FOR\u00a0TREATMENT\u00a0OF\u00a0PATIENT\u00a0OVER\u00adANTICOAGULATED\nWITH\u00a0WARFARIN\nSource:\u00a0The\u00a08th\u00a0Edition\u00a0ACCP\u00a0Conference\u00a0on\u00a0antithrombotic\u00a0and\u00a0thrombolytic\ntherapy\u00a0Evidence\u00adbased\u00a0guidelines. CHEST\u00a0June\u00a02008. INR\n<5.0\nRecommendations\nNo\u00a0bleeding\nRapid\u00a0reversal\nrequired\n>9.0\nNo\u00a0bleeding\nRapid\u00a0reversal\nrequired\n5\u00ad8.9\nNo\u00a0bleeding\nRapid\u00a0reversal\nrequired\nAny\u00a0INR\nSerious\nbleeding\nAny\u00a0INR\nLife\u00adthreatening\nbleeding\nLower\u00a0dose\u00a0or\u00a0omit\u00a0dose,\u00a0monitor\u00a0more\u00a0frequently\nand\u00a0resume\u00a0at\u00a0a\u00a0lower\u00a0dose\u00a0when\u00a0the\u00a0INR\u00a0is\ntherapeutic. If\u00a0only\u00a0minimally\u00a0above\u00a0therapeutic\nrange,\u00a0no\u00a0dose\u00a0reduction\u00a0may\u00a0be\u00a0required. E.g. Patient\u00a0require\u00a0urgent\u00a0surgery. Hold\u00a0warfarin\nand\u00a0give\u00a0vitamin\u00a0K\u00a01\u00a0mg\u00a0IV\u00a0infusion\u00a0or\u00a02\u00a0mg\u00a0PO. Omit\u00a0one\u00a0or\u00a0two\u00a0doses,\u00a0monitor\u00a0more\u00a0frequently\u00a0and\nresume\u00a0warfarin\u00a0at\u00a0lower\u00a0dose\u00a0when\u00a0INR\u00a0is\ntherapeutic. Alternatively,\u00a0omit\u00a0dose\u00a0and\u00a0give\nQ1C)=19\"]\"T47\"=>\"$%)<<*UR\";)%C1/8<)%<*\"1#\")C\"19/%0)+0(\"\nrisk\u00a0of\u00a0bleeding. Hold\u00a0warfarin\u00a0and\u00a0give\u00a0Vitamin\u00a0K\u00a01\u00ad2\u00a0mg\u00a0IV\u00a0infusion\nor\u00a02\u00ad5\u00a0mg\u00a0PO,\u00a0with\u00a0the\u00a0expectation\u00a0that\u00a0a\u00a0reduction\nof\u00a0INR\u00a0will\u00a0occur\u00a0in\u00a024h. Hold\u00a0warfarin\u00a0until\u00a0INR\u00a0in\u00a0therapeutic\u00a0range\u00a0and\ngive\u00a0vitamin\u00a0K\u00a0(2.5\u00ad5\u00a0mg\u00a0PO\u00a0or\u00a01\u00ad2\u00a0mg\u00a0IV\u00a0infusion),\nwith\u00a0the\u00a0expectation\u00a0that\u00a0the\u00a0INR\u00a0will\u00a0be\nsubstantially\u00a0reduced\u00a0in\u00a024\u00ad48h. Monitor\u00a0frequently\nand\u00a0use\u00a0additional\u00a0vitamin\u00a0K\u00a0if\u00a0required. Resume\ntherapy\u00a0at\u00a0lower\u00a0dose\u00a0when\u00a0INR\u00a0therapeutic. Hold\u00a0warfarin\u00a0and\u00a0give\u00a0vitamin\u00a0K\u00a01\u00ad10\u00a0mg\u00a0IV\u00a0and\nmay\u00a0repeat\u00a06\u00ad24h\u00a0as\u00a0necessary. Hold\u00a0warfarin\u00a0and\u00a0give\u00a0vitamin\u00a0K\u00a0(10\u00a0mg\u00a0slow\u00a0IV)\nand\u00a0supplement\u00a0with\u00a0FFP\u00a0(fresh\u00a0frozen\u00a0plasma)\u00a0or\nPPC\u00a0(prothrombin\u00a0complex\u00a0concentrate),\u00a0depending\non\u00a0the\u00a0urgency\u00a0of\u00a0the\u00a0situation.", "chunk_order": 74}
{"chunk_id": "38091616-f03e-486e-b7f2-5d025ac41eed", "source_document_filename": "CPG Prevention and Treatment of Venous Thrombosis_cleaned_ultra_minimal.txt", "source_document_title": "CPG Prevention and Treatment of Venous Thrombosis cleaned ultra minimal", "text": "Hold\u00a0warfarin\u00a0until\u00a0INR\u00a0in\u00a0therapeutic\u00a0range\u00a0and\ngive\u00a0vitamin\u00a0K\u00a0(2.5\u00ad5\u00a0mg\u00a0PO\u00a0or\u00a01\u00ad2\u00a0mg\u00a0IV\u00a0infusion),\nwith\u00a0the\u00a0expectation\u00a0that\u00a0the\u00a0INR\u00a0will\u00a0be\nsubstantially\u00a0reduced\u00a0in\u00a024\u00ad48h. Monitor\u00a0frequently\nand\u00a0use\u00a0additional\u00a0vitamin\u00a0K\u00a0if\u00a0required. Resume\ntherapy\u00a0at\u00a0lower\u00a0dose\u00a0when\u00a0INR\u00a0therapeutic. Hold\u00a0warfarin\u00a0and\u00a0give\u00a0vitamin\u00a0K\u00a01\u00ad10\u00a0mg\u00a0IV\u00a0and\nmay\u00a0repeat\u00a06\u00ad24h\u00a0as\u00a0necessary. Hold\u00a0warfarin\u00a0and\u00a0give\u00a0vitamin\u00a0K\u00a0(10\u00a0mg\u00a0slow\u00a0IV)\nand\u00a0supplement\u00a0with\u00a0FFP\u00a0(fresh\u00a0frozen\u00a0plasma)\u00a0or\nPPC\u00a0(prothrombin\u00a0complex\u00a0concentrate),\u00a0depending\non\u00a0the\u00a0urgency\u00a0of\u00a0the\u00a0situation. Recombinant\u00a0factor\nVIIa\u00a0may\u00a0be\u00a0considered\u00a0as\u00a0alternative\u00a0to\u00a0PCC\u037e\nvitamin\u00a0K\u00a0can\u00a0be\u00a0repeated\u00a0every\u00a012h. Hold\u00a0warfarin\u00a0and\u00a0give\u00a0PPC\u00a0(prothrombin\u00a0complex\nconcentrate)\u00a0supplemented\u00a0with\u00a0vitamin\u00a0K\u00a0(10\u00a0mg\nslow\u00a0IV)\u037e\u00a0recombinant\u00a0factor\u00a0VIIa\u00a0may\u00a0be\nconsidered\u00a0as\u00a0alternative\u00a0to\u00a0PCC\u037e\u00a0repeat\u00a0if\nnecessary,\u00a0depending\u00a0on\u00a0INR. Clinical\u00a0Setting\nAppendix\u00a02\nMTAC\u00a0WARFARIN\u00a0CLINIC\u00a0WORKFLOW\n1. Transcribe\u00a0prescription\u00a0for\u00a0warfarin\u00a0tablets\n2. Complete\u00a0documentation\u00a0and\u00a0file\u00a0form\u00a0in\npatient\u2019s\u00a0clinical\u00a0notes. General\u00a0Counseling\n1. Emphasis\u00a0on\u00a0compliance\n2. Advice\u00a0to\u00a0maintain\u00a0consistent\u00a0diet\n3. No\u00a0dose\u00a0adjustment\nNew\u00a0Case\nChecking\u00a0&\u00a0Counseling\u00a0(Refer\u00a0appendix)\n1. Check\u00a0Drug\u00a0Interactions\n2. Check\u00a0on\u00a0dietary\u00a0changes\n3. Advice\u00a0to\u00a0stabilize\u00a0food\u00a0type/intake\n4. Emphasis\u00a0on\u00a0compliance\u00a0&\u00a0check\u00a0for\u00a0missed\u00a0dose(s)\nRegistration\nBlood\u00a0taking\u00a0for\u00a0INR\nObtain\u00a0patient\u2019s\nINR\u00a0results\u00a0and\nwarfarin\u00a0book\nFollow\u00a0up\u00a0case\nDispense\u00a0warfarin\u00a0tablets\n1. Document\u00a0patient\u2019s\u00a0clinical\u00a0progresses\u00a0in\nFollow\u00a0up\u00a0Visit\u00a0Form\u00a0(MTAC_warfarin/F3)\n2. Check\u00a0INR\n3. Check\u00a0bleeding\u00a0/\u00a0thrombosis\u00a0symptoms\n1. Obtain\u00a0referral\u00a0form\u00a0(MTAC_Warfarin/F1)\u00a0\u00a0completed\nby\u00a0physician\n2. Check\u00a0Indication,\u00a0Duration\u00a0of\u00a0Treatment\u00a0&\u00a0INR\u00a0target\n1. Document\u00a0patient\u2019s\u00a0clinical\u00a0progresses\nin\u00a0First\u00a0Visit\u00a0Form\u00a0(MTAC_warfarin/F2)\n2. Check\u00a0INR\n3. Check\u00a0bleeding\u00a0/\u00a0thrombosis\u00a0symptoms\nSign\u00a0&\u00a0Symptoms\u00a0of\nBleeding\u00a0/\u00a0Thrombosis\n*INR\u00a0more\u00a0than\u00a01\nand\u00a0less\u00a0than\u00a04\nINR\u00a0within\u00a0target\u00a0range\n1. Do\u00a0dose\u00a0adjustment\u00a0according\u00a0to\u00a0protocol\n(Refer\u00a0appendix)\n2. Refer\u00a0physician\u00a0if\u00a0necessary\nRefer\u00a0to\u00a0Physician\nYes\nYes\nYes\nNo\nNo\nNo\nSend\u00a0prescription\u00a0for\u00a0countersign\u00a0by\u00a0physician\u00a0and\u00a0clinical\u00a0note\u00a0for\u00a0comments\n*INR\u00a0range\u00a0is\u00a0based\u00a0on\u00a0agreement\u00a0between\u00a0Head\u00a0of\u00a0Cardiology/Medical/Hematology\u00a0and\u00a0pharmacy\u00a0department. Concurrent\u00a0Drug\u00a0Therapy\nName\nDose\nFreq\nDate:\nPatient\u00a0Details\nName:\nAge:\nRace:\u00a0M\u00a0\u00a0/\u00a0\u00a0I\u00a0\u00a0/\u00a0\u00a0C\u00a0\u00a0/\u00a0\u00a0O\nMRN:\nIC\u00a0No:\nGender:\u00a0M\u00a0/\u00a0F\nPhone\u00a0No:\nWarfarin\u00a0Indication\n^\"S%C0%1)<\"I=_$<1+=\"\n^\"SC%1)<\"P1_%1<<)C1$9\n^\"`0%0_%$Q)+/8<)%\"S//1(09C\"\n^\"Y00;\"G019\"HE%$=_$+1+\"T(0+/%1_0UZ\n^\"a0)%C\"G)<Q0\"-0;<)/0=09C\"T(0+/%1_0UZ\"\n^\".8<=$9)%*\"I=_$<1+=\"\n^\".8<=$9)%*\"a*;0%C09+1$9\"\n^\"`$)>8<$;)CE*\"TY0%+/%1_0Ub\n^\"H%)9+109C\"2+/E)0=1/\"SCC)/B\"\n^\"G09$8+\"HE%$=_$+1+\"$#\"$CE0%\"+;0/1#1/\"G019\n^\",CE0%\"T;<0)+0\"+;0/1#*UZ\"\"\"\"\"\"\"\"\nClinical\u00a0Information\nIs\u00a0this\u00a0patient\u00a0on\u00a0Antiplatelet\u00a0Drugs? Yes\u00a0/\u00a0No\no\u00a0 AspirinIs\nthis\u00a0to\u00a0continue\u00a0during\u00a0anticoagulation:\u00a0Yes\u00a0/\u00a0No\no\u00a0 Clopidogrel\no\u00a0 Other\u00a0(please\u00a0specify):\u00a0\u2026\u2026\u2026\u2026\u2026\u2026\u2026.", "chunk_order": 75}
{"chunk_id": "6dba92b2-fabb-41b7-9eff-6ed2c22ec565", "source_document_filename": "CPG Prevention and Treatment of Venous Thrombosis_cleaned_ultra_minimal.txt", "source_document_title": "CPG Prevention and Treatment of Venous Thrombosis cleaned ultra minimal", "text": "Concurrent\u00a0Drug\u00a0Therapy\nName\nDose\nFreq\nDate:\nPatient\u00a0Details\nName:\nAge:\nRace:\u00a0M\u00a0\u00a0/\u00a0\u00a0I\u00a0\u00a0/\u00a0\u00a0C\u00a0\u00a0/\u00a0\u00a0O\nMRN:\nIC\u00a0No:\nGender:\u00a0M\u00a0/\u00a0F\nPhone\u00a0No:\nWarfarin\u00a0Indication\n^\"S%C0%1)<\"I=_$<1+=\"\n^\"SC%1)<\"P1_%1<<)C1$9\n^\"`0%0_%$Q)+/8<)%\"S//1(09C\"\n^\"Y00;\"G019\"HE%$=_$+1+\"T(0+/%1_0UZ\n^\"a0)%C\"G)<Q0\"-0;<)/0=09C\"T(0+/%1_0UZ\"\n^\".8<=$9)%*\"I=_$<1+=\"\n^\".8<=$9)%*\"a*;0%C09+1$9\"\n^\"`$)>8<$;)CE*\"TY0%+/%1_0Ub\n^\"H%)9+109C\"2+/E)0=1/\"SCC)/B\"\n^\"G09$8+\"HE%$=_$+1+\"$#\"$CE0%\"+;0/1#1/\"G019\n^\",CE0%\"T;<0)+0\"+;0/1#*UZ\"\"\"\"\"\"\"\"\nClinical\u00a0Information\nIs\u00a0this\u00a0patient\u00a0on\u00a0Antiplatelet\u00a0Drugs? Yes\u00a0/\u00a0No\no\u00a0 AspirinIs\nthis\u00a0to\u00a0continue\u00a0during\u00a0anticoagulation:\u00a0Yes\u00a0/\u00a0No\no\u00a0 Clopidogrel\no\u00a0 Other\u00a0(please\u00a0specify):\u00a0\u2026\u2026\u2026\u2026\u2026\u2026\u2026. Concurrent\u00a0Illness\n^\"`SY\"\n^\"Y1)_0C0+\"\n^\"W2\"_<00(+\"\n^\"a0)%C\"P)1<8%0\"\n^\"a*;0%C09+1$9\n^\"a*;0%\\a*;$CE*%$1(1+=\"\"\"\"\"^\"V1Q0%\"(1+0)+0\"\"\n^\".0;C1/\"X</0%\"(1+0)+0\"\n^\"-09)<\"2=;)1%=09C\"\n^\"L01c8%0\"Y1+$%(0%\n^\",CE0%\"T;<0)+0\"+;0/1#*UZ\"\"\"\nBleeding\u00a0Risk\u00a0Factors\u00a0(Tick\u00a0all\u00a0that\u00a0applies)\u00a01\n1\u00a0Age\u00a0&65\n(1\u00a0point)\n4\nOne/more\u00a0of\u00a0the\u00a0following:\u00a0\u00a0(1\u00a0point)\nO\"a1+C$%*\"$#\"+C%$B0\"\nT5\";$19CU\"\n\"\n^\"-0/09C\"D2\"\n^\"`%\"d5''\"8=$<\\V\"\n'\"a1+C$%*\"$#\">)+C%$19C0+C19)<\"_<00(19>\"\" T5\";$19CU\"\n\"\"\"\"\n^\"a/C\"<'@e\"\n^\"Y1)_0C0+\nClassify\u00a0Your\u00a0Patient\u00a0Overall\u00a0Bleeding\u00a0Risk\u00a0(Total\u00a0of\u00a01\u00ad4)\n\"\n^\"a1>E\"-1+B\"T\"'\"J\"M\".$19C+U\" \"\"\"\"\"^\"29C0%=0(1)C0\"-1+B\"T\"5\"J\"O\".$19C+U\"\"\n^\"V$A\"-1+B\"T\"@\".$19CU\nWarfarin\u00a0Therapy\nDate\u00a0warfarin\u00a0started:\nAnticipated\u00a0Duration:\nAnticipated\u00a0Stop\u00a0Date:\nTarget\u00a0INR\u00a0Range\n^\"567\"J\"O67\"\"\"\"\"\"\"\"\"\"\n^\"O6@\"J\"'6@\"\"\"\"\"\"\"\"\"\"\"\"^\"O67\"J\"\"'67\n^\",CE0%\"T;<0)+0\"+;0/1#*UZ\nAppendix\u00a03\nMTAC\u00adWARFARIN:\u00a0REFERRAL\u00a0FORM\nMTAC\u00adW/F1\nName\nDose\nFreq\nComments:\nReferring Physician\u2019s Signature and Chop:\n1. Beth\u00a0RJ,\u00a0Quinn\u00a0LM,\u00a0Landefeld\u00a0SC. Prospective\u00a0Evaluation\u00a0of\u00a0an\u00a0Index\u00a0for\u00a0Predicting\u00a0the\u00a0Risk\u00a0of\u00a0Major\nBleeding\u00a0in\u00a0Outpatients\u00a0Treated\u00a0with\u00a0Warfarin..AM\u00a0J\u00a0Med.1998\u037e105:91\u00ad99\nPhysician\u00a0Review\u00a0&\u00a0Notes\nAppendix\u00a04\nCHECKLIST\u00a0FOR\u00a0WARFARIN\u00a0COUNSELLING\n4\u00a0 Use\u00a0layman\u00a0terms\u00a0throughout\u037e\u00a0medical\u00a0terms\u00a0are\u00a0in\u00a0parenthesis. 4\u00a0 Italicized\u00a0notes\u00a0should\u00a0only\u00a0be\u00a0addressed\u00a0if\u00a0asked\u00a0by\u00a0the\u00a0patient. ! Introduction\nt Name____________________________\nt Pharmacist\u00a0from\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\nt \u201c\u00a0I\u2019m\u00a0here\u00a0to\u00a0educate\u00a0you\u00a0a\u00a0new\u00a0drug\u00a0you\u00a0will\u00a0be\u00a0starting\u00a0soon\u00a0called\u00a0warfarin\u201d\nt \u201cHave\u00a0you\u00a0been\u00a0told\u00a0what\u00a0this\u00a0drug\u00a0is\u00a0for?\u201d\n! Warfarin\u00a0is\u2026\nt A\u00a0blood\u00a0thinner\u00a0also\u00a0known\u00a0as\u00a0an\u00a0anticoagulant. t Decreases\u00a0formation\u00a0of\u00a0blood\u00a0clots\nt Blood\u00a0clots\u00a0can\u00a0cause\u00a0a\u00a0stroke,\u00a0heart\u00a0attack,\u00a0or\u00a0blood\u00a0clots\u00a0in\u00a0the\u00a0legs\u00a0(DVT)\nor\u00a0lungs\u00a0(PE). t MOA:\u00a0the\u00a0liver\u00a0makes\u00a0clotting\u00a0factors\u00a0to\u00a0help\u00a0the\u00a0blood\u00a0clot\u00a0and\u00a0prevents\u00a0you\nfrom\u00a0bleeding. With\u00a0some\u00a0serious\u00a0conditions,\u00a0your\u00a0blood\u00a0can\u00a0clot\u00a0too\u00a0much. Warfarin\u00a0blocks\u00a0the\u00a0clotting\u00a0factors\u00a0made\u00a0by\u00a0the\u00a0liver,\u00a0preventing\u00a0your\u00a0blood\nfrom\u00a0clotting\u00a0(thins\u00a0your\u00a0blood). Formation\u00a0of\u00a0clotting\u00a0factors\u00a0are\u00a0dependent\u00a0on\nvitamin\u00a0 K. Therefore,\u00a0 taking\u00a0 more\u00a0 vitamin\u00a0 K\u00a0 than\u00a0 usual\u00a0 may\u00a0 decrease\u00a0 the\neffects\u00a0of\u00a0warfarin\u00a0and\u00a0may\u00a0put\u00a0you\u00a0at\u00a0risk\u00a0for\u00a0clot\u00a0formation. ! You\u00a0are\u00a0asked\u00a0to\u00a0take\u00a0warfarin\u00a0because\u2026\nt\u0001You\u00a0just\u00a0experienced\u00a0____________\nt A\u00a0leg\u00a0clot\u00a0(DVT)\nt A\u00a0lung\u00a0clot\u00a0(PE)\nt An\u00a0arrhythmia\u00a0(Atrial\u00a0fibrillation)\nt A\u00a0heart\u00a0attack\u00a0(MI)\nt The\u00a0placement\u00a0of\u00a0a\u00a0mechanical\u00a0or\u00a0bioprosthetic\u00a0heart\u00a0valve. \u0001t\u0001By\u00a0taking\u00a0warfarin,\u00a0it\u00a0will\u00a0treat\u00a0your\u00a0_________\u00a0(current\u00a0event)\u00a0and\u00a0prevent\nyou\u00a0from\u00a0having\u00a0another\u00a0clotting\u00a0event\u00a0(thromboembolic\u00a0event). \u0001t\u0001OR\n\u0001t\u0001You\u00a0 are\u00a0 receiving\u00a0 a\u00a0 cancer\u00a0 treatment\u00a0 of\u00a0 thalidomide\u00a0 in\u00a0 combination\u00a0 with\nchemotherapy\u00a0 and\u00a0 dexamethasone\u00a0 \u00ad\u00a0 by\u00a0 taking\u00a0 warfarin,\u00a0 it\u00a0 will\u00a0 help\u00a0 to\u00a0 \u201cto\nreduce\u00a0 the\u00a0 risk\u00a0 of\u00a0 getting\u00a0 a\u00a0 clot\u201d\u00a0 which\u00a0 is\u00a0 sometimes\u00a0 associated\u00a0 with\u00a0 this\ngroup\u00a0of\u00a0patients. ! Your\u00a0initial\u00a0warfarin\u00a0dose\u2026\n\u0001\nt\u0001Will\u00a0be\u00a0determined\u00a0by\u00a0your\u00a0doctor. \u0001\nt\u0001Your\u00a0dose\u00a0may\u00a0change\u00a0based\u00a0on\u00a0your\u00a0regular\u00a0blood\u00a0tests.", "chunk_order": 76}
{"chunk_id": "2b3e58ff-42bc-47be-a81c-72f5b1effb79", "source_document_filename": "CPG Prevention and Treatment of Venous Thrombosis_cleaned_ultra_minimal.txt", "source_document_title": "CPG Prevention and Treatment of Venous Thrombosis cleaned ultra minimal", "text": "\u0001t\u0001By\u00a0taking\u00a0warfarin,\u00a0it\u00a0will\u00a0treat\u00a0your\u00a0_________\u00a0(current\u00a0event)\u00a0and\u00a0prevent\nyou\u00a0from\u00a0having\u00a0another\u00a0clotting\u00a0event\u00a0(thromboembolic\u00a0event). \u0001t\u0001OR\n\u0001t\u0001You\u00a0 are\u00a0 receiving\u00a0 a\u00a0 cancer\u00a0 treatment\u00a0 of\u00a0 thalidomide\u00a0 in\u00a0 combination\u00a0 with\nchemotherapy\u00a0 and\u00a0 dexamethasone\u00a0 \u00ad\u00a0 by\u00a0 taking\u00a0 warfarin,\u00a0 it\u00a0 will\u00a0 help\u00a0 to\u00a0 \u201cto\nreduce\u00a0 the\u00a0 risk\u00a0 of\u00a0 getting\u00a0 a\u00a0 clot\u201d\u00a0 which\u00a0 is\u00a0 sometimes\u00a0 associated\u00a0 with\u00a0 this\ngroup\u00a0of\u00a0patients. ! Your\u00a0initial\u00a0warfarin\u00a0dose\u2026\n\u0001\nt\u0001Will\u00a0be\u00a0determined\u00a0by\u00a0your\u00a0doctor. \u0001\nt\u0001Your\u00a0dose\u00a0may\u00a0change\u00a0based\u00a0on\u00a0your\u00a0regular\u00a0blood\u00a0tests. \u0001\nt\u0001No\u00a0matter\u00a0what\u00a0the\u00a0dose,\u00a0you\u00a0must\u00a0take\u00a0your\u00a0warfarin\u00a0everyday\u00a0and\u00a0at\u00a0the\nsame\u00a0time\u00a0every\u00a0day. \u0001\nt\u0001If\u00a0you\u00a0miss\u00a0a\u00a0dose,\u00a0take\u00a0the\u00a0dose\u00a0as\u00a0soon\u00a0as\u00a0you\u00a0remember\u00a0if\u00a0within\u00a0the\u00a0same\nday. DO\u00a0NOT\u00a0double\u00a0your\u00a0dose\u00a0the\u00a0next\u00a0day\u00a0to\u00a0make\u00adup\u00a0for\u00a0the\u00a0missed\u00a0dose. \u0001\nt\u0001Warfarin\u00a0can\u00a0be\u00a0taken\u00a0with\u00a0food\u00a0or\u00a0on\u00a0an\u00a0empty\u00a0stomach. ! Your\u00a0regular\u00a0blood\u00a0tests\u2026\nt Will\u00a0 check\u00a0 your\u00a0 response\u00a0 to\u00a0 warfarin\u00a0 (is\u00a0 your\u00a0 blood\u00a0 too\u00a0 thin\u00a0 or\u00a0 not\u00a0 thin\nenough?\u037e\u00a0how\u00a0quickly\u00a0will\u00a0you\u00a0blood\u00a0clot\u00a0on\u00a0the\u00a0dose\u00a0your\u00a0on?)\nt This\u00a0blood\u00a0test\u00a0is\u00a0called\u00a0an\u00a0INR\u00a0test\u00a0(International\u00a0Normalized\u00a0Ratio). t The\u00a0goal\u00a0is\u00a0to\u00a0keep\u00a0your\u00a0INR\u00a0between\u00a0a\u00a0certain\u00a0range\u00a0that\u00a0will\u00a0be\u00a0determined\nby\u00a0your\u00a0doctor. This\u00a0will\u00a0assure\u00a0us\u00a0that\u00a0warfarin\u00a0is\u00a0effectively\u00a0working. t VTE\u00a0(DVT,\u00a0PE),\u00a0A\u00a0fib,\u00a0post\u00adMI,\u00a0AVR\u00a0without\u00a0risk\u00a0factors:\u00a0INR\u00a0range\u00a02\u00ad3\nt MVR\u00a0or\u00a0AVR\u00a0with\u00a0risk\u00a0factors\u00a0(AF,\u00a0low\u00a0EF,\u00a0previous\u00a0embolism,\nhypercoagulable\u00a0state):\u00a0INR\u00a0range\u00a02.5\u00ad3.5. t If\u00a0you\u00a0fall\u00a0out\u00a0of\u00a0this\u00a0range,\u00a0your\u00a0warfarin\u00a0dose\u00a0may\u00a0change. t It\u00a0 is\u00a0 very\u00a0 important\u00a0 that\u00a0 you\u00a0 meet\u00a0 all\u00a0 of\u00a0 your\u00a0 appointments\u00a0 so\u00a0 the\u00a0 most\neffective\u00a0dose\u00a0is\u00a0given\u00a0to\u00a0you. t You\u00a0may\u00a0need\u00a0to\u00a0have\u00a0your\u00a0blood\u00a0tested\u00a0more\u00a0frequently\u00a0at\u00a0first\u037e\u00a0however,\nonce\u00a0 we\u00a0 determine\u00a0 your\u00a0 dose,\u00a0 your\u00a0 scheduled\u00a0 appointments\u00a0 will\u00a0 be\u00a0 less\nfrequent. ! Possible\u00a0side\u00a0effects\u00a0of\u00a0warfarin\u00a0are\u2026\nt Bleeding\u00a0 problems,\u00a0 allergies,\u00a0 liver\u00a0 problems,\u00a0 low\u00a0 BP,\u00a0 swelling,\u00a0 paleness,\nfever,\u00a0and\u00a0rash. t If\u00a0any\u00a0of\u00a0these\u00a0side\u00a0effects\u00a0or\u00a0other\u00a0unusual\u00a0events\u00a0occur\u00a0after\u00a0the\u00a0start\u00a0of\nwarfarin,\u00a0alert\u00a0your\u00a0healthcare\u00a0provider. t THESE\u00a0SIDE\u00a0EFFECTS\u00a0CAN\u00a0BE\u00a0PREVENTED\u00a0AS\u00a0LONG\u00a0AS\u00a0REGULAR\nBLOOD\u00a0TESTS\u00a0ARE\u00a0DONE\u00a0AND\u00a0DIET\u00a0IS\u00a0CONSISTENT\u00a0TO\u00a0ASSURE\u00a0AN\nAPPROPRIATE\u00a0DOSE\u00a0IS\u00a0GIVEN. t The\u00a0most\u00a0concerning\u00a0side\u00a0effect\u00a0is\u00a0the\u00a0bleeding,\u00a0which\u00a0is\u00a0the\u00a0result\u00a0of\u00a0the\nblood\u00a0being\u00a0too\u00a0thin. t Alert\u00a0your\u00a0healthcare\u00a0provider\u00a0if\u00a0you\u00a0have\u00a0signs\u00a0and\u00a0symptoms\u00a0of\u00a0bleeding. t Pain,\u00a0swelling,\u00a0or\u00a0discomfort\nt Headache,\u00a0dizziness,\u00a0or\u00a0weakness\nt Bruising\u00a0(careful\u00a0with\u00a0machinery,\u00a0sharp\u00a0object\u00a0or\u00a0aggressive\u00a0sports)\nt Avoid\u00a0activities\u00a0that\u00a0may\u00a0cause\u00a0bleeding\u00a0(acupuncture,\u00a0massage,\u00a0cupping/\n\u2018bekam\u2019)\nt Nosebleeds\nt Bleeding\u00a0gums\u00a0(careful\u00a0when\u00a0brushing\u00a0teeth\u00a0\u2013\u00a0use\u00a0soft\u00a0toothbrush)\nt Pink\u00a0or\u00a0brown\u00a0urine\nt Red\u00a0or\u00a0black\u00a0stools\nt Vomiting\u00a0blood\u00a0or\u00a0material\u00a0that\u00a0looks\u00a0like\u00a0coffee\u00a0grinds\n!", "chunk_order": 77}
{"chunk_id": "c491cc56-82fd-4f1c-878a-8fe99dabd75d", "source_document_filename": "CPG Prevention and Treatment of Venous Thrombosis_cleaned_ultra_minimal.txt", "source_document_title": "CPG Prevention and Treatment of Venous Thrombosis cleaned ultra minimal", "text": "t The\u00a0most\u00a0concerning\u00a0side\u00a0effect\u00a0is\u00a0the\u00a0bleeding,\u00a0which\u00a0is\u00a0the\u00a0result\u00a0of\u00a0the\nblood\u00a0being\u00a0too\u00a0thin. t Alert\u00a0your\u00a0healthcare\u00a0provider\u00a0if\u00a0you\u00a0have\u00a0signs\u00a0and\u00a0symptoms\u00a0of\u00a0bleeding. t Pain,\u00a0swelling,\u00a0or\u00a0discomfort\nt Headache,\u00a0dizziness,\u00a0or\u00a0weakness\nt Bruising\u00a0(careful\u00a0with\u00a0machinery,\u00a0sharp\u00a0object\u00a0or\u00a0aggressive\u00a0sports)\nt Avoid\u00a0activities\u00a0that\u00a0may\u00a0cause\u00a0bleeding\u00a0(acupuncture,\u00a0massage,\u00a0cupping/\n\u2018bekam\u2019)\nt Nosebleeds\nt Bleeding\u00a0gums\u00a0(careful\u00a0when\u00a0brushing\u00a0teeth\u00a0\u2013\u00a0use\u00a0soft\u00a0toothbrush)\nt Pink\u00a0or\u00a0brown\u00a0urine\nt Red\u00a0or\u00a0black\u00a0stools\nt Vomiting\u00a0blood\u00a0or\u00a0material\u00a0that\u00a0looks\u00a0like\u00a0coffee\u00a0grinds\n! Rare\u00a0side\u00a0effect\u00a0include\u2026\nt Death\u00a0of\u00a0skin\u00a0(RARE\u037e\u00a0skin\u00a0necrosis\u00a0or\u00a0gangrene\u037e\u00a0can\u00a0occur\u00a0soon\u00a0after\u00a0starting\nCoumadin\u00a0(3\u00ad8\u00a0days)\u00a0because\u00a0blood\u00a0clots\u00a0form\u00a0and\u00a0block\u00a0blood\u00a0flow\u00a0to\u00a0area\nof\u00a0the\u00a0body(high\u00a0adipose\u00a0tissue). Patients\u00a0may\u00a0be\u00a0protein\u00a0C\u00a0deficient)\nt Purple\u00a0 toes\u00a0 syndrome\u00a0 (MORE\u00a0 RARE\u037e\u00a0 painful\u00a0 purple\u00a0 lesions\u00a0 on\u00a0 the\u00a0 toe\u037e\noccurs\u00a0 3\u00ad8\u00a0 weeks\u00a0 after\u00a0 starting\u00a0 warfarin. Patients\u00a0 may\u00a0 have\u00a0 vascular\natherosclerosis. Warfarin\u00a0induces\u00a0bleeding\u00a0into\u00a0the\u00a0cholesterol\u00a0plague\u00a0and\ncholesterol\u00a0crystal\u00a0emboli\u00a0are\u00a0released\u00a0and\u00a0travel\u00a0to\u00a0the\u00a0small\u00a0arteries\u00a0of\u00a0the\nfeet\u00a0and\u00a0hands). ! Many\u00a0Rx/OTC/herbals/vitamins\u00a0can\u00a0interact\u00a0with\u00a0warfarin\nt\u00a0 Try\u00a0 to\u00a0 avoid\u00a0 NSAIDs\u00a0 (ibuprofen,\u00a0 naproxen)\u00a0 and\u00a0 aspirin\u00a0 for\u00a0 pain\u00a0 or\ninflammation\u00a0as\u00a0these\u00a0can\u00a0increase\u00a0your\u00a0risk\u00a0for\u00a0bleeding\u00a0while\u00a0on\u00a0warfarin. t\u00a0Always\u00a0 alert\u00a0 your\u00a0 healthcare\u00a0 provider\u00a0 before\u00a0 starting\u00a0 or\u00a0 stopping\u00a0 any\nRx/OTC/herbal/vitamin\u00a0agents. ! Many\u00a0foods\u00a0can\u00a0interact\u00a0with\u00a0warfarin\nt\u00a0Do\u00a0you\u00a0eat\u00a0a\u00a0lot\u00a0of\u00a0vegetables\u00a0or\u00a0salads? t\u00a0Large\u00a0amounts\u00a0of\u00a0green\u00a0leafy\u00a0vegetables,\u00a0which\u00a0contain\u00a0high\u00a0amounts\u00a0of\nvitamin\u00a0 K,\u00a0 can\u00a0 lower\u00a0 the\u00a0 effects\u00a0 of\u00a0 warfarin\u00a0 (vitamin\u00a0 K\u00a0 works\u00a0 against\u00a0 or\nantagonizes\u00a0warfarin). t Kale\nt Parsley\nt Spinach\nt Turnip\u00a0greens\nt Broccoli\nt Brussels\u00a0sprouts\nt\u00a0Try\u00a0 to\u00a0 maintain\u00a0 a\u00a0 consistent\u00a0 diet,\u00a0 try\u00a0 to\u00a0 eat\u00a0 the\u00a0 same\u00a0 amount\u00a0 to\u00a0 leafy\nvegetables\u00a0every\u00a0day. t\u00a0Avoid\u00a0cranberry\u00a0juice\u00a0or\u00a0products\u00a0and\u00a0alcohol. t\u00a0Always\u00a0alert\u00a0your\u00a0healthcare\u00a0provider\u00a0before\u00a0making\u00a0any\u00a0changes\u00a0to\u00a0your\u00a0diet. ! Always\u00a0alert\u00a0any\u00a0healthcare\u00a0provider\u00a0you\u00a0interact\u00a0with\u00a0that\u00a0you\u00a0are\u00a0on\nwarfarin\u00a0(surgical,\u00a0medical,\u00a0dental)\n! Signs/symptoms\u00a0of\u00a0a\u00a0stroke\u00a0(for\u00a0pts. with\u00a0A.fib.,\u00a0CVA,\u00a0post\u00adMI,\u00a0or\u00a0valve\nreplacements)\nt\u00a0Facial\u00a0droop\nt\u00a0Arm\u00a0drift\nt\u00a0Slurred\u00a0speech\nt\u00a0Weakness\u00a0 or\u00a0 numbness\u00a0 in\u00a0 extremities\u00a0 (usually\u00a0 unilateral,\u00a0 but\u00a0 may\u00a0 be\nbilateral)\nt\u00a0Abnormal\u00a0or\u00a0loss\u00a0of\u00a0vision\u00a0\u00a0(usually\u00a0unilateral,\u00a0but\u00a0may\u00a0be\u00a0bilateral)\nt\u00a0Abnormal\u00a0or\u00a0loss\u00a0of\u00a0hearing\u00a0(usually\u00a0unilateral,\u00a0but\u00a0may\u00a0be\u00a0bilateral)\nt\u00a0Difficulty\u00a0walking\u00a0(unsteady\u00a0gait)\nt\u00a0If\u00a0 you\u00a0 experience\u00a0 any\u00a0 of\u00a0 these\u00a0 symptoms\u00a0 go\u00a0 to\u00a0 emergency\u00a0 department\nimmediately\n! Sign/symptoms\u00a0of\u00a0a\u00a0DVT\u00a0and\u00a0PE\u00a0(for\u00a0pts.", "chunk_order": 78}
{"chunk_id": "50380a44-6405-41d9-a75e-71a46b4a2c1a", "source_document_filename": "CPG Prevention and Treatment of Venous Thrombosis_cleaned_ultra_minimal.txt", "source_document_title": "CPG Prevention and Treatment of Venous Thrombosis cleaned ultra minimal", "text": "Signs/symptoms\u00a0of\u00a0a\u00a0stroke\u00a0(for\u00a0pts. with\u00a0A.fib.,\u00a0CVA,\u00a0post\u00adMI,\u00a0or\u00a0valve\nreplacements)\nt\u00a0Facial\u00a0droop\nt\u00a0Arm\u00a0drift\nt\u00a0Slurred\u00a0speech\nt\u00a0Weakness\u00a0 or\u00a0 numbness\u00a0 in\u00a0 extremities\u00a0 (usually\u00a0 unilateral,\u00a0 but\u00a0 may\u00a0 be\nbilateral)\nt\u00a0Abnormal\u00a0or\u00a0loss\u00a0of\u00a0vision\u00a0\u00a0(usually\u00a0unilateral,\u00a0but\u00a0may\u00a0be\u00a0bilateral)\nt\u00a0Abnormal\u00a0or\u00a0loss\u00a0of\u00a0hearing\u00a0(usually\u00a0unilateral,\u00a0but\u00a0may\u00a0be\u00a0bilateral)\nt\u00a0Difficulty\u00a0walking\u00a0(unsteady\u00a0gait)\nt\u00a0If\u00a0 you\u00a0 experience\u00a0 any\u00a0 of\u00a0 these\u00a0 symptoms\u00a0 go\u00a0 to\u00a0 emergency\u00a0 department\nimmediately\n! Sign/symptoms\u00a0of\u00a0a\u00a0DVT\u00a0and\u00a0PE\u00a0(for\u00a0pts. with\u00a0either\u00a0a\u00a0DVT\u00a0or\u00a0PE)\nt\u00a0DVT\nt Leg\u00a0swelling\nt Leg\u00a0pain/tenderness\nt Leg\u00a0discoloration\nt Leg\u00a0warm\u00a0to\u00a0the\u00a0touch\nt Call\u00a0your\u00a0doctor\u00a0immediately\u00a0or\u00a0go\u00a0to\u00a0the\u00a0emergency\u00a0room\u00a0if\u00a0you\u00a0have\u00a0any\nsigns\u00a0of\u00a0a\u00a0DVT\nt\u00a0PE\nt Sudden\u00a0unexplained\u00a0difficulty\u00a0breathing\nt Cough\nt Rapid\u00a0breathing\nt Rapid\u00a0heart\u00a0rate\u00a0or\u00a0palpitations\nt Chest\u00a0pain\u00a0when\u00a0you\u00a0breath\u00a0in\u00a0(pleuritic\u00a0chest\u00a0pain)\nt Anxiety\nt Go\u00a0to\u00a0emergency\u00a0department\u00a0immediately\u00a0if\u00a0you\u00a0have\u00a0any\u00a0signs\u00a0of\u00a0a\u00a0PE\n! Always\u00a0alert\u00a0your\u00a0healthcare\u00a0provider\u00a0if\u00a0you\u00a0make\u00a0changes\u00a0in\u00a0your\u00a0diet,\nexercise,\u00a0or\u00a0Rx/OTC/herbals/vitamin\u00a0use. ! Final\u00a0verification\u00a0of\u00a0indication,\u00a0dosing/administration,\u00a0side\u00a0effects,\u00a0drug/food\ninteractions,\u00a0and\u00a0appropriate\u00a0signs/symptoms\u00a0of\u00a0VTE. Target\u00a0INR:\nInitiation\u00a0Date:\nPlan\u00a0Duration:\nAnticipated\u00a0Stop\u00a0Date:\nDate\u00a0of\u00a0Visit:\nPatient\u00a0Information\nIndication:\nName:\nCurrent\u00a0Medications\nAge:\nRace:\u00a0M\u00a0\u00a0/\u00a0\u00a0I\u00a0\u00a0/\u00a0\u00a0C\u00a0\u00a0/\u00a0\u00a0O\nMRN:\nIC\u00a0No:\nGender:\u00a0M\u00a0/\u00a0F\nOTC\u00a0/\u00a0Supplement\u00a0/\u00a0Traditional\u00a0Medicines\nAddress:\nTelephone\u00a0No\nHome\u00a0/\u00a0Office:\nHandphone:\nAnticoagulation\u00a0Plan\nRisk\u00a0Factors:\nCo\u00admorbid\u00a0Medical\u00a0Conditions:\nRisk\u00a0Factors\u00a0&\u00a0Co\u00admorbid\u00a0conditions\nMedications\nDose\nFreq\nAppendix\u00a05\nMTAC\u00adWARFARIN:\u00a0FIRST\u00a0VISIT\u00a0FORM\nMTAC\u00adW/F2\nName\nObjective\u00a0Information\n126\nINR\u00a0(Laboratory):\nCurrent\u00a0Warfarin\u00a0Regimen:\nINR\u00a0(Point\u00a0of\u00a0Care):\nTotal\u00a0mg\u00a0/\u00a0week:\nSigns\u00a0of\u00a0bleeding:\u00a0Y\u00a0/\u00a0N\n(Describe\u00a0if\u00a0Yes)\nSigns\u00a0of\u00a0thrombosis:\u00a0Y\u00a0/\u00a0N\n(Describe\u00a0if\u00a0Yes)\nChanges\u00a0In\u00a0Medical\u00a0Status\u00a0/\u00a0Illness:\u00a0Y\u00a0/\u00a0N\n(Describe\u00a0if\u00a0Yes)\nMedications\u00a0Changes:\u00a0Y\u00a0/\u00a0N\n(Describe\u00a0if\u00a0Yes)\nChange\u00a0in\u00a0Physical\u00a0Activity:\u00a0Y\u00a0/\u00a0N\n(Specify\u00a0if\u00a0Yes)\nDiet / Herbal / Supplements changes: Y / N\n(Specify if Yes)\n1. Pregnancy\u00a0/\u00a0plan\u00a0to\u00a0get\u00a0pregnant? No\nYes:\u00a0Is\u00a0doctor\u00a0aware? If\u00a0no,\u00a0refer\u00a0to\u00a0doctor\n2. Alcohol\u00a0consumption? No\nYes:\u00a0amount\u00a0&\u00a0frequency? 3. Smoker? No\nYes:\u00a0How\u00a0many\u00a0sticks/day?", "chunk_order": 79}
{"chunk_id": "b1976298-e511-41c2-8eff-3df2246c2b02", "source_document_filename": "CPG Prevention and Treatment of Venous Thrombosis_cleaned_ultra_minimal.txt", "source_document_title": "CPG Prevention and Treatment of Venous Thrombosis cleaned ultra minimal", "text": "Pregnancy\u00a0/\u00a0plan\u00a0to\u00a0get\u00a0pregnant? No\nYes:\u00a0Is\u00a0doctor\u00a0aware? If\u00a0no,\u00a0refer\u00a0to\u00a0doctor\n2. Alcohol\u00a0consumption? No\nYes:\u00a0amount\u00a0&\u00a0frequency? 3. Smoker? No\nYes:\u00a0How\u00a0many\u00a0sticks/day? Any\u00a0changes\u00a0in\u00a0smoking\u00a0habit\u00a0(stop\u00a0or\u00a0just\u00a0started\u00a0smoking)\nSubjective\u00a0Information\nPharmacist\u2019s\u00a0Signature\u00a0and\u00a0Chop\nPhysician\u2019s\u00a0Signature\u00a0and\u00a0Chop\nOther\u00a0complain\u00a0/\u00a0Patients\u00a0Plans:\u00a0Y\u00a0/\u00a0N\n(Describe\u00a0if\u00a0Yes)\nIs\u00a0INR\u00a0therapeutic:\u00a0Y\u00a0/\u00a0N\nDescribe:\nAssessment\nPharmacist\u00a0Review\u00a0/\u00a0Plan\nPhysician\u00a0Review\u00a0&\u00a0Notes\nCorrect\u00a0dose\u00a0taken:\u00a0Y\u00a0/\u00a0N\nMissed\u00a0doses\u00a0in\u00a0past\u00a01\u00a0week:\u00a0Y\u00a0/\u00a0N\n(Specify\u00a0if\u00a0Yes)\nMon\nTues\nWed Thurs\nFri\nSat\nSun\nAppendix\u00a06\nMTAC\u00adWARFARIN:\u00a0FOLLOW\u00adUP\u00a0FORM\nMTAC\u00adW/F3\nMRN\u00a0/\u00a0IC:\nAge:\nDiagnosis\u00a0/\u00a0Indication:\nPatient\u00a0Information\nObjective\u00a0Information\nSubjective\u00a0Information\nSame\u00a0Indication:\u00a0Y\u00a0/\u00a0N\n(Describe\u00a0if\u00a0No)\nSameTarget\u00a0INR:\u00a0Y\u00a0/\u00a0N\n(Describe\u00a0if\u00a0No)\nSigns\u00a0of\u00a0bleeding:\u00a0Y\u00a0/\u00a0N\n(Describe\u00a0if\u00a0Yes)\nSigns\u00a0of\u00a0thrombosis:\u00a0Y\u00a0/\u00a0N\n(Describe\u00a0if\u00a0Yes)\nMedications\u00a0Changes:\u00a0Y\u00a0/\u00a0N\n(Describe\u00a0if\u00a0Yes)\nChanges\u00a0In\u00a0Medical\u00a0Status\u00a0/\u00a0Illness:\u00a0Y\u00a0/\u00a0N\n(Describe\u00a0if\u00a0Yes)\nChange\u00a0in\u00a0Physical\u00a0Activity:\u00a0Y\u00a0/\u00a0N\n(Specify\u00a0if\u00a0Yes)\nDiet\u00a0/\u00a0Herbal\u00a0/\u00a0Supplements\u00a0changes:\u00a0Y\u00a0/\u00a0N\n(Specify\u00a0if\u00a0Yes)\nINR\u00a0(Laboratory):\nCurrent\u00a0Warfarin\u00a0Regimen:\nINR\u00a0(Point\u00a0of\u00a0Care):\nTotal\u00a0mg\u00a0/\u00a0week:\nDate\u00a0of\u00a0Visit:\nMissed\u00a0appointments:\u00a0Y\u00a0/\u00a0N\n(Explain\u00a0if\u00a0Yes)\nCorrect\u00a0dose\u00a0taken:\u00a0Y\u00a0/\u00a0N\nMissed\u00a0doses\u00a0in\u00a0past\u00a01\u00a0week:\u00a0Y\u00a0/\u00a0N\n(Specify\u00a0if\u00a0Yes)\nMon\nTues\nWed\nThurs\nFri\nSat\nSun\n4. Pregnancy\u00a0/\u00a0plan\u00a0to\u00a0get\u00a0pregnant? No\nYes:\u00a0Is\u00a0doctor\u00a0aware? If\u00a0no,\u00a0refer\u00a0to\u00a0doctor\n5. Alcohol\u00a0consumption? No\nYes:\u00a0amount\u00a0&\u00a0frequency? 6. Smoker? No\nYes:\u00a0How\u00a0many\u00a0sticks/day? Any\u00a0changes\u00a0in\u00a0smoking\u00a0habit\u00a0(stop\u00a0or\u00a0just\u00a0started\u00a0smoking)\nOther\u00a0complain\u00a0/\u00a0Patients\u00a0Plans:\u00a0Y\u00a0/\u00a0N\n(Describe\u00a0if\u00a0Yes)\nIs\u00a0INR\u00a0therapeutic:\u00a0Y\u00a0/\u00a0N\nDescribe:\nAssessment\nPharmacist\u00a0Review\u00a0/\u00a0Plan\nPharmacist\u2019s\u00a0Signature\u00a0and\u00a0Chop\nPhysician\u00a0Review\u00a0&\u00a0Notes\nPhysician\u2019s\u00a0Signature\u00a0and\u00a0Chop\nAppendix\u00a07\nMTAC\u00adWARFARIN:\u00a0DRUG\u00a0CHECK\u00a0LIST\n4\n4\nAcarbose\nIII\nUnknown. 4\nAlcohol\n(acute\u00a0use)\nI\nLarge\u00a0intermittent\u00a0doses\u00a0of\u00a0alcohol\u00a0cause\nsome\u00a0inhibition\u00a0of\u00a0warfarin\u00a0metabolism. 4\nAllopurinol\nNo\u00a0evidence\nfound\nIncrease\u00a0 in\u00a0 the\u00a0 hypoprothrombinemic\nresponse. 4\nAmiodarone\nI\nAmiodarone\ninhibits\nmetabolism\nof\nwarfarin,\u00a0 increasing\u00a0 its\u00a0 anticoagulant\neffect\u00a0 and\u00a0 risk\u00a0 of\u00a0 bleeding\u037e\u00a0 reduce\nwarfarin\u00a0 dose\u00a0 by\u00a0 about\u00a0 one\u00adquarter,\nmonitor\u00a0INR\u00a0frequently\u00a0and\u00a0adjust\u00a0dose\nfurther\u00a0as\u00a0necessary. Antibiotics\n4\nBroad\u00a0Spectrum\nAntibiotics\nNo\u00a0evidence\nfound\nInhibition\u00a0 of\u00a0 vitamin\u00a0 K\u00a0 synthesis\u00a0 by\nintestinal\u00a0flora. 4\nCephalosporins\n\u0001 t\u0001Cefotetan\n\u0001 t\u0001Cefamandole\n\u0001 t\u0001Cefoperazone\n\u0001 t\u0001Cefmetazole\nIV\nInterfere\nwith\nvitamin\nK\u00adproducing\nbacteria\u00a0in\u00a0the\u00a0gut. Use\u00a0in\u00a0combination\u00a0is\nsafe\u00a0in\u00a0most\u00a0situations,\u00a0provided\u00a0vitamin\nK\u00a0intake\u00a0is\u00a0normal. Direct\u00a0prolongation\u00a0of\nprothrombin\u00a0 time\u00a0 affects\u00a0 liver\u00a0 enzyme\nclotting\u00a0factors. Cephalosporins\u00a0with\u00a0an\nN\u00adMethylthiotetrazol\u00a0(N\u00adMTT)\u00a0side\u00a0chain\nhave\u00a0 the\u00a0 most\u00a0 pronounced\u00a0 interaction\u00ad\nexamples\u00a0 are\u00a0 cefotetan,\u00a0 cefamandole,\ncefoperazone. 4\nErythromycin\nI\nSeveral\u00a0case\u00a0reports\u00a0of\u00a0marked\u00a0increase\u00a0in\nhypoprothrombinemic\u00a0response\u00a0to\u00a0warfarin,\nbut\u00a0 studies\u00a0 in\u00a0 healthy\u00a0 subjects\u00a0 suggest\nsmaller\u00a0 interaction. It\u00a0 might\u00a0 occur\u00a0 only\u00a0 in\ncertain\u00a0predisposed\u00a0individuals.", "chunk_order": 80}
{"chunk_id": "76d58850-9e70-4e03-8f0d-b1ba674ca530", "source_document_filename": "CPG Prevention and Treatment of Venous Thrombosis_cleaned_ultra_minimal.txt", "source_document_title": "CPG Prevention and Treatment of Venous Thrombosis cleaned ultra minimal", "text": "4\nCephalosporins\n\u0001 t\u0001Cefotetan\n\u0001 t\u0001Cefamandole\n\u0001 t\u0001Cefoperazone\n\u0001 t\u0001Cefmetazole\nIV\nInterfere\nwith\nvitamin\nK\u00adproducing\nbacteria\u00a0in\u00a0the\u00a0gut. Use\u00a0in\u00a0combination\u00a0is\nsafe\u00a0in\u00a0most\u00a0situations,\u00a0provided\u00a0vitamin\nK\u00a0intake\u00a0is\u00a0normal. Direct\u00a0prolongation\u00a0of\nprothrombin\u00a0 time\u00a0 affects\u00a0 liver\u00a0 enzyme\nclotting\u00a0factors. Cephalosporins\u00a0with\u00a0an\nN\u00adMethylthiotetrazol\u00a0(N\u00adMTT)\u00a0side\u00a0chain\nhave\u00a0 the\u00a0 most\u00a0 pronounced\u00a0 interaction\u00ad\nexamples\u00a0 are\u00a0 cefotetan,\u00a0 cefamandole,\ncefoperazone. 4\nErythromycin\nI\nSeveral\u00a0case\u00a0reports\u00a0of\u00a0marked\u00a0increase\u00a0in\nhypoprothrombinemic\u00a0response\u00a0to\u00a0warfarin,\nbut\u00a0 studies\u00a0 in\u00a0 healthy\u00a0 subjects\u00a0 suggest\nsmaller\u00a0 interaction. It\u00a0 might\u00a0 occur\u00a0 only\u00a0 in\ncertain\u00a0predisposed\u00a0individuals. 4\nPenicillins\n\u0001 t\u0001Nafcillin\n\u0001 t\u0001Dicloxacillin\nIV\nGenerally\u00a0 have\u00a0 little\u00a0 effect\u00a0 on\u00a0 INR. Additional\u00a0monitoring\u00a0generally\u00a0not\u00a0needed\nunless\u00a0 high\u00a0 doses\u00a0 are\u00a0 used\u00a0 more\u00a0 than\u00a0 7\nday. Nafcillin\u00a0and\u00a0dicloxacillin\u00a0may\u00a0decrease\nthe\u00a0 INR\u00a0 and\u00a0 require\u00a0 a\u00a0 dose\u00a0 increase\u00a0 of\nwarfarin. 4\nAspirin\nII\nCombination\u00a0increases\u00a0risk\u00a0of\u00a0bleeding. Low\u00addose\u00a0 aspirin\u00a0 may\u00a0 be\u00a0 justified\u00a0 for\nsome\u00a0 clinical\u00a0 indications\u00a0 for\u00a0 additional\nanticoagulant\u00a0 effects. Prolongation\u00a0 of\nprothrombin\u00a0 time\u00a0 may\u00a0 occur\u00a0 at\u00a0 higher\ndoses\u00a0(>3grams)\u00a0of\u00a0aspirin. Drugs/Drug\nClasses\nEFFECT\u00a0ON\u00a0INR\nLevel\u00a0of\nCausation\nMode\u00a0of\u00a0Action\n$\n! \"\n4\nAzathioprine\nII\nUnknown. 4\n4\nBarbiturates\nI\nInduce\u00a0metabolism\u00a0of\u00a0warfarin. 4\nCarbamazepine\nI\nCarbamazepine\u00a0may\u00a0increase\u00a0warfarin\u2019s\nmetabolism. 4\nCimetidine\nI\nInhibits\u00a0warfarin\u00a0metabolism. Substitute\nwith\u00a0other\u00a0H2\u00a0antagonists. 4\nCiprofloxacin\nI\nInhibit\u00a0CYP\u00a01A2,\u00a0decrease\u00a0metabolism\u00a0of\nwarfarin. 4\nClarithromycin\nII\nInhibit\u00a0warfarin\u00a0metabolism\u00a0by\u00a0inhibiting\nCYP\u00a03A4. 4\nClopidogrel\nI\nClopidogrel\u00a0may\u00a0enhance\u00a0the\u00a0anticoagulant\neffect\u00a0of\u00a0Warfarin. 4\nCyclosporine\nIII\nCyclosporine\u00a0 inhibits\u00a0 warfarin\u00a0 by\u00a0 an\nunknown\u00a0 mechanism. An\u00a0 increase\u00a0 in\ndose\u00a0may\u00a0be\u00a0required. 4\nDisulfiram\nII\nInhibits\u00a0metabolism\u00a0of\u00a0warfarin. Avoid\u00a0using\nin\u00a0 combination\u00a0 if\u00a0 possible,\u00a0 otherwise\u00a0 a\ndecrease\u00a0in\u00a0warfarin\u00a0dose\u00a0may\u00a0be\u00a0required\nwhen\u00a0 initiating\u00a0 disulfuram\u00a0 therapy. When\nstopping\u00a0disulfuram\u00a0therapy,\u00a0an\u00a0increase\u00a0in\nwarfarin\u00a0dose\u00a0may\u00a0be\u00a0required. 4\n4\nCorticosteroid\nNo\u00a0evidence\nfound\nUnexplained\u00a0mechanism. 4\nCyclophosphamide\nNo\u00a0evidence\nfound\nUnexplained\u00a0mechanism. 4\nCholestyramine\nI\nCholestyramine\u00a0reduces\u00a0warfarin\u00a0absorption,\nreducing\u00a0its\u00a0anticoagulant\u00a0effect\u037e\u00a0give\u00a01\u00a0hour\nbefore,\u00a0 or\u00a0 4\u00ad6\u00a0 hours\u00a0 after,\u00a0 cholestyramine\nand\u00a0monitor\u00a0INR\u00a0and\u00a0adjust\u00a0warfarin\u00a0dose\u00a0as\nneeded. 4\nClofibrate\nI\nUnkown. (May\u00a0 alter\u00a0 protein\u00a0 binding,\nindirect\u00a0 potentiation)\u00a0 Avoid\u00a0 using\u00a0 in\ncombination. Interaction\u00a0is\u00a0usually\u00a0dose\nrelated. 4\nColestipol\nNo\u00a0evidence\nfound\nBinds\u00a0warfarin\u00a0in\u00a0the\u00a0gut\u00a0and\u00a0inhibits\u00a0total\nwarfarin\u00a0 absorption. Administer\u00a0 warfarin\nat\u00a0least\u00a02\u00a0hrs\u00a0prior\u00a0to\u00a0colestipol\u00a0or\u00a06\u00a0hours\nafter\u00a0colestipol. Drugs/Drug\nClasses\nEFFECT\u00a0ON\u00a0INR\nLevel\u00a0of\nCausation\nMode\u00a0of\u00a0Action\n$\n! \"\n4\nEstrogen\nNo\u00a0evidence\nfound\nEstrogens\u00a0 induce\u00a0 coagulant\u00a0 factors. Estrogens\u00a0 increase\u00a0 the\u00a0 risk\u00a0 for\u00a0 clot\nformation\u00a0 and\u00a0 decrease\u00a0 the\u00a0 effects\u00a0 of\nwarfarin. 4\nHeparin\nIV\nOral\u00a0 anticoagulants\u00a0 may\u00a0 prolong\u00a0 the\nactivated\u00a0partial\u00a0thromboplastin\u00a0time\u00a0(aPTT)\nin\u00a0patients\u00a0receiving\u00a0heparin,\u00a0while\u00a0heparin\nmay\u00a0 prolong\u00a0 the\u00a0 International\u00a0 Normalized\nRatio\u00a0(INR)\u00a0in\u00a0patients\u00a0receiving\u00a0warfarin. 4\nInfluenza\u00a0Vaccine\nII\nUnknown. Has\u00a0 been\u00a0 associated\u00a0 with\naltered\u00a0 hypoprothrombinemic\u00a0 response\nto\u00a0warfarin\u00a0in\u00a0some\u00a0patients,\u00a0but\u00a0the\u00a0effect\nappears\u00a0to\u00a0be\u00a0minimal\u00a0in\u00a0most\u00a0cases. 4\nImatinib\nNo\u00a0evidence\nfound\nCompetitive\u00a0inhibition\u00a0of\u00a0isoenzyme\u00a0CYP3A4\nand\u00a0imatinib\u00adprovoked\u00a0inhibition\u00a0of\u00a0CYP2C9\nand\u00a0CYP2D6\u00admediated\u00a0warfarin\u00a0metabolism.", "chunk_order": 81}
{"chunk_id": "41d48396-925d-4a69-9576-cd75a5e684cd", "source_document_filename": "CPG Prevention and Treatment of Venous Thrombosis_cleaned_ultra_minimal.txt", "source_document_title": "CPG Prevention and Treatment of Venous Thrombosis cleaned ultra minimal", "text": "\"\n4\nEstrogen\nNo\u00a0evidence\nfound\nEstrogens\u00a0 induce\u00a0 coagulant\u00a0 factors. Estrogens\u00a0 increase\u00a0 the\u00a0 risk\u00a0 for\u00a0 clot\nformation\u00a0 and\u00a0 decrease\u00a0 the\u00a0 effects\u00a0 of\nwarfarin. 4\nHeparin\nIV\nOral\u00a0 anticoagulants\u00a0 may\u00a0 prolong\u00a0 the\nactivated\u00a0partial\u00a0thromboplastin\u00a0time\u00a0(aPTT)\nin\u00a0patients\u00a0receiving\u00a0heparin,\u00a0while\u00a0heparin\nmay\u00a0 prolong\u00a0 the\u00a0 International\u00a0 Normalized\nRatio\u00a0(INR)\u00a0in\u00a0patients\u00a0receiving\u00a0warfarin. 4\nInfluenza\u00a0Vaccine\nII\nUnknown. Has\u00a0 been\u00a0 associated\u00a0 with\naltered\u00a0 hypoprothrombinemic\u00a0 response\nto\u00a0warfarin\u00a0in\u00a0some\u00a0patients,\u00a0but\u00a0the\u00a0effect\nappears\u00a0to\u00a0be\u00a0minimal\u00a0in\u00a0most\u00a0cases. 4\nImatinib\nNo\u00a0evidence\nfound\nCompetitive\u00a0inhibition\u00a0of\u00a0isoenzyme\u00a0CYP3A4\nand\u00a0imatinib\u00adprovoked\u00a0inhibition\u00a0of\u00a0CYP2C9\nand\u00a0CYP2D6\u00admediated\u00a0warfarin\u00a0metabolism. 4\nLepirudin\nNo\u00a0evidence\nfound\nAdditive\u00a0 anticoagulation\u00a0 via\u00a0 different\nmechanism. 4\nLow\u00a0Molecular\nWeight\u00a0Heparin\nNo\u00a0evidence\nfound\nAdditive\u00a0anticoagulation. 4\nGemfibrozil\nIII\nUnknown\u00a0 mechanism\u00a0 due\u00a0 to\u00a0 poor\ndocumentation. Interaction\u00a0 is\u00a0 usually\ndose\u00a0related. 4\nGriseofulvin\nI\nUnknown. 4\nIfosfamide/Mesna\nIII\nUnknown. 4\nIsoniazid\nI\nUnknown. 4\nItraconazole\nII\nDecreased\u00a0warfarin\u00a0metabolism. 4\nKetoconazole\nII\nDecreased\u00a0warfarin\u00a0metabolism. 4\nFluoroquinolones\nNo\u00a0evidence\nfound\nInhibition\u00a0of\u00a0warfarin\u00a0metabolism. 4\nFluvoxamine\nII\nInhibitor\u00a0of\u00a0CYP\u00a01A2,\u00a0CYP\u00a03A4,\u00a0and\u00a0CYP\n2C9. Decrease\u00a0metabolism\u00a0of\u00a0warfarin. 4\nFenofibrates\nI\nUnexplained\u00a0metabolism. 4\nFluoxetine\nI\nInhibition\u00a0of\u00a0warfarin\u00a0metabolism. 4\nFlurouracil\nII\nInhibition\u00a0of\u00a0warfarin\u00a0metabolism. 4\nFluconazole\nI\nUnknown. Alters\u00a0clearance\u00a0of\u00a0warfarin. Drugs/Drug\nClasses\nEFFECT\u00a0ON\u00a0INR\nLevel\u00a0of\nCausation\nMode\u00a0of\u00a0Action\n$\n! \"\n4\nLovastatin\nIII\nUnknown. Paracetamol\nII\nInhibition\u00a0 of\u00a0 warfarin\u00a0 metabolism\u00a0 or\ninterference\u00a0with\u00a0clotting\u00a0factor\u00a0formation. 4\nParoxetine\nNo\u00a0evidence\nfound\nInhibitor\u00a0of\u00a0CYP\u00a01A2. Decrease\u00a0metabolism\nof\u00a0warfarin. 4\nQuetiapine\nIV\nInhibit\u00a0of\u00a0warfarin\u00a0metabolisme. 4\nMesalamine\nI\nUnknown. 4\nMetronidazole\nI\nDecreased\u00a0warfarin\u00a0metabolism. 4\nMoxalactam\nNo\u00a0evidence\nfound\nInhibition\u00a0 of\u00a0 platelet\u00a0 function,\u00a0 decreased\nclotting\u00a0factor\u00a0synthesis. 4\nOmeprazole\nI\nInhibits\u00a0 warfarin\u00a0 metabolism\u00a0 although\nmoderate\u00a0clinical\u00a0significance. 4\n4\nPhenytoin\nII\nDisplacement\u00a0 of\u00a0 warfarin\u00a0 from\u00a0 protein\nbinding\u00a0sites,\u00a0increased\u00a0warfarin\u00a0metabolism\n4\nPrimidone\nNo\u00a0evidence\nfound\nInduces\u00a0CYP1A2,\u00a02B6,\u00a02C8/9,\u00a03A4.Induces\nof\u00a0warfarin\u00a0metabolisme. 4\nPropafenone\nNo\u00a0evidence\nfound\nInhibit\u00a0 CYP1A2,\u00a0 2D6. Inhibit\u00a0 of\u00a0 warfarin\nmetabolisme\n4\nPropylthiouracil\nNo\u00a0evidence\nfound\nReduces\u00a0catabolisme\u00a0of\u00a0clotting\u00a0factors. 4\nQuinidine\nII\nInhibit\u00a0CYP1\u00a02C8/9,\u00a02D6,\u00a03A4. Inhibit\u00a0of\nwarfarin\u00a0metabolisme. 4\nRifampicin\nI\nInduces\u00a0 CYP1A2,2A6,\u00a0 2B6,2C8/9,\u00a0 2C19. Induces\u00a0metabolisme\u00a0of\u00a0warfarin. Careful\nmonitoring\u00a0 of\u00a0 INR\u00a0 and\u00a0 dose\u00a0 (20%\u00ad50%)\nare\u00a0required. The\u00a0interaction\u00a0is\u00a0maximal1\u00ad2\nweeks\u00a0following\u00a0additional\u00a0of\u00a0rifampicin. 4\nNonsteroidal\nAnti\u00adinflammatory\nDrugs\nNo\u00a0evidence\nfound\nAll\u00a0 NSAIDs\u00a0 (including\u00a0 selective\u00a0 COX\u00ad2\ninhibitors)\u00a0increase\u00a0the\u00a0risk\u00a0of\u00a0serious\u00a0GI\nbleeding. Nonselective\u00a0 agents\u00a0 (antiplatelet\u00a0 effect)\nand\u00a0 selective\u00a0 COX\u00ad2\u00a0 inhibitors\u00a0 (may\nincrease\u00a0 INR)\u00a0 may\u00a0 further\u00a0 increase\u00a0 the\nrisk\u00a0of\u00a0bleeding. 4\nMiconazole\nIII\nDecreased\u00a0 warfarin\u00a0 intrinsic\u00a0 clearance\nand\u00a0 increased\u00a0 plasma\u00a0 free\u00a0 fraction\u037e\ninhibition\u00a0of\u00a0cytochrome\u00a0P450\u00admediated\nmetabolism\u00a0of\u00a0warfarin\u00a0by\u00a0miconazole. Drugs/Drug\nClasses\nEFFECT\u00a0ON\u00a0INR\nLevel\u00a0of\nCausation\nMode\u00a0of\u00a0Action\n$\n! \"\n4\nSulfamethoxazole\nNo\u00a0evidence\nfound\nInhibit\u00a0 CYP2C8/9. Inhibit\u00a0 of\u00a0 warfarin\nmetabolisme\u00a0and\u00a0delays\u00a0warfarin\u00a0protein\nbinding. A\u00a0 decrease\u00a0 in\u00a0 warfarin\u00a0 dose\nmaybe\u00a0required. Monitoring\u00a0INR\u00a03\u00ad5\u00a0days\nof\u00a0starting,at\u00a0least\u00a0weekly\u00a0during\u00a0treatment\nand\u00a0again\u00a0one\u00a0week\u00a0following.", "chunk_order": 82}
{"chunk_id": "83abe528-766f-4cf5-bba0-16a82371760c", "source_document_filename": "CPG Prevention and Treatment of Venous Thrombosis_cleaned_ultra_minimal.txt", "source_document_title": "CPG Prevention and Treatment of Venous Thrombosis cleaned ultra minimal", "text": "Nonselective\u00a0 agents\u00a0 (antiplatelet\u00a0 effect)\nand\u00a0 selective\u00a0 COX\u00ad2\u00a0 inhibitors\u00a0 (may\nincrease\u00a0 INR)\u00a0 may\u00a0 further\u00a0 increase\u00a0 the\nrisk\u00a0of\u00a0bleeding. 4\nMiconazole\nIII\nDecreased\u00a0 warfarin\u00a0 intrinsic\u00a0 clearance\nand\u00a0 increased\u00a0 plasma\u00a0 free\u00a0 fraction\u037e\ninhibition\u00a0of\u00a0cytochrome\u00a0P450\u00admediated\nmetabolism\u00a0of\u00a0warfarin\u00a0by\u00a0miconazole. Drugs/Drug\nClasses\nEFFECT\u00a0ON\u00a0INR\nLevel\u00a0of\nCausation\nMode\u00a0of\u00a0Action\n$\n! \"\n4\nSulfamethoxazole\nNo\u00a0evidence\nfound\nInhibit\u00a0 CYP2C8/9. Inhibit\u00a0 of\u00a0 warfarin\nmetabolisme\u00a0and\u00a0delays\u00a0warfarin\u00a0protein\nbinding. A\u00a0 decrease\u00a0 in\u00a0 warfarin\u00a0 dose\nmaybe\u00a0required. Monitoring\u00a0INR\u00a03\u00ad5\u00a0days\nof\u00a0starting,at\u00a0least\u00a0weekly\u00a0during\u00a0treatment\nand\u00a0again\u00a0one\u00a0week\u00a0following. 4\n4\nRitonavir\nII\nInhibit\u00a0CYP\u00a02C8/9,\u00a02C19,\u00a02D6,2E1,\u00a03A4. Induces\u00a0CYP1A2,\u00a02C8/9,\u00a03A4. 4\nSaquinavir\nIII\nInhibit\u00a0 CYP2C8/9,\u00a0 2C19,\u00a0 2D6,\u00a0 3A4. Inhibit\u00a0of\u00a0warfarin\u00a0metabolism. 4\nSertraline\nI\nInhibit\u00a0 CYP1A2,\u00a0 2B6,\u00a0 2C8/9,\u00a0 2D6,\u00a0 3A4. Inhibit\u00a0of\u00a0warfarin\u00a0metabolism. 4\nThyroid\nhormones\nNo\u00a0evidence\nfound\nIncrease\u00a0catabolisme\u00a0of\u00a0clotting\u00a0factors. 4\nTiclopidine\nIII\nInhibit\u00a0\u00a0CYP1A2,\u00a02C8/9,\u00a02C19,\u00a02D6. Inhibit\nof\u00a0warfarin\u00a0metabolisme. 4\nTricyclic\nAntidepressants\nNo\u00a0evidence\nfound\nIncrease\u00a0hypoprothrombinemic\u00a0response\nreportedly\u00a0 has\u00a0 occurred,\u00a0 but\u00a0 clinical\nevidence\u00a0is\u00a0minimal. 4\nVitamin\u00a0E\nI\nAlter\u00a0 the\u00a0 effect\u00a0 of\u00a0 vitamin\u00a0 K\u00a0 action\u00a0 on\nclotting\u00a0 factors\u00a0 resulting\u00a0 in\u00a0 an\u00a0 increase\nhypoprotrombinemic\u00a0response\u00a0to\u00a0warfarin. 4\nZarfirlukast\nNo\u00a0evidence\nfound\nInhibit\u00a0 CYP1A2,\u00a0 2C8/9,\u00a0 2C19,2D6,3A4. Inhibit\u00a0of\u00a0warfarin\u00a0metabolisme\n4\nVitamin\u00a0K\nI\nInhibit\u00a0effectiveness\u00a0\u00a0of\u00a0warfarin. 4\nSildenafil\nNo\u00a0evidence\nfound\nInhibit\u00a0CYP1A2,\u00a02C8/9,\u00a02C19,\u00a02D6,\u00a02E1,\n3A4. Inhibit\u00a0of\u00a0warfarin\u00a0metabolism. 4\nSimvastatin\nII\nInhibit\u00a0CYP2C8/9,\u00a02D6. Inhibit\u00a0of\u00a0warfarin\nmetabolism. 4\nSucralfate\nI\nAltered\u00a0absorption\u00a0of\u00a0warfarin. 4\nTamoxifen\nII\nInhibit\u00a0CYP2B6,\u00a02C8/9,\u00a03A4. INCREASE\nEFFECT\u00a0ON\u00a0INR\nLEVEL\u00a0OF\u00a0CAUSATION\nDECREASE\nNO\u00a0EFFECT\n(INCREASED\u00a0RISK\u00a0OF\u00a0BLEEDING)\nI\nHIGHLY\u00a0PROBABLE\nII\nPROBABLE\nIII\nPOSSIBLE\nIV\nHIGHLY\u00a0IMPROBABLE\nDrugs/Drug\nClasses\nEFFECT\u00a0ON\u00a0INR\nLevel\u00a0of\nCausation\nMode\u00a0of\u00a0Action\n! $\n\"\n$\n! \"\nAppendix\u00a08\nWARFARIN\u00a0LABEL\nWARFARIN\u00a01MG/2MG/3MG/5MG\nNAMA:_______________________\u00a0\u00a0\u00a0TARIKH:__________\nMAKAN\n____BIJI\u00a0PADA\u00a0HARI\u00a0ISNIN\n____BIJI\u00a0PADA\u00a0HARI\u00a0SELASA\n____BIJI\u00a0PADA\u00a0HARI\u00a0RABU\n____BIJI\u00a0PADA\u00a0HARI\u00a0KHAMIS\n____BIJI\u00a0PADA\u00a0HARI\u00a0JUMAAT\n____BIJI\u00a0PADA\u00a0HARI\u00a0SABTU\n____BIJI\u00a0PADA\u00a0HARI\u00a0AHAD\nSEKALI\u00a0SEHARI\u00a0SEBELUM\u00a0MAKAN. PADA\u00a0JAM\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026. JABATAN\u00a0FARMASI\u00a0,\nHOSPITAL\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026.", "chunk_order": 83}
{"chunk_id": "e6f67ef0-9b59-429a-845a-70113760f2e3", "source_document_filename": "CPG Prevention and Treatment of Venous Thrombosis_cleaned_ultra_minimal.txt", "source_document_title": "CPG Prevention and Treatment of Venous Thrombosis cleaned ultra minimal", "text": "4\nTamoxifen\nII\nInhibit\u00a0CYP2B6,\u00a02C8/9,\u00a03A4. INCREASE\nEFFECT\u00a0ON\u00a0INR\nLEVEL\u00a0OF\u00a0CAUSATION\nDECREASE\nNO\u00a0EFFECT\n(INCREASED\u00a0RISK\u00a0OF\u00a0BLEEDING)\nI\nHIGHLY\u00a0PROBABLE\nII\nPROBABLE\nIII\nPOSSIBLE\nIV\nHIGHLY\u00a0IMPROBABLE\nDrugs/Drug\nClasses\nEFFECT\u00a0ON\u00a0INR\nLevel\u00a0of\nCausation\nMode\u00a0of\u00a0Action\n! $\n\"\n$\n! \"\nAppendix\u00a08\nWARFARIN\u00a0LABEL\nWARFARIN\u00a01MG/2MG/3MG/5MG\nNAMA:_______________________\u00a0\u00a0\u00a0TARIKH:__________\nMAKAN\n____BIJI\u00a0PADA\u00a0HARI\u00a0ISNIN\n____BIJI\u00a0PADA\u00a0HARI\u00a0SELASA\n____BIJI\u00a0PADA\u00a0HARI\u00a0RABU\n____BIJI\u00a0PADA\u00a0HARI\u00a0KHAMIS\n____BIJI\u00a0PADA\u00a0HARI\u00a0JUMAAT\n____BIJI\u00a0PADA\u00a0HARI\u00a0SABTU\n____BIJI\u00a0PADA\u00a0HARI\u00a0AHAD\nSEKALI\u00a0SEHARI\u00a0SEBELUM\u00a0MAKAN. PADA\u00a0JAM\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026. JABATAN\u00a0FARMASI\u00a0,\nHOSPITAL\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026. Appendix\u00a09\nWARFARIN\u00a0DOSING\u00a0NOTE\nJADUAL\u00a0PENGAMBILAN\u00a0UBAT\nMTAC\u00adANTITROMBOSIS\nJABATAN\u00a0FARMASI,\nHOSPITAL\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026.\u2026\nNama:\u00a0\u00a0_______________________________________\nTarikh:\u00a0\u00a0_______________\u00a0 INR:\u00a0\u00a0\u00a0___________________\nDos\u00a0Mingguan\u00a0Warfarin:\nAhad\u00a0\u00a0\u00a0\u00a0\u00a0_______________\u00a0 Isnin\u00a0\u00a0\u00a0__________________\nSelasa\u00a0\u00a0_______________\u00a0 Rabu\u00a0___________________\nKhamis\u00a0_______________\u00a0 Jumaat\u00a0_________________\nSabtu\u00a0\u00a0\u00a0_______________\nArahan\u00a0Khas:\n______________________________________________\n______________________________________________\nTarikh\u00a0Temujanji\u00a0akan\u00a0datang:\n______________________________________________\nMISSED\u00a0APPOINTMENT\nMTAC\u00a0WARFARIN\nJABATAN\u00a0FARMASI,\u00a0HOSPITAL\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026.\u2026\nPatient\u00a0Name\u00a0\u00a0\u00a0\u00a0:\u00a0\u00a0___________________________________\u00a0\u00a0\u00a0R/N:\u00a0_____________________\nPhone\u00a0Number\u00a0:\u00a0\u00a0___________________________________\nDate\nInitials\nContact\u00a0Details\nPatient\u00a0Response\nReschedule\nAppointment\nAppendix\u00a010\nMISSED\u00a0APPOINTMENT\u00a0RECORD\nAbbreviationsin\u00a0this\u00a0guideline\nPT\u00adINR\nProthrombin\u00a0time,\u00a0International\u00a0Normalised\u00a0Ratio\nTWD\nTotal\u00a0weekly\u00a0dose\nDosing\u00a0preparations\u00a0(University\u00a0Malaya\u00a0Medical\u00a0Centre)\nStrength\nColour\nBrand\n1\u00a0mg\nBrown\n\u00ad\u00ad\u00ad\n2\u00a0mg\nPurple\nApo\u00adWarfarin\n3\u00a0mg\nBlue\nOrfarin\n5\u00a0mg\nOrange\nApo\u00adWarfarin\nAppendix\u00a011\nMANAGEMENT\u00a0OF\u00a0WARFARIN\u00a0ANTICOAGULATION\u00a0IN\u00a0CHILDREN\n(UMMC\u00a0GUIDELINES\u00a02013)\nChallenges\u00a0of\u00a0warfarin\u00a0therapy\u00a0in\u00a0children\nChallenges\u00a0in\u00a0achieving\u00a0optimal\u00a0warfarin\u00a0anticoagulation\u00a0in\u00a0children\u00a0include\nt\u0001Wide\u00a0variations\u00a0in\u00a0dietary\u00a0vitamin\u00a0K\u00a0intake,\u00a0especially\u00a0during\u00a0infancy\nt\u0001Intercurrent\u00a0common\u00a0childhood\u00a0illnesses,\u00a0associated\u00a0with\u00a0poor\u00a0oral\u00a0intake\u00a0and\nuse\u00a0of\u00a0antibiotics,\u00a0factors\u00a0that\u00a0destabilise\u00a0warfarin\u00a0therapy\nt\u0001Requirement\u00a0for\u00a0regular\u00a0monitoring,\u00a0including\u00a0need\u00a0for\u00a0regular\u00a0venous\u00a0sampling\u00a0for\nPT\u00adINR\u00a0testing\nt\u0001Adherence\u00a0to\u00a0warfarin\u00a0therapy\u00a0in\u00a0adolescents\nIndications\nLong\u00adterm\u00a0(indefinite\u00a0duration)\u00a0anticoagulation\u00a0in\u00a0children\u00a0with\nt\u0001Some\u00a0forms\u00a0of\u00a0congenital\u00a0heart\u00a0surgery\u00a0\u00a0(typically,\u00a0cavopulmonary\u00a0shunt\nsurgery\u00a0[e.g. Fontan\u00a0procedure])\nt\u0001mechanical\u00a0heart\u00a0valve\u00a0replacement\nt\u0001dilated\u00a0cardiomyopathy\u00a0complicated\u00a0by\u00a0dysrythmia\u00a0or\u00a0heart\u00a0failure\nt\u0001recurrent\u00a0arterial\u00a0or\u00a0venous\u00a0thromboembolism\nt\u0001primary\u00a0pulmonary\u00a0arterial\u00a0hypertension\nIntermediate\u00adduration\u00a0anticoagulation\u00a0(6\u00a0months)\u00a0in\u00a0children\u00a0with\nt\u0001first\u00a0episode\u00a0of\u00a0idiopathic\u00a0vascular\u00a0thrombosis\nN.B:\u00a0Children\u00a0who\u00a0experience\u00a0a\u00a0first\u00a0event\u00a0of\u00a0provoked\u00a0vascular\u00a0thrombosis\u00a0may\nbe\u00a0more\u00a0easily\u00a0managed\u00a0with\u00a0extended\u00a0low\u00admolecular\u00a0weight\u00a0heparin\u00a0therapy\n(duration:\u00a0at\u00a0least\u00a03\u00a0months). Extended\u00a0low\u00admolecular\u00a0weight\u00a0heparin\u00a0therapy\u00a0is\nsimilarly\u00a0appropriate\u00a0for\u00a0children\u00a0with\u00a0venous\u00a0thrombosis\u00a0in\u00a0the\u00a0context\u00a0of\u00a0cancer. Dosing\u00a0principles\nt\u0001Family\u00a0 education\u00a0 is\u00a0 critical\u00a0 to\u00a0 safe\u00a0 successful\u00a0 long\u00adterm\u00a0 warfarin\nanticoagulation\nt\u0001Warfarin\u00a0 is\u00a0 best\u00a0 avoided\u00a0 in\u00a0 children\u00a0 less\u00a0 than\u00a0 2\u00a0 months\u00a0 old\u00a0 (greater\nhaemorrhagic\u00a0risk\u00a0since\u00a0levels\u00a0of\u00a0clotting\u00a0factors\u00a0are\u00a0physiologically\u00a0lower). Warfarin\u00a0is\u00a0typically\u00a0prescribed\u00a0in\u00a0children\u00a0&6\u00a0months\u00a0old.", "chunk_order": 84}
{"chunk_id": "55b64fa5-8345-4fa0-9d93-79a9fd6ed6c1", "source_document_filename": "CPG Prevention and Treatment of Venous Thrombosis_cleaned_ultra_minimal.txt", "source_document_title": "CPG Prevention and Treatment of Venous Thrombosis cleaned ultra minimal", "text": "Extended\u00a0low\u00admolecular\u00a0weight\u00a0heparin\u00a0therapy\u00a0is\nsimilarly\u00a0appropriate\u00a0for\u00a0children\u00a0with\u00a0venous\u00a0thrombosis\u00a0in\u00a0the\u00a0context\u00a0of\u00a0cancer. Dosing\u00a0principles\nt\u0001Family\u00a0 education\u00a0 is\u00a0 critical\u00a0 to\u00a0 safe\u00a0 successful\u00a0 long\u00adterm\u00a0 warfarin\nanticoagulation\nt\u0001Warfarin\u00a0 is\u00a0 best\u00a0 avoided\u00a0 in\u00a0 children\u00a0 less\u00a0 than\u00a0 2\u00a0 months\u00a0 old\u00a0 (greater\nhaemorrhagic\u00a0risk\u00a0since\u00a0levels\u00a0of\u00a0clotting\u00a0factors\u00a0are\u00a0physiologically\u00a0lower). Warfarin\u00a0is\u00a0typically\u00a0prescribed\u00a0in\u00a0children\u00a0&6\u00a0months\u00a0old. t\u0001Maintain\u00a0heparin\u00a0anticoagulation\u00a0until\u00a0lower\u00a0limit\u00a0of\u00a0target\u00a0PT\u00adINR\u00a0is\nTarget\u00a0PT\u00adINR\nCondition\nTarget\u00a0PT\u00adINR\u00a0(Range)\nCongenital\u00a0heart\u00a0surgery\u00a0(cavopulmonary\u00a0shunts)\u00a0\u00a0 2.5\u00a0(2.0\u00a0\u00ad\u00a03.0)\nMechanical\u00a0heart\u00a0valve\u00a0recipients\nAll\u00a0mechanical\u00a0mitral\u00a0valves\n3.0\u00a0(2.5\u00a0\u00ad\u00a03.5)\nCaged\u00adball\u00a0or\u00a0tilting\u00addisk\u00a0aortic\u00a0valves\n3.0\u00a0(2.5\u00a0\u00ad\u00a03.5)\nBileaflet\u00a0or\u00a0Medtronic\u00adHall\u00a0aortic\u00a0valve\n2.5\u00a0(2.0\u00a0\u00ad\u00a03.0)\nDilated\u00a0cardiomyopathy,\u00a0with\u00a0complications\n2.5\u00a0(2.0\u00a0\u00ad\u00a03.0)\nRecurrent\u00a0vascular\u00a0thromboembolism\n2.5\u00a0(2.0\u00a0\u00ad\u00a03.0)\nPre\u00adtreatment\u00a0checks\nClinical\nt\u0001Ascertain\u00a0that\u00a0child\u00a0is\u00a0clinically\u00a0stable\u00a0and\u00a0that\u00a0oral\u00a0therapy\u00a0is\u00a0feasible\nt\u0001Ensure\u00a0no\u00a0active\u00a0bleeding\nt\u0001Obtain\u00a0diet\u00a0and\u00a0drug\u00a0history,\u00a0exploring\u00a0factors\u00a0that\u00a0could\u00a0influence\u00a0warfarin\naction\nt\u0001Explore\u00a0factors\u00a0that\u00a0could\u00a0increase\u00a0risk\u00a0of\u00a0bleeding\u00a0(recent\u00a0surgery,\u00a0non\u00adsteroidal\nanti\u00adinflammatory\u00a0drugs,\u00a0scheduled\u00a0invasive\u00a0procedures\u00a0including\u00a0intramuscular\ninjections,\u00a0hepatic\u00a0dysfunction)\nt\u0001Consider\u00a0possibility\u00a0of\u00a0pregnancy\u00a0in\u00a0older\u00a0girls\u00a0(warfarin\u00a0is\u00a0teratogenic)\nLaboratory\nt\u0001I9+8%0\"+)#0\";<)C0<0C\"/$89C\"T;<)C0<0C\"/$89C\"&5@@\":5@9/L)\nt\u0001Ensure\u00a0safe\u00a0baseline\u00a0PT\u00adINR\u00a0(PT\u00adINR\u00a041.3)\nachieved\u00a0with\u00a0warfarin\u037e\u00a0this\u00a0may\u00a0take\u00a0between\u00a05\u00a0and\u00a010\u00a0days. t\u0001Dose\u00a0warfarin\u00a0by\u00a0whole\u00a0tablets\u00a0since\u00a0active\u00a0warfarin\u00a0is\u00a0not\u00a0evenly\u00a0distributed\nwithin\u00a0a\u00a0tablet\nt\u0001For\u00a0 younger\u00a0 children,\u00a0 warfarin\u00a0 may\u00a0 be\u00a0 administered\u00a0 as\u00a0 solution\u00a0 by\ncrushing/dissolving\u00a0the\u00a0tablet\u00a0extemporaneously\u00a0in\u00a0water\u00a0(Note:\u00a0the\u00a0impact\nof\u00a0 such\u00a0 reconstitution\u00a0 on\u00a0 drug\u00a0 activity\u00a0 has\u00a0 not\u00a0 been\u00a0 systematically\nascertained)\nt\u0001Warfarin\u00a0 is\u00a0 administered\u00a0 daily,\u00a0 usually\u00a0 in\u00a0 the\u00a0 evening\u00a0 (allowing\u00a0 for\u00a0 dose\nchanges\u00a0following\u00a0PT\u00adINR\u00a0tests\u00a0in\u00a0the\u00a0morning)\nt\u0001Consider\u00a0 a\u00a0 dose\u00a0 as\u00a0 \u2018missed\u2019\u00a0 if\u00a0 more\u00a0 than\u00a0 12\u00a0 hours\u00a0 have\u00a0 elapsed\u00a0 since\nscheduled\u00a0intake. Do\u00a0not\u00a0substitute\u00a0with\u00a0booster\u00a0doses\u00a0(risk\u00a0of\u00a0overshoot\nanticoagulation). t\u0001Daily\u00a0 or\u00a0 alternate\u00adday\u00a0 monitoring\u00a0 of\u00a0 PT\u00adINR\u00a0 is\u00a0 required\u00a0 during\u00a0 the\u00a0 initial\ntreatment\u00a0phase\nt\u0001During\u00a0the\u00a0maintenance\u00a0phase,\u00a0dose\u00a0changes\u00a0are\u00a0made\u00a0based\u00a0on\u00a0the\u00a0total\nweekly\u00a0dose\nt\u0001In\u00a0 patients\u00a0 experiencing\u00a0 wide\u00a0 swings\u00a0 in\u00a0 PT\u00adINR\u00a0 while\u00a0 on\u00a0 warfarin,\nsupplementation\u00a0with\u00a0daily\u00a0oral\u00a0vitamin\u00a0K\u00a0helps\u00a0minimise\u00a0the\u00a0fluctuations\u00a0in\nPT\u00adINR\ne.g. Daily\u00a0\u00a0\u00a0administration\u00a0\u00a0\u00a0of\u00a0\u00a0\u00a0Konakion\u00a0\u00a0MM\u00a0\u00a0paediatric\u00a0\u00a0(phytomenadione\u00a0\u00a0or\nvitamin\u00a0K1,\u00a02\u00a0mg/0.2\u00a0mL),\u00a030\u00a0mcg/kg\ne.g. Supplementation\u00a0\u00a0with\u00a0\u00a01\u00ad2\u00a0\u00a0ounces\u00a0\u00a0of\u00a0\u00a0formula\u00a0\u00a0milk\u00a0in\u00a0exclusively\u00a0breast\u00ad\nfed\u00a0infants\nMaintenance\u00a0treatment\u00a0phase\nDose\u00a0adjustments\u00a0based\u00a0on\u00a0total\u00a0weekly\u00a0dose\u00a0(TWD)\ne.g. A\u00a0patient\u00a0taking\u00a02\u00a0mg\u00a0Warfarin\u00a0daily\u00a0on\u00a0Monday\u00a0\u00ad\u00a0Friday\u00a0and\u00a01\u00a0mg\u00a0on\nSaturday\u00a0and\u00a0Sunday\u00a0will\u00a0receive\u00a0a\u00a0total\u00a0weekly\u00a0dose\u00a0(TWD)\u00a0of\u00a012\u00a0mg.", "chunk_order": 85}
{"chunk_id": "b138dd88-1b18-4318-bd45-c2071636c8ee", "source_document_filename": "CPG Prevention and Treatment of Venous Thrombosis_cleaned_ultra_minimal.txt", "source_document_title": "CPG Prevention and Treatment of Venous Thrombosis cleaned ultra minimal", "text": "Daily\u00a0\u00a0\u00a0administration\u00a0\u00a0\u00a0of\u00a0\u00a0\u00a0Konakion\u00a0\u00a0MM\u00a0\u00a0paediatric\u00a0\u00a0(phytomenadione\u00a0\u00a0or\nvitamin\u00a0K1,\u00a02\u00a0mg/0.2\u00a0mL),\u00a030\u00a0mcg/kg\ne.g. Supplementation\u00a0\u00a0with\u00a0\u00a01\u00ad2\u00a0\u00a0ounces\u00a0\u00a0of\u00a0\u00a0formula\u00a0\u00a0milk\u00a0in\u00a0exclusively\u00a0breast\u00ad\nfed\u00a0infants\nMaintenance\u00a0treatment\u00a0phase\nDose\u00a0adjustments\u00a0based\u00a0on\u00a0total\u00a0weekly\u00a0dose\u00a0(TWD)\ne.g. A\u00a0patient\u00a0taking\u00a02\u00a0mg\u00a0Warfarin\u00a0daily\u00a0on\u00a0Monday\u00a0\u00ad\u00a0Friday\u00a0and\u00a01\u00a0mg\u00a0on\nSaturday\u00a0and\u00a0Sunday\u00a0will\u00a0receive\u00a0a\u00a0total\u00a0weekly\u00a0dose\u00a0(TWD)\u00a0of\u00a012\u00a0mg. A\u00a0~10%\u00a0increase\u00a0in\u00a0TWD\u00a0would\u00a0result\u00a0in\u00a0a\u00a0dose\u00a0change\u00a0to\u00a02\u00a0mg\u00a0on\nMondays\u00a0to\u00a0Saturdays\u00a0and\u00a01\u00a0mg\u00a0on\u00a0Sunday\u00a0(TWD\u00a0of\u00a013\u00a0mg)\nINR*\nIntervention\n<1.5\nCheck\u00a0patient\u00a0adherence\nIncrease\u00a0TWD\u00a0by\u00a010\u00a0\u00ad\u00a020%\nRepeat\u00a0PT\u00adINR\u00a0in\u00a01\u00a0week\n&567\"_8C\"<0++\"CE)9\"\n`E0/B\";)C109C\")(E0%09/0\ntherapeutic\u00a0range\nMake\u00a0no\u00a0dose\u00a0change\u037e\u00a0repeat\u00a0PT\u00adINR\u00a0in\u00a01\u00a0week\nIf\u00a0repeat\u00a0PT\u00adINR\u00a0still\u00a0below\u00a0therapeutic\u00a0range,\nincrease\u00a0TWD\u00a0by\u00a05\u00a0\u00ad\u00a010%\n2\u00a0\u00ad\u00a03\nNo\u00a0change\n3.1\u00a0\u00ad\u00a03.5\nDecrease\u00a0TWD\u00a0by\u00a010%\nRepeat\u00a0PT\u00adINR\u00a0in\u00a01\u00a0week\n>3.5\nWithhold\u00a0warfarin\u00a0until\u00a0INR\u00a0<3.5\u00a0(see\u00a0section\u00a0on\n\u2018Overanticoagulation\u2019)\nThen\u00a0restart\u00a0at\u00a0a\u00a0reduced\u00a0TWD\u00a0(reduction\u00a0by\u00a020%)\nRepeat\u00a0PT\u00adINR\u00a0in\u00a01\u00a0week\n*\u00a0For\u00a0patients\u00a0treated\u00a0to\u00a0a\u00a0target\u00a0PT\u00adINR\u00a0of\u00a02\u00a0\u00ad\u00a03\nInitial\u00a0treatment\u00a0phase\nDay\u00a01\u0001\nt\u0001Administer\u00a00.2\u00a0mg/kg\u00a0orally\u00a0as\u00a0a\u00a0single\u00a0evening\u00a0dose\n(maximum,\u00a05\u00a0mg)\n\u0000\u0001\u0001 \u0001\nt\u0001In\u00a0frail\u00a0patients,\u00a0patients\u00a0with\u00a0liver\u00a0dysfunction\u00a0or\u00a0severe\nrenal\u00a0impairment,\u00a0reduce\u00a0loading\u00a0dose\u00a0to\u00a00.1\u00a0mg/kg\u00a0(maximum,\n5\u00a0mg)\n\u0000\u0001\u0001 \u0001\nt\u0001For\u00a0young\u00a0adult\u00a0patients,\u00a0commence\u00a0warfarin\u00a0at\u00a0a\u00a0loading\u00a0dose\nof\u00a05\u00a0mg\nDays\u00a02\u00a0\u00ad\u00a04 1.1\u00a0\u00ad\u00a01.3\u00a0\u00a0\u00a0Repeat\u00a0initial\u00a0loading\u00a0dose\n1.4\u00a0\u00ad\u00a01.9\u00a0\u00a0\u00a050%\u00a0of\u00a0initial\u00a0loading\u00a0dose\n2.0\u00a0\u00ad\u00a03.0\u00a0\u00a0\u00a050%\u00a0of\u00a0initial\u00a0loading\u00a0dose\n3.1\u00a0\u00ad\u00a03.5\u00a0\u00a0\u00a025%\u00a0of\u00a0initial\u00a0loading\u00a0dose\n>3.5\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Hold\u00a0until\u00a0INR\u00a043.5\u037e\u00a0restart\u00a0at\u00a050%\u00a0less\u00a0than\u00a0previous\ndose\nIf\u00a0the\u00a0INR\u00a0is\u00a0not\u00a0>1.5\u00a0on\u00a0Day\u00a04,\u00a0reassess\u00a0and\u00a0consider\u00a0increasing\u00a0the\u00a0loading\u00a0dose\nMonitoring\u00a0while\u00a0on\u00a0warfarin\u00a0therapy\nt\u0001Clinical\u00a0monitoring\n$ Assessment\u00a0 for\u00a0 features\u00a0 of\u00a0 thrombosis\u00a0 (including\u00a0 cutaneous\u00a0 vascular\nthrombosis)\u00a0and\u00a0haemorrhage\u00a0(cutaneous,\u00a0mucosal\u00a0and\u00a0intracranial)\n$ Assessment\u00a0 for\u00a0 other\u00a0 complications\u00a0 of\u00a0 warfarin\u00a0 (e.g. alopecia,\u00a0 bone\ndensity)\nt\u0001Assessment\u00a0of\u00a0adherence\u00a0to\u00a0therapy\nt\u0001Evaluation\u00a0of\u00a0factors\u00a0that\u00a0could\u00a0influence\u00a0warfarin\u00a0therapy\n$ Dietary\u00a0changes\u00a0(e.g. switch\u00a0from\u00a0largely\u00a0breast\u00adfeeding\u00a0to\u00a0formula\u00a0milk\nfeeds)\n$ Intercurrent\u00a0infections\n$ Medications\u00a0 (e.g. dose\u00a0 change\u00a0 of\u00a0 cardiac\u00a0 drugs\u00a0 or\u00a0 prescription\u00a0 of\u00a0 new\ndrugs\u00a0[e.g. antibiotics])\nt\u0001Non\u00adprescription\u00a0agents\u00a0that\u00a0could\u00a0influence\u00a0warfarin\u00a0therapy\n$ Herbal\u00a0supplements\u00a0(typically\u00a0through\u00a0effect\u00a0on\u00a0platelet\u00a0function)\n$ Cranberry\u00a0juice\u00a0(inhibits\u00a0warfarin\u00a0metabolism,\u00a0prolongs\u00a0warfarin\u00a0effect)\nCOMMONLY\u00a0PRESCRIBED\u00a0DRUGS\u00a0THAT\u00a0TEND\u00a0TO\u00a0INCREASE\u00a0PT\u00adINR\nBY\u00a0PROLONGING\u00a0WARFARIN\u00a0EFFECT\nt Antimicrobials\u00a0including\u00a0cotrimoxazole,\u00a0metronidazole,\u00a0azole\nantifungals\u00a0(especially\u00a0fluconazole),\u00a0macrolides\u00a0(e.g. erythromycin),\nquinolones\u00a0(e.g. ciprofloxacin)\u00a0and\u00a0isoniazid. Note:\u00a0all\u00a0antibacterials\nalter\u00a0gut\u00a0flora\u00a0and\u00a0thus\u00a0potentially\u00a0enhance\u00a0warfarin\u00a0activity\nt\u0001Paracetamol,\u00a0typically\u00a0with\u00a0long\u00adterm\u00a0use\nt\u0001Corticosteroids,\u00a0typically\u00a0at\u00a0high\u00a0doses\nt\u0001Proton\u00a0pump\u00a0inhibitors\u00a0(e.g. omeprazole)\nt\u0001L\u00adthyroxine,\u00a0especially\u00a0during\u00a0dose\u00a0titration\nt\u0001Amiodarone\nCOMMONLY\u00a0 USED\u00a0 DRUGS\u00a0 THAT\u00a0 TEND\u00a0 TO\u00a0 DECREASE\u00a0 PT\u00adINR\u00a0 BY\nACCELERATING\u00a0WARFARIN\u00a0ELIMINATION\nt\u0001Anticonvulsants\u00a0(e.g.", "chunk_order": 86}
{"chunk_id": "3ef78ded-24d0-4241-9ede-c9bf6bcedabf", "source_document_filename": "CPG Prevention and Treatment of Venous Thrombosis_cleaned_ultra_minimal.txt", "source_document_title": "CPG Prevention and Treatment of Venous Thrombosis cleaned ultra minimal", "text": "erythromycin),\nquinolones\u00a0(e.g. ciprofloxacin)\u00a0and\u00a0isoniazid. Note:\u00a0all\u00a0antibacterials\nalter\u00a0gut\u00a0flora\u00a0and\u00a0thus\u00a0potentially\u00a0enhance\u00a0warfarin\u00a0activity\nt\u0001Paracetamol,\u00a0typically\u00a0with\u00a0long\u00adterm\u00a0use\nt\u0001Corticosteroids,\u00a0typically\u00a0at\u00a0high\u00a0doses\nt\u0001Proton\u00a0pump\u00a0inhibitors\u00a0(e.g. omeprazole)\nt\u0001L\u00adthyroxine,\u00a0especially\u00a0during\u00a0dose\u00a0titration\nt\u0001Amiodarone\nCOMMONLY\u00a0 USED\u00a0 DRUGS\u00a0 THAT\u00a0 TEND\u00a0 TO\u00a0 DECREASE\u00a0 PT\u00adINR\u00a0 BY\nACCELERATING\u00a0WARFARIN\u00a0ELIMINATION\nt\u0001Anticonvulsants\u00a0(e.g. carbamazepine,\u00a0phenytoin,\u00a0phenobarbitone)\nt\u0001Rifampicin\nCOMMONLY\nPRESCRIBED\nDRUGS\nTHAT\nINDEPENDENTLY\nINCREASE\u00a0RISK\u00a0OF\u00a0BLEEDING\n\u0000t\u0001Non\u00adsteroidal\u00a0anti\u00adinflammatory\u00a0drugs\u00a0(e.g. aspirin\u00a0and\u00a0ibuprofen)\nCOMMONLY\u00a0USED\u00a0DRUGS\u00a0THAT\u00a0ARE\u00a0PROTHROMBOTIC\u00a0AND\u00a0THUS\nANTAGONISE\u00a0WARFARIN\u00a0EFFECT\nt\u0001Oestrogen\u00adprogesterone\u00a0medications\nt\u0001Laboratory\u00a0monitoring\u00a0of\u00a0PT\u00adINR\nTreatment\u00a0context\nFrequency\u00a0of\u00a0monitoring\nInitial\u00a0treatment\u00a0phase\u00a0until\u00a0therapeutic\u00a0PT\u00adINR\nDaily\u00a0or\u00a0every\u00a0other\u00a0day\nInitiation\u00a0of\u00a0total\u00a0weekly\u00a0dosing\nWithin\u00a03\u00a0\u00ad\u00a05\u00a0days\nFirst\u00a0month\u00a0of\u00a0maintenance\u00a0phase\u00a0therapy\nWeekly\nAny\u00a0dose\u00a0change\u00a0during\u00a0maintenance\u00a0phase\nWithin\u00a01\u00a0\u00ad\u00a02\u00a0weeks\nDose\u00a0withheld\u00a0due\u00a0to\u00a0significant\u00a0overanticoagulation\nWithin\u00a01\u00a0\u00ad\u00a02\u00a0days\nRoutine\u00a0follow\u00adup,\u00a0medically\u00a0stable,\u00a0reliable\nEvery\u00a04\u00a0\u00ad\u00a06\u00a0weeks\nRoutine\u00a0follow\u00adup,\u00a0medically\u00a0unstable\u00a0or\u00a0unreliable\nEvery\u00a01\u00a0\u00ad\u00a02\u00a0weeks\nt\u0001Maintain\u00a0a\u00a0warfarin\u00a0treatment\u00a0diary\u00a0(sample\u00a0below)\nManagement\u00a0of\u00a0overanticoagulation\nAlways\u00a0explore\u00a0possible\u00a0explanations\u00a0for\u00a0overanticoagulation\nHAEMORRHAGE\nNot\u00a0life\u00adthreatening\u00a0\u00a0Stop\u00a0Warfarin\nOral\u00a0Vitamin\u00a0K*\u00a00.5\u00a0\u00ad\u00a02\u00a0mg\u00a0(based\u00a0on\u00a0body\u00a0weight)\nAlternatively,\u00a0intravenous\u00a0or\u00a0subcutaneous\u00a0vitamin\u00a0K\u00a00.5\n\u00ad\u00a01\u00a0mg\nHigher\u00a0doses\u00a0(e.g. 2\u00a0\u00ad\u00a05\u00a0mg)\u00a0of\u00a0oral\u00a0vitamin\u00a0K\u00a0are\nappropriate\u00a0in\u00a0patients\u00a0who\u00a0will\u00a0not\u00a0require\u00a0warfarin\u00a0again\nLife\u00adthreatening\nStop\u00a0Warfarin\nProthrombin\u00a0complex\u00a0concentrate**\u00a025\u00a0\u00ad\u00a050\u00a0units/kg\nIntravenous\u00a0(or\u00a0subcutaneous)\u00a0Vitamin\u00a0K\u00a05mg\u00a0(slow\nintravenous)\nResuscitate\u00a0as\u00a0appropriate\nActively\u00a0assess\u00a0for\u00a0intracranial\u00a0haemorrhage\nNO\u00a0HAEMORRHAGE\nPT\u00adINR\u00a0<5\nStop\u00a0Warfarin\nDaily\u00a0or\u00a0alternate\u00a0day\u00a0PT\u00adINR\u00a0monitoring\u00a0until\u00a0PT\u00adINR\u00a0<3.5\nResume\u00a0with\u00a0reduced\u00a0total\u00a0weekly\u00a0dose\u00a0(reduction\u00a0by\u00a020%)\nCheck\u00a0PT\u00adINR\u00a0a\u00a0week\u00a0later\nDate\nPT\u00adINR\nCurrent\nwarfarin\u00a0dose\nRecommended\ndose\nDate\u00a0of\u00a0next\nblood\u00a0test\nPT\u00adINR\u00a05\u00a0\u00ad\u00a09\nStop\u00a0Warfarin\nConsider\u00a0oral\u00a0vitamin\u00a0K\u00a0at\u00a00.5\u00a0\u00ad\u00a02.0\u00a0mg\u00a0(based\u00a0on\u00a0body\u00a0weight)\nin\u00a0patients\u00a0at\u00a0high\u00a0risk\u00a0of\u00a0bleeding\nDaily\u00a0or\u00a0alternate\u00a0day\u00a0PT\u00adINR\u00a0monitoring\u00a0until\u00a0PT\u00adINR\u00a0<3.5\nResume\u00a0with\u00a0reduced\u00a0total\u00a0weekly\u00a0dose\u00a0(reduction\u00a0by\u00a010\u00ad20%)\nCheck\u00a0PT\u00adINR\u00a0a\u00a0week\u00a0later\nPT\u00adINR\u00a0>\u00a09\nStop\u00a0warfarin\nAdminister\u00a0oral\u00a0vitamin\u00a0K\u00a0at\u00a00.5\u00a0\u00ad\u00a02.0\u00a0mg\u00a0(based\u00a0on\u00a0body\nweight)\nRepeat\u00a0oral\u00a0vitamin\u00a0K\u00a0if\u00a0repeat\u00a0PT\u00adINR\u00a0remains\u00a0elevated\u00a0(>5)\n12h\u00a0later\nDaily\u00a0or\u00a0alternate\u00a0day\u00a0PT\u00adINR\u00a0monitoring\u00a0until\u00a0PT\u00adINR\u00a0<3.5\nResume\u00a0with\u00a0reduced\u00a0total\u00a0weekly\u00a0dose\u00a0(reduction\u00a0by\u00a020%)\nCheck\u00a0PT\u00adINR\u00a0a\u00a0week\u00a0later\n*\u00a0\u00a0\u00a0Oral\u00a0Vitamin\u00a0K,\u00a0using\u00a0the\u00a0Konakion\u00a0MM\u00a0Paediatric\u00a0preparation\u00a0(2\u00a0mg/0.2\u00a0mL)\n**\u00a0Four\u00adfactor\u00a0prothrombin\u00a0complex\u00a0concentrate\u00a0is\u00a0the\u00a0most\u00a0suitable\u00a0(enriched\nin\u00a0Factors\u00a0II,\u00a0VII,\u00a0IX,\u00a0X). Where\u00a0not\u00a0available,\u00a0fresh\u00a0frozen\u00a0plasma\u00a0(FFP)\u00a0may\nbe\u00a0administered\u00a0(20\u00a0mL/kg)\nt\u0001Assess\u00a0risk\u00a0of\u00a0periprocedure\u00a0bleeding\nPatients\u00a0 undergoing\u00a0 procedures\u00a0 with\u00a0 low\u00a0 risk\u00a0 of\u00a0 bleeding\u00a0 do\u00a0 not\u00a0 require\ninterruption\u00a0of\u00a0warfarin\u00a0therapy. These\u00a0procedures\u00a0include\n\u0001\u0001\u0001\u0001\u0001t\u0001tooth\u00a0extractions\u00a0and\u00a0endodontic\u00a0(root\u00a0canal)\u00a0procedures\n\u0001\u0001\u0001\u0001\u0001t\u0001small\u00a0skin\u00a0excisions\u00a0(e.g.", "chunk_order": 87}
{"chunk_id": "fe23a378-7772-4b6a-bd77-755148a45a91", "source_document_filename": "CPG Prevention and Treatment of Venous Thrombosis_cleaned_ultra_minimal.txt", "source_document_title": "CPG Prevention and Treatment of Venous Thrombosis cleaned ultra minimal", "text": "Where\u00a0not\u00a0available,\u00a0fresh\u00a0frozen\u00a0plasma\u00a0(FFP)\u00a0may\nbe\u00a0administered\u00a0(20\u00a0mL/kg)\nt\u0001Assess\u00a0risk\u00a0of\u00a0periprocedure\u00a0bleeding\nPatients\u00a0 undergoing\u00a0 procedures\u00a0 with\u00a0 low\u00a0 risk\u00a0 of\u00a0 bleeding\u00a0 do\u00a0 not\u00a0 require\ninterruption\u00a0of\u00a0warfarin\u00a0therapy. These\u00a0procedures\u00a0include\n\u0001\u0001\u0001\u0001\u0001t\u0001tooth\u00a0extractions\u00a0and\u00a0endodontic\u00a0(root\u00a0canal)\u00a0procedures\n\u0001\u0001\u0001\u0001\u0001t\u0001small\u00a0skin\u00a0excisions\u00a0(e.g. skin\u00a0biopsy)\nt\u0001Stop\u00a0warfarin\u00a05\u00a0days\u00a0prior\u00a0to\u00a0the\u00a0scheduled\u00a0operative\u00a0procedure\nt\u0001Determine\u00a0strategy\u00a0for\u00a0periprocedure\u00a0bridging\u00a0therapy\u00a0based\u00a0on\u00a0estimated\u00a0risk\u00a0for\nthrombosis\nPeriprocedure\u00a0management\u00a0of\u00a0warfarin\u00a0and\u00a0requirement\u00a0for\u00a0bridging\nheparin\u00a0therapy\nPrinciples\nt\u0001Assess\u00a0thrombotic\u00a0risk\nLow\u00a0risk\nPrimary\u00a0low\u00adrisk\u00a0thromboprophylaxis\u00a0(e.g. Fontan\nsurgery,\u00a0stable)\nMedium\u00a0risk\nVascular\u00a0thromboembolism\u00a0>3\u00a0months\u00a0from\u00a0onset\nPrimary\u00a0thromboprophylaxis\u00a0for\u00a0dilated\u00a0cardiomyopathy,\nrheumatic\u00a0valvular\u00a0heart\u00a0disease\u00a0and\u00a0mechanical\u00a0heart\nvalves\na1>E\"%1+B\"\"\nG)+/8<)%\"CE%$=_$0=_$<1+=\"4'\"=$9CE+\"#%$=\"$9+0C\nPulmonary\u00a0embolism\nRecurrent\u00a0thromboembolism\nPrimary\u00a0thromboprophylaxis\u00a0for\u00a0primary\u00a0pulmonary\nhypertension\nPast\u00a0history\u00a0of\u00a0prosthetic\u00a0valve\u00a0thrombosis\nHomozygous\u00a0protein\u00a0C\u00a0deficiency\nLow\nNo\nNo\nIntermediate\nHigh\nEnoxaparin,\u00a01\u00a0mg/kg\nBD\nwhen\u00a0PT\u00adINR\u00a0<2\u037e\ncontinue\u00a0until\u00a0AM\u00a0of\nday\u00a0prior\u00a0to\nprocedure. Commence\nunfractionated\nheparin\u00a0(starting\u00a0at\n20\u00a0u/kg/hr)\u00a04\u00a0hours\nafter\u00a0last\u00a0dose\u00a0of\nenoxaparin\u00a0and\ncontinue\u00a0until\u00a01\u00a0hour\nprior\u00a0to\u00a0procedure\nRestart\nunfractionated\nheparin\u00a0(UFH)\u00a01\u00a0hour\npostprocedure\u00a0(if\u00a0no\nbleeding\u00a0concerns)\nand\u00a0adjust\u00a0using\nAPTT\u00a0(target,\u00a060\u00ad80\nsecs). Maintain\u00a0on\u00a0UFH\u00a0as\nlong\u00a0as\nhigher\u00a0bleeding\u00a0risk. Restart\u00a0enoxaparin\n1\u00a0mg/kg\u00a0BD\u00a0as\u00a0soon\nas\u00a0bleeding\u00a0risk\u00a0low\n(start\u00a0at\u00a0same\u00a0time\u00a0of\nstopping\u00a0UFH)\nRestart\u00a0Warfarin\u00a0at\nusual\u00a0maintenance\ndose\u00a0at\u00a0Day\u00a05\npostprocedure\nprovided\u00a0no\ncontraindications\nCheck\u00a0PT\u00adINR\u00a03\ndays\u00a0later\u00a0and\u00a0titrate\ndose. Continue\u00a0enoxaparin\nuntil\u00a0PT\u00adINR\u00a0>2\u00a0(aim\nfor\u00a0anti\u00adXa\u00a0activity\u00a0of\n0.5\u00ad1\u00a0unit/mL)\nRisk\nPreprocedure\nbridging\nPostprocedure\nbridging*\nRestart\u00a0of\nwarfarin*\nEnoxaparin,\n1\u00a0mg/kg\u00a0BD\u00a0when\nPT\u00adINR\u00a0<2\u037e\u00a0continue\nuntil\u00a0AM\u00a0of\u00a0day\u00a0prior\nto\u00a0procedure\u00a0(PM\ndose\u00a0on\u00a0day\u00a0before\nand\u00a0AM\u00a0dose\u00a0on\nday\u00a0of\u00a0procedure\nomitted)\nEnoxaparin\u00a01\u00a0mg/kg\nBD,\u00a0beginning\u00a0PM\nof\u00a0day\u00a0of\u00a0procedure\n(if\u00a0no\u00a0bleeding\nconcerns)\u037e\u00a0else\nbegin\u00a0on\u00a0AM\u00a0of\u00a0day\nafter\u00a0procedure\nRestart\u00a0warfarin\u00a0at\nusual\u00a0maintenance\ndose\u00a0on\u00a0PM\u00a0of\u00a0the\nday\u00a0after\u00a0the\nprocedure\u00a0provided\nno\u00a0contraindications\nCheck\u00a0PT\u00adINR\u00a03\ndays\u00a0later\u00a0and\u00a0titrate\ndose\nContinue\nenoxaparin\u00a0until\nPT\u00adINR\u00a0>2\nUsual\u00a0maintenance\ndose\u00a0on\u00a0night\u00a0of\nprocedure\n*\u00a0 Timing\u00a0 of\u00a0 postprocedure\u00a0 anticoagulation\u00a0 depends\u00a0 on\u00a0 assessment\u00a0 of\u00a0 risk\u00a0 of\npostprocedure\u00a0 bleeding. Close\u00a0 consultation\u00a0 advised\u00a0 with\u00a0 surgeon/physician\nperforming\u00a0the\u00a0procedure\nEndpoint\u00a0of\u00a0successful\u00a0therapy\nPercent\u00a0time\u00a0spent\u00a0in\u00a0target\u00a0therapeutic\u00a0range\nReferences\n1. Monagle\u00a0 P,\u00a0 Chalmers\u00a0 E,\u00a0 Chan\u00a0A,\u00a0 deVeber\u00a0 G,\u00a0 Kirkham\u00a0 F,\u00a0 Massicote\u00a0 P,\nMichelson\u00a0AD. Antithrombotic\u00a0therapy\u00a0in\u00a0Neonates\u00a0and\u00a0Children. Chest. 2008\u037e133:887S\u00ad968S\n2. Wittkowsky\u00a0 A. Warfarin. Clinical\u00a0 Pharmacokinetics. 2012. Bethesda,\nMaryland:\u00a0American\u00a0Society\u00a0of\u00a0Health\u00adSystem\u00a0Pharmacists\n3. Monagle\u00a0 P,\u00a0 Newall\u00a0 F. Anticoagulation\u00a0 in\u00a0 children. Thromb\u00a0 Res. 2012\u037e130:142\u00ad146\n4. Sun\u00a0 JCJ,\u00a0 Davidson\u00a0 MJ,\u00a0 Lamy\u00a0 A,\u00a0 Eikelboom\u00a0 JW. Antithrombotic\nmanagement\u00a0of\u00a0patients\u00a0with\u00a0prosthetic\u00a0valves:\u00a0current\u00a0evidence\u00a0and\u00a0future\ntrends. Lancet. 2009\u037e374:565\u00ad576\n5. Anticoagulation\u00a0Therapy\u00a0Guidelines. Clinical\u00a0Practice\u00a0Guidelines.", "chunk_order": 88}
{"chunk_id": "0c207ca7-ac76-4219-8b0b-a589c41973b9", "source_document_filename": "CPG Prevention and Treatment of Venous Thrombosis_cleaned_ultra_minimal.txt", "source_document_title": "CPG Prevention and Treatment of Venous Thrombosis cleaned ultra minimal", "text": "Close\u00a0 consultation\u00a0 advised\u00a0 with\u00a0 surgeon/physician\nperforming\u00a0the\u00a0procedure\nEndpoint\u00a0of\u00a0successful\u00a0therapy\nPercent\u00a0time\u00a0spent\u00a0in\u00a0target\u00a0therapeutic\u00a0range\nReferences\n1. Monagle\u00a0 P,\u00a0 Chalmers\u00a0 E,\u00a0 Chan\u00a0A,\u00a0 deVeber\u00a0 G,\u00a0 Kirkham\u00a0 F,\u00a0 Massicote\u00a0 P,\nMichelson\u00a0AD. Antithrombotic\u00a0therapy\u00a0in\u00a0Neonates\u00a0and\u00a0Children. Chest. 2008\u037e133:887S\u00ad968S\n2. Wittkowsky\u00a0 A. Warfarin. Clinical\u00a0 Pharmacokinetics. 2012. Bethesda,\nMaryland:\u00a0American\u00a0Society\u00a0of\u00a0Health\u00adSystem\u00a0Pharmacists\n3. Monagle\u00a0 P,\u00a0 Newall\u00a0 F. Anticoagulation\u00a0 in\u00a0 children. Thromb\u00a0 Res. 2012\u037e130:142\u00ad146\n4. Sun\u00a0 JCJ,\u00a0 Davidson\u00a0 MJ,\u00a0 Lamy\u00a0 A,\u00a0 Eikelboom\u00a0 JW. Antithrombotic\nmanagement\u00a0of\u00a0patients\u00a0with\u00a0prosthetic\u00a0valves:\u00a0current\u00a0evidence\u00a0and\u00a0future\ntrends. Lancet. 2009\u037e374:565\u00ad576\n5. Anticoagulation\u00a0Therapy\u00a0Guidelines. Clinical\u00a0Practice\u00a0Guidelines. The\u00a0Royal\nChildren\u2019s\u00a0Hospital,\u00a0Melbourne\n(URL:www.rch.org.au/clinicalguide/guideline_index/Anticoagulation_\nTherapy_Guidelines\u037e\u00a0last\u00a0accessed\u00a014\u00a0Jan\u00a02013)\nFamily\u00a0education\nEducation\u00a0of\u00a0caregivers\u00a0on\u00a0the\u00a0following\u00a0aspects\u00a0of\u00a0warfarin\u00a0therapy\nt\u0001Rationale\u00a0for\u00a0warfarin\u00a0therapy\nt\u0001Mechanism\u00a0of\u00a0action\u00a0of\u00a0warfarin\nt\u0001Importance\u00a0of\u00a0adherence\u00a0to\u00a0therapy\nt\u0001Action\u00a0in\u00a0the\u00a0case\u00a0of\u00a0missed\u00a0doses\nt\u0001Necessity\u00a0for\u00a0regular\u00a0monitoring\u00a0while\u00a0on\u00a0warfarin\u00a0therapy\nt\u0001Target\u00a0PT\u00adINR\nt\u0001Diet,\u00a0prescription\u00a0and\u00a0non\u00adprescription\u00a0medications\u00a0and\u00a0other\u00a0factors\u00a0that\u00a0could\ninterfere\u00a0with\u00a0warfarin\u00a0action\nt\u0001Importance\u00a0 of\u00a0 maintaining\u00a0 consistent\u00a0 balanced\u00a0 dietary\u00a0 intake\u00a0 to\u00a0 avoid\nwide\u00a0swings\u00a0in\u00a0vitamin\u00a0K\u00a0intake\nt\u0001Risk\u00a0of\u00a0haemorrhage\u00a0with\u00a0warfarin\u00a0anticoagulation\nt\u0001Minimising\u00a0 risk\u00a0 of\u00a0 injuries\u00a0 (e.g. avoiding\u00a0 contact\u00a0 sports,\u00a0 wearing\u00a0 bicycle\nhelmets\u00a0etc)\nt\u0001Access\u00a0to\u00a0advice\u00a0and\u00a0care\u00a0in\u00a0the\u00a0event\u00a0of\u00a0queries\u00a0or\u00a0concerns\nt\u0001Medic\u00adalert\u00a0badge\u00a0or\u00a0bracelet\nt\u0001Written\u00a0anticoagulation\u00a0advice\nAppendix\u00a012\nLEVEL\u00a0OF\u00a0EVIDENCE\nA\u00a0(evidence\u00a0levels\u00a0Ia\nand\u00a0Ib)\nRequires\u00a0at\u00a0least\u00a0one\u00a0randomised\u00a0controlled\u00a0trial,\nas\u00a0 part\u00a0 of\u00a0 the\u00a0 body\u00a0 of\u00a0 literature,\u00a0 of\u00a0 overall\u00a0 good\nquality\u00a0 and\u00a0 consistency\u00a0 addressing\u00a0 the\u00a0 specific\nrecommendation\nGrade\nRecommendation\nC\u00a0(evidence\u00a0level\u00a0IV)\nRequired\nevidence\nobtained\nfrom\nexpert\ncommittee\u00a0 reports\u00a0 or\u00a0 opinions\u00a0 and / or\u00a0 clinical\nexperiences\u00a0 of\u00a0 respected\u00a0 authorities. Indicates\nabsence\u00a0 of\u00a0 directly\u00a0 applicable\u00a0 clinical\u00a0 studies\u00a0 of\ngood\u00a0quality\nB\u00a0(evidence\u00a0levels\u00a0IIa,\u00a0IIb\nand\u00a0III)\nRequires\u00a0 availability\u00a0 of\u00a0 well\u00a0 conducted\u00a0 clinical\nstudies\u00a0 but\u00a0 no\u00a0 randomised\u00a0 clinical\u00a0 trials\u00a0 on\u00a0 the\ntopic\u00a0of\u00a0recommendation\nIa\nIb\nEvidence\u00a0obtained\u00a0from\u00a0at\u00a0least\u00a0one\u00a0RCT\nIIa\nEvidence\u00a0obtained\u00a0from\u00a0at\u00a0least\u00a0one\u00a0well\u00a0designed\u00a0controlled\u00a0study\nwithout\u00a0randomisation\nIIb\nEvidence\u00a0 obtained\u00a0 from\u00a0 at\u00a0 least\u00a0 one\u00a0 other\u00a0 type\u00a0 of\u00a0 well\u00addesigned\nquasi\u00adexperimental\u00a0study\nIII\nIV\nEvidence\u00a0obtained\u00a0from\u00a0expert\u00a0committee\u00a0reports\u00a0or\u00a0opinions\u00a0and\u00a0/\nor\u00a0clinical\u00a0\u00a0experience\u00a0of\u00a0respected\u00a0authorities,\u00a0or\u00a0both\nLevels\nType\u00a0of\u00a0Evidence\nAdapted\u00a0from\u00a0the\u00a0National\u00a0Guidelines\u00a0Clearinghouse\u00a0(www.guidelines.gov),\nAgency\u00a0for\u00a0Healthcare\u00a0Research\u00a0and\u00a0Quality,\u00a0U.S. Department\u00a0of\u00a0Health\u00a0&\nHuman\u00a0Services,\u00a0USA. Adapted\u00a0from\u00a0the\u00a0Scottish\u00a0Intercollegiate\u00a0Guidelines\u00a0Network\u00a0(SIGN). Evidence\u00a0obtained\u00a0from\u00a0well\u00addesigned\u00a0non\u00adexperimental\u00a0descriptive\nstudies\ne.g. comparative\u00a0studies,\u00a0correlation\u00a0studies,\u00a0case\u00adcontrol\u00a0studies\nEvidence\u00a0 obtained\u00a0 from\u00a0 meta\u00adanalysis\u00a0 of\u00a0 randomised\u00a0 controlled\ntrials\u00a0(RCTs)\nAppendix\u00a013\nCLINICAL\u00a0QUESTIONS\n1. What\u00a0is\u00a0the\u00a0epidemiology\u00a0of\u00a0VTE\u00a0in\u00a0Asia? 2. What\u00a0is\u00a0the\u00a0pathogenesis\u00a0and\u00a0natural\u00a0history\u00a0of\u00a0VTE? 3. How\u00a0do\u00a0we\u00a0prevent\u00a0VTE? t\u0001What\u00a0are\u00a0the\u00a0methods\u00a0of\u00a0prophylaxis? t\u0001Who\u00a0are\u00a0the\u00a0patients\u00a0at\u00a0risk\u00a0of\u00a0VTE? t\u0001Who\u00a0are\u00a0the\u00a0patients\u00a0at\u00a0risk\u00a0of\u00a0bleeding? t\u0001When\u00a0is\u00a0the\u00a0right\u00a0timing\u00a0and\u00a0initiation\u00a0of\u00a0prophylaxis? t\u0001What\u00a0is\u00a0the\u00a0duration\u00a0of\u00a0prophylaxis? t\u0001How\u00a0do\u00a0we\u00a0use\u00a0antithrombotic\u00a0therapy\u00a0with\u00a0regional\u00a0anaesthesia?", "chunk_order": 89}
{"chunk_id": "c18afd41-cb5f-4089-8322-f1c5198dae41", "source_document_filename": "CPG Prevention and Treatment of Venous Thrombosis_cleaned_ultra_minimal.txt", "source_document_title": "CPG Prevention and Treatment of Venous Thrombosis cleaned ultra minimal", "text": "Evidence\u00a0obtained\u00a0from\u00a0well\u00addesigned\u00a0non\u00adexperimental\u00a0descriptive\nstudies\ne.g. comparative\u00a0studies,\u00a0correlation\u00a0studies,\u00a0case\u00adcontrol\u00a0studies\nEvidence\u00a0 obtained\u00a0 from\u00a0 meta\u00adanalysis\u00a0 of\u00a0 randomised\u00a0 controlled\ntrials\u00a0(RCTs)\nAppendix\u00a013\nCLINICAL\u00a0QUESTIONS\n1. What\u00a0is\u00a0the\u00a0epidemiology\u00a0of\u00a0VTE\u00a0in\u00a0Asia? 2. What\u00a0is\u00a0the\u00a0pathogenesis\u00a0and\u00a0natural\u00a0history\u00a0of\u00a0VTE? 3. How\u00a0do\u00a0we\u00a0prevent\u00a0VTE? t\u0001What\u00a0are\u00a0the\u00a0methods\u00a0of\u00a0prophylaxis? t\u0001Who\u00a0are\u00a0the\u00a0patients\u00a0at\u00a0risk\u00a0of\u00a0VTE? t\u0001Who\u00a0are\u00a0the\u00a0patients\u00a0at\u00a0risk\u00a0of\u00a0bleeding? t\u0001When\u00a0is\u00a0the\u00a0right\u00a0timing\u00a0and\u00a0initiation\u00a0of\u00a0prophylaxis? t\u0001What\u00a0is\u00a0the\u00a0duration\u00a0of\u00a0prophylaxis? t\u0001How\u00a0do\u00a0we\u00a0use\u00a0antithrombotic\u00a0therapy\u00a0with\u00a0regional\u00a0anaesthesia? t\u0001How\u00a0do\u00a0we\u00a0use\u00a0antithrombotic\u00a0prophylaxis\u00a0in\u00a0stroke\u00a0patients? 4. How\u00a0do\u00a0we\u00a0diagnose\u00a0VTE? t\u0001What\u00a0are\u00a0the\u00a0investigations\u00a0for\u00a0VTE? t\u0001When\u00a0do\u00a0we\u00a0investigate\u00a0for\u00a0cancer\u00adrelated\u00a0VTE? t\u0001Is\u00a0thrombophilia\u00a0testing\u00a0useful? 5. How\u00a0do\u00a0we\u00a0treat\u00a0VTE? t\u0001What\u00a0are\u00a0the\u00a0modalities\u00a0of\u00a0treatment? t\u0001What\u00a0is\u00a0the\u00a0preferred\u00a0first\u00a0line\u00a0treatment\u00a0for\u00a0VTE? t\u0001What\u00a0is\u00a0the\u00a0role\u00a0of\u00a0newer\u00a0and\u00a0more\u00a0expensive\u00a0drugs\u00a0for\u00a0the\u00a0management\nof\u00a0VTE\nt\u0001When\u00a0is\u00a0thrombolytic\u00a0therapy\u00a0indicated? t\u0001What\u00a0is\u00a0the\u00a0indication\u00a0for\u00a0IVC\u00a0filter? t\u0001How\u00a0do\u00a0we\u00a0prevent\u00a0post\u00adthrombotic\u00a0syndrome? 6. How\u00a0do\u00a0we\u00a0monitor\u00a0anticoagulation\u00a0therapy? 7. How\u00a0do\u00a0we\u00a0manage\u00a0a\u00a0patient\u00a0on\u00a0anticoagulant\u00a0who\u00a0is\u00a0going\u00a0for\u00a0surgery? t\u0001How\u00a0do\u00a0we\u00a0stratify\u00a0patients\u00a0at\u00a0risk\u00a0of\u00a0thromboembolism\u00a0when\u00a0stopping\nanticoagulation? t\u0001How\u00a0do\u00a0we\u00a0stratify\u00a0bleeding\u00a0risks\u00a0according\u00a0to\u00a0surgical\u00a0procedures? 8. How\u00a0do\u00a0we\u00a0manage\u00a0over\u00adanticoagulation? t\u0001What\u00a0are\u00a0the\u00a0advantages\u00a0of\u00a0prothrombin\u00a0complex\u00a0concentrate\u00a0(PCC)\nover\u00a0fresh\u00a0frozen\u00a0plasma\u00a0(FFP)\u00a0in\u00a0the\u00a0management\u00a0of\u00a0life\u00adthreatening\nhaemorrhage\u00a0due\u00a0to\u00a0warfarin? t\u0001How\u00a0do\u00a0we\u00a0manage\u00a0bleeding\u00a0complications\u00a0in\u00a0the\u00a0new\u00a0anticoagulants? 9. What\u00a0is\u00a0the\u00a0pathogenesis\u00a0and\u00a0risk\u00a0factors\u00a0for\u00a0VTE\u00a0in\u00a0pregnancy? t\u0001How\u00a0is\u00a0VTE\u00a0diagnosed\u00a0in\u00a0pregnancy? t\u0001What\u00a0is\u00a0the\u00a0treatment\u00a0of\u00a0VTE\u00a0in\u00a0pregnancy? 10. How\u00a0do\u00a0we\u00a0manage\u00a0pregnant\u00a0women\u00a0with\u00a0the\u00a0antiphospholipid\nsyndrome? 11. How\u00a0do\u00a0we\u00a0manage\u00a0anticoagulation\u00a0in\u00a0the\u00a0elderly,\u00a0obese\u00a0or\u00a0renal\nimpaired\u00a0patients? 12. How\u00a0do\u00a0we\u00a0manage\u00a0anticoagulation\u00a0in\u00a0stroke\u00a0patients? 13. How\u00a0do\u00a0we\u00a0manage\u00a0anticoagulation\u00a0in\u00a0children? 14. How\u00a0do\u00a0we\u00a0manage\u00a0VTE\u00a0following\u00a0fertility\u00a0treatment? 15. What\u00a0is\u00a0the\u00a0risk\u00a0of\u00a0VTE\u00a0in\u00a0a\u00a0woman\u00a0who\u00a0is\u00a0on\u00a0combined\u00a0oral\ncontraception\u00a0(COC)? t\u0001What\u00a0is\u00a0the\u00a0eligibility\u00a0criteria\u00a0for\u00a0starting\u00a0COC? 16. How\u00a0do\u00a0we\u00a0manage\u00a0VTE\u00a0in\u00a0cancer\u00a0patients? 17. How\u00a0do\u00a0we\u00a0manage\u00a0thrombosis\u00a0in\u00a0unsual\u00a0sites\u00a0such\u00a0as\u00a0upper\nextremity,\u00a0cerebral\u00a0venous\u00a0sinuses\u00a0and\u00a0splanchnic\u00a0veins? 18. What\u00a0are\u00a0the\u00a0objectives\u00a0and\u00a0function\u00a0of\u00a0the\u00a0medication\u00a0therapy\nadherence\u00a0clinic\u00a0warfarin\u00a0(MTAC\u00adW)? REFERENCES\n1. National\u00a0Institute\u00a0for\u00a0Health\u00a0and\u00a0Clinical\u00a0Excellence\u00a0(NICE)\u00a0clinical\u00a0guidelines\u00a092. Venous\nthromboembolism:\u00a0reducing\u00a0the\u00a0risk. Jan\u00a02010\n2. National\u00a0 Institute\u00a0 for\u00a0 Health\u00a0 and\u00a0 Clinical\u00a0 Excellence\u00a0 (NICE)\u00a0 clinical\u00a0 guideline. Venous\nthromboembolic\u00a0diseases:\u00a0the\u00a0management\u00a0of\u00a0venous\u00a0thromboembolic\u00a0diseases\u00a0and\u00a0the\nrole\u00a0of\u00a0thrombophilia\u00a0testing. June\u00a02012\n3. Naess\u00a0 IA,\u00a0 Christiansen\u00a0 SC,\u00a0 Romundstad\u00a0 P,\u00a0 et\u00a0 al. Incidence\u00a0 and\u00a0 mortality\u00a0 of\u00a0 venous\nthrombosis:\u00a0a\u00a0population\u00adbased\u00a0study. J\u00a0Thromb\u00a0Haemost\u00a02007\u037e5:692\u00ad9\n4. Anderson\u00a0FA\u00a0Jr,\u00a0Wheeler\u00a0HB,\u00a0Goldberg\u00a0RJ,\u00a0et\u00a0al.", "chunk_order": 90}
{"chunk_id": "6068844d-d637-4c0b-9e43-8b2d77dfcf41", "source_document_filename": "CPG Prevention and Treatment of Venous Thrombosis_cleaned_ultra_minimal.txt", "source_document_title": "CPG Prevention and Treatment of Venous Thrombosis cleaned ultra minimal", "text": "18. What\u00a0are\u00a0the\u00a0objectives\u00a0and\u00a0function\u00a0of\u00a0the\u00a0medication\u00a0therapy\nadherence\u00a0clinic\u00a0warfarin\u00a0(MTAC\u00adW)? REFERENCES\n1. National\u00a0Institute\u00a0for\u00a0Health\u00a0and\u00a0Clinical\u00a0Excellence\u00a0(NICE)\u00a0clinical\u00a0guidelines\u00a092. Venous\nthromboembolism:\u00a0reducing\u00a0the\u00a0risk. Jan\u00a02010\n2. National\u00a0 Institute\u00a0 for\u00a0 Health\u00a0 and\u00a0 Clinical\u00a0 Excellence\u00a0 (NICE)\u00a0 clinical\u00a0 guideline. Venous\nthromboembolic\u00a0diseases:\u00a0the\u00a0management\u00a0of\u00a0venous\u00a0thromboembolic\u00a0diseases\u00a0and\u00a0the\nrole\u00a0of\u00a0thrombophilia\u00a0testing. June\u00a02012\n3. Naess\u00a0 IA,\u00a0 Christiansen\u00a0 SC,\u00a0 Romundstad\u00a0 P,\u00a0 et\u00a0 al. Incidence\u00a0 and\u00a0 mortality\u00a0 of\u00a0 venous\nthrombosis:\u00a0a\u00a0population\u00adbased\u00a0study. J\u00a0Thromb\u00a0Haemost\u00a02007\u037e5:692\u00ad9\n4. Anderson\u00a0FA\u00a0Jr,\u00a0Wheeler\u00a0HB,\u00a0Goldberg\u00a0RJ,\u00a0et\u00a0al. A\u00a0population\u00adbased\u00a0perspective\u00a0of\u00a0the\nhospital\u00a0 incidence\u00a0 and\u00a0 case\u00adfatality\u00a0 rates\u00a0 of\u00a0 deep\u00a0 vein\u00a0 thrombosis\u00a0 and\u00a0 pulmonary\nembolism. The\u00a0Worcester\u00a0DVT\u00a0Study. Arch\u00a0Intern\u00a0Med\u00a01991\u037e151:933\u00ad8\n5. Cohen\u00a0AT,\u00a0Agnelli\u00a0G,\u00a0Anderson\u00a0FA,\u00a0et\u00a0al. Venous\u00a0Thromboembolism\u00a0(VTE)\u00a0in\u00a0Europe. The\nnumber\u00a0 of\u00a0 VTE\u00a0 events\u00a0 and\u00a0 associated\u00a0 morbidity\u00a0 and\u00a0 mortality. Thromb\u00a0 Haemost\n2007\u037e98:756\u00ad64\n6. Leizorovicz\u00a0A,\u00a0Turpie\u00a0AGG,\u00a0Cohen\u00a0AT,\u00a0et\u00a0al. for\u00a0the\u00a0SMART\u00a0study\u00a0group. Epidemiology\u00a0of\nPost\u00adOperative\u00a0 Venous\u00a0 Thromboembolism\u00a0 in\u00a0 Asian\u00a0 Countries. Intern\u00a0 J\u00a0 Angio\n2004\u037e13:101\u00ad108\n7. Leizorovicz\u00a0A,\u00a0Turpie\u00a0AGG,\u00a0Cohen\u00a0AT,\u00a0et\u00a0al. for\u00a0the\u00a0SMART\u00a0Study\u00a0Group. Epidemiology\u00a0of\nvenous\u00a0thromboembolism\u00a0in\u00a0Asian\u00a0patients\u00a0undergoing\u00a0major\u00a0orthopedic\u00a0surgery\u00a0without\nthromboprophylaxis. The\u00a0SMART\u00a0Study. J\u00a0Thromb\u00a0Haemost\u00a02005\u037e3:28\u00ad34\n8. Piovella\u00a0F,\u00a0Wang\u00a0C\u00adJ,\u00a0Lu\u00a0H,\u00a0et\u00a0al. Deep\u00a0Vein\u00a0Thrombosis\u00a0rates\u00a0after\u00a0major\u00a0orthopedic\nsurgery\u00a0in\u00a0Asia. An\u00a0epidemiological\u00a0study\u00a0based\u00a0on\u00a0post\u00adoperative\u00a0screening\u00a0with\u00a0centrally\nadjudicated\u00a0bilateral\u00a0venography. J\u00a0Thromb\u00a0Haemost\u00a02005\u037e3:2664\u00ad70\n9. Douketis\u00a0JD,\u00a0Eikelboom\u00a0JW,\u00a0Quinlan\u00a0DJ,\u00a0et\u00a0al. Short\u00adDuration\u00a0Prophylaxis\u00a0Against\u00a0Venous\nThromboembolism\u00a0After\u00a0Total\u00a0Hip\u00a0or\u00a0Knee\u00a0Replacement. A\u00a0Meta\u00adanalysis\u00a0of\u00a0Prospective\nStudies\u00a0Investigating\u00a0Symptomatic\u00a0Outcomes. Arch\u00a0Intern\u00a0Med\u00a02002\u037e162:1465\u00ad1471\n10. Samama\u00a0CM,\u00a0Clergue\u00a0F,\u00a0Barre\u00a0J,\u00a0et\u00a0al. Low\u00a0molecular\u00a0weight\u00a0heparin\u00a0associated\u00a0with\nspinal\u00a0anaesthesia\u00a0and\u00a0gradual\u00a0compression\u00a0stockings\u00a0in\u00a0total\u00a0hip\u00a0replacement\u00a0surgery. Br\u00a0J\u00a0Anaesth\u00a01997\u037e78:660\u00ad5\n11. Turpie\u00a0 AGG,\u00a0 Bauer\u00a0 KA,\u00a0 Eriksson\u00a0 BI,\u00a0 et\u00a0 al. for\u00a0 the\u00a0 Steering\u00a0 Committees\u00a0 of\u00a0 the\nPentasaccharide\u00a0 Orthopedic\u00a0 Prophylaxis\u00a0 Studies. Fondaparinux\u00a0 versus\u00a0 enoxaparin\u00a0 for\nthe\u00a0prevention\u00a0of\u00a0venous\u00a0thromboembolism\u00a0in\u00a0major\u00a0orthopedic\u00a0surgery. A\u00a0meta\u00adanalysis\nof\u00a04\u00a0randomised\u00a0double\u00adblind\u00a0studies. Arch\u00a0Intern\u00a0Med\u00a02002\u037e162:1833\u00ad40\n12. Sun\u00a0 KK,\u00a0 Wang\u00a0 C,\u00a0 Pang\u00a0 BS,\u00a0 Yang\u00a0 TH. The\u00a0 prevalence\u00a0 of\u00a0 deep\u00a0 vein\u00a0 thrombosis\u00a0 in\nhospitalised\u00a0patients\u00a0with\u00a0stroke. Natl\u00a0Med\u00a0J\u00a0China\u00a0(CHIN)\u00a02004\u037e84:637\u00ad641\n13. Tan\u00a0 KS,\u00a0 Rashid\u00a0 AR,\u00a0 Tan\u00a0 CT. Venous\u00a0 thromboembolism\u00a0 in\u00a0 ischaemic\u00a0 stroke\u00a0 in\u00a0 Asia. Neurology\u00a0Asia\u00a02008\u037e13:95\u00ad101\n14. Sun\u00a0 KK,\u00a0 Wang\u00a0 C,\u00a0 Guli\u00a0 XT,\u00a0 Luo\u00a0 Q. Risk\u00a0 factors\u00a0 and\u00a0 clinical\u00a0 features\u00a0 of\u00a0 deep\u00a0 vein\nthrombosis:\u00a0a\u00a0report\u00a0of\u00a0388\u00a0cases. Chin\u00a0J\u00a0Tuberc\u00a0Respir\u00a0Dis\u00a0(Chin)\u00a02004\u037e27:727\u00ad730\n15. Sakon\u00a0M,\u00a0Maehara\u00a0Y,\u00a0Yoshikawa\u00a0H,\u00a0Akaza\u00a0H. Incidence\u00a0of\u00a0thromboembolism\u00a0following\nmajor\u00a0abdominal\u00a0surgery:\u00a0\u00a0multicenter,\u00a0prospective\u00a0epidemiological\u00a0study\u00a0in\u00a0Japan. J\u00a0Thromb\u00a0Haemost\u00a02006\u037e4:581\u00ad6\n16. Aniwan\u00a0S,\u00a0Rojnuckarin\u00a0P. High\u00a0incidence\u00a0of\u00a0symptomatic\u00a0VTE\u00a0in\u00a0Thai\u00a0hospitalised\u00a0medical\npatients\u00a0without\u00a0thromboprophylaxis. Blood\u00a0Coagul\u00a0Fibrinolysis\u00a02010\u037e21(4):334\u00ad8\n17. Leung\u00a0V,\u00a0Leung\u00a0V,\u00a0Lui\u00a0W,\u00a0et\u00a0al. Incidence\u00a0of\u00a0DVT\u00a0in\u00a0hospitalised\u00a0Chinese\u00a0medical\u00a0patients\nis\u00a0similar\u00a0to\u00a0that\u00a0of\u00a0Western\u00a0population. Thrombosis\u00a0Research\u00a02006\u037e118:763\u00ad764\n18.", "chunk_order": 91}
{"chunk_id": "771a55d8-161f-46a3-8fa2-ad86f18ed76a", "source_document_filename": "CPG Prevention and Treatment of Venous Thrombosis_cleaned_ultra_minimal.txt", "source_document_title": "CPG Prevention and Treatment of Venous Thrombosis cleaned ultra minimal", "text": "Risk\u00a0 factors\u00a0 and\u00a0 clinical\u00a0 features\u00a0 of\u00a0 deep\u00a0 vein\nthrombosis:\u00a0a\u00a0report\u00a0of\u00a0388\u00a0cases. Chin\u00a0J\u00a0Tuberc\u00a0Respir\u00a0Dis\u00a0(Chin)\u00a02004\u037e27:727\u00ad730\n15. Sakon\u00a0M,\u00a0Maehara\u00a0Y,\u00a0Yoshikawa\u00a0H,\u00a0Akaza\u00a0H. Incidence\u00a0of\u00a0thromboembolism\u00a0following\nmajor\u00a0abdominal\u00a0surgery:\u00a0\u00a0multicenter,\u00a0prospective\u00a0epidemiological\u00a0study\u00a0in\u00a0Japan. J\u00a0Thromb\u00a0Haemost\u00a02006\u037e4:581\u00ad6\n16. Aniwan\u00a0S,\u00a0Rojnuckarin\u00a0P. High\u00a0incidence\u00a0of\u00a0symptomatic\u00a0VTE\u00a0in\u00a0Thai\u00a0hospitalised\u00a0medical\npatients\u00a0without\u00a0thromboprophylaxis. Blood\u00a0Coagul\u00a0Fibrinolysis\u00a02010\u037e21(4):334\u00ad8\n17. Leung\u00a0V,\u00a0Leung\u00a0V,\u00a0Lui\u00a0W,\u00a0et\u00a0al. Incidence\u00a0of\u00a0DVT\u00a0in\u00a0hospitalised\u00a0Chinese\u00a0medical\u00a0patients\nis\u00a0similar\u00a0to\u00a0that\u00a0of\u00a0Western\u00a0population. Thrombosis\u00a0Research\u00a02006\u037e118:763\u00ad764\n18. Xu\u00a0 XF,\u00a0Yang\u00a0YH,\u00a0 Zhai\u00a0 ZG,\u00a0 et\u00a0 al. Prevalence\u00a0 and\u00a0 incidence\u00a0 of\u00a0 deep\u00a0 veous\u00a0 thombosis\namong\u00a0 patients\u00a0 in\u00a0 medical\u00a0 intensive\u00a0 care\u00a0 unit. Natl\u00a0 Med\u00a0 J\u00a0 China\u00a0 (Chin)\u00a0 2008\u037e\n29:1034\u00ad1037. 19. Jang\u00a0 MJ,\u00a0 Bang\u00a0 S\u00adM,\u00a0 Oh\u00a0 D. Incidence\u00a0 of\u00a0 venous\u00a0 thromboembolism\u00a0 in\u00a0 Korea:\u00a0 from\u00a0 the\nHealth\u00a0Insurance\u00a0Review\u00a0and\u00a0Assessment\u00a0Service\u00a0database. J\u00a0Thromb\u00a0Haemost\u00a02011\u037e9:\n85\u00ad91\n20. Ng\u00a0HJ,\u00a0Lee\u00a0LH. Trends\u00a0in\u00a0prevalence\u00a0of\u00a0deep\u00a0vein\u00a0thrombosis\u00a0among\u00a0hospitalised\u00a0patients\nin\u00a0an\u00a0Asian\u00a0institution. Thromb\u00a0Haemost\u00a02009\u037e101:1095\n21. Kobayashi\nT. Incidence\nof\nVenous\nThrombembolism\nand\nGuidelines\nfor\nThromboembolism\u00a0 Prophylaxis\u00a0 in\u00a0 Japan:\u00a0 Obstetric\u00a0 and\u00a0 Gynaecology. Spinger\u00adVerlag\nTokyo\u00a02005\u037e4\u037e133\u00ad142\nOO6\" D191+C%*\" $#\" a0)<CE\" D)<)*+1)6\" G)%1$8+\" *0)%+6\" -0;$%C\" $9\" CE0\" `$9f(09C1)<\" I9K81%10+\" 19C$\"\nMaternal\u00a0Deaths\u00a0in\u00a0Malaysia. Kuala\u00a0Lumpur,\u00a02007\n23. Nicolaides\u00a0 AN,\u00a0 Kakkar\u00a0 VV,\u00a0 Field\u00a0 ES,\u00a0 et\u00a0 al. The\u00a0 origin\u00a0 of\u00a0 deep\u00a0 vein\u00a0 thrombosis:\u00a0 a\nvenographic\u00a0study. Br\u00a0J\u00a0Radiol\u00a01971\u037e44:653\u00ad663\n24. Kakkar\u00a0 VV,\u00a0 Howe\u00a0 CT,\u00a0 Flanc\u00a0 C,\u00a0 et\u00a0 al. Natural\u00a0 history\u00a0 of\u00a0 postoperative\u00a0 deep\u00advein\nthrombosis. Lancet\u00a01969\u037e2:230\u00ad232\n25. Moser\u00a0 KM,\u00a0 LeMoine\u00a0 JR. Is\u00a0 embolic\u00a0 risk\u00a0 conditioned\u00a0 by\u00a0 location\u00a0 of\u00a0 deep\u00a0 venous\nthrombosis? Ann\u00a0Intern\u00a0Med\u00a01981\u037e94:439\u00ad444\n26. Flanc\u00a0C,\u00a0Kakkar\u00a0VV,\u00a0Clarke\u00a0MB. The\u00a0detection\u00a0of\u00a0venous\u00a0thrombosis\u00a0of\u00a0the\u00a0legs\u00a0using\n125\u00adI\u00adlabelled\u00a0fibrinogen. Br\u00a0J\u00a0Surg\u00a01968\u037e55:742\u00ad747\n27. Maynard\u00a0MJ,\u00a0Sculco\u00a0TP,\u00a0Ghelman\u00a0B. Progression\u00a0and\u00a0regression\u00a0of\u00a0deep\u00a0vein\u00a0thrombosis\nafter\u00a0total\u00a0knee\u00a0arthroplasty. Clin\u00a0Orthop\u00a0RelatedRes\u00a01991\u037e273:125\u00ad130\n28. White\u00a0 RH,\u00a0 Romano\u00a0 PS,\u00a0 Zhou\u00a0 H,\u00a0 et\u00a0 al. Incidence\u00a0 and\u00a0 time\u00a0 course\u00a0 of\u00a0 thromboembolic\noutcomes\u00a0following\u00a0total\u00a0hip\u00a0or\u00a0knee\u00a0arthroplasty. Arch\u00a0Intern\u00a0Med\u00a01998\u037e158:1525\u00ad1531\n29. Prandoni\u00a0 P,\u00a0 Lensing\u00a0AWA,\u00a0 Cogo\u00a0A,\u00a0 et\u00a0 al. The\u00a0 long\u00adterm\u00a0 clinical\u00a0 course\u00a0 of\u00a0 acute\u00a0 deep\nvenous\u00a0thrombosis. Ann\u00a0Intern\u00a0Med\u00a01996\u037e125:1\u00ad7\n30. Research\u00a0Committee\u00a0of\u00a0the\u00a0British\u00a0Thoracic\u00a0Society. Optimum\u00a0duration\u00a0of\u00a0anticoagulation\nfor\u00a0deep\u00advein\u00a0thrombosis\u00a0and\u00a0pulmonary\u00a0embolism. Lancet\u00a01992\u037e340:873\u00ad876\n31. Stein\u00a0 PD,\u00a0 Henry\u00a0 JW. Prevalence\u00a0 of\u00a0 acute\u00a0 pulmonary\u00a0 embolism\u00a0 among\u00a0 patients\u00a0 in\u00a0 a\ngeneral\u00a0hospital\u00a0and\u00a0at\u00a0autopsy. Chest\u00a01995\u037e108:978\u00ad981\n32. Bell\u00a0 WR,\u00a0 Simon\u00a0 TL. Current\u00a0 status\u00a0 of\u00a0 pulmonary\u00a0 embolic\u00a0 disease:\u00a0 pathophysiology,\ndiagnosis,\u00a0prevention,\u00a0and\u00a0treatment. Am\u00a0Heart\u00a0J\u00a01982\u00a0Feb\u037e103(2):239\u00ad262\n33. Morganthaler\u00a0TI,\u00a0Ryu\u00a0JH. Clinical\u00a0characteristics\u00a0of\u00a0fatal\u00a0pulmonary\u00a0embolism\u00a0in\u00a0a\u00a0referral\nhospital. Mayo\u00a0Clin\u00a0Proc\u00a01995\u037e70:417\u00ad424\n34. Bergqvist\u00a0D,\u00a0Lindblad\u00a0B. A\u00a030\u00a0year\u00a0survey\u00a0of\u00a0pulmonary\u00a0embolism\u00a0verified\u00a0at\u00a0autopsy:\u00a0an\nanalysis\u00a0of\u00a01274\u00a0surgical\u00a0patients. Br\u00a0J\u00a0Surg\u00a01985\u037e72:105\u00ad108\n35. Rasmussen\u00a0 MS,\u00a0 Wille\u00adJorgensen\u00a0 P,\u00a0 Jorgensen\u00a0 LN. Postoperative\u00a0 fatal\u00a0 pulmonary\nembolism\u00a0in\u00a0a\u00a0general\u00a0surgical\u00a0department. Am\u00a0J\u00a0Surg\u00a01995\u037e169:214\u00ad216\n36. Douketis\u00a0JD,\u00a0Kearon\u00a0C,\u00a0Bates\u00a0S,\u00a0et\u00a0al.", "chunk_order": 92}
{"chunk_id": "789d0c58-561e-4266-bed9-4498e736ce5e", "source_document_filename": "CPG Prevention and Treatment of Venous Thrombosis_cleaned_ultra_minimal.txt", "source_document_title": "CPG Prevention and Treatment of Venous Thrombosis cleaned ultra minimal", "text": "Chest\u00a01995\u037e108:978\u00ad981\n32. Bell\u00a0 WR,\u00a0 Simon\u00a0 TL. Current\u00a0 status\u00a0 of\u00a0 pulmonary\u00a0 embolic\u00a0 disease:\u00a0 pathophysiology,\ndiagnosis,\u00a0prevention,\u00a0and\u00a0treatment. Am\u00a0Heart\u00a0J\u00a01982\u00a0Feb\u037e103(2):239\u00ad262\n33. Morganthaler\u00a0TI,\u00a0Ryu\u00a0JH. Clinical\u00a0characteristics\u00a0of\u00a0fatal\u00a0pulmonary\u00a0embolism\u00a0in\u00a0a\u00a0referral\nhospital. Mayo\u00a0Clin\u00a0Proc\u00a01995\u037e70:417\u00ad424\n34. Bergqvist\u00a0D,\u00a0Lindblad\u00a0B. A\u00a030\u00a0year\u00a0survey\u00a0of\u00a0pulmonary\u00a0embolism\u00a0verified\u00a0at\u00a0autopsy:\u00a0an\nanalysis\u00a0of\u00a01274\u00a0surgical\u00a0patients. Br\u00a0J\u00a0Surg\u00a01985\u037e72:105\u00ad108\n35. Rasmussen\u00a0 MS,\u00a0 Wille\u00adJorgensen\u00a0 P,\u00a0 Jorgensen\u00a0 LN. Postoperative\u00a0 fatal\u00a0 pulmonary\nembolism\u00a0in\u00a0a\u00a0general\u00a0surgical\u00a0department. Am\u00a0J\u00a0Surg\u00a01995\u037e169:214\u00ad216\n36. Douketis\u00a0JD,\u00a0Kearon\u00a0C,\u00a0Bates\u00a0S,\u00a0et\u00a0al. Risk\u00a0of\u00a0fatal\u00a0pulmonary\u00a0embolism\u00a0in\u00a0patients\u00a0with\ntreated\u00a0venous\u00a0thromboembolism. JAMA\u00a01998\u037e279:458\u00ad462\n37. Holmstrom\u00a0M,\u00a0Lindmarker\u00a0P,\u00a0Granqvist\u00a0S,\u00a0et\u00a0al. A\u00a06\u00admonth\u00a0venographic\u00a0follow\u00adup\u00a0in\u00a0164\npatients\u00a0with\u00a0acute\u00a0deep\u00a0vein\u00a0thrombosis. Thromb\u00a0Haemost\u00a01997\u037e78:803\u00ad807\n38. Prandoni\u00a0P,\u00a0Lensing\u00a0AW,\u00a0Prins\u00a0MH,\u00a0et\u00a0al. Which\u00a0is\u00a0the\u00a0outcome\u00a0of\u00a0the\u00a0post\u00adthrombotic\nsyndrome? [letter]\u00a0[published\u00a0erratum\u00a0appears\u00a0in\u00a0Thromb\u00a0Haemost. 1999\u037e82:XII]\u00a0Thromb\nHaemost\u00a01999\u037e82:1358\n39. Brandjes\u00a0DPM,\u00a0Bu\u00a8ller\u00a0HR,\u00a0Heijboer\u00a0H,\u00a0et\u00a0al. Randomised\u00a0trial\u00a0of\u00a0effect\u00a0of\u00a0compression\nstockings\u00a0in\u00a0patients\u00a0with\u00a0symptomatic\u00a0proximal\u00advein\u00a0thrombosis. Lancet\u00a01997\u037e349:759\n\u00ad762\n40. Dalen\u00a0JE,\u00a0Alpert\u00a0JS,\u00a0Hirsh\u00a0J. Thrombolytic\u00a0therapy\u00a0for\u00a0pulmonary\u00a0embolism. Is\u00a0it\u00a0effective? Is\u00a0it\u00a0safe? When\u00a0is\u00a0it\u00a0indicated? Arch\u00a0Intern\u00a0Med\u00a01997\u037e157:2550\u00ad2556\n41. Ribeiro\u00a0A,\u00a0Lindmarker\u00a0P,\u00a0Johnsson\u00a0H,\u00a0et\u00a0al. Pulmonary\u00a0embolism. One\u00a0year\u00a0follow\u00adup\u00a0with\nechocardiography\u00a0doppler\u00a0and\u00a0five\u00adyear\u00a0survival\u00a0analysis. Circulation\u00a01999\u037e99:1325\u00ad1330\n42. Paraskos\u00a0JA,\u00a0Adelstein\u00a0SJ,\u00a0Smith\u00a0RE,\u00a0et\u00a0al. Late\u00a0prognosis\u00a0of\u00a0acute\u00a0pulmonary\u00a0embolism. N\u00a0Engl\u00a0J\u00a0Med\u00a01973\u037e289:55\u00ad58\n43. Hall\u00a0RJC,\u00a0Sutton\u00a0GC,\u00a0Kerr\u00a0IH. Long\u00adterm\u00a0prognosis\u00a0of\u00a0treated\u00a0acute\u00a0massive\u00a0pulmonary\nembolism. Br\u00a0Heart\u00a0J\u00a01977\u037e39:1128\u00ad1134\n44. Riedel\u00a0 M,\u00a0 Stanek\u00a0 V,\u00a0 Widimsky\u00a0 J. Longterm\u00a0 follow\u00adup\u00a0 of\u00a0 patients\u00a0 with\u00a0 pulmonary\nthromboembolism:\u00a0 late\u00a0 prognosis\u00a0 and\u00a0 evolution\u00addynamic\u00a0 and\u00a0 respiratory\u00a0 data. Chest\n1982\u037e81:151\u00ad158\n45. Heit\u00a0 JA,\u00a0 Mohr\u00a0 DN,\u00a0 Silverstein\u00a0 MD,\u00a0 et\u00a0 al. Predictors\u00a0 of\u00a0 recurrence\u00a0 after\u00a0 deep\u00a0 vein\nthrombosis\u00a0and\u00a0pulmonary\u00a0embolism:\u00a0a\u00a0population\u00adbased\u00a0cohort\u00a0study. Arch\u00a0Intern\u00a0Med\n2000\u037e160:761\u00ad768\n46. Levine\u00a0 JS,\u00a0 Branch\u00a0 DW,\u00a0 Rauch\u00a0 J. The\u00a0 antiphospholipid\u00a0 syndrome. NEngl\u00a0 J\u00a0 Med\n2002\u037e346:752\u00ad763\n47. Schulman\u00a0S. The\u00a0effect\u00a0of\u00a0the\u00a0duration\u00a0of\u00a0anticoagulation\u00a0and\u00a0other\u00a0risk\u00a0factors\u00a0on\u00a0the\nrecurrence\u00a0of\u00a0venous\u00a0thromboembolisms. Duration\u00a0of\u00a0Anticoagulation\u00a0Study\u00a0Group. Wien\nMed\u00a0Wochenschr\u00a01999\u037e149:66\u00ad69\n48. Flordal\u00a0PA,\u00a0Bergqvist\u00a0D,\u00a0Ljungstrom\u00a0KG,\u00a0et\u00a0al. Clinical\u00a0relevance\u00a0of\u00a0the\u00a0fibrinogen\u00a0uptake\ntest\u00a0in\u00a0patients\u00a0having\u00a0general\u00a0abdominal\u00a0surgery\u00a0\u00ad\u00a0relation\u00a0to\u00a0major\u00a0thromboembolism\nand\u00a0mortality. Thromb\u00a0Res\u00a01995\u037e80:491\u00ad497\n49. Cogo\u00a0A,\u00a0Bernardi\u00a0E,\u00a0Prandoni\u00a0P,\u00a0et\u00a0al. Acquired\u00a0risk\u00a0factors\u00a0for\u00a0deep\u00advein\u00a0thrombosis\u00a0in\nsymptomatic\u00a0outpatients. Arch\u00a0Intern\u00a0Med\u00a01994\u037e154:164\u00ad167\n50. Chan\u00a0WS,\u00a0Spencer\u00a0FA,\u00a0Ginsberg\u00a0JS. Anatomic\u00a0distribution\u00a0of\u00a0deep\u00a0vein\u00a0thrombosis\u00a0in\npregnancy. CMAJ\u00a02010\u037e182:657\u00ad60\n51. Ray\u00a0 J,\u00a0 Chan\u00a0 WS. Deep\u00a0 vein\u00a0 thrombosis\u00a0 during\u00a0 pregnancy\u00a0 and\u00a0 the\u00a0 puerperium:\u00a0 a\nmeta\u00adanalysis\u00a0 of\u00a0 the\u00a0 period\u00a0 of\u00a0 risk\u00a0 and\u00a0 the\u00a0 leg\u00a0 of\u00a0 presentation. Obstet\u00a0 Gynecol\u00a0 Surv\n1999\u037e54:265\u00ad71\n54. Kearon\u00a0C. Natural\u00a0History\u00a0of\u00a0Venous\u00a0Thromboembolism. Circulation\u00a02003\u037e107:\u00a01\u00ad22\n55. Amaragiri\u00a0 SV,\u00a0 Lees\u00a0 TA. Elastic\u00a0 compression\u00a0 stockings\u00a0 for\u00a0 prevention\u00a0 of\u00a0 deep\u00a0 vein\nthrombosis.", "chunk_order": 93}
{"chunk_id": "23f895f2-0ea1-4859-99fd-bf8a5d421630", "source_document_filename": "CPG Prevention and Treatment of Venous Thrombosis_cleaned_ultra_minimal.txt", "source_document_title": "CPG Prevention and Treatment of Venous Thrombosis cleaned ultra minimal", "text": "Thromb\u00a0Res\u00a01995\u037e80:491\u00ad497\n49. Cogo\u00a0A,\u00a0Bernardi\u00a0E,\u00a0Prandoni\u00a0P,\u00a0et\u00a0al. Acquired\u00a0risk\u00a0factors\u00a0for\u00a0deep\u00advein\u00a0thrombosis\u00a0in\nsymptomatic\u00a0outpatients. Arch\u00a0Intern\u00a0Med\u00a01994\u037e154:164\u00ad167\n50. Chan\u00a0WS,\u00a0Spencer\u00a0FA,\u00a0Ginsberg\u00a0JS. Anatomic\u00a0distribution\u00a0of\u00a0deep\u00a0vein\u00a0thrombosis\u00a0in\npregnancy. CMAJ\u00a02010\u037e182:657\u00ad60\n51. Ray\u00a0 J,\u00a0 Chan\u00a0 WS. Deep\u00a0 vein\u00a0 thrombosis\u00a0 during\u00a0 pregnancy\u00a0 and\u00a0 the\u00a0 puerperium:\u00a0 a\nmeta\u00adanalysis\u00a0 of\u00a0 the\u00a0 period\u00a0 of\u00a0 risk\u00a0 and\u00a0 the\u00a0 leg\u00a0 of\u00a0 presentation. Obstet\u00a0 Gynecol\u00a0 Surv\n1999\u037e54:265\u00ad71\n54. Kearon\u00a0C. Natural\u00a0History\u00a0of\u00a0Venous\u00a0Thromboembolism. Circulation\u00a02003\u037e107:\u00a01\u00ad22\n55. Amaragiri\u00a0 SV,\u00a0 Lees\u00a0 TA. Elastic\u00a0 compression\u00a0 stockings\u00a0 for\u00a0 prevention\u00a0 of\u00a0 deep\u00a0 vein\nthrombosis. Cochrane\u00a0Database\u00a0Syst\u00a0Rev\u00a02000\u037e\u00a0issue\u00a01\u037e\u00a0article\u00a0No. CD001484\n56. Agu\u00a0 O,\u00a0 Hamilton\u00a0 G,\u00a0 Baker\u00a0 D. Graduated\u00a0 compression\u00a0 stockings\u00a0 in\u00a0 the\u00a0 prevention\u00a0 of\nvenous\u00a0thromboembolism. Br\u00a0J\u00a0Surg\u00a01999\u037e\u00a086:992\u20131004\n57. Bauersachs\u00a0 RM. Fondaparinux:\u00a0 an\u00a0 update\u00a0 on\u00a0 new\u00a0 study\u00a0 results. Eur\u00a0 J\u00a0 Clin\u00a0 Invest\n2005\u037e35(Suppl\u00a01):27\u00ad32\n58. Collins\u00a0 R,\u00a0 Scrimgeour\u00a0A,\u00a0 Yusuf\u00a0 S,\u00a0 et\u00a0 al. Reduction\u00a0 in\u00a0 fatal\u00a0 pulmonary\u00a0 embolism\u00a0 and\nvenous\u00a0thrombosis\u00a0by\u00a0perioperative\u00a0administration\u00a0of\u00a0subcutaneous\u00a0heparin. Overview\u00a0of\nresults\u00a0 randomized\u00a0 trials\u00a0 in\u00a0 general,\u00a0 orthopedics,\u00a0 and\u00a0 urologic\u00a0 surgery. N\u00a0 Engl\u00a0 Med\u00a0 J\n1988\u037e318:1162\u00ad73\n59. The\nEINSTEIN\nInvestigators. Oral\nRivaroxaban\nfor\nSymptomatic\nVenous\nThromboembolism. N\u00a0Engl\u00a0J\u00a0Med\u00a02010\u037e363:2499\u00ad2510\n60. Falck\u00adYtter\u00a0Y,\u00a0Francis\u00a0CW,\u00a0Johanson\u00a0NA,\u00a0et\u00a0al. Prevention\u00a0of\u00a0VTE\u00a0in\u00a0orthopedic\u00a0surgery\npatients:\u00a0antithrombotic\u00a0therapy\u00a0and\u00a0prevention\u00a0of\u00a0thrombosis,\u00a09th\u00a0ed:\u00a0American\u00a0College\nof\u00a0 Chest\u00a0 Physicians\u00a0 evidence\u00adbased\u00a0 clinical\u00a0 practice\u00a0 guidelines. Chest\u00a0 2012\u037e\n141(2)(suppl):e278S\u00ade325S\n61. Garcia\u00a0DA,\u00a0Baglin\u00a0TP,\u00a0Weitz\u00a0JI,\u00a0MM\u00a0Samama. Parenteral\u00a0Anticoagulants:\u00a0antithrombotic\ntherapy\u00a0 and\u00a0 prevention\u00a0 of\u00a0 thrombosis,\u00a0 9th\u00a0 ed:\u00a0American\u00a0 College\u00a0 of\u00a0 Chest\u00a0 Physicians\nevidence\u00adbased\u00a0clinical\u00a0practice\u00a0guidelines. Chest\u00a02012\u037e141(2)(suppl):e24S\u00ade43S\n62. Geerts\u00a0WH,\u00a0Pineo\u00a0GF,\u00a0Heit\u00a0JA,\u00a0et\u00a0al. Prevention\u00a0of\u00a0venous\u00a0thromboembolism:\u00a0the\u00a0Seventh\nACCP\nConference\non\nAntithrombotic\nand\nThrombolytic\nTherapy. Chest\n2004\u037e126:338S\u00ad400S\n63. Gould\u00a0 MK,\u00a0 Garcia\u00a0 DA,\u00a0 Wren\u00a0 SM,\u00a0 et\u00a0 al. Prevention\u00a0 of\u00a0 VTE\u00a0 in\u00a0 nonorthopedic\u00a0 surgical\npatients:\u00a0antithrombotic\u00a0therapy\u00a0and\u00a0prevention\u00a0of\u00a0thrombosis,\u00a09th\u00a0ed:\u00a0American\u00a0College\nof\u00a0 Chest\u00a0 Physicians\u00a0 evidence\u00adbased\u00a0 clinical\u00a0 practice\u00a0 guidelines. Chest\u00a0 2012\u037e141(2)\n(suppl):e227S\u00ade277S\n64. Jorgensen\nLN,\nWille\u00adJorgensen\nP,\nHauch\nO. Prophylaxis\nof\npostoperative\nthromboembolism\u00a0with\u00a0low\u00a0molecular\u00a0weight\u00a0heparins. Br\u00a0J\u00a0Surg\u00a01993\u037e80:689\u00ad704\n65. Kahn\u00a0SR,\u00a0Lim\u00a0W,\u00a0Dunn\u00a0AS,\u00a0et\u00a0al. Prevention\u00a0of\u00a0VTE\u00a0in\u00a0nonsurgical\u00a0patients:\u00a0antithrombotic\ntherapy\u00a0 and\u00a0 prevention\u00a0 of\u00a0 thrombosis,\u00a0 9th\u00a0 ed:\u00a0American\u00a0 College\u00a0 of\u00a0 Chest\u00a0 Physicians\nevidence\u00adbased\u00a0clinical\u00a0practice\u00a0guidelines. Chest\u00a02012\u037e141(2)(suppl):e195S\u00ad226S\n66. Kakkar\u00a0VV,\u00a0Corrigan\u00a0TP,\u00a0Fossard\u00a0DP,\u00a0et\u00a0al. Prevention\u00a0of\u00a0fatal\u00a0post\u00adoperative\u00a0pulmonary\nembolism\u00a0by\u00a0low\u00a0doses\u00a0of\u00a0heparin. Re\u00adappraisal\u00a0of\u00a0results\u00a0of\u00a0international\u00a0multicentre\u00a0trial. Lancet\u00a01977\u037e1:567\u00ad9\n67. Kakkar\u00a0VV,\u00a0Cohen\u00a0AT,\u00a0Edmonson\u00a0RA,\u00a0et\u00a0al. Low\u00a0molecular\u00a0weight\u00a0versus\u00a0standard\u00a0heparin\nfor\u00a0prevention\u00a0of\u00a0venous\u00a0thromboembolism\u00a0after\u00a0major\u00a0abdominal\u00a0surgery. Lancet\u00a01993\u037e\n341:259\u00ad265\n68. Kearon\u00a0\u00a0C\u00a0,\u00a0\u00a0O\u2019Donnell\u00a0\u00a0\u00a0M. Should\u00a0patients\u00a0with\u00a0stroke\u00a0wear\u00a0compression\u00a0stockings\u00a0to\nprevent\u00a0venous\u00a0thromboembolism? Ann\u00a0Intern\u00a0Med\u00a02010\u037e153(9):610\u00ad611\n69. Mismetti\u00a0 P,\u00a0 Laporte\u00a0 S,\u00a0 Zufferey\u00a0 P,\u00a0 Epinat\u00a0 M,\u00a0 Decousus\u00a0 H,\u00a0 Cucherat\u00a0 M. Prevention\u00a0 of\nvenous\u00a0 thromboembolism\u00a0 in\u00a0 orthopedic\u00a0 surgery\u00a0 with\u00a0 vitamin\u00a0 K\u00a0 antagonists:\u00a0 A\nmeta\u00adanalysis. J\u00a0Thromb\u00a0Haemost\u00a02004\u037e2(7):1058\u00ad70\n70. National\u00a0Institute\u00a0for\u00a0Health\u00a0and\u00a0Clinical\u00a0Excellence\u00a0(NICE).", "chunk_order": 94}
{"chunk_id": "507979ab-cebb-41ce-afc4-8d65ffe442ba", "source_document_filename": "CPG Prevention and Treatment of Venous Thrombosis_cleaned_ultra_minimal.txt", "source_document_title": "CPG Prevention and Treatment of Venous Thrombosis cleaned ultra minimal", "text": "Re\u00adappraisal\u00a0of\u00a0results\u00a0of\u00a0international\u00a0multicentre\u00a0trial. Lancet\u00a01977\u037e1:567\u00ad9\n67. Kakkar\u00a0VV,\u00a0Cohen\u00a0AT,\u00a0Edmonson\u00a0RA,\u00a0et\u00a0al. Low\u00a0molecular\u00a0weight\u00a0versus\u00a0standard\u00a0heparin\nfor\u00a0prevention\u00a0of\u00a0venous\u00a0thromboembolism\u00a0after\u00a0major\u00a0abdominal\u00a0surgery. Lancet\u00a01993\u037e\n341:259\u00ad265\n68. Kearon\u00a0\u00a0C\u00a0,\u00a0\u00a0O\u2019Donnell\u00a0\u00a0\u00a0M. Should\u00a0patients\u00a0with\u00a0stroke\u00a0wear\u00a0compression\u00a0stockings\u00a0to\nprevent\u00a0venous\u00a0thromboembolism? Ann\u00a0Intern\u00a0Med\u00a02010\u037e153(9):610\u00ad611\n69. Mismetti\u00a0 P,\u00a0 Laporte\u00a0 S,\u00a0 Zufferey\u00a0 P,\u00a0 Epinat\u00a0 M,\u00a0 Decousus\u00a0 H,\u00a0 Cucherat\u00a0 M. Prevention\u00a0 of\nvenous\u00a0 thromboembolism\u00a0 in\u00a0 orthopedic\u00a0 surgery\u00a0 with\u00a0 vitamin\u00a0 K\u00a0 antagonists:\u00a0 A\nmeta\u00adanalysis. J\u00a0Thromb\u00a0Haemost\u00a02004\u037e2(7):1058\u00ad70\n70. National\u00a0Institute\u00a0for\u00a0Health\u00a0and\u00a0Clinical\u00a0Excellence\u00a0(NICE). Reducing\u00a0the\u00a0risk\u00a0of\u00a0venous\nthromboembolism\u00a0 (deep\u00a0 vein\u00a0 thrombosis\u00a0 and\u00a0 pulmonary\u00a0 embolism)\u00a0 in\u00a0 inpatients\nundergoing\nsurgery. NICE\nclinical\nguideline\nNo. 46:1\u00ad160. (Available\nat:\nhttp://www.nice.org.uk/CG046. Accessed\u00a0March\u00a031,\u00a02008)\n71. National\u00a0Institute\u00a0for\u00a0Health\u00a0and\u00a0Clinical\u00a0Excellence\u00a0(NICE)\u00a0technology\u00a0appraisal\u00a0guidance\n245. Apixaban\u00a0 for\u00a0 the\u00a0 prevention\u00a0 of\u00a0 venous\u00a0 thromboembolism\u00a0 after\u00a0 total\u00a0 hip\u00a0 or\u00a0 knee\nreplacement\u00a0in\u00a0adults,\u00a0Jan\u00a02012. 72. Urbankova\u00a0J,\u00a0Quiroz\u00a0R,\u00a0Kucher\u00a0N,\u00a0et\u00a0al. Intermittent\u00a0pneumatic\u00a0compression\u00a0and\u00a0deep\nvein\u00a0thrombosis\u00a0prevention:\u00a0a\u00a0meta\u00adanalysis\u00a0in\u00a0postoperative\u00a0patients. Thromb\u00a0Haemost\n2005\u037e\u00a094:1181\u00ad1185\n73. Wolowacz\u00a0 SE,\u00a0 Roskell\u00a0 NS,\u00a0 Plumb\u00a0 jM,\u00a0 Caprini\u00a0 jA,\u00a0 Eriksson\u00a0 BI. Efficacy\u00a0 and\u00a0 safety\u00a0 of\ndabigatran\u00a0etexilate\u00a0for\u00a0the\u00a0prevention\u00a0of\u00a0venous\u00a0thromboembolism\u00a0following\u00a0total\u00a0hip\u00a0or\nknee\u00a0arthroplasty. A\u00a0meta\u00adanalysis. Thromb\u00a0Haemost\u00a02009\u037e101(1):77\u00ad85\n74. Barbar\u00a0S,\u00a0Noventa\u00a0F,\u00a0Rossetto\u00a0V,\u00a0et\u00a0al. A\u00a0risk\u00a0assessment\u00a0model\u00a0for\u00a0the\u00a0identification\u00a0of\nhospitalised\u00a0medical\u00a0patients\u00a0at\u00a0risk\u00a0for\u00a0venous\u00a0thromboembolism:\u00a0the\u00a0Padua\u00a0Prediction\nScore. J\u00a0Thromb\u00a0Haemos\u00a02010\u037e8(11):2450\u00ad7\n75. Geerts\u00a0et\u00a0al. Prevention\u00a0of\u00a0venous\u00a0thromboembolism:\u00a0the\u00a0ACCP\u00a0evidence\u00adbased\u00a0clinical\npractice\u00a0guidelines\u00a0(8th\u00a0edition). Chest\u00a02008\u037e133(Suppl\u00a06):381S\u00ad453S\n76. Gould\u00a0 MK,\u00a0 Garcia\u00a0 DA,\u00a0 Wren\u00a0 SM,\u00a0 et\u00a0 al. Prevention\u00a0 of\u00a0 VTE\u00a0 in\u00a0 nonorthopedic\u00a0 surgical\npatients:\u00a0antithrombotic\u00a0therapy\u00a0and\u00a0prevention\u00a0of\u00a0thrombosis,\u00a09th\u00a0ed:\u00a0American\u00a0College\nof\u00a0 Chest\u00a0 Physicians\u00a0 evidence\u00adbased\u00a0 clinical\u00a0 practice\u00a0 guidelines. Chest\u00a0 2012\u037e\n141(2)(suppl):e227S\u00ade277S\n77. Decousus\u00a0H,\u00a0Tapson\u00a0VF,\u00a0Bergmann\u00a0JF. Factors\u00a0at\u00a0admission\u00a0associated\u00a0with\u00a0bleeding\u00a0risk\nin\u00a0medical\u00a0patients:\u00a0findings\u00a0from\u00a0the\u00a0IMPROVE\u00a0investigations. Chest\u00a02011\u037e139(1):69\u00ad79\n78. Kahn\u00a0SR,\u00a0Lim\u00a0W,\u00a0Dunn\u00a0AS,\u00a0et\u00a0al. Prevention\u00a0of\u00a0VTE\u00a0in\u00a0nonsurgical\u00a0patients:\u00a0antithrombotic\ntherapy\u00a0 and\u00a0 prevention\u00a0 of\u00a0 thrombosis,\u00a0 9th\u00a0 ed:\u00a0American\u00a0 College\u00a0 of\u00a0 Chest\u00a0 Physicians\nevidence\u00adbased\u00a0clinical\u00a0practice\u00a0guidelines. Chest\u00a02012\u037e141(2)(suppl):e195S\u00ad226S\n79. Gould\u00a0 MK,\u00a0 Garcia\u00a0 DA,\u00a0 Wren\u00a0 SM,\u00a0 et\u00a0 al. Prevention\u00a0 of\u00a0 VTE\u00a0 in\u00a0 nonorthopedic\u00a0 surgical\npatients:\u00a0antithrombotic\u00a0therapy\u00a0and\u00a0prevention\u00a0of\u00a0thrombosis,\u00a09th\u00a0ed:\u00a0American\u00a0College\nof\u00a0 Chest\u00a0 Physicians\u00a0 evidence\u00adbased\u00a0 clinical\u00a0 practice\u00a0 guidelines. Chest\u00a0 2012\u037e\n141(2)(suppl):e227S\u00ade277S\n80. Falck\u00adYtter\u00a0Y,\u00a0Francis\u00a0CW,\u00a0Johanson\u00a0NA,\u00a0et\u00a0al. Prevention\u00a0of\u00a0VTE\u00a0in\u00a0orthopedic\u00a0surgery\npatients:\u00a0antithrombotic\u00a0therapy\u00a0and\u00a0prevention\u00a0of\u00a0thrombosis,\u00a09th\u00a0ed:\u00a0American\u00a0College\nof\u00a0 Chest\u00a0 Physicians\u00a0 evidence\u00adbased\u00a0 clinical\u00a0 practice\u00a0 guidelines. Chest\u00a0 2012\u037e\n141(2)(suppl):e278S\u00ade325S\n81. Moen\u00a0V,\u00a0Dahlgren\u00a0N,\u00a0Irestedt\u00a0L. Severe\u00a0neurological\u00a0complications\u00a0after\u00a0central\u00a0neuraxial\nblockades\u00a0in\u00a0Sweden\u00a01990\u00ad1999. Anesthesiology\u00a02004\u037e101:950\u00ad959\n82. Liu\u00a0 SS,\u00a0 Mulroy\u00a0 MF. Neuraxial\u00a0 anesthesia\u00a0 and\u00a0 analgesia\u00a0 in\u00a0 the\u00a0 presence\u00a0 of\u00a0 standard\nheparin. Reg\u00a0Anesth\u00a0Pain\u00a0Med\u00a01998\u037e23:157\u00ad63\n83. Geerts\u00a0 WH,\u00a0 Bergqvist\u00a0 D,\u00a0 Pineo\u00a0 GF,\u00a0 et\u00a0 al. Prevention\u00a0 of\u00a0 venous\u00a0 thromboembolism:\nAmerican\u00a0College\u00a0of\u00a0Chest\u00a0Physicians\u00a0Evidence\u00adBased\u00a0Clinical\u00a0Practice\u00a0Guidelines\u00a0(8th\nEdition). Chest\u00a02008\u037e133:381S\u00ad453S\n84.", "chunk_order": 95}
{"chunk_id": "951889a8-8979-428a-b545-7e71eab3d843", "source_document_filename": "CPG Prevention and Treatment of Venous Thrombosis_cleaned_ultra_minimal.txt", "source_document_title": "CPG Prevention and Treatment of Venous Thrombosis cleaned ultra minimal", "text": "Prevention\u00a0of\u00a0VTE\u00a0in\u00a0orthopedic\u00a0surgery\npatients:\u00a0antithrombotic\u00a0therapy\u00a0and\u00a0prevention\u00a0of\u00a0thrombosis,\u00a09th\u00a0ed:\u00a0American\u00a0College\nof\u00a0 Chest\u00a0 Physicians\u00a0 evidence\u00adbased\u00a0 clinical\u00a0 practice\u00a0 guidelines. Chest\u00a0 2012\u037e\n141(2)(suppl):e278S\u00ade325S\n81. Moen\u00a0V,\u00a0Dahlgren\u00a0N,\u00a0Irestedt\u00a0L. Severe\u00a0neurological\u00a0complications\u00a0after\u00a0central\u00a0neuraxial\nblockades\u00a0in\u00a0Sweden\u00a01990\u00ad1999. Anesthesiology\u00a02004\u037e101:950\u00ad959\n82. Liu\u00a0 SS,\u00a0 Mulroy\u00a0 MF. Neuraxial\u00a0 anesthesia\u00a0 and\u00a0 analgesia\u00a0 in\u00a0 the\u00a0 presence\u00a0 of\u00a0 standard\nheparin. Reg\u00a0Anesth\u00a0Pain\u00a0Med\u00a01998\u037e23:157\u00ad63\n83. Geerts\u00a0 WH,\u00a0 Bergqvist\u00a0 D,\u00a0 Pineo\u00a0 GF,\u00a0 et\u00a0 al. Prevention\u00a0 of\u00a0 venous\u00a0 thromboembolism:\nAmerican\u00a0College\u00a0of\u00a0Chest\u00a0Physicians\u00a0Evidence\u00adBased\u00a0Clinical\u00a0Practice\u00a0Guidelines\u00a0(8th\nEdition). Chest\u00a02008\u037e133:381S\u00ad453S\n84. Hirsh\u00a0J,\u00a0Bauer\u00a0KA,\u00a0Donati\u00a0MB,\u00a0et\u00a0al. Parenteral\u00a0anticoagulants:\u00a0American\u00a0College\u00a0of\u00a0Chest\nPhysicians\u00a0 Evidence\u00adBased\u00a0 Clinical\u00a0 Practice\u00a0 Guidelines\u00a0 (8th\u00a0 Edition). Chest\u00a0 2008\u037e\n133:141S\u00ad159S\n85. Horlocker\u00a0TT,\u00a0 Wedel\u00a0 DJ. Neuraxial\u00a0 block\u00a0 and\u00a0 low\u00a0 molecular\u00adweight\u00a0 heparin:\u00a0 balancing\nperioperative\u00a0analgesia\u00a0and\u00a0thromboprophylaxis. Reg\u00a0Anesth\u00a0Pain\u00a0Med\u00a01998\u037e23:164\u00ad177\n86. Horlocker\u00a0 TT,\u00a0 Wedel\u00a0 DJ,\u00a0 Benzon\u00a0 H,\u00a0 et\u00a0 al. Regional\u00a0 anesthesia\u00a0 in\u00a0 the\u00a0 anticoagulated\npatient:\u00a0 defining\u00a0 the\u00a0 risks\u00a0 (the\u00a0 second\u00a0 ASRA\u00a0 Consensus\u00a0 Conference\u00a0 on\u00a0 Neuraxial\nAnesthesia\u00a0and\u00a0Anticoagulation). Reg\u00a0Anesth\u00a0Pain\u00a0Med\u00a02003\u037e28:172\u00ad197\n87. Turpie\u00a0 AG,\u00a0 Gallus\u00a0 AS,\u00a0 Hoek\u00a0 JA. A\u00a0 synthetic\u00a0 pentasaccharide\u00a0 for\u00a0 the\u00a0 prevention\u00a0 of\ndeep\u00advein\u00a0thrombosis\u00a0after\u00a0total\u00a0hip\u00a0replacement. N\u00a0Engl\u00a0J\u00a0Med\u00a02001\u037e344:619\u00ad625\n88. Landow\u00a0L. A\u00a0synthetic\u00a0pentasaccharide\u00a0for\u00a0the\u00a0prevention\u00a0of\u00a0deep\u00advein\u00a0thrombosis. N\u00a0Engl\nJ\u00a0Med\u00a02001\u037e345:291\u00ad292\n89. Geerts\u00a0WH,\u00a0Pineo\u00a0GF,\u00a0Heit\u00a0JA,\u00a0et\u00a0al. Prevention\u00a0of\u00a0venous\u00a0thromboembolism:\u00a0the\u00a0Seventh\nACCP\u00a0 Conference\u00a0 on\u00a0 Antithrombotic\u00a0 and\u00a0 Thrombolytic\u00a0 Therapy. Chest\u00a0 2004\u037e\n126:338S\u00ad400S\n90. Gould\u00a0 MK,\u00a0 Garcia\u00a0 DA,\u00a0 Wren\u00a0 SM,\u00a0 et\u00a0 al. Prevention\u00a0 of\u00a0 VTE\u00a0 in\u00a0 nonorthopedic\u00a0 surgical\npatients:\u00a0antithrombotic\u00a0therapy\u00a0and\u00a0prevention\u00a0of\u00a0thrombosis,\u00a09th\u00a0ed:\u00a0American\u00a0College\nof\u00a0 Chest\u00a0 Physicians\u00a0 evidence\u00adbased\u00a0 clinical\u00a0 practice\u00a0 guidelines. Chest\u00a0 2012\u037e141(2)\n(suppl):e227S\u00ade277S\n91. Falck\u00adYtter\u00a0Y,\u00a0Francis\u00a0CW,\u00a0Johanson\u00a0NA,\u00a0et\u00a0al. Prevention\u00a0of\u00a0VTE\u00a0in\u00a0orthopedic\u00a0surgery\npatients:\u00a0antithrombotic\u00a0therapy\u00a0and\u00a0prevention\u00a0of\u00a0thrombosis,\u00a09th\u00a0ed:\u00a0American\u00a0College\nof\u00a0 Chest\u00a0 Physicians\u00a0 evidence\u00adbased\u00a0 clinical\u00a0 practice\u00a0 guidelines. Chest\u00a0 2012\u037e141(2)\n(suppl):e278S\u00ade325S\n92. De\u00a0Silva\u00a0DA,\u00a0Pey\u00a0HB,\u00a0Wong\u00a0MC,\u00a0et\u00a0al. Deep\u00a0vein\u00a0thrombosis\u00a0following\u00a0ischemic\u00a0stroke\namong\u00a0Asians. Cerebrovasc\u00a0Dis\u00a02006\u037e22(4):245\u00ad50\n93. Malaysian\u00a0Society\u00a0of\u00a0Neuroscience,\u00a0Ministry\u00a0of\u00a0Health\u00a0Malaysia,\u00a0Academy\u00a0of\u00a0Medicine\nMalaysia. Clinical\u00a0Practice\u00a0Guidelines\u00a0on\u00a0Management\u00a0of\u00a0Ischemic\u00a0Stroke,\u00a02nd\u00a0Edition,\n2012\n94. Dennis\u00a0M,\u00a0Sandercock\u00a0P,\u00a0Reid\u00a0J,\u00a0et\u00a0al. Does\u00a0intermittent\u00a0pneumatic\u00a0compression\u00a0reduce\nthe\u00a0risk\u00a0of\u00a0post\u00a0stroke\u00a0deep\u00a0vein\u00a0thrombosis? The\u00a0CLOTS\u00a03\u00a0trial:\u00a0study\u00a0protocol\u00a0for\u00a0a\nrandomized\u00a0controlled\u00a0trial. Trials\u00a02012\u037e13:26\n95. Somarouthu\u00a0B,\u00a0Yeddula\u00a0K,\u00a0Wicky\u00a0S,\u00a0et\u00a0al. Long\u00adterm\u00a0safety\u00a0and\u00a0effectiveness\u00a0of\u00a0inferior\nvena\u00a0cava\u00a0filters\u00a0in\u00a0patients\u00a0with\u00a0stroke. J\u00a0Neurointerv\u00a0Surg\u00a02011\u037e3(2):141\u00ad6\n96. Goldhaber\u00a0SZ,\u00a0Bounameaux\u00a0H. Pulmonary\u00a0embolism\u00a0and\u00a0deep\u00a0vein\u00a0thrombosis. Lancet\n2012\u037e379(9828):1835\u00ad46\n97. Orken\u00a0 DN,\u00a0 Kenangil\u00a0 G,\u00a0 Ozkurt\u00a0 H,\u00a0 et\u00a0 al. Prevention\u00a0 of\u00a0 deep\u00a0 venous\u00a0 thrombosis\u00a0 and\npulmonary\u00a0 embolism\u00a0 in\u00a0 patients\u00a0 with\u00a0 acute\u00a0 intracerebral\u00a0 haemorrhage. Neurologist\n2009\u037e15(6):329\u00ad31\n98. Paciaroni\u00a0 M,\u00a0 Agnelli\u00a0 G,\u00a0 Venti\u00a0 M,\u00a0 et\u00a0 al. Efficacy\u00a0 and\u00a0 safety\u00a0 of\u00a0 anticoagulants\u00a0 in\u00a0 the\nprevention\u00a0of\u00a0venous\u00a0thromboembolism\u00a0in\u00a0patients\u00a0with\u00a0acute\u00a0cerebral\u00a0haemorrhage:\u00a0a\nmeta\u00adanalysis\u00a0of\u00a0controlled\u00a0studies. J\u00a0Thromb\u00a0Haemost\u00a02011\u037e9(5):893\u00ad8\n99. Kakkos\u00a0SK,\u00a0Caprini\u00a0JA,\u00a0Nicolaides\u00a0AN,\u00a0Reddy\u00a0D.", "chunk_order": 96}
{"chunk_id": "654a2343-78d2-4798-b882-9553191158fe", "source_document_filename": "CPG Prevention and Treatment of Venous Thrombosis_cleaned_ultra_minimal.txt", "source_document_title": "CPG Prevention and Treatment of Venous Thrombosis cleaned ultra minimal", "text": "Long\u00adterm\u00a0safety\u00a0and\u00a0effectiveness\u00a0of\u00a0inferior\nvena\u00a0cava\u00a0filters\u00a0in\u00a0patients\u00a0with\u00a0stroke. J\u00a0Neurointerv\u00a0Surg\u00a02011\u037e3(2):141\u00ad6\n96. Goldhaber\u00a0SZ,\u00a0Bounameaux\u00a0H. Pulmonary\u00a0embolism\u00a0and\u00a0deep\u00a0vein\u00a0thrombosis. Lancet\n2012\u037e379(9828):1835\u00ad46\n97. Orken\u00a0 DN,\u00a0 Kenangil\u00a0 G,\u00a0 Ozkurt\u00a0 H,\u00a0 et\u00a0 al. Prevention\u00a0 of\u00a0 deep\u00a0 venous\u00a0 thrombosis\u00a0 and\npulmonary\u00a0 embolism\u00a0 in\u00a0 patients\u00a0 with\u00a0 acute\u00a0 intracerebral\u00a0 haemorrhage. Neurologist\n2009\u037e15(6):329\u00ad31\n98. Paciaroni\u00a0 M,\u00a0 Agnelli\u00a0 G,\u00a0 Venti\u00a0 M,\u00a0 et\u00a0 al. Efficacy\u00a0 and\u00a0 safety\u00a0 of\u00a0 anticoagulants\u00a0 in\u00a0 the\nprevention\u00a0of\u00a0venous\u00a0thromboembolism\u00a0in\u00a0patients\u00a0with\u00a0acute\u00a0cerebral\u00a0haemorrhage:\u00a0a\nmeta\u00adanalysis\u00a0of\u00a0controlled\u00a0studies. J\u00a0Thromb\u00a0Haemost\u00a02011\u037e9(5):893\u00ad8\n99. Kakkos\u00a0SK,\u00a0Caprini\u00a0JA,\u00a0Nicolaides\u00a0AN,\u00a0Reddy\u00a0D. Combined\u00a0modalities\u00a0in\u00a0the\u00a0prevention\nof\u00a0venous\u00a0thromboembolism:\u00a0a\u00a0review\u00a0of\u00a0the\u00a0literature\u00a0(Brief\u00a0record). Phlebology\u00a02006\u037e\n21(Suppl\u00a01):1\u00ad6\n100. Bates\u00a0SM,\u00a0Jaeschke\u00a0R,\u00a0Stevens\u00a0SM,\u00a0Goodacre\u00a0S,\u00a0Wells\u00a0PS,\u00a0Stevenson\u00a0MD,\u00a0Kearon\u00a0C,\u00a0et\nal. Diagnosis\u00a0 of\u00a0 DVT:\u00a0Antithrombotic\u00a0 Therapy\u00a0 and\u00a0 Prevention\u00a0 of\u00a0 Thrombosis,\u00a0 9th\u00a0 ed:\nAmerican\u00a0 College\u00a0 of\u00a0 Chest\u00a0 Physicians\u00a0 Evidence\u00adBased\u00a0 Clinical\u00a0 Practice\u00a0 Guidelines. Chest\u00a02012\u037e141\u037ee351S\u00ade418S\n101. Kearon\u00a0C. Natural\u00a0history\u00a0of\u00a0Venous\u00a0Thromboembolism. Circulation\u00a02003\u037e107:I\u00ad22\u00adI\u00ad30\n102. Stein\u00a0PD,\u00a0Saltzman\u00a0HA,\u00a0Weg\u00a0JG. Clinical\u00a0characteristics\u00a0of\u00a0patients\u00a0with\u00a0acute\u00a0pulmonary\nembolism. Am\u00a0J\u00a0Cardiol\u00a01991\u037e68:1723\n103. Wells\u00a0 PS,\u00a0 Hirsh\u00a0 J,\u00a0Anderson\u00a0 DR,\u00a0 et\u00a0 al. Accuracy\u00a0 of\u00a0 clinical\u00a0 assessment\u00a0 of\u00a0 deep\u00a0 vein\nthrombosis. Lancet\u00a01995\u037e345:1325\u00ad30\n104. Wells\u00a0PS,\u00a0Owen\u00a0C,\u00a0Doucette\u00a0S,\u00a0Ferguson\u00a0D,\u00a0Tran\u00a0H. Does\u00a0this\u00a0patient\u00a0have\u00a0deep\u00a0vein\nthrombosis? JAMA\u00a02006\u037e295(2):199\u00ad207\n105. Wells\u00a0PS,\u00a0Anderson\u00a0DR,\u00a0Bormanis\u00a0J,\u00a0Guy\u00a0F,\u00a0Mitchell\u00a0M,\u00a0Gray\u00a0L,\u00a0et\u00a0al. Value\u00a0of\u00a0assessment\nof\u00a0 pretest\u00a0 probability\u00a0 of\u00a0 deep\u00advein\u00a0 thrombosis\u00a0 in\u00a0 clinical\u00a0 management. Lancet\n1997\u037e350:1795\u00ad98\n106. Wells\u00a0PS,\u00a0Anderson\u00a0DR,\u00a0Rodger\u00a0M,\u00a0Forgie\u00a0M,\u00a0Kearon\u00a0C,\u00a0Dreyer\u00a0J,\u00a0et\u00a0al. Evaluation\u00a0of\nD\u00addimer\u00a0 in\u00a0 the\u00a0 Diagnosis\u00a0 of\u00a0 Suspected\u00a0 Deep\u00adVein\u00a0 Thrombosis. N\u00a0 Engl\u00a0 J\u00a0 Med\n2003\u037e349:1227\u00ad35\n107. Wells\u00a0PS,\u00a0Anderson\u00a0DR,\u00a0Ginsberg\u00a0J. Assessment\u00a0of\u00a0deep\u00a0vein\u00a0thrombosis\u00a0or\u00a0pulmonary\nembolism\u00a0by\u00a0the\u00a0combined\u00a0use\u00a0of\u00a0clinical\u00a0model\u00a0and\u00a0non\u00adinvasive\u00a0test. Semin\u00a0Thromb\nHaemost\u00a02002\u037e26:643\u00ad656\n108. Wells\u00a0 PS,\u00a0 Anderson\u00a0 DR,\u00a0 Rodger\u00a0 M,\u00a0 et\u00a0 al. Derivation\u00a0 of\u00a0 a\u00a0 simple\u00a0 clinical\u00a0 model\u00a0 to\ncategorized\u00a0patients\u2019\u00a0probability\u00a0of\u00a0pulmonary\u00a0embolism:\u00a0increasing\u00a0the\u00a0model\u2019s\u00a0utility\u00a0with\nthe\u00a0SimpliRED\u00a0D\u00addimer. Thromb\u00a0Haemost\u00a02000\u037e83:416\u00ad20\n109. Kline\u00a0JA,\u00a0Courtney\u00a0DM,\u00a0Kabhrel\u00a0C,\u00a0Moore\u00a0CL,\u00a0Smithline\u00a0HA,\u00a0et\u00a0al. Prospective\u00a0multicenter\nevaluation\u00a0of\u00a0the\u00a0pulmonary\u00a0embolism\u00a0rule\u00adout\u00a0criteria. J\u00a0Thromb\u00a0Haemost\u00a02008\u037e6:772\u00ad80\n110. Piccioli\u00a0A,\u00a0Lensing\u00a0AW,\u00a0Prins\u00a0MH,\u00a0Falanga\u00a0A,\u00a0Scannapieco\u00a0GL,\u00a0Ieran\u00a0M\u00a0et\u00a0al. Extensive\nscreening\u00a0 for\u00a0 occult\u00a0 malignant\u00a0 disease\u00a0 in\u00a0 idiopathic\u00a0 venous\u00a0 thromboembolism:\u00a0 a\nprospective\u00a0randomized\u00a0clinical\u00a0trial. J\u00a0Thromb\u00a0Haemost\u00a02004\u037e2(6):884\u00ad889\n111. Middeldorp\u00a0 S,\u00a0 van\u00a0 Hylckama\u00a0 Vlieg\u00a0A. Does\u00a0 thrombophilia\u00a0 testing\u00a0 help\u00a0 in\u00a0 the\u00a0 clinical\nmanagement\u00a0of\u00a0patients? Br\u00a0J\u00a0Haematol\u00a02008\u037e143(3):321\u00ad335\n112. Baglin\u00a0T. Thrombophilia\u00a0testing:\u00a0what\u00a0do\u00a0we\u00a0think\u00a0the\u00a0tests\u00a0mean\u00a0and\u00a0what\u00a0should\u00a0we\u00a0do\nwith\u00a0the\u00a0results? J\u00a0Clin\u00a0pathol\u00a02000\u037e53:167\u00ad170\n113. Ho\u00a0 WK,\u00a0 Hankey\u00a0 GJ,\u00a0 Quinlan\u00a0 DJ,\u00a0 Eikelboom\u00a0 JW. Risk\u00a0 of\u00a0 recurrent\u00a0 venous\nthromboembolism\u00a0 in\u00a0 patients\u00a0 with\u00a0 common\u00a0 thrombophilia:\u00a0 a\u00a0 systematic\u00a0 review. Arch\nIntern\u00a0Med\u00a02006\u037e166(7):729\u00ad736\n114. Angchaisuksiri\u00a0 P,\u00a0 Atichartakarn\u00a0 V,\u00a0 Aryurachai\u00a0 K,\u00a0 et\u00a0 al. Risk\u00a0 factors\u00a0 of\u00a0 venous\nthromboembolism\u00a0in\u00a0Thai\u00a0patients. Int\u00a0J\u00a0Hematol\u00a02007\u037e86(5):397\u00ad402\n115.", "chunk_order": 97}
{"chunk_id": "63998d3d-b856-42d1-a834-702e79ebf2af", "source_document_filename": "CPG Prevention and Treatment of Venous Thrombosis_cleaned_ultra_minimal.txt", "source_document_title": "CPG Prevention and Treatment of Venous Thrombosis cleaned ultra minimal", "text": "J\u00a0Thromb\u00a0Haemost\u00a02004\u037e2(6):884\u00ad889\n111. Middeldorp\u00a0 S,\u00a0 van\u00a0 Hylckama\u00a0 Vlieg\u00a0A. Does\u00a0 thrombophilia\u00a0 testing\u00a0 help\u00a0 in\u00a0 the\u00a0 clinical\nmanagement\u00a0of\u00a0patients? Br\u00a0J\u00a0Haematol\u00a02008\u037e143(3):321\u00ad335\n112. Baglin\u00a0T. Thrombophilia\u00a0testing:\u00a0what\u00a0do\u00a0we\u00a0think\u00a0the\u00a0tests\u00a0mean\u00a0and\u00a0what\u00a0should\u00a0we\u00a0do\nwith\u00a0the\u00a0results? J\u00a0Clin\u00a0pathol\u00a02000\u037e53:167\u00ad170\n113. Ho\u00a0 WK,\u00a0 Hankey\u00a0 GJ,\u00a0 Quinlan\u00a0 DJ,\u00a0 Eikelboom\u00a0 JW. Risk\u00a0 of\u00a0 recurrent\u00a0 venous\nthromboembolism\u00a0 in\u00a0 patients\u00a0 with\u00a0 common\u00a0 thrombophilia:\u00a0 a\u00a0 systematic\u00a0 review. Arch\nIntern\u00a0Med\u00a02006\u037e166(7):729\u00ad736\n114. Angchaisuksiri\u00a0 P,\u00a0 Atichartakarn\u00a0 V,\u00a0 Aryurachai\u00a0 K,\u00a0 et\u00a0 al. Risk\u00a0 factors\u00a0 of\u00a0 venous\nthromboembolism\u00a0in\u00a0Thai\u00a0patients. Int\u00a0J\u00a0Hematol\u00a02007\u037e86(5):397\u00ad402\n115. Galli\u00a0M,\u00a0Barbui\u00a0T. Anti\u00adphospholipid\u00a0syndrome:\u00a0clinical\u00a0and\u00a0diagnostic\u00a0utility\u00a0of\u00a0laboratory\ntests. Semin\u00a0Thromb\u00a0Hemost\u00a02005\u037e31(1):17\u00ad24\n116. Boekholdt\u00a0 SM,\u00a0 Kramer\u00a0 MH. Arterial\u00a0 thrombosis\u00a0 and\u00a0 the\u00a0 role\u00a0 of\u00a0 thrombophilia. Semin\nThromb\u00a0Hemost\u00a02007\u037e33(6):588\u00ad596\n117. Robertson\u00a0L,\u00a0Wu\u00a0O,\u00a0Langhorne\u00a0P,\u00a0et\u00a0al. Thrombophilia\u00a0in\u00a0pregnancy:\u00a0a\u00a0systematic\u00a0review. Br\u00a0J\u00a0Haematol\u00a02006\u037e132(2):171\u00ad196\n118. Bezemer\u00a0ID,\u00a0van\u00a0der\u00a0Meer\u00a0FJ,\u00a0Eikenboom\u00a0JC,\u00a0et\u00a0al. The\u00a0value\u00a0of\u00a0family\u00a0history\u00a0as\u00a0a\u00a0risk\nindicator\u00a0for\u00a0venous\u00a0thrombosis. Arch\u00a0intern\u00a0Med\u00a02008\u037e169(6):610\u00ad615\n119. Baglin\u00a0 T,\u00a0 Luddington\u00a0 R,\u00a0 Brown\u00a0 K,\u00a0 Baglin\u00a0 C. Incidence\u00a0 of\u00a0 recurrent\u00a0 venous\nthromboembolism\u00a0in\u00a0relation\u00a0to\u00a0clinical\u00a0and\u00a0thrombophilic\u00a0risk\u00a0factors:\u00a0prospective\u00a0cohort\nstudy. Lancet\u00a02003\u037e362(9383):523\u00ad526\n120. Christiansen\u00a0 SC,\u00a0 Cannegieter\u00a0 SC,\u00a0 Koster\u00a0 T,\u00a0 et\u00a0 al. Thrombophilia,\u00a0 clinical\u00a0 factors\u00a0 and\nrecurrent\u00a0venous\u00a0thrombotic\u00a0events. JAMA\u00a02005\u037e293(19):2352\u00ad2361\n121. Coppens\u00a0M,\u00a0Reijnders\u00a0JH,\u00a0Middeldorp\u00a0S,\u00a0et\u00a0al. Testing\u00a0for\u00a0inherited\u00a0thrombophilia\u00a0does\u00a0not\nreduce\u00a0recurrence\u00a0of\u00a0venous\u00a0thrombosis. J\u00a0Thromb\u00a0Haemost\u00a02008\u037e6(9):1474\u00ad1477\n122. Ruiz\u00adIrastorza\u00a0 G,\u00a0 Hunt\u00a0 BJ,\u00a0 Khamashta\u00a0 MA. A\u00a0 systematic\u00a0 review\u00a0 of\u00a0 secondary\nthromboprophylaxis\u00a0 in\u00a0 patients\u00a0 with\u00a0 antiphospholipid\u00a0 antibodies. Arthritis\u00a0 Rheum\n2007\u037e57(8):1487\u00ad1495\n123. Cohn\u00a0 DM,\u00a0 Vansenne\u00a0 F,\u00a0 Kaptein\u00a0 AA,\u00a0 et\u00a0 al.. The\u00a0 psychological\u00a0 impact\u00a0 of\u00a0 testing\u00a0 for\nthrombophilia:\u00a0a\u00a0systematic\u00a0review. J\u00a0Thromb\u00a0Haemost\u00a02008\u037e6:1099\u00ad1104\n124. Baglin\u00a0 T,\u00a0 Gray\u00a0 E,\u00a0 Greaves\u00a0 M,\u00a0 et\u00a0 al. Clinical\u00a0 guidelines\u00a0 for\u00a0 testing\u00a0 for\u00a0 heritable\nthrombophilia. Br\u00a0J\u00a0Haematol\u00a02010,149\u037e209\u00ad220\n125. Venous\u00a0thromboembolic\u00a0diseases:\u00a0the\u00a0management\u00a0of\u00a0venous\u00a0thromboembolic\u00a0diseases\nand\u00a0the\u00a0role\u00a0of\u00a0thrombophilia\u00a0testing. National\u00a0Institute\u00a0for\u00a0Health\u00a0and\u00a0Clinical\u00a0Excellence\n(NICE)\u00a02012\n126. Amaragiri\u00a0 SV,\u00a0 Lees\u00a0 TA. Elastic\u00a0 compression\u00a0 stockings\u00a0 for\u00a0 prevention\u00a0 of\u00a0 deep\u00a0 vein\nthrombosis. Cochrane\u00a0Database\u00a0Syst\u00a0Rev\u00a02000\u037e\u00a0issue\u00a01\u037e\u00a0article\u00a0No. CD001484\n127. Agu\u00a0 O,\u00a0 Hamilton\u00a0 G,\u00a0 Baker\u00a0 D. Graduated\u00a0 compression\u00a0 stockings\u00a0 in\u00a0 the\u00a0 prevention\u00a0 of\nvenous\u00a0thromboembolism. Br\u00a0J\u00a0Surg\u00a01999\u037e86:992\u00ad1004\n128. Barritt\u00a0DW,\u00a0Jordan\u00a0SC. Anticoagulant\u00a0drugs\u00a0in\u00a0the\u00a0treatment\u00a0of\u00a0pulmonary\u00a0embolism:\u00a0a\ncontrolled\u00a0trial. Lancet\u00a01960\u037e1:1309\u00ad1312\n129. Buller\u00a0HR,\u00a0Davidson\u00a0BL,\u00a0Decousus\u00a0H,\u00a0Gallus\u00a0A,\u00a0Gent\u00a0M,\u00a0Piovella\u00a0F\u00a0et\u00a0al. Fondaparinux\u00a0or\nenoxaparin\u00a0 for\u00a0 the\u00a0 initial\u00a0 treatment\u00a0 of\u00a0 symptomatic\u00a0 deep\u00a0 venous\u00a0 thrombosis:\u00a0 a\nrandomized\u00a0trial. Ann\u00a0Intern\u00a0Med\u00a02004\u037e140(11):867\u00ad873\n130. The\nEINSTEIN\nInvestigators. Oral\nRivaroxaban\nfor\nSymptomatic\nVenous\nThromboembolism. N\u00a0Engl\u00a0J\u00a0Med\u00a02010\u037e363:2499\u00ad2510\n131. Garcia\u00a0DA,\u00a0Baglin\u00a0TP,\u00a0Weitz\u00a0JI,\u00a0MM\u00a0Samama. Parenteral\u00a0Anticoagulants:\u00a0antithrombotic\ntherapy\u00a0 and\u00a0 prevention\u00a0 of\u00a0 thrombosis,\u00a0 9th\u00a0 ed:\u00a0American\u00a0 College\u00a0 of\u00a0 Chest\u00a0 Physicians\nevidence\u00adbased\u00a0clinical\u00a0practice\u00a0guidelines. Chest\u00a02012\u037e141(2)(suppl):e24S\u00ade43S\n132. Goldhaber\u00a0SZ,\u00a0Haire\u00a0WD,\u00a0Feldstein\u00a0ML,\u00a0et\u00a0al. Aleptase\u00a0versus\u00a0heparin\u00a0in\u00a0acute\u00a0pulmonary\nembolism:\u00a0randomized\u00a0trial\u00a0assessing\u00a0right\u00adventricular\u00a0function\u00a0and\u00a0pulmonary\u00a0perfusion.", "chunk_order": 98}
{"chunk_id": "c964d380-e06d-462d-8d88-541d657c0008", "source_document_filename": "CPG Prevention and Treatment of Venous Thrombosis_cleaned_ultra_minimal.txt", "source_document_title": "CPG Prevention and Treatment of Venous Thrombosis cleaned ultra minimal", "text": "Fondaparinux\u00a0or\nenoxaparin\u00a0 for\u00a0 the\u00a0 initial\u00a0 treatment\u00a0 of\u00a0 symptomatic\u00a0 deep\u00a0 venous\u00a0 thrombosis:\u00a0 a\nrandomized\u00a0trial. Ann\u00a0Intern\u00a0Med\u00a02004\u037e140(11):867\u00ad873\n130. The\nEINSTEIN\nInvestigators. Oral\nRivaroxaban\nfor\nSymptomatic\nVenous\nThromboembolism. N\u00a0Engl\u00a0J\u00a0Med\u00a02010\u037e363:2499\u00ad2510\n131. Garcia\u00a0DA,\u00a0Baglin\u00a0TP,\u00a0Weitz\u00a0JI,\u00a0MM\u00a0Samama. Parenteral\u00a0Anticoagulants:\u00a0antithrombotic\ntherapy\u00a0 and\u00a0 prevention\u00a0 of\u00a0 thrombosis,\u00a0 9th\u00a0 ed:\u00a0American\u00a0 College\u00a0 of\u00a0 Chest\u00a0 Physicians\nevidence\u00adbased\u00a0clinical\u00a0practice\u00a0guidelines. Chest\u00a02012\u037e141(2)(suppl):e24S\u00ade43S\n132. Goldhaber\u00a0SZ,\u00a0Haire\u00a0WD,\u00a0Feldstein\u00a0ML,\u00a0et\u00a0al. Aleptase\u00a0versus\u00a0heparin\u00a0in\u00a0acute\u00a0pulmonary\nembolism:\u00a0randomized\u00a0trial\u00a0assessing\u00a0right\u00adventricular\u00a0function\u00a0and\u00a0pulmonary\u00a0perfusion. Lancet\u00a01993\u037e341:507\u00ad511\n133. Hull\u00a0 RD,\u00a0 Raskob\u00a0 GL,\u00a0 Pineo\u00a0 GF,\u00a0 et\u00a0 al:\u00a0 Subcutaneous\u00a0 low\u00admolecular\u00adweight\u00a0 heparin\ncompared\u00a0 with\u00a0 continuous\u00a0 intravenous\u00a0 heparin\u00a0 in\u00a0 the\u00a0 treatment\u00a0 of\u00a0 proximal\u00a0 vein\nthrombosis. N\u00a0Engl\u00a0J\u00a0Med\u00a01992\u037e326:975\u00ad982\n134. Kearon\u00a0 C,\u00a0 Akl\u00a0 EA,\u00a0 Comerota\u00a0 AJ,\u00a0 et\u00a0 al. Antithrombotic\u00a0 therapy\u00a0 for\u00a0 VTE\u00a0 disease:\nantithrombotic\u00a0therapy\u00a0and\u00a0prevention\u00a0of\u00a0thrombosis,\u00a09th\u00a0ed:\u00a0American\u00a0College\u00a0of\u00a0Chest\nPhysicians\nevidence\u00adbased\nclinical\npractice\nguidelines. Chest\n2012\u037e141(2)\n(suppl):e419S\u00ade494S\n135. Merli\u00a0 G,\u00a0 Spiro\u00a0 TE,\u00a0 Olsson\u00a0 C\u00adG,\u00a0 et\u00a0 al:\u00a0 Subcutaneous\u00a0 enoxaparin\u00a0 once\u00a0 or\u00a0 twice\u00a0 daily\ncompared\nwith\nintravenous\nunfractionated\nheparin\nfor\ntreatment\nof\nvenous\nthromboembolic\u00a0disease. Ann\u00a0Intern\u00a0Med\u00a02001\u037e134:191\u00ad202\n136. NICE\u00a0clinical\u00a0guideline. Venous\u00a0thromboembolic\u00a0diseases:\u00a0the\u00a0management\u00a0of\u00a0venous\nthromboembolic\u00a0diseases\u00a0and\u00a0the\u00a0role\u00a0of\u00a0thrombophilia\u00a0testing,\u00a0June\u00a02012\n137. Nigel\u00a0SK,\u00a0Raj\u00a0SK. Current\u00a0Treatment\u00a0of\u00a0Venous\u00a0Thromboembolism. Arterioscler\u00a0Thromb\nVasc\u00a0Biol\u00a02010\u037e30:372\u00ad375\n138. Prandoni\u00a0 P,\u00a0 Lensing\u00a0AW,\u00a0 Buller\u00a0 HR,\u00a0 Carta\u00a0 M,\u00a0 Cogo\u00a0A,\u00a0 Vigo\u00a0 M\u00a0 et\u00a0 al. Comparison\u00a0 of\nsubcutaneous\u00a0 low\u00admolecular\u00adweight\u00a0 heparin\u00a0 with\u00a0 intravenous\u00a0 standard\u00a0 heparin\u00a0 in\nproximal\u00a0deep\u00advein\u00a0thrombosis. Lancet\u00a01992\u037e339(8791):441\u00ad445\n139. Segal\u00a0 jB,\u00a0 Streiff\u00a0 MB,\u00a0 Hofmann\u00a0 LV,\u00a0 Thornton\u00a0 K,\u00a0 Bass\u00a0 EB. Management\u00a0 of\u00a0 venous\nthromboembolism:\u00a0 a\u00a0 systematic\u00a0 review\u00a0 for\u00a0 a\u00a0 practice\u00a0 guideline. Ann\u00a0 Intern\u00a0 Med\n2007\u037e146(3):211\u00ad22\n140. Agnelli\u00a0G,\u00a0Becattini\u00a0C. Treatment\u00a0of\u00a0DVT:\u00a0how\u00a0long\u00a0is\u00a0enough\u00a0and\u00a0how\u00a0do\u00a0you\u00a0predict\nrecurrence. J\u00a0Thromb\u00a0Thrombolysis\u00a02008\u037e25:37\u00ad44\n141. Bauer\u00a0KA. Duration\u00a0of\u00a0Anticoagulation:\u00a0Applying\u00a0the\u00a0Guidelines\u00a0and\u00a0Beyond. Hematology\n2010\u037e21\u00ad15\n142. Eichinger\u00a0 S,\u00a0 Kyrle\u00a0 PA. Duration\u00a0 of\u00a0 anticoagulation\u00a0 after\u00a0 initial\u00a0 idiopathic\u00a0 venous\nthrombosis\u00a0\u2013\u00a0the\u00a0swinging\u00a0pendulum:\u00a0risk\u00a0assessment\u00a0to\u00a0predict\u00a0recurrence. J\u00a0Thromb\nHaemost\u00a02009\u037e\u00a07(suppl. 1):\u00a0291\u00ad295\n143. Kearon\u00a0 C,\u00a0 Akl\u00a0 EA,\u00a0 Comerota\u00a0 AJ,\u00a0 et\u00a0 al. Antithrombotic\u00a0 Therapy\u00a0 for\u00a0 VTE\u00a0 Disease:\nAntithrombotic\u00a0Therapy\u00a0and\u00a0Prevention\u00a0of\u00a0Thrombosis,\u00a09th\u00a0ed:\u00a0American\u00a0College\u00a0of\u00a0Chest\nPhysicians\u00a0Evidence\u00adBased\u00a0Clinical\u00a0Practice\u00a0Guidelines. Chest\u00a02012\u037e141\u037ee419S\u00ade494S\n144. Kyrle\u00a0PA,\u00a0Minar\u00a0E,\u00a0Bialonczyk\u00a0C,\u00a0et\u00a0al. The\u00a0risk\u00a0of\u00a0recurrent\u00a0venous\u00a0thromboembolism\u00a0in\nmen\u00a0and\u00a0women. N\u00a0Engl\u00a0J\u00a0Med\u00a02004\u037e350:2558\u00ad2563\n145. McRae\u00a0S,\u00a0Tran\u00a0H,\u00a0Schulman\u00a0S,\u00a0et\u00a0al. Effect\u00a0of\u00a0patient\u2019s\u00a0sex\u00a0on\u00a0risk\u00a0of\u00a0recurrent\u00a0venous\nthromboembolism:\u00a0a\u00a0meta\u00adanalysis. Lancet\u00a02006\u037e368:371\u00ad378\n146. Prandoni\u00a0P,\u00a0Lensing\u00a0AW,\u00a0Cogo\u00a0A,\u00a0et\u00a0al. The\u00a0long\u00adterm\u00a0clinical\u00a0course\u00a0of\u00a0acute\u00a0deep\u00a0venous\nthrombosis. Ann\u00a0Intern\u00a0Med\u00a01996\u037e125:1\u00ad7\n147. Prandoni\u00a0P,\u00a0Noventa\u00a0F,\u00a0Ghirarduzzi\u00a0A,\u00a0et\u00a0al. The\u00a0risk\u00a0of\u00a0recurrent\u00a0thromboembolism\u00a0after\ndiscontinuing\u00a0 anticoagulation\u00a0 in\u00a0 patients\u00a0 with\u00a0 acute\u00a0 proximal\u00a0 deep\u00a0 vein\u00a0 thrombosis\u00a0 or\npulmonary\u00a0 embolism. A\u00a0 prospective\u00a0 cohort\u00a0 study\u00a0 in\u00a0 1,626\u00a0 patients. Haematologica\n2007\u037e92:199\u00ad205\n148. Adam\u00a0 DJ\u00a0 and\u00a0 Ruckley\u00a0 CV. Venous\u00a0 thromboembolism. Essential\u00a0 Surgical\u00a0 Practice,\u00a0 4th\nEdition,\u00a0Cuschieri\u00a0A,\u00a0Steele\u00a0RJC,\u00a0Moosa\u00a0AR\u00a0(Eds).", "chunk_order": 99}
{"chunk_id": "18ef227f-0cca-4a73-b64d-e46a4db629f5", "source_document_filename": "CPG Prevention and Treatment of Venous Thrombosis_cleaned_ultra_minimal.txt", "source_document_title": "CPG Prevention and Treatment of Venous Thrombosis cleaned ultra minimal", "text": "Effect\u00a0of\u00a0patient\u2019s\u00a0sex\u00a0on\u00a0risk\u00a0of\u00a0recurrent\u00a0venous\nthromboembolism:\u00a0a\u00a0meta\u00adanalysis. Lancet\u00a02006\u037e368:371\u00ad378\n146. Prandoni\u00a0P,\u00a0Lensing\u00a0AW,\u00a0Cogo\u00a0A,\u00a0et\u00a0al. The\u00a0long\u00adterm\u00a0clinical\u00a0course\u00a0of\u00a0acute\u00a0deep\u00a0venous\nthrombosis. Ann\u00a0Intern\u00a0Med\u00a01996\u037e125:1\u00ad7\n147. Prandoni\u00a0P,\u00a0Noventa\u00a0F,\u00a0Ghirarduzzi\u00a0A,\u00a0et\u00a0al. The\u00a0risk\u00a0of\u00a0recurrent\u00a0thromboembolism\u00a0after\ndiscontinuing\u00a0 anticoagulation\u00a0 in\u00a0 patients\u00a0 with\u00a0 acute\u00a0 proximal\u00a0 deep\u00a0 vein\u00a0 thrombosis\u00a0 or\npulmonary\u00a0 embolism. A\u00a0 prospective\u00a0 cohort\u00a0 study\u00a0 in\u00a0 1,626\u00a0 patients. Haematologica\n2007\u037e92:199\u00ad205\n148. Adam\u00a0 DJ\u00a0 and\u00a0 Ruckley\u00a0 CV. Venous\u00a0 thromboembolism. Essential\u00a0 Surgical\u00a0 Practice,\u00a0 4th\nEdition,\u00a0Cuschieri\u00a0A,\u00a0Steele\u00a0RJC,\u00a0Moosa\u00a0AR\u00a0(Eds). Arnold\u00a02002\u037e869\u00ad878\n149. Hirsh\u00a0J,\u00a0Warketin\u00a0TE,\u00a0Shaughnessy\u00a0SG.,\u00a0Anand\u00a0SS.,\u00a0Halperin\u00a0\u00a0JL.,\u00a0Raschke\u00a0R.,\u00a0Granger\nC.,\u00a0Othman\u00a0EM.,\u00a0and\u00a0Dalen\u00a0JE.,\u00a0(2001),\u00a0Heparin\u00a0and\u00a0Low\u00a0Molecular\u00a0Weight\u00a0Heparin\u00a0\u2013\nMechanisms\u00a0of\u00a0Action,\u00a0Pharmacokinetics,\u00a0Dosing,\u00a0Monitoring,\u00a0Efficacy\u00a0and\u00a0Safety,\u00a0Chest\n2001\u037e119:64S\u00ad94S\n150. Goldhaber\u00a0 SZ. Thrombolysis\u00a0 for\u00a0 pulmonary\u00a0 embolism. Prog\u00a0 Cardiovasc\u00a0 Dis\u00a0 1991\u037e\n34:113\u00ad134\n151. Molina\u00a0JE,\u00a0Hunter\u00a0DW,\u00a0Yedlick\u00a0JW,\u00a0et\u00a0al. Thrombolytic\u00a0therapy\u00a0for\u00a0the\u00a0treatment\u00a0of\u00a0acute\npulmonary\u00a0embolism. Can\u00a0Med\u00a0Assoc\u00a0J\u00a01992\u037e146:1317\u00ad1324\n152. Bjarnason\u00a0H,\u00a0Kruse\u00a0JR,\u00a0Asinger\u00a0DA,\u00a0et\u00a0al. Iliofemoral\u00a0deep\u00a0venous\u00a0thrombosis:\u00a0safety\u00a0and\nefficacy\u00a0outcome\u00a0during\u00a05\u00a0years\u00a0of\u00a0catheter\u00a0directed\u00a0thrombolytic\u00a0therapy. J\u00a0Vasc\u00a0Intervent\nRadiology\u00a01997\u037e8:405\u00ad18\n153. Benotti\u00a0 JR,\u00a0 Dalen\u00a0 JE. The\u00a0 Natural\u00a0 History\u00a0 Of\u00a0 Pulmonary\u00a0 Embolism. Clin\u00a0 Chest\u00a0 Med\n1984\u037e5:403\u00ad410\n154. Plate\u00a0G,\u00a0Eklof\u00a0B,\u00a0Norgren\u00a0L,\u00a0et\u00a0al. Venous\u00a0thrombectomy\u00a0for\u00a0Illiofemoral\u00a0vein\u00a0thrombosis\u00a0\u2013\n10\u00a0 year\u00a0 results\u00a0 of\u00a0 a\u00a0 propective\u00a0 randomised\u00a0 study. Eur\u00a0 J\u00a0 Vasc\u00a0 Endovasc\u00a0 Surg\u00a0 1997\u037e\n14(5):367\u00ad374\n155. Ivan\u00a0A\u037e\u00a0Markus\u00a0K\u037e\u00a0Ulf\u00a0H\u037e\u00a0et\u00a0al. \"Chirurgische\u00a0Therapie\u00a0der\u00a0fulminanten\u00a0Lungenembolie\n[Surgical\u00a0 treatment\u00a0 for\u00a0 massive\u00a0 pulmonary\u00a0 embolism]\"\u00a0 (in\u00a0 German). Herz\u00a0 2005\u037e\n30(4):269\u00ad273\n156. Gupta\u00a0 S,\u00a0 Gupta\u00a0 BM. Acute\u00a0 pulmonary\u00a0 embolism\u00a0 advances\u00a0 in\u00a0 treatment. J\u00a0 Assoc\nPhysicians\u00a0India\u00a02008\u037e56:185\u00ad91\n157. Sanchez\u00a0O,\u00a0Planquette\u00a0B,\u00a0Wermert\u00a0D\u00a0\"Emboliespulmonaires\u00a0graves\u00a0[Massive\u00a0pulmonary\nembolism]\"\u00a0(in\u00a0French). Presse\u00a0Med\u00a02008\u037e37(10):1439\u00ad46\n158. Platts\u00a0 A,\u00a0 Preston\u00a0 E,\u00a0 Watkinson\u00a0 A. Diagnosis\u00a0 and\u00a0 Management\u00a0 of\u00a0 Complex\u00a0 Venous\nThromboembolic\u00a0 disease\u00a0 of\u00a0 The\u00a0 Lower\u00a0 Limb. A\u00a0 Companion\u00a0 to\u00a0 Specialist\u00a0 Surgical\nPractice:\u00a0Vascular\u00a0and\u00a0Endovascular\u00a0Surgery,\u00a03rd\u00a0Ed. Elsevier\u00a0Limited\u00a02006\u037e340\u00ad344\n159. Greenfield\u00a0 LJ,\u00a0 Rutherford\u00a0 RB. Recommended\u00a0 reporting\u00a0 standards\u00a0 for\u00a0 vena\u00a0 caval\u00a0 filter\nplacement\u00a0and\u00a0patient\u00a0follow\u00adup:\u00a0Vena\u00a0cava\u00a0filter\u00a0consensus\u00a0conference. J\u00a0Vasc\u00a0Interv\nRadiol\u00a01999\u037e10:1013\u00ad1019\n160. Streiff\u00a0MB. Vena\u00a0Caval\u00a0Filters:\u00a0A\u00a0Comprehensive\u00a0review. Blood\u00a02000\u037e95(12):3669\u00ad3677\n161. Abenhaim\u00a0L,\u00a0Kurz\u00a0X,\u00a0Nargren\u00a0L. The\u00a0management\u00a0of\u00a0chronic\u00a0venous\u00a0disorders\u00a0of\u00a0the\u00a0leg\nPhlebology\u00a01999\u037e14\u00a0Suppl(1)1\u00ad26\n162. Pradoni\u00a0R,\u00a0Prensing\u00a0AWA,\u00a0Cogo\u00a0A. The\u00a0Long\u00a0Term\u00a0Course\u00a0of\u00a0Acute\u00a0DVT. Ann\u00a0Intern\u00a0Med\n1996\u037e125:1\u00ad7\n163. Scottish\u00a0 Intercollegiate\u00a0 Guidelines\u00a0 Netweork\u00a0 (SIGN):\u00a0 Prevention\u00a0 and\u00a0 Management\u00a0 of\nVenous\u00a0Thromboembolism,\u00a0A\u00a0National\u00a0Clinical\u00a0Guidelines. December\u00a02010\n164. Sachdeva\u00a0A,\u00a0Dalton\u00a0M,\u00a0Amaragiri\u00a0SV,\u00a0Lees\u00a0T. Elastic\u00a0compression\u00a0stockings\u00a0for\u00a0prevention\nof\u00a0deep\u00a0vein\u00a0thrombosis. Cochrane\u00a0Database\u00a0Syst\u00a0Rev\u00a02010\u037e(7):CD001484\n165. Baglin\u00a0T,\u00a0Barrowcliffe\u00a0TW,\u00a0Cohen\u00a0A,\u00a0Greaves\u00a0M. Guidelines\u00a0on\u00a0the\u00a0use\u00a0and\u00a0monitoring\u00a0of\nheparin. Bri\u00a0Soc\u00a0Haematol\u00a02006\u037e133:19\u00ad34\n166. Brill\u00adEdwards,\u00a0P,\u00a0Ginsberg,\u00a0J,\u00a0Johnston\u00a0M,\u00a0Hirsh,\u00a0J. Establishing\u00a0a\u00a0therapeutic\u00a0range\u00a0for\nheparin\u00a0therapy. Annal\u00a0Intern\u00a0Med\u00a01993\u037e119:169\u00ad170\n167.", "chunk_order": 100}
{"chunk_id": "daa004c6-b34d-41dc-bebe-fa9c82a72ed9", "source_document_filename": "CPG Prevention and Treatment of Venous Thrombosis_cleaned_ultra_minimal.txt", "source_document_title": "CPG Prevention and Treatment of Venous Thrombosis cleaned ultra minimal", "text": "Pradoni\u00a0R,\u00a0Prensing\u00a0AWA,\u00a0Cogo\u00a0A. The\u00a0Long\u00a0Term\u00a0Course\u00a0of\u00a0Acute\u00a0DVT. Ann\u00a0Intern\u00a0Med\n1996\u037e125:1\u00ad7\n163. Scottish\u00a0 Intercollegiate\u00a0 Guidelines\u00a0 Netweork\u00a0 (SIGN):\u00a0 Prevention\u00a0 and\u00a0 Management\u00a0 of\nVenous\u00a0Thromboembolism,\u00a0A\u00a0National\u00a0Clinical\u00a0Guidelines. December\u00a02010\n164. Sachdeva\u00a0A,\u00a0Dalton\u00a0M,\u00a0Amaragiri\u00a0SV,\u00a0Lees\u00a0T. Elastic\u00a0compression\u00a0stockings\u00a0for\u00a0prevention\nof\u00a0deep\u00a0vein\u00a0thrombosis. Cochrane\u00a0Database\u00a0Syst\u00a0Rev\u00a02010\u037e(7):CD001484\n165. Baglin\u00a0T,\u00a0Barrowcliffe\u00a0TW,\u00a0Cohen\u00a0A,\u00a0Greaves\u00a0M. Guidelines\u00a0on\u00a0the\u00a0use\u00a0and\u00a0monitoring\u00a0of\nheparin. Bri\u00a0Soc\u00a0Haematol\u00a02006\u037e133:19\u00ad34\n166. Brill\u00adEdwards,\u00a0P,\u00a0Ginsberg,\u00a0J,\u00a0Johnston\u00a0M,\u00a0Hirsh,\u00a0J. Establishing\u00a0a\u00a0therapeutic\u00a0range\u00a0for\nheparin\u00a0therapy. Annal\u00a0Intern\u00a0Med\u00a01993\u037e119:169\u00ad170\n167. Chunilal\u00a0SD,\u00a0Young\u00a0E,\u00a0Johnston\u00a0MA,\u00a0et\u00a0al. The\u00a0APTT\u00a0Response\u00a0of\u00a0Pregnant\u00a0Plasma\u00a0to\nUnfractionated\u00a0Heparin. Thromb\u00a0Haemost\u00a02001\u037e87:92\u00ad7\n168. Cuker\u00a0A,\u00a0Raby\u00a0A,\u00a0Moffat\u00a0KA,\u00a0et\u00a0al. Interlaboratory\u00a0variation\u00a0in\u00a0heparin\u00a0monitoring:\u00a0Lessons\nfrom\u00a0the\u00a0Quality\u00a0Management\u00a0Program\u00a0of\u00a0Ontario\u00a0coagulation\u00a0surveys. Thromb\u00a0Haemost\n2010\u037e104:837\u00ad844\n169. Hirsh\u00a0 J,\u00a0 Raschke\u00a0 R. Heparin\u00a0 and\u00a0 low\u00admolecular\u00adweight\u00a0 heparin. The\u00a0 Seventh\u00a0 ACCP\nConference\u00a0on\u00a0Antithrombotic\u00a0and\u00a0Thrombolytic\u00a0Therapy. Chest\u00a02004\u037e126:188S\u00ad203S\n170. Kearon\u00a0C,\u00a0Kahn\u00a0SR,\u00a0Agnelli\u00a0G,\u00a0et\u00a0al. Anti\u00ad\u00a0thrombotic\u00a0therapy\u00a0for\u00a0venous\u00a0thromboembolic\ndisease:\u00a0 American\u00a0 College\u00a0 of\u00a0 Chest\u00a0 Physicians\u00a0 Evidence\u00adBased\u00a0 Clinical\u00a0 Practice\nGuidelines\u00a0(8th\u00a0Edition). Chest\u00a02008\u037e133:454S\u00ad545S\n171. Keeling\u00a0D,\u00a0Baglin\u00a0T,\u00a0Tait\u00a0C,\u00a0et\u00a0al. Guidelines\u00a0on\u00a0oral\u00a0anticoagulation\u00a0with\u00a0warfarin\u00a0\u00ad\u00a0fourth\nedition. Br\u00a0J\u00a0Haematol\u00a02011\u037e154(3):311\u00ad24\n172. Kitchen\u00a0S,\u00a0Theaker\u00a0J,\u00a0Preston\u00a0FE. Monitoring\u00a0unfractionated\u00a0heparin\u00a0therapy:\u00a0relationship\nbetween\u00a0 eight\u00a0 anti\u00adXa\u00a0 assays\u00a0 and\u00a0 a\u00a0 protamine\u00a0 titration\u00a0 assay. Blood\u00a0 Coag\u00a0 Fibrinol\n2002\u037e11:137\u00ad144\n173. Kovacs\u00a0MJ,\u00a0Keeney\u00a0M,\u00a0MacKinnon\u00a0K,\u00a0Boyle\u00a0E. Three\u00a0different\u00a0chromogenic\u00a0methods\u00a0do\nnot\u00a0 give\u00a0 equivalent\u00a0 anti\u00adXa\u00a0 levels\u00a0 for\u00a0 patients\u00a0 on\u00a0 therapeutic\u00a0 low\u00a0 molecular\u00a0 weight\u00a0 or\nunfractionated\u00a0heparin. Clin\u00a0Lab\u00a0Haematol\u00a01999\u037e21:55\u00ad60\n174. Levine\u00a0 MN,\u00a0 Hirsh\u00a0 J,\u00a0 Gent\u00a0 M,\u00a0 et\u00a0 al. A\u00a0 randomized\u00a0 trial\u00a0 comparing\u00a0 the\u00a0 activated\nthromboplastin\u00a0 time\u00a0 with\u00a0 the\u00a0 heparin\u00a0 assay\u00a0 in\u00a0 patients\u00a0 with\u00a0 acute\u00a0 venous\nthromboembolism\u00a0requiring\u00a0large\u00a0daily\u00a0doses\u00a0of\u00a0heparin. Arch\u00a0Intern\u00a0Med\u00a01994\u037e154:49\u00ad56\n175. Schulman\u00a0S,\u00a0\u00a0Parpia\u00a0S,\u00a0\u00a0Stewart\u00a0C,\u00a0\u00a0et\u00a0al. Warfarin\u00a0dose\u00a0assessment\u00a0every\u00a04\u00a0weeks\u00a0versus\nevery\u00a012\u00a0weeks\u00a0in\u00a0patients\u00a0with\u00a0stable\u00a0international\u00a0normalized\u00a0ratios:\u00a0a\u00a0randomized\u00a0trial. Ann\u00a0Intern\u00a0Med\u00a02011\u037e155(10):653\u00ad659\n176. Smith\u00a0ML,\u00a0Wheeler\u00a0KE. Weight\u00adbased\u00a0heparin\u00a0protocol\u00a0using\u00a0anti\u00adfactor\u00a0Xa\u00a0monitoring. Am\u00a0J\u00a0Health\u00adSyst\u00a0Pharm\u00a02010\u037e67:371\u00ad4\n177. Van\u00a0 den\u00a0 Besselaar\u00a0AMHP,\u00a0 Meevwisse\u00adBraun\u00a0 J,\u00a0 Jansen\u00adGruter\u00a0 R,\u00a0 Bertina\u00a0 RM\u00a0 (1987)\nMonitoring\u00a0heparin\u00a0therapy\u00a0by\u00a0the\u00a0APTT\u00a0\u00ad\u00a0the\u00a0effect\u00a0of\u00a0pre\u00adanalytical\u00a0conditions. Thromb\nHaemost\u00a01987\u037e57:226\u00ad231\n178. Kearon\u00a0C,\u00a0Hirsch\u00a0J. Management\u00a0of\u00a0Anticoagulation\u00a0Before\u00a0and\u00a0After\u00a0Elective\u00a0Surgery. N\nEngl\u00a0J\u00a0Med\u00a01997\u037e1506\u00ad1511\n179. Dunn\u00a0 AS,\u00a0 Turpie\u00a0 AGG. Perioperative\u00a0 Management\u00a0 of\u00a0 Patients\u00a0 Receiving\u00a0 Oral\nAnticoagulants:\u00a0A\u00a0Systematic\u00a0Review. Arch\u00a0Intern\u00a0Med\u00a02003\u037e163:901\u00ad908\n180. Garg\u00a0P,\u00a0House\u00a0J,\u00a0Rana\u00a0F. Management\u00a0of\u00a0Anticoagulation\u00a0in\u00a0the\u00a0Perioperative\u00a0Period. Northeast\u00a0Florida\u00a0Medicine\u00a02008\u037e59:28\u00ad30\n181. Douketis\u00a0JD. Perioperative\u00a0management\u00a0of\u00a0patients\u00a0who\u00a0are\u00a0receiving\u00a0warfarin\u00a0therapy:\nan\u00a0evidence\u00adbased\u00a0and\u00a0practical\u00a0approach. Blood\u00a02011\u037e117:5044\u00ad5049\n182. Douketis\u00a0JD,\u00a0Spyropoulos\u00a0AC,\u00a0Spencer\u00a0FA,\u00a0et\u00a0al. Antithrombotic\u00a0Therapy\u00a0and\u00a0Prevention\nof\u00a0Thrombosis,\u00a09th\u00a0ed:\u00a0American\u00a0College\u00a0of\u00a0Chest\u00a0Physicians\u00a0Evidence\u00adBased\u00a0Clinical\nPractice\u00a0Guidelines. Chest\u00a02012\u037e141(2)(Suppl):e326S\u00ade350S\n183.", "chunk_order": 101}
{"chunk_id": "8d16c02e-19b2-4c2a-b4ed-e716f6415631", "source_document_filename": "CPG Prevention and Treatment of Venous Thrombosis_cleaned_ultra_minimal.txt", "source_document_title": "CPG Prevention and Treatment of Venous Thrombosis cleaned ultra minimal", "text": "Management\u00a0of\u00a0Anticoagulation\u00a0Before\u00a0and\u00a0After\u00a0Elective\u00a0Surgery. N\nEngl\u00a0J\u00a0Med\u00a01997\u037e1506\u00ad1511\n179. Dunn\u00a0 AS,\u00a0 Turpie\u00a0 AGG. Perioperative\u00a0 Management\u00a0 of\u00a0 Patients\u00a0 Receiving\u00a0 Oral\nAnticoagulants:\u00a0A\u00a0Systematic\u00a0Review. Arch\u00a0Intern\u00a0Med\u00a02003\u037e163:901\u00ad908\n180. Garg\u00a0P,\u00a0House\u00a0J,\u00a0Rana\u00a0F. Management\u00a0of\u00a0Anticoagulation\u00a0in\u00a0the\u00a0Perioperative\u00a0Period. Northeast\u00a0Florida\u00a0Medicine\u00a02008\u037e59:28\u00ad30\n181. Douketis\u00a0JD. Perioperative\u00a0management\u00a0of\u00a0patients\u00a0who\u00a0are\u00a0receiving\u00a0warfarin\u00a0therapy:\nan\u00a0evidence\u00adbased\u00a0and\u00a0practical\u00a0approach. Blood\u00a02011\u037e117:5044\u00ad5049\n182. Douketis\u00a0JD,\u00a0Spyropoulos\u00a0AC,\u00a0Spencer\u00a0FA,\u00a0et\u00a0al. Antithrombotic\u00a0Therapy\u00a0and\u00a0Prevention\nof\u00a0Thrombosis,\u00a09th\u00a0ed:\u00a0American\u00a0College\u00a0of\u00a0Chest\u00a0Physicians\u00a0Evidence\u00adBased\u00a0Clinical\nPractice\u00a0Guidelines. Chest\u00a02012\u037e141(2)(Suppl):e326S\u00ade350S\n183. Spyropoulos\u00a0AC,\u00a0 Bauersachs\u00a0 RM,\u00a0 Omran\u00a0 H,\u00a0 et\u00a0 al. Periprocedural\u00a0 bridging\u00a0 therapy\u00a0 in\npatients\u00a0 receiving\u00a0 chronic\u00a0 oral\u00a0 anticoagulation\u00a0 therapy. Curr\u00a0 Med\u00a0 Res\u00a0 Opin\u00a0 2006\u037e\n22(6):1109\u00ad1122\n184. Bauer\u00a0KA. New\u00a0anticoagulants. Curr\u00a0Opin\u00a0Hematol\u00a02008\u037e15:509\u00ad515\n185. Makris\u00a0 M,\u00a0 Graves\u00a0 M,\u00a0 Phillips\u00a0 WS,\u00a0 et\u00a0 al. Emergency\u00a0 oral\u00a0 anticoagulant\u00a0 reversal:\u00a0 The\nrelative\u00a0 efficacy\u00a0 of\u00a0 infusions\u00a0 of\u00a0 fresh\u00a0 frozen\u00a0 plasma\u00a0 and\u00a0 clotting\u00a0 factor\u00a0 concentrate\u00a0 on\ncorrection\u00a0of\u00a0the\u00a0coagulopathy. Thromb\u00a0Haemost\u00a01997\u037e77:477\u00ad80\n186. Dentali\u00a0 F,\u00a0Ageno\u00a0 W,\u00a0 Crowther\u00a0 M. Treatment\u00a0 of\u00a0 coumarin\u00adassociated\u00a0 coagulopathy:\u00a0 a\nsystemic\u00a0review\u00a0and\u00a0proposed\u00a0algorithms. J\u00a0Thromb\u00a0Haemost\u00a02006\u037e4:1853\u00ad1863\n187. Lankiewicz\u00a0MW,\u00a0Hays\u00a0Y,\u00a0Friedman\u00a0KD,\u00a0et\u00a0al. Urgent\u00a0reversal\u00a0of\u00a0warfarin\u00a0with\u00a0prothrombin\ncomplex\u00a0concentrate. J\u00a0Thromb\u00a0Haemost\u00a02006\u037e4:967\u00ad970\n188. Thachil\u00a0J,\u00a0Gatt\u00a0A,\u00a0Martlew\u00a0V. Management\u00a0of\u00a0surgical\u00a0patients\u00a0receiving\u00a0anticoagulation\nand\u00a0antiplatelet\u00a0agents. Br\u00a0J\u00a0Surg\u00a02008\u037e95:1437\u00ad1448\n189. White\u00a0 RH,\u00a0 McKittrick\u00a0 T,\u00a0 Hutchinson\u00a0 R,\u00a0 et\u00a0 al. Temporary\u00a0 discontinuation\u00a0 of\u00a0 warfarin\ntherapy:\u00a0changes\u00a0in\u00a0the\u00a0international\u00a0normalized\u00a0ratio. Ann\u00a0Intern\u00a0Med\u00a01995\u037e122(1):40\u00ad42\n190. Docket\u2019s\u00a0 JD,\u00a0 Johnson\u00a0 JA,\u00a0 Turpie\u00a0 AG. Low\u00a0 molecular\u00adweight\u00a0 heparin\u00a0 as\u00a0 bridging\nanticoagulation\u00a0 during\u00a0 interruption\u00a0 of\u00a0 warfarin:\u00a0 assessment\u00a0 of\u00a0 a\u00a0 standardised\nperiprocedural\u00a0anticoagulation\u00a0therapy\u00a0in\u00a0patients\u00a0on\u00a0long\u00adterm\u00a0oral\u00a0anticoagulants\u00a0who\nrequire\u00a0surgery:\u00a0the\u00a0Prospective\u00a0Peri\u00adoperative\u00a0Enoxaparin\u00a0Cohort\u00a0Trial\u00a0(PROSPECT). J\nThromb\u00a0Haemost\u00a02007\u037e5(11):2211\u00ad2218\n191. Dunn\u00a0 AS,\u00a0 Spyropoulos\u00a0 A,\u00a0 Turpie\u00a0 AG. Bridging\u00a0 therapy\u00a0 in\u00a0 patients\u00a0 on\u00a0 long\u00adterm\u00a0 oral\nanticoagulants\u00a0 who\u00a0 require\u00a0 surgery:\u00a0 the\u00a0 Prospective\u00a0 Perioperative\u00a0 Enoxaparin\u00a0 Cohort\nTrial\u00a0(PROSPECT). J\u00a0Thromb\u00a0Haemost\u00a02007\u037e5(11):2211\u00ad2218\n192. Douketis\nJD,\nWoods\nK,\nFoster\nGA,\net\nal. Bridging\nanticoagulation\nwith\nlow\u00admolecular\u00adweight\u00a0heparin\u00a0after\u00a0interruption\u00a0of\u00a0warfarin\u00a0therapy\u00a0is\u00a0associated\u00a0with\u00a0a\nresidual\u00a0anticoagulant\u00a0effect\u00a0prior\u00a0to\u00a0surgery. Thromb\u00a0Haemost\u00a02005\u037e94(3):528\u00ad531\n193. Jamula\u00a0E,\u00a0Anderson\u00a0J,\u00a0Douketis\u00a0JD,\u00a0et\u00a0al. Safety\u00a0of\u00a0continuing\u00a0warfarin\u00a0therapy\u00a0during\ncataract\u00a0 surgery:\u00a0 a\u00a0 systematic\u00a0 review\u00a0 and\u00a0 meta\u00adanalysis. Thromb\u00a0 Res\u00a0 2009\u037e\n124(3):292\u00ad299\n194. Pengo\u00a0V,\u00a0Cucchini\u00a0U,\u00a0Denas\u00a0G,\u00a0et\u00a0al. Standardised\u00a0low\u00admolecular\u00adweight\u00a0heparin\u00a0bridging\nregimen\u00a0in\u00a0outpatients\u00a0on\u00a0oral\u00a0anticoagulants\u00a0undergoing\u00a0invasive\u00a0procedure\u00a0or\u00a0surgery:\nan\u00a0inception\u00a0cohort\u00a0management\u00a0study. Circulation\u00a02009\u037e119(22):2920\u00ad2927\n195. Palareti\u00a0 G,\u00a0 Legnani\u00a0 C. Warfarin\u00a0 withdrawal:\u00a0 pharmacokinetic\u00adpharmacodynamic\nconsiderations. Clin\u00a0Pharmacokinet\u00a01996\u037e30(4):300\u00ad313\n196. Spyropoulos\u00a0AC,\u00a0 Turpie\u00a0AGG,\u00a0 Dunn\u00a0AS,\u00a0 et\u00a0 al. Clinical\u00a0 outcomes\u00a0 with\u00a0 unfractionated\nheparin\u00a0or\u00a0low\u00admolecular\u00adweight\u00a0heparin\u00a0as\u00a0bridging\u00a0therapy\u00a0in\u00a0patients\u00a0on\u00a0long\u00adterm\u00a0oral\nanticoagulants:\u00a0the\u00a0REGIMEN\u00a0registry. J\u00a0Thromb\u00a0Haemost\u00a02006\u037e4(6):1246\u00ad1252\n197. Douketis\u00a0JD. Perioperative\u00a0anticoagulation\u00a0management\u00a0in\u00a0patients\u00a0who\u00a0are\u00a0receiving\u00a0oral\nanticoagulant\u00a0therapy:\u00a0a\u00a0practical\u00a0guide\u00a0for\u00a0clinicians. Thromb\u00a0Res\u00a02003\u037e108:3\u00ad13\n198. Baker\u00a0 RI,\u00a0 Coughlin\u00a0 PB,\u00a0 Salem\u00a0 HH,\u00a0 et\u00a0 al.", "chunk_order": 102}
{"chunk_id": "b39038a5-cc66-4665-82b1-bd1d77e66b50", "source_document_filename": "CPG Prevention and Treatment of Venous Thrombosis_cleaned_ultra_minimal.txt", "source_document_title": "CPG Prevention and Treatment of Venous Thrombosis cleaned ultra minimal", "text": "Standardised\u00a0low\u00admolecular\u00adweight\u00a0heparin\u00a0bridging\nregimen\u00a0in\u00a0outpatients\u00a0on\u00a0oral\u00a0anticoagulants\u00a0undergoing\u00a0invasive\u00a0procedure\u00a0or\u00a0surgery:\nan\u00a0inception\u00a0cohort\u00a0management\u00a0study. Circulation\u00a02009\u037e119(22):2920\u00ad2927\n195. Palareti\u00a0 G,\u00a0 Legnani\u00a0 C. Warfarin\u00a0 withdrawal:\u00a0 pharmacokinetic\u00adpharmacodynamic\nconsiderations. Clin\u00a0Pharmacokinet\u00a01996\u037e30(4):300\u00ad313\n196. Spyropoulos\u00a0AC,\u00a0 Turpie\u00a0AGG,\u00a0 Dunn\u00a0AS,\u00a0 et\u00a0 al. Clinical\u00a0 outcomes\u00a0 with\u00a0 unfractionated\nheparin\u00a0or\u00a0low\u00admolecular\u00adweight\u00a0heparin\u00a0as\u00a0bridging\u00a0therapy\u00a0in\u00a0patients\u00a0on\u00a0long\u00adterm\u00a0oral\nanticoagulants:\u00a0the\u00a0REGIMEN\u00a0registry. J\u00a0Thromb\u00a0Haemost\u00a02006\u037e4(6):1246\u00ad1252\n197. Douketis\u00a0JD. Perioperative\u00a0anticoagulation\u00a0management\u00a0in\u00a0patients\u00a0who\u00a0are\u00a0receiving\u00a0oral\nanticoagulant\u00a0therapy:\u00a0a\u00a0practical\u00a0guide\u00a0for\u00a0clinicians. Thromb\u00a0Res\u00a02003\u037e108:3\u00ad13\n198. Baker\u00a0 RI,\u00a0 Coughlin\u00a0 PB,\u00a0 Salem\u00a0 HH,\u00a0 et\u00a0 al. Warfarin\u00a0 reversal:\u00a0 consensus\u00a0 guidelines,\u00a0 on\nbehalf\u00a0of\u00a0the\u00a0Australasian\u00a0Society\u00a0of\u00a0Thrombosis\u00a0and\u00a0Haemostasis. Med\u00a0J\u00a0Aust\u00a02001\u037e\n181(9):492\u00ad497\n199. Baker\u00a0 P,\u00a0 Gleghorn\u00a0A,\u00a0Tripp\u00a0T,\u00a0 et\u00a0 al. Reversal\u00a0 of\u00a0 asymptomatic\u00a0 over\u00adanticoagulation\u00a0 by\norally\u00a0administered\u00a0vitamin\u00a0K. Br\u00a0J\u00a0Haem\u00a02006\u037e133:331\u00ad336\n200. Crowther\u00a0MA,\u00a0Douketis\u00a0JD,\u00a0Schnurr\u00a0T. Oral\u00a0vitamin\u00a0K\u00a0lowers\u00a0the\u00a0international\u00a0normalized\nratio\u00a0more\u00a0rapidly\u00a0than\u00a0subcutaneous\u00a0vitamin\u00a0K\u00a0in\u00a0the\u00a0treatment\u00a0of\u00a0warfarin\u00adassociated\ncoagulopathy:\u00a0a\u00a0randomized\u00a0control\u00a0trial. Ann\u00a0Intern\u00a0Med\u00a02002\u037e137:251\u00ad254\n201. Crowther\u00a0MA,\u00a0Garcia\u00a0D,\u00a0Ageno\u00a0W,\u00a0et\u00a0al. Oral\u00a0vitamin\u00a0K\u00a0effectively\u00a0treats\u00a0INR\u00a0values\u00a0in\nexcess\u00a0of\u00a010. Results\u00a0of\u00a0prospective\u00a0cohort\u00a0study. Thromb\u00a0Haemost\u00a02010\u037e104:118\u00ad121\n202. Holland\u00a0L,\u00a0Warkentin\u00a0TE,\u00a0Refaai\u00a0M,\u00a0et\u00a0al. Suboptimal\u00a0effect\u00a0of\u00a0a\u00a0three\u00adfactor\u00a0prothrombin\ncomplex\u00a0 concentrate\u00a0 (Profilnine\u00adSD)\u00a0 in\u00a0 correcting\u00a0 supratherapeutic\u00a0 international\nnormalized\u00a0ratio\u00a0due\u00a0to\u00a0warfarin\u00a0overdose. Transfusion\u00a02009\u037e49:1171\u00ad1177\n203. Keeling\u00a0D,\u00a0Baglin\u00a0T,\u00a0Tait\u00a0C,\u00a0et\u00a0al. Guidelines\u00a0on\u00a0oral\u00a0anticoagulation\u00a0with\u00a0warfarin\u00a0\u00ad\u00a0fourth\nedition. Br\u00a0J\u00a0Haematol\u00a02011\u037e154(3):311\u00ad24\n204. Levine\u00a0MN,\u00a0Raskob\u00a0G,\u00a0Landefeld\u00a0S. Hemorrhagic\u00a0complications\u00a0of\u00a0anticoagulant\u00a0therapy. Chest\u00a01998\u037e114:511S\u00ad523S\n205. Makris\u00a0M,\u00a0Greaves\u00a0M,\u00a0Phillips\u00a0WS,\u00a0et\u00a0al. Emergency\u00a0oral\u00a0anticoagulant\u00a0reversal:\u00a0the\u00a0relative\nefficacy\u00a0of\u00a0infusions\u00a0of\u00a0fresh\u00a0frozen\u00a0plasma\u00a0and\u00a0clotting\u00a0factor\u00a0concentrate\u00a0on\u00a0correction\u00a0of\nthe\u00a0coagulopathy. Thromb\u00a0Haemost\u00a01997\u037e77:477\u00ad480\n206. Makris\u00a0M,\u00a0van\u00a0Veen\u00a0JJ,\u00a0Maclean\u00a0R. Warfarin\u00a0anticoagulation\u00a0reversal:\u00a0management\u00a0of\u00a0the\nasymptomatic\u00a0and\u00a0bleeding\u00a0patient. J\u00a0Thromb\u00a0Thrombolys\u00a02010\u037e29:171\u00ad181\n207. Pesaro\u00a0AE,\u00a0D\u2019Amico\u00a0E,\u00a0Aranha\u00a0FC. Dengue:\u00a0Cardiac\u00a0Manifestations\u00a0and\u00a0Implications\u00a0in\nAntithrombotic\u00a0Treatment. Arq\u00a0Bras\u00a0Cardiology\u00a02007\u037e89(2):e12\u00ade15\n208. Prowse\u00a0SJ,\u00a0Sloan\u00a0J. NICE\u00a0guidelines\u00a0for\u00a0the\u00a0investigation\u00a0of\u00a0head\u00a0injuries\u00a0\u00ad\u00a0an\u00a0anticoagulant\nloop\u00adhole. Emerg\u00a0Med\u00a0J\u00a02010\u037e27:277\u00ad278\n209. Raj\u00a0G,\u00a0Kumar\u00a0R,\u00a0McKinney\u00a0WP. Time\u00a0course\u00a0of\u00a0reversal\u00a0of\u00a0anticoagulant\u00a0effect\u00a0of\u00a0warfarin\nby\u00a0intravenous\u00a0and\u00a0subcutaneous\u00a0phytonadione. Arch\u00a0Intern\u00a0Med\u00a01999:159:2721\u00ad2724\n210. Rosovsky\u00a0RP,\u00a0Crowther\u00a0MA. What\u00a0is\u00a0the\u00a0evidence\u00a0for\u00a0the\u00a0off\u00adlabel\u00a0use\u00a0of\u00a0recombinant\u00a0factor\nVIIa\u00a0 (rFVIIa)\u00a0 in\u00a0 the\u00a0 acute\u00a0 reversal\u00a0 of\u00a0 warfarin. Am\u00a0 Soc\u00a0 Haematol\u00a0 Programme\u00a0 Book\n2008:36\u00ad38\n211. Watson\u00a0HG,\u00a0Baglin\u00a0T,\u00a0Laidlaw\u00a0SL,\u00a0et\u00a0al. A\u00a0comparison\u00a0of\u00a0the\u00a0efficacy\u00a0and\u00a0rate\u00a0of\u00a0response\nto\u00a0 oral\u00a0 and\u00a0 intravenous\u00a0 vitamin\u00a0 K\u00a0 in\u00a0 reversal\u00a0 of\u00a0 over\u00adanticoagulation\u00a0 with\u00a0 warfarin. Br\u00a0 J\nHaem\u00a02001\u037e115:145\u00ad149\n212. Whitling\u00a0AM,\u00a0Bussey\u00a0HI,\u00a0Lyons\u00a0RM. Comparing\u00a0different\u00a0routes\u00a0and\u00a0doses\u00a0of\u00a0phytonadione\nfor\u00a0reversing\u00a0excessive\u00a0anticoagulation. Arch\u00a0Intern\u00a0Med\u00a01998\u037e158:2136\u00ad2140\n213. Marik\u00a0 PE,\u00a0 Plante\u00a0 LA. Venous\u00a0 thromboembolic\u00a0 disease\u00a0 and\u00a0 pregnancy. N\u00a0 Engl\u00a0 J\u00a0 Med\n2008\u037e359(19):2025\n214. Greer\u00a0 IA. Thrombosis\u00a0 in\u00a0 pregnancy:\u00a0 maternal\u00a0 and\u00a0 fetal\u00a0 issues.", "chunk_order": 103}
{"chunk_id": "2ba46d4f-c440-4c36-836f-3f1f2b3d4105", "source_document_filename": "CPG Prevention and Treatment of Venous Thrombosis_cleaned_ultra_minimal.txt", "source_document_title": "CPG Prevention and Treatment of Venous Thrombosis cleaned ultra minimal", "text": "Am\u00a0 Soc\u00a0 Haematol\u00a0 Programme\u00a0 Book\n2008:36\u00ad38\n211. Watson\u00a0HG,\u00a0Baglin\u00a0T,\u00a0Laidlaw\u00a0SL,\u00a0et\u00a0al. A\u00a0comparison\u00a0of\u00a0the\u00a0efficacy\u00a0and\u00a0rate\u00a0of\u00a0response\nto\u00a0 oral\u00a0 and\u00a0 intravenous\u00a0 vitamin\u00a0 K\u00a0 in\u00a0 reversal\u00a0 of\u00a0 over\u00adanticoagulation\u00a0 with\u00a0 warfarin. Br\u00a0 J\nHaem\u00a02001\u037e115:145\u00ad149\n212. Whitling\u00a0AM,\u00a0Bussey\u00a0HI,\u00a0Lyons\u00a0RM. Comparing\u00a0different\u00a0routes\u00a0and\u00a0doses\u00a0of\u00a0phytonadione\nfor\u00a0reversing\u00a0excessive\u00a0anticoagulation. Arch\u00a0Intern\u00a0Med\u00a01998\u037e158:2136\u00ad2140\n213. Marik\u00a0 PE,\u00a0 Plante\u00a0 LA. Venous\u00a0 thromboembolic\u00a0 disease\u00a0 and\u00a0 pregnancy. N\u00a0 Engl\u00a0 J\u00a0 Med\n2008\u037e359(19):2025\n214. Greer\u00a0 IA. Thrombosis\u00a0 in\u00a0 pregnancy:\u00a0 maternal\u00a0 and\u00a0 fetal\u00a0 issues. Lancet\u00a0 1999\u037e\n353(9160):1258\u00ad65\n215. Kujovich\u00a0JL. Hormones\u00a0and\u00a0pregnancy:\u00a0thromboembolic\u00a0risks\u00a0for\u00a0women. Br\u00a0J\u00a0Haematol\n2004\u037e126(4):443\n216. Heit\u00a0 JA,\u00a0 Kobbervig\u00a0 CE,\u00a0 James\u00a0 AH,\u00a0 et\u00a0 al.. Trends\u00a0 in\u00a0 the\u00a0 incidence\u00a0 of\u00a0 venous\nthromboembolism\u00a0during\u00a0pregnancy\u00a0or\u00a0postpartum:\u00a0a\u00a030\u00adyear\u00a0population\u00adbased\u00a0study. Ann\nIntern\u00a0Med\u00a02005\u037e143(10):697\n217. Morris\u00a0JM,\u00a0Algert\u00a0CS,\u00a0Roberts\u00a0CL. Incidence\u00a0and\u00a0risk\u00a0factors\u00a0for\u00a0pulmonary\u00a0embolism\u00a0in\u00a0the\npostpartum\u00a0period. J\u00a0Thromb\u00a0Haemost\u00a02010\u037e8(5):998\n218. Ginsberg\u00a0JS,\u00a0Brill\u00adEdwards\u00a0P,\u00a0Burrows\u00a0RF,\u00a0et\u00a0al. Venous\u00a0thrombosis\u00a0during\u00a0pregnancy:\u00a0leg\nand\u00a0trimester\u00a0of\u00a0presentation. Thromb\u00a0Haemost\u00a01992\u037e67(5):519\n219. Rutherford\u00a0S,\u00a0Montoro\u00a0M,\u00a0McGehee\u00a0W,\u00a0Strong\u00a0T. Thromboembolic\u00a0disease\u00a0associated\u00a0with\npregnancy:\u00a0an\u00a011\u00adyear\u00a0review. Am\u00a0J\u00a0Obstet\u00a0Gynecol\u00a01991\u037e164(Suppl):286\n220. Kierkegaard\u00a0A. Incidence\u00a0and\u00a0diagnosis\u00a0of\u00a0deep\u00a0vein\u00a0thrombosis\u00a0associated\u00a0with\u00a0pregnancy. Acta\u00a0Obstet\u00a0Gynecol\u00a0Scand\u00a01983\u037e62(3):239\n221. Treffers\u00a0PE,\u00a0Huidekoper\u00a0BL,\u00a0Weenink\u00a0GH,\u00a0Kloosterman\u00a0GJ. Epidemiological\u00a0observations\u00a0of\nthrombo\u00adembolic\u00a0disease\u00a0during\u00a0pregnancy\u00a0and\u00a0in\u00a0the\u00a0puerperium,\u00a0in\u00a056,022\u00a0women. Int\u00a0J\nGynaecol\u00a0Obstet\u00a01983\u037e21(4):327\n222. Simpson\u00a0 EL,\u00a0 Lawrenson\u00a0 RA,\u00a0 Nightingale\u00a0AL,\u00a0 Farmer\u00a0 RD. Venous\u00a0 thromboembolism\u00a0 in\npregnancy\u00a0 and\u00a0 the\u00a0 puerperium:\u00a0 incidence\u00a0 and\u00a0 additional\u00a0 risk\u00a0 factors\u00a0 from\u00a0 a\u00a0 London\nperinatal\u00a0database. BJOG\u00a02001\u037e108(1):56\u00ad60\n223. Stein\u00a0PD,\u00a0Hull\u00a0RD,\u00a0Kayali\u00a0F,\u00a0et\u00a0al. Venous\u00a0thromboembolism\u00a0in\u00a0pregnancy:\u00a021\u00adyear\u00a0trends. Am\u00a0J\u00a0Med\u00a02004\u037e117(2):121\n224. Sultan\u00a0AA,\u00a0 West\u00a0 J,\u00a0Tata\u00a0 LJ,\u00a0 et\u00a0 al. Risk\u00a0 of\u00a0 first\u00a0 venous\u00a0 thromboembolism\u00a0 in\u00a0 and\u00a0 around\npregnancy:\u00a0a\u00a0population\u00adbased\u00a0cohort\u00a0study. Br\u00a0J\u00a0Haematol\u00a02012\u037e156(3):366\n225. Gherman\u00a0RB,\u00a0Goodwin\u00a0TM,\u00a0Leung\u00a0B,\u00a0et\u00a0al. Incidence,\u00a0clinical\u00a0characteristics,\u00a0and\u00a0timing\u00a0of\nobjectively\u00a0 diagnosed\u00a0 venous\u00a0 thromboembolism\u00a0 during\u00a0 pregnancy. Obstet\u00a0 Gynecol\n1999\u037e94(5\u00a0Pt\u00a01):730\n226. Cockett\u00a0 FB,\u00a0 Thomas\u00a0 ML,\u00a0 Negus\u00a0 D. Iliac\u00a0 vein\u00a0 compression\u00a0 \u00ad\u00a0 Its\u00a0 relation\u00a0 to\u00a0 iliofemoral\nthrombosis\u00a0and\u00a0the\u00a0post\u00adthrombotic\u00a0syndrome. Br\u00a0Med\u00a0J\u00a01967\u037e2(5543):14\n227. The\u00a0 PIOPED\u00a0 Investigators. Value\u00a0 of\u00a0 the\u00a0 ventilation/perfusion\u00a0 scan\u00a0 in\u00a0 acute\u00a0 pulmonary\nembolism. Results\u00a0 of\u00a0 the\u00a0 prospective\u00a0 investigation\u00a0 of\u00a0 pulmonary\u00a0 embolism\u00a0 diagnosis\n(PIOPED). JAMA\u00a01990\u037e263(20):2753\n228. Goldhaber\u00a0SZ. Pulmonary\u00a0embolism. N\u00a0Engl\u00a0J\u00a0Med\u00a01998\u037e339(2):93\n229. Lee\u00a0 RV,\u00a0 McComb\u00a0 LE,\u00a0 Mezzadri\u00a0 FC. Pregnant\u00a0 patients,\u00a0 painful\u00a0 legs:\u00a0 the\u00a0 obstetrician's\ndilemma. Obstet\u00a0Gynecol\u00a0Surv\u00a01990\u037e45(5):290\n230. Bates\u00a0 SM,\u00a0 Jaeschke\u00a0 R,\u00a0 Stevens\u00a0 SM,\u00a0 et\u00a0 al. American\u00a0 College\u00a0 of\u00a0 Chest\u00a0 Physicians. Diagnosis\u00a0of\u00a0DVT:\u00a0Antithrombotic\u00a0Therapy\u00a0and\u00a0Prevention\u00a0of\u00a0Thrombosis,\u00a09th\u00a0ed:\u00a0American\nCollege\u00a0 of\u00a0 Chest\u00a0 Physicians\u00a0 Evidence\u00adBased\u00a0 Clinical\u00a0 Practice\u00a0 Guidelines. Chest\u00a0 2012\nFeb\u037e141(2\u00a0Suppl):e351S\u00ad418S\n231. Bates\u00a0 SM,\u00a0 Greer\u00a0 IA,\u00a0 Middeldorp\u00a0 S,\u00a0 et\u00a0 al. American\u00a0 College\u00a0 of\u00a0 Chest\u00a0 Physicians. VTE,\nthrombophilia,\u00a0 antithrombotic\u00a0 therapy,\u00a0 and\u00a0 pregnancy:\u00a0 Antithrombotic\u00a0 Therapy\u00a0 and\nPrevention\u00a0of\u00a0Thrombosis,\u00a09th\u00a0ed:\u00a0American\u00a0College\u00a0of\u00a0Chest\u00a0Physicians\u00a0Evidence\u00adBased\nClinical\u00a0Practice\u00a0Guidelines. Chest\u00a02012\u037e141(2\u00a0Suppl):e691S\n232.", "chunk_order": 104}
{"chunk_id": "81feb152-518e-4d87-9d8b-735d681ed1a3", "source_document_filename": "CPG Prevention and Treatment of Venous Thrombosis_cleaned_ultra_minimal.txt", "source_document_title": "CPG Prevention and Treatment of Venous Thrombosis cleaned ultra minimal", "text": "Lee\u00a0 RV,\u00a0 McComb\u00a0 LE,\u00a0 Mezzadri\u00a0 FC. Pregnant\u00a0 patients,\u00a0 painful\u00a0 legs:\u00a0 the\u00a0 obstetrician's\ndilemma. Obstet\u00a0Gynecol\u00a0Surv\u00a01990\u037e45(5):290\n230. Bates\u00a0 SM,\u00a0 Jaeschke\u00a0 R,\u00a0 Stevens\u00a0 SM,\u00a0 et\u00a0 al. American\u00a0 College\u00a0 of\u00a0 Chest\u00a0 Physicians. Diagnosis\u00a0of\u00a0DVT:\u00a0Antithrombotic\u00a0Therapy\u00a0and\u00a0Prevention\u00a0of\u00a0Thrombosis,\u00a09th\u00a0ed:\u00a0American\nCollege\u00a0 of\u00a0 Chest\u00a0 Physicians\u00a0 Evidence\u00adBased\u00a0 Clinical\u00a0 Practice\u00a0 Guidelines. Chest\u00a0 2012\nFeb\u037e141(2\u00a0Suppl):e351S\u00ad418S\n231. Bates\u00a0 SM,\u00a0 Greer\u00a0 IA,\u00a0 Middeldorp\u00a0 S,\u00a0 et\u00a0 al. American\u00a0 College\u00a0 of\u00a0 Chest\u00a0 Physicians. VTE,\nthrombophilia,\u00a0 antithrombotic\u00a0 therapy,\u00a0 and\u00a0 pregnancy:\u00a0 Antithrombotic\u00a0 Therapy\u00a0 and\nPrevention\u00a0of\u00a0Thrombosis,\u00a09th\u00a0ed:\u00a0American\u00a0College\u00a0of\u00a0Chest\u00a0Physicians\u00a0Evidence\u00adBased\nClinical\u00a0Practice\u00a0Guidelines. Chest\u00a02012\u037e141(2\u00a0Suppl):e691S\n232. Kline\u00a0JA,\u00a0Williams\u00a0GW,\u00a0Hernandez\u00adNino\u00a0J. D\u00addimer\u00a0concentrations\u00a0in\u00a0normal\u00a0pregnancy:\nnew\u00a0diagnostic\u00a0thresholds\u00a0are\u00a0needed. Clin\u00a0Chem\u00a02005\u037e51(5):825\n233. Wright\u00a0H,\u00a0Osborn\u00a0S,\u00a0Edmunds\u00a0D. Changes\u00a0in\u00a0the\u00a0rate\u00a0of\u00a0flow\u00a0of\u00a0venous\u00a0blood\u00a0in\u00a0the\u00a0leg\nduring\u00a0pregnancy,\u00a0measured\u00a0with\u00a0radioactive\u00a0sodium. Surg\u00a0Gynecol\u00a0Obstet\u00a01950\u037e\u00a090:481\n234. Powrie\u00a0RO,\u00a0Larson\u00a0L,\u00a0Rosene\u00adMontella\u00a0K,\u00a0et\u00a0al. Alveolar\u00adarterial\u00a0oxygen\u00a0gradient\u00a0in\u00a0acute\npulmonary\u00a0embolism\u00a0in\u00a0pregnancy. Am\u00a0J\u00a0Obstet\u00a0Gynecol\u00a01998\u037e178(2):394\n235. Chan\u00a0 WS,\u00a0 Lee\u00a0 A,\u00a0 Spencer\u00a0 FA,\u00a0 et\u00a0 al. D\u00addimer\u00a0 testing\u00a0 in\u00a0 pregnant\u00a0 patients:\u00a0 towards\ndetermining\u00a0the\u00a0next\u00a0'level'\u00a0in\u00a0the\u00a0diagnosis\u00a0of\u00a0deep\u00a0vein\u00a0thrombosis. J\u00a0Thromb\u00a0Haemost\n2010\u037e8(5):1004\n236. Le\u00a0 Gal\u00a0 G,\u00a0 Prins\u00a0AM,\u00a0 Righini\u00a0 M,\u00a0 et\u00a0 al. Diagnostic\u00a0 value\u00a0 of\u00a0 a\u00a0 negative\u00a0 single\u00a0 complete\ncompression\u00a0 ultrasound\u00a0 of\u00a0 the\u00a0 lower\u00a0 limbs\u00a0 to\u00a0 exclude\u00a0 the\u00a0 diagnosis\u00a0 of\u00a0 deep\u00a0 venous\nthrombosis\u00a0 in\u00a0 pregnant\u00a0 or\u00a0 postpartum\u00a0 women:\u00a0 a\u00a0 retrospective\u00a0 hospital\u00adbased\u00a0 study. Thromb\u00a0Res\u00a02006\u037e118(6):691\n237. Shellock\u00a0FG,\u00a0Kanal\u00a0E. Policies,\u00a0guidelines,\u00a0and\u00a0recommendations\u00a0for\u00a0MR\u00a0imaging\u00a0safety\nand\u00a0patient\u00a0management. SMRI\u00a0Safety\u00a0Committee. J\u00a0Magn\u00a0Reson\u00a0Imaging\u00a01991\u037e1(1):97\n238. Stein\u00a0PD,\u00a0Hull\u00a0RD,\u00a0Saltzman\u00a0HA,\u00a0Pineo\u00a0G. Strategy\u00a0for\u00a0diagnosis\u00a0of\u00a0patients\u00a0with\u00a0suspected\nacute\u00a0pulmonary\u00a0embolism. Chest\u00a01993\u037e103(5):1553\n239. Turkstra\u00a0F,\u00a0Kuijer\u00a0PM,\u00a0van\u00a0Beek\u00a0EJ,\u00a0et\u00a0al. Diagnostic\u00a0utility\u00a0of\u00a0ultrasonography\u00a0of\u00a0leg\u00a0veins\u00a0in\npatients\u00a0suspected\u00a0of\u00a0having\u00a0pulmonary\u00a0embolism. Ann\u00a0Intern\u00a0Med\u00a01997\u037e126(10):775\n240. Ridge\u00a0CA,\u00a0McDermott\u00a0S,\u00a0Freyne\u00a0BJ,\u00a0et\u00a0al. Pulmonary\u00a0embolism\u00a0in\u00a0pregnancy:\u00a0comparison\nof\u00a0 pulmonary\u00a0 CT\u00a0 angiography\u00a0 and\u00a0 lung\u00a0 scintigraphy. AJR\u00a0 Am\u00a0 J\u00a0 Roentgenol\n2009\u037e193(5):1223\n241. Remy\u00adJardin\u00a0M,\u00a0Remy\u00a0J. Spiral\u00a0CT\u00a0angiography\u00a0of\u00a0the\u00a0pulmonary\u00a0circulation. Radiology\n1999\u037e212:615\u00ad36\n242. Cook\u00a0 JV,\u00a0 Kyriou\u00a0 J. Radiation\u00a0 from\u00a0 CT\u00a0 and\u00a0 perfusion\u00a0 scanning\u00a0 in\u00a0 pregnancy. BMJ\n2005\u037e331:350\n243. Fidler\u00a0JL,\u00a0Patz\u00a0Jr\u00a0EF,\u00a0Ravin\u00a0CE. Cardiopulmonary\u00a0complications\u00a0of\u00a0pregnancy:\u00a0radiographic\nfindings. Am\u00a0J\u00a0Roentgenol\u00a01993\u037e161:937\u00ad42\n244. Ministry\u00a0 of\u00a0 Health\u00a0 Malaysia. Various\u00a0 years. Report\u00a0 on\u00a0 the\u00a0 Confidential\u00a0 Enquiries\u00a0 into\nMaternal\u00a0Deaths\u00a0in\u00a0Malaysia,\u00a0Kuala\u00a0Lumpur,\u00a02009. 245. Royal\u00a0College\u00a0of\u00a0Obstetricians\u00a0and\u00a0Gynaecologist. Green\u00adtop\u00a0Guideline\u00a0No. 37B. The\u00a0acute\nmanagement\u00a0of\u00a0thrombosis\u00a0and\u00a0embolism\u00a0during\u00a0pregnancy\u00a0and\u00a0the\u00a0puerperium,\u00a02007. Reviewed\u00a02010. 246. Ahearn\u00a0GS,\u00a0Hadjiliadis\u00a0MD,\u00a0Govert\u00a0JA,\u00a0Tapson\u00a0VF. Massive\u00a0pulmonary\u00a0embolism\u00a0during\npregnancy\u00a0 successfully\u00a0 treated\u00a0 with\u00a0 recombinant\u00a0 tissue\u00a0 plasminogen\u00a0 activator. Arch\u00a0 Int\nMed\u00a02002\u037e162:1221\u00ad7\n247. Gillis\u00a0A,\u00a0 Shushan\u00a0A,\u00a0 Eldor\u00a0A. Use\u00a0 of\u00a0 low\u00a0 molecular\u00a0 weight\u00a0 heparin\u00a0 for\u00a0 prophylaxis\u00a0 and\ntreatment\u00a0of\u00a0thromboembolism\u00a0in\u00a0pregnancy. Int\u00a0J\u00a0Gynecol\u00a0Obstet\u00a01992\u037e39:297\u00ad301\n248. Brandjes\u00a0 DP,\u00a0 Buller\u00a0 HR,\u00a0 Heijboer\u00a0 H,\u00a0 et\u00a0 al.", "chunk_order": 105}
{"chunk_id": "426fb2ed-263f-48c4-91a0-2094b9c5d941", "source_document_filename": "CPG Prevention and Treatment of Venous Thrombosis_cleaned_ultra_minimal.txt", "source_document_title": "CPG Prevention and Treatment of Venous Thrombosis cleaned ultra minimal", "text": "Report\u00a0 on\u00a0 the\u00a0 Confidential\u00a0 Enquiries\u00a0 into\nMaternal\u00a0Deaths\u00a0in\u00a0Malaysia,\u00a0Kuala\u00a0Lumpur,\u00a02009. 245. Royal\u00a0College\u00a0of\u00a0Obstetricians\u00a0and\u00a0Gynaecologist. Green\u00adtop\u00a0Guideline\u00a0No. 37B. The\u00a0acute\nmanagement\u00a0of\u00a0thrombosis\u00a0and\u00a0embolism\u00a0during\u00a0pregnancy\u00a0and\u00a0the\u00a0puerperium,\u00a02007. Reviewed\u00a02010. 246. Ahearn\u00a0GS,\u00a0Hadjiliadis\u00a0MD,\u00a0Govert\u00a0JA,\u00a0Tapson\u00a0VF. Massive\u00a0pulmonary\u00a0embolism\u00a0during\npregnancy\u00a0 successfully\u00a0 treated\u00a0 with\u00a0 recombinant\u00a0 tissue\u00a0 plasminogen\u00a0 activator. Arch\u00a0 Int\nMed\u00a02002\u037e162:1221\u00ad7\n247. Gillis\u00a0A,\u00a0 Shushan\u00a0A,\u00a0 Eldor\u00a0A. Use\u00a0 of\u00a0 low\u00a0 molecular\u00a0 weight\u00a0 heparin\u00a0 for\u00a0 prophylaxis\u00a0 and\ntreatment\u00a0of\u00a0thromboembolism\u00a0in\u00a0pregnancy. Int\u00a0J\u00a0Gynecol\u00a0Obstet\u00a01992\u037e39:297\u00ad301\n248. Brandjes\u00a0 DP,\u00a0 Buller\u00a0 HR,\u00a0 Heijboer\u00a0 H,\u00a0 et\u00a0 al. Randomised\u00a0 trial\u00a0 of\u00a0 effect\u00a0 of\u00a0 compression\nstockings\u00a0in\u00a0patients\u00a0with\u00a0symptomatic\u00a0proximal\u2013vein\u00a0thrombosis. Lancet\u00a01997\u037e349:759\u00ad62\n249. Royal\u00a0College\u00a0of\u00a0Obstetricians\u00a0and\u00a0Gynaecologist. Green\u00adtop\u00a0Guideline\u00a0No. 37a. Reducing\nthe\u00a0risk\u00a0of\u00a0thrombosis\u00a0and\u00a0embolism\u00a0during\u00a0pregnancy\u00a0and\u00a0the\u00a0puerperium. Nov\u00a02009. O7@6\"Y0=;g0\"`I\"6\"\"D19$%\"C%)9+;<)/09C)<\";)++)>0\"$#\"#$9();)%198:\"19\"Q1Q$6\"N\u00a0Engl\u00a0J\u00a0Med\u00a0\u00a02004\u037e\n350(18):1914\u00ad1915\n251. Baglin\u00a0T,\u00a0Barrowcliffe\u00a0TW,\u00a0Cohen\u00a0A,\u00a0Greaves\u00a0M. Guidelines\u00a0on\u00a0the\u00a0use\u00a0and\u00a0monitoring\u00a0of\nheparin. B\u00a0Soc\u00a0Haematol\u00a02006\u037e133:19\u00ad34\n252. Bazinet\u00a0A,\u00a0Almanric\u00a0 K,\u00a0 Brunet\u00a0 C,\u00a0 et\u00a0 al. Dosage\u00a0 of\u00a0 enoxaparin\u00a0 among\u00a0 obese\u00a0 and\u00a0 renal\nimpairment\u00a0patients. Thromb\u00a0Res\u00a02005\u037e116:41\u00ad50\n253. J\u00a0Van\u00a0ES,\u00a0Eerenberg\u00a0ES,\u00a0Kamphuisen\u00a0PW,\u00a0Buller\u00a0HR. How\u00a0to\u00a0prevent,\u00a0treat\u00a0and\u00a0overcome\ncurrent\u00a0clinical\u00a0challenges\u00a0of\u00a0VTE. J\u00a0Thromb\u00a0Haemost\u00a02011\u037e9:265\u00ad274\n254. Kearon\u00a0 C,\u00a0 Akl\u00a0 EA,\u00a0 Comerota\u00a0 AJ,\u00a0 et\u00a0 al. Antithrombotic\u00a0 Therapy\u00a0 for\u00a0 VTE\u00a0 Disease:\nAntithrombotic\u00a0Therapy\u00a0and\u00a0Prevention\u00a0of\u00a0Thrombosis,\u00a09th\u00a0ed:\u00a0American\u00a0College\u00a0of\u00a0Chest\nPhysicians\u00a0Evidence\u00adBased\u00a0Clinical\u00a0Practice\u00a0Guidelines. Chest\u00a02012\u037e141\u037ee419S\u00ade494S\n255. Rondina\u00a0 MT,\u00a0 Pendelton\u00a0 RC,\u00a0 Wheeler\u00a0 M,\u00a0 Rodgers\u00a0 GM. The\u00a0 treatment\u00a0 of\u00a0 venous\nthromboembolism\u00a0in\u00a0special\u00a0populations. Thromb\u00a0Res\u00a02006\u037e1\u00ad12\n256. Smith\u00a0ML,\u00a0Wheeler\u00a0KE. Weight\u00adbased\u00a0heparin\u00a0protocol\u00a0using\u00a0anti\u00adfactor\u00a0Xa\u00a0monitoring. Am\nJ\u00a0Health\u00adSyst\u00a0Pharm\u00a02010\u037e67:371\u00ad4\n257. Wilson\u00a0SJ,\u00a0Wilbur\u00a0K,\u00a0Burton\u00a0E,\u00a0Anderson\u00a0DR. Effect\u00a0of\u00a0patient\u00a0weight\u00a0on\u00a0the\u00a0anticoagulant\nresponse\u00a0to\u00a0adjusted\u00a0therapeutic\u00a0dosage\u00a0of\u00a0low\u00a0molecular\u00a0weight\u00a0heparin\u00a0for\u00a0the\u00a0treatment\nof\u00a0venous\u00a0thromboembolism. Haemostasis\u00a02001\u037e31:42\u00ad8\n258. Goldhaber\u00a0SZ,\u00a0Bounameaux\u00a0H. Pulmonary\u00a0embolism\u00a0and\u00a0deep\u00a0vein\u00a0thrombosis. Lancet\n2012\u037e\u00a0379(9828):1835\u00a0\u00ad\u00a046\n259. Ho\u00a0 WK,\u00a0 Hankey\u00a0 JG,\u00a0 Lee\u00a0 CH,\u00a0 Eikelboom\u00a0 JW. Venous\u00a0 thromboembolism:\u00a0 diagnosis\u00a0 and\nmanagement\u00a0of\u00a0deep\u00a0vein\u00a0thrombosis. Med\u00a0J\u00a0Aust\u00a02005\u037e182:476\u00a0\u00ad\u00a0481\n260. Monagle\u00a0 P,\u00a0 Chan\u00a0AKC,\u00a0 Goldenberg\u00a0 NA,\u00a0 et\u00a0 al. Antithrombotic\u00a0 therapy\u00a0 in\u00a0 neonates\u00a0 and\nchildren. ACCP\u00a09th\u00a0edition. Chest\u00a02012\u037e141(2)(Suppl)e737S\u00ade801S\n261. Newall\u00a0F,\u00a0Johnston\u00a0L,\u00a0Ignjatovic\u00a0V,\u00a0Monagle\u00a0P. Unfractionated\u00a0heparin\u00a0therapy\u00a0in\u00a0infants\u00a0and\nchildren. Pediatrics\u00a02009\u037e123(3):e510\u00ade518\n262. Buck\u00a0ML. Heparin\u00a0and\u00a0Enoxaparin\u00a0in\u00a0Infants\u00a0and\u00a0Children:\u00a0 Lliterature\u00a0 Update. Pediatric\nPharmacotherapy\u00a02011\u037e17(9)\n263. Chan\u00a0WS,\u00a0Dixon\u00a0ME. The\u00a0\u2018ART\u2019\u00a0of\u00a0thromboembolism:\u00a0a\u00a0review\u00a0of\u00a0assisted\u00a0reproductive\ntechnology\u00a0and\u00a0thromboembolic\u00a0complications. Thromb\u00a0Res\u00a02008\u037e121(6):713\u00ad26\n264. Andersen\u00a0 BS,\u00a0 Steffensen\u00a0 FH,\u00a0 S\u00f8rensen\u00a0 HT,\u00a0 et\u00a0 al. The\u00a0 cumulative\u00a0 incidence\u00a0 of\u00a0 venous\nthromboembolism\u00a0during\u00a0pregnancy\u00a0and\u00a0puerperium:\u00a0an\u00a011\u00a0year\u00a0Danish\u00a0population\u00adbased\nstudy\u00a0of\u00a063,300\u00a0pregnancies. Acta\u00a0Obstet\u00a0Gynecol\u00a0Scand\u00a01998\u00a0Feb\u037e77(2):170\u00ad3\n265. Kierkegaard\u00a0A. Incidence\u00a0and\u00a0diagnosis\u00a0of\u00a0deep\u00a0vein\u00a0thrombosis\u00a0associated\u00a0with\u00a0pregnancy. Acta\u00a0Obstet\u00a0Gynecol\u00a0Scand\u00a01983\u037e62:239\u00ad243\n266. Golan\u00a0A,\u00a0Ron\u00adEl\u00a0R,\u00a0Herman\u00a0A,\u00a0et\u00a0al. Ovarian\u00a0hyperstimulation\u00a0syndrome:\u00a0an\u00a0update\u00a0review.", "chunk_order": 106}
{"chunk_id": "77ece295-d14a-42bc-8813-42acecac6e4d", "source_document_filename": "CPG Prevention and Treatment of Venous Thrombosis_cleaned_ultra_minimal.txt", "source_document_title": "CPG Prevention and Treatment of Venous Thrombosis cleaned ultra minimal", "text": "Heparin\u00a0and\u00a0Enoxaparin\u00a0in\u00a0Infants\u00a0and\u00a0Children:\u00a0 Lliterature\u00a0 Update. Pediatric\nPharmacotherapy\u00a02011\u037e17(9)\n263. Chan\u00a0WS,\u00a0Dixon\u00a0ME. The\u00a0\u2018ART\u2019\u00a0of\u00a0thromboembolism:\u00a0a\u00a0review\u00a0of\u00a0assisted\u00a0reproductive\ntechnology\u00a0and\u00a0thromboembolic\u00a0complications. Thromb\u00a0Res\u00a02008\u037e121(6):713\u00ad26\n264. Andersen\u00a0 BS,\u00a0 Steffensen\u00a0 FH,\u00a0 S\u00f8rensen\u00a0 HT,\u00a0 et\u00a0 al. The\u00a0 cumulative\u00a0 incidence\u00a0 of\u00a0 venous\nthromboembolism\u00a0during\u00a0pregnancy\u00a0and\u00a0puerperium:\u00a0an\u00a011\u00a0year\u00a0Danish\u00a0population\u00adbased\nstudy\u00a0of\u00a063,300\u00a0pregnancies. Acta\u00a0Obstet\u00a0Gynecol\u00a0Scand\u00a01998\u00a0Feb\u037e77(2):170\u00ad3\n265. Kierkegaard\u00a0A. Incidence\u00a0and\u00a0diagnosis\u00a0of\u00a0deep\u00a0vein\u00a0thrombosis\u00a0associated\u00a0with\u00a0pregnancy. Acta\u00a0Obstet\u00a0Gynecol\u00a0Scand\u00a01983\u037e62:239\u00ad243\n266. Golan\u00a0A,\u00a0Ron\u00adEl\u00a0R,\u00a0Herman\u00a0A,\u00a0et\u00a0al. Ovarian\u00a0hyperstimulation\u00a0syndrome:\u00a0an\u00a0update\u00a0review. Obstet\u00a0Gynecol\u00a0Surv\u00a01989\u037e44(6):430\u2013440\n267. Chan\u00a0WS. The\u00a0\u2018ART\u2019\u00a0of\u00a0thrombosis:\u00a0a\u00a0review\u00a0of\u00a0arterial\u00a0and\u00a0venous\u00a0thrombosis\u00a0in\u00a0assisted\nreproductive\u00a0technology. Curr\u00a0Opin\u00a0Obstet\u00a0Gynecol\u00a02009\u037e21(3):207\u00ad18\n268. ESHRE. The\u00a0 European\u00a0 IVF\u00admonitoring\u00a0 programme\u00a0 (EIM),\u00a0 for\u00a0 the\u00a0 European\u00a0 Society\u00a0 of\nHuman\u00a0 Reproduction\u00a0 and\u00a0 Embryology\u00a0 (ESHRE). Assisted\u00a0 reproductive\u00a0 technology\u00a0 in\nEurope,\u00a01997. Results\u00a0generated\u00a0from\u00a0European\u00a0registers\u00a0by\u00a0ESHRE. Hum\u00a0Reprod\u00a02001\nto\u00a02010\n269. Dinger\u00a0 JC,\u00a0 Heinemann\u00a0 LAJ,\u00a0 Kuhl\u00adHabichl\u00a0 D. The\u00a0 safety\u00a0 of\u00a0 drospirenone\u00adcontaining\u00a0 oral\ncontraceptive:\u00a0 final\u00a0 results\u00a0 from\u00a0 the\u00a0 European\u00a0 Active\u00a0 Surveillance\u00a0 study\u00a0 on\u00a0 Oral\nContraceptives\u00a0 based\u00a0 on\u00a0 142,475\u00a0 women\u00adyears\u00a0 of\u00a0 observation. Contraception\u00a0 2007\u037e\n75:344\u00ad354\n270. Jick\u00a0 H,\u00a0 Kaye\u00a0 JA,\u00a0 Vasilakis\u00adScaramozza\u00a0 C,\u00a0 Jick\u00a0 SS. Risk\u00a0 of\u00a0 venous\u00a0 thromboembolism\namong\u00a0 users\u00a0 of\u00a0 third\u00a0 generation\u00a0 oral\u00a0 contraceptives\u00a0 compared\u00a0 with\u00a0 users\u00a0 of\u00a0 oral\ncontraceptives\u00a0with\u00a0levonorgestrel\u00a0before\u00a0and\u00a0after\u00a01995:\u00a0cohort\u00a0and\u00a0case\u00adcontrol\u00a0analysis. BMJ\u00a02000\u037e321:1190\u00ad1195\n271. Lidegaard\u00a0 O,\u00a0 Kreiner\u00a0 S. Contraceptives\u00a0 and\u00a0 cerebral\u00a0 thrombosis\u037e\u00a0 a\u00a0 five\u00a0 year\u00a0 national\ncase\u00adcontrol\u00a0study. Contraception\u00a02002\u037e65:197\u00ad205\n272. Suissa\u00a0S,\u00a0Blais\u00a0L,\u00a0Spitzer\u00a0WO,\u00a0Cusson\u00a0J,\u00a0Lewis\u00a0M,\u00a0Heinemann\u00a0L. First\u00adtime\u00a0use\u00a0of\u00a0newer\noral\u00a0 contraceptives\u00a0 and\u00a0 the\u00a0 riskof\u00a0 venous\u00a0 thromboembolism. Contraception\u00a0 1997\u037e\n56:141\u00ad146. 273. World\u00a0 Health\u00a0 Organization\u00a0 Collaborative\u00a0 Study\u00a0 of\u00a0 Cardiovascular\u00a0 Disease\u00a0 and\u00a0 Steroid\nHormone\u00a0 Contraception. Effect\u00a0 of\u00a0 different\u00a0 progestagens\u00a0 in\u00a0 low\u00a0 oestrogen\u00a0 oral\ncontraceptives\u00a0on\u00a0venous\u00a0thromboembolic\u00a0disease. Lancet\u00a01995\u037e346:1582\u20131588\n274. Plu\u00adBureau\u00a0G,\u00a0Maitrot\u00adMantelet\u00a0L,\u00a0Hugon\u00adRodin\u00a0J,\u00a0Canonico\u00a0M. Hormonal\u00a0contraceptives\nand\u00a0venous\u00a0thromboembolism:\u00a0An\u00a0epidemiological\u00a0update. Best\u00a0Pract\u00a0Res\u00a0Clin\u00a0Endocrinol\nMetab\u00a02013\u037e27(1):25\u00ad34\n275. Combined\u00a0hormonal\u00a0contraception. Faculty\u00a0of\u00a0Sexual\u00a0and\u00a0Reproductive\u00a0Healthcare,\u00a0Royal\nCollege\u00a0of\u00a0Obstetricians\u00a0and\u00a0Gynaecologists,\u00a02012\n276. Medical\u00a0eligibility\u00a0criteria\u00a0for\u00a0contraceptive\u00a0use\u00a0\u00ad\u00a04th\u00a0ed. World\u00a0Health\u00a0Organization\u00a02010\n277. Bergqvist\u00a0D,\u00a0Burmark\u00a0US,\u00a0Flordal\u00a0PA,\u00a0et\u00a0al. Low\u00a0molecular\u00a0weight\u00a0heparin\u00a0started\u00a0before\nsurgery\u00a0as\u00a0prophylaxis\u00a0against\u00a0deep\u00a0vein\u00a0thrombosis:\u00a02500\u00a0versus\u00a05000\u00a0XaI\u00a0units\u00a0in\u00a02070\npatients. Br\u00a0J\u00a0Surg\u00a01995\u037e82:496e501\n278. Deitcher\u00a0 SR. Cancer\u00adrelated\u00a0 deep\u00a0 venous\u00a0 thrombosis. Clinical\u00a0 importance,\u00a0 treatment\nchallenges,\u00a0and\u00a0management\u00a0strategies. Semin\u00a0Thromb\u00a0Haemost\u00a02003\u037e29:247\u00ad258\n279. East\u00a0AT,\u00a0Wakefield\u00a0TW. What\u00a0is\u00a0the\u00a0optimal\u00a0duration\u00a0of\u00a0treatment\u00a0for\u00a0DVT? An\u00a0update\u00a0on\nevidence\u00adbased\u00a0medicine\u00a0of\u00a0treatment\u00a0for\u00a0DVT,\u00a0Semin\u00a0Vasc\u00a0Surg\u00a02010\u037e23:182\u00ad191\n280. Goldhaber\u00a0 SZ. Venous\u00a0 thromboembolism:\u00a0 Epidemiology\u00a0 and\u00a0 magnitude\u00a0 of\u00a0 the\u00a0 problem,\nBest\u00a0Prac\u00a0Res\u00a0Clin\u00a0Haematol\u00a02012\u037e25(3):235\u00ad242\n281. Kakkar\u00a0AK,\u00a0 Levine\u00a0 MN,\u00a0 Kadziola\u00a0 Z,\u00a0 et\u00a0 al. Low\u00a0 molecular\u00a0 weight\u00a0 heparin\u00a0 therapy\u00a0 with\ndalteparin\u00a0 and\u00a0 survival\u00a0 in\u00a0 advanced\u00a0 cancer:\u00a0 the\u00a0 framing\u00a0 advanced\u00a0 malignancy\u00a0 outcome\nstudy\u00a0(FAMOUS). J\u00a0Clin\u00a0Oncol\u00a02004\u037e22:1944\u00ad8\n282. Klerk\u00a0CP,\u00a0Smorenburg\u00a0SM,\u00a0Otten\u00a0HM,\u00a0et\u00a0al.", "chunk_order": 107}
{"chunk_id": "05337315-54d4-4cb4-bea6-39d9ae7ea7c8", "source_document_filename": "CPG Prevention and Treatment of Venous Thrombosis_cleaned_ultra_minimal.txt", "source_document_title": "CPG Prevention and Treatment of Venous Thrombosis cleaned ultra minimal", "text": "Cancer\u00adrelated\u00a0 deep\u00a0 venous\u00a0 thrombosis. Clinical\u00a0 importance,\u00a0 treatment\nchallenges,\u00a0and\u00a0management\u00a0strategies. Semin\u00a0Thromb\u00a0Haemost\u00a02003\u037e29:247\u00ad258\n279. East\u00a0AT,\u00a0Wakefield\u00a0TW. What\u00a0is\u00a0the\u00a0optimal\u00a0duration\u00a0of\u00a0treatment\u00a0for\u00a0DVT? An\u00a0update\u00a0on\nevidence\u00adbased\u00a0medicine\u00a0of\u00a0treatment\u00a0for\u00a0DVT,\u00a0Semin\u00a0Vasc\u00a0Surg\u00a02010\u037e23:182\u00ad191\n280. Goldhaber\u00a0 SZ. Venous\u00a0 thromboembolism:\u00a0 Epidemiology\u00a0 and\u00a0 magnitude\u00a0 of\u00a0 the\u00a0 problem,\nBest\u00a0Prac\u00a0Res\u00a0Clin\u00a0Haematol\u00a02012\u037e25(3):235\u00ad242\n281. Kakkar\u00a0AK,\u00a0 Levine\u00a0 MN,\u00a0 Kadziola\u00a0 Z,\u00a0 et\u00a0 al. Low\u00a0 molecular\u00a0 weight\u00a0 heparin\u00a0 therapy\u00a0 with\ndalteparin\u00a0 and\u00a0 survival\u00a0 in\u00a0 advanced\u00a0 cancer:\u00a0 the\u00a0 framing\u00a0 advanced\u00a0 malignancy\u00a0 outcome\nstudy\u00a0(FAMOUS). J\u00a0Clin\u00a0Oncol\u00a02004\u037e22:1944\u00ad8\n282. Klerk\u00a0CP,\u00a0Smorenburg\u00a0SM,\u00a0Otten\u00a0HM,\u00a0et\u00a0al. The\u00a0effect\u00a0of\u00a0low\u00a0molecular\u00a0weight\u00a0heparin\u00a0on\nsurvival\u00a0in\u00a0patients\u00a0with\u00a0advanced\u00a0malignancy. J\u00a0Clin\u00a0Oncol\u00a02005\u037e23:2130\u00ad5\n283. Kearon\u00a0C,\u00a0Kahn\u00a0SR,\u00a0Agnelli\u00a0G,\u00a0et\u00a0al. Antithrombotic\u00a0therapy\u00a0for\u00a0venous\u00a0thromboembolic\ndisease:\u00a0 American\u00a0 College\u00a0 of\u00a0 Chest\u00a0 Physicians\u00a0 Evidence\u00a0 \u00ad\u00a0 Based\u00a0 Clinical\u00a0 Practice\nGuidelines\u00a0(8th\u00a0Edition). Chest\u00a02008\u037e133(suppl):454S\u00ad545S\n284. Lee\u00a0AY,\u00a0 Rickles\u00a0 FR,\u00a0 Julian\u00a0 JA,\u00a0 et\u00a0 al. Randomized\u00a0 comparison\u00a0 of\u00a0 low\u00a0 molecular\u00a0 weight\nheparin\u00a0 and\u00a0 coumarin\u00a0 derivatives\u00a0 on\u00a0 the\u00a0 survival\u00a0 of\u00a0 patients\u00a0 with\u00a0 cancer\u00a0 and\u00a0 venous\nthromboembolism. J\u00a0Clin\u00a0Oncol\u00a02005\u037e23:2123\u00ad9\n285. Heit\u00a0JA,\u00a0Mohr\u00a0DN,\u00a0Silverstein\u00a0MD,\u00a0et\u00a0al:\u00a0Predictors\u00a0of\u00a0recurrence\u00a0after\u00a0deep\u00a0vein\u00a0thrombosis\nand\u00a0 pulmonary\u00a0 embolism:\u00a0 a\u00a0 population\u00adbased\u00a0 cohort\u00a0 study. Arch\u00a0 Intern\u00a0 Med\u00a0 2000\u037e\n160:761\u00ad768\n286. Huber\u00a0O,\u00a0Bounameaux\u00a0H,\u00a0Borst\u00a0F,\u00a0et\u00a0al. Postoperative\u00a0pulmonary\u00a0embolism\u00a0after\u00a0hospital\ndischarge. An\u00a0underestimated\u00a0risk. Arch\u00a0Surg\u00a01992\u037e127:310e313\n287. Prandoni\u00a0P,\u00a0Lensing\u00a0AW,\u00a0Piccioli\u00a0A,\u00a0et\u00a0al. Recurrent\u00a0venous\u00a0thromboembolism\u00a0and\u00a0bleeding\ncomplications\u00a0 during\u00a0 anticoagulant\u00a0 treatment\u00a0 in\u00a0 patients\u00a0 with\u00a0 cancer\u00a0 and\u00a0 venous\nthrombosis. Blood\u00a02002\u037e100:3484\u00ad3488\n288. Merli\u00a0 G,\u00a0 Spiro\u00a0 TE,\u00a0 Olsson\u00a0 C\u00adG,\u00a0 et\u00a0 al. Subcutaneous\u00a0 enoxaparin\u00a0 once\u00a0 or\u00a0 twice\u00a0 daily\ncompared\u00a0with\u00a0intravenous\u00a0unfractionated\u00a0heparin\u00a0for\u00a0treatment\u00a0of\u00a0venous\u00a0thromboembolic\ndisease. Ann\u00a0Intern\u00a0Med\u00a02001\u037e134:191\u00ad202\n289. Hull\u00a0 RD,\u00a0 Raskob\u00a0 GL,\u00a0 Pineo\u00a0 GF,\u00a0 et\u00a0 al. Subcutaneous\u00a0 low\u00admolecular\u00adweight\u00a0 heparin\ncompared\u00a0with\u00a0continuous\u00a0intravenous\u00a0heparin\u00a0in\u00a0the\u00a0treatment\u00a0of\u00a0proximal\u00a0vein\u00a0thrombosis. N\u00a0Engl\u00a0J\u00a0Med\u00a01992\u037e326:975\u00ad982\n290. Hainer\u00a0JW,\u00a0Barrett\u00a0JS,\u00a0Assaid\u00a0CA,\u00a0et\u00a0al. Dosing\u00a0in\u00a0heavy\u00adweight/obese\u00a0patients\u00a0with\u00a0the\nLMWH,\u00a0tinzaparin:\u00a0a\u00a0pharmacodynamic\u00a0study. Thromb\u00a0Haemost\u00a02002\u037e87:817\u00ad823\n291. Romera\u00a0A,\u00a0Cairols\u00a0MA,\u00a0Vila\u00adColl\u00a0R,\u00a0et\u00a0al. A\u00a0randomised\u00a0open\u00adlabel\u00a0trial\u00a0comparing\u00a0long\u00adterm\nsub\u00adcutaneous\u00a0low\u00admolecular\u00adweight\u00a0heparin\u00a0compared\u00a0with\u00a0oral\u00adanticoagulant\u00a0therapy\u00a0in\nthe\u00a0 treatment\u00a0 of\u00a0 deep\u00a0 venous\u00a0 thrombosis. Eur\u00a0 J\u00a0 Vasc\u00a0 Endovasc\u00a0 Surg\u00a0 2009\u00a0 Mar\u037e\n37(3):349\u00ad56\n292. Dentali\u00a0F,\u00a0Gianni\u00a0M,\u00a0Crowther\u00a0MA,\u00a0Ageno\u00a0W. Natural\u00a0history\u00a0of\u00a0cerebral\u00a0vein\u00a0thrombosis:\u00a0a\nsystematic\u00a0review. Blood\u00a02006\u037e108(4):1129\u00ad34\n293. Ferro\u00a0JM,\u00a0Canhao\u00a0P,\u00a0Stam\u00a0j,\u00a0et\u00a0al. Prognosis\u00a0of\u00a0cerebral\u00a0vein\u00a0and\u00a0dural\u00a0sinus\u00a0thrombosis:\nresults\u00a0of\u00a0the\u00a0International\u00a0Study\u00a0on\u00a0Cerebral\u00a0Vein\u00a0and\u00a0Dural\u00a0Sinus\u00a0Thrombosis\u00a0(ISCVT). Stroke\u00a02004\u037e35(3):664\u00ad70\n294. Flinterman\u00a0LE,\u00a0Van\u00a0Der\u00a0Meer\u00a0Fj,\u00a0Rosendaal\u00a0FR,\u00a0Doggen\u00a0Cj. Current\u00a0perspective\u00a0of\u00a0venous\nthrombosis\u00a0in\u00a0the\u00a0upper\u00a0extremity. J\u00a0Thromb\u00a0Haemost\u00a02008\u037e6(8):1262\u00ad6\n295. Lechner\u00a0 D,\u00a0 Wiener\u00a0 C,\u00a0 Weltermann\u00a0 A,\u00a0 Eischer\u00a0 L,\u00a0 Eichinger\u00a0 S,\u00a0 Kyrle\u00a0 PA. Comparison\nbetween\u00a0idiopathic\u00a0deep\u00a0vein\u00a0thrombosis\u00a0of\u00a0the\u00a0upper\u00a0and\u00a0lower\u00a0extremity\u00a0regarding\u00a0risk\nfactors\u00a0and\u00a0recurrence. J\u00a0Thromb\u00a0Haemost\u00a02008\u037e6(8):1269\u00ad74\n296. Martinelli\u00a0 I,\u00a0 Franchini\u00a0 M,\u00a0 Mannucci\u00a0 PM. How\u00a0 I\u00a0 treat\u00a0 rare\u00a0 venous\u00a0 thromboses.", "chunk_order": 108}
{"chunk_id": "38a439ed-740d-435e-8514-a1c79e720a55", "source_document_filename": "CPG Prevention and Treatment of Venous Thrombosis_cleaned_ultra_minimal.txt", "source_document_title": "CPG Prevention and Treatment of Venous Thrombosis cleaned ultra minimal", "text": "Prognosis\u00a0of\u00a0cerebral\u00a0vein\u00a0and\u00a0dural\u00a0sinus\u00a0thrombosis:\nresults\u00a0of\u00a0the\u00a0International\u00a0Study\u00a0on\u00a0Cerebral\u00a0Vein\u00a0and\u00a0Dural\u00a0Sinus\u00a0Thrombosis\u00a0(ISCVT). Stroke\u00a02004\u037e35(3):664\u00ad70\n294. Flinterman\u00a0LE,\u00a0Van\u00a0Der\u00a0Meer\u00a0Fj,\u00a0Rosendaal\u00a0FR,\u00a0Doggen\u00a0Cj. Current\u00a0perspective\u00a0of\u00a0venous\nthrombosis\u00a0in\u00a0the\u00a0upper\u00a0extremity. J\u00a0Thromb\u00a0Haemost\u00a02008\u037e6(8):1262\u00ad6\n295. Lechner\u00a0 D,\u00a0 Wiener\u00a0 C,\u00a0 Weltermann\u00a0 A,\u00a0 Eischer\u00a0 L,\u00a0 Eichinger\u00a0 S,\u00a0 Kyrle\u00a0 PA. Comparison\nbetween\u00a0idiopathic\u00a0deep\u00a0vein\u00a0thrombosis\u00a0of\u00a0the\u00a0upper\u00a0and\u00a0lower\u00a0extremity\u00a0regarding\u00a0risk\nfactors\u00a0and\u00a0recurrence. J\u00a0Thromb\u00a0Haemost\u00a02008\u037e6(8):1269\u00ad74\n296. Martinelli\u00a0 I,\u00a0 Franchini\u00a0 M,\u00a0 Mannucci\u00a0 PM. How\u00a0 I\u00a0 treat\u00a0 rare\u00a0 venous\u00a0 thromboses. Blood\n2008\u037e112(13):4818\u00ad23\n297. SIGN\u00a0122. Prevention\u00a0and\u00a0management\u00a0of\u00a0venous\u00a0thromboembolism. A\u00a0national\u00a0clinical\nguideline,\u00a0Dec\u00a02010\n298. Stam\u00a0J,\u00a0De\u00a0Bruijn\u00a0SF,\u00a0DeVeber\u00a0G. Anticoagulation\u00a0for\u00a0cerebral\u00a0sinus\u00a0thrombosis. Cochrane\nDatabase\u00a0of\u00a0Systematic\u00a0Reviews\u00a02002\n299. Kearon\u00a0 C,\u00a0 Akl\u00a0 EA,\u00a0 Comerota\u00a0 AJ,\u00a0 et\u00a0 al. Antithrombotic\u00a0 therapy\u00a0 for\u00a0 VTE\u00a0 disease:\nantithrombotic\u00a0therapy\u00a0and\u00a0prevention\u00a0of\u00a0thrombosis,\u00a09th\u00a0ed:\u00a0American\u00a0College\u00a0of\u00a0Chest\nPhysicians\nevidence\u00adbased\nclinical\npractice\nguidelines. Chest\n2012\u037e141(2)\n(suppl):e419S\u00ade494S\n300. Garabedian\u00adRuffalo\u00a0 SM,\u00a0 Gray\u00a0 DR,\u00a0 Sax\u00a0 MJ,\u00a0 et\u00a0 al. Retrospective\u00a0 evaluation\u00a0 of\u00a0 a\npharmacist\u00admanaged\u00a0 warfarin\u00a0 anticoagulation\u00a0 clinic. Am\u00a0 J\u00a0 Health\u00a0 Syst\u00a0 Pharm\u00a0 1985\u037e42\n(2):304\u00ad308\n301. Wilson\u00a0 SJ,\u00a0 Wells\u00a0 PS,\u00a0 Kovacs\u00a0 MJ,\u00a0 et\u00a0 al. Comparing\u00a0 the\u00a0 quality\u00a0 of\u00a0 oral\u00a0 anticoagulant\nmanagement\u00a0by\u00a0anticoagulation\u00a0clinics\u00a0and\u00a0by\u00a0family\u00a0physicians:\u00a0a\u00a0randomized\u00a0controlled\ntrial. CMAJ\u00a02003\u037e169(4):293\u00ad298\n302. Protocol\u00adMedication\u00a0Therapy\u00a0Adherence\u00a0Clinic:\u00a0Warfarin. Pharmaceutical\u00a0Services\u00a0Division,\nMinistry\u00a0of\u00a0Health\u00a0Malaysia. First\u00a0Edition\u00a02010303. Bennett\nS. Warfarin\nManagement\nGuidelines. NSH\u00a0Cumbria,\u00a02011\n304. Bussey\u00a0HI,\u00a0Chiquette\u00a0E,\u00a0Bianco\u00a0TM,\u00a0et\u00a0al. A\u00a0statistical\u00a0and\u00a0clinical\u00a0evaluation\u00a0of\u00a0fingerstick\nand\u00a0routine\u00a0laboratory\u00a0prothrombin\u00a0time\u00a0measurements. Pharmacotherapy\u00a01997\u037e17:861\u00ad66\n305. Ortel\u00a0TL. Thrombosis\u00a0and\u00a0the\u00a0antiphospholipid\u00a0syndrome. Hematology\u00a02005\u037e462\u00ad468\n306. Kathleen\u00a0 M. Mazor,\u00a0 Joann\u00a0 L. Baril,\u00a0 Elizabeth\u00a0 Dugan,\u00a0 et\u00a0 al. Patient\u00a0 education\u00a0 about\nanticoagulant\u00a0 medication:\u00a0 is\u00a0 narrative\u00a0 evidence\u00a0 or\u00a0 statistical\u00a0 evidence\u00a0 more\u00a0 effective? Patient\u00a0education\u00a0and\u00a0counseling\u00a02007\u037e69(1\u00ad3):145\u00ad157\n307. Hixson\u00adWallace\u00a0JA,\u00a0Blakey\u00a0SA,\u00a0Dotson\u00a0JB,\u00a0et\u00a0al. Effect\u00a0of\u00a0Regimen\u00a0Complexity\u00a0on\u00a0Patient\nSatisfaction,\u00a0 Compliance\u00a0 with\u00a0 Warfarin\u00a0 Therapy. Clin\u00a0 Appl\u00a0 Thromb\u00a0 Hemost\u00a0 2001\u00a0 Jan\u037e\n7(1):33\u00ad7\n308. Witticke\u00a0D,\u00a0Seidling\u00a0HM,\u00a0Klimm\u00a0HD,\u00a0et\u00a0al. Do\u00a0we\u00a0prescribe\u00a0what\u00a0patients\u00a0prefer? Pilot\u00a0study\nto\u00a0 assess\u00a0 patient\u00a0 preferences\u00a0 for\u00a0 medication\u00a0 regimen\u00a0 characteristics. Patient\u00a0 Prefer\nAdherence\u00a02012\u037e6:679\u00ad84\n309. Rivaroxaban\u00a0for\u00a0the\u00a0treatment\u00a0of\u00a0deep\u00a0vein\u00a0thrombosis\u00a0and\u00a0prevention\u00a0of\u00a0recurrent\u00a0deep\nvein\u00a0thrombosis\u00a0and\u00a0pulmonary\u00a0embolism. NICE\u00a0technology\u00a0appraisal\u00a0guidance\u00a0261. July\n2012\n310. Schulman\u00a0S,\u00a0Crowther\u00a0MA. How\u00a0I\u00a0anticoagulate\u00a0in\u00a02012,\u00a0new\u00a0and\u00a0old\u00a0anticoagulant\u00a0agents,\nand\u00a0when\u00a0and\u00a0how\u00a0to\u00a0switch. Blood\u00a02012\n311. Cosmi\u00a0 B,\u00a0 Legnani\u00a0 C,\u00a0Tosetto\u00a0A,\u00a0 Pengo\u00a0 V,\u00a0 Ghirarduzzi\u00a0A. Usefulness\u00a0 of\u00a0 repeat\u00a0 D\u00addimer\ntesting\u00a0 after\u00a0 stopping\u00a0 anticoagulation\u00a0 for\u00a0 a\u00a0 first\u00a0 episode\u00a0 of\u00a0 unprovoked\u00a0 venous\nthromboembolism:\u00a0the\u00a0PROLONG\u00a0II\u00a0prospective\u00a0study. Blood\u00a02010\u037e115:481\u00ad488\n312. Goldhaber\nSZ,\nPiazza\nG. Optimal\nDuration\nof\u00a0 Anticoagulation\nafter\nVenous\nThromboembolism. Circulation\u00a02011\u037e123:664\u00ad667\n313. Garcia\u00a0DA,\u00a0Baglin\u00a0TP,\u00a0Weitz\u00a0JI,\u00a0Samama\u00a0MM. Parenteral\u00a0Anticoagulants. Antithrombotic\nTherpy\u00a0 and\u00a0 Prevention\u00a0 of\u00a0 Thrombosis,\u00a0 9th\u00a0 ed:\u00a0American\u00a0 College\u00a0 of\u00a0 Chest\u00a0 Physicians\nEvidence\u00adBased\u00a0Clinical\u00a0Practice\u00a0Guidelines. Chest\u00a02012\u037e141(2)(Suppl):e24S\u00ade43S\n314. Schulman\u00a0S,\u00a0Crowther\u00a0MA.", "chunk_order": 109}
{"chunk_id": "ed246aaf-63d5-4cd0-b386-8dd3d8f7f82d", "source_document_filename": "CPG Prevention and Treatment of Venous Thrombosis_cleaned_ultra_minimal.txt", "source_document_title": "CPG Prevention and Treatment of Venous Thrombosis cleaned ultra minimal", "text": "Blood\u00a02012\n311. Cosmi\u00a0 B,\u00a0 Legnani\u00a0 C,\u00a0Tosetto\u00a0A,\u00a0 Pengo\u00a0 V,\u00a0 Ghirarduzzi\u00a0A. Usefulness\u00a0 of\u00a0 repeat\u00a0 D\u00addimer\ntesting\u00a0 after\u00a0 stopping\u00a0 anticoagulation\u00a0 for\u00a0 a\u00a0 first\u00a0 episode\u00a0 of\u00a0 unprovoked\u00a0 venous\nthromboembolism:\u00a0the\u00a0PROLONG\u00a0II\u00a0prospective\u00a0study. Blood\u00a02010\u037e115:481\u00ad488\n312. Goldhaber\nSZ,\nPiazza\nG. Optimal\nDuration\nof\u00a0 Anticoagulation\nafter\nVenous\nThromboembolism. Circulation\u00a02011\u037e123:664\u00ad667\n313. Garcia\u00a0DA,\u00a0Baglin\u00a0TP,\u00a0Weitz\u00a0JI,\u00a0Samama\u00a0MM. Parenteral\u00a0Anticoagulants. Antithrombotic\nTherpy\u00a0 and\u00a0 Prevention\u00a0 of\u00a0 Thrombosis,\u00a0 9th\u00a0 ed:\u00a0American\u00a0 College\u00a0 of\u00a0 Chest\u00a0 Physicians\nEvidence\u00adBased\u00a0Clinical\u00a0Practice\u00a0Guidelines. Chest\u00a02012\u037e141(2)(Suppl):e24S\u00ade43S\n314. Schulman\u00a0S,\u00a0Crowther\u00a0MA. How\u00a0I\u00a0anticoagulate\u00a0in\u00a02012,\u00a0new\u00a0and\u00a0old\u00a0anticoagulant\u00a0agents,\nand\u00a0when\u00a0and\u00a0how\u00a0to\u00a0switch. Blood\u00a02012\n315. Watson\u00a0 H,\u00a0 Davidson\u00a0 S,\u00a0 Keeling\u00a0 D. Guidelines\u00a0 on\u00a0 the\u00a0 diagnosis\u00a0 and\u00a0 management\u00a0 of\nheparin\u00adinduced\u00a0thrombocytopenia:\u00a0second\u00a0edition. BJH\u00a02012\n316. Warkentin,\u00a0T.E.,\u00a0Greinacher,\u00a0A.,\u00a0Koster,\u00a0A. &\u00a0Lincoff,\u00a0A.M. (2008a)\u00a0Treatment\u00a0and\u00a0prevention\nof\nheparin\u00adinduced\nthrombocytopenia:\u00a0 American\nCollege\nof\nChest\nPhysicians\nEvidence\u00adBased\u00a0Clinical\u00a0Practice\u00a0Guidelines\u00a0(8th\u00a0Edition). Chest\u00a0133,\u00a0340S\u00ad380S\n317. Schulman\u00a0S,\u00a0Crowther\u00a0MA. How\u00a0I\u00a0anticoagulate\u00a0in\u00a02012,\u00a0new\u00a0and\u00a0old\u00a0anticoagulant\u00a0agents,\nand\u00a0when\u00a0and\u00a0how\u00a0to\u00a0switch. Blood\u00a02012\n318. van\u00a0Ryn\u00a0J,\u00a0Stangier\u00a0J,\u00a0Haertter\u00a0S,\u00a0et\u00a0al. Dabigatran\u00a0etexilate\u00ad\u00a0a\u00a0novel,\u00a0reversible\u00a0oral\u00a0direct\nthrombin\u00a0inhibitor:\u00a0interpretation\u00a0of\u00a0coagulation\u00a0assays\u00a0and\u00a0reversal\u00a0of\u00a0anticoagulant\u00a0activity. Thromb\u00a0Haemost\u00a02010\u037e103(6):1116\u00ad1127\n319. Gerotziafas\u00a0GT,\u00a0Depasse\u00a0F,\u00a0Chakroun\u00a0T,\u00a0Samama\u00a0MM,\u00a0Elalamy\u00a0I. Recombinant\u00a0factor\u00a0VIIa\npartially\u00a0reverses\u00a0the\u00a0inhibitory\u00a0effect\u00a0of\u00a0fondaparinux\u00a0on\u00a0thrombin\u00a0generation\u00a0after\u00a0tissue\nfactor\u00a0 activation\u00a0 in\u00a0 platelet\u00a0 rich\u00a0 plasma\u00a0 and\u00a0 whole\u00a0 blood. Thromb\u00a0 Haemost\u00a0 2004\u037e\n91:531\u00ad537\n320. Eerenberg\u00a0ES,\u00a0Kamphuisen\u00a0PW,\u00a0Sijpkens\u00a0MK,\u00a0Meijers\u00a0JC,\u00a0Buller\u00a0HR,\u00a0Levi\u00a0M. Reversal\u00a0of\nrivaroxaban\u00a0 and\u00a0 dabigatran\u00a0 by\u00a0 prothrombin\u00a0 complex\u00a0 concentrate:\u00a0 a\u00a0 randomized\nplacebo\u00adcontrolled,\ncrossover\nstudy\nin\nhealthy\nsubjects. Circulation\n2011\u037e\n124(14):1573\u00ad1579\n321. van\u00a0Ryn\u00a0J,\u00a0Stangier\u00a0J,\u00a0Haertter\u00a0S,\u00a0et\u00a0al. Dabigatran\u00a0etexilate\u00ad\u00a0a\u00a0novel,\u00a0reversible\u00a0oral\u00a0direct\nthrombin\u00a0inhibitor:\u00a0interpretation\u00a0of\u00a0coagulation\u00a0assays\u00a0and\u00a0reversal\u00a0of\u00a0anticoagulant\u00a0activity. Thromb\u00a0Haemost\u00a02010\u037e103(6):1116\u00ad1127\n322. Schulman\u00a0S,\u00a0Crowther\u00a0MA. How\u00a0I\u00a0anticoagulate\u00a0in\u00a02012,\u00a0new\u00a0and\u00a0old\u00a0anticoagulant\u00a0agents,\nand\u00a0when\u00a0and\u00a0how\u00a0to\u00a0switch. Blood\u00a02012\n323. Mak\u00a0A,\u00a0Cheung\u00a0MW,\u00a0Cheak\u00a0AA,\u00a0Ho\u00a0RC. Combination\u00a0of\u00a0heparin\u00a0and\u00a0aspirin\u00a0is\u00a0superior\u00a0to\naspirin\u00a0alone\u00a0in\u00a0enhancing\u00a0live\u00a0births\u00a0in\u00a0patients\u00a0with\u00a0recurrent\u00a0pregnancy\u00a0loss\u00a0and\u00a0positive\nanti\u00adphospholipid\u00a0 antibodies:\u00a0 a\u00a0 meta\u00adanalysis\u00a0 of\u00a0 randomized\u00a0 controlled\u00a0 trials\u00a0 and\nmeta\u00adregression. Rheumatology\u00a0(Oxford)\u00a02010\u037e49(2):281\u00ad8\n324. Ruiz\u00adIrastorza\u00a0 G,\u00a0 Crowther\u00a0 M,\u00a0 Branch\u00a0 W,\u00a0 Khamashta\u00a0 MA. Antiphospholipid\u00a0 syndrome. Lancet\u00a02010\u037e376(9751):1498\u00ad509\n325. Newall\u00a0F,\u00a0Ignjatovic\u00a0V,\u00a0Johnston\u00a0L,\u00a0Summerhayes\u00a0R,\u00a0et\u00a0al. Clinical\u00a0use\u00a0of\u00a0unfractionated\nheparin\u00a0therapy\u00a0in\u00a0children:\u00a0time\u00a0for\u00a0change? Br\u00a0J\u00a0Haematol\u00a02010\u00a0Sep\u037e150(6):674\u00ad8\n326. Summerhayes\u00a0R,\u00a0Chan\u00a0M,\u00a0Ignjatovic\u00a0V,\u00a0Prankerd\u00a0R,\u00a0et\u00a0al. Stability\u00a0and\u00a0sterility\u00a0of\u00a0diluted\nenoxaparin\u00a0 under\u00a0 three\u00a0 different\u00a0 storage\u00a0 conditions. J\u00a0 Paediatr\u00a0 Child\u00a0 Health\u00a0 2011\u037e\n47(5):299\u00ad301\n327. Whelan\u00a0 JG\u00a0 3rd,\u00a0 Vlahos\u00a0 NF. The\u00a0 ovarian\u00a0 hyperstimulation\u00a0 syndrome. Fertil\u00a0 Steril\u00a0 2000\nMay\u037e73(5):883\u00ad96\n328. Rova\u00a0 K,\u00a0 Passmark\u00a0 H,\u00a0 Lindqvist\u00a0 PG. Venous\u00a0 thromboembolism\u00a0 in\u00a0 relation\u00a0 to\u00a0 in\u00a0 vitro\nfertilization:\u00a0an\u00a0approach\u00a0to\u00a0determining\u00a0the\u00a0incidence\u00a0and\u00a0increase\u00a0in\u00a0risk\u00a0in\u00a0successful\ncycles. Fertil\u00a0Steril\u00a02012\u00a0Jan\u037e97(1):95\u00ad100\n329. Jenkins\u00a0 JM,\u00a0 Drakeley\u00a0 AJ,\u00a0 Mathur\u00a0 RS.", "chunk_order": 110}
{"chunk_id": "8c564258-9e16-4680-b2ac-74991a79b8c0", "source_document_filename": "CPG Prevention and Treatment of Venous Thrombosis_cleaned_ultra_minimal.txt", "source_document_title": "CPG Prevention and Treatment of Venous Thrombosis cleaned ultra minimal", "text": "Clinical\u00a0use\u00a0of\u00a0unfractionated\nheparin\u00a0therapy\u00a0in\u00a0children:\u00a0time\u00a0for\u00a0change? Br\u00a0J\u00a0Haematol\u00a02010\u00a0Sep\u037e150(6):674\u00ad8\n326. Summerhayes\u00a0R,\u00a0Chan\u00a0M,\u00a0Ignjatovic\u00a0V,\u00a0Prankerd\u00a0R,\u00a0et\u00a0al. Stability\u00a0and\u00a0sterility\u00a0of\u00a0diluted\nenoxaparin\u00a0 under\u00a0 three\u00a0 different\u00a0 storage\u00a0 conditions. J\u00a0 Paediatr\u00a0 Child\u00a0 Health\u00a0 2011\u037e\n47(5):299\u00ad301\n327. Whelan\u00a0 JG\u00a0 3rd,\u00a0 Vlahos\u00a0 NF. The\u00a0 ovarian\u00a0 hyperstimulation\u00a0 syndrome. Fertil\u00a0 Steril\u00a0 2000\nMay\u037e73(5):883\u00ad96\n328. Rova\u00a0 K,\u00a0 Passmark\u00a0 H,\u00a0 Lindqvist\u00a0 PG. Venous\u00a0 thromboembolism\u00a0 in\u00a0 relation\u00a0 to\u00a0 in\u00a0 vitro\nfertilization:\u00a0an\u00a0approach\u00a0to\u00a0determining\u00a0the\u00a0incidence\u00a0and\u00a0increase\u00a0in\u00a0risk\u00a0in\u00a0successful\ncycles. Fertil\u00a0Steril\u00a02012\u00a0Jan\u037e97(1):95\u00ad100\n329. Jenkins\u00a0 JM,\u00a0 Drakeley\u00a0 AJ,\u00a0 Mathur\u00a0 RS. The\u00a0 management\u00a0 of\u00a0 ovarian\u00a0 hyperstimulation\nsyndrome. In:\u00a0 Green\u00adtop\u00a0 guideline\u00a0 NO.5. London:\u00a0 Royal\u00a0 College\u00a0 of\u00a0 Obstetricians\u00a0 and\nGynaecologists,\u00a02006\n330. Vloeberghs\u00a0V,\u00a0Peeraer\u00a0K,\u00a0Pexsters\u00a0A,\u00a0D'Hooghe\u00a0T. Ovarian\u00a0hyperstimulation\u00a0syndrome\u00a0and\ncomplications\u00a0 of\u00a0ART. Best\u00a0 practice\u00a0 &\u00a0 research\u00a0 Clinical\u00a0 Obstetrics\u00a0 and\u00a0 Gynaecology\n2009\u037e23(5):691\u00ad709\n331. Dunn\u00a0N,\u00a0Thorogood\u00a0M,\u00a0Farahar\u00a0B,\u00a0de\u00a0Caestecker\u00a0L,MacDonald\u00a0TM,\u00a0McCollum\u00a0C,\u00a0et\u00a0al. Oral\ncontraceptives\u00a0 and\u00a0 myocardial\u00a0 infarction:\u00a0 results\u00a0 of\u00a0 the\u00a0 MICA\u00a0 case\u00adcontrol\u00a0 study. BMJ\n1999\u037e318:1579\u00ad84. 332. Venous\u00a0 Thromboembolism\u00a0 and\u00a0 Hormonal\u00a0 Contraception. RCOG\u00a0 Green\u00adtop\u00a0 Guideline\nNo.40. London:\u00a0Royal\u00a0College\u00a0of\u00a0Obstetricians\u00a0and\u00a0Gynaecologists,\u00a02010\n333. Adam\u00a0SS,\u00a0Key\u00a0NS,\u00a0Greenbery\u00a0CS. D\u00addimer\u00a0antigen:\u00a0current\u00a0concepts\u00a0and\u00a0future\u00a0prospects. Blood\u00a02009\u037e113:2878\u00ad2887", "chunk_order": 111}
